(21) 3 181 733

(12) DEMANDE DE BREVET CANADIEN CANADIAN PATENT APPLICATION

(13) **A1**

- (86) Date de dépôt PCT/PCT Filing Date: 2021/06/04
- (87) Date publication PCT/PCT Publication Date: 2021/12/09
- (85) Entrée phase nationale/National Entry: 2022/12/06
- (86) N° demande PCT/PCT Application No.: US 2021/036031
- (87) N° publication PCT/PCT Publication No.: 2021/248087
- (30) Priorité/Priority: 2020/06/06 (US63/035,692)

- (51) Cl.Int./Int.Cl. C12N 9/10 (2006.01), *C12N 15/09* (2006.01), *C12N 15/52* (2006.01)
- (71) Demandeur/Applicant: CB THERAPEUTICS, INC., US
- (72) Inventeurs/Inventors: PEIFFER, LAURA FLATAUER, US; VOGAN, JACOB MICHAEL, US; WADE, JAMES LEE, US; YACOUB, TYRONE JACOB, US; TANG, KIRSTEN, US; BURNETT, RACHEL NADINE, US
- (74) Agent: GOWLING WLG (CANADA) LLP

(54) Titre: ENZYMES ET PROTEINES REGULATRICES DANS LE METABOLISME DE LA TRYPTAMINE

(54) Title: ENZYMES AND REGULATORY PROTEINS IN TRYPTAMINE METABOLISM




FIG. 1

(57) Abrégé/Abstract:

Provided are non-naturally occurring nucleic acids comprising a sequence encoding an enzyme or regulatory protein in tryptamine metabolism. Also provided are a recombinant microorganisms expressing the enzyme or regulatory protein. Methods of expressing the enzyme or regulatory protein are additionally provided.





Date Submitted: 2022/12/06

CA App. No.: 3181733

Abstract:

Provided are non-naturally occurring nucleic acids comprising a sequence encoding an enzyme or regulatory protein in tryptamine metabolism. Also provided are a recombinant microorganisms expressing the enzyme or regulatory protein. Methods of expressing the enzyme or regulatory protein are additionally provided.

ENZYMES AND REGULATORY PROTEINS IN TRYPTAMINE METABOLISM

CROSS-REFERENCE TO RELATED APPLICATION

This application claims the benefit of U.S. Provisional Application No. 63/035,692, filed June 6, 2020, and incorporated by reference herein in its entirety.

INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A COMPACT DISC

The Sequence Listing, which is a part of the present disclosure, includes a computer readable form and a written sequence listing comprising nucleotide and/or amino acid sequences of the present invention. The sequence listing information recorded in computer readable form is identical to the written sequence listing. The subject matter of the Sequence Listing is incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION

(1) Field of the Invention

The present invention generally relates to the production of substituted indoles, e.g. N-methyl-L-tryptophan (NMTP), N,N-dimethyl-L-tryptophan (DMTP), and N,N,N-trimethyl-L-tryptophan (TMTP), and related tryptamines, e.g. N-methyltryptamine (NMT), N,N-dimethyltryptamine (DMT), and N,N,N-trimethyltryptamine (TMT), in a modified heterologous microorganism.

(2) Description of the related art

Mental health problems, which may also be referred to as mental illness or psychiatric disorder, are behavioral or mental patterns which impair the functioning of individuals across the world. Such mental health disorders include: personality disorders, anxiety disorders, major depressions, and various addictions. Indolic and tryptamine-based compounds similar in structure to the endogenous neurotransmitter serotonin have been increasingly evaluated for treating mental health problems. In contrast to anxiolytic medicines, usage of substituted indoles and methylated tryptamines, such as N,N-dimethyltryptamine does not lead to physical dependence.

The chemical synthesis of hydroxy, methoxy, phosphorylated, prenylated, and halogenated substituted tryptamines and indoles typically involve tedious techniques of organic chemistry.

Often, reproducibility is elusive and the solvents used during the syntheses of substituted tryptamines are environmentally toxic. Decarboxylations and selective methylations can be difficult to obtain via the techniques of organic chemistry. Further, the yields and purity of the intermediates for obtaining the target molecules can be low, where, for example, the starting molecule is L-tryptophan and the target molecule is N,N-dimethyltryptophan (DMTP), bufotenine, 5-MeO-dimethyltryptamine (5-MeO-DMT), 7-dimethylallyltryptophan, psilocybin, aeruginascin, among others.

The present invention provides for producing substituted tryptamines and indoles in recombinant microorganisms, providing for a more environmentally benign and higher yielding processes for production of those compounds.

BRIEF SUMMARY OF THE INVENTION

In some embodiments, provided is a non-naturally occurring nucleic acid comprising a sequence encoding an enzyme or regulatory protein in tryptamine metabolism, where the enzyme or regulatory protein is an N-methyltransferase (INMT, PsiM, TrpM), a tryptophan decarboxylase (AADC), a tryptophan hydroxylase (TPH), a tryptamine 4' hydroxylase (T4H), a tryptamine 5' hydroxylase (T5H), a truncated cytochrome p450 reductase (T4H-CPR, T5H-CPR), an hydroxytryptamine O-methyltransferase (IOMT or CaffOMT), an N-acetyltransferase (NAT), a deacetylase (DAC), a hydroxyl tryptamine kinase (PsiK), a tryptophan synthase (TrpS), a toluene monooxygenase (TMO), an aminotransferase/methyltransferase fusion (ATMT), a phosphatase, an oxidase, a dimethylallyltryptophan synthase (DMAT), an isopentenyl-diphosphate isomerase (IDI1), a tryptophan halogenase (TrpHalo), an aspartate oxidase/quinolinic acid synthase fusion (AOQS), a tryptophan importer (TAT2), a methionine importer (MUP1), or a SAMe importer (SAM3).

Also provided is an expression cassette comprising any of the above nucleic acids with a promoter functional in a recombinant microorganism.

Additionally provided is a recombinant microorganism comprising the above expression cassette, that expresses the enzyme or regulatory protein encoded therein.

Further provided is a non-naturally occurring enzyme or regulatory protein comprising an amino acid sequence encoded by any of the above-identified nucleic acids.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

FIG. 1 depicts the chemical structures of tryptophan and tryptamine, including various modifications which are performed by the enzymes disclosed within.

- FIG. 2 depicts various substituted indole compounds in the tryptamine and tryptophan pathways utilized in the present invention. Panel A depicts the indole ring structure with positional numbering, and tryptophan and tryptamine. Panel B depicts examples of hydroxy modified tryptophan and tryptamine. Panel C depicts the 5-hydroxy indole ring structure with positional numbering, and examples of modified 5-hydroxy tryptamines. Panel D depicts the 4-hydroxy indole ring structure with positional numbering, and examples of modified 4-hydroxy tryptamines.
- FIG. 3 depicts biosynthetic pathways utilized herein. Panel A depicts the biosynthetic pathways to tryptophan and genetic manipulations to increase tryptophan flux toward modified indoles and tryptamines. Panel B depicts the biosynthetic pathways to the methyl donor, SAMe and genetic manipulations to increase SAMe flux toward modified indoles and tryptamines.
- FIG. 4 depicts enzymatic reactions utilized herein. Panel A depicts SAMe usage by INMT for methyltransferase activity. Panel B depicts BH4 usage by TPH for hydroxylase activity. Panel C depicts SAMe usage by INMT for methyltransferase activity on hydroxy tryptamine. Panel D depicts SAMe usage by IOMT (or CaffOMT) for methyltransferase activity. Panel E depicts NAD(P)H usage by T5H for hydroxylase activity. Panel F depicts acetyl-CoA usage by NAT for acetylation activity.
- FIG. 5 depicts routes of modification of tryptamine by combinatorial usage of INMT, T5H, and IOMT enzymes.
- FIG. 6 depicts routes of modification of tryptophan by combinatorial usage of TrpM, TPH, and IOMT enzymes (Panel A) and example branch points where modified tryptophan becomes modified tryptamine via use of the AADC enzyme (Panel B).
- FIG. 7 depicts (A) routes of modification of serotonin by combinatorial usage of INMT and IOMT enzymes; (B) conversion of 5-HTP to serotonin by the AADC enzyme; (C) conversion of serotonin to N-acetylserotonin by the NAT enzyme, and N-acetylserotonin conversion to melatonin via the IOMT enzyme; (D) conversion of serotonin to 5-MT by the IOMT enzyme, and 5-MT conversion to melatonin via the NAT enzyme; and (E) conversion of melatonin to 5-MeOtryptamine by the DAC enzyme, and subsequent N-methylation by INMT to generate compounds such as 5-MeO-DMT.
- FIG. 8 depicts (A) halogenation of tryptophan and tryptamine on the indole ring by the TrpHalo enzyme; (B) example route to halogenated DMT via combinatorial use of TrpHalo,

AADC, and INMT enzymes; (C) prenylation of tryptophan and tryptamine on the indole ring by the DMAT-IDI1 fusion enzyme; and (D) example route to prenylated DMT via combinatorial use of DMAT-IDI1, AADC, and INMT enzymes.

- FIG. 9 depicts (A) a modified host organism expressing gene combinations with TPH, AADC, and TrpM enzymes to convert tryptophan into various hydroxy tryptamines; (B) a modified host organism expressing gene combinations with TPH, AADC, TrpM, and IOMT enzymes to convert tryptophan into various methoxy tryptamines; (C) a modified host organism expressing gene combinations with AADC, T5H, and INMT enzymes to convert tryptophan into various hydroxy tryptamines; and (D) a modified host organism expressing gene combinations with AADC, T5H, INMT, and IOMT enzymes to convert tryptophan into various methoxy tryptamines.
- FIG. 10 depicts (A) a modified host organism which can generate various hydroxy tryptamines through bioconversion of serotonin provided exogenously or generated within the host organism; and (B) a modified host organism which can generate various methoxy tryptamines through bioconversion of melatonin provided exogenously or generated within the host organism.
- FIG. 11 depicts (A) a scaffolded biosynthesis pathway of colocalized AADC, T5H-CPR fusion, IOMT, and NAT enzymes for conversion of tryptophan to melatonin; and (B) a modified host organism expressing the biosynthesis pathway from FIG. 11A to convert tryptophan to melatonin and related products.
- FIG. 12 depicts (A) a scaffolded biosynthesis pathway of colocalized AADC, T4H-CPR fusion, PsiK, and PsiM enzymes for conversion of tryptophan to psilocybin related products; and (B) a modified host organism expressing the biosynthesis pathway from FIG. 12A to convert tryptophan to psilocybin and related products.
- FIG. 13 depicts (A) example routes to halogenated, prenylated, and N-methylated alphamethyl-tryptamine (AMT); and (B) a modified host organism expressing gene combinations to modify exogenously provided AMT to generate alpha-methylated-tryptamine variants.
- FIG. 14 depicts (A) a heterologous tryptophan synthase (TrpS) route to combine synthetically modified indole with serine or threonine to generate indole modified tryptophan or indole modified beta-methyl tryptophan; and (B) a host organism expressing gene combinations to generate variants of indole modified tryptophan or indole modified beta-methyl tryptophan.

FIG. 15 depicts (A) the ATMT fusion enzyme converted tryptophan to beta-methyl tryptophan; and (B) a host organism expressing the ATMT fusion enzyme with gene combinations to generate beta-methyl tryptophan variants.

- FIG. 16 depicts (A) the conversion of phosphorylated tryptamines to the corresponding hydroxy tryptamines by dephosphorylation; and (B) the oxidation of example hydroxy tryptamines which can catalyze polymerization.
- FIG. 17 depicts HPLC chromatograms and UV-vis spectral matching of fermentation derived tryptamine via expression of the AADC enzyme.
- FIG. 18 depicts HPLC chromatograms of fermentation derived methylated tryptamine via expression of the TrpM enzyme.
- FIG. 19 depicts HPLC chromatograms of fermentation derived 4-OH tryptamine with improvements in yield via an optimal T4H-CPR fusion.
- FIG. 20 depicts HPLC chromatograms of fermentation derived 5-OH-NMT via bioconversion of exogenous serotonin.
- FIG. 21 depicts (A) a biosynthetic route to serotonin and 5-OH-NMT with a T5H enzyme or with a T5H-CPR fusion enzyme; and HPLC chromatograms of fermentation derived serotonin and 5-OH-NMT with improvements in yield via an optimal T5H-CPR fusion.
 - FIG. 22 depicts HPLC chromatograms of fermentation derived serotonin and melatonin.
 - FIG. 23 depicts HPLC chromatograms of fermentation derived 5-OH NMT and bufotenine.
 - FIG. 24 depicts HPLC chromatograms of fermentation derived psilocybin.
 - FIG. 25 depicts a synthetic route to methylate various tryptamines.
- FIG. 26 depicts HPLC chromatograms and UV-vis spectral matching of fermentation derived DMT.

DETAILED DESCRIPTION OF THE INVENTION

Abbreviations and Definitions

To facilitate understanding of the invention, a number of terms and abbreviations as used herein are defined below as follows:

Conservative amino acid substitutions: As used herein, when referring to mutations in a protein, "conservative amino acid substitutions" are those in which at least one amino acid of the polypeptide encoded by the nucleic acid sequence is substituted with another amino acid having similar characteristics. Examples of conservative amino acid substitutions are ser for ala, thr, or

cys; lys for arg; gln for asn, his, or lys; his for asn; glu for asp or lys; asn for his or gln; asp for glu; pro for gly; leu for ile, phe, met, or val; val for ile or leu; ile for leu, met, or val; arg for lys; met for phe; tyr for phe or trp; thr for ser; trp for tyr; and phe for tyr.

Functional variant: The term "functional variant," as used herein, refers to a recombinant enzyme such as an INMTenzyme that comprises a nucleotide and/or amino acid sequence that is altered by one or more nucleotides and/or amino acids compared to the nucleotide and/or amino acid sequences of the parent protein and that is still capable of performing an enzymatic function (e.g., synthesis of DMT) of the parent enzyme. In other words, the modifications in the amino acid and/or nucleotide sequence of the parent enzyme may cause desirable changes in reaction parameters without altering fundamental enzymatic function encoded by the nucleotide sequence or containing the amino acid sequence. The functional variant may have conservative change including nucleotide and amino acid substitutions, additions and deletions. These modifications can be introduced by standard techniques known in the art, such as site-directed mutagenesis and random PCR-mediated mutagenesis, and may comprise natural as well as non-natural nucleotides and amino acids. Also envisioned is the use of amino acid analogs, e.g. amino acids not DNA or RNA encoded in biological systems, and labels such as fluorescent dyes, radioactive elements, electron dense agents, or any other protein modification, now known or later discovered.

Recombinant nucleic acid and recombinant protein: As used herein, a recombinant nucleic acid or protein is a nucleic acid or protein produced by recombinant DNA technology, e.g., as described in Green and Sambrook (2012).

Polypeptide, protein, and peptide: The terms "polypeptide," "protein," and "peptide" are used herein interchangeably to refer to amino acid chains in which the amino acid residues are linked by peptide bonds or modified peptide bonds. The amino acid chains can be of any length of greater than two amino acids. Unless otherwise specified, the terms "polypeptide," "protein," and "peptide" also encompass various modified forms thereof. Such modified forms may be naturally occurring modified forms or chemically modified forms. Examples of modified forms include, but are not limited to, glycosylated forms, phosphorylated forms, myristoylated forms, palmitoylated forms, ribosylated forms, acetylated forms, and the like. Modifications also include intra-molecular crosslinking and covalent attachment of various moieties such as lipids, flavin, biotin, polyethylene glycol or derivatives thereof, and the like. In addition, modifications may also include protein cyclization, branching of the amino acid chain, and cross-linking of the

protein. Further, amino acids other than the conventional twenty amino acids encoded by genes may also be included in a polypeptide.

The term "protein" or "polypeptide" may also encompass a "purified" polypeptide that is substantially separated from other polypeptides in a cell or organism in which the polypeptide naturally occurs (e.g., 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 100% free of contaminants).

Primer, probe and oligonucleotide: The terms "primer," "probe," and "oligonucleotide" may be used herein interchangeably to refer to a relatively short nucleic acid fragment or sequence. They can be DNA, RNA, or a hybrid thereof, or chemically modified analogs or derivatives thereof. Typically, they are single-stranded. However, they can also be double-stranded having two complementing strands that can be separated apart by denaturation. In certain aspects, they are of a length of from about 8 nucleotides to about 200 nucleotides. In other aspects, they are from about 12 nucleotides to about 100 nucleotides. In additional aspects, they are about 18 to about 50 nucleotides. They can be labeled with detectable markers or modified in any conventional manners for various molecular biological applications.

Vector: As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is an episome, i.e., a nucleic acid capable of extra-chromosomal replication. Various vectors are those capable of autonomous replication and/expression of nucleic acids to which they are linked. Vectors capable of directing the expression of genes to which they are operatively linked are referred to herein as "expression vectors."

Linker: The term "linker" refers to a short amino acid sequence that separates multiple domains of a polypeptide. In some embodiments, the linker prohibits energetically or structurally unfavorable interactions between the discrete domains.

Codon optimized: As used herein, a recombinant gene is "codon optimized" when its nucleotide sequence is modified to accommodate codon bias of the host organism to improve gene expression and increase translational efficiency of the gene.

Expression cassette: As used herein, an "expression cassette" is a nucleic acid that comprises a gene and a regulatory sequence operatively coupled to the gene such that the promoter drives the expression of the gene in a cell. An example is a gene for an enzyme with a promoter functional in yeast, where the promoter is situated such that the promoter drives the expression of the enzyme in a yeast cell.

Compounds and abbreviations in use of or contained within systems and methods herein are provided in Table 1.

Table 1

Compounds		
tryptamine		
L-tryptophan		
L-methionine		
bufotenin		
4-hydroxy-tryptamine		
norbaeocystin		
norpsilocin		
baeocystin		
psilocybin		
psilocin		
aeruginascin		
NMT = N-methyltryptamine		
DMT = N,N-dimethyltryptamine		
TMT = N, N, N-trimethyltryptamine		
NMTP = N-methyltryptophan or L-Abrine		
DMTP = N,N-dimethyltryptophan		
TMTP = N,N,N-trimethyltryptophan or Hypaphorine or Lenticin		
5-HTP = 5-hydroxytryptophan		
SAMe = S-Adenosyl-L-methionine		
SAH = S-Adenosyl-L-homocysteine		
DMC = dimethylcarbonate		
DMAPP = dimethylallyl diphosphate		
DMSO = dimethyl sulfoxide		
5-HT = 5-hydroxytryptamine or Serotonin		
NAS = N-acetylserotonin or Normelatonin		
NA-MeO-T = N-acetyl-5-methoxy-tryptamine or Melatonin		

5-MT = 5-methoxy-tryptamine or Mexamine			
5-MeO-NMT = 5-methoxy-N-methytryptamine			
5-MeO-DMT = 5-methoxy-N,N-Dimethyltryptamine			
5-MeO-TMT = 5-methoxy-N,N,N-trimethyltryptamine			
5-HO-NMT = 5-hydroxy-methyltryptamine			
5-HO-DMT = 5-hydroxy-dimethyltryptamine or Bufotenine			
5-HO-TMT = 5-hydroxy-trimethyltryptamine or Bufotenidine			
NMT = N-methyltryptamine			
DMT = N,N-dimethyltryptamine			
TMT = N, N, N-trimethyltryptamine			
NMTP = N-methyltryptophan or L-abrine			
DMTP = N,N-dimethyltryptophan			
TMTP = N,N,N-trimethyltryptophan or Hypaphorine or Lenticin			
5-HO-NMTP = 5-hydroxy-methyltryptophan			
5-HO-DMTP = 5-hydroxy-dimethyltryptophan			
5-HO-TMTP = 5-hydroxy-methyltryptophan			
5-MeO-NMTP = 5-methoxy-methyltryptophan			
5-MeO-DMTP = 5-methoxy-dimethyltryptophan			
5-MeO-TMTP = 5-methoxy-methyltryptophan			
BH4 = Tetrahydrobiopterin			
BH2 = Dihydrobiopterin			
NADPH = Reduced nicotinamide adenine dinucleotide phosphate			
NADP+ = Nicotinamide adenine dinucleotide phosphate			
Acetyl-CoA = Acetyl coenzyme A			
β-Methyltryptophan (β-mTrp)			
N-acetyl-4-hydroxy-tryptamine			
N-acetyl-psilocybin			
N-acetyl-psilocin			

Enzymes and regulatory proteins, and abbreviations, in use of or contained within systems and methods herein are provided in Table 2.

Table 2

Enzymes and Regulatory Proteins		
INMT = Indolethylamine-N-methyltransferase; tryptamine		
N-methyltransferase		
IOMT = indole-O-methyltransferase; hydroxytryptamine		
O-methyltransferase		

CaffOMT = caffeic acid-O-methyltransferase			
T5H = tryptamine 5' hydroxylase			
TrpM = tryptophan N-methyltransferase			
PsiM = psilocybin synthase			
AADC = Aromatic amino acid decarboxylase; tryptophan			
decarboxylase			
TPH - tryptophan hydroxylase			
T4H = tryptamine 4' hydroxylase			
T4H-CPR, T5H-CPR = chimeras with cytochrome p450			
reductase			
NAT = N-acetyltransferase			
DAC = deacetylase			
BH4syn = Tetrahydrobiopterin synthesis			
BH4reg = Tetrahydrobiopterin regeneration			
PsiK = hydroxy tryptamine kinase			
TrpS = tryptophan synthase			
TMO = toluene monooxygenase			
ΛΤΜΤ = aminotransferase/methyltransferase fusion			
oxidase = multi-copper oxidase			
DMATS = dimethylallyltryptophan synthase			
IDI1 = isopentenyl-diphosphate isomerase			
TrpHalo = tryptophan halogenase			
T5H-IOMT fusion polypeptide			
AOQS = aspartate oxidase/quinolinic acid synthase fusion			
TAT2 = tryptophan importer			
MUP1 = methionine importer			
SAM3 = SAMe importer			
FEX1 = fluoride exporter			

The present invention is directed to biosynthetic production of molecules that are analogs of indoles, tryptophans, and tryptamines, which can also serve as precursors to larger tryptamine

alkaloids, such as tryptamines and tryptophans modified by hydroxylation, halogenation, methylation, phosphorylation, prenylation, and halogenation in recombinant organisms.

FIG. 1 shows the chemical structures of tryptophan (top left) and tryptamine (top right), along with enzyme modifications at specific reaction sites of the tryptophan molecule. Tryptophan is the precursor to a wide array of complex natural products. The electron-rich indole of tryptophan is a weak base. These properties allow for enhanced reactivity as a substrate for numerous enzymes that perform but are not limited to the following activities: methylation, halogenation, prenylation, hydroxylation, isonitrile synthesis, nitration, O-phosphorylation, O-methylation, O-acetylation, N-acetylation, glycosylation, sulfation, cleavage, deamination, decarboxylation, and oligomerization of the molecule. This diverse array of indole intermediates provides a way to tune psychedelic effects. For example, 5-MeO-DMT is reported to be more potent than DMT in neural rodent studies (Lima da Cruz, Rafael Vitor, et al.).

FIG. 2 shows examples of various substituted indole compounds in the tryptamine and tryptophan pathways utilized in the present invention. Panel A depicts the indole ring structure with positional numbering, and tryptophan and tryptamine. Examples of 5-hydroxy modified tryptophan and tryptamine compounds are shown in Panel B; Panel C shows examples of modified 5-hydroxy tryptamines. Additionally, Panel D shows examples of modified 4-hydroxy tryptamines.

By engineering various enzymes and regulatory proteins into a microorganism, tryptophan, tryptamine and other substituted indoles can be modified into a large array of useful compounds, which can be harvested from cultures of the microorganisms.

As depicted in FIG. 3, the *de novo* biosynthesis pathway of L-tryptophan and SAMe are utilized as directing molecules in the systems and methods herein. The directing molecules lead to target molecules of the substituted indoles and tryptamine pathways, when on-pathway. In the systems and methods herein, glycolysis leads to chorismate via the shikimate pathway; glutamate biosynthesis pathway leads to L-glutamine via L-glutamate; and L-serine biosynthesis pathway leads to L-serine via 3-phospho-L-serine (i.e., dephosphorylation). Chorismate, glutamine, and L-serine are combined to form L-tryptophan as a directing molecule to be steered on-pathway for yielding substituted indoles and tryptamine pathways. In the systems and methods herein, L-methionine is a direct precursor leading to SAMe, when combined with ATP in the presence of Sam2 and Adk1 enzymes. A conversion cycle for yielding SAMe as a directing molecule also

involves the formation of S-adenyl-L-homocysteine; S-ribosyl-L-homocysteine; 4-5-dihydroxy-2,3-pentanedione; and homocysteine.

Nucleic acids

Thus, in some embodiments, provided is a non-naturally occurring nucleic acid comprising a sequence encoding an enzyme or regulatory protein in tryptamine metabolism, where the enzyme or regulatory protein is an N-methyltransferase (INMT, PsiM, TrpM), a tryptophan decarboxylase (AADC), a tryptophan hydroxylase (TPH), a tryptamine 4' hydroxylase (T4H), a tryptamine 5' hydroxylase (T5H), a truncated cytochrome p450 reductase (T4H-CPR, T5H-CPR), an hydroxytryptamine O-methyltransferase (IOMT or CaffOMT), an N-acetyltransferase (NAT), a deacetylase (DAC), a hydroxyl tryptamine kinase (PsiK), a tryptophan synthase (TrpS), a toluene monooxygenase (TMO), an aminotransferase/methyltransferase fusion (ATMT), a phosphatase, an oxidase, a dimethylallyltryptophan synthase (DMAT or DMATS), an isopentenyl-diphosphate isomerase (IDI1), a tryptophan halogenase (TrpHalo), an aspartate oxidase/quinolinic acid synthase fusion (AOQS), a tryptophan importer (TAT2), a methionine importer (MUP1), or a SAMe importer (SAM3).

These enzymes and regulatory proteins are further characterized as follows.

Indolethylamine N-methyltransferase (INMT) catalyzes the alkylation (i.e., adding a methyl (CH₃) group) of the primary amine on a tryptamine substrate. The methylation reaction uses up the methyl donor cofactor, SAMe (see FIG. 4, Panels A and C). As an example of INMT activity, INMT can act on serotonin to create 5-OH-DMT (bufotenine) or tryptamine to create DMT (FIG. 4, Panels A and C; FIG. 10, Panel A).

Indole-O-methyltransferase (IOMTor CaffOMT) catalyzes the alkylation of the primary amine on the 5-hydroxy moiety on an indole ring. The methylation reaction uses up the methyl donor cofactor, SAMe (FIG. 4, Panel D). As an example of IOMT activity, IOMT can act on bufotenine (5-OH-DMT) to create 5-MeO-DMT, or N-acetylserotonin to create melatonin (FIG. 4, Panel D).

Tryptamine 5' hydroxylase (T5H) is a p450 tryptamine hydroxylase which prefers hydroxylation at the 5' position of the indole ring, such as generating serotonin from tryptamine (FIG. 4, Panel E), in conjunction with the cofactors NAD(P)H, FMN, and FAD+. P450s such as the T5Hs are generally membrane-associated, with the N-termini imparting an effect on the efficiency of the p450 enzymatic function, including a p450's interaction with an associated CPR, which assists with electron transfer.

FIG. 5 shows a matrix of various compounds that can be made with INMT, IOMT and T5H.

Tryptophan methyltransferase (TrpM) catalyzes the alkylation of the primary amine of L-tryptophan to produce N-methyltryptophan (NMTP, also called L-abrine), the mono-methylated product; N,N-dimethyltryptophan (DMTP), the di-methylated product; and N,N,N-trimethyltryptophan (TMTP), the tri-methylated product. See FIG. 6, Panel A.

Psilocybin synthase (PsiM) is an N-methyltransferase that prefers a substituted tryptamine, such as the phosphorylated tryptamine, norbaeocystin. Novel chimeric PsiMs, were generated to remove potentially deleterious regulatory regions of the enzymes by swapping PsiM domains with the related small rRNA methyltransferases from Ascomycota, the phylum of *S. cerevisiae*.

Aromatic amino acid decarboxylase or tryptophan decarboxylase (AADC) catalyzes the decarboxylation of an aliphatic carboxylic acid (i.e., releases carbon dioxide) from compounds such as L-tryptophan to create tryptamine, 5-HTP to create serotonin; 5-OH-DMTP to create bufotenine; and 5-MeO-DMTP to create 5-MeO-DMT, as depicted in FIG. 6, Panel B.

Tryptophan hydroxylase (TPH), adds a hydroxy group to the 5-carbon of L-tryptophan. The L-tryptophan hydroxylase can catalyze the OH addition to the 5-carbon with the cofactor BH4 and oxygen (Biotechnol J. 2016 May;11(5):717-24) (FIG. 6, Panel A). BH4 is synthesized and regenerated in the cell with the BH4syn and BH4reg heterologous enzymes described herein. The BH4syn genes are enzymes that function as a GTP hydroxylase I, a 6-pyruvoyl-tetrahydropterin synthase, and a sepiapterin reductase to generate the BH4 cofactor necessary for TPH enzyme function. The BH4reg genes are enzymes that function as a 4a-hydroxytetrahydropterin dehydratase and a 6-pyruvoyl-tetrahydropterin synthase to regenerate the BH4 cofactor after conversion to HTHB by the TPH enzyme. As an example of TPH activity, TPH can act on L-tryptophan to generate 5-hydroxy-L-tryptophan (5-HTP), and 5-HTP can then be acted on by an AADC to generate serotonin.

Tryptamine 4' hydroxylase (T4H) is a p450 tryptamine hydroxylase which prefers hydroxylation at the 4' position of the indole ring, in conjunction with the cofactors NAD(P)H, FMN, and FAD+. When derived from psychedelic mushrooms, these are also called PsiH. The T4H enzyme can convert tryptamine to 4-OH-tryptamine, which is a part of the psilocybin pathway. P450s such as the T4Hs are generally membrane-associated, with the N-termini imparting an effect on the efficiency of the p450 enzymatic function, including a p450's interaction with an associated CPR, which assists with electron transfer.

From psychedelic a mushroom derived PsiH and CPR, we generated chimeric p450s and CPRs to better match a heterologous host (SEQ ID NO:162, 179-180, and 451, 468-469), where the N termini of a yeast p450 and CPR replaced the N terminus. Due to the enhancing action of CPRs on p450 enzymatic activity, we determined an optimal fusion between T4H and T4H_CPR, where the T4H_CPR listed are truncated at the N termini and replaced with a linker region. In some embodiments, the T4H nucleic acids have, at the 3' end, an optimized nucleic acid encoding a T4H_CPR, e.g., having SEQ ID NOs:171-180, joining the sequences together to form a fusion polypeptide, e.g., having the amino acid sequence of SEQ ID NOs:460-469 fused at the C terminus of the enzyme polypeptide, generating recombinant T4H-CPR fusion polypeptides.

Similar to the T4H CPR fusions, we generated T5H CPR fusions to enhance the hydroxylation activity. In those embodiments, the T5H nucleic acids have, at the 3' end, an optimized nucleic acid encoding a T5H-CPR, e.g., having **SEQ ID NOs:181-192**, joining the sequences together to form a fusion polypeptide, e.g., having the amino acid sequence of **SEQ ID NOs:470-481** fused at the C terminus of the enzyme polypeptide, generating recombinant T5H-CPR fusion polypeptides.

Examples of the utilization of the T4H-CPR and T5H-CPR in recombinant cells are shown in FIG. 9, Panels C and D; FIGS. 11 and 12; FIG. 13, Panel B; FIG. 14, Panel B; and FIG. 15, Panel B.

Localizing O-methyltransferase activity to hydroxylation can be beneficial for generating methoxytryptamines, such as 5-MT, 5-MeO-DMT, and melatonin. In some embodiments, the T5H nucleic acids have, at the 3' end, an optimized nucleic acid encoding an IOMT e.g., having **SEQ ID NOs:99-130**, joining the sequences together to form a fusion polypeptide, e.g., having the amino acid sequence of **SEQ ID NOs:388-419** fused at the C terminus of the enzyme polypeptide, generating recombinant T5H-IOMT fusion polypeptides.

In all of the fusions described herein, the N-terminal coding sequence has any STOP codon removed, if present, before fusion to a C-terminal coding sequence. If the N-terminal coding sequence does not have a START (ATG) codon, a START codon is added.

N-acetyltransferase (NAT) adds an acetyl group from acetyl-CoA to the terminal amino group of e.g., a tryptamine such as serotonin (FIG. 4, Panel F; FIG. 7, Panels C and D). As an example of NAT activity, NAT can act on serotonin to generate N-acetylserotonin, which in turn can be acted on by an IOMT to generate melatonin (FIG. 11).

Deacetylase (DAC) removes an acetyl group from the terminal amino group of a tryptamine such as melatonin. As an example of DAC activity, DAC can act on melatonin to create 5-MeO-tryptamine, which in turn can be acted on by an INMT to generate 5-MeO-DMT (FIG. 10, Panel B).

Hydroxy tryptamine kinase (PsiK) phosphorylates a hydroxy-indole, in conjunction with ATP. For example, PsiK can act on 4-OH tryptamine to generate norbaeocystin as part of the psilocybin pathway. PsiKs are found in certain mushrooms and parasitic fungi. For psychedelic mushroom derived PsiKs, we generated chimeric PsiKs based on yeast choline kinase to better match a heterologous host.

Non-natural tryptamine analogs can be created with the addition of a synthetic precursor to the fermentation of a recombinant host expressing enzymes capable of utilizing the substrate. For example, the addition of an alpha-methylated amino acid such as alpha-methyl tryptophan to a fermentation where an organism expresses a an indole-N-methyltransferase (INMT) leads to the generation of alpha-methylated DMT (e.g., FIG. 13).

For certain indole ring modifications, such as non-natural indoles, bacterial tryptophan synthases (TrpS) can be used to combine an indole with L-serine or L-threonine to create variants of tryptophan and beta-methyl tryptophan, respectively (FIG. 14, Panel A). While previous groups have made use of the flexibility of versions of bacterial tryptophan synthases to generate exotic tryptamines (De novo Biosynthesis of "Non-Natural" Thaxtomin Phytotoxins. Angew Chem Int Ed Engl. 2018 Jun 4;57(23):6830-6833), efficient bioproduction is limited by the toxic nature of indole. In one embodiment, TrpS is expressed as a modified secreted fusion polypeptide version of the *Salmonella* tryptophan synthase that is able to combine indole or a modified indole with L-serine or L-threonine in the extracellular space, allowing indole conversion away from the cell host. In some embodiments, a multidrug efflux exporter such as mdtEF (accessions: P37636, P37637) can be coexpressed with TrpS with exogenous indole, to enable the host cell to export indole and continue bioproduction of tryptophan and tryptamine analogs.

Alternatively to T4H, T5H, and TPH enzymes, hydroxylation of the indole ring of tryptamines and related indole-like compounds can be carried out by complexes known as toluene-monooxygenases (TMO) typically found in bacteria within the genus *Pseudomonas*. The polypeptides that form this complex can be expressed in a modified host as an alternative to P450-based hydroxylation for compounds such as psilocybin and aeruginascin, whose biosynthetic pathway involves 4'OH hydroxylation. Other non-P450 monooxygenases from genuses of

Pseudomonas and Burkeholderia can be optimized and expressed in a modified host for hydroxylation of different indole positions, such as the 3' carbon of the indole ring. TMO complexes are made up of several subunits. For efficient expression of TMOs in a recombinant heterologous host, we generated fusion polypeptide pairs of the four core subunits.

Beta-methylated tryptamine analogs are created by combined expression of a recombinant aminotransferase-methyltransferase (ATMT) fusion polypeptide and an aromatic amino acid decarboxylase (AADC) (FIG. 15). In nature, organisms which produce beta-methyl tryptophan typically express the aminotransferase (AT) and the methyltransferase (MT) as separate genes. Recombinant ATMT genes herein encode both domains as a single polypeptide. Combinatorial expression of ATMTs and other tryptamine modifying genes can be used to create compounds such as beta-methylated DMT and beta-methylated psilocybin.

In some embodiments, recombinant phosphatases and oxidases are used to generate hydroxylated tryptamine dimers such as one psilocin or bufotenine molecule conjugated to another psilocin or bufotenine molecule (FIG. 16). When certain psychedelic mushrooms which contain compounds such as psilocybin are damaged and cellular compartments compromised, phosphatases and oxidases, such as laccases or laccase-like multi-copper oxidases, can then come in contact with tryptamine substrate to dephosphorylate and catalyze hydroxy tryptamine polymerization. Similar polymerization which leads to 'blueing' can occur when psilocybin comes into contact with mitochondria. (Levine, Walter G), In some embodiments, the phosphatase is a recombinant alkaline phosphatase, which dephosphorylates phosphorylated tryptamines and tryptophans (FIG. 16, Panel A), such as psilocybin to psilocin. In some embodiments, the oxidase is a non-laccase member of the multi-copper oxidase superfamily, which creates hydroxy tryptamine radicals which catalyze polymerization (FIG. 16, Panel B). This dimer example and oligomerization of hydroxylated tryptamines can generate a blue color, lending the effect to colorimetric readout for compound production. Dimer variants and other oligomerized tryptamines can be separated from each other through chromatographic methods for purification. Efficient heterologous expression of certain oxidases such as laccases presents several challenges, such as N and C termini processing which may fail in a heterologous host. In some embodiments, to improve heterologous oxidase expression to biosynthetically produce tryptamine dimers and oligomers, we engineered chimeric oxidase yeast oxidase. Example includes SEQ ID NO:274,563 In one embodiment, the oxidases are also coexpressed with the yeast t-SNARE, SSO2, to improve protein expression, processing, and secretion for active enzyme SEQ ID NO:170,459.

Dimethylallyl tryptophan synthase (DMATS or DMAT) generates prenylated tryptophans and tryptamines. DMATS is a prenyltransferase that prefers the dimethylallyl diphosphate (DMAPP) prenyl donor to prenylate tryptophan and tryptamine compounds.

Localizing DMAPP generation to the DMATS enzyme can be beneficial for generating prenylated tryptophans, such as 7-dimethylallyltryptophan. In yeast, IDI1 is the enzyme which generates DMAPP as part of the mevalonate pathway. In some embodiments, the DMATS nucleic acids have, at the 3' end, an optimized nucleic acid encoding IDI1 e.g., having SEQ ID NO:67, joining the sequences together to form a fusion polypeptide, e.g., having the amino acid sequence of SEQ ID NO:356 fused at the C terminus of the enzyme polypeptide, generating recombinant DMATS-IDI1 fusion polypeptides (FIG. 8, Panel C).

Tryptophan halogenase (TrpHalo) is a flavin-associated halogenase that adds fluorine (F), chlorine (Cl), bromine (Br), and/or iodine (I) to various indoles and biogenic amines (FIG. 8, Panel A). In some embodiments, TrpHalo nucleic acids have, at the 5'end, a nucleic acid encoding an vacuolar localization tag to localize TrpHalo to a yeast vacuole, where Cl ions are stored, e.g., having SEQ ID NOs:287-289, joining the sequences together to form a fusion polypeptide, e.g., having the amino acid sequence of SEQ ID NOs:576-578 fused at the N terminus of the enzyme polypeptide, generating recombinant fusion polypeptides.

In other embodiments, TrpHalo nucleic acids have, at the 5'end, a nucleic acid encoding a secretion tag with or without a 6xHIS tag for purification, e.g., having SEQ ID NO:1, joining the sequences together to form a fusion polypeptide, e.g., having the amino acid sequence of SEQ ID NO:290 fused at the N terminus of the enzyme polypeptide, generating recombinant fusion polypeptides. In one embodiment, TrpHalo is also coexpressed with the yeast fluoride exporter, Fex1, SEQ ID NO:66,355, to limit halide toxicity on the heterologous host.

To improve the yield of tryptophan and tryptamine variants discussed herein, modifying the heterologous host which expresses these genes and enzymes, in various combinatorial ways, to prevent tryptophan and tryptamine compound degradation is beneficial. Replacing the yeast pathway which degrades certain tryptamine and tryptophan compounds for *de novo* NAD+ production, which is an important source of cofactors for cell viability, with an alternative route to NAD+ production can preserve tryptophan as a precursor and increase product yields. In some embodiments, a new *de novo* pathway is expressed in a heterologous host, where the pathway is composed of a fusion protein containing the two enzymatic functions required to convert the amino

acid aspartate into quinolinic acid (AOQS), SEQ ID NO: 26-27,315-316, which replaces the endogenous use of tryptophan for generating quinolinic acid in the pathway for NAD+.

In some embodiments, the nucleic acids have, at the 5' end, a nucleic acid encoding codon optimized cofolding peptides to create a fusion protein, e.g., having SEQ ID NOs:256-269, joining the sequences together to form a fusion polypeptide, e.g., having the amino acid sequence of SEQ ID NOs:554-558 fused at the N terminus of the enzyme polypeptide, generating recombinant fusion polypeptides.

In some embodiments, the nucleic acids have, at the 5' end, a nucleic acid encoding a secretion signal, creating a secreted protein, e.g., having SEQ ID NOs:282-286, joining the sequences together to form a fusion polypeptide, e.g., having the amino acid sequence of SEQ ID NOs:571-575 fused at the N terminus of the enzyme polypeptide, generating recombinant fusion polypeptides.

In some embodiments, the nucleic acids have, at the 5' or 3' end, an optimized nucleic acid encoding a localization scaffold composed of multiple domains where proteins tagged with affibodies can bind and colocalize together (for example, FIG. 11, Panel A; FIG. 12, Panel A), creating a protein scaffold fusion, e.g., having SEQ ID NO:281, joining the sequences together to form a fusion polypeptide, e.g., having the amino acid sequence of SEQ ID NO:570 fused at the N or C terminus of the enzyme polypeptide, generating recombinant fusion polypeptides.

In some embodiments, the nucleic acids have, at the 5' or 3' end, an optimized nucleic acid encoding an affibody tag that can bind one of the domains of the localization scaffold, thereby colocalizing multiple enzymes and creating protein scaffold fusion, e.g., having SEQ ID NOs:259-264, joining the sequences together to form a fusion polypeptide, e.g., having the amino acid sequence of SEQ ID NOs:548-553 fused at the N or C terminus of the enzyme polypeptide, generating recombinant fusion polypeptides.

The initial substrates for DMTP, DMT, and related compound production are L-tryptophan and S-Adenosyl-L-methionine (SAMe). The initial substrate can be produced endogenously in a recombinant host as described and/or provided exogenously to a fermentation involving a recombinant host, whereby the host uptakes the starting substrates to feed into the biosynthetic pathway for indoles and tryptamines. The recombinant hosts herein described that are expressing all, one, or multiple combinations of the engineered INMT, AADC, TPH, T4H, T5H, T4H-CPR, T5H-CPR, IOMT, NAT, DAC, PsiK, TrpS, TMO, ATMT, DMATS, IDI1, and TrpHalo genes can produce tryptamine, NMTP, DMTP, TMTP, NMT, DMT, TMT, psilocybin, bufotenine, 5-MeO

DMT, 4-bromo-tryptamine, 4-dimethylallyl tryptamine, alpha-methylated DMTP, beta-methylated DMTP, melatonin, etc.

As depicted in FIGS. 4 and 9, the engineered INMT, IOMT and TrpM and INMT enzymes require a methyl donor in the form of SAMe to act on substrates in the biosynthetic pathway for substituted indoles and tryptamines such as DMTP, DMT, intermediates, and analogs. The methyltransferase activity of TrpM and INMT subsequently convert the methyl donor cofactor SAMe to SAH. Methylations can occur successively with multiple rounds of methyl donor usage. For instance, TrpM can methylate L-tryptophan to produce NMTP and continue to methylate NMTP to DMTP, and then TMTP (FIG. 6, Panel A). Similarly, an INMT can methylate tryptamine to produce NMT, and then continue to methylate NMT to DMT, and then TMT (FIG. 5).

The methylation occurs selectively at the primary amine of L-tryptophan and tryptamine in the presence of TrpM and INMT enzymes. The nitrogen in the heterocycle and hydroxyl group in the carboxylic acid of L-tryptophan are also sites of alkylation, as SAMe is a highly reactive methylating agent. The TrpM enzyme directs methylation such that di-methylation of the primary amine occurs. Using the traditional techniques of organic chemistry where robust methylating agents, such as methyl iodide, trimethyl sulfonium iodide, and dimethyl sulfate, are employed, a mixture of products is formed. The mixture of products may include: mono, di, and tri-methylation of the amine; O-methylation of the carboxylic acid (i.e., the methyl ester), and N-methylation of the indole ring. Separation of these products are tedious and reduces the yield of a desired product. Additionally, SAMe has a primary amine group which may readily undergo intramolecular methylation at the amine. The systems and methods herein in the recombinant host with TrpM and INMT enzymes maintain the structure of SAMe without methylation of the amine of the SAMe prior to methylating the amine of L-tryptophan and tryptamine.

Heterologous pathway enzymes that are expressed to produce substituted indole and tryptamine compounds such as DMTP and DMT use L-tryptophan as a directing molecule. Tryptophan production in cells is normally tightly regulated. Tryptophan accumulation in a recombinant host is increased by: (a) overexpressing feedback-resistant versions of the endogenous tryptophan-producing enzymes; (b) knocking out off-pathway tryptophan-consuming genes and enzymes; and (c) overexpressing a recombinant L-tryptophan transporter. This allows for exogenous tryptophan to be fed to the cells and transported in the recombinant host. These modifications, genes, and methods are disclosed in U.S. Patent Publication 2021/0147888, incorporated by reference.

On-pathway genes and enzymes can be overexpressed for L-tryptophan accumulation. The immediate precursors for L-tryptophan include chorismate, L-serine, and L-glutamine. To increase the on-pathway flux to L-tryptophan and the substituted indole and tryptamine pathway, off-pathway genes which consume L-tryptophan are deleted. The genes that encode the enzymes, Pdc5 and Aro10 are deleted to reduce pathway flux through the pathways that produce aromatic alcohols. The gene encoding the Aro7 enzyme is deleted to reduce production of tyrosine and phenylalanine from L-tryptophan. The genes that encode the enzymes Pdz1 and Pdz2 are also deleted to reduce pathway flux through the pABA production pathway. The gene encoding the enzyme Bna2 is deleted to reduce consumption of L-tryptophan by the kynurenine pathway.

In some embodiments, a recombinant host is modified to increase the accumulation of the methyl donor, SAMe, which is used by the recombinant TrpM and INMT enzymes to methylate indole and tryptamine molecules, such as L-tryptophan and NMT. SAMe accumulation in the recombinant host cell is increased by: (a) overexpressing enzymes to promote conversion of L-methionine to SAMe; (b) deleting off-pathway genes which encode for enzymes that deplete SAMe for unwanted side products; and (c) overexpressing a permease. This enables exogenous L-methionine to be fed to and transported into the cells.

The TrpM and INMT methyltransferase reactions consume one equivalent of adenosine triphosphate (ATP) and of SAMe. SAMe is a robust methyl donor synthesized from methionine and ATP via the L-methionine adenosyltransferase enzyme, Sam2. In various embodiments, Sam2 is overexpressed in a recombinant host to increase the conversion of L-methionine to SAMe. In other embodiments, to support the increased pathway flux and generate more ATP, the adenylate kinase enzyme, Adk1, is overexpressed. In additional embodiments, to increase the uptake of exogenous L-methionine fed into the SAMe pathway, recombinant Mup1 is overexpressed, which is a methionine transporter. SAMe is a precursor molecule for spermidine production and glycogen biosynthesis. To keep SAMe levels high in the pathways of the recombinant host and decrease off-pathway usage of SAMe, the SPE2 gene can be deleted in the recombinant host, thereby blocking the conversion of SAMe to spermidine. Glycogen biosynthesis consumes ATP, which is required for the conversion of L-methionine to SAMe. The gene encoding the enzyme Glc3 can be deleted in the recombinant host, thereby reducing production of glycogen, maintaining higher levels of ATP in the host cell, and increasing on-pathway flux of SAMe for methyltransferase activity.

As depicted in FIG. 5, the engineered INMT, T5H, and IOMT enzymes act on tryptamine substrates to generate hydroxy and methoxy tryptamine analogs such as serotonin, bufotenine (5-

OH-DMT) and 5-MeO-DMT. The initial substrates for this series of reactions includes compounds such as tryptamine and serotonin, which can be produced within a modified cell or added exogenously, in addition to L-tryptophan and S-Adenosyl-L-methionine (SAMe). The initial substrate can be produced endogenously in a recombinant host as described and/or provided exogenously to a fermentation involving a recombinant host, whereby the host uptakes the starting substrates to feed into the biosynthetic pathway for indoles and tryptamines.

As depicted in FIG. 3, de novo biosynthesis pathway of L-tryptophan and SAMe utilize L-tryptophan and SAMe as directing molecules in the systems and methods herein. The directing molecules lead to target molecules of substituted indoles and tryptamine pathways, when on-pathway. In the systems and methods herein, glycolysis leads to chorismate via the shikimate pathway; glutamate biosynthesis pathway leads to L-glutamine via L-glutamate; and L-serine biosynthesis pathway leads to L-serine via 3-phospho-L-serine (i.e., dephosphorylation). Chorismate, glutamine, and L-serine are combined to form L-tryptophan as a directing molecule to be steered on-pathway for yielding substituted indoles and tryptamine pathways. In the systems and methods herein, L-methionine is a direct precursor leading to SAMe, when combined with ATP in the presence of Sam2 and Adk1 enzymes. A conversion cycle for yielding SAMe as a directing molecule also involves the formation of S-adenyl-L-homocysteine; S-ribosyl-L-homocysteine; 4-5-dihydroxy-2,3-pentanedione; and homocysteine.

Heterologous pathway enzymes that are expressed to produce substituted indole and tryptamine compounds such as DMTP and DMT use L-tryptophan as a directing molecule. Tryptophan production in cells is normally tightly regulated. Tryptophan accumulation in a recombinant host is increased by: (a) overexpressing feedback-resistant versions of the endogenous tryptophan-producing enzymes; (b) knocking out off-pathway tryptophan-consuming genes and enzymes; and (c) overexpressing a recombinant L-tryptophan transporter. This allows for exogenous tryptophan to be fed to the cells and transported in the recombinant host. See also U.S. Patent Publication 2021/0147888.

On-pathway genes and enzymes can be overexpressed for L-tryptophan accumulation. The immediate precursors for L-tryptophan include chorismate, L-serine, and L-glutamine. To increase the on-pathway flux to L-tryptophan and the substituted indole and tryptamine pathway, off-pathway genes which consume L-tryptophan may be deleted. In some embodiments, the genes that encode the enzymes Pdc5 and Aro10 are deleted to reduce pathway flux through the pathways that produce aromatic alcohols. In other embodiments, the gene encoding the Aro7 enzyme is deleted

to reduce production of tyrosine and phenylalanine from L-tryptophan. In additional embodiments, the genes that encode the enzymes Pdz1 and Pdz2 are also deleted to reduce pathway flux through the pABA production pathway. In further embodiments, the gene encoding the enzyme Bna2 is deleted to reduce consumption of L-tryptophan by the kynurenine pathway.

In some embodiments, the nucleic acids described herewith encode a polypeptide or oligopeptide having an amino acid sequence that is naturally occurring. In other embodiments, the nucleic acids encode a polypeptide or oligopeptide having an amino acid sequence that is not naturally occurring. The encoded polypeptides or oligopeptides that are not naturally occurring can vary from a naturally occurring polypeptide or oligopeptide, or portion thereof, by a small amount (e.g., one conservative amino acid substitution or a histidine tag) or extensively (e.g., further comprising a fusion peptide, a substituted or added domain from another protein, a scaffold, etc.).

The nucleic acids can be derived from a naturally occurring gene from any source, e.g., any microorganism, protist, plant, or animal.

In some embodiments, the gene for the enzyme or regulatory protein is derived from a bacterium. It is envisioned that an enzyme or regulatory protein derived from any bacterium now known or later discovered can be utilized in the present invention. For example, the bacterium can from phylum Abditibacteriota, including class Abditibacteria, including order be Abditibacteriales; phylum Abyssubacteria or Acidobacteria, including class Acidobacteriia, Blastocatellia, Holophagae, Thermoanaerobaculia, or Vicinamibacteria, including order Acidobacteriales, Bryobacterales, Blastocatellales, Acanthopleuribacterales, Holophagales, Thermotomaculales, Thermoanaerobaculales, or Vicinamibacteraceae; phylum Actinobacteria, including class Acidimicrobiia, Actinobacteria, Actinomarinidae, Coriobacteriia, Nitriliruptoria, Rubrobacteria, or Thermoleophilia, including orders Acidimicrobiales, Acidothermales, Actinomycetales, Actinopolysporales, Bifidobacteriales, Nanopelagicales, Catenulisporales, Corunebacteriales, Cryptosporangiales, Frankiales, Geodermatophilales, Glycomycetales, Jiangellales, Micrococcales, Micromonosporales, Nakamurellales, Propionibacteriales, Pseudonocardiales, Sporichthyales, Streptomycetales, Streptosporangiales, Actinomarinales, Coriobacteriales, Eggerthellales, Egibacterales, Egicoccales, Euzebyales, Nitriliruptorales, Gaiellales, Rubrobacterales, Solirubrobacterales, or Thermoleophilales; phylum Aquificae, including class Aquificae, including order Aquificales or Desulfurobacteriales; phylum Armatimonadetes, including class Armatimonadia, including order Armatimonadales,

Chthonomonadales, Capsulimonadales, Chthonomonadetes, Fimbriimonadia. or Fimbriimonadales; phylum Aureabacteria or Bacteroidetes, including class Armatimonadia, Bacteroidia, Chitinophagia, Cytophagia, Flavobacteria, Saprospiria or Sphingobacteriia, including order Bacteroidales, Marinilabiliales, Chitinophagales, Cytophagales, Flavobacteriales, Saprospirales, or Sphingopacteriales; phylum Balneolaeota, Caldiserica, Calditrichaeota, or Chlamydiae, including class Balneolia, Caldisericia, Calditrichae, or Chlamydia, including order Balneolales, Caldisericales, Calditrichales, Anoxychlamydiales, Chlamydiales, or Parachlamydiales; phylum Chlorobi or Chloroflexi, including class Chlorobia, Anaerolineae, Ardenticatenia, Caldilineae, Thermofonsia, Chloroflexia, Dehalococcoidia, Ktedonobacteria, Thermoflexia, Thermomicrobia, Tepidiformia, or Sphaerobacteridae, including Chlorobiales, Anaerolineales, Ardenticatenales, Caldilineales, Chloroflexales, Herpetosiphonales, Kallotenuales, Dehalococcoidales, Dehalogenimonas, Ktedonobacterales, Thermogenmatisporales, Tepidiformales, Thermoflexales, Thermomicrobiales, Sphaerobacterales; phylum Chrysiogenetes, Cloacimonetes, Coprothermobacterota, Cryosericota, or Cyanobacteria, including class Chrysiogenetes, Coprothermobacteria, Gloeobacteria, or Oscillatoriophycideae, including order Chrysiogenales, Coprothermobacterales, Chroococcidiopsidales, Gloeoemargaritales, Nostocales, Pleurocapsales, Spirulinales, Synechococcales, Gloeobacterales, Chroococcales, or Oscillatoriales; phyla: Eferribacteres, Deinococcus-thermus, Dictyoglomi, Dormibacteraeota, Elusimicrobia, Eremiobacteraeota, Fermentibacteria, or Fibrobacteres, including class Deferribacteres, Deinococci, Dictyoglomia, Elusimicrobia, Endomicrobia, Chitinispirillia, Chitinivibrionia, or Fibrobacteria, including order Deferribacterales, Deinococcales. Thermales, Dictyoglomales, Elusimicrobiales, Endomicrobiales, Chitinspirillales, Chitinvibrionales, Fibrobacterales, or Fibromonadales; phylum Firmicutes, Fusobacteria, Gemmatimonadetes, or Hydrogenedentes, including class Clostridia, Erysipelotrichia, Limnochordia, Negativicutes, Thermolithobacteria, Tissierellia, Fusobacteriia, Gemmatimonadetes, Longimicrobia, including order Bacillales, Clostridiales, Lactobacillales, Borkfalkiales, Halanaerobiales, Natranaerobiales, Thermoanaerobacterales. Erysipelotrichales, Limnochordales. Acidaminococcales, Selenomonadales. Veillonellales, Thermolithobacterales, Tissierellales, Fusobacteriales, Gemmatimonadales, or Longimicrobia; phylum Hydrogenedentes, Ignavibacteriae, Kapabacteria, Kiritimatiellaeota, Krumholzibacteriota, Kryptonia, Latescibacteria, LCP-89, Lentisphaerae, Margulisbacteria, Marinimicrobia, Melainabacteria, Nitrospinae, or Omnitrophica, including class

Ignavibacteria, Kiritimatiellae, Krumholzibacteria, Lentisphaeria, Oligosphaeria, or Nitrospinae, including order Ignavibacteriales, Kiritimatiellales, Krumholzibacteriales, Lentisphaerales, Victivallales, Oligosphaerales, or Nitrospinia; phylum Omnitrophica or Planctomycetes, including class Brocadiae, Phycisphaerae, Planctomycetia, or Phycisphaerales, including order Sedimentisphaerales, Tepidisphaerales, Gemmatales, Isosphaerales, Pirellulales, or Planctomycetales; phylum Proteobacteria including class Acidithiobacillia, Alphaproteobacteria, Betaproteobacteria, Lambdaproteobacteria, Muproteobacteria, Deltaproteobacteria, Epsilonproteobacteria, Gammaproteobacteria, Hydrogenophilalia, Oligoflexia, or Zetaproteobacteria, including order Acidithiobacillales, Caulobacterales, Emcibacterales, Holosporales, Iodidimonadales. Kiloniellales, Kopriimonadales, Kordiimonadales, Magnetococcales, Micropepsales, Minwuiales, Parvularculales, Pelagibacterales, Rhizobiales, Rhodobacterales, Rhodospirillales, Rhodothalassiales, Rickettsiales, Sneathiellales, Sphingomonadales, Burkholderiales, Ferritrophicales, Ferrovales, Neisseriales, Nitrosomonadales, Procabacteriales, Rhodocyclales, Bradymonadales, Acidulodesulfobacterales, Desulfarculales, Desulfobacterales, Desulfovibrionales, Desulfurellales, Desulfuromonadales, Myxococcales, Syntrophobacterales, Campylobacterales, Nautiliales, Acidiferrobacterales, Aeromonadales. Arenicellales. Cardiobacteriales. Alteromonadales. Cellvibrionales, Chromatiales, Enterobacterales, Immundisolibacterales, Legionellales, Methylococcales, Nevskiales, Oceanospirillales, Orbales, Pasteurellales Pseudomonadales, Salinisphaerales, Thiotrichales, Vibrionales, Xanthomonadales, Hydrogenophilales, Bacteriovoracales, Bdellovibrionales, Oligoflexales, Silvanigrellales, or Mariprofundales; phylum Rhodothermaeota, Saganbacteria, Sericytochromatia, Spirochaetes, Synergistetes, Tectomicrobia, or Tenericutes, including class Rhodothermia, Spirochaetia, Synergistia, Izimaplasma, or Mollicutes, including Brachyspirales, Brevinematales, Leptospirales, Rhodothermales. Spirochaetales. Synergistales, Acholeplasmatales, Anaeroplasmatales, Entomoplasmatales, or Mycoplasmatales; phylum Thermodesulfobacteria, Thermotogae, Verrucomicrobia, or Zixibacteria, including class Thermodesulfobacteria, Thermotogae, Methylacidiphilae, Opitutae, Spartobacteria, Verrucomicrobiae, including order Thermodesulfobacteriales, Kosmotogales, Mesoaciditogales, Petrotogales, Thermotogales, Methylacidiphilales, Opitutales, Puniceicoccales, Xiphinematobacter, Chthoniobacterales, Terrimicrobium, or Verrucomicrobiales.

In other embodiments, the gene for the enzyme or regulatory protein is derived from an archaeon. It is envisioned that an enzyme or regulatory protein derived from any archaeon now

known or later discovered can be utilized in the present invention. For example, the archaeon can be from phylum Euryarchaeota, including class Archaeoglobi, Hadesarchaea, Halobacteria, Methanobacteria. Methanococci. Methanofastidiosa. Methanomicrobia. Methanopyri. Nanohaloarchaea. Theionarchaea. Thermococci, or Thermoplasmata, including order Archaeoglobales, Hadesarchaeales, Halobacteriales, Methanobacteriales, Methanococcales, Methanocellales, Methanomicrobiales, Methanophagales, Methanosarcinales, Methanopyrales, Thermococcales, Methanomassiliicoccales, Thermoplasmatales, or Nanoarchaeales; DPANN superphylum, including subphyla Aenigmarcheota, Altiarchaeota, Diapherotrites, Micrarchaeota, Nanoarchaeota, Pacearchaeota, Parvarchaeota, or Woesearchaeota; TACK superphylum, including subphylum Korarchaeota, Crenarchaeota, Aigarchaeota, Geoarchaeota, Thaumarchaeota, or Bathyarchaeota, Asgard superphylum including subphylium Odinarchaeota, Thorarchaeota, Lokiarchaeota, Helarchaeota, or Heimdallarchaeota.

In additional embodiments, the gene for the enzyme or regulatory protein is derived from a fungus. It is envisioned that an enzyme or regulatory protein derived from any fungus now known or later discovered can be utilized in the present invention. This includes but is not limited to the phyla Chytridiomycota, Basidiomycota, Ascomycota, Blastocladiomycota, Ascomycota, Microsporidia, Basidiomycota, Glomeromycota, Symbiomycota, and Neocallimastigomycota. For example, the fungus can be from the phylum Ascomycota, including classes and orders Pezizomycotina, Arthoniomycetes, Coniocybomycetes, Dothideomycetes, Eurotiomycetes, Geoglossomycetes, Laboulbeniomycetes, Lecanoromycetes, Lectiomycetes, Lichinomycetes, Orbiliomycetes, Pezizomycetes, Sordariomycetes, Xylonomycetes, Lahmiales, Itchiclahmadion, Triblidiales, Saccharomycotina, Saccharomycetes, Taphrinomycotina, Archaeorhizomyces, Neolectomycetes, Pneumocystidomycetes, Schizosaccharomycetes, Taphrinomycetes; phylum Basidiomycota including subphyla or classes Pucciniomycotina, Ustilaginomycotina, Wallemiomycetes, and Entorrhizomycetes; subphylum Agaricomycotina including classes Tremellomycetes, Dacrymycetes, and Agaricomycetes; phylum Symbiomycota, including class Entorrhizomycota; subphylum Ustilaginomycotina including classes Ustilaginomycetes and Exobasidiomycetes; phylum Glomeromycota including classes Archaeosporomycetes, Glomeromycetes, and Paraglomeromycetes; subphylum Pucciniomycotina including orders and classes: Pucciniomycotina, Cystobasidiomycetes, Agaricostilbomycetes, Microbotryomycetes, Atractiellomycetes, Classiculomycetes, Mixiomycetes, and Cryptomycocolacomycetes; subphylum incertae sedis Mucoromyceta including orders Calcarisporiellomycota and

Mucoromycota; phylum Mortierellomyceta including class Mortierellomycota; subphylum Entomophthoromycotina including order incertae sedis Entomophthorales; phylum Zoopagomyceta including classes Basidiobolomycota, Entomophthoromycota, Kickxellomycota, and Zoopagomycotina; subphylum incertae sedis Mucoromycotina including orders Mucorales, phylum Endogonales, and Mortierellales; Neocallimastigomycota including class Neocallimastigomycetes; phylum Blastocladiomycota including classes Physodermatomycetes and Blastocladiomycetes; phylum Rozellomyceta including classes Rozellomycota and Microsporidia; phylum Aphelidiomyceta including class Aphelidiomyceta; Chytridiomyceta including classes Chytridiomycetes and Monoblepharidomycetes; and phylum Oomycota including classes or orders Leptomitales, Myzocytiopsidales, Olpidiopsidales, Peronosporales, Pythiales, Rhipidiales, Salilagenidiales, Saprolegniales, Sclerosporales, Anisolpidiales, Lagenismatales, Rozellopsidales, and Haptoglossales.

In additional embodiments, the gene for the enzyme or regulatory protein is derived from the organism below. This includes but is not limited to: Acanthurus tractus, Aplysina aerophoba, Bos Taurus, Bufo bufo, Bufotes viridis, Chrysochloris asiatica, Fukomys damarensis, Homo sapiens, Rattus norvegicus, Rhinella marina, Rhinella spinulosa, Schistosoma mansoni, Xenopus laevis, Xenopus tropicalis, Acacia koa, Arabidopsis thaliana, Brassica oleracea, Citrus sinensis, Hordeum vulgare, Juglans cinereal, Lophophora williamsii, Nymphaea colorata, Oryza sativa, Ricinus communis, Solanum lycopersicum, Sorghum bicolor, Theobroma cacao, and Triticum aestivum.

In some embodiments, the nucleic acids are codon optimized to improve expression, e.g., using techniques as disclosed in US Patent No. 10,435,727. More specifically, optimized nucleotide sequences are generated based on a number of considerations: (1) For each amino acid of the recombinant polypeptide to be expressed, a codon (triplet of nucleotide bases) is selected based on the frequency of each codon in the Saccharomyces cerevisiae genome; the codon can be chosen to be the most frequent codon or can be selected probabilistically based on the frequencies of all possible codons. (2) In order to prevent DNA cleavage due to a restriction enzyme, certain restriction sites are removed by changing codons that cover those sites. (3) To prevent low-complexity regions, long repeats (sequences of any single base longer than five bases) are modified. (2) and (3) are performed recursively to ensure that codon modification does not lead to additional undesirable sequences. (4) A ribosome binding site is added to the N-terminus. (5) A stop codon is added. (6) A localization signal is removed or replaced.

In some of the above embodiments, the nucleic acid provided herein comprises the sequence of any one of SEQ ID NOs:1-289.

In various embodiments, the nucleic acids further comprise additional nucleic acids encoding amino acids that are not part of the included enzymes or regulatory proteins herein. In some of these embodiments, the additional sequences encode additional amino acids present when the nucleic acid is translated, encoding, for example, a cofolding peptide, as previously discussed, or an additional protein domain, with or without a linker sequence, creating a fusion protein. Other examples are localization sequences, i.e., signals directing the localization of the folded protein to a specific subcellular compartment or membrane. Additional nonlimiting examples are an affibody tag, a localization scaffold, a vacuolar localization tag, a secretion signal, and a 6xhis tag.

In some embodiments, the nucleic acid comprises additional nucleotide sequences that are not translated. Nonlimiting examples include promoters, terminators, barcodes, Kozak sequences, targeting sequences, and enhancer elements. Particularly useful here are promoters that are functional in yeast.

Expression of a gene encoding an enzyme or regulatory protein is determined by the promoter controlling the gene. In order for a gene to be expressed, a promoter must be present within 1,000 nucleotides upstream of the gene. A gene is generally cloned under the control of a desired promoter. The promoter regulates the amount of enzyme expressed in the cell and also the timing of expression, or expression in response to external factors such as sugar source.

Any promoter now known or later discovered can be utilized to drive the expression of the enzymes and regulatory proteins described herein. See e.g. http://parts.igem.org/Yeast for a listing of various yeast promoters. Exemplary promoters listed in Table 3 below drive strong expression, constant gene expression, medium or weak gene expression, or inducible gene expression. Inducible or repressible gene expression is dependent on the presence or absence of a certain molecule. For example, the *GAL1*, *GAL7*, and *GAL10* promoters are activated by the presence of the sugar galactose and repressed by the presence of the sugar glucose. The *HO* promoter is active and drives gene expression only in the presence of the alpha factor peptide. The *HXT1* promoter is activated by the presence of glucose while the *ADH2* promoter is repressed by the presence of glucose.

Table 3: Exemplary yeast promoters

Strong constitutive promoters	Medium and weak constitutive promoters	Inducible/repressible promoters
TEF1	STE2	GAL1
PGK1	TPI1	GAL7
PGI1	PYK1	GAL10
TDH3		НО
		HXT1
		ADH2

In various embodiments, the nucleic acid is in an expression cassette, e.g., a yeast expression cassette. Any yeast expression cassette capable of expressing the enzyme in a yeast cell can be utilized.

Additional regulatory elements can also be present in the expression cassette, including restriction enzyme cleavage sites, antibiotic resistance genes, integration sites, auxotrophic selection markers, origins of replication, and degrons.

The expression cassette can be present in a vector that, when transformed into a host cell, either integrates into chromosomal DNA or remains episomal in the host cell. Such vectors are well-known in the art. See e.g. http://parts.igem.org/Yeast for a listing of various yeast vectors.

A nonlimiting example of a yeast vector is a yeast episomal plasmid (YEp) that contains the pBluescript II SK(+) phagemid backbone, an auxotrophic selectable marker, yeast and bacterial origins of replication and multiple cloning sites enabling gene cloning under a suitable promoter (see Table 3). Other exemplary vectors include pRS series plasmids.

Host cells

The present invention is also directed to genetically engineered host cells that comprise the above-described nucleic acids. Such cells may be, e.g., any species of filamentous fungus, including but not limited to any species of *Aspergillus*, which have been genetically altered to produce precursor molecules, intermediate molecules, or cannabinoid molecules. Host cells may also be any species of bacteria, including but not limited to *Escherichia*, *Corynebacterium*, *Caulobacter*, *Pseudomonas*, *Streptomyces*, *Bacillus*, or *Lactobacillus*.

In some embodiments, the genetically engineered host cell is a yeast cell, which may comprise any of the above-described expression cassettes, and capable of expressing the recombinant enzyme encoded therein.

Any yeast cell capable of being genetically engineered can be utilized in these embodiments. Nonlimiting examples of such yeast cells include species of *Saccharomyces*, *Candida*, *Pichia*, *Schizosaccharomyces*, *Scheffersomyces*, *Blakeslea*, *Rhodotorula*, or *Yarrowia*.

These cells can achieve gene expression controlled by inducible promoter systems; natural or induced mutagenesis, recombination, and/or shuffling of genes, pathways, and whole cells performed sequentially or in cycles; overexpression and/or deletion of single or multiple genes and reducing or eliminating parasitic side pathways that reduce precursor concentration.

The host cells of the recombinant organism may also be engineered to produce any or all precursor molecules necessary for the biosynthesis of substituted indoles, tryptophans and tryptamines.

Construction of *Saccharomyces cerevisiae* strains expressing the enzymes and regulatory proteins provided herein is carried out via expression of a gene which encodes for the enzyme. The gene encoding the enzyme can be cloned into vectors with the proper regulatory elements for gene expression (e.g. promoter, terminator) and the derived plasmid can be confirmed by DNA sequencing. As an alternative to expression from an episomal plasmid, the gene encoding the enzyme may be inserted into the recombinant host genome. Integration may be achieved by a single or double cross-over insertion event of a plasmid, or by nuclease-based genome editing methods, as are known in the art e.g. CRISPR, TALEN and ZFR. Strains with the integrated gene can be screened by rescue of auxotrophy and genome sequencing. See, e.g., Green and Sambrook (2012).

FIGS. 9-15 provide nonlimiting examples of host cells utilizing the nucleic acids provided herein.

In some embodiments, the recombinant microorganism expresses TPH, TrpM, and AADC, where the recombinant microorganism produces at least one hydroxy substituted tryptamine compound, e.g., bufotenine, 5-OH-NMT, or 5-OH-TMT (FIG. 9, Panel A).

In other embodiments, the recombinant microorganism expresses TPH, TrpM, AADC, and IOMT, where the recombinant microorganism produces at least one methoxy substituted tryptamine compound, e.g., 5-MeO-NMT, 5-MeO-DMT, or 5-MeO-TMT (FIG. 9, Panel B).

In additional embodiments, the recombinant microorganism expresses AADC, T5H or T5H-CPR and INMT, where the recombinant microorganism produces at least one hydroxy substituted tryptamine compound, e.g., bufotenine, 5-OH-NMT, or 5-OH-TMT (FIG. 9, Panel C).

In further embodiments, the recombinant microorganism expresses AADC, T5H or T5H-CPR, INMT, and IOMT, where the recombinant microorganism produces at least one methoxy substituted tryptamine compound, e.g., 5-MeO-NMT, 5-MeO-DMT, or 5-MeO-TMT (FIG. 9, Panel D).

In other embodiments, the recombinant microorganism expresses TrpM and TPH, where the recombinant microorganism produces at least one hydroxy substituted tryptophan compound, e.g., 5-HTP, 5-OH-NMTP, 5-OH-DMTP or 5-OH-TMTP.

In additional embodiments, the recombinant microorganism expresses TrpM, TPH and IOMT, where the recombinant microorganism produces at least one methoxy substituted tryptophan compound, e.g., 5-MeO-NMTP, 5-MeO-DMTP or 5-MeO-TMTP.

In further embodiments, the recombinant microorganism expresses INMT and T5H, where the recombinant microorganism produces at least one hydroxy substituted tryptamine compound, e.g., bufotenine, 5-OH-NMT, or 5-OH-TMT.

In other embodiments, the recombinant microorganism expresses INMT, T5H and IOMT, where the recombinant microorganism produces at least one methoxy substituted tryptamine compound, e.g., 5-MeO-NMT, 5-MeO-DMT, or 5-MeO-TMT.

In additional embodiments, the recombinant microorganism expresses INMT, where the recombinant microorganism produces at least one hydroxy substituted tryptophan compound, e.g., 5-OH-NMTP, 5-OH-DMTP or 5-OH-TMTP.

In further embodiments, the recombinant microorganism expresses INMT and IOMT, where the recombinant microorganism produces at least one methoxy substituted tryptophan compound, e.g., 5-MeO-NMTP, 5-MeO-DMTP or 5-MeO-TMTP.

In other embodiments, the recombinant microorganism expresses INMT and AADC, where the recombinant microorganism produces at least one hydroxy substituted tryptamine compound, e.g., bufotenine, 5-OH-NMT, or 5-OH-TMT.

In additional embodiments, the recombinant microorganism expresses INMT, AADC and IOMT, where the recombinant microorganism produces at least one methoxy substituted tryptamine compound, e.g., 5-MeO-NMT, 5-MeO-DMT, or 5-MeO-TMT.

In further embodiments, the recombinant microorganism expresses INMT, where the recombinant microorganism produces at least one hydroxy substituted tryptamine compound, e.g., bufotenine, 5-OH-NMT, or 5-OH-TMT.

In other embodiments, the recombinant microorganism expresses INMT and IOMT, where the recombinant microorganism produces at least one methoxy substituted tryptamine compound, e.g., 5-MeO-NMT, 5-MeO-DMT, or 5-MeO-TMT.

In additional embodiments, the recombinant microorganism expresses INMT, where the recombinant microorganism produces at least one methoxy substituted tryptamine compound, e.g., 5-MeO-NMT, 5-MeO-DMT, or 5-MeO-TMT.

As depicted in FIG. 11, in some embodiments, the recombinant microorganism expresses AADC, IOMT, T5H or T5H-CPR, and NAT, where the recombinant microorganism produces a compound in the melatonin pathway, e.g., serotonin or melatonin. In some of these embodiments, the enzymes are on a scaffold to facilitate pathway throughput.

As depicted in FIG. 12, in some embodiments, the recombinant microorganism expresses AADC, T4H or T4H-CPR, PsiK and INMT (PsiM), where the recombinant microorganism produces a compound in the psilocybin pathway, e.g., baeocystin, psilocybin or aeruginascin. In some of these embodiments, the enzymes are on a scaffold to facilitate pathway throughput.

In accordance with the present invention, a recombinant host may also be modified to increase the accumulation of the methyl donor, SAMe, which is used by the recombinant TrpM and INMT enzymes to methylate indole and tryptamine molecules such as L-tryptophan and NMT. SAMe accumulation in the recombinant host cell may be increased by: (d) overexpressing enzymes to promote conversion of L-methionine to SAMe; (e) deleting off-pathway genes that encode for enzymes that deplete SAMe for unwanted side products; and (f) overexpressing a permease, which enables exogenous L-methionine to be fed to and transported into the cells.

The TrpM and INMT methyltransferase reactions consume one equivalent of adenosine triphosphate (ATP) and of SAMe. SAMe is a robust methyl donor synthesized from methionine and ATP via the L-methionine adenosyltransferase enzyme, Sam2. Sam2 may be overexpressed in a recombinant host to increase the conversion of L-methionine to SAMe. To support the increased pathway flux and generate more ATP, the adenylate kinase enzyme, Adk1, may also be overexpressed. To increase the uptake of exogenous L-methionine to feed into the SAMe pathway, recombinant Mup1, which is a methionine transporter, may be overexpressed.

SAMe is a precursor molecule for spermidine production and glycogen biosynthesis. To keep SAMe levels high in the pathways of the recombinant host and decrease off-pathway usage of SAMe, the SPE2 gene may be deleted in the recombinant host, thereby blocking the conversion of SAMe to spermidine. Glycogen biosynthesis consumes ATP, which is required for the conversion of L-methionine to SAMe. The gene encoding the enzyme Glc3 may be deleted in the recombinant host, thereby reducing production of glycogen, maintaining higher levels of ATP in the host cell, and increasing on-pathway flux of SAMe for methyltransferase activity. FIG. 10 depicts a recombinant host modified to express the enzymes enabling uptake and biosynthesis of indole and tryptamine precursors and the enzymes to create tryptamine, DMTP, DMT, and related substituted indole and tryptamine compounds.

Recombinant enzymes and regulatory proteins

The present invention is also directed to a non-naturally occurring enzyme or regulatory protein comprising an amino acid sequence encoded by any of the nucleic acids described above. In some embodiments, the amino acid sequence is 85%, 90%, 95%, 98%, or 100% identical to any one of SEQ ID NO:290-578. In these embodiments, the enzyme or regulatory protein can be isolated *in vitro* and used *in vitro* to provide enzyme activity. Alternatively, as discussed above, the enzyme can be expressed in a recombinant organism, e.g., a microorganism or a plant. In some of these embodiments, the recombinant microorganism is a bacterium, for example an *E. coli*. In other embodiments, the recombinant microorganism is a yeast cell, e.g., a species of Saccharomyces (for example S. cerevisiae), Candida, Pichia, Schizosaccharomyces, Scheffersomyces, Blakeslea, Rhodotorula, Aspergillus or Yarrowia.

Methods

The systems and methods herein include: (i) growing modified recombinant host cells and thereby yielding a recombinant host organism; (ii) expressing engineered indole and tryptamine biosynthesis genes and enzymes in the recombinant host organism; (iii) producing or synthesizing substituted indoles and tryptamines in the recombinant host organism; (iv) fermenting the recombinant host organism; and (v) isolating the substituted indoles and tryptamines from the recombinant host organism. Endogenous pathways of the recombinant host can be modified by the systems and methods herein to produce high purity substituted indoles and tryptamines.

To produce the desired substituted indole, the nucleic acid encoding the enzymes and/or regulatory proteins are introduced into a host cell using standard cell (e.g., yeast) transformation techniques (Green and Sambrook, 2012). Cells are subjected to fermentation under conditions that activate the promoter controlling the synthesis of the enzyme and/or regulatory protein. The broth may be subsequently subjected to HPLC analysis to determine the presence or yield of the desired substituted indole, as in FIGS. 17-24 and 26.

In various embodiments, the host cells are provided with various feedstocks to drive production of the desired substituted indole, e.g., glucose, fructose, sucrose, ethanol, fatty acids, glycerol, molasses, corn steep liquor, dairy, fish waste, etc. for example as discussed in US Patent Application 17/078636.

In some embodiments, for recombinant enzyme purification, the gene encoding the enzyme and/or regulatory protein is cloned into an expression vector such as the pET expression vectors from Novagen, transformed into a protease deficient strain of *E. coli* such as BL21 and expressed by induction with IPTG. The protein of interest may be tagged with an affinity tag to facilitate purification, e.g. hexahistidine, GST, calmodulin, TAP, AP, CAT, HA, FLAG, MBP etc. Coexpression of a bacterial chaperone such as dnaK, GroES/GroEL or SecY may help facilitate protein folding. See Green and Sambrook (2012).

Any of the enzymes and/or regulatory proteins described above can also be produced in transgenic plants, using techniques known in the art (see, e.g., Keshavareddy et al., 2018). In these embodiments, the above-described nucleic acid encoding the enzyme and/or regulatory protein further comprises a promoter functional in a plant. In various embodiments, the nucleic acid is in a plant expression cassette. Any plant capable of being transformed with the nucleic acid can be utilized here. In some embodiments, the plant is a tobacco or cannabis.

Preferred embodiments are described in the following examples. Other embodiments within the scope of the claims herein will be apparent to one skilled in the art from consideration of the specification or practice of the invention as disclosed herein. It is intended that the specification, together with the examples, be considered exemplary only, with the scope and spirit of the invention being indicated by the claims, which follow the examples.

In the examples below, genetically engineered host cells may be any species of yeast herein, including but not limited to any species of *Saccharomyces*, *Candida*, *Schizosaccharomyces*, *Yarrowia*, etc., which have been genetically altered to produce precursor

molecules, intermediate molecules, and psilocybin molecules. Additionally, genetically engineered host cells may be any species of filamentous fungus, including but not limited to any species of *Aspergillus*, which have been genetically altered to produce precursor molecules such as L-tryptophan and substituted indole and tryptamine molecules. Some of the species of yeast herein for the recombinant host organism include but are not limited to: *Schizosaccharomyces cerevisiae*, *Schizosaccharomyces japonicus*, *Schizosaccharomyces pombe*, *Schizosaccharomyces cryophilus*, *Saccharomyces cerevisiae*, *Kluyveromyces lactis*, *Kluyveromyces dobzhanskii*, and *Yarrowia lipolytica*.

In these examples, the gene sequences from gene source organisms are codon optimized to improve expression using techniques disclosed in U.S. Patent 10,435,727.

DNA sequences are synthesized and cloned using techniques known in the art. Gene expression can be controlled by inducible or constitutive promoter systems using the appropriate expression vectors. Genes are transformed into an organism using standard yeast or fungus transformation methods to generate modified host strains (i.e., the recombinant host organism). The modified strains express genes for: (i) producing L-tryptophan, SAMe and precursor molecules to L-tryptophan and SAMe; (ii) increasing an output of L-tryptophan molecules and precursor molecules to L-tryptophan and SAMe molecules; (iii) increasing the import of exogenous L-tryptophan, L-methionine, SAMe and TMG into the host strain; and (iv) the genes for biosynthetic pathways that generate DMT, DMTP, bufotenine, 5-MeO-DMT and all intermediate indole and tryptamine compounds synthesized and described herein. In the presence or absence of exogenous L-tryptophan, L-methionine, SAMe, TMG, 5-HTP, melatonin, and serotonin, fermentations are run to determine if the cell will convert the fed precursors into tryptamine, serotonin, methylated versions of serotonin, melatonin, or methylated versions of melatonin. The L-tryptophan, SAMe, hydroxylation, decarboxylation, and methylation pathway genes herein can be integrated into the genome of the cell or maintained as an episomal plasmid. Samples are: (i) prepared and extracted using a combination of fermentation, dissolution, and purification steps; and (ii) analyzed by HPLC for the presence of directing molecules (e.g., SAMe and L-tryptophan), precursor molecules, intermediate molecules, and target molecules such as bufotenine and 5-MeO-DMT.

Using the systems and methods herein, the genes which can be expressed to encode for a corresponding enzyme or other type of proteins include but are not limited to: ENO2, TAL1, ARO1, ADK1, MUP1, SAM2, MHT1, SAM4, SAM3, TAT2, AADC, TRPM, INMT, TPH, genes

encoding enzymes for the BH4 biosynthesis pathway, genes encoding enzymes for the BH4 regeneration pathway, T5H, IOMT, caffOMT, NAT, DAC, T4H, PsiK, oxidase, phosphatase, TrpHalo, DMAT, T4H-CPR, T5H-CPR, TrpS, and ATMT. For example, the AADC gene is expressed, or overexpressed, to encode for the aromatic amino decarboxylase enzyme; the TRPM gene is expressed to encode for the TrpM enzyme; and so forth. Gene sequences can be determined using standard techniques known in the art, e.g., the techniques disclosed in U.S. Patent 10,671,632.

EXAMPLES

Example 1 - Construction of Saccharomyces cerevisiae platform strains with elevated indole and tryptamine precursors.

The construction of *Saccharomyces cerevisiae* platform strains with elevated metabolic flux towards L-tryptophan is carried out by overexpressing five optimized enzymes in or upstream of the shikimate pathway to make the aromatic compound intermediate, chorismate, and one optimized enzyme in the tryptophan pathway to make L-tryptophan. Further, tryptophan levels in the cell are enhanced with the expression of TAT2, a tryptophan importer, and L-tryptophan supplementation in the media up to 1% mass to volume. Finally, five enzymes are deleted in the cell to decrease off-pathway consumption of the L-tryptophan. The genetically modified host described herein can be the same host used for production of psilocybin and DMT as both production pathways use the precursor, L-tryptophan. A specific description of the strain with elevated L-tryptophan is disclosed in U.S. Patent Publication 2021/0147888.

Example 2 - Construction of Saccharomyces cerevisiae platform strains with synthesis of methyl donor

Construction of *Saccharomyces cerevisiae* platform strains with elevated SAMe production is carried out via expression of SAM2, a SAMe synthetase gene. The SAM2 gene is cloned from *Saccharomyces cerevisiae* using techniques known in the art. The gene can be cloned into vectors with the proper regulatory elements for gene expression (e.g. promoter, terminator) and the derived plasmid can be confirmed by DNA sequencing. As an alternative to expression from an episomal plasmid, the SAM2 gene is inserted into the recombinant host genome. Integration is achieved by a single cross-over insertion event of the plasmid. Strains with the integrated gene can be screened by rescue of auxotrophy and genome sequencing.

Example 3 – Construction of *Saccharomyces cerevisiae* platform strains with elevated methyl donor production

Construction of *Saccharomyces cerevisiae* platform strains with elevated SAMe production via expression of the ADK1, adenylate kinase gene. The ADK1 gene is cloned from *Saccharomyces cerevisiae* using techniques known in the art. The gene can be cloned into vectors with the proper regulatory elements for gene expression (e.g. promoter, terminator) and the derived plasmid can be confirmed by DNA sequencing. As an alternative to expression from an episomal plasmid, the ADK1 gene is inserted into the recombinant host genome. Integration is achieved by a single cross-over insertion event of the plasmid. Strains with the integrated gene can be screened by rescue of auxotrophy and genome sequencing.

Further SAM accumulation for methyl donor availability is achieved herein by engineering the homocysteine to methionine side of the methylation pathway. SAH is generated after methylation of serotonin and other intermediates to produce bufotenine and other compounds described herein. SAH is recycled back to methionine after methyl donation by TMG (trimethylglycine) or betaine. TMG is fed to the cells up to 1% (v/v) in the growth media. Two *Saccharomyces cerevisiae* genes, MHT1 and SAM4 encode the enzymes, Mht1 and Sam4, that are responsible for homocysteine re-methylation using TMG as a methyl donor. MHT1 and SAM4 are overexpressed from a high copy vector with a strong promoter.

Example 4 – Construction of *Saccharomyces cerevisiae* platform strains with enhanced uptake of methyl donor precursors.

Construction of *Saccharomyces cerevisiae* platform strains with elevated SAMe production is carried out via expression of MUP1, the methionine permease gene. The MUP1 gene is cloned from *Saccharomyces cerevisiae* using techniques known in the art. The gene can be cloned into vectors with the proper regulatory elements for gene expression (e.g. promoter, terminator) and the derived plasmid can be confirmed by DNA sequencing. As an alternative to expression from an episomal plasmid, the MUP1 gene is inserted into the recombinant host genome. Integration is achieved by a single cross-over insertion event of the plasmid. Strains with the integrated gene can be screened by rescue of auxotrophy and genome sequencing.

Example 5 – Construction of *Saccharomyces cerevisiae* platform strains with enhanced uptake of methyl donors.

Herein we describe a strategy to increase the SAM accumulation by increasing transport of exogenous SAM into the cell. SAM levels are increased by overexpressing the gene, SAM3. SAM3 encodes for the Sam3 protein, the predominant *Saccharomyces cerevisiae* transporter that is responsible for SAM import. SAM3 is expressed from a high-copy vector with a strong promoter and media is supplemented with 0.5 - 1.0 mM SAMe.

Example 6 – Construction of *Saccharomyces cerevisiae* platform strains with decreased offpathway flux of methyl donors

Construction of *Saccharomyces cerevisiae* platform strains with elevated metabolic flux towards SAMe is carried out via deletion of SPE2 to reduce SAMe decarboxylation. Deletion of SPE2 is performed by replacement of the SPE2 gene with the URA3 cassette in the recombinant host. The SPE2 URA3 knockout fragment, carrying the marker cassette, URA3, and homologous sequence to the targeted gene, SPE2, can be generated by bipartite PCR amplification. The PCR product is transformed into a recombinant host and transformants can be selected on synthetic URA drop-out media. Further verification of the modification in said strain can be carried out by genome sequencing, then analyzed by the techniques disclosed in U.S. Patent 10,671,632.

Example 7 – Construction of *Saccharomyces cerevisiae* platform strains with decreased offpathway flux of methyl donor precursors

Saccharomyces cerevisiae platform strains are constructed with elevated metabolic flux towards SAMe via deletion of GLC3 to reduce ATP consumption. Deletion of GLC3 is performed by replacement of the GLC3 gene with the URA3 cassette in the recombinant host. The GLC3 URA3 knockout fragment, carrying the marker cassette, URA3, and homologous sequence to the targeted gene, GLC3, can be generated by bipartite PCR amplification. The PCR product is transformed into a recombinant host and transformants can be selected on synthetic URA drop-out media. Further verification of the modification in said strain can be carried out by genome sequencing and analyzed by the techniques disclosed in U.S. Patent 10,671,632.

Example 8 – Construction of *Saccharomyces cerevisiae* platform strains with increased Tryptophan accumulation

Saccharomyces cerevisiae platform strains with accumulation of tryptophan are generated by deletion of BNA2. Bna2 is an enzyme necessary for de novo NAD+ production from

tryptophan. Deletion of BNA2 is performed by replacement of the BNA2 gene with the URA3 cassette in the recombinant host. The BNA2 URA3 knockout fragment, carrying the marker cassette, URA3, and homologous sequence to the targeted gene, BNA2, can be generated by bipartite PCR amplification. The PCR product is transformed into a recombinant host and transformants can be selected on synthetic URA drop-out media. Further verification of the modification in said strain can be carried out by genome sequencing and analyzed by the techniques disclosed in U.S. Patent 10,671,632.

Example 9 – Expression of recombinant L-tryptophan methyltransferases in a modified host organism

Construction of *Saccharomyces cerevisiae* NMTP, DMTP, and TMTP production strains is carried out via expression of the TrpM methyltransferase gene. The optimized TrpM gene is synthesized using DNA synthesis techniques known in the art. The optimized gene can be cloned into vectors with the proper regulatory elements for gene expression (e.g. promoter, terminator) and the derived plasmid can be confirmed by DNA sequencing. As an alternative to expression from an episomal plasmid, the optimized TrpM gene is inserted into the recombinant host genome. Integration is achieved by a single cross-over insertion event of the plasmid. Strains with the integrated gene can be screened by rescue of auxotrophy and genome sequencing.

$\begin{tabular}{ll} Example 10-Expression of recombinant aromatic amino acid decarboxylases in a modified host organism \end{tabular}$

Construction of *Saccharomyces cerevisiae* tryptamine production strains is carried out via expression of the AADC gene which encodes the enzyme that converts L-tryptophan to tryptamine. AACD also encodes the enzyme that converts 5HTP to serotonin. This specific conversion may be carried out by the same enzyme encoded by the AADC gene that converts L-tryptophan to tryptamine. It also may be carried out by the gene product of a novel AADC described herein. The optimized AADC gene is synthesized using DNA synthesis techniques known in the art. The optimized gene can be cloned into vectors with the proper regulatory elements for gene expression (e.g. promoter, terminator) and the derived plasmid can be confirmed by DNA sequencing. As an alternative to expression from an episomal plasmid, the optimized AADC gene is inserted into the recombinant host genome. Integration is achieved by a single

cross-over insertion event of the plasmid. Strains with the integrated gene can be screened by rescue of auxotrophy and genome sequencing.

Example 11 – Expression of recombinant L-tryptophan hydroxylases in a modified host organism

Construction of the *Saccharomyces cerevisiae* 5-HTP production strains is carried out via expression of the gene that encodes tryptophan hydroxylase. 5-HTP is a precursor compound for production of serotonin and variants described herein. Tryptophan hydroxylase activity is dependent on the availability of the BH4 cofactor. The optimized TPH, BH4 biosynthesis and BH4 regeneration genes are synthesized using DNA synthesis techniques known in the art. The optimized genes can be cloned into vectors with the proper regulatory elements for gene expression (e.g. promoter, terminator) and the derived plasmid can be confirmed by DNA sequencing. As an alternative to expression from an episomal plasmid, the optimized TPH, BH4 biosynthesis and BH4 regeneration genes are inserted into the recombinant host genome. Integration is achieved by a single cross-over insertion event of the plasmid. Strains with the integrated gene can be screened by rescue of auxotrophy and genome sequencing.

Example 12 – Expression of recombinant tryptamine 5-hydroxylases in a modified host organism

Construction of the *Saccharomyces cerevisiae* serotonin production strains is carried out via expression of the gene that encodes tryptamine 5-hydroxylase (T5H). 5-HT or serotonin is a precursor compound for production of bufotenine and variants described herein. T5H activity is dependent on the availability of the intermediate indole compound, tryptamine, production of which is disclosed in U.S. Patent Publication 2021/0147888 and further described herein.

T5H, as a cytochrome p450-containing monooxygenase, is also dependent on the cytochrome p450 reductase enzyme (CPR) for full activity. The CPR facilitates electron transfer from the NAD(P)H. The optimized T5H and CPR genes are synthesized using DNA synthesis techniques known in the art. The optimized genes can be cloned into vectors with the proper regulatory elements for gene expression (e.g. promoter, terminator) and the derived plasmid can be confirmed by DNA sequencing. As an alternative to expression from an episomal plasmid, the optimized T5H and CPR genes are inserted into the recombinant host genome. Integration is

achieved by a single cross-over insertion event of the plasmid. Strains with the integrated gene can be screened by rescue of auxotrophy and genome sequencing.

Example 13 – Expression of recombinant indolethylamine-N-methyltransferase (INMT) in a modified host organism

Construction of *Saccharomyces cerevisiae* DMT production strains is carried out via expression of the INMT gene which encodes the enzyme that methylates tryptamine to DMT. INMT also encodes the enzyme that converts serotonin to bufotenine. Finally, INMT encodes the enzyme that converts 5-MeO-tryptamine to 5-Meo-DMT. These unique conversions may be carried out by the same enzyme encoded by the INMT gene that converts tryptamine to DMT. It also may be carried out by the gene product of a novel INMT described herein. The optimized INMT gene is synthesized using DNA synthesis techniques known in the art. The optimized gene can be cloned into vectors with the proper regulatory elements for gene expression (e.g. promoter, terminator) and the derived plasmid can be confirmed by DNA sequencing. As an alternative to expression from an episomal plasmid, the optimized INMT gene is inserted into the recombinant host genome. Integration is achieved by a single cross-over insertion event of the plasmid. Strains with the integrated gene can be screened by rescue of auxotrophy and genome sequencing.

Example 14 – Expression of 5-hydroxyindole-O-methyltransferase (IOMT) or caffeic acid-O-methyltransferase (CaffOMT) in a modified host organism

Construction of Saccharomyces cerevisiae 5-MeO-DMT production strains is carried out via expression of the IOMT gene which encodes the enzyme that methylates the 5-OH in bufotenine, an intermediate derived from the INMT conversion of serotonin, described herein. The IOMT gene also encodes for the enzyme that converts serotonin to 5-MeO-tryptamine in the first intermediate to make melatonin. The IOMT enzyme also methylates the 5-OH of N-acetyl-serotonin to generate melatonin as an intermediate to make 5-MeO-tryptamine and further, 5-MeO-DMT. Alternatively, the enzyme that converts serotonin to 5-MeO-tryptamine can be carried out with a CaffOMT enzyme, an enzyme shared with the phenylpropanoid biosynthesis pathway. This same CaffOMT enzyme can also methylate N-acetyl-serotonin to generate melatonin. The optimized IOMT or CaffOMT gene is synthesized using DNA synthesis techniques known in the art. The optimized gene can be cloned into vectors with the proper regulatory elements for gene expression (e.g. promoter, terminator) and the derived plasmid can be confirmed by DNA

sequencing. As an alternative to expression from an episomal plasmid, the optimized IOMT or CaffOMT gene is inserted into the recombinant host genome. Integration is achieved by a single cross-over insertion event of the plasmid. Strains with the integrated gene can be screened by rescue of auxotrophy and genome sequencing.

Example 15 – Expression of recombinant N-acetyl transferase (NAT) and melatonin deacetylase (NAD) in a modified host organism

Construction of *Saccharomyces cerevisiae* 5-MeO-DMT production strains can alternatively be carried out via expression of the two more enzymes, NAT and NAD. NAT acetylation of serotonin produces the intermediate N-acetyl-serotonin or NAS. NAS is converted to melatonin with the IOMT (or CaffOMT) enzyme described herein. DAC deacetylases melatonin to 5-MeO-tryptamine which is converted to 5-MeO-DMT via the INMT enzyme described herein. The optimized NAT and DAC genes are synthesized using DNA synthesis techniques known in the art. The optimized gene can be cloned into vectors with the proper regulatory elements for gene expression (e.g. promoter, terminator) and the derived plasmid can be confirmed by DNA sequencing. As an alternative to expression from an episomal plasmid, the optimized NAT and DAC genes are inserted into the recombinant host genome. Integration is achieved by a single cross-over insertion event of the plasmid. Strains with the integrated gene(s) can be screened by rescue of auxotrophy and genome sequencing.

Example 16 – Construction of *Saccharomyces cerevisiae* platform strains with accumulation of serotonin

Serotonin is the precursor molecule for both bufotenine and 5-MeO-DMT. Construction of a *Saccharomyces cerevisiae* serotonin strain is carried out by expression of AADC and TPH or AADC and T5H genes described herein for the enzymatic conversion of L-tryptophan to serotonin. Exogenous serotonin is also fed to the strains to increase precursor levels at concentrations of 0.5 mM to 2 mM. Exogenous 5-HTP with expression of the AADC gene is fed to the cells as a mechanism to increase the serotonin precursor.

In order to accumulate serotonin in the cell and prevent off pathway conversion of serotonin to unwanted products, the endogenous Saccharomyces cerevisiae gene, PAA1 (YDR071C) is deleted. PAA1 is a polyamine acetyltransferase that would acetylate serotonin and use up valuable acetyl-CoA.

Example 17 – Method of Growth

Modified host cells that yield substituted indoles and tryptamine compounds, such as a bufotenine-producing strain herein, express engineered bufotenine biosynthesis genes and enzymes. More specifically, the bufotenine-producing strain herein is grown in a minimal, complete culture media containing yeast nitrogen base, amino acids, vitamins, ammonium sulfate, and a carbon source of glucose and galactose. The recombinant host cells are grown in 24-well plates or shake flasks in a volume range of 2 mL to 100 mL of media starting from an inoculation density of OD_{600nm}=1. Exogenous serotonin, melatonin, tryptamine, 5HTP, SAMe and TMG can be added to media to supplement the precursor pool for final compound production or support methyl donor accumulation.

Example 18 - Conversion of melatonin to 5-methoxy-tryptamine using a bio-based enzyme factory

Herein we describe a strategy for 5-methoxy-tryptamine (5-MT) production by recombinant expression and secretion of the melatonin deacetylase, DAC in BL21(DE3)pLysS E. coli. The DAC enzyme is cloned into a high-copy vector with key features that allow 1) tight induction by the lactose analog, β -D-thiogalactoside (IPTG) 2) an N-terminal secretory signal peptide [MKKTAIAIAVALAGFATVAQA (SEQ ID NO:286,575)] and 3) C-terminal fusion to a HIS tag for purification. E. coli cells harboring the NAD-expression vector are grown in M9 minimal media with 1% glucose for 18h at 37 °C and shaking at 300 rpm. Concentrated cell culture is diluted to an OD₆₀₀ =1 in fresh M9 minimal media with 1% glucose and 0.2 mM IPTG. After a 3h induction at 18 °C and 300 rpm shaking, melatonin is added to the media at a final concentration of 1-2 mM. Cells are grown at room temperature for 48h, shaking at 300 rpm. Media is collected at 24h and 48h and analyzed by HPLC as described herein.

Alternatively, we describe a strategy for production of the compound, 5-methoxy-tryptamine (5-MT) by recombinant expression and secretion of the melatonin deacetylase, DAC in *Saccharomyces cerevisiae*. The DAC enzyme is cloned into a high-copy vector with key features that allow 1) tight induction by the sugar, galactose 2) an N-terminal alpha factor secretion leader sequence, [MEGVSLEKREAEA (SEQ ID NO:574] and 3) c-terminal fusion to a HIS tag for purification. *Saccharomyces cerevisiae* cells harboring the DAC-expression vector are grown in CM minimal media with 2% glucose for 18h at 30 degrees C and shaking at 300 rpm. Concentrated

cell culture is diluted to an $OD_{600} = 1$ in fresh CM minimal media with 2% galactose. After 24h of induction at 30 degrees C and 300 rpm shaking, melatonin is added to the media at a final concentration of 1-2 mM. Cells are grown at 30 °C and 300 rpm shaking for 48h. Media is collected at 24h and 48h and analyzed by HPLC as described herein.

Alternatively, we describe a strategy for production of the compound, 5-methoxytryptamine (5-MT) by recombinant expression and secretion of the melatonin deacetylase (DAC) in Komagataella phaffii (Pichia pastoris). The DAC enzyme is cloned into a high-copy vector with key features that allow 1) induction by methanol with the AOX1 promoter and 2) a secretion signal consisting of the α-factor pro region. K. phaffii cells harboring the DAC enzyme are inoculated into 5 mL of YPD in a 15-mL culture tube. After a day of incubation at 30 °C with shaking at 220 rpm, an aliquot of the culture is diluted to an OD₆₀₀=0.2 in 5 mL of BMG (buffered minimal glycerol media) in a 15-mL culture tube. This tube is incubated under the same conditions as before. The following day, the culture is centrifuged at 3000 rpm (2000×g) for 5 min and resuspended in 25 mL BMM (buffered minimal methanol media) to attain an $OD_{600} = 1.0$. 25 mL of this culture is placed in a 250-mL baffled flask, and during this induction phase, the cells are incubated at 25 °C with shaking at 150 rpm to reduce loss of methanol. After 1 day of induction, an additional dose of 125 µL methanol is added (yielding a final concentration of 0.5%), melatonin is added to the media at a final concentration of 1-2 mM, and the incubation is continued for another day. After 48 h of induction, media is collected at at 24h and 48h and analyzed by HPLC as described herein.

Example 19 - Conversion of melatonin to 5-methoxy-NMT, 5-methoxy-DMT, and 5-methoxy-TMT using a bio-based enzyme factory

Herein we describe a strategy for 5-MeO-NMT, 5-MeO-DMT, and 5-MeO-TMT production by recombinant expression and secretion of the indolethylamine-N-methyltransferase (INMT) in in BL21(DE3)pLysS $E.\ coli$. The INMT enzyme is cloned into a high-copy vector with key features that allow 1) tight induction by the lactose analog, β -D-thiogalactoside (IPTG) 2) an N-terminal secretory signal peptide [MKKTAIAIAVALAGFATVAQA (SEQ ID NO:574)] and 3) C-terminal fusion to a HIS tag for purification. $E.\ coli$ cells harboring the INMT-expression vector are grown in M9 minimal media with 1% glucose for 18h at 37 °C and shaking at 300 rpm. Concentrated cell culture is diluted to an OD₆₀₀ =1 in fresh M9 minimal media with 1% glucose and 0.2 mM IPTG. After a 3h induction at 18 °C and 300 rpm shaking, melatonin is added to the

media at a final concentration of 1-2 mM and SAMe is added to the media at a final concentration of 1-2 mM. Cells are grown at room temperature for 48h, shaking at 300 rpm. Media is collected at 24h and 48h and analyzed by HPLC as described herein.

Alternatively, we describe a strategy for production of the compounds, 5-MeO-NMT, 5-MeO-DMT, and 5-MeO-TMT by recombinant expression and secretion of the indolethylamine-N-methyltransferase (INMT) in *Saccharomyces cerevisiae*. The INMT enzyme is cloned into a high-copy vector with key features that allow 1) tight induction by the sugar, galactose 2) an N-terminal alpha factor secretion leader sequence, [MEGVSLEKREAEA (SEQ ID NO:574)] and 3) c-terminal fusion to a HIS tag for purification. *Saccharomyces cerevisiae* cells harboring the INMT-expression vector are grown in CM minimal media with 2% glucose for 18h at 30 °C and shaking at 300 rpm. Concentrated cell culture is diluted to an OD₆₀₀ =1 in fresh CM minimal media with 2% galactose. After 24h of induction at 30 °C and 300 rpm shaking, melatonin is added to the media at a final concentration of 1-2 mM and SAMe is added to the media at a final concentration of 1-2 mM. Cells are grown at 30 °C and 300 rpm shaking for 48h. Media is collected at 24h and 48h and analyzed by HPLC as described herein.

Alternatively, we describe a strategy for production of the compounds, 5-MeO-NMT, 5-MeO-DMT, and 5-MeO-TMT by recombinant expression and secretion of the indolethylamine-N-methyltransferase (INMT) in Komagataella phaffii. The INMT enzyme is cloned into a highcopy vector with key features that allow 1) induction by methanol with the AOX1 promoter and 2) a secretion signal consisting of the α -factor pro region. K. phaffii cells harboring the DAC enzyme are inoculated into 5 mL of YPD in a 15-mL culture tube. After a day of incubation at 30 °C with shaking at 220 rpm, an aliquot of the culture is diluted to an OD₆₀₀=0.2 in 5 mL of BMG (buffered minimal glycerol media) in a 15-mL culture tube. This tube is incubated under the same conditions as before. The following day, the culture is centrifuged at 3000 rpm (2000×g) for 5 min and resuspended in 25 mL BMM (buffered minimal methanol media) to attain an $OD_{600} = 1.0.25$ mL of this culture is placed in a 250-mL baffled flask, and during this induction phase, the cells are incubated at 25 °C with shaking at 150 rpm to reduce loss of methanol. After 1 day of induction, an additional dose of 125 µL methanol is added (yielding a final concentration of 0.5%), melatonin is added to the media at a final concentration of 1-2 mM, SAMe is added to the media at a final concentration of 1-2 mM, and the incubation is continued for another day. After 48 h of induction, media is collected at 24h and 48h and analyzed by HPLC as described herein.

Example 20 - Conversion of tryptamine to NMT, DMT, and TMT using a bio-based enzyme factory

Herein we describe a strategy for NMT, DMT, and TMT production by recombinant of the indolethylamine-N-methyltransferase expression and secretion (INMT) BL21(DE3)pLysS E. coli. The INMT enzyme is cloned into a high-copy vector with key features that allow 1) tight induction by the lactose analog, β-D-thiogalactoside (IPTG) 2) an N-terminal secretory signal peptide [MKKTAIAIAVALAGFATVAQA (SEQ ID NO:574)] and 3) C-terminal fusion to a HIS tag for purification. E. coli cells harboring the INMT-expression vector are grown in M9 minimal media with 1% glucose for 18h at 37 °C and shaking at 300 rpm. Concentrated cell culture is diluted to an $OD_{600} = 1$ in fresh M9 minimal media with 1% glucose and 0.2 mM IPTG. After a 3h induction at 18 °C and 300 rpm shaking, tryptamine is added to the media at a final concentration of 1-2 mM and SAMe is added to the media at a final concentration of 1-2 mM. Cells are grown at room temperature for 48h, shaking at 300 rpm. Media is collected at 24h and 48h and analyzed by HPLC as described herein.

Alternatively, we describe a strategy for production of the compounds, NMT, DMT, and TMT by recombinant expression and secretion of the indolethylamine-*N*-methyltransferase (INMT) in *Saccharomyces cerevisiae*. The INMT enzyme is cloned into a high-copy vector with key features that allow 1) tight induction by the sugar, galactose 2) an N-terminal alpha factor secretion leader sequence, [MEGVSLEKREAEA (SEQ ID NO:574)] and 3) c-terminal fusion to a HIS tag for purification. *Saccharomyces cerevisiae* cells harboring the INMT-expression vector are grown in CM minimal media with 2% glucose for 18h at 30 °C and shaking at 300 rpm. Concentrated cell culture is diluted to an OD₆₀₀ =1 in fresh CM minimal media with 2% galactose. After 24h of induction at 30 °C and 300 rpm shaking, tryptamine is added to the media at a final concentration of 1-2 mM and SAMe is added to the media at a final concentration of 1-2 mM. Cells are grown at 30 °C and 300 rpm shaking for 48h. Media is collected at 24h and 48h and analyzed by HPLC as described herein.

Alternatively, we describe a strategy for production of the compounds, NMT, DMT, and TMT by recombinant expression and secretion of the indolethylamine-*N*-methyltransferase (INMT) in *Komagataella phaffii*. The INMT enzyme is cloned into a high-copy vector with key features that allow 1) induction by methanol with the AOX1 promoter and 2) a secretion signal consisting of the α-factor pro region. *K. phaffii* cells harboring the DAC enzyme are inoculated into 5 mL of YPD in a 15-mL culture tube. After a day of incubation at 30 °C with shaking at 220

rpm, an aliquot of the culture is diluted to an OD_{600} =0.2 in 5 mL of BMG (buffered minimal glycerol media) in a 15-mL culture tube. This tube is incubated under the same conditions as before. The following day, the culture is centrifuged at 3000 rpm (2000×g) for 5 min and resuspended in 25 mL BMM (buffered minimal methanol media) to attain an OD_{600} = 1.0. 25 mL of this culture is placed in a 250-mL baffled flask, and during this induction phase, the cells are incubated at 25 °C with shaking at 150 rpm to reduce loss of methanol. After 1 day of induction, an additional dose of 125 μ L methanol is added (yielding a final concentration of 0.5%), tryptamine is added to the media at a final concentration of 1-2 mM, SAMe is added to the media at a final concentration of 1-2 mM, and the incubation is continued for another day. After 48 h of induction, media is collected at at 24h and 48h and analyzed by HPLC as described herein.

Example 21 - Conversion of serotonin to 5-OH-NMT, 5-OH-DMT, and 5-OH-TMT using a bio-based enzyme factory

Herein we describe a strategy for 5-OH-NMT, 5-OH-DMT, and 5-OH-TMT production by recombinant expression and secretion of the indolethylamine-*N*-methyltransferase (INMT) in BL21(DE3)pLysS *E. coli*. The INMT enzyme is cloned into a high-copy vector with key features that allow 1) tight induction by the lactose analog, β-D-thiogalactoside (IPTG) 2) an N-terminal secretory signal peptide [MKKTAIAIAVALAGFATVAQA (SEQ ID NO:574)] and 3) C-terminal fusion to a HIS tag for purification. *E. coli* cells harboring the INMT-expression vector are grown in M9 minimal media with 1% glucose for 18h at 37 °C and shaking at 300 rpm. Concentrated cell culture is diluted to an OD₆₀₀ =1 in fresh M9 minimal media with 1% glucose and 0.2 mM IPTG. After a 3h induction at 18 °C and 300 rpm shaking, serotonin is added to the media at a final concentration of 5 mM and SAMe is added to the media at a final concentration of 1-2 mM. Cells are grown at room temperature for 48h, shaking at 300 rpm. Media is collected at 24h and 48h and analyzed by HPLC as described herein.

Alternatively, we describe a strategy for production of the compounds, 5-OH-NMT, 5-OH-DMT, and 5-OH-TMT by recombinant expression and secretion of the indolethylamine-*N*-methyltransferase (INMT) in *Saccharomyces cerevisiae*. The INMT enzyme is cloned into a high-copy vector with key features that allow 1) tight induction by the sugar, galactose 2) an N-terminal alpha factor secretion leader sequence, [MEGVSLEKREAEA (SEQ ID NO:574)] and 3) c-terminal fusion to a HIS tag for purification. *Saccharomyces cerevisiae* cells harboring the INMT-expression vector are grown in CM minimal media with 2% glucose for 18h at 30 °C and shaking

at 300 rpm. Concentrated cell culture is diluted to an OD_{600} =1 in fresh CM minimal media with 2% galactose. After 24h of induction at 30 °C and 300 rpm shaking, serotonin is added to the media at a final concentration of 5 mM and SAMe is added to the media at a final concentration of 1-2 mM. Cells are grown at 30 °C and 300 rpm shaking for 48h. Media is collected at 24h and 48h and analyzed by HPLC as described herein.

Alternatively, we describe a strategy for production of the compounds, 5-OH-NMT, 5-OH-DMT, and 5-OH-TMT by recombinant expression and secretion of the indolethylamine-Nmethyltransferase (INMT) in Komagataella phaffii. The INMT enzyme is cloned into a high-copy vector with key features that allow 1) induction by methanol with the AOX1 promoter and 2) a secretion signal consisting of the α-factor pro region. K. phaffii cells harboring the DAC enzyme are inoculated into 5 mL of YPD in a 15-mL culture tube. After a day of incubation at 30 °C with shaking at 220 rpm, an aliquot of the culture is diluted to an OD₆₀₀=0.2 in 5 mL of BMG (buffered minimal glycerol media) in a 15-mL culture tube. This tube is incubated under the same conditions as before. The following day, the culture is centrifuged at 3000 rpm (2000×g) for 5 min and resuspended in 25 mL BMM (buffered minimal methanol media) to attain an $OD_{600} = 1.0$. 25 mL of this culture is placed in a 250-mL baffled flask, and during this induction phase, the cells are incubated at 25 °C with shaking at 150 rpm to reduce loss of methanol. After 1 day of induction, an additional dose of 125 µL methanol is added (yielding a final concentration of 0.5%), serotonin is added to the media at a final concentration of 5 mM, SAMe is added to the media at a final concentration of 1-2 mM and the incubation is continued for another day. After 48 h of induction, media is collected at 24h and 48h and analyzed by HPLC as herein.

Example 22 - Purification of recombinant INMT enzyme to use for in vitro reactions

The INMT enzyme is cloned into a high-copy vector with key features that allow 1) tight induction by the lactose analog, β -D-thiogalactoside (IPTG) 2) an N-terminal secretory signal peptide [MKKTAIAIAVALAGFATVAQA (SEQ ID NO:574] and 3) C-terminal fusion to a HIS tag for purification. *E. coli* cells harboring the INMT-expression vector are grown in M9 minimal media with 1% glucose for 18h at 37 °C and shaking at 300 rpm. Concentrated cell culture is diluted to an OD₆₀₀ =1 in fresh M9 minimal media with 1% glucose and 0.2 mM IPTG and grown for 48h.

The supernatant containing the recombinant proteins is equilibrated in binding buffer (50 mM sodium phosphate, 0.5 M NaCl, 20 mM imidazole, 10% glycerol, 10 mM 2-mercaptoethanol,

1 mM PMSF, Complete EDTA-free (1 tablet/100 ml), 20 mM 1-phenyl-2- thio-urea; pH 7.4) and centrifuged at 2,500g for 5 min to remove insoluble matter. Then the supernatant is filtered through a 0.45 μm filter (Millipore, MA, USA) and applied onto a HisTrap HP column (GE Healthcare Bioscience). The recombinant proteins are eluted with a step gradient of imidazole (concentrations of 5, 20, 40 and 300 mM). Fractions are analyzed by SDS-PAGE and stored at -80 °C before use.

Example 23 - In vitro reactions with purified INMT enzyme or INMT lysate

Purified INMT protein is resuspended in activity buffer [100 mM sodium phosphate buffer, pH 6.55, PMSF (1mM), EDTA-free protease inhibitor] cocktail at working concentration (Roche, Meylan, France) for use in *in vitro* assays. 0.1 mg/mL of INMT protein is added to a tube with a final volume of 600 uL per sample and added to 100 mM sodium phosphate buffer (pH 7.5), 2 mM tryptamine, serotonin, or melatonin, 2 mM S-adenosylmethionine, and 5 mM MgCl₂.

Alternatively, 0.1 mg/mL BSA protein-equivalent of INMT lysate is used in the same reaction. INMT lysate is derived from $E.\ coli$ cells harboring the INMT-expression vector. They are grown in M9 minimal media with 1% glucose for 18h at 37 °C and shaking at 300 rpm. Concentrated cell culture is diluted to an OD₆₀₀ =1 in fresh M9 minimal media with 1% glucose and 0.2 mM IPTG and grown for 48h. Cell pellets are resuspended in 100 mM sodium phosphate buffer at pH 7.5 and lysed using sonication. After lysis, samples are pelleted by centrifugation (16,000g, 4 °C, 20 min) and supernatant containing INMT is harvested.

Example 24 – Method of Growth

Modified host cells that yield substituted indoles and tryptamine compounds, such as the DMTP-producing strain herein, express engineered DMTP biosynthesis genes and enzymes. More specifically, the DMTP-producing strain herein is grown in a minimal, complete culture media containing yeast nitrogen base, amino acids, vitamins, ammonium sulfate, and a carbon source of glucose and galactose. The recombinant host cells are grown in 24-well plates or shake flasks in a volume range of 2 mL to 100 mL of media starting from an inoculation density of OD600nm=1. Exogenous L-tryptophan and L-methionine up to 1% can be added to media to supplement the precursor pool for DMTP production. Exogenous L-tryptophan can be taken up by strains expressing the TAT2 L-tryptophan importer protein. Exogenous L-methionine can be taken up by strains expressing the MUP1 L-methionine permease protein. The strains herein can be harvested

during a fermentation period ranging from 12 hours onward from the start of pathway enzyme induction.

Example 25 – Detection of Isolated Product

To identify fermentation-derived tryptamine, DMTP, NMT, DMT, and all other products of a recombinant host expressing an engineered biosynthetic pathway for substituted indoles (see Fig. 11), an Agilent 1100 series liquid chromatography (LC) system equipped with a HILIC column (Primesep 100, SIELC, Wheeling, IL USA) is used. A gradient is used of mobile phase A (ultraviolet (UV) grade H₂O+0.2% TFA) and mobile phase B (UV grade acetonitrile+0.2% TFA). Column temperature is set at 40 °C. Compound absorbance is measured at 270 nm using a diode array detector (DAD) and spectral analysis from 200nm to 400nm wavelengths. A secondary wavelength of 315 nm is used to selectively detect 4-hydroxy and 4-methoxy substituted indoles. A 0.1 milligram (mg)/milliliter (mL) analytical standard is made from certified reference material for each of the substituted indoles (Cayman Chemical Company, USA). Each sample is prepared by diluting fermentation biomass from a recombinant host expressing the engineered biosynthesis pathway 1:1 in 100% ethanol and filtered in 0.2 um nanofilter vials. The retention time and UVvisible absorption spectrum (i.e., spectral fingerprints) of the samples are compared to the analytical standard retention time and UV-visible spectra (i.e. spectral fingerprint) when identifying the substituted indole compounds. For example, FIG. 17 depicts the detection of tryptamine isolated from a fermentation with a recombinant host expressing enzymes for Ltryptophan to tryptamine conversion. Detection and isolation is depicted by retention time matching of fermentation derived tryptamine with a tryptamine analytical standard, along with a matching UV-vis spectral fingerprint (i.e. spectral fingerprint) of the fermentation derived tryptamine with the tryptamine analytical standard. This also corroborates that the recombinant host is able to successfully convert L-tryptophan to tryptamine, which further validates that the systems and methods herein direct molecules into tryptamine pathways.

As another example, Fig. 18 depicts the production, detection, and isolation of the substituted indole, DMTP, from a fermentation of a modified recombinant host expressing the DMTP pathway. The retention time and UV-vis spectral absorption (i.e. spectral fingerprint) of the DMTP isolated from fermentation is identical to the retention time and UV-vis spectral absorption (i.e. spectral fingerprint) of the DMTP analytical standard. FIG. 18 also depicts a negative control fermentation from a host strain not expressing the TrpM enzyme or the DMTP

pathway, and this strain does not produce DMTP. The modified host strain expressing the TrpM and DMTP producing pathway, highlighted in FIG. 18, is able to produce DMTP. FIG. 26 depicts the production, isolation, and identification of the dimethylated tryptamine, DMT, derived from a fermentation of a recombinant host expressing the pathway for substituted indoles and tryptamines. The fermentation derived DMT is identified by matching retention times with the DMT analytical standard. Spectral library identification of the fermentation derived DMT matches the UV-vis absorption spectrum (i.e. spectral fingerprint) of the DMT analytical standard.

Example 26 - Synthetic preparation of substituted indoles from recombinant host products

In some instances, it may be preferable, for reasons of either cost or product quality, to utilize recombinant host pathways to accomplish the first part of a substituted indole synthesis and complete the remaining steps synthetically. The tryptamine, as obtained from the recombinant organism, is of a particular grade such that methylations with robust methylating agents selectively leads to mono- or di-methylation. One of ordinary skill in the art would appreciate this as improvement when a primary amine subjected to robust methylating agents as a mixture of alkylation products are not obtained, while obviating the need for tedious chromatography.

One example would be the production of tryptamine via fermentation of a recombinant host organism, followed by N,N-methylation via methylation chemistry to yield DMT. In one embodiment, the reaction of tryptamine would proceed with a 30-fold molar excess of dimethyl carbonate (DMC) under an inert atmosphere, utilizing a Y-type zeolite catalyst (see Fig. 25. This reaction is carried out at 190°C for 6 hours in a pressurized reactor vessel or autoclave; another embodiment would utilize a microwave oven for 15-60 minutes. The DMT product is recovered from the volatile DMC reactant via distillation. Another embodiment of the combined biosynthetic and chemical synthesis route is the production of tryptamine via recombinant host organism, followed by its reaction with DMC in the presence of the catalyst: 1,8-Diazabicyclo[5.4.0]undec-7-one (DBU). This catalyst can be used in a thermally heated reactor system at 90 °C for 6-24 hours or used in a pressurized microwave reactor system for less than one hour. Another embodiment of the combined biosynthetic and chemical synthesis route is the production of tryptamine via recombinant host organism, followed by its methylation to DMT using dimethylsulfoxide (DMSO). The catalysts for this system is acetic acid, and the reaction is carried out in a thermally heated reactor at 150 °C for 6-15 hours.

References

Bishop et al., 2006, J Virol. 80:8225-8235.

Blei et al., 2018, Chembiochem. 19:2160-2166.

Boyce et al., 2019, Fungal Ecol. 41:147-164.

Buller et al., 2015, Proc Natl Acad Sci USA. 112:14599-604.

Byeon Y and Back K, 2016, Appl Microbiol Biotechnol, 100:6683-6691.

Fan, Aili, and Shu-Ming Li, 2014, Tetrahedron Letters 55: 5199-5202.

Francis et al., 2017, Chembiochem. 18:382-386.

Fricke et al., 2017, Angewandte Chemie International Edition 56:12352-12355.

Fujiwara et al., 2010, J Biol Chem. 285:11308-13.

Germann et al., 2016, Biotechnol J. 11:717-24.

Green and Sambrook, 2012, Molecular Cloning: A Laboratory Manual (Fourth Edition), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.

Hemmi et al., 2001, Biochemistry 40: 3512-3524.

Horita, A., and L. J. Weber, 1961, Proceedings of the Society for Experimental Biology and Medicine 106: 32-34.

Huang et al., 2018, AJSH 40:1-7.

Kong et al., 2016, Sci Rep. 6:20273.

Lenz, C., et al., 2019, Angewandte Chemie (International ed. in English) 59.4 (2019): 1450-1454.

Levine, WG, 1967, Nature 215: 1292-1293.

Lima da Cruz et al., 2018, Frontiers in molecular neuroscience 11: 312.

Nemoto et al., 1995, European Journal of Biochemistry, 233:1-8.

Keshavareddy et al., 2018, Int. J. Curr. Microbiol. App. Sci. 7:2656-2668.

Ruohonen, et al., 1997, Yeast 13: 337-351.

Winn et al., 2018, Angew Chem Int Ed Engl. 57:6830-6833.

Zehner, et al., 2005, Chemistry & biology 12: 445-452.

Zou et al., 2013, Angew Chem Int Ed Engl. 52:12951-5.

US Patent No. 10,435,727.

US Patent No. 10,671,632.

US Patent Application 16/553103.

US Patent Application 16/553120.

US Patent Application 17/068636.

US Provisional Patent Application 63/035692.

US Provisional Patent Application 63/053539.

US Provisional Patent Application 63/141486.

US Provisional Patent Application 63/164126.

US Patent Application Publication 2020/0063170.

US Patent Application Publication 2020/0063171.

U.S. Patent Application Publication 2021/0147888.

US Patent Application Publication 20210108238A1.

Finnish Patent Application Publication FI20185254A1.

http://parts.igem.org/Yeast.

In view of the above, it will be seen that several objectives of the invention are achieved and other advantages attained.

As various changes could be made in the above methods and compositions without departing from the scope of the invention, it is intended that all matter contained in the above description and shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense.

All references cited in this specification, including but not limited to patent publications and non-patent literature, and references cited therein, are hereby incorporated by reference. The discussion of the references herein is intended merely to summarize the assertions made by the authors and no admission is made that any reference constitutes prior art. Applicants reserve the right to challenge the accuracy and pertinence of the cited references.

As used herein, in particular embodiments, the terms "about" or "approximately" when preceding a numerical value indicates the value plus or minus a range of 10%. Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the disclosure. That the upper and lower limits of these smaller ranges can independently be included in the smaller ranges is also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.

The indefinite articles "a" and "an," as used herein in the specification and in the embodiments, unless clearly indicated to the contrary, should be understood to mean "at least one."

The phrase "and/or," as used herein in the specification and in the embodiments, should be understood to mean "either or both" of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with "and/or" should be construed in the same fashion, i.e., "one or more" of the elements so conjoined. Other elements can optionally be present other than the elements specifically identified by the "and/or" clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to "A and/or B", when used in conjunction with open-ended language such as "comprising" can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.

As used herein in the specification and in the embodiments, "or" should be understood to have the same meaning as "and/or" as defined above. For example, when separating items in a list, "or" or "and/or" shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as "only one of" or "exactly one of," or, when used in the embodiments, "consisting of," will refer to the inclusion of exactly one element of a number or list of elements. In general, the term "or" as used herein shall only be interpreted as indicating exclusive alternatives (i.e. "one or the other but not both") when preceded by terms of exclusivity, such as "either," "one of," "only one of," or "exactly one of." "Consisting essentially of," when used in the embodiments, shall have its ordinary meaning as used in the field of patent law.

As used herein in the specification and in the embodiments, the phrase "at least one," in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements can optionally be present other than the elements specifically identified within the list of elements to which the phrase "at least one" refers, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, "at least one of A and B" (or,

equivalently, "at least one of A or B," or, equivalently "at least one of A and/or B") can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.

SEQUENCE LISTING

Seq. ID No: 1

>6xHIS

CACCACCACCATCAC

Seq. ID No: 2

>AADC 1

Seq. ID No: 3

>AADC 2

ATGTGGGGTTGCGGGAACGGTGATTGTATCCACGTTTTACTGCTTATCAGCCATACGAGTCCACCACCCCTTAGTCC
GCATCTGTTGCACTCCCACAGGGACTCCCCGGTTCTGAAAATCATCCACAGTATCGTCCTTACAGTCCAGAACAATC
ATTCCTGCCTACAGGGCCATGTGCCATTTTATGTTAGTGCCACTGCGGGAACAACGGTGTATGGAGCTTTCGATCCT
TTCGTCAAGATTGCGGATATATGCCAGAAACACGGACTTTGGATGCTGCACGTAGACGCGGCTTGGGGTGGGGGTTT
GCTTATGTCTCGAAAACACAGGCACAAGATGAACGGGATAGAAAGGGCGGACAGCGTGACTTGGAACCCACATAAGA
TGATGGGAGTCCTTTTGCAATGTAGTGCAATCCTTCTGAAGGAAAAGGGTATACTACAGGGTTGTAATCAAATGTGC
GCAGGGTACTTATTTCAGCAGGACAAGCAATATGATATTTCTTACGATACCGGCGACAAAGCCATCCAGTGTGGCAG
ACACGTTGATATTTTCAAATTTTGGCTGATGTGGAAAGCAAAAGGGACAGTTGGCTTCGAGCAACAAATTAACAAGT
GCTTAGAGTTGTCCGAGTACCTATACTCTAAGATTTGCAACCGTGAAGATTTTGAGATGGTTTTTAAGGGAGAGAAGTG
TCTTTACACCGTTTGGAAGAGGGAATTAAG

Seq. ID No: 4

>AADC 3

Seq. ID No: 5

>AADC 4

ATGAATGCCTCAGAATTTCGTAGGAGGGGAAGGAGATGGTCGATTACGTAGCAAATTACATGGAAGGGATTGAGGG GCGTCAGGTATACCCAGACGTGGAACCTGGGTATTTAAGGCCGCTTATTCCAGCTGCAGCCCCACAGGAGCCCGATA CCTTCGAAGACATCATAAATGACGTTGAGAAAATCATAATGCCTGGCGTCACTCATTGGCATTCTCCATACTTTTTC GCCTACTTTCCCACTGCTTCTTCCTACCCAGCCATGCTTGCAGACATGTTATGTGGCGCAATAGGATGTATTGGGTT CTCCTGGGCGGCATCCCCCGCCTGCACGGAGCTAGAGACAGTTATGATGGATTGGGTTAAAATGCTTGAGCTGC CCAAAGCGTTCTTGAACGAGAAGGCAGGAGAAGGGGGTGGCGTGATCCAAGGCTCTGCTAGTGAAGCCACCCTAGTC GCCTTGCTGGCAGCAGAACTAAGGTGATACACAGACTTCAAGCCGCCTCTCCCGAGTTAACTCAGGCTGCAATTAT GGAGAAATTGGTAGCCTATTCTAGCGACCAGGCTCACTCCAGCGTAGAACGTGCCGGTCTGATTGGGGGGCGTGAAGT TGAAAGCTATTCCGAGCGATGGGAATTTTGCCATGAGAGCGTCCGCGCTTCAAGAGGCCTTGGAACGTGACAAGGCT GCCGGATTAATCCCGTTCTTTATGGTCGCTACGCTTGGTACTACCACGTGTTGTTCTTTTGATAACCTACTGGAAGT GGGTCCTATCTGCAATAAGGAGGACATTTGGCTTCATGTAGACGCTGCCTATGCAGGTTCTGCTTTCATTTGTCCCG AATTTAGGCACCTGCTTAATGGCGTGGAGTTCGCGGATAGTTTTAATTTTAACCCTCATAAATGGTTGCTGGTGAAT TTTGACTGTAGCGCCATGTGGGTCAAGAAAAGAACGGATCTAACTGGAGCCTTTAGACTTGACCCCACGTACCTTAA ACACAGCCATCAGGATTCCGGGCTAATAACCGATTATCGTCACTGGCAAATCCCGTTGGGAAGACGTTTTCGTAGCC TGAAGATGTTGTTTTAGAATGTATGGGGTGAAAGGGCTACAGGCGTACATACGTAAGCATGTCCAACTTTCT CACGAGTTTGAGTCTCTTGTACGTCAAGACCCGAGATTTGAGATTTGCGTTGAGGTAATACTAGGTCTAGTCTGTTT CCTGCCATCTACGTGATAAGTTTGTCTTACGTTTTGCGATATGTAGTAGGACGGTAGAAAGCGCACACGTTCAGCGT GCGTGGGAGCACATAAAGGAGTTAGCCGCTGATGTTTGAGAGCTGAACGTGAG

Seq. ID No: 6

>AADC_5

Seq. ID No: 7

>AADC_6

Seq. ID No: 8 >AADC 7

ATGGTGAGGGCCGTTGAAAAGCCAGTACAAGCCATAGTAAATGCCGCGTTTAGAGGGAAAGATGCATATCATGTTTT CAGAACACAGTTCTAGCGGCCGTGCTGTTAAGACTGTGGAGACACTTGAGACGTGTGATGGCTCATGAAGGTTTGA AAGCATACTTTATGTCCTTAGTCGCACCGCATCTGAAGAAACTTCCGTACGTCCAAAACAAGTTGAAGAAGGAGATG GATAAAACTATGACGAAAATGAGAAATACCTTTCGTAAGGAGGTGACAGATCCAAGGACATCATTACCTGTTGATGG GATTCCTGAGAAACAGATCTTGGAACTGATTCAACATCGTAAAGAGTTAGATACTAAGGAATGGACAAAGGGTATGA CCACTGGCTGTGTTTACCACGGTGGTCAGGACCATTATGACTTTGTAGGACAGATCTTTGCATCATGGGGGTTCGCT AATCCATTGCACCCCACAACCTTTCCAAGCCTACGTCAGATGGATAGCGAGGTCGTACAGATGGTTATCAACATGTA CCACGGGGATTCAGAGTGCTGCGGGGCGTTCACTACTGGAGGAACGGAGAGCATTCTGATGGCGATGAAGGCCTATC GTGATTGGGGTAAGGCAGAAAAGGGTATTACCGATCCCAATATCGTTATCTGTAACACCGCCCATGCTGCTTTTGAT ACGTAGCCTTATCGACTCCAATACCGTGGCCATCGTAGGCTCAGCCTGCCAATTTTCTCATGGAACCGTGGACCCGA TCCAGGAAATGGCAAAGATTGCCATGAAGCGTAGAGTTGGCCTACACGTTGATTGTTGCCTAGGCGGTTTTCTAGTT CCGTTCATGGAAAAAGCTGGATTCCAACTTCCGCCCTTTGACTTCAGAGTCAAGGGGGTAACGTCCATATCCTGTGA TCCCCACAAATATGGGTTTGCCCCAAAGGGCTCCTCTGTTGTAATGTTTAGTAACCGTCACCTGAGGCACTACATGT ATTGTTTCTTAACAGAATGGAGCGGAGGAATATACGCGACTGCAACGATGACTGGTTCCAGAGCAGGTGGCCCGGTG GCCGCCACATGGGCGAGCATGTGCAAATTTGGGGAGAAAGGCTATATTGAGACAACTAAACAGATCGTCGGGGCCAC TCACCTGTACTGAGGGTTCCGGAATGAATTGCTACGCCGTTGGGGACTGTATGCATCAGGACTTTCATTGGGAGTTG CAATCTTGTCAGAATCCGGCTTGTGTTCACTTGGCTTTAACCCTGCCGACCAGTAGAAATGCTGATAAATTCGTAGC TGATTTGCGTCAGGCTGTGGAGGCGGTGAGGAGCGATAAGGACGGCAAATTCGCATCCACGGCGGGCATGTATGGGA CCGCAGCTTCTTTGCCAGCCGCGTTTTTCGAAGACGGCGCAGCAGCATACCTTGATGCGATGTGTGAAGCCATCCCA GCGGGAGACGCTCTACTGCCGGAGGAACCTGCCACGAAGGAATCCCCTGCAGCTGCCGGGGCACCGGCTCAAGCAAC AGGGGGTGCT

Seq. ID No: 9 >AADC 8

ATGAATGCGAGCGAGTTTAGGCGTCGTGGGAAGGAAATGGTTGACTACGTAATCACGAATTATCTGGAACAGATAGA
GTTACGTCAGGTCTACCCTTCCGTCGAGCCGGGGTATCTTAGACCTATGATTCCTGATTCCGCGCCGGAAGAAGGTG
AGACGTATGAAGATATCATGAAAGACATCGAGAGAGTCATAATGCCGGGAGGTTACTCCATTGGAATAGCCCGTACTTC
TTTGCGTACTTCCCTGCGGCAACAAGTTACCCTGCTATGTTGGCCGACATGTTATGCGGCAGCCTGGGGTGCATCGG
GTTCTCATGGGCCGCTTCACCCGCCTGCACAGAGTTGGAAACCGTAATGCTTGACTGGTTGGGCAAAACAATCGGCC
TACCAGAACAGTTTCTGGCTGGTACCAACGGAGAGGGTGGCGGTGTAATCCAAGGTACTGCCAGCGAAGCGACCTTG
ATGGCACTATTGGCGGCCCCGTACTAAGGTTACAAGAAGGTTACAAGCTGAGAACCCTGACCTTTCTGAAGCAGAGAT
CATTAGCCGTATGGTGGCATATTCTAGCGACCAGGCCCATTCCAGCGTGGAGAACCCTGACCTTTCTGAAGCAGAAA
GCTGAAAGAAAAAGATCCCATCTGATGAAAACTTCACTGCTAGAGGTGAAGCACTAAAGAAAAGCACTTGAGGAGACAAA
GCTGAAGGTTTCATACCAGTCTTTCTTTGCGCGACACCTGGGCACAACAACTTCTTGCGCGTTCGACAATCTTATGGA
ACTGGGTCCGATATGTAATGCGGAGAACATGTGGTTGCATATCGACGCCGCCTATGCTGGGAGTGCTTTCATCTGCC
CGGAGAACAGATATTTAATGAAGGGTGTCGAGTTCCGCGGACTCCTTCAATTTCAACCCACATAAGTGGTTGTTAGTC
AACTTCGACTGCAGTGCTTTCTTGGGTAAAGAAAAGGTCCGATCTTATATGTGCATTTTAAGATAGACCCCGTCTACCTT
ACAACACCGACCAGCAGGAGAGCGGTTTAGTAACGGATTACAGACACTGGCAGATTCCTCTAGGAAGAAAAGGTTCCGTA

Seq. ID No: 10

>AADC 9

Seq. ID No: 11

>AADC 10

Seq. ID No: 12

>AADC 11

ATGGGGTCTTTGGGAACAAATCCGACGAGCTTTAGCGCCTTCCCTGATGACAAGGCCGCATTTGAACCATTAAACCC AGAAGATGTTAGAGCTTATCTTCACAAGGCGGTCGATTTTATCTCAGACTACACGAACGTTGAAAGTATGCCTG GTTACAATGAAGGAACTAAGGACCAGCGTTGTACCAGGCATGACACCTGGGCGTCACCAAACTTCTTTGCATTTTT CCCATCAACCAATTCAGCGGCGGCAATAGCCGGTGATCTAATAGCTTCTGCGATGAATACGGTAGGCTTCACATGGC AGGCGAGTCCCGCAGCAACGGAGATGGAAGTTTTGGCCCTGGACTGGTTAGCACAGCTACTACATCTTCCGACGACT TTTATGAATAGAACCTCCACTGGCAGGGGTACAGGCGGAGGAGTCATATTGGGTACGACGTCAGAGGCCATGTTAGT TACGCTTGTCGCAGCTAGGGACGCTGCTCTGAGGAGAGCGGCAGCGTGGGAGTGAGCGACATTCCTAGACTGGCAG TATATGCTGCGGATCAAACACATTCCACCTTCTTTAAAGCGTGCCGTTTAGCAGGATTTGACCCAGCTAACATTAGG AGTATCCCCACTGGACCTGAGACTAATTACGGCTTAGACCCCGCTAAACTATTGGAAGTGATGCAGGCTGACGCGGA TGCGGGGCTAGTCCCGACTTACGTATGCGCCACCGTCGGTACTACATCTTCCAATGCTGTGGACCCGGTTGGCGCGG TTGCCGATGTCGCCGCCATGTTTAATGCCTGGGTACATGTAGATGCCGCTTACGCCGGCAGCGCGTGTATATGTCCT GAGTTCCGTCACCATCTTGACGGCGTAGAGAGAGTCGATAGCATCTCAATGTCCCCTCACAAATGGCTTTTAACCTG CCTAGATTGCACTTGTCTGTATGTTAGGGATGCTCACAGGTTGAGTGACTCTCTGGAGACCAACCCCGAGTACTTGA AGAACGACGTTACCGACAGTGGTGAGGTTACCGACCTAAAAGATATGCAGGTTGGGGGTTGGTAGAAGGTTCCGTGGA CTGAAGCTGTGGATGGTTATGAGAACCTATGGCACTGCGAAACTACAGGAGCACATTCGTTCCGACGTCGCAATGGC CAAAATGTTCGAGGATAGCGTTAGAGCTGATAATCGTTTTGAGGTCGTCGTACCGAGGAACTTTGCCCTTGTATGCT TCCGTATTAAGGCTAGAGGAGATATGACTGAGGAAGACGCGGACGAAGTAAACAGGTTACTGATGGAGAATTTAAAC

AAGACGGGTAAAGCATACTTAGCTCACACTGTGGTCGGGGACCGTTTTGTTTTACGTTTTTGCGGTTGGGAGTAGTCTGCAAGAAGAAGAAGACATGTGAGGTCAGCCTGGGATTTGATCAAGAAGACGACTTCATCATTATGGAT

Seq. ID No: 13 >AADC 12

ATGGACCCTCTAAAAGCCGTTGAAATGGTTGACGAAAATACTATCTGCGTAGCAGCCATCTTGGGCTCCACTCTGAC CGGGGAGTTTGAGAACGTTAAAATGAGCTATTAAATAACTAAAAAGAACAAGGATACAGGGTGGGACACGCCTA TACACGTTGACGCAGCTTCAGGCGGCTTCATAGCTCCCCTTTCTATACCCGGACCTAGAATGGGATTTTCGTCTTCCC CTTGTGAAGAGTATCAACGTTTCTGGACACAAATATGGCTTAGTCTACCCCGGCGTGGGATGGGTAGTATGGCGTAG CAAAGGGGATCTACCTGACGAACTGATATTTCATATCAATTATCTGGGAAGCGATCAGCCCACTTTTACCTTGAATT TCAGTAAAGGTAACAATATCAGCACGCACGCTTACAAGAAGCCCAAGTGCCGTTTCTACTTCCTAACCAATCAAATC TTATCTAGGCGTTATTTATTACACCGTCTGAAAAGTGGAACTTCTTTGAATAGTCTTCTA

Seq. ID No: 14

>AADC_13

Seq. ID No: 15

>AADC_14

Seq. ID No: 16

>AADC 15

Seq. ID No: 17

>AADC_16

ATGGACGGCAAATGCTAAAGCCAATGGACGCTGAACAACTGAGGGAGTATGGTCACCAGATGGTGGACTTTGTAGC GGACTACTACAAAACTATTGAGAGCTTCCCCGTGCTAAGCCAAGTTCAACCTGGATACTTACGTGAGCTAGTCCCTA CAAACCCTCCAACGCACCCGGAGTCCCTTCAGGATGTTCTGGACGATGTTAAAGCGAAGATATTACAAGGCGTAACC CATTGGCAAAGCCCGGGATATTTCGCCTATTTTCCGTGCAACTCTAGTACCGCGGGATTCTTAGGAGAGATGCTGTC CGCCGGGATCAATATCGTAGGATTTTCCTGGATGTCCTGCCCTGCGGCTACTGAGCTTGAAGTAATCGTCCTTGACT **GGTTAAGCAAACTG**

Seq. ID No: 18

>AADC 17

ATGGTGTTGAGGTTATACGGCCAGGAAGGTCTTCAAAGCTACATAAGAAACCATATTGCTTTAGCGAAACAGTTCGA GGAGTTGGTCATTCAGGATTCCAGATTCGAGATGGTCACCCCACGTAGGTTTAGTCTTGTGTGCTTTCGTTTACTGC CCAGAAGCACAGACGAGAACCAGGCGGATAAGCTAAATAGGGCACTGCTAGATGCGGTGAATCTTACGGGTGCGATA TTTATCTCTCACACAGTCTTGTCAGGGATGTACGTGTTACGTCTTGCGGTGGGGGCACCGTTGACTGAAGAGAGGCA TGTGATAGCCGCGTGGAAGGTCTTGCAAGAGAAGGCAACGGCATTACTGGAGGGTAATGTAGCGCAAGAACCTAACG GTCACGCGCAATTATCCAATGGTGTCGTCGAGCTTGATGGTGCGCTAGATAATGGTGTCACCACTGAACAGCATGGA CATGTGGACGATCTTCCTATTAAATCTAAA

Seq. ID No: 19 >AADC 18

ATGAGCCTTTCCCGTCACATAGACGCGGAGCGTTTAATCGAGCAAATCAAGGAACACCCACATAAGAAACATTCTTC TGCGGAGTCCCGTAGGGGTTTGCACAGGTCTTGGAGACGTGATGAGGATGCTGCGGACTTACCAAAGTACACCTTAC CCAAACATGGAATTAATTCAAAAGCCGCTTACCAACTGTTACACGATGAAACTGCTCTGGACGGAAATCCTTTGCTT AACCTGGCGAGCTTTGTGCACACCTGGATGCCGGAAGATGCGGACAAGTTAATAATGGAGAATATAAACAAAAATAT AGTGGACATGGATGAATACCCTGCCGCCTCCCTTATCCACAACAGATGTATATCAATGCTGGCGGATTTATGGAAAG CCCCTAAAGAAGGTAAAGTAATCGGCACGGCAACGGCAGGATCATCTGAGGCTATTATGCTAGGCGGTCTGGCTTTG AAGAAGAGATGGCAGGAAGCGAGAAAGGCTGCTGGTAAGGATTATTTCCATCCGAACATTGTGTTCGGGAGCAATGC TCAGGTAGCCTTGGAAAAATTTGCGCGTTATTTCGATGTCGAGACGAGACTTGTGCCGGTCAAAGAGGAGAACGGCT TTGTTATGAATCCTCATGATGCCATACCTTATATCGACGAGAATACGATAGGAGTGATTGTGATACTGGGAAGTACT TACACGGGGCACTTCGAGGACGTCAAATTGATGAGTGATCTGTTAGATGACTTAGAGAAAAGAACTGGGCTAGACGT AAAAATACACGTCGATGGCGCATCAGGCGCATTCATAGCACCTTTCGCTTACCCGCACCTGAAATGGAGCTTTGACG CGTGACGAGTCATTTCTACATCGTGACTTGGTTTTTTGAGTTGCATTACTTGGGCTCAACCGAGTATAGTTTCACTCT AAATTTCTCCAAGCCAGCGGCTCCAGTCATAGCGCAAATGTTTAACTTTCTAAACTTGGGTTTTGAGGGATACAAGA AGATTGCATACAAGGATATGAGAAACGCAAGGATGCTTAGCAGAGCCCTGGAGTCTACGACGTATTTTAAGGTATTC AGTAATATTCATGTCCCTCGTAACTCAGACAGTGCTCACGTTTCCAGCAACAACAACAAGACGACCCGGAGACTTACCA TGCAGGCTTGCCCGTTGTCGCATTTAGGCTGTCTGACGAATTTAATCAGAACTACCCGAACGTTCGTCAAGTGTGGA TTCAGACCCTGCTGCGTACGAAAGGTTGGATTGTGCCCAATTATAACGCACCCCTTGGGGCTGAGAATATAGAGATT TTGAGAATCGTTGTCAGGGAAACACTTAGTGAGGATCTTATTGAAAGACTGATCGTTGACATTGTCGCCGTTACCGA AAGTTTGACTACCGAGGAAGGTAACGTATTCGCCGGTATCACGGCGTTGGCGCGGTGGTTAAGCCCGATCTGGACG AAGCCCGTCCAGACAGTAGTAATTTTAACGATTCAGGTGACGGCGAAGCGCAGGGCCAGACGGGTTATTCACGTCAG TGC

Seq. ID No: 20 >AADC 19

ATGGCTCTATCTAAACATGTTAATACGGATAAATTGATTCGTGATAGCAGAGATAAAAAGTCACCAAAGGAAAAGGC CCATCACACGGCCACTGCTCATCAGGAGGCAACTTACTCCTACGGGGATCGTTATGTCACTAACCCCGTGCCTAAAT ACAACATAGCGAGTAAGGGAATTAGTGCCGACGCCGCATATAGACTTATTCACGACGAACTAGCCCTAGACGGGTCT ACTGTGCTTAACCTTGCCTCATTTGTTCACACTTGGATGCCGCCCCAAGGCGAACAGCTAGTACATGAAAATATTGC TATGGCATGCACCGTCCGCTAAGCAGGCGGTAGGCACTGCAACTACGGGCTCCTCAGAGGCGATACAGTTAGGCGGT CTGGCGATGAAAAAGATGTGGCAAGCGCGTATGAAAGCAGCTGGTAAAAAACATCCACGAACCGGGTCCCAATATAGT

Seq. ID No: 21 >AADC 20

ATGGCCTTAAACGCAGTAAGCGCAGCTAGAGGTAGCGCAAGACAGTATATTTCCACGTTCTTAACGCTAGACAACGC TAAGAGCGGATTATTTATTATGTATTATTGGTTCAAGCCATTAAAGTGAAACGTCACCTGCGTGCCAGAGGTATCA GTGCCTCCCTAAAAGAATTATACACATGGATTTCTCAGCAGATCATACGTTTGCTTCTGAGGCTGCCGGCCACACGT AAGAAAGTTGCTAGTCAGATGGATCAAGCAAAGTTGGATATCGAGAACAGACTGGTCCCCAAAGGGGCCCAATGTTAC CAGGCATTTAAGTCTGCCGTCTGAAGGCAAGTCCTTGGAATGGATTACACAGGAGATGGACAAGATGGATACCGAGC TTGGTGGCACAAGTGACGCGTGGAGACAGGGGAAGCTATCCGGGGCTGTATATCATGGAGGTGACGAGCTTGCGAAA ATTATCGTCGCGGCCTATAGTAGATATTGCGTCTCTAACCCACTTCATCCGGATGTTTTTCCAGCTGTACGTAAAAT GGAAGCTGAGATCGTTGCTATGTGTCTAAAGATGTATAGAGGGCCTGAAGGTGCTGCCGGCGCTATGACGAGCGGGG GAACCGAATCAATCGTTATGTCCGTTAAAACCCACAGAGACTGGGCAAGGAGTGTAAAGGGAATTAAAGAACCCGAG ATGGTTGTACCCGTTTCAGCCCATGCCGCCTTTGATAAGGCGGCGGCGTATCTTGGGATCAAGCTACATTCTATACC AGTTGATTCCTATACAAGACAGGTTAACATAAAGCACGTGAAAAGAGCTATCAACTCAAATACTATCATGATAGTTG GCTCCTGCATCGGGTTCCCTGACGGTAATCAAGACGATATTGAAGCCCTTGGTGCATTGGCCAAGAAGTACAACATA GGCCTGCATGTTGATTGCTGCTTAGGCAGTTTCATTGTACCGTTTCTTGAGCCAGCGGGCCTAGCAAAAGGCGATAA CAAAGGAAGATACAAGTTGACTCCTTTCGACTTCACGGTAGATGGCGTCACCGCAATCTCCTGCGATACCCATAAGT ATGGGTTTGCTCCAAAGGGCACGAGTGTAATAATGTACCGTAGTGCGGAACTGCGTAGATTCCAATACTACGTTAAC CCGATCTGGCCAGGGGGCGTCTACGCATCTCCATCTCTTAGTGGGTCTCGTCCCGGTGCACTGATAGCAGGCTGTTG GGCGGTGATGCAATATATGGGTACAGAGGGGTACCTTAGCAGTTGCCGTGATATAGTAATTGCTACTAGAAAGATAG CTGACGCGATTACAGATGATATCCCTGAGTTATACGTCCTGGGTAATCCTCCGGCTTCAGTCGTAGCATTCGGGTCA CGTAATCCAACTGTAGACCCTCTTGAAGTCGGAGATGGCATGCGTAAGAGGGGGTGGCATCTGAACGGCTTGAGTTC ACCAAAATCTGTCCATATTGCTTGTACCCGTCTGACTTTACCCGTCGTGGACCAGTTCATTGCAGACCTAAAGGATT GCGTCAGGGAAGCAAAGGTGGCACCTAGTGGGAAAGGTACGATGGTTTCCGTGTACGGGCTAGGCAACAGCTCTGCG GTGGGACCCGACATGGTTTCCCAACTTGCCAGTGCCTTTCTGGACGCCCTGTACAAAGCA

Seq. ID No: 22 >AADC 21

ATGGAACTAAAGACTGCGGCCAATGAGATCTGTAACAGTAATCAGATGTGTCAAGGTGAGAACTATTCACAGAACAT GCTATTGAGAGATGGGCCAATTGATTTGAAGAACCAGATCAAAGAAGAAGAGGAGATCAAGGTCTAGGTCATGGCTTTAGCG ACTTCTCAAACGTATTTGCATCAGACCTACTACCAGCGCGTAACGGCGAAAAATACACAGAGGGATTCCTATTAGAG GTATTCAATATACTATTCAGTTATATCAGGAAGACCTTTGACAGAAAATCCAAGGTATTGGATTTCCACCACCCCCA CCAGCTGTTGGAGGGACTGGAAGGGTTTAACTTGGAATTGAGCGATCAGCCAGAACCACTGGAGCAAATTCTTGGTG ACTGTAGAGATACGTTAAAATACCGGGTTAAGACGGCACATCCGAGGTACTTTAATCAATTAAGCTCCGGCCTTGAC ATGGTGGGCCTTGCAGGGGAATGGCTTACGGGTGCAGAATACCAATATGTTCACCTACGAGATCGCTCCCGTCTT CATCATAATGGAGGGACTACTTATAAAGAAGATGCATGAGTTGGTAGGGTGGGGAGAGTTGGAGGCGGATGGGATAT TCTCTCCAGGGGGCCACATTTCAAATCTGTACAGTTTTTAGTAGCCAGATACCAAATTTTTCCCTATAGTCAAGCTA

AAAGGTATGGCTGCGTTACCCAGAATCGTCCTGTTCACTTCTGAGCACTCACATTACTCTTTTCAGAAGGCAAGTGC AACTCTTGGAATTGGAATAGAGAATGTTATCGCTGTCAAATGCGATGAGAGGGGTAAGATGATACCATCCGATCTGG ATGAGAAGATTATGGCACAGAAAGAAAA

Seq. ID No: 23 >AADC 22

ATGTGGAAAGCTAAGGGAACAAGAGGTTTCGAGCTACAGATAGACAGTTGTTTGGAGAACGCTGAGTACCTGTACAA GAAACTAAAAAGCAGGAACGGCTTTGAGCTTGTTTTCCCCGACGAGCCGGAGCACCAATGTCTGCTTCTGGTATA TTCCCCCTAGTTTGAAGGGTATGCCCCAGGGACAAGGAATGGAATACGAAACTTCATAAGGGTAGCGGCCAAAATTAAG GCTCAAATGATGGAAGAGGGAACGGTCATGGTGTCATACCAGCCGCTTAAAAATAAGCCAAACTTCTTTAGGATGGT GTTCTCAAACCCCAGCTTCCAAGAAAAGTGACATAGACTTTTTGCTAGATGAGATAGAGAGGGTTAGGAAGTGACCTTG AATTT

Seq. ID No: 24

>AADC_23

GCCACTACTTCTGGTTGCAAATGCGGGAACACCGGGTGCAGGACACACGGACAAGTTGGCCAGGTTGAAAGAACTTT GTCATCAGTACAACATCTGGCTTCATGTTGAGGGAGTCAATTTAGCGACCTTGGCCCTTGGGTATGTAAGCGCATCT GTGCTGGCGGCAACGAAATGCGATAGCATGACCTTGACACTTGGACCTTGGTTAGGTCTACCAGCCGTACCGGCGGT TACCCTATACAGACACGAAGATCCGAGTCTTAGCCTGGCTGCAGGGTTGACAACATCTCAACCCGTGGAAAAGTTGA GAGCCTTGCCGCTATGGCTGAGTCTGCAGTACCTAGGCCATAACGGGATAGTTGAGAGAATTAAACACGCCTCTCAA TTATCCCAAAGGCTATTGGAAAATCTTAAAGATGTGACATCCATTAAAACATCCGTGGAGCCCGATGGCAATTCTCC GGTGGTCGTGTTTAAGTTTTTCTATGACGGACCAGGCTCAGGGTCCACCATTAATCTTAACACGATTGAACGTGAGT CCGACGCAATGAATCAGTGGTTGGGCGAACAGTTGGCCGCCCTTATCCCAAGTTGCGCTGTAGATACTGTTGAGTTG GAAGACGAAGGTGTGTGTGTGAGATTTAACCCTATGATGACATCTGCAGTACTTGGCACAACCATAGAGGACGTAGA TCAGCTGGTTGAATGCGTCAAGGTTAAAATTCCCATAATACACAATACACTACAGCTAAAGGAGGAGTTCAGGCTTG AAGTAGAAAGGATTGCGGGCCTAACATATGTTGTTGATTATTCTTGGGCGGGGTTGGGCGTTTTACGTTATGATCAC GTTTCAGAAGAGCTAGATGGGTCCAGACGTGAAGCCGAATTAGAGAAGATTAATGCTTCCCTATTAAAGAAGTTGAA TGAGCTTGAAAGCGACTTGTCATTTAGTTCCGGACCCGAGTTTGGTGCCGAGAAAAATTGTGTCTACATAGGTATGG CAACAGAGGACGTAGATGTTAGTGAATTGGTTGAAACAATTGCTGTCATGGGCAGGGAGATAGAGGAAAATAGCAAA CTGTTAGAGAACATGACTGAAGTAGTTCGTAAGGGCATCCTAGAAGCTGAGGTGCAACTACAGAAAGCAAACGAAGA CAAGCTAATGGAACTTCACCCCCACCAACACCAAGCCTAGGGCATGCCAAGAGACATCCTGGCCAGAAGCTGTTTAA GCGTTTGAGTAGAAACAGTGACGCAATGTCCGAGACTAGCTCAGTTTCTCACCTAGAGGAAGTGGAAAATCTGGAGG CGAGTCCCACCCCGAGCCACAACCTGGACATCCTACCGAACCTCCTGTTCCATCCGTTGAATCAAACTCTGAGGAG CCACATGAGGCGGAAGCGTTAGATACTAAAACTGTAGAATCTGAAAGTCTACGT

Seq. ID No: 25

>ADK1

Seq. ID No: 26

>A0QS_1

ATGTCTAATGCAGCCATAAGATCCTCCCGTGCCGTATCCGTATCATCCAGCACGAAGTATTACGACTTCACGGTAAT AGGTAGTGGTGTTGCGGGGTTAAGGTATGCCCTTGAGGTAGCCAAACAGGGTACTGTGGCAGTGATAACAAAAGACG AGCCACACGAAAGCAATACAAACTATGCACAGGGAGGAGTAAGTGCAGTGCTTTGCCCGTTGGATTCAGTTGAGAGT CACATGAGAGACACGATGGTGGCAGGTGCGCACTTATGTGACGAAGAAACCGTCAGGGTCGTGTGTACTGAGGGGCC CGAGCGTATCCGTGAGCTAATAGCTATGGGAGCATCATTCGATCACGGTGAGGACCGGAACCTACACCTAGCGAGGG AGGGCGGCCACTCCCACTGTCGTATTGTCCATGCCGCTGACATGACGGGTAGGGAAATCGAACGTGCTCTGCTTGAG AAATACTGTCTGCCACGGGGTTGACACCTTAAACATCAAGACTAACGAAGTAGTTAGATTTATCTCCAAGGTGACCT TACTAGCTTCTGGAGGTGCAGGTCATATCTACCCGTCAACAACGAACCCCCTGGTAGCGACCGGAGATGGTATGGCA ATGGCCCATAGGGCGCAAGCCGTCATTTCAAATATGGAATTTGTCCAGTTTCATCCCACTGCACTGGCTGATGAAGG TGTATAATCTGGGCATGGAAAGGTTTATGCCCGTCTATGATGAGAGAGCTGAGCTTGCTCCTAGGGATGTGGTCGCG AGGTCAATAGACGACCAATTGAAGAAACGTAATGAAAAGTATGTACTACTAGATATCAGTCACAAACCGAGGGAAAA GATCCTGGCGCATTTTCCCAACATCGCGAGCGAGTGTCTTAAACATGGATTGGATATTACTCGTCAGCCTATCCCAG GTAGCAGGAGAAGTCGCATGTACAGGCCTTCACGGTGCGAATAGGCTGCCTTCCAATTCATTACTTGAAGCCCTTGT CTTCGCTCGTCGTGCAGTACAACCCAGCACGGAATTAATGAAGCGTACACGTTTGGACGTGTGTGCATCTGAAAAGT GGACTAGGCCAGTGGTGGCCACCGCGCGTCTGTTAGGGGATGAAGTGATTGCCAAGATCATCGCTTTAACAAAGGAG GTCAGACGTGAATTACAAGAGGTTATGTGGAAGTACGTGGGGATAGTAAGGTCTACTATTAGACTGACAACGGCTGA GAGGAAAATTGCGGAGTTGGAAGCTAAGTGGGAGACGTTTCTGTTCGAGCACGGGTGGGAACAGACGGTTGTTGCCT TGGAAGCCTGCGAGATGCGTAACCTATTCTGTTGCGCAAAACTTGTAGTGTCATCTGCGCTTGCCAGACACGAAAGC AGGGGGCTGCATTATATGACGGATTTCCCGTTTGTCGAAGAGAGCAAGCGTATTCCAACCATAATTTTACCGAGCAG TCCAACTACTGCCAGCTGGTCAAGTAGGAGATTGCAAAATATTTCTTCAAGCAGCTTGATAGATTGTGGGAGTGGCG AAGGACGTGGCTCTCTACTGACTTGCGGTGACGTTGAAGAGAATCCAGGACCTAGCAGCTCCTCTTCTAGTCAAACA ACAGAGTTAGTCCCCTATAAACTGCAGCGTCTTGTTAAAGAATTTAAATCATTGACAGAACCGATTGACAGGCTGAA ATGGGTGTTACATTATGCGTCCCTTTTGCCACAGATGCCTGAGTCCTCAAAAACCGAATCAAATAGGGTGATGGGCT GTACAGCGAGGGTTTGGCTGGATGCCGAATTAGGCCAGGATGGCAAGATGAGATTTTGTGCCGACAGTGATTCAGAC GTGTCTAAGGGGATGTGTAGCTGTTTAATACAGGTTCTGGACGAGGCAAGCCCTGTCGAGGTAATGGAGCTTAAAAC TGAGGACTTGGCAGAGTTAAATGTCGGTCTGCTTGGCGGAGAAAGGTCACGTGTTAACACTTGGTATAACGTACTTG TCAGCATGCAAAAGAAAACTAGAAGGTTAGTTGCAGAGCGTGAAGGGAAGGTGCCGTCCTTTGAGCCATTTCCTTCG AAGTAGAGTCGAAGAGCTAGTTAATGTATTAAAGGAGAAGAAGATCGGTGTCGTGGCACACTTTTATATGGACCCAG AAGTGCAGGGTGTTTTGACAGCTGCACAGAAACATTGGCCCCATATCTCAATCTCAGACTCTTTAGTCATGGCTGAT TCCGCGGTGACTATGGCAAAGGCTGGATGCCAGTTTATAACTGTCCTTGGAGTCGATTTCATGTCAGAAAACGTGAG GGCCATCTTGGACCAAGCCGGTTTTGAGAAAGTTGGAGTCTATAGGATGTCTGACGAAACAATTGGTTGCTCATTGG CTGATGCAGCTTCAGCCCCAGCTTACCTTAATTATCTGGAGGCGGCGTCCAGGAGCCCACCGTCTCTACATGTTGTT TACATAAACACTTCCTTGGAGACGAAAGCATTCGCGCATGAGCTGGTTCCTACAATAACGTGCACATCCTCAAACGT AGTACAGACTATTCTGCAGGCTTTTGCTCAGATGCCGGAACTGACAGTATGGTACGGACCCGATTCATACATGGGCG CTGGACTCAATAAAAAGTTTATTACCGAGGCTGCACTACTTCCAAGAAGGTACATGTATAGTGCATCATCTTTTCGG GCATGAGGTTGTAGAAAGGATAAAGTATATGTATTGCGATGCCTTCCTGACAGCCCACCTAGAGGTGCCCGGTGAAA TGTTCTCCCTAGCGATGGAGGCAAAGAAAAGGGAAATGGGCGTCGTCGGTTCCACGCAAAACATACTAGACTTTATC AAGCAGAAAGTCCAGGAAGCGGTAGACCGTAACGTCGATGACCATTTGCAGTTTGTTCTAGGTACTGAATCAGGAAT GGTGACGTCCATCGTTGCAGTAATTAGAAGCCTATTAGGGAGCAGCGCCAACTCCAAACTTAAAGTGGAGGTAGTGT TTCCAGTATCCTCCGATTCTATGACAAAGACTTCTTCTGACTCCAGCAATAGTATAAAAGTCGGAGATGTGGCCCTA CCGGTGGTACCAGGGGTGGCGGAGGGTGCTCCATACACGGAGGCTGTGCAAGTTGCCCCTACATGAAGAT GAACTCCCTATCTAGCCTTCTGAAAGTCTGTCATAAACTGCCTGATTTGGAAAATGTGTACGGTGGGTTTATCGCGG AGAGGTTCAAGAGACAGCCACAGGGAAAACTAATAGCAGATGTGGGCTGTGAGCCAATTCTACATATGAGGCAC TTCCAGGCAAATAAGGAACTTCCTGATAAACTGGTTCATCAGGTCTTATCATGCGAGTCCAAGCGT

Seq. ID No: 27

>AOQS_2

ATGAATACCCTACCTGAACACTCATGTGACGTACTAATTATCGGCAGTGGAGCGGGGGGACTGAGCCTGGCACTTAG GTTGGCGGACCAGCATCAGGTCATTGTACTGTCTAAGGGACCGGTAACAGAAGGTTCAACTTTCTATGCGCAAGGTG GCATTGCCGCGGTGTTCGATGAGACGGATTCTATAGACTCCCATGTTGAAGATACCCTAATAGCCGGTGCCGGCATC TGCGATAGGCACGCCGTTGAGTTTGTGGCCAGCAATGCCAGAAGCTGTGTACAGTGGCTGATTGACCAAGGGGTGCT GTTTGATACCCACATTCAGCCTAATGGCGAAGAATCTTACCACCTGACACGTGAAGGTGGCCACTCCCACAGGCGTA TATTGCACGCCGCTGACGCCACGGGCCGTGAAGTGGAGACACTCTGGTCAGTAAGGCGCTAAATCACCCGAACATC CGTGTGTTGGAACGTAGCAATGCGGTGGACCTTATAGTCTCTGACAAAATCGGGCTTCCCGGGACTAGACGTGTCGT GGGCGCCTGGGTCTGGAACCGTAATAAAGAGACGGTAGAAACATGCCACGCCAAAGCTGTGGTTCTGGCTACAGGTG GCGCATCAAAAGTATACCAATACACGACTAACCCCGATATTTCTAGCGGTGACGGCATAGCAATGGCTTGGCGTGCA GCTAACGGAGGCGTTGAGAGGTGAAGGTGCCTATTTAAAAAGACCTGATGGAACGAGATTCATGCCCGACTTCGATG AGCGTGGCGAATTAGCCCCAAGGGACATCGTCGCACGTGCTATTGATCATGAGATGAAAAGATTGGGTGCTGACTGT ATGTTCTTAGATATTAGCCATAAGCCAGCTGATTTTATCAGACAACACTTTCCAATGATTTATGAGAAGCTATTAGG CTTAGGTATTGACCTGACCCAAGAACCTGTCCCAATAGTGCCCGCTGCTCATTATACCTGCGGTGGCGTCATGGTGG ACGATCACGGCCGTACGGACGTTGAAGGCTTGTATGCAATTGGGGAGGTGAGTTACACCGGGTTACATGGTGCTAAT CGTATGGCATCCAACAGCCTGTTGGAATGTCTAGTATACGGCTGGTCAGCAGCTGAAGACATCACGCGTAGAATGCC GTACGCGCACGATATCAGTACATTACCGCCGTGGGACGAGTCTAGGGTCGAAAACCCTGATGAAAGAGTTGTAATTC AACATAATTGGCATGAACTAAGGCTTTTTATGTGGGACTATGTGGGTATAGTAAGGACCACAAAACGTTTGGAACGT GCTCTTCGTCGTATAACCATGCTACAGCAGGAAATAGACGAGTATTACGCTCACTTTAGAGTCTCAAATAATCTTCT TGAGTTGAGGAATTTGGTCCAAGTCGCGGAGCTAATCGTGAGGTGCGCAATGATGAGAAAGGAGTCCAGAGGGCTGC ATTTCACTTTAGACTATCCCGAACTTCTGACACACTCAGGCCCCTCTATATTGTCCCCAGGAAACCACTATATTAAT AGAGGTAGTGGTGAAGGCAGGGGATCTCTTTTGACTTGCGGAGACGTAGAAGAGAATCCTGGACCCGGAAGTGTGAT GGGAGAAGATTAAGCGTTTGTTAAAGGAACGTAACGCGGTGATGGTGGCCCATTATTATACCGACCCGGAAATACAA CAACTTGCAGAAGAGACAGGGGGCTGTATCAGTGATTCACTAGAAATGGCAAGGTTTGGAGCCAAACACCCGGCCAG TACTTTACTGGTGGCTGGAGTACGTTTCATGGGGGAAACCGCAAAGATACTATCCCCAGAAAAGACCATCTTAATGC CAACCTTGCAAGCGGAGTGTAGCCTGGATCTTGGCTGCCCCGTTGAGGAGTTCAACGCATTTTGTGATGCCCATCCC GATCGTACAGTCGTAGGCCAACACCAGTGCAGCCGTCAAAGCTAGGGCTGATTGGGTGGTAACGTCAAGTAT CGCGGTGGAGTTAATCGATCATTTAGACAGTCTAGGAGAAAAATTATTTGGGCCCCAGATAAACACCTGGGAAGGT ACGTCCAAAAGCAGACGGGTGGGGACATACTATGCTGGCAGGGTGCTTGTATCGTGCACGATGAGTTCAAGACGCAA GCATTGACAAGGCTACAAGAAGAAGTACCCAGACGCAGCGATCTTAGTACACCCGGAATCACCGCAGGCGATTGTGGA CATGGCGGATGCTGTCGGCAGCACCTCCCAATTAATTGCGGCGGCAAAGACTTTACCTCACCAGAGATTAATAGTGG CTACAGACAGAGGCATATTTTACAAGATGCAGCAGGCCGTACCAGACAAAGAATTATTAGAGGCGCCGACGGCTGGA GAGGGCGCGACCTGTAGGAGTTGTGCACATTGTCCTTGGATGGCTATGAATGGCCTTCAAGCAATCGCAGAAGCCCT GGAACAAGAAGGCTCCAACCATGAAGTCCACGTGGATGAGAGACTGAGAGAACGTGCCCTGGTCCCTTTAAATAGGA TGTTAGACTTTGCTGCAACCTTGAGAGGA

Seq. ID No: 28

>ATMT 1

CCCTGATTTTGTTGACGGAGTTAGGAGAGCACTGCTGAAAGGCGTAGGTGGTTTGTAGGCGAGTTGGACAGGCGTG GCAGGGCTCATTTGCCGTCCGTAACGAACTTTGTCGCCGTTGCAGCTAGAGACTGTGCGCGTGCACAGGACAGACTG GCTGCTGACTTCGGTATCTTGGTCAGAAACGCGGGCTTATTCGGGTTCCCTGGCTACCTGAGGACTTCACTAGGCGA GAAGAAGGACTTAGAGAGGTTTTTGGACGCTCTGGATGAGATTGAACAAAACCCCGGTGGCGGATCAGGTGAAGGGC GTGGCTCTCTACTTACGTGTGACGTAGAAGAGAACCCGGGTCCCATGACTGCCCCGTTAAGCCGTGATGGTTTA TTTCAACGGCTTTATCAGTACACATGTTGTTTTTGCCCTTGAACAACTAGGTTTGTTCGCCTGGTTTGATGAAAGCG ATAGGTTAGATGTTCCTCAGTACTGCTGGCGTCGTAAGTTAGATGAACGTGTTTTTCGTCAACTTGTGAGTGCCGCC GAGGCATTCGGTTATCTTGATGTTCATGATGACTTGGTGACCCCAACGCCAGCTTGGTCCGAACTGAGGAGAAAAAT TGGCTTCTTCACCTGGGGCGTAGGCGGATACCACGATGTATTTGCCAACGCGGCTTCAATAGCTCGTGGGGAGAGGG CCTTCGGTAAAGACGTGCTACGTGATGAGGCTATGGTGGCCCTAGGCTCAGCACAAGCGGACATGGCGCTGATGAGA GACCTGCTGGATGAGCAGATTGCTGCGTTGGACTTTTCCGTAATAGCCGATCTTGGTTCAGGTATAAGCGAACGTGT CTGTCGTCTGGTGAAGTCAAGACCGGGAGCCAGAGGTCTTGGGGTCGATATATCAGCGTCTGCGACCGCATTGGCAG CTGGGACGGTTGAACGTCACGAACTAGCTGATAGAGTTCAACCTATTTGCGCAGACGTCTTAGATGTTCTGTTTCAC CAGTTCGTCCTAGGGACGAGAAGGATACATTGCCCGTATTCTCAAGCGGTTTTGAGTTAGCACATGCGTTAATGGGC TGGAGCGCCTCATACATATTTATTCGTTCTTGAAGCTCAG

Seq. ID No: 29

>ATMT 2

ATGCAGGCATTGCCCGTTAAGGGTGACACTGTAAGCCGTCCTCCCACTGTCCACAGCCTGCACCATGAACATGAAAG GGCTGATGGAATGTTGAGACTGCACTGTAACGAAAATCCTTACGGTCCGCCTTCCGGTGTTATCGCTTCTGTAACTA AAGAACTGGAGGGAAGATGTAGCACGTATCCTGACTCCGAAGTCACTGCTCTGCGTGAGGCTTTAGCTGGGCAGGTA GGGGTTGGTACCGACATGGTAGCTGTGGGTAACGGGGCTGATGAATTAGTCCTACTTATTACGTTAGCCTCTGCGGG TCCTGGGGATACTGTGGTTGTGACCGAATCTACGTTTCCAGGTTATGCAGCTTCAGCTGCAGTGGCAGGCGCGACTG TAAGAGGGGTGCCTCTACACCGTGACCGTGTATCTGCGACAGCGTTGGTAGAAGCTGTCGATGATGGAGCGAGGTTA GTCTTTGTATGTAACCCTCATAACCCAACGGGTACCGTGCTTAGCCCCGCAGCAGTCGAAGAAATCTTGAGGGCATG TGAGAGGACTGGTGCCGGTGCCTGTTTTTGACGAAGCATACATTGAATTTGCTGGTCCCGGGTTTGATCATGCATTGG ATGCAGTCAGAGCCGGGAGACGTCTACTGGTACTGAGAACTTTTTCAAAGGCCTGGGGACTGGCAGCACTGAGGGCG GGGTACGCCGTCGGTCCAGCCGATCTTGTCGCGGGTATAATGGAGGCCAGGAGACCCCTGCCATTTTCCGTAAATAG GTTGGCGCAACAGGCTGCACTTGCCGCGCTAGGATCTCCCGATCATATTGCAGAGGTCTACGAAAGGACAACACGTG AAGACTCCTGGAAACTCCACGAGATTTGCTTCTCGTTTGGCTGATGAGCATGGAATCTTAGTAAGGGATCTAGCACC CTTCGGTTATCCTGGTCACGTGAGAGTAAGCGTGGGTACAGCTGAGGACACTGATCAATTCTGCGCAGCCCTAGGAA GCCTTCTTGCTTCTCCGCGTTCTCATGCCGCCACCGGGCATGGTTTGGGGGGCATCCTCTGGTGCTGGCGGAGCGGGA AACGCTGCCATCAGGTCCGCGAGAGATGTTCTGCCGGTACCAACGCTTGATCCCGTCGCTCCTCAAGACCTTTTCAA CGGTTATGTCGGGGCTCATGCAGTATTCGCGCTAACTCGTTTGGGCGTATGGGATAGATTGGCGGAAGGTTCTGAGC CAACTGTAGATGCCTTAGCGGTTCAGGCAGGAACGGATGCTACAGGCCTGATGCCACTACTGCGTGTTGCCGCCTTA GCGTGGCTTTTTCACGTGGGGCGTCGGAGGATATCACGAAGTTCTTAGATCGTTGCCGGCATTGGCCAGGGGGACCT CCGTATTCGAGCAGGACGTCGATCGTGATGGAGGGATGGTAGCCGTGGGGTCTGGCGAGGTCGGACGTGAAATGATG CTTCCTTTGGAACAGAAGTCCTTGCAACAGTTGACTTCAGGACTGTGGCCGACTTGGGATGTGGAGATGCCACTAG GTTGTTGAGGTTGTGCGATGGACACCCACACAGGAGGGGGGACAGGCATCGAAATTAACCAAGGCGCTTGCGTACAGG CTAATAAGCGTGTTGCAGACGCGGGGCTGGCTGATAGAGTGGACATTGTGCATGGTGATGCTCTTGACCTTTCAGGA CGTACGTTTCCGGAAGTCGATCTAGTCACTTCCTTCCTGATGATGCACGATCTATTTGACGCGACAGGTGACCCCGT GGGAGTCATGAGGACCTTGAGGGAGGTCTTCCCGAGAGCGCGTCACTTCCTTATAGGGGATACAGTAGCCCAGGACT GGGAAGAGAGACGTGAGGGTTTGCCAATGTTCTCAGTGGGCTTTGAATTGGTTCACGCGTTTATGGACACTCCTATC ATGAATAGGGGCACCTACGAGGACGCTTTCGCGGGCGCCGGTCTTCGTGTAGCCAGAAGGGAGCCACTAGGGGCTCC TAGTACGTGGCTTTGGCTATTGTCTACAGAA

Seq. ID No: 30

>ATMT 3

ATGAGGCGTCGTTGGGCCGTTACGGCCTCTGCATCCTGGTGGGGGACCGCCTGTGAACTTCATGCCAGTGCGTCTGC CGCATATACGCCACCGTGCCACTCTCCGGGTACAGGAGGAAGGGGTACCGAGTCTGGCCCTATGACGGCACCTGTCC GTCAGGAGACGAGAAACTATAACGCATCTGTACCATCCGCTGACGACCTTGTCCGTTTACATCTTAGCGAGAGTCCG AGAGGGTTTGGTCCAGGCTTTGGCAAGACACTGGGAACTACCCGAGGAGCATATAGCTGTCGCCAATGGGAGCGACG AGTTAGTTCTAGCCACGGCGCTAACTTTAGGTGACCCCGGGTCACCTGGTCTAGTCACCGCGGGGACCTTCCCTGGG TACCTTGCAGCCCTAGAAAGAATAGGACGTGGTGCGGTACAGGTTCCCTTAGCAGGATCTGGAACCGACACTGCAGC CTTTGCAGACCGTCTTCCAGGTTGCGGAATTGGTTACGTGTGTAATCCACAACCCTTGCGGGTCCGCATTGACCC ATGATGAACTACACCGTTTAGTCGCCGCGGCGCGTGACTCTGGGACCCCATTGGTGTTCGACGAGGCATACCATGAA TTTGGGCCCCGGCGCAGCCCCAAGCACGTACCCACCTAAGGGAGGATACTCCAGTCTTAGCTCTAAGGACGTTCAG CAAGGCATACGGCCTGGCCGCACTTAGGATAGGGTACGCGTTGGGTCCTGCCGATCTGATTGCTGAGGTGAGGAGAA CATTAACTGTGCTTCCTTTCAGCGTGAATAGAGCAGCGCAGGCTGCCGCTCTTGCTGCATTAGATGATCAGGAGTTC TTAGGTAGCGTGAGAGGGATTCAGCCGCCAGACGTCAGTGGTTTTGCGCTGAGCTGGAGCGTAGGGGGTTATAGATA CCTTCCGTCTGTTACGAATTTTGTGGCGGTAGAAGTTGCTGCCTCTGCAGAGGCACAAGACGTGCTGGCAAGGGATC ATGGTATTTTGGTGAGAGATACCGGAATGTTTGGATTCCCCGGTCACCTGAGAGTGAGCTTGGGCTCAGTGGAAGAA CTACGTGGATTCCTGGACGCCCTGGATAGAGTTACGGCTGGCAGTAGGGGTGGGGGCTCTGGAGAGGGAAGAGGTTC CCTTCTAACTTGCGGGGATGTAGAAGAAAACCCAGGACCGATGACCGGGCCAGTTAGTACTTCAGCTCCAAGTCGTT GGCCAAGAACTTGGAGGCCTAACAGGCTGGAACCCACCTCACGTGGTGGCCAACCAGGTCATGCAGCGAGGAGGAGGAGT CCTGCAGCGGGACGTAGGAGGAGAAGGGCTTCAGAAGCCCGTCCGCCCCTAGCGGAAGACAACCGGCTGTGAGGAC GGAAAGGTGTGAGAGAGTGAGCCCGTTAAATACGCTGCCAAGTGAATGGCAGGGCCAGGCACCTACTCCACTGAACC CAGACACTGCATTCAATGGGTACATCTGTGCTAACGTATTGCATGGACTTTGAGCGTCTTGGAGTATTCGAACTTTTG AGGGATGAAAAGAGCTTAGATATGGATCGTTTCTGCGAGACGAATGGTCTCGATTCTGCGGTTTTTAGGGCGCTTGT CGGAGCTGCAGAGTCATTCGGCTATCTTGACGTCAGAGGAGCCCAAGTAAGAGCCACGTCTGTGGGTGAGGATGTTG CTAGATACTTGGGTTTCTTTACGTGGGGTGTTGGGGGATACCACGATATTTTTGCAAGTGCTGCTCCTGTCGCCAGG GGCGAGAGGAGGTTTGGCGTTGATTTGCACAGGGATGAGGGGATGGTCGCCCTGGGAAGTGCCCAGGCTGATACCGC GTTAATGAGACACCTTGACGAGGAAATAGCAGGTATAGACTTCAGAACCCTGGTCGATCTTGGAGCCGGGGTAT CCGAGCGTGTGAGTAGACTCGTGAAGGCACGTCCTGGTACTCGTGGGATCGGGATCGATATATCACGTCCAGCCACT GAACTTGCCAGAGACACCGTCGCAGGATACGGCCTGGCGGGAACGGTCGAGCCTGTGTGCGCCGACGTCTTGGACAT ATTGTTCAATGGTCAAGAGATTGACGGTGGGGATGCAGCAGACGTTGTAATGTCATTTATGTTCCTACATGACTTAT TAGCTGCGCCCGAAAGAAGGAAGAAGTAGTACCTAGATTACGTAAGGCTTTTCCGAGGGCCCACACGTTCTTGTTG GCTGACACTACGATAAGGCCACGTAACGAGGAAGGAGGCGGCAGGTTGCCTGTCTTCTCATCCGGGTTTGAACTTGC TCATGCCCTTATGGGTGTTCCTCTGCACACCAGAGAAGAATACGAAGAACTATTTGAACGTGGAGGTATGAAGCTAC GTAGAAGTGTACCTTTCGGGGCGCCTCATACCTACCTATTCGTCCTGGAGGCGAGT

Seq. ID No: 31

>ATMT_4

GAGGTAACGGAAAGCGACGCGAACTTCGTACAATTTGGCCGTTTTGATGATTCACATGCTGTCTGGCGTCAGATATT GGATAGAGGTGTTCTGGTCAGGGACAACGGCGTACCTGGGTGGTTGAGGGTAACTGCTGGTACCCCAGAGGAGAACG ATGCCTTCTTAGACGCCGTTAGAGAGCTTAAAAAGGAGCACGATGCCGGCGGTGGAAGTGGGGAAGGGCGTGGGTCC CTGCTTACTTGCGGTGACGTAGAAGAGAACCCCGGCCCATCTAGTTCATCTTCCACACGTACTGATTTTGCCCAGTC TGCAGTGGCCAGCATCTTTACAGGTGCGATAGCGTCACACGCTGCGGTTTTAGCAGATGATCTGGGATTGTTTGATG CACTAGCTAAAGGCAAGCTGAGGAACAGAGACTTAGACCGTTCCCCTTGGTTGAGAAATCGTATCAGGATTAGCGGT GCCCTAGAGGCTCTGTGCAGGGTCGGAGCCGTCCAGAGATGCACAGACGGCTACGAGCTGACCGACGTAGGGACGGA GCGCTGACCCTGCGACGGGTGTCCACGGGGGAATCGTGGCCGAATCAAGCGGTGCTATCGGGGCACGTTACCTAGAT GAGACGATAGTCAACTTGTTAGAGTCACTGAGGCCAGAGGGTAGGATATGCGATATTGGATGTGGAACCGGGGCTAG ACTGTTAAGAGTCTGTCGTAGAGTCAATCAACCCGGTATTGGATACGATTTGTCAGCCAAGGCTGTGGAAGCAGCAA GGGAGACTGTTGATGAAGCCAGAAGGATTGGTGTAGATATCGACGTGAGGCAGGGAGACGCCACTGCGCTTACTCAA GATCATCCTGATGTGGACATAGTGACCCAGGCGTTTATGACTCACCACATAGCTCCTGACGACTACTGCGCGGCCGT TTTGAGGAGTTATCGTTCCCGTTTTCCCAGAGCTAGGTATTTGGTTATTTTCGACACTGTTCCGTCTCAGGACTCCG AGGAACCCGAAATCTTCGCCCCCGGCTTCGACTATATTCATGCACTACAAAATATGGAGCCGAGGTCACGAGGGGCG GCTAGGAGAATGTTCACGGAAGCGGGTTATATTTGCCGTGAGGAAGTTGAGTTGCCTGTTCCCAACAGTTACGCGTG GGTTCTGGAGATGCGTGATAGAGAAGGCCCGGCTTCC

Seq. ID No: 32
>ATMT 5

ATGACCAATGACCCTTCCCCACGTGATGCCCGTGACGAATTGCCGGTGCGTGACGAATTGAGGGGACAAAGTCCATA TGGTGCACCACAGCTAGATGTTCCGGTTCGTCTTAATACTAACGAGAATCCTTACCCACTTCCTGAGGCATTAGTAG AAAGGATCGCTGAGAGAGTAAGGGAAGCAGCAAGGTCCTTGAACAGGTACCCAGATAGAGACGCCGTAGAATTAAGA ACCGAACTAGCGAGGTACCTGACAAGAACCGCAGGCCATGAGGTTACCGCTGCACACGTATGGGCCGCAAATGGCTC CAATGAAGTACTTCAGCAGCTTCTGCAGACTTTCGGAGGGCCTGGCAGAACTGCTATTGGGTTCGAACCGTCTTACT GTTGATGCCGCCAGAGCTGCCATTGCCGAGCACAGGCCCGAAGTGGTTTTCATCACCTCCCCCAACAATCCAACCGG TACGGCAGTGCGTGCCGAGACAGTTCTGGCGCTATATGAAGCGGCGCAAGCGGCCCGTCCCTCCATTGTGGTAGTGG ATGAAGCATACGGCGAGTTCAGCCATCATCCTTCACTGTTACCATTGATAGAAGGTAGGAGGCACCTTGTCCTATCC CGTACTATGTCCAAGGCCTTTGGGGCAGCCGGTTTAAGATTGGGGGTATCTGGCCGCCGACCCAGCAGTGGTCGATGC GGTACAATTAGTCAGGCTTCCCTATCATTTAAGCAGTGTCACCCAAGCGACTGCCCTGGCAGCGTTGGAGCACACGG GAAGTCACCGAGAGTGACGCAAACTTTGTGCAGTTTGGCCGTTTTGATGATAGCCATGCAGTTTTGGAGGCAGATCCT TTGCTGACTTGCGGTGACGTCGAGGAGAACCCGGGGCCTGCTCAGGCGGCACCCACACGGTGACAGAGGTGTTCAA TCACGCGATAACTGCATCCGCTATCAGTGCAGCTTGGGAGATGGGGGCCTTTGACGCTCTGAGGGTTAGTGAGAGGC TAGACGCTGATGAGTTTGCTGCGCGTGAAGGACTTGACACTAGATCCACACATGAACTTTTTCGTGCTCTGGCTGCT GCTGACATCGTATCAAGAGACGCGCGCAGATTCGTCGTGGTCCGAATTTCGCTGAAGCTGATAGATGCAAAAGCCT GTTCCTTTTACCGTAGAGATGCCGCAGCCATCTCAGTTGCATGCCGTGAAATTAACGCGGAATGGTGGGACCCTGTT TTCTGGCCAGTCGTCTCTGGTCTTGATTTCACGAGTGTTGCAGACCTTGGATGCGGTTCTGGTGAACGTTTGATTCG TTTAGCTAGGACGGGACCGGAGGTGATGGCCCTAGGTATTGACTTTGCCGCTGGGGCGATCGAAGTTGCTACGGCGG CTGTTGCTGAGGCTGGTTTGTCAGACCGTATCTCATTAGTCCAGGGCGATGCCACAGCTTTAGAGCCTCGTCCCGAA TTTGCTGGTGTAGATTTACTAACTTGTTTCATGATGGGGCATGATTTCTGGCCGAGAGCAGAGCAGTGGCTAGTCT GAGTGGAGACCCGTGTTTGAAGAAGCCGGTTGGAGATGTGAGGGGGAGCATCCTATCAGCGTACCTGCTGATAGCGT **AATGTTCCACTTGGTACCTAAT**

Seq. ID No: 33

>ATMT 6

ATGACAAATGATCCTTCACCGAGGGACGCGCGTGACGAGCTACCTGTACGTGACGAATTGAGAGGTCAATCACCCTA AGCGTATTGCTGAGAGAGTGCGTGAGGCCGCGAGAAGTTTAAACAGGTACCCTGACAGGGACGCCGTTGAGCTTAGA ACAGAATTGGCTAGATACCTAACTCGTACCGCGGGTCATGAAGTTACAGCAGCACATGTCTGGGCCGCCAACGGGTC TAATGAAGTTCTGCAGCAACTACTGCAGACGTTCGGCGGACCGGGCAGGACAGCTATCGGCTTTGAACCTTCCTATA GCATGCATGCGCTGATATCAAGATCTACCGGGACGGGGTGGATCTCCGGACCCAGGAACGACGATTTCACGATAGAT GACGGCGGTACGTGCTGAAACTGTACTTGCTCTGTATGAGGCGGCTCAAGCAGCAAGGCCTTCCATTGTTGTTGTGG ATGAAGCGTACGGCGAATTTTCACATCATCCGTCTCTGCTACCGCTGATAGAGGGTCGTCGTCACCTGGTATTGAGT AGGACGATGTCAAAGGCCTTTGGGGCGGCTGGACTGAGACTGGGCTACCTAGCCGCAGATCCTGCGGTCGTCGATGC AGTTCAATTGGTAAGGTTACCCTACCACCTATCTAGCGTCACACAGGCTACCGCTCTAGCAGCATTAGAACATACTG ATACACTGTTAGGCTATGTGGCTCAGCTAAAAGGGGAACGTGATAGATTAGTCGCAGAGCTTAGAGCGATCGGATAT GAGGTGACCGAGAGTGATGCGAACTTTGTGCAGTTTGGGAGATTTGACGACAGTCACGCTGTCTGGAGGCAAATTTT GGACAGGGGAGTTTTAGTTAGAGATAACGGGGTACCCGGGTGGCTGAGGGTAACTGCTGGGACACCAGAAGAAAATG ATGCTTTTCTGGACGCAGTCCGTGAGCTGAAGAAAGAGCACGACGCAGGAGGAGGATCTGGAGAGGGTAGAGGCTCC CTATTGACATGCGGCGACGTCGAGGAAAATCCGGGCCCATCCACTGAGGTTAGCGAAGCCCAGGCAAGGAGGGCGGT AGCGGACATTTTTAATAGCACTTTGGCGTCTTCCGCTATTGGCGCCGCTTGGGAGCTAGGGGCACTGGACGAACTGA GAGAAAATGGGAAACTAGACGTGAGCGATTTTGCGGTTCGTCACGATCTGCACGAACCTGCTGTAGTAGGGATGTTT ACGGCGCTGGCAAGCGTTGGCATTGTGCGTCGAAGGCGCCACCGTTGTTGTAGGTCCTTATTTCGACGAGGCAAA TCACCACCGTTCCTTATTTCATTGGCTTAACCAGGGCTCTGGAGAACTGTTCAGAAGGATGCCACAAGTGCTGCCCA ATGAGAATCGTACTGGAAAATTCTACCAACGTGACGCCGGAGCCATCAGTTACGCCTGTCGTGAGATCTCTGAACGT TATTTTGACCCAGCATTCTGGGCGGCAGTAGATGGTCTTGGCTACACCCCAACTACAGTCGCAGACCTTGGCTCAGG CTCAGGGGAGAGGCTGATTCAGATTGCGAGAAGATTCCCGGGGGTGAGGGGTTTGGGGGGTAGATATCGCCGATGGAG CCATCGCTATGGCCGAAAAAGAGGTAGCCGCTAAAGGGTTCGGTGATCAGATCTCATTTGTCAGAGGCGATGCGCGT ACCATCGACCAAGTATCTGCCAGAGGTGAATTTGCCGAAGTGGATTTGTTAACATGCTTTATGATGGGGCATGACTT TTGGCCCCGTGAGAATTGCGTACAGACCTTACGCAAATTGCGTGCAGCGTTCCCGAATGTGAGGAGGTTTTTACTGG GAGACGCAACAAGGACGGTCGGGATACCGGATAGAGAGCTGCCGGTTTTTACTCTGGGTTTTGAATTTGGTCATGAC GCATGCAATCGATAGCTTATCTGTGAGTGTTGTTTTCGAACTAGAG

Seq. ID No: 34 >BH4reg 1

ATGGCAGCGTCAGGGGAAGCCCGTAGGGTGCTAGTATATGGTGGTAGGGGAGCCCTGGGTTCCCGTTGCGTACAGGC
TTTTAGAGCGAGAAACTGGTGGGTGGCTAGTATCGATGTGGTCGAGAACGAAGAAGCTAGTGCTTCAGTGATAGTTA
AGATGACAGATTCATTTACTGAGCAGGCTGATCAGGTTACTGCTGAAGTTGGGAAACTTTTAGGGGACCAGAAGGTA
GACGCAATCCTTTGCGTCGCAGGTGGGTGGGCTGGCGGGAATGCGAAAAGCAAATCTCTGTTTAAAAATTGCGATTT
AATGTGGAAGCAATCAATCTGGACCAGCACCATTTCTTCTCATCTAGCTACAACACCCTAAAAGAAGCAGGCGGCTGT
TAACATTGGCAGGAGCAAAAGCCGCCCTTGACGGTACCCCAGGAATGATTGGATATGGTATGGCTAAAGGAGCTGTT
CACCAGCTATGTCAAAGCCTGGCTGGTAAGAACTCTGGAATGCCGTCCGGCGCAGCGGCGATAGCAGTATTCCCGT
AACCCTGGATACTCCTATGAATAGGAAGTCCATGCCTGAAGCCGATTTCTCTAGTTGGACTCCGCTGGAATTTCTAG
TAGAAACTTTCCATGATTAGATAACCGGAAATAAGCGTCCTAATAGTGGTAGTCTAATACAAGTCGTCACCACGGAT
GGGAAAACCGAGCTGACCCCAGCGTACTTT

Seq. ID No: 35 >BH4reg 2

ATGACCGCTCTTACCCAAGCTCATTGTGAAGCCTGCCGTGCGGATGCACCTCACGTTAGCGATGAGGAGCTTCCAGT TTTGTTAAGGCAAATACCTGATTGGAATATAGAGGTCCGTGATGGGATAATGCAACTTGAGAAGGTGTATCTTTTTA AGAATTTCAAACATGCCTTAGCCTTCACGAATGCAGTGGGGGAAATATCAGAGGCCGAGGGGCACCACCCGGGCCTT CTTACTGAATGGGGTAAAGTTACTGTGACTTGGTGGAGTCACTCTATCAAAGGTCTGCACAGGAATGATTTTATTAT GGCAGCCAGAACGGATGAGTCGCGAAGACAGCAGAAGGGCGTAAA

Seq. ID No: 36 >BH4syn 1

ATGGAAGGGGTCGTCTTGGCTGTCTGATGCGTACTAACTGGGGCCAGCAGAGGATTCGGCAGGGCCTTGGCTCC
ACAATTAGCTGGACTACTGTCCCCGGGATCTGTGCTGTTGCTTTCTTCTGCGCGTTCCGACTCCATGCTAAGACAGTTGA
AAGAGGAGTTATGTACCCAGCAACCCGGTTTACAGGTAGTTTTTGGCTGCCGCCGCCGACCTTGGTACTGAGTCCGGCGTG
CAACAACTACTTTCTGCAGTCAGAGAATTACCCCGTCCAGAAAGACTTCAGAGGCTGCTGTTGATAAACAATGCGGG
CACACTGGGTGATGTGTCAAAGGGATTTCTAAATATCAATGATCTAGCAGAGGTGAATAACTATTGGGCCTTAAATT
TAACCAGCATGCTTTGTTTGACGACAGGGACATTAAACGCATTTTCTAACAGCCCCGGACTTTCAAAGACAGTAGTC
AATATTTCTTCACTGTGTGCGCTGCAGCCCTTCAAGGGGTGGGGACTGTACTGTGCTGGTAAAGCAGCTCGTGACAT
GCTGTACCAGGTGCTGGCCCGTTGAAGAACCAAGTGTTAGAGTTTTAAGCTACGCCCCTGGACCACTAGACACGAACA
TGCAACAGTTGGCCCGTGAAACCTCTATGGACCCAGAGCTGAGATCCAGGGTGCAAAAACTTAACTCTGAGGGAGAG
CTAGTTGATTGTGGAACTAGCGCACAAAAACTATTGTCCTTGTTACAAAGGGATACCTTCCAAAGTGGAGCGCACGT
CGATTTCTACGACATT

Seq. ID No: 37 >BH4syn 2

Seq. ID No: 38 >BH4syn 3

Seq. ID No: 39 >BH4syn_4

Seq. ID No: 40 >BH4syn 5

ATGCATCACCATCACCATAGCTCCAAGGAGCATCACTTGGTCATAATCAACGGTGTCAATAGAGGGTTTTGGGCA
TTCAGTTGCCTTAGACTACATTAGGCATTCTGGGGCGCATGCCGTCAGCTTCGTGCTTGTAGGGCGTACGCAACACT
CTTTAGAACAAGTGCTAACTGAGTTGCATGAAGCAGCATCCCATGCTGGAGTGGTCTTCAAGGGCGTCGTTGTTAGT
GAGGTCGATTTAGCACCATTTAAATAGCTTAGACTCTAATCTAGCCCGTATTCAGTCTGCCGCAGCAGACCTAAGGGA
TGAGGCGGCGCAGAGCACTAGAACAATAACGAAGAGCGTGTTGTTTAACAACGCCGGTTCACTAGGGGACCTGTCAA
AGACTGTAAAAGAGTTCACCTGGCAAGAGGCAAGGTCATATCTGGACTTCAACGTGGTCTCACTTGTGGGACTATGC

TCTATGTTTCTTAAAGACACGTTAGAAGCGTTTCCAAAAGAACAATATCCCGACCACAGAACTGTCGTTGTCTCCAT TTCTTCCCTGTTGGCTGTCCAGGCGTTCCCAAATTGGGGGCTATACGCTGCTGGGAAAGCGGCCCGTGATAGATTGT TAGGCGTCATAGCGTTAGAGAAGCCGCCAATAATGTTAAGACTTTAAAATTACGCGCCCGGGTCCCTTAGACAATGAA ATGCAGGCCGATGTCAGACGTACTCTTGGCGATAAAGAGCAGTTAAAAAATTTACGATGACATGCATAAATCCGGCTC TCTAGTTAAGATGGAAGACCTCAAGTAGAAAACTTATTCATTTACTAAAAAGCTGATACGTTCACGTCTGGCGGGCATA TAGACTTTTACGACGAG

Seq. ID No: 41

>DAC 1

Seq. ID No: 42

>DAC_2

Seq. ID No: 43

>DAC 3

Seq. ID No: 44

>DAC_4

ATGGACGCGGGTACGCGTAGAGTGGATGATGCGGCCGTTCCAAGTACGGGTCCATCCGCATCCTTACTAAGATCAGC GAATATGTTAAGTGCCGCGTTCGGTCTAACAGCATCTCTATACTCCAGATTACGTGGGGTGTGCTCCAGTAGAAGAG CCCTATCCACGTCAGCTCGTACGTCTGAGGCGGCCGGAGTAGGGGGCGAAACCCGGAGTCGCTGCCGCATTAACCGTT CCCTCAACTGGGCCCTCTGCTTCCGAAGCATCACCAGCTGCTCTATTAAGGATTCAAGTCGCGGAAGAGTGGGCGCG TGCCAGTGGACTATTGGATAGGGAAGACTGCCAGGTTGGTCTGGCATTCGATGAAGCCATGCATTTACATAGTGGAC CAGCTGGTCATCCTGAAAGACCAGCCAGGACCAAAGAAATACTGGCGCAGCTACACGCGTCAGGTTTAGTGAGAGCT TGTGCCCAAGTCCCTAGTAGGGAAGCGACTGAAGAAGAATTACTATTGGTCCATGACGCCAGACATGTAGAGAGGGT GTTACGTCATGAAGCGGCTGGTCATAAAAAGGCTAAGGCTTTCAGTTTCCCTTTCGGCCCCGATACATATGTTTGCG AGCATACAGCGAGATGCGCTCGTCTAGCTGTAGGTTGCTTATTGTCTCTTGTTGACGCTTCTTTAGATCCAGCAAGT CCGGTTCGTACAGGGATGGCGGTAGTTAGACCGCCCGGGCACCACGCAACCAGTGATCGTGCGTCCGGATTCTGCTT GTTTAATAATGTCGCTGTTGCCGCCAGACACTTGCAGAGACGTCATGGTTTAAAAAGAGTTGCAATTGTTGACTGGG ATGTTCATCACGGTAACGGTACGAACGATCTGTTTACCGAAGACCCAAATATACTGTTTTTCTCCGTTCACCGTTTT GATAATCACGGGTTTTTCCCCGGGAGTGGTTTTCTTGAGGATGTTGGTCATGCGCAAGCTCGTGGTTACACGGTGAA CGTCCCCTGGAGAAAGGCTATGGGGATCTTGATATCGTTCATGTCGTAAAATACGTGCTTTGCCCCGTCCTAGAGA GATTCAAGCCCGATGCGATCCTGGTCTCCGCTGGGTTCGATGCCGTAAAGGGCGATCCACTAGGCGAGTGCAGAGTG TCTCCGGAGGCTTTTGGCTGGATGACGCGTTGTCTACATCGTTTAGCTCAGCGTTATTGCGACGGCAGGTTGTTCCT GGTACTAGAGGGCGGGTATAATCCTGACATGATAGCACAGTGTTGCATCGAATGCGTTCAGTCCCTAGTGGCAGAGG CTGCTGGATTAAGGGGCCCTTGGCCCGAGTTCCCTGCTGTGGGAGTTCCGTTGGCAGAAGGAGCGCAGCTGAGTGCA AGCACCACCTTTAGCTTCCCCCGGTAGCACACCAACTTCCTCTCTTGTTTAAGGCCAAGTGGGGGTGAAGCACCGC CTAGATCACCTCCGTCTGCCAGCGCGTCAGCGGGAGGAGGGCGCAAGGCCAAAGGGCGCGTGCTCCAAGTTCTAAGACA GTCAGGGCGGTAAGACAGCTGACAGAGATACATCACCTGCTACCTTTGGAGCTGCCTGTTGCGCCGCGTCCAGGGGA CGGTCCCGGCGCTGCAAATAAGTCCGCCAGAAAGAATGAACGTAGGAGACTTGGGAGAGGTAGGAGGGGACCGGAAG AGGAGGGAGCCAGTAGTGACAGTTCAGGCTGGGCCATCGCTTGTGGTTTAAGTGATGCTGAACCCTGGCCGAGTCCA ATAGTGCATCTTCATGGCTAGGTTCTCCGACTACAGCAGCGACCGCAGTCGCCCCTCCCGCGAGGGGCGACAGGAAG **GTGAAACGTCGT**

Seq. ID No: 45

>DAC 5

Seq. ID No: 46

>DAC 6

ATGAGGAATAGGTCAAGTGGGTTCTGTCTTGTAAACAATGTCGCTGTGGCAGCCGAATATGCAAGAGATCGTTACCC TGAAGTGGAGCGTGTTCTAATCTTCGACTGGGACGTTCATCACCGGCCAGGGAACGCAGCAGATCTTCGAGCAGTCCC CAGATGTACTGGTAATCTCAGTGCACAGGCACGATGGTCACAGCTTCTATCCTGCAACTGGAAGTGCAGGGGAAGTA GGCTCTGGGCCGGGAAGAAGTATCTGTCAATGTGGCTCTTCCTGCAGGTTATGGCGGGGCTGCACTTTGGACAGC TTGTGCCCATGTCCTTCTGCCTGCGGCAAGAAATTTTCAACCCCAACTTATTCTAGTCTCCGCTGGCTTCGATGCAG CGGCGAGTGATCCACTAGGGGGAATTTAAGGAGGCTG

Seq. ID No: 47

ATGGTGAGAAGTAGTCAGGCTACAACATTTAGTTCTTCCCCCTACTTTGCGGATAGGGGGATTCACGGTACCGCACA GCCGATCACTGAAAGAATAAACCCGCGTAAGTGTACTTTTCACATATTGCCACCAGGCCTTGGGGGATGGTTGTATC TTTTTCCAAAAATGAGTAAAACAGTTGCTTATTTTTATGATCCGGACGTCGGCAACTTTCACTACGGCACAGGACAT CCGATGAAGCCGCACAGGCTGGCGCTTACACATAGCTTGGTTCTGCACTATGGGTTATACAAGAAGATGATTGTCTT CAAACCATACCAGGCAAGTCAGCATGACATGTGCAGATTCCACTCAGAAGATTATATTGACTTCCTGCAACGTGTAA GCCCAAATAATATGCAGGGATTCACGAAGAGCTTAAACGCGTTCAACGTAGGAGACGACTGCCCTGTGTTTCCGGGG TTGTTTGAGTTTTGCAGTCGTTATACCGGCGCATCTTTGCAGGGAGCCACGCAACTAAACAACAAAATTTGCGATAT AGCGATTAACTGGGCAGGGGGCCTGCATCATGCGAAGAAGTTTGAGGCCTCAGGTTTCTGTTATGTGAATGATATAG TCATCGGGATTCTTGAGTTGTTGAAATACCACCCTAGAGTCCTATACATTGATATTGACATTCATCATGGAGACGGT GTTCAAGAGGCATTCTACCTAACTGACAGAGTAATGACCGTAAGTTTCCACAAATACGGAAATTACTTTTTCCCAGG AACAGGAGATATGTACGAGGTCGGCGCAGAATCAGGGAGATACTACTGTCTTAATGTTCCTCTTAGGGATGGAATTG ATGATCAGAGCTATCGTCACTTGTTTCAGCCAGTAATCAAACAGGTCGTTGATTTCTATCAGCCAACTTGCATTGTT CTTCAGTGCGGGGCGGATTCTCTGGGATGTGACCGTTTGGGTTGCTTCAACTTATCCATACGTGGGCATGGGGATTG TGTACAATATGTTAAATCTTTCAATATACCACTGCTAGTATTGGGCGGTGGTGGTACACAGTTAGGAACGTCGCCC GTTGCTGGACATACGAGACGTCACTTCTAGTGGACGAAACGATATCTGAGGAGCTACCATACAGTGAGTACTTCGAG TATTTTGCTCCGGATTTTACGCTACATCCAGACGTTAGTACAAGGATTGAGAACCAGAATACGCGTCAATATCTTGA CCAAATTAGGCAAACAATCTTCGAGAATCTGAAAATGTTGAATCACGCCCCCTCCGTTCAGATCCATGACGTGCCGA GCGATTTGCTTTCCTACGACAGGACAGATGAGCCGGACCCCGAAGAACGTGGGGCCGAGGATAATTATACGAGACCA GAGGCATCTAACGAGTTTTACGATGGAGACCATGATAATGATAAGGAAAGTGATGTGGAGATC

Seq. ID No: 48 >DAC 8

ATGTGGGATGTTCATCATGGTCAGGGGATACAGTACATTTTTGAAGATGACCCTAGCGTGCTATATTTTAGTTGGCA
TAGGTATGAGCACGGTTCCTTCTGGCCCAATCTTTCAGAAAGCGATTACGATAGCATAGGGAAGGGTAGAGGGACGG
GTTTTAACATCAACCTACCCTGGAATCAGACTGGGATGGGTAATGCGGATTACGTGGCCGCCTTTTTCCATGTATTG
TTGCCACTTGCCTTTGAGTTCAACCCAGAGTTAGTCCTTGTTTCTGCCGGATATGATTCTGGGATCGGTGACCCCGA
GGGACATATGAGAGCTACACCTGAGTGTTTTTCTCACCTAACTCACATGTTGATGCACCTTGCAGGGGGCAAGCTGT
GCATGATATTAGAAGGTGGCTACCACCTACGTAGTTTGTCCGAGAGCGTAAGTATGACCGTAAGGACTTTGCTACGT
GATCCAGTGCCCAGGCTTTCAGGTGAAATGACGCCCTGCTATTCAGCCCTTGAGTCTATACAGAATACGCGTCATGC
TCACTCACCATATTGGAAATGCCTTCTTCACGACGAAACTAGACTGGTGGAAGAGATTTCTACGAAAGGACTTGCACCCT
ACTCCCCCAATTACAACTATGGTCGTCGCAAGCGTGGAGAAATTTCTTGAAAACCACATGAAGAAGATCTTGCACCCT
ACTCCCCCAATTACAACTATGGTCGTCGCAAGCGTGGAGAAATCCGCTTAACTTACCCGCGGGTGTTCAGTTAGAGGA
GTCCACTGTCACGCCAGAGCAGGCCAGACATGCAATCTCCGTATTCAACCCCAGATGAGTTAAATGAGAACGTGCTTA
ACTCAGTTTCAAAGATGCTTCCCGCCCTAGAGAAACTCGTCAAT

Seq. ID No: 49

>DAC_9

ATGAAAACCCATCCCCATCCTGAACGTCCGGATCGTCTTCAAGCGATTGCCGCAAGTTTGGCTACAGCAGGAATATT CCCAGGGAGATGTTACCCTATCCCGGCAAGAGAGATCACTAAGGAAGAGTTACAGATGGTACATAGTTTGGAGCATA TAGAGACGGTCGAATTGACAGGTCAGATTCTATATAGCTATTTCACGCCGGACACCTATGCGAATCAACACTCAGCT CACGCTGCGAGGCTTGCGGCGGGTTTGTGCGCTGACCTAGCTAAAGAGGTCTTTAGTGGCAGGGCTAAGAACGGCTT TAGCGGCGCTTGCCGCCCAAGTGGCGGAGCCAAGAAGATCTTGATAGTAGACTGGGACGTTCATCATGGGAACGGC ACACAGGAAATATTCGAGCAAAATAAATCTGTTTTATACATATCGTTACACAGGCACGAGGGCGGAAAGTTCTACCC GGGTACAGGGGCGCGCACGAATTTGGTACTATGGGAGCCGAGGGCTATTGCGTGAATATTCCTTGGAGTCGTGGTG GCGTCGGCGACAATGATTATATTTTGCGTTCCAGCATGTTGTCTTGCCTATAGCGTCCGATTTCGCTCCTGATTTC ACGATAATATCCGCCGGCTTTGACGCTGCAAGGGGTGATCCACTAGGGTGCTGCGACGTGACTCCCGCTGGTTACGC TCAGATGACGCATATGTTAAACATTTTAAGCGGGGGCAAACTACTTGTAATTTTGGAGGGTGGATACAACCTACGTT CTATCTCAAGTTCAGCAACAGCAGTAATCAAGGTGTTGCTGGGTGAATCTCCCGGCTGCAATCCCAAAAATTTCCTT CCGTCCAAGGCGGGTGTTCAAACTGTCCTAGAGGTCTTGAAGATACAAATGAACTTCTGGCCGGCTCTAGGCTCAAT TTATAGTGACCTACAAACGCAATGGGGAATGTACTGCATGAAGACCAAAAAGAAGCAAATAAAGAAAAGACAACGTG CGGCGCGCCCTTTGGTGGAAGTGGGGGCAGAAAAGTTTCTTATATCACTTGCTTAATGGTCATCTGCATGTAAAA AGCAAGGGCTGC

Seq. ID No: 50

>DAC 10

ATGTTTCTAGTCAGACACCACTTATATAAATGGAAATCACATTTTCGTATCGATGCCGACGGTAAATTCGTCGAAGA TCAGTTCTTTCCAAAGAACTTGAAAAGCGGCAGACGTTTCTTACGTAGCATAGGCGCTTCTATCACGTGCTCTAATG GCATTGGAAAAGATCCATATATTTTGAGCAATGAGAAAATTTCAGACGCTAGGCTAATATACGCAGTCGCCCAGCG ATGGGTCATAATCAGGAAAGCCACCCTGAGAGTCACTTTAGGGTTCCTGCCATAGTCAACGCCTTAGAGAAGATGGA AATGACGCCTAAATTCAGGGGTTCCGAGATTATTGAGTTGCAATCTTTTAAGCCCGCTTTAGTTGATGATATAGCGT GGTCGATTCTGTGGTTGCGGCTTCTAAAAACCATTTAGACCCGCCAGTGGGTTTTGCGCTAATAAGGCCCCCGGGCC ACCACGCCATACCACTGGGCCCGATGGGGTTCTGTGTTTTGGGAATGTCGCTATTGCCGCAAGATATGCTCAGCGT GCCCACGGGCTAAAAAGGGTTTTTATAATTGATTTCGATGTGCACCACGGCAACGGAACCAATGATGCGTTTTATGA TGACCCAGATATATTTTTCCTATCCACTCACCAAGACGGGTCTTATCCCGGCACGGGGAAGGTGGATGAAGTAGGAA GGGGCGATGGAGAGGGTACCACACTGAACCTGCCATTGCCCGGGGGTAGTGGCGACATAGCTATGACAACAGTATTC GACGAAGTCATTGCTCCATGCGCTCAACGTTTTAAACCCGACATAATTTTGGTTTCTGCAGGCTATGATGGGCATGT ATTAGATCCATTAGCAAGCCTTCAATTTACAACTGGCACGTACTACATGTTAGCCAGTAAAATTAAGTTGCTGGCGA AAGATTTATGCGGCGGTAGGTGTATTCTTTCTGGAGGGCGGTTATAACCTGGAGTCTCTATCCTATAGCGTAGCG GATAGCTTCAGGGCATTTTTAGGAGAACAGTCCTTGGCATCAGAGTTTGATAACCCAGCGATCTTGTACGAAGAGCC ATCTACGAAAGTAAAACAAGCTATCCAGAGGGTTAAGCATATTCACTCCTTA

Seq. ID No: 51

>DAC 11

Seq. ID No: 52

>DAC_12

ATGTGTTCAGACGCAAATGGGAAGGTTGGTAACATTTCTGTGATGAGCACTGAGGGAATATCACAGGTGGAGAGTAA AAAGGCTCGTCTTAATGGCTTACTTACACTAGAAGATATCTATAATCTGCCAGACGAGCTAGATGATGATGAAGACG ACAGTGACTGGGAGCCTTTACTTGAACCTCTTGCGGTACGTAAATGGTTTTGCACCAACTGCACGATGGTCAATTTT GATGGATTTGACTTCTGCGAGACGTGCGAGGAGCATAAGGAAAGTGGCATCCTGAAACAAGGCTTCTTCGCCTCTCC TGCCTTACAAGGCACAAGAAGCACTCAAATCGAGTCTGAGGTTATCGAGAGATATACTGAGTCTATATGTGACATCT CAGCTTCTGCGCTTAGTACCGTGGTCGGTTTCGACGAGAGGATGCTACTACATAGCGAAGTGGTCTTAAAACCACAT CCTCACCCACATCCAGAAAGACCGGATAGACTGAGAGCAATTGCGGCATCACCGCAGGGATCTTCCCTGG GCGCGTTTGGCGGCCGGCCTTTGTGCAGATCTAGCATCTGAAATCTATTCCGGAAGGGCCAAAAATGGATTCGCCCT GATTAGGCCCCCTGGACACCACGCGGGTGTACACCAGAGCATGGGTTTCTGTCTTCACAACAACGCGGCGGTTGCCG CATTAGCCGCACAAGTAGCTGGTGCCAAAAAGGTCCTGATTGTGGATTGGGATGTCCATCACGGTAACGGCACACAA GAGATTTTTGAAAGGAACAAGAGCGTTTTATATGTCAGTCTGCACAGGCACGAAGCGGGCAAATTCTATCCAGGAAC CGGAGCCGCCCATGAAGTTGGTACTATGGGTGCTGAAGGTTATTGCGTTAACGTACCTTGGTCCAGGGGGAGGGTTG GCGACAACGACTACATCTTCGCGTTCCAAAATGTTGTGATCCCAATTGCACACGAGTTTTCCCCAGACTTCATTATC GTTCATCCGCCACGGCGGTGATTAAGGTATTACTAGGTGAAAAGCCGAAGTGCCAGTTTGAGAACATAGAGCCTTCC GCAAGCGGGCTTCAGGCTCTTCTTGAGGTCCTGAAGGTACAGACTAACTTCTGGCCCTGTCTGAGTTCTAAACTGAC ACAACTACAAAGCTGCTGGGAAGCATACTTGTCTGGTCGTAAAAAGCAGAAGAAACGTAGGTTTCGTACTGTTGCTC CGCCACCAATATGGTGGGCCTGGGGACGTAAAAGGTTCCTATACTTTTTAAGATGTCAAAGGTTCAGGATGAAACCA

Seq. ID No: 53 >DAC 13

Seq. ID No: 54

>DAC_14

ATGGGCTTTTGTATCTTTGGTAACATAGCGATCGCAGCCCGTTACGCCCAAAGAGTCCACGGATTGAAAAGGGTTTTCATCATCGACGTTCATCACGGGAATGGCACCCAGGATGTCTTTTACGAGGACCCTGACATCTTCTTTTTGT

Seq. ID No: 55
>DAC 15

ATGGAACAATTGTGGGTTCCATCATTACCGATTTTAGGTGGGAGAATCTTGCCTATGCTGAGGCACTATTGTGGTTT TGGTAGTCACCATCCGCTAACATGGAGATCCTTACAGATTACTGGCCGTAAACAAAAACACAACGGCTGCTGGATAG AATCTTTTAAGAGATGCGCACATCCTATATTGCACTTCTCCCGCTATGGGTCATAATAAAGAAGCACACCCGGAGAC GAATAAAAGAGTCCCGGCAATAGTGGACGCACTTGAGAAGCTAGAGCTGACATCTAAACACAGAGGTTCACAGGTTT TAGAAATTCAGGACTTCCAGCCAGCATCCCTTGACGATATAGCATTGGTCCACAGTAGATCATATAAACGGGACTG GAGAAGGCTATGTCTCGTGCCTCTGACGAAGGACTGATCTTCATTGAGGGTACGGGGCCGACATACGCGACACAGAC TACCTTTCAGGAGTGCTTATTGTCTGCTGGTGCTGGCATAACGTTAGTGGACTCTGTTGTCGCTGCTTCTAAGTTAG GCCCGAAGCCCCACTTGGCTTTGCGTTAGTTAGGCCGCCCGGTCACCACGCCGTTCCTGAGGGCCCGATGGGATTC TGCGTCTTTGGTAATATAGCTGTAGCTGCAAGGTACGCGCAAAACCAACACGGCTTGAAGAGAGTCATGATAATAGA AACTAGGCTCCTACCCTGGCACGGGGAAAATACACCAGGTCGGCCAAGGAAACGGAGAGGGGACCACCTTAAACCTT CCATTACCTGGGGGAAGTGGCGATTACGCAATGAGATGTGCGTTTGACGAAGTCATCGCACCCGCAGCCCAGAGGTT CAAACCCGATATCATCCTAGTCAGCGCAGGATATGACGCTCACGCTCTGGACCCTCTGGCAGGCCTACAATTCACAA CTGGCACCTTTTACATGCTGGCAGCACGGATTCGTGAGGTCGCTGCCGAACTATGCGGAGGTAGATGCGTTTTCTTC TTAGAGGGTGGATATAATTTGGAAAGTCTGAGCAGTAGTGTGGCCGACACCTTCAGAGCGTTTCTGGGGGAGCCTAG CCTAGCCGCTCGTTTCGATGATCCAGCAATGTTATATGAAGAGCCGACACGTAAAATCAGGGAGGCTATCGACAAGG CTAAGCACCTACACAGTCTA

Seq. ID No: 56
>DAC 16

ATGATGGCCACCGAACCGATTGCCTCCGGTTCAGGTACAATGGACATAGATTCAGAGAAAACGCCGTCTACCAGTCA AGCTAACCCTATGGCAGATACGTTCCAAACAAGAAGACCAAGGGCTTCTTCCCTGCCACTTCAACCATCTAATTTAA AGGTAGGCTATATTTATAGCAGCGAGATGATGAATCACTTCTGCCCTGGAGGGCATCCTGAACAACCTTTGCGTATT CAACAGATCTGGGCGACAATCGTCAATGAGCAACTGCATAAAAGAATGAAGTGGATGCCGATCAGAGAAGTCAAGAA AGGTGAAGCACTGTTGGTCCATAGCGAGGATCACTGGAACAAGGTCATTGCAATTCAGTACCTTACCGATCAGCAAC GTGCAGATTCCGTTGATTATTACGAGCAAATGTCACTTTACGTGATGTCAGGCACGACTAGGAGTGCGCTACTAAGT TGTGGAGGGGTAGTCGAGGCATGTTTAGCTGTTGCAAGGAACGAGTTGAAGAAGACCTTTGCCATTGTTCGTCCTCC AGGACACCACGCTGAACCCGATGAACATATGGGGTTTTGTTTCTTCAATAATGTAGCCGTGGCGGCGCGTGTTGTCC AACAGAGGACTAAGTTAAAGAAGATACTAATACTAGATTGGGACGTTCATCACGGCAATGGTACACAGAGAGCCTTC AACGATGACCCATCCGTTCTGTACATCAGTCTTCATAGGTACGAGCAAGGGACATTTTACCCATGCGGTCCCTTCGG TTCTCTTACTTCTTGTGGTGAAGGGCCGGGGACCGGTTTTTCCGTAAATGTGCCCTGGCCGTGTGCGGGCATGGGAG ATGCCGAGTACATATATGCGTTTCAAAAGGTTATACTGCCCATAGCGACCGAGTTTGCCCCGGAATTGGTTATAATT TCCGCTGGGTTCGATGCTGCGGGGGATGAGCTGGGTGAGTGCCTTGTGTCCCCCGCGGGGTATGCTCACATGAC TCACATGTTAGCGGGCCTTGCAGGCGGCAGGATGGTGGTGGCGCTAGAAGGCGGTTATAACCTTGATAGCATTTCCC AGTCCGCCTTGGCAGTTACTAAGGTGCTTCTAGGAGAGCCGCCGGACGAGCTGCCACCTTTGAAGGCCAATGAGGAA GGTACCGAAACCGTTTGGTTGGTAGCTAGAGAGCAATCCAAATATTGGAAGTCAGTGGACCCCAAAGCATGCGAACC TCAGGCTGATGTTGAGCCTATTAGCTTTAGTGTCCCTGAGATCCTAAAAGCCCACCGTCAACATTACTTGTACACCA AACATGATATGATGCAAGTCCCTATGATGACGCCAGAATTAGAAGAAAAGTTTAGTAGCCAAATCATGTGTACTTCC GACATTTTCGAATCAAAGACCTTAGTAATCTTTGTTCATGAATTTGGGAACTTGAGGTTAGAGTTAGAGTCTAGCAC AACATGTGATGTACATCTGGAGAGATCCTATCTAATAGACTTCTCCAAGGAGCTAGTGGGCTGGGTTAAATCAGAGG

Seq. ID No: 57

>DAC_17

ATGTCAAAGCGTAAAGTTGCGTACTTTTATGATCCAGATGTCGGCGCTTACACATATGGTTGGAGTCATCTAATGAA GCCTCATAGAATGCGTATCACTCACGAATTAGCAACCGCTTACGGGATGCTAGATAAAATGCATGTTCTTCGTCCCA ATTTTGTTCCATTTCAGCCGGAGGATCAATTGGAGCGGCGGAGAGGATAGCTTCTGGCGCTGCTGATATAGCTATCA ATTGGGCAGGGGGTTTGCATCACGCGAAGAAGAGAGAGGGCGGCCGGGTTCTGCTATATAAACGATATAGTCTTGGGC AGGAGGACACCGGGACCGGAAAGGGGAAAGGCTACAGCGTCAATGTGCCGCTTAAAGATGGCATTCAAGATGAGTCA TTTAAGTCCGTGTTTGACCCAGTGATCTCTAAGATCCTAGAAGTATTCCAGCCATCTGCCGTTGTGTTACAATGCGG AGCCGACAGTCTTGCCGGCGACAAGTTGGGGTGTCTGAACCTTACCATGCAAGGTCATGCTCATTGCGTCCAGTTTT TGAGAAAATCTAACATTCCATTAATCCTACTAGGTGGTGGAGGATATACGGTTAAGAATGTAGCAAGGGCTTGGACA TATGAAACCGCATGCGCAATCGGAATAGAAAACGAAATAGACTTGAACATGCCGTGGTCTCAATACTTCGAGTGGTT CGGCCCGACCTACCGTCTGGAAGTTCCAGAAAACAACATGGAAGATATGAACGTTAAAGAAGGCACTTTGGATCATG TTAGAACGACTGCACTAGCCCAGCTGCAGCAGCTTGCGTCACGTTGTGCACCTTCTGTGCAAATGCAGGACGTCCCG CCAGCATACTCGTTATTTGTACGACCTTCAAGAGTCCGAGTCAGAAAGCGAGGATACGGAAAGCTCAGACAGTGATG CTTCCTCTGTGTCTTTCGTAAATAACTGGAGAAGAGCGCCCCATAGAGCTAACAGCCTTCCCCGTATCTTGTCTGGT AGGCATTCCAGCAATCCCCCTGGACACATAAGTGCCTCCGAAAGAAGAAGAATGAGCATCGTAACCGGCAAGTACTT CGACATCCCCATACACGAGAGCGGTTATAACCACTACGAATATGGCGCAGCCCCCACTAAATCATCAAAAAGGATCT TTTTCCAATCAGGTCTTGACATTTACAACGATGACAATGATTTCGAGGGCATTATCAATGCTAGAACCTCAGTTAGC AACGGATTTGGTAACGGAATACACGATCTTCACGGCTTAATGGAACGTGGAGGCAGAAGTTTGAACGAAAACCTGGA AGACGGGGACGATGAGGTGAAGGTGAGGAATACGAGGATGACGCAGCCATGTCAGATAGT

Seq. ID No: 58

>DAC_18

Seq. ID No: 59

>DMAT_1

ATGACCATAATAAATTCCCGTATAATTGACATTAGACAGAGTACCTTCGAAGAGAGTATCCCCGACCAAGTAACGGCCCGGTTTATCTACCACCCCCCAAGACCCTGCCCGCACTGTTTTTACTCAGGCGAGGGTATTCGTCATTGGATTGAGC

Seq. ID No: 60

>DMAT_2

Seq. ID No: 61 >DMAT 3

Seq. ID No: 62

>DMAT_4

Seq. ID No: 63

>DMAT 5

Seq. ID No: 64

>DMAT 6

Seq. ID No: 65

>DMAT_7

ATGGCAGCACCTTCAGTTATTGACATCCGTTCTCACCTGGTGGAAGATAGTTTACCAGATCAGGTGGTGAAAGGGTT AGGGTCCGATCCCAAGACCCTTCCAGCTTTGTTCTTCTATTCAAACGAGGGCTTGGAGTACTGGAATCATCACGCAC

Seq. ID No: 66

>FEX1

Seq. ID No: 67
>IDI1_for_fusion

Seq. ID No: 68

>INMT_1

ATGGCTGCTCCTCACACCTCTCAACAAGATTATATCGACAACTTTAACGCCAGAGACTATCTGCAAACAAGCTACAC CCCGGGGAAAGGTATTCTTTTTGGTGAGTGGATTGAATTTGCTACGCAGAATCTTCACGAAACCTTTACGACAGGTG GTGTAAGAGGTGATACGTTGCTTGATTTCGGAACTGGGCCAACAATCTACCAGTTAATATCAGCCTGCGAAGTCTTC

GACAAAATCATCGTAAGCGACTTTCTGGAACAAAATAGGGCGGAGTTCAGGAAATGGCTAAATAAGGACCCTGACGC
CTTCGACTGGACACCCATAATCAAAGGAGTGTGCGAACTGGAAGGTAATAGGGAAGACTGGGAGAAGAAAGCCACAA
AACTGCGTTCCAAGGTTAAAGAGGTTCTAAAATGCGATGCCCTAAAAAGAAACCCTTACGACCCCATTGTCGTGCCA
CCAGTAGATTGTTTGTTAAGCTGTTTATGCTTGGAGGCACCCTGTAAAGACATTAAAAGTTACTGCGAAGTCCTGAA
GAATTTTCAAAGTCTGATAAAGCCCGGTGGGCACCTTTTAATCCTTTCAGGTCTGAATGCCACATTCTATTATGTAG
GTAAAACTTATTTCTCAAGCATGACAACAAAGAAGGAGGAGCTAGAAATGGCCTTCAAGGAAGCGGGATACATCATA
AAGAAGGCAGTCTATACGCCGAGAGCGGATAAATCCAAAATAGACGTTGCCGATTACGAGGGCCATTACTTTATCCA
TGCCCACAAGCCAAAG

Seq. ID No: 69

>INMT 2

Seq. ID No: 70

>INMT 3

Seq. ID No: 71

>INMT_4

Seq. ID No: 72

>INMT_5

Seq. ID No: 73

>INMT_6

Seq. ID No: 74

>INMT 7

ATGAAGGTTGTTTCACAGGTGGAGATGAGTATCAAAAGCACTTTTTTGCCCAGGGACTATTTTGGCTACGTATTACTC
CTTTGACGGGTCCCCTTCCCCGGAGGCTGAAATGCTGAAATTTAACCTAGAGTGCCTACACAAAACTTTTGGTCCTG
GAGGGCTTCAGGGTGACACTTTAATAGATATAGGAAGCGGACCCACCATTTACCAAGTGCTTGCAGCATGTGACTCA
TTTCAAGATATTACTTTAAGCGATTTTACCGATAGAAAACAGAGAAGAGCTTGAAAAAATGGTTGAAAAAAGGAACCTGG
AGCATATGACTGGACACCAGCGGTGAAGTTCGCTTGTGAATTAGAAGGCAATAGCGGACGTTGGGAGGAAAAAAGGG
AAAAACTAAGAGCTGCCGTTAAGCGTGTGCTAAAGTGCGATGTGCATTTGGGAAACCCCCTTAGCACCAGCCGTATTG
CCGCTTGCAGACTGTGTTAACCCTATTGGCAATGGAGTGCGCTTGCTGTTCACTGGACGCCATACAGGGCCGCGCT
ATGCAACTTAGCGTCTCTGCTAAAACCCGGAGGTCATCTTGTAACAACAGTGACCCTGAGACTGCCGTCCTATATGG
TAGGCAAGCGTGAATTTAGTTGCGTGGCTCTGGAAAAAGGGTGAAGTCGAGCAAGCCGTATTGGACGCAGGATTCGAC
ATCGAGCAGCTACTGCATAGCCCGCAATCTTACTCAGTCACAAATGCAGCGAATAACGGAGTTTGCTGTATCGTCGC
ACGTAAGAAGCCAGGACCT

Seq. ID No: 75

>INMT 8

Seq. ID No: 76

>INMT_9

Seq. ID No: 77

>INMT 10

ATGGAAATCGTGTCTACCTCATATAACCACATCTACGACAACTTTGATGCAAGGAAGTACCTGGACAGATACTATGG
GTTGGCATCTGAAACCCAAGAAATTGAGGAAGAGAGTGTTTTTCTTTTAACCTTTCTTAGTAACGTATTTTCTAGCG
GGAGGGTGAAGGGACATTCTTTTATTGAGATTGGTGTAGGGCCGTCCATACATTCTATACTTTCAGCATGTGAGGTG
TTTGAAAAGATTTACCTGACTGATTACTCCCAAGGAAATTTGAACGAAATCGAGAAGTGGTTGAATAGCGAAAATGA
TGCATTCGATTGGACTCCCTATATAAGATTCGTGTGCGACTTAGAGAATAATGGTTCTACTCCTAAGGGCAAGAAG
AGAAGTTACGTAGAGCTGTCAGTTTAATGAAGTGTGACGTAAACTTGTCCAACCCGCTACACCCCCATTCACTTCCA
CTTACTGATTGCCTACTGACGGCGTCATGCCTTAGTGCTACCTGCAAAACCTTCACAGATTTTAAGATGTCTCTTAA
AATCATCGTAAGCCTAATCAAACCAGGCGGACATCTAATCCTTATTGACTATCTGAGGGCGAGATTATTACTGGGTTG
GAGAAGTCAAGCTGCCCATTTTGTCATTGGACGAACATGTTGTGAGGGAAACCTGTCGTGGAAAGCGGCTGTAAGATA
GAAGAGTTCAAATGGTTTAAGGAGTTTCACATGCCTGACGAGTTGTCAGACTGTAAAACTGTGTTCTCCTTACTAGC
TCAGAAGTTG

Seq. ID No: 78

>INMT 11

Seq. ID No: 79

>INMT 12

ATGGACCCGTGTCTTAATCTGTACTATCCATCTCATGAGGTAAACGCCAAGAGATTGTTACATGAATACTTTTCCCA
GAATGTCCCCTACTCTATATTCAAAGAATCAACTATAAATATCATGAAATGCTGTTACAAGGCTTTTAGTTCAGGTT
TGCTTAGCGGTACAACCCTTATAGACATTAGTGTCGGCCCGTCCATAGTACATCTTCTATCTGTGTGAGGTTTGTG
GAGGAAATAAGTATCCTAAAAGTCAATGACGCCTCAATTAGGGAGCTGGAACTTTGGAAAAACAAAGATCCTGAAAC
GTTCGACTGGACTCATACTTTGAAGCTGTTTATGGAATTGAAAGGTACTAGCCGTGACGGATGGAAAGACGCTCAAG
AAATGCTGCGTAGGAAAGTTAAACACATAGTCAAATGCGATTTCTCTAAATCCAATCTGACTAAGCCCTTCGCCTTA
CCTAGGGCTGACTGCGTTACTTGCATTTGGGGTCTTGAGACTATCAGCAGAGATCACGACGACGAGTGGAAAACTACCCT
TAGGAAAATTAGTGATCTGGTTAAACTTGGCGGTCATGTGTTGATTCATGCTGATATTAACGCTTCATACTTTAAAA

TTGGTGAGGACAAATATCACTTGTTTAACTTCGATGATGCGTTTCTTAGGAAAACTCTTACTGACGGTGGGTTCGCT ATTGTTCATTACGAAAATCTGGAACGTGAGGCATGCACCGATTGTTTGGACCATTCCCACAAG

Seq. ID No: 80
>INMT 13

Seq. ID No: 81

>INMT 14

Seq. ID No: 82

>INMT 15

ATGAGCGACTTCACCAATACTTCAGAATACGAAGAGCAATTTGACCCGAGGTTATACTTGGAAACATACTTCCACTT
GGGATCTGGGAGCCTGGCGGATGATTTTCTAAGATCGTTTTAGACAATTTTAATAAAAACTTTTAAATCTGGGGCGG
TGAAGGGATCTACATTAATCGATATAGGCACTGCACCATCTATTTATCAGCTTTTAAGTGCGTGTGAATCATTTGAT
GATATAACAGTTACATGGCACCACTAACAGAGAGTTGAAAGAATTACAGAAGTGGCTTAACAATGAAGCTGACGCTTT
TGACTGGAGCAGTATTGTGAAGCATGTGTGTGAGATTGAAGGTAACAGAATGGGTCAGAAGGAAAAAGAAGAAAAGC
TGAAGGGCAAAATTAAACAGGTGCTGATGTGCGATGTTAGCAAGTCAAATCCTCTGAGCCCTCATGAGGTTCCGAAG
GCTGATTGTCTGCTTACGACCGTTTGTTTAGAAAGCGGCCTGTAAGAATTATGAATCTTATGGTACTGCCCTTAAAAA
CCTATCCAATCTATTGAAGCCAAAAGGTCACCTTCTGATGGCCGGCGATCTAGGCCGCTAATTACTACGAAGTTGGGT
CCAACAAGGTATTTAGTCTTCCCGTTAATGAAAAATTCTTAAAGAAGGTCATCTCAGAGTCCGGGTATGAGATTATA
CAGCTAGTCAGCTTCGGAAAACCCCGAGAACGCTGACTTTGACACTTCAGATTATGAAGGTTTCTATTTCGTTCACGC
GCAGAAAGTC

Seq. ID No: 83

>INMT_16

Seq. ID No: 84

>INMT_17

Seq. ID No: 85

>INMT 18

ATGGACGCTAACAAGAGATACCACGGTCCGCCGGTGTTGCTGGGGGTGTAAGGGACTCAGAGAAGTTTGACTTCTG
TATGTGTAATCCTCCGTTCTTTGAGACAATGGAAGAGGCTGGCCTTAACCCCAAGACTAGCTGCGGAGGTACCCCAG
AGGAGATGATTTGTCCAGGCGGGGAAAAAGCCTTTATCACCCGTATAATAGAAGACAGTGCTGTTTTAAACCAATCA
TTCAGGTGGTACACGAGCATGGTTGGAAGGAAGAAGACTGAAGAGTCTTATATCTAAACTGAGGGAAGTCGGTGT
GACTATCGTTAAGACAACGGAGTTTGTACAAGGGCAGACATGCCGTTGGGGTCTAGCCTGGTCCTTTGTTCCTCCCG
TGAGGAAGATAGTTTCACCGCATGTGGCCGAGAAGAACATCATTAGCTTCATGCTAGAGGTGTGGGTCCCCGGATTT
AGTATATGTAGGGTTGGCCGACGATCTTGTTCCGAAGAGTAAGTCTCCTCATCTGTCTCCCATACTTGGAACGAAGAA
C

Seq. ID No: 86

>INMT 19

Seq. ID No: 87

>INMT_20

ATGAATAGGAGCAATTATATTCATTGGATTGAGGACTTGTTAGCGTCTGACATAACCGAAAAGAACGAAGCGAACGG
AGGCAAGGTAAGGGGGTTTGACATTGGAACGGAGCGAACTGCATATATCCACTGTTGGGCGCTTCCCTGCTGGGTT
GGAGCTTTGTAGGATCAGATGTCACTGAGGTAGCCCTAGATTGGGCTGAACAGAATGTAAGGAGTAACCCACATATC
TCAGAGCTGATAGAAATCAGGAGGGTGGATGTCGATGATCCTGCGAGTTCCTCAGGGACCGTAGAGTCATCCGGTGG
CAGTAGAATGGAAGACTCTTCACAGGGTCAGTGGACGTAGTAGAGTTGGCATCCCTTGAAATGAAGGAGTTCTGTG
ACGTTGGCGTTACCTGTAAGGGAGGAACTGATAAGAACCAAAGGAGATACGATGAAGCAAAGCACTCAAACGTAGCT
AAGGGCTACCAAGGTCCTCCCATTTTGCTGGGGGTAGTCAAAGAGGGAGAAAAATTCGATTTCTGTATGTGT

Seq. ID No: 88

>INMT 21

Seq. ID No: 89

>INMT_22

Seq. ID No: 90

>INMT 23

Seq. ID No: 91

>INMT 24

ATGGAAAGTGGATTCACTTCCAAAGACACCTATTTGTCTCATTTCAATCCCAGGGACTACTTGGAGAAATACTATTC ATTTGGTAGCAGACACTGTGCAGAGAACGAAATTCTACGTCACTTGCTGAAAAAACCTTTTTAAGATATTCTGCTTAG ATGGCGTTAAGGGAGAGCTGCTGATAGACATAGGAAGTGGCCCAACCATTTATCAATTGTTGTCCGCTTGCGAATCA TTCACTGAAATAATCGTAACAGACTACACAGATCAAAATCTATGGGAACTACAGAAGTGGCTTAAAAAGGAGCCCGG TGCTTTTGATTGGAGTCCTGTAGTTACGTACGTGCGACCTTGAAGGCAATCGTACTAAAGGGCCCGGAAAAGGAAG AAAAGCTGAGGAGCCATTAAACAGGTCCTTAAATGCGACGTGTCCCAAAGTCAACCCCTTGGAGGGGTCTCTCTT

CCACCCGCAGATTGTCTATTAAGTACACTATGCCTAGACGCTGCCCAGATTTACCGGCTTACAGGACCGCCTT ACGTCATTAGACTCTACTTACACCTAGACGGCTGCCCAGATTTACCGGCTTACACGCCCTT ACGTCATTAGATCTTAGATCATGATTTAGATAGAACAGAAGAAGTTTTCCAGTCTTAGATTTGGATAGAAGAAGCAGTGAGGGATGCTGTGGAAGAGGCTGGTTACACA ATCGAACAGTTCGAGGGTCATATCACAATCCTATAGTTCTACAACTAGCAACAACGAAGGCTTATTCTCCCTGGTCGGCGTAAGCCCGTGGGGGAGCGAG

Seq. ID No: 92

>INMT 25

Seq. ID No: 93

>INMT 26

ATGAGGAACCTGCACGAGACTTTTGGCCCCGGCGGCGTCAAGGGAGATATTCTAATTGACTTCGGGGCTGGTCCGAC GATATATCAGTTGTTATCAGCGTGCGACGACTTTTAACACACAATTATTACCTCAGACTTCTTAGAACAAAATCGTGAAC AATTGAAAAAGTGGTTAAGGAAAGATCCAGATGCACTAGATTGGAGTAATTTCGCCAAATACGTTTGCGAATTGGAG GGTAAGTCCGACAATTGGGAGAAGAAGAAGAAGAAGAAGAAGACGCTGAGACGTAAAGTTCTGAAGTTCTGAAGTGTGACGCCTT AGCAGAGAAGACCCTTATGACCCGGTCCCAATGCCTGAGGCGGACTGCCTGATATCTTGCCTATGCTTAGAAGTGGCCT GCAAAGACCTTGAGGATTTC

Seq. ID No: 94

>INMT 27

Seq. ID No: 95

>INMT 28

CCACCCGCCGACTGCGTTCTTACGTTACTGGCGATGGAGTGCGCCTGTTGTTCACTGGACGCATACAGGGCTGCATT ATGCAATCTGGCCTCACTTCTAAAGCCCGGAGGTCACCTAGTGACCACGGTGACCCTAGGCATTTCATCGTATATGG TTGGCAAGAGGGAATTTTCCTGTGTAGTCCTTGAGAAGGAGGGTGTGGAACAAGCTGTCTTAGACGCGGGTTTTGAC ATCCAGCAGTTTCTACACATCCCTAAATGTTACTCTGCAACTATAGCCGCGAACAATGGTGTCTGCTTTATCGTGGC TAGAAAGAAGCCTGCCCC

Seq. ID No: 96

>INMT 29

Seq. ID No: 97

>INMT 30

Seq. ID No: 98

>INMT_31

Seq. ID No: 99

>IOMT_1

ATGAGTAGTAAGTTAGACAATCAAAATATTACCGCTAATGAAGAAGAGGGGGCTTTCCACCAGGCCATGCAGCTGGCCCATGTCCACTATTTTACCGATGGTCCTGAAAGCCGCAATAGACCTAGACCTGTTAGAGATTATAGCGAAAGCTGGAC

Seq. ID No: 100

>IOMT 2

ATGGGAAGCCAAGCCGAGGTTGGGAAGGCGATGACGGAGGAAGAGGCTTGCGAATTTGCAATGCAGCTAGTCTCTTC
CAGTATCTTGCCTATGACTCTTAAAGCAGCTCTTGAGCTTGAGCTTCTTGAAATTATGGCAACGGCTGGTGAAGGAG
CCCAACTGACTCCAGCGGAGATTGCTGCTCAACTTCCTACCTCTAATCCAGACGCCCCCTATAATGCTAGACAGGATG
TTAAGACTTCTTGCCTGCCACTCTGTATTAACGGCATCAACTTATACCGACGACGACGACGATGGGAAGGTCAGAAGACGTTA
TGGCTTGGCGCCTGTATGTAAGTTTTTAGTCAGGAATCAGGATGGTGTTTCTACGGCCGCGCGCTATCCTTGGTGAACC
AGGATAAGGTGACGATGGAGTCTTGGTATTACTTAAAAGACGCCGTACTGGAGGGCGGCGCTATCCATTTAACCGTGCT
CATGGGATGACGGCTTTCGACTATCCGGGGACTGATCCTAGGTTCAATAGGGGTGTTTAACCAGGGAATGTCTAACCA
CTCAACCCTGACCATGAAGAAAATCCTAGAGACTTATACTGGCTTTCGTGGCCTTCACTCCTTAGTCGATGTAGGCG
GTGGCATCGGAGCTATTCTTTCCCTAATCGTCGCCAAATTCCCTCATATCAAGGGGATTAATTTCGACCTACCACAC
GTTATAGACGATGCGCCACAATTCCCAGGTGTTGAACACGTGGGAGGCGACATGTTTGCATCCGTGCCAACAGCCGA
GGCCATTTTATTAAAGCTAATTCTACATGATTGGGGTGACGAACATTGTGTGAAAATTGTTGAAAAAACTGCTGCAAAG
CGTTACCGGAAGATGGAAAGGTAGTCGTAGTGGAGGCCATTCTACCAGAAGGGAATTGATCACTTTATGCGTCAGCT
TGCGTTTATCAAGTCGATATGATTATGTTAGTCACAAAACCCCGGGGGAAAGGAAAGGACCTTGAAAGAGGTTTGAAGA
ACTTGCCAAGGCCGGAGGGTTCGCTGGCATAAGGCCAATTTTGCTGCGTCTATGGAAGCTTTGAAAGAATTTTACA
AGAAGATG

Seq. ID No: 101

>IOMT_3

Seq. ID No: 102

>IOMT 4

Seq. ID No: 103

>IOMT 5

Seq. ID No: 104

>IOMT_6

TGAAGCGTTGGCAAAGGGCTCAGGTTTTAAGGGAATCAACGTGGCATGTAATGCATTTGGCGTGTATGTGATAGAGC TGTTGAAGAAAATG

Seq. ID No: 105

>IOMT 7

ATGGAAATGATAAACTTCATGCATCATATGGATTCAACGTGGAATCTTTGTGGTAAAGATGTAGTGCAAGCCTTTGA
CTTTTCTGAGTTCCACACGGTTTATGATCTAGGTGGCTGTTCAGGCGGCCTAGCGAAGCAGTTCGTCTCCACGTATA
ACGATTCCACGGTAACGATTATGGATCTACCAAAGGTAGTACAAACTGCCAAGAAGTACTTCGTGACGGATCAAGAA
CAACAGATTCACTTCATCGAGGGCGACCTTTTCAATGACCCCATCCCTGAGGCGGACCTGTTCATTATGGCCAGGAT
AATCCATGACTGGACAGAAGAGAAATGCCTAGAGCTGCTGAGGAAAATTTACCAGTCCTGTCGTCCAGGTGGTGGTG
TGCTGTTGGTCGAAGTTCTTTTGAATGAGGGATAAGTCTGGACCCCTAATGAGCCAATTATTCAGCTTGAACATGCTA
GTTCAAACAGAGGGCAGAGAGAGCGTACACCAAGTGAGTACACAAAACTTCTGACCGACTCAGGCTTTCGTGACATTCA
AGTGAAGATTACTGGGAAAATATACGATGCA

Seq. ID No: 106

>IOMT 8

Seq. ID No: 107

>IOMT 9

ATGATCCCATTCAATAAGGCTTACGGTATGACCGCCTTTGAGTACCACGGAAAGGACGATAGATTTAACAAGGTCTT TAACGCTGGCATGTTTAATCACTCAACGATGACCATGAAGAAGATCCTGGACATCTACGACGGCTTCAACAACCTAA CGACGCTAGTAGACGTGGGAGGAGGAACTGGGGCTTCTCTAAATATGATCGTGAGTAAGCATCCCAGCGTAAAAGGT ATTAATTTCGACCTTCCACACGTCATTCAAGATGCCACTACTTATCCGGGCATAGAGCACGTAGGAGGTGACATGTT TGAATCTGTTCCAAAAGGTGATGCCACTCTTTATGAAGTGGATCTGTCACGATTGGTCAGATGCCCACTGCTTAAAAT TTCTTAAAAATTGCTACAAGGCGCTACCAGACAATGGTAAAGTCATTGTAGCC

Seq. ID No: 108

>IOMT_10

Seq. ID No: 109
>IOMT 11

ATGAGCAGGACATCATGGGACGAAGGCGAGGATGTCGATCTGGATTCAGTTGCTTATGGTTTCATGGCAAGCCAAGC
ATTGTTTACTGGTCTGGAGCTTGGCATTTTTGATCACCATCGCTGCAGCGGGAGCTGGTGGCTTGTCAGCGGCTGGCA
TCGGGAAGGCTTGTGGGATAGAAGCGCCCCAGGGTTCAAACGCTGCTTACTTCATTGGTCGCAGTTAAGTGCCTGAAG
CGTGACGCATCTGCCATGTACACCTTGAGTCCAAATACGGCACAATATATGGTAACTAGCAGTAGACATTTTTATGG
CGACTATTTAAGGTATCAAATAGGGCGTCAGTTTTACCACCGTATGGGGGCCTTGCCTGAGGTGATGACGTCTGGTA
AAGCCCCGAGTTACGCATCATGGTTTAGTGATCCTGAAGTAGCTAGAACTTACACACAAGCACAGCATAACGGTTCC
GTTGCCACAGCCAAGTATTTGATAAAGAAGAAATTGCAACTAGGGGGCATATCAGCGATGTTAGACGTCGGCGGGGG
TTCAGGGGCGTTTTCCTATGTCTTTACTCAGGCCACACCGGGTTTGCACAGTAAGGTACTGGAACTGCCAGAGGTCT
GCCGTACCGGTGAGGGTATCCGTGAGAAGCAACCCGAGGATGTCCGTAGCAGGGTTAGCTTTGTCGAGTTAGATGCG
AGTAGCCCGACGTGGCCGGTTGATGACTCTGCGTTTGACGTCGTAATGTCCTATATATCAGGCTCAGTTCCCGA
GCCGATCATTGGATCATTATACGCCAACGCTATGAAGGCTTTAAGGCCCGGAGGACGTCTTCTTTGTGCATGACTTTA
TGGTCAACGACTCACTAGACGGACCGGCGTTAGGGGGCTCTTGTGGGGACTTGCACACAGTCAACGCGGACGGT
TTGGGACTGTGCCCAAAGGAGGTTATCGCGCGTTAGGGGCTCTTGTGGGGACTTTGACACACAAGTAAATGTGAAGCAATGGA
GATGATTCACGGGATGACTAAGCTGATAGTCGGACACAAAGGGC

Seq. ID No: 110
>IOMT 12

Seq. ID No: 111
>IOMT_13

Seq. ID No: 112
>IOMT 14

Seq. ID No: 113
>IOMT 15

Seq. ID No: 114

>IOMT_**1**6

Seq. ID No: 115
>IOMT 17

Seq. ID No: 116
>IOMT 18

Seq. ID No: 117

>10M1_19

ATGGAGAAAGGAGGAGGTCGCGTTACTGAAAGGGCAGGCGGAAATCTGGCAGCATCTTTTCGCGTTCGCAGACAG TATGGCGCTGAAATGCGCTGTAGAGCTGAGACTAGCCAGACATCTCACCGGTGTACCTATAACACTTAGCC AAATAGCCTCCGCCATCGACTCACCCTTCACCCGACATCGCGTATTTGTCACGTATTATGCGTTCCCTTGTGTATAAG AAAATTTTCACTGAGCATCATCCCAGTGACGGTGGAAACAGTGCTGTACGGTCCAACCCATACGTCTAGGTGGCT ATTACACGACGCCGAGCTGACTCTGGCCCCTTCGTTCTAATGGAGAATAATCAATGGCAACTTGCCCCTTGGCACT TCCTAAGCCAGTGTGTGAAAGAGGGGAGAATAACCAGTGGTTTGAAATGTGGGATTTCGCCGCG

CGTAATCCGGAGTTCAATAAGATCTTTAATGATGCAATGGCCTGTACTACGAAGATTCTTATGGGAGTTTTACTAGC GGAATACAAAGACGGCTTTGGGTCAATTGGCTCTCTTGTAGATGTGGGAGGTGGGACCGGGGAAATGATCGCTGAGA TTATAAAACAGCATCCTCACATTAAGGGTATGAAT

Seq. ID No: 118

>IOMT_20

ATGGGCAGTGCGAGTGGTAGCGCAGAGCGTACACAGATGGGCGAGGACGAGGCTTGTAGTTTTGCTATGACAATAAC
ATCTGGCAGTGTCCCTCCAATGGTCTTGAAAGCAGTTATAGAACTGGACGTGCTAGAGATTATTAAAAGAGCTGGAC
CAGGGGCACACCTATCTCCTGCTGAAATTGCAGCCCAACTACCCCACCACTAACCCCGGCGCAGCCGCTATGTTAGAC
AGAATGCTAAGACTTCTTGCCAGCTATGACGTCCTTAGTTATTCTCTGCATACTCTTCCTGACGGTCGTGTCGAACG
TCTATACGGTCTAGCGCCCGTCTGTCAGTTTCTGACTAATAACGAGGACGGGGTGACTCTATCTGCACTATCCTTAA
TGAATCAGGATAAGGTTCTGATGGAGTCTTGGTACCATCTGAAGGATGCTGTCCTTGATGGGGGCCATCCCCTTTAAT
AAGGCTTACGGCATGACTGCCTTTGAGTATCACGGAACGGACCCGAGATTTAACAAGGTGTTCAACAATGGAATGAG
CAACCATTCCACAATTACAATGAAGAAACTACTAGAAAACTATAAAGGTTTTGAAGGCGTGTCAACATTAGTGGATG
TCGGCGGAGGTACTGGGGCAACCTTAAATATGATAATTTCTAAACATCCAACTATTAAGGGTATCAACATTCGACCTT
CCGCACGTTATAGAAGACGCCCCAACGTACCCCGGCGTTGAGCATATCGGCGGCGACATGTTCGTCTCAGTACCAAA
AGGTGATGCTATCTTCATGAAATGGATTTGCCATGACTGGTCCGATGAACATTGTCTTAAGGATTTTTAAAGAATTGTT
ATGCGGCCCTTGCAGATCACGGAAAAGTAATTGTTTTGTGAGTACCATTCTCCCGTCGCACCGGAGACTAATCACGCT
GCGCGTACCGTTTTCCACGTAGACGCGATCATGCTTGCCCCATAACCCTGGTGGGAAGGAGAAACCGAGCAAGAGTT
CGAATCTTTAGCTAAGGGTGCCGGATTTGAGGCTTTCGTGTAGCCTTCTTTTTC

Seq. ID No: 119

>IOMT 21

Seq. ID No: 120

>IOMT_22

Seq. ID No: 121
>IOMT 23

ATGTCACCCATAGACCTGGCGAATGAACTGCAGACGCTAGTGACAAGTACCTACTCCGGTGACGTAACCGACCCCTT CAAACTTTATAAAGCTAAACATAGCATTAGCGACCTGTGTCTAAGTCTATTGAGGGCAGTTCAGGGGCCGGAAGAAT ATACTGCCATATTAGCCGAGAGCTGCCAGGAATCCAGTGCCCTTAACGTAGTGGCCTCTCTGGGAGTTGCCGACCAT ATTGCCGAGAGCCCTAACGGAGAACTGACTCTACAGGAGTTAAGCGAAAAAGTGAAAGCGGATGAGAAGTATTTAAG CGTTGTTTTAAGCTCATTGGTGTACCACGGTTATTTCAAAGAAGTTGGAGGCTTCGGATCTCAAGTCTATGCGAACA ATGATTTCAGCTCTTTGCTACTATCCGAGGAAACGAATGCGAAGGGCGGCAAGAGTATGAAGGACGCGATCGGTTTG AGCGCGGATGACGGGGCGAAAGCTACTACGAGATTGTTAGATGCGGCAACCGGCAAGGCAAAGGGGGAGGCAAAGAC AACGTACGGCCAAGGCTATGGTTCAATTACATGGGATGGCCAATGGAGGAATCGGAGAAGACTACCCTTGGGAGAAA CTGGCGACGCCTATTATCGACATTGGTGGTGGGATAGGATCATTTCAAGGCATGTTGTTGGCTTTACCAAAGAACAA AGAGTTAACTTTTACAATCTTTGACATTGAGAAAACGGTTGAGCATGCCAAGAAAGTCTGGGCCGGTAAGCCTCAAT GGATGCAAGATAAGGTAAGTTTTATCGCTGGCGATTTCATGAAATCCTCCCCAAATGATAGTAAAATACCAACACCG GCTCAGGGTGCCGGCACCTACGTGATTAGACACGTACTACATGACTGGGATGATGCCCAAGTAGTCACAATATTAAA ACACGTCAGGAACGCAATGCTTGGGAGTCCGGCAAGCACCGCCTAAGTTACTGCTTGTGGAGATGATGTTAAACG AAACATCTTCTAGGTTCACCAGGACCACGTCCTTACAACTGTTAAGCCTAAACGGGGGTATAACGAGGACTGAGGTT CAATTCAGGAGGTTGATCAAAGAGGCTGGGTTCACGGTTGATAGTGTAACGGAAGTGAGGGGTGTTGACCTGGTGGT **GGAGTTATCCCCTGCGAGCTTA**

Seq. ID No: 122
>IOMT 24

ATGCCTTCTACCACAATTTCCCAATTGGTGGGTCTAATACAACAGTCCGTCATGGCGTTAGAGAAGCTATGCTTGGA GAATAGGACGAGTTTGCCTGACCTAGACGCATTCCACTTCGATCAGTCCTCCGAAACCTTCAGGAGCCTGCCCGGTG TATAGAGCAGCTCTTGGGGGTCACCTTTCTTTTGCGACCAGAACATGTCTGGAGGCTAACATTACAGAGATTCTTAG GGAAGCGGGACCCGAGGGATTACATATAAATGATATAGCTTCTAAATGCGGGCTAGACCCGTCCAAATTGGGAAGAG TGATTAGGTATTTGGTTATTCATCATATATATAGAGAAGTCAAGCCCGACGTGTTTACTAATAACAGAACATCTTCA ACAATGGATACTGGTAAGCCACTAGACAAACTTATCTCAGAACCGGATAGAAAGTATGACGACACTGGGTTTCCGGC ATTGATTAGTCATTTTATGGACGTGGACCAGAAGTGCGGAGCCGTGGGCTGGGACGTATTAAAGGACCCAGTTCTAG GCCATTCATGTGATCTTACAGAAACGATATTCAGTAGGGCTTTCAACACAAAGTCAAAGTATTGGGACTTCTTTGAC CATCCCGAAAACCATTATATGCGTAGGCGTTTCGACTATGCTATGAAGGGACTGGGAGCGATCGAAGATCACGATAT GGTGCTACATGCTTTCTCATGGGAGGATCTTGACAAAGGATCTGTTATAGTAGATGTTGGCGGAGGTATTGGAACGG CCATGCTACCCCTGGCCAGGAAATATCCTAATTTCGATATCGTCATCCAAGACCTTCCGATAGTAATCGAGGAAGGC CGAGCAACCTATTAAGAACGCATCTGTATTTTACTTACGACACGTATTGCACGACTGGCCAATGCCCGACATGGTCA AAATATTGAGGCGTCTTCGTGACGTTGCCGCCGCGAACACGCCGATTATATTAGACTACATCTTACCCTATTCC TGTAAGATGTTTGCTGACAAGGACGCCGTTTCAATCGCCTCCGCTCGTTATTATAGCGAAGCGCCGGAACCACTGTT ACCAAACTATACCCATAAGAATGTCATAAGCGATAGTGATATGTTTTTCAGATGATGTTCCACTACAATTCAC CCCAGGAATGACTATTTTCAATCAATTGAGTGCAAGATTCTAGCC

Seq. ID No: 123
>IOMT_25

ATGGCCCAGCCCATGATGCTGGCCCTGGCAAAGTTAATATCCGACAGTGTTGCAAAAGTAGACCAGCTATGCATTGA ACAGGGTGTCATTTTCCCAAGTCTGGACGACCCTTTTACGACGGAAAGTGAGTCCATTAAGTTACACCCAGATGTTG CAGAGGCCTCAAACTATATTATATCCGCGGCGGCTCAGCTAATCGCAATACTGAGACCTGTGCCCGTCACCTTATCT ACGAGTGCTATCCATGTTCCTCAGCTCTACGTGTGGTTGTGGATTCTAATGTCGTCGAGATTCTACGTGA GGCTGGGCCTCAGGGACTGCATGTGAAGAAGATTAGTGAGAAAAATGGCGTGGAAGCAGGTAAATTAGGAAGATTGT TAAGGCTTCTTGCGTCCGGCCATATGTTCAAAGAGATCACTCCTGATGTGTTCGCGACAAACAGAATTTCAAGTGCT CTGGATACCGGCAAGCCTTATGAGGAGCTAGTCAAAAATCCGGGCGAGAAATTAATCGGGACAAATGGGATCGCTGC CTATATATCAAGATCAACAGATGAGTCCGTCAAGAGCAGTGGGTTTCTGTATGAGGCTCTGACATATAGCTCAAGCG AGAAAGTACCCCTTCCTCCGTCACCTTTTAACCTAGCGTTTAACACGGAATTGCATATCTTTTCCTGGCTTGCACAA AAAGGCAATGAACATCGTTTGCAAAGGTTCGGAATTGCGTTTGACGGCTTTGACAAGATGTTGCCCGTTAACGGTGT GACCAAAGGCTATAGGTGGGGCTCCTTGCCAAAGGGTTCTATTGTCGTGGACGTGGGCGGTGGTGTTGGAAGCGAAT CAATGAAGATCGCCAAGACATTTCCAGATCTGAAGGTTATAATACAGGATGCTGAAGGCGTCGTAGCAAATGGAGTA AAATTTTATGAGACCCGTTTCCCAGAAGGGCTATCCTCCGGCCAGGTTACGTTTCAAGCACACGATTTCTTCACGCC GAATCCTGTAACCAACGCGAGGGTTTTCTTCATGAGGTTTGTGCTGCACGATTGGCCTGACGCCACCTGTGTCAAGA TACTTAAAAACCTGAGGGCGGCTGCCGCGCCTGATACAGAACTTATCATAAACGAGTGTCTAATCCAGTACGCGTGC AGTACCGAGTCAGAAATTTCCAAGTCAATTCCCGGTGGTAGGTTCAAACCCCCACCTTCCCCGTTGCTGCCAAATTT GGGCTATGCACGTATTTTTCATTATCTTATTGATTTACAGATGGCGATAGTTGCGCATGGAGTCGAGAGGACTGTTG AACAATATGCGAGTATCCTTCAGAAAAGTGGATGGAAGCTGAAAGAAGTTCTGAGGATGCCTGAGTCAGCCTATAGC TTACACAAGCTGGTAGCCGTCCCCCAGCCTGAG

Seq. ID No: 124

>IOMT 26

Seq. ID No: 125

>IOMT_27

ATCACCGACCAAGATCTGCCTGAAGTGTTAGAAGCCGCCAGATCCGTATGGGAAAAGGAGGCATTCGAAGCGTTGCG
TGAAAAGAGGGTAGAATTTCTGACGCTTGACTTCTTTAAGGAGGCGCCCGTCCCAGGCAAAGATGTATACTACCTAA
GGCACATCATCCATGATTGGCCAGATGCCGAAGCAGCTGTTATCCTTAGGAACATAAGCAAAGCAATGGAACCGCAT
TCAAGATTGCTTATCCACAATTATGTAATCGCTGGAGCCAACCGTAGACCAGATGAAGAACAACGTGCGCCCGAGCC
AATGCTACCTAATTTTGGGGCGGGGGATAGTAGAAAGTACAGGCAAGACCTAAATATGTGGATTCTGCATAACGCTA
AAGAGAGGACGGTCGATGATCAAATCACACTAGCC

Seq. ID No: 126

>IOMT 28

ATGGCCCCTGGCCGTGAGGGGAACTGGATAGAGATTTTAGAGTGCTAATGTCTCTAGCGCATGGGTTCATGGTATC ACAGGTCCTATTCGCCGCATTAGACTTAGGCATCTTCGATCTGGCTGCCCAGGGCCCTGTCGCTGCCGAGGCAGTTG CGCAAACGGGTGGCTGGTCACCAAGGGGGACACAGCTGCTTATGGATGCTTGCACTCGTCTAGGGCTACTTAGGGGT GCGGGCGATGGTTCTTACACTAACAGTGCGTTAAGTAGTACCTTTCTGGTGAGCGGCAGCCCGCAATCACAAAGATG AGTACAGTAGGGCGGTCGGTATTTCAGCTGAGGACCCCTTTTCTGCTATTTATCGTTCTGAGCCAGAGAGACTACTG TTTATGAGGGGCCTGCAGGAAACGTGGTCCCTGTGCGGAGGTCGTGTCCTAACCGCGTTTGACCTGAGCAGATTTAG AGTGATATGCGACCTGGGAGGGGTTCAGGGGCACTTGCTCAGGAGGCCGCTAGGTTATATCCAGGCTCATCAGTAT GGCTGATGGGGCGTGCGTCGAGCTATTGGGCCGTCTACACAGAGCGTGCCGTCCCGGTGGGGCGCTTCTGCTAGTGG AAGCAGTATTAGCTAAGGGAGGCGCCGGTCCGTTGAGGTCACTACTGCTATCTTTAAATATGATGTTGCAAGCGGAA GGATGGGAGCGTCAGGCCTCCGACTATAGAAATTTGGCGACGAGGGCTGGTTTTCCACGTTTACAACTACGTAGACC TGGCGGTCCATATCATGCTATGTTGGCACGTCGTGGGCCCAGGCCCGGCATTATTACGGGAGTTGGCTCTAACACCA CTGGAACTGGGTCATTCGTAACCGGTATTAGGCGTGACGTGCCGGGCGCGAGGTCCGATGCAGCAGGCACTGGCTCT TTCCGACGTTGGCGGCGCTGGTAATGAACCCCGTAGCGGTACACTGAAGCAGGGTGATTGGAAA

Seq. ID No: 127

>IOMT 29

ATGGAGGTTGTACCATCTTGGTTCAAGGAAACTCTTGATAAAAGTCAATTTTCTGCGCCATATGAATATGCAGTTGA GACAGCAAAACAAAAGCACTGGAAGTTGCTAGGAGAATGCATGTTAAACACCCTAAAGACCCCGGACATCGTAATCG GAGCAGACACCATCGTCACGCTAGAGGGGGCCATATTAGAAAAGCCGTTTGATAAACAGGATGCTTACAATATGCTT AGTAGACTAAGTGGGAAGGAGCACAGTGTTTTCACCGGAGTGGTAATCGTCCATTGTCGTTCCAAGGAAGAACCA TTTAGAGACGGATATTATCGACTTTTACGAGGAAACGAAGGTTAAGTTCGCAGACCTGTCCGAGGACTTGTTATGGG TCAGTGCATGGCGACTTCCTAAACGTAGTCGGCTTCCCCTTAAATCACTTCTGTCGTAAGCTCACTGAAATATACTA CCCGCCCCAAAACAAGCCATATGCCGTGTAAAGCACGATTCTATTCCATATGTAGAATCATTTGAGAATCTGAGTG ATGTCGAGACGGATTGCACCTCTACTAGCAAAGCATGTGAAGCGAAGAAAGCCGTGCAGGACGGCGTATGCAAGGCG GATGGTTCAGGTTCAGCTGTTCTTCAAAATGGAATCGAAGAGAGCCCGTCCATTGTGCCCAGCAATTAAGTAAAAT TACACAGCTGCTTGACGGATTTAAAGCCTCCCAGACTCTATTCGCAGCATCTAAGTTGAAAGTTTTTGACAAATTAA AAGATAAGGGGGCGCTTAAAGCGATGGAGATTGCGGAAAAGATTAATGCGTCTGTACACGGAACGGAAAGACTACTA GACGCCTGCGTGGCTTTAGGCCTACTAGAGAAAACCCACCAGGTTTATTCCAATACGGAACTTGCTAACACGTATTT AGTGTCAGATGGAGCGTTCTCCATACATGAATATATTACCTACTCAAGCGATCATTTATGGTCCCACTTCACTCATT TAGATTCTGCCGTCGTAGAGGGCGGGGGACAACATCAGACGCCGTTAAAAAGGCGTGCGATAATAGAAATGGGTCT GAGGTAAAGGAGAGTTTATGAGAGCCATGCATTGCATGCTTAAAATAACGGCCAGAGATTTGGTCACCGCATTTGA TCTGTCAAAGTATTCAAGCGCCTGTGACTTGGGCGGATGTACGGGCGCCCTAGCACACGAACTGGTCTGGACTTACC CTGAAATGAAAGTCAATGTATTTGACCTACCTGAAGTAATCAAGCATACCAGTCAATTCCAGCCTGAAAGTTTTGAC TCAAGTAGAGTCACCTTTAGTTCCGGGAACTTTATGGAAGATACACTTCCAGAAGCAGATCTGTATATTTTGTCAAG

GGAGAAGGGAAACAGAGAAGCGGGACTGAATACAAGAAGTTGCTAGAAAACCACGGATTCAATAGCGTCCAGATCAA
AAGTACCGGAAATCTATTAGATGCGATTCTTGCAATTAAGACCAGT

Seq. ID No: 128
>IOMT 30

Seq. ID No: 129

>IOMT_31

Seq. ID No: 130

>IOMT_32

TGGAAGTACTATTGAACGAAGATAGGAGCGGCCCTCTGACCAGTCAGCTTTACAGTTTGAATATGCTTGTTCAGACT GAAGGTAGGGAAAGAAGCCCGTGTGAGTATACGAAATTGTTGGCCCACTCCGGGTTCAGGGACATCCAAGTAAAGGC GACGGGCAAGATTTATGATGCCATTCTAGGAAGGAAA

Seq. ID No: 131

>MUP1

ATGTCAGAAGGCAGAACGTTCTTGAGTCAACTGAATGTGTTTAATAAAGAAAACTACCAGTTTTCAAGCTCAACAAC GAAGAAAGAGGTATCCAATTCAACGGTGGACGCAGACAACGGAGCCTCAGATTTCGAGGCGGGACAGCAATTTGCGA CCGAATTGGATCAAGGAGAAACAACTTGGCATATTGAGCTGTATCGGTTTGATCTGCAATAGAATGTTGGGTACT GGGGTATTCGCAGTATCTTCTACCATCTATACATTATGCGGTAGTGTAGGACTGGCTCTTATTATGTGGGCGGTCGG CGCAATAATCGCAATTAGCGGATTGTATGTCTACATGGAGTTTGGAACAGCGATTCCCAAGAATGGCGGTGAGAAGA TGGGCAGCCGGTAACAGTATTAACACTGCTATCATGTTTTTTGACTGCTGCGGACACGGAAGTCACCAAATGGAACCA GAGGGGGATTGGAGTTGCTGTGGTGTTTTTCGCTTTCCTGATCAACAGTCTTAATGTTAAAAATTGGACTTTATCTGC AGAATATACTTGGAATTTTCAAAATCGGTATTGTACTTTTCATCTCCATAACTGGTTGGGTGGCGTTGGGAGGCGGG CTGAAGGATGGATATCAATCTCATAATTTTAGAAATGCCTTTGAAGGAACGGAGACCGCTACTGCCTATGGGATCGT CAACGCATTGTATTCTGTTATTTGGTCTTTTGTTGGATACTCTAATGTCAATTACGCTTTAGGAGAGGTAAAGAACC CTGTAAGGACGTTAAAAATAGCCGGTCCCACGTCAATGGTGTTTTTTGGCTATCATCTATATATTTTGTAAACATAGCT TACTTCGCAGTGGTACCCAAGGATAAGCTAATAAGTAGTAAACTAATCCTTGCAGCCGATTTCTTCGATATTGTCTT TGGCGGTCAAGCTAAGCGTGCTGCAGCAGCGTTGGTTTGAGTGCGTTGGGCAACGTCTTGAGTGTAATCTTTT CACAGGGCCGTATTATACAACAGCTAGGGAGGGAGGGCGTACTACCCTTTAGCAACTTCTTCGCAAGTTCAAAACCC TTCAACTCTCCAATGGTCGGCCTTTTCCAGCACTTCATTGTCTGCACAGTAACTATACTGGCCCCACCACCACCGGCGA CGCTTATCTGCTGGTCCAAAATCTAATTAGTTACCCTATGAACATTATCAACTTCGCTATCTCCGCAGGGTTGCTGT GGATCTATTGGCAGAGGCAAGGTAAAATAGAGTGGAACCCACCTATCAAAGCTGGGGTTTTTTGTAACCGGCTTT TTCACCCTTTCAAACTTATACTTGATCATAGCGCCCTATGTCCCTCCGAGTAATGGCGAATCTGTGTACAGTAGTAT GCCCTATTGGATACATTGCGTCATAGCCTGGGGCATCTTCTTTTTCGGGGGTGTATATTATGTGGTATGGGCTCAGT TGTTGCCCCGTTGGGGGCATTACAAGCTCGTCTCAAAAGATGTTTTGGGTGAGGACGGTTTCTGGAGGGTGAAAATC GCAAAAGTATATGATGACACCATCGGTGACGTGGATACGCAGGAGGATGGTGAATCGAAACCAATATAATTGAGCA CTATAAGAGTGAACAGGAGAAGTCTCTA

Seq. ID No: 132

>NAT 1

Seq. ID No: 133

>NAT 2

Seq. ID No: 134

>NAT 3

Seq. ID No: 135

>NAT 4

Seq. ID No: 136

>NAT 5

Seq. ID No: 137

>NAT 6

ATGAAAGGCTCAAGAATAGAGCTAGGTGACGTCACACCACATAATATCAAACAGTTAAAAAGGCTAAATCAGGTCAT CTTCCCCGTTAGTTACAACGATAAGTTCTACAAAGATGTGTTGGAAGTAGGGGAGCTGGCGAAACTAGCGTATTTTA ACGACATAGCAGTAGGGGGTGTGTTGCAGAGTCGATCATTCCCAAAATCAGAAGAGGCTATACATTATGACTCTA GGCTGCCTTGCGCCATACAGGCGTCTGGGTATAGGAACTAAGGATCTAAACCATGTTTTGAACATCTGCGAAAAGGA TGGTACTTTCGATAACATATTTTGCATGTCCAAATAAGCAATGAGTCCGCTATTGACTTTTATCGTAAGTTTTGGTT TCGAGATTATCGAGACGAAGAAGAATTACTATAAACGTATAGAGCCGGCGGACGCGCATGTCTTACAGAAAAATCTA AAAGTAAGTTCCCCTGCTCCCAATGCCGACGTCCAAAAATCCGAAAAT

Seq. ID No: 138

>NAT_7

Seq. ID No: 139

>NAT 8

Seq. ID No: 140

>NAT 9

Seq. ID No: 141

>NAT 10

Seq. ID No: 142

>NAT 11

Seq. ID No: 143

>NAT 12

ATGAATATACGTGTCGCAAAGGTTGAGGACCTTATGGGAATGCAAGCATGTAACTTGCAAAATTTACCCGAAAATTA TATGATGAAATTTTGGATGATCACAGCATGACCTGGCCACAAATTTCATTTGTCGCCGAAGATCATAAGGGGCGTA TTGTGGGGTACCTAGCAAAGATAGAAGATCCGTCTGAAGAGGGTACGACTGAAGAGATTCATGGCCATGTTAAT TCAATATCCGTGCTTAGGTCCTACAGGCGTCTAGGCCTTAGGCCTAGGCTAAGTCTAAGTATTTACAAGGCTTCCTACGTCTCTTCATGTCCGTAAGTCAAATAAGGCGGCCATTGCCCTGTATAAGGACA CCCTTGGCTTTGAAGTGGAGAAGAAATACTACGGGGACGGTGAAGATGCGTTATCAATGAGACTAAGT CTGAAGAACCCT

Seq. ID No: 144

>NAT 13

ATGAGTGACTTCCAAGTTGCTCCACTTACTGCAAGGGAACTTGCTAGGGTCAGGGATTTGCACGCAAAACTGCTGCC GGTGCAGTATCCAGGTAGTCTCCACTTACTCCACCTATTAGTGATACCCAGTAGGGCCTGTTACGTCGCCTATAGTCATG GGAGTCCAGTAGGGCTTCATTAGTGCTGCACCTACACAATCCTACCAGATGCTTCATATCTGGGGATTCTGAAGTGAGC CCCCGTTTGGAGATTTTAACCCTTGGGGTGCTACCCGCTTTTCAACACAGAGGTTTGGCCCGTAGACTAATCATGAG TCTTGTAAACGCCTTCAAGCAGGACCCGGCTACCCCTATTTTGATATACCGCAAACGTATCAACCACAAACACTCGTG CGTTACAATTCTATGAAAGAATGGGCATCTTGGTTTCTTCCGACATAATAACTAATTTGTACAGAACTTTATCTTAC GGGTCTCGTGATGCTTACCTAGTGGTAGGAGCCCTT

Seq. ID No: 145

>NAT_14

ATGTTGTCTATACATCCTCTGAAACCAGAGGCGCTGCACCTTCCTCTGGGCACATCAGAGTTCCTTGGGTGTCAACG
TCGTCACACATTACCCGCGAGCGAGTTTCGTTGTCTAACGCCGGAAGATGCCACTTCAGCATTCGAAATAGAGAGA
AAGCATTCATAAGCGTCAGCGGCACATGCCCGCTGCACTTAGATGAAATTCGTCATTTCTTGACCTTATGTCCCGAA
CTTAGTCTTGGATGGTTCGAAGAAGGATGTCTGGTGGCTTTCATTATCGGATCTCTATGGGACAAGGAAAGACTAAC
ACAGGAATCTCTAACTCTTCACAGGCCCGGTGGGAGAACTGCACATCTTCACGTGTTAGCTGTACACAGAACTTTA
GACAGCAAGGAAAGGGCTCAGTGTTACTTTGGAGATACTTACATCATCTAGGGTCTCAACCTGCGGTTCGTAGAGCG
GTCTTGATGTGCGAGAATGCGCTAGTGCCATTCTATGAGAAGTTTCCAAGGCAATGGGACCCTGTGCTATCAC
TATGGGTAGTTTAACCTTTACAGAGTTACAATGCTCACTTCGTTGTCATACATTTCTAAGGAGAAACAGTGGATGT

Seq. ID No: 146

>NAT_15

Seq. ID No: 147

>NAT_16

Seq. ID No: 148

>NAT_17

Seq. ID No: 149

>PSIK_1

Seq. ID No: 150

>PSIK_2

AGGCGATGACGAATGACGAAACCTTGGTAATGGGAGACTTTTGGACTGCGAACGTACTTATTGACGTTCAAGAGTCA
CATACCGGGGAGCAGGTCCTGAAGAAACTGTGGGTGATTGACTGGGAATCATGCCGTTATGGTAACCCCGCGACCGA
CATCGCGAGCTTCGCGGGAGACTCTTACCTTGTGTCCCGTTTCCAGGACCACGGTTTAGGTGAAGCCTTGAGACACA
GTTTTCTTGAAACCTATGCGGCGTTAGCAAAAGTCGATCCACTACGTGTTGCTTTGGGTCTGGGCGCGCACTGGATA
ATGTGGACCGATGATCTAGGGCAAGGTGGAGAAGCCGGAAACCCGTGAATGCGTCGATAAAGGCTTAGAGTATATTCA
ACGTGCGTGGGATCAAAGCGCCGAGTGGGTCTCATTGTCTTTTGGCAAAAGAGTTTGTTCTTG

Seq. ID No: 151

>PSIK 3

Seq. ID No: 152

>PSIK 4

Seq. ID No: 153

>PSIM 1

GCATTGGACATTTCCGTGACCGTAGGCAACCACTTTCTAACAGCGGAAGTGAAAGACCCAACGTGGACAAGAGCGTG GAGACGTAGCTCTAAGGTAACTTCTAAGATCACCCCTTTTAGTTTCTCTGGACAGTTTTCCGATCCACCAGAGAGGT TGTTAGTATTACAGCTTCTTGTCGATGAGAGTCAGACCAGCGAAGACATTCTACTGTCATTCCAGAGCTTG

Seq. ID No: 154

>PSIM 2

ATGCACCCTCGTAATCCTTACAGAACCCCTCCGGATTACGCAGCTTTGGCGAGGAGCTTCCCGGAACTGAAGCCTTA CGTAAGTAGGAACGCCAACGGCACAGTTTCCGTCGATTATCAAGATGAAGCCGCCCTAAGGTGCCTAACCAGAGCCC TACTGTATAGAGATTTTGGACTATCCGTGGATCTTCCCAAGGATAGGTTGTCCCACCGTTCCAAACAGGCTAAAC TATATTCTTTGGATTGAGGATATTTTGAACGTCTCATCTTTAAGCAGACTACAAAGCAACTCTGAGGCAACTGTGAG AGGTCTTGACATAGGAACCGGCGCCAGCGCGATCTACCCGTTGCTAGGCTGCAGGGTTAGTCCAAGATGGGATTTCT ATGCCACGGACATAGATGCCCAGAGCCTTGCCCATGCCAGGGCCAACATAACCCGTAATGGGCTACAGGGAAGGATT AACCTGGTTGCTGCGGACCCCAAGGGTTCTATATTTGGACCATTGGAGAGCAAACACGATACGACTTTTGAGTTCAC CATGTGCAATCCCCCATTCTATTCATCAGAGGAGGACATCGCCCAGAGCGCAGCCGTTAAGAAACTTGCTTCTAACG CCGTCTGTACAGGGGCAGCAGTCGAAATGATCACTCCTGGAGGTGAGGCTGCGTTTGTGGTTAGGATGGTAAGAGAG AGCCTTGCTCTAAAAATGAGGTGTCAATGGTACACGTCCATGCTAGGAAAAATGAGTAGTCTGACAGAAATAGTGGG GCTGTTAAGGGAAAATAGTATTGATAACTACGCTATCACGGAATTTGTCCAAGGGAAAACAAGGCGTTGGGCGATTG CATGGTCATTCGGCCACGTAAGGCTACTTGATAGTCTGGCGAGACTTTCAGGTGGGCCACTTCAGTCATTAATGCCA ACTAGGAACACATGTCGTAGGTCTTTCGCCGTTCCTCGTATGGTCTTACATAAGCATCTAATTTTGGTGCTTGACGG CATAGAGGGAACATCCCAGACTCCCATGTCAATCCCAGTAGGCGCTGGGGACGCCGACGGGTTGTACGGGCTACAGA TCTCAGCTAGTAGAGACACTTGGTCCAGAGCGGCGAGGAGAAAAAGGCAACACGGTGCAATGGATATATCATTAGAT AATGATGAAGTAGGGATGAAGTGCCTGATAAAGGTGTTATCCGTAGAGGAAGCAAGAGAAGGAGCAGAGGCCGTAGT GCTAGAGTGTACCTGGGTGTATGGGCATGAAAGGGCGTTATTTGAGAGTTTTTTGGGGCCCACGTATGCCGTAAGATTG **GGGAAGCAAACGGG**

Seq. ID No: 155

>PSIM 3

ATGCACGCGAGAAGCATATTCAACCCTAATTCAGCTCAGTTTCAGGCACGTCTGACATTTTCTGAGTTGTCTAACGA GTTTCCCAAGTTGAAACCATTCTTGAAGTATAAGAGGTCCAGGAAGCAGAATGAAGCGGACCCTTTATCATCCCAGT GTACGTTTATTGATTTCAAAGATCCAGTCGCTACGCGTGCCTATAATGAGGTGTTACTAAAGAAGTACTTTGACCTT AGCTTGGAATTTCTGCCTGGCTCATTATGTCCGGCGGTTCCCAATAGATTAAATTACACCTTGTGGCTAGAGGACGT CTTGAACGTCTTCCCAGGGAGTATGGGGGCAAATAACCAACGTGATGAGCTAAGAGGACTGGACATAGGAACTGGTT CATCATGCATATATCCCCTACTTATATGTAGGACGCACCCGAACTGGAGGATGGCGGGGTCAGACATCAATCCCTCT TCAATAGAGATCGCCAAGAAGAACGTGCAGGAGAATAGGCTGCTGGATCGTATACAGCTTTTCTTAACAACCGATAA GAGGGATAGCGTCCTAGAGGGGCAAATATTTCAGACCCACTTGTTCTTCAATTCAAAGAAATGCCTGCAAGATGAAA AACCTGCCAGATTCTGCTATGACTTCACGATGTGCAATCCACCATTTTATTCCGACGTTGAAGACCTTAATAACAGT AGACAAGCGAAAACCACGACCATATTAGGTGGTGGACATGAAGGGGTGTCGTCAGAATTGTTCACTACAGGTGGAGA ATTACTGTTCTTATCGCAGATGGTGGAGGAAAGTTTCTTGTATAAAGACAAGGTGGGGCTTGTTAGTTCATATTTCT TTGTGCTTAAATGCATAGTGGAGATTCTTCGTCTTCTGGGACAGCATAAGATACAGGAAACTATTGCGTCTAAGCTA ATACAAGGCAAAACCATAAGATGGGTAATAGGATGGACGTTCCACAAAGACCTTTTTGATCTGAAGCATCCCTCCTG TTCCCCTTAACTCTAAGGAACACATTCCGTCTAAGCAGCTTATATCTTCATCCCAGTCAAGCGACATTGGCTGGACC AGACTGAAAAGCAGACTTGGGGACCTTAGAATCGAGTTCTCTCTTGAAAAGTTATCCCTGATTGGAAAAGTTGTCTA AGTCAGATGCAAGTGAGACAACAATACAATTGGAACTGTTAGCGTCCGAGATAGAGGAGCCCGACGAAAATACTCTA GTCAGCTTTCAAAGTTTGTGTAATCACCTGCGTAGCTACTTGAAAGAC

Seq. ID No: 156

>PSIM_4

ATGAGCGATATAGATGCTCAAAGTCTTGTTTACGCCCGTGCGAACGTGGCTCGTAATGCACTGGAAGGCAGGATTGCTGTCGTGACAGCCGAACCTGAAGGCTCCATCTTTGGGCCGATTGAAGCGGAGAAGGAGATACAGTTCGACTTTACTA

Seq. ID No: **1**57 > PSIM 5

GAGGGACTATCCCCCTTCCTGCTTATGCACCCAAGAAATCAATACTGTAAAAAGAAGCCGGATTTCGCAGATCTAGC TAAAAGCCACCCTCCGTTAAGAGAACATTTAAAGTGGAAAACTGAGGACTACGCGACTATTGATTTCAAATCTCCAT CCGCACAGAAGGAGTTGACACGTGCATTACTGAAACAAGACTTCCATCTGGACGTTGATATGCCTGTTGACAAATTG GTCCCAACAGTTCCCCAGAAATTAAATTACATTCACTGGATTGAAGACCTGCTGAGCGGCGGCCGTTCAGATTCTAT CCCGCGTGGAGAAGGGATCAGGGGCATAGATATAGGAACCGGGCCGGCGTGCATCTACCCGCTACTGGCGACTTCAC TTAATAAATGGACCTTCGTCGCGACTGATATCGACGCTGTTTCACTAGAGTACGCTGTTAAGAATGTGAGCCGTAAT GATATGGAAGGTCGTATCAGGGTGAAAGGGGTGGACCCAGATACGTTACTTGTCGGTGTGGTCCGTGACGAACAGTT TGACTTCTGCATGTGAACCCGCCATTTTATGGGATCGATGAAGACCATCACGACAACCAGAGGCCCCCACCTCCCT ATAGCAGCTGCAGTGCCCAGGCACACGAAGTCCGTGTGCAGGGAGGTGAGGTTGGCTTTGTAAGTAGAATGGTTGAG GAAAGCCTGCTGTTGCCCTCCGTGTGCGTTGGTTTACCTCTATGGTGGGCAAGAAAGGATCTCTTAAAAGTCTAAG GGCACTGCTGAGGAAGAGGGGGGGTGCCCACGGTAACCACGACGGAGTTCGTGCAGGGTGTAACAAAAAGGTGGGCTG ACCAGTAGCGCAGAAGGACGTGCATACGCTGAACAATGGTTAGAAAGGGTCCTTAACCATATGGAGGTAACATTCAC AAAGAAGGATCAGGATGGGTACACTTGCACCGCAGAACGTGCTACTTGGGCTAATCAGAGGAGGAAGAAGAGGAGGCTTA TGCAGCGTCCGATGATGTCCCCCGAGGCTGCAGCAAAGAGATCCTGCGGAGGAAGCGATAATACGAGTGAAGGAGTC CCTAGGAATGACTCAGACACCTTAGTCAGCGCCGGACACCTAAGTCCGAAGGCTGACAGCCTAGAAAGGAACGCTAG TACCTCCCAGCACTAACAAAGCGGAGTTAGAACTAAAGATGGTACTGATTGACGGCGGAAGCGGTACTCAGCCGCTA CAGCCCATTGCTCAATACATGAAGAATAACTGGAGTGCCACAGATTCAAGACCAACATCTGATCGTAGTAGCCAA

Seq. ID No: 158 >PSIM 6

TGCATCTACCCACTGCTAGGGGCCACGATGAACGGATGGTATTTCTTGGCGACTGAAGTGGACGACATTTGCTTCGA TTATGGACGCATTGAAGGAGGAAACCGAAATAGTCTATGACTTCTGTATGTGCAACCCGCCCTTTTTCGCGAATCAG TTGGAAGCCAAGGGGGTCAATTCCCGTAATTCCCGTAGGCCTCCTCCGTCTTCAGTAAACACAGGTGGAGTCACTGA GATAATGGCAGAAGGGGGTGAATTGGAATTTGTAAAAAGAATTATTCACGACAGTCTACAGTTAAAGAAGCGTTTAA GGTGGTATAGTTGCATGTTAGGAAAGAAGTGTTCTCTTGCACCTCTGAAAGAGGGGGTTAAGAAAACAGGGGGTCCCT AAGGTAACCCATACTGAGTTCTGCCAAGGGCGTACCATGAGGTGGGCCCTTGCATGGAGCTTTTATGATGACGTTAT AGTGCCCTCACCACCTAATAAAAAGAGGAAACTGGAAAGGGCAAGGAAGCCGCTATCTTTCACTTTACCGGAAGCCG GACTGAAGGAATTACAGAGTAAAGCACTTGCTCTTGGAGGCACTGCATGTAGCCCGGTGGACCGTGTAGCAGCACTT TTGGAGAAAACTCTTACCGACCTTAGAGTCCTACATAAACGTGTTCCGTGTAGGAAGCAAGAACAAAGCCTATTTCT AACTGCCGTTGAGAATACATGGATACATGGTCGTCAGAAAAAGGCGTGAACAAAGTCGTCAGCTTAGAGAGCTGCCCC GTGCGCCACCTTGCGCGGGTACATCCTCCCAAACTACAGTTGCTACGGCCGACTCTGTGAAAACCCCAGCATCACAG ACTCAATCCGCATCTACTCAAAATTCCAACTCCCAAGACGATAGCAGTCAGAACAAGCGTGCGAGTGCGCAGGAATT AGCCGGTCAACAACCCACGGATAAGGCCGGCAGTAGCGCATCTTCTGATGAAATATCAATTAAAGTGCTGCATAACT CTACGGGAGAGCAAAAGGAGGTCACGGAAAATCTTTCAAGCGAGGCAGTAGACATGGAGTTCAGTACAAGCACAGAA GCAGTCCAGGAGACGGGTTCTAAAGAGGCTCCCTCTGCTGAAAGCGAGCCTCCCAGCAAGAGACCCCTTTCTCCCGG TACGGTCGAACAATTTCTATTTAAATGTTTACTAAACGTAATGCTTGAGGAAAGTGACGTCATGATCGAAATGCATT

GGGTGGAGGGTCAGAACAAGGATCTTATGAACCAATTATGCACTTACCTGAAAAACACTCTACTGAAGTCTGTCGCTAAATCC

Seq. ID No: 159

>PSIM 7

Seq. ID No: 160

>PSIM 8

ATGCATCCTCGTAACCCTTATAGGCAATTGCTTGACTTCGCCAGTTTGGCAGAGGCATACGAGCCACTAAAGCCCCA CTTGAAACCTACCAGATCTCCCACCGCAGGCGGTTTATCATACACCATAGATTTTAAGAACTCCGAGTCTCAGAGGC AACTGACAAAGGCAATCCTGTATAGGGATTTCGGGCTGCGTATTGCGCTGCCAGATCACCGTCTATGTCCGCCTGTG CCAAACTCTCGTTTAAATTACATTTTGTGGTTACAAGACATCATTAAAGCGCACGACGAGTATATGGATAGGCCCGC CTCTTGCATATGCGGATTAGATATAGGCACTGGAGCAAGCGCCATCTACCTTTTGCTTGGGTGTAGAGTAGAGCCCA GTTTTAGGTTCATAGGCACAGAACTAGACGATATATCATTCAGCTACGCCACTCAAAACGTCGAGTCTAACGGCCTG TCTGACAGGATACACCTGATAAAAACGACAAGCAACGATCCCATCCTGCTACCGTTCGATCTAAATCCGGCATGGTC TTGCGATTTTACGATGTGCAATCCCCCTTTCTACGAGAGCGAAGAGGAAATGGCCCGTAGTGCGCAGGCGAAAGAAT TAGCTCCAAATGCGGTTTGTACGGGGGCTCAAGTGGAGATGGTTACCCCCGGTGGAGAACTAGCGTTTGTATCACAA ATTGTCAAGGAATCTTTAAAGTACACCACCCGTTGTAGGTGGTATACTTCAATGTTAGGTAAATTGAGCAGCTTAAC AAAGTTAGTAGGACTGCTTAGAGAGTACGCGATCTCCAATTATGCTATTACGGAGTTCGTCCAGGGGCAGACAAGGA GATGGGCTGTGGCTTGGAGCTTCGGCGAGACACACTTGCCGGATTCTGTGGCCAGGATTAGTAACCCTACGCTGCAA CCCTTGCTGCCGGAGAGGAATACGAGTAGGCACGTGATCAATATCAGTCTTCCTCCGTTTAGCACAAGGACAGTGAA ATCAAAACAGTCTATCAAGGCGCTTTCTGAGGTTCTTAGTCAGATCAAAGATGTGACTGTGCAGAGATTATATCAAG TGGAACACCTAGAACCCACCGAAGAGGAAGAGGACAAGAGTCTGTATAGATTGCTTGTTTACGCGAAGCAGAAT ATGTGGAGCAGGTCTGCTCGTCGAAAGAGGAAGGGAGACTGGCCATAAAGCCAACGATAAAGGATGCGCTGTAGG GGGTCCTTTAACTTCAATTCCGGCTACTTTAGATGGATTACTTTGCGGGATAGAGATAAAGGCACCGTTGATAAAGC AAGAGCAACAGGATGTAGAGATTTGTATTTCAGTGGGTTCACGGGCAAGATAGAAGTATGTTTGAATCCTTC GTGAACCATGTAACTAGAAAGATGAAATGTAATATAGTACTGGAC

Seq. ID No: 161

>PSIM 9

ATGGCTCTGAATAAATCCATGCACCCGCGTAACAGATATAAAGATAAGCCGCCAGATTTTGCGTTCCTAGCATCCAA GTACCCGGAATTTAAGCAGCACCGCGTTGACGTTGGTTTAAGTGGTAAGGTAGGACTGAATTTTAAGGACCCAGGCGCGG TCAGGGCTCTCACGTGTACACTTCTAAAGGAGGATTTTGGGCTGACTATCGATATCCCCCTTGAGCGTCTTATTCCC ACCGTTCCATTGCGTCTGAACTACATTGGGTAGAGGACCTGATAAATTTTCATGATAGCGACAAGACTACCGT GAGAAGAGGTATAGATATAGGCACAGGCGCAAGTTGTATCTACCCCCTTTTAGGAGCAACATTAAATGGCTGGTATT TCCTAGCGACCGAGGTAGATATTTGCTACAATTACGCTAAGAAGAACGTGGAACAGAACCATCTAGCCGATCTT

TTGTATGTGCAATCCACCATTCTTTGCAAATCAAATGGAGGCTCAGGGCGTCAATTCCAGGAACCCCAGACGTCCTC CTCCGAGCAGCGTAAATACGGGAGGGATTACCGAAATAATGGCAGAAGGTGGAGAACTTGAATTTGTGAAGCGTATC ATTCACGATTCACTACAACTGAAGAAGAGGCTTCGTTGGTATTCCTGTATGCTGGGGAAAAAGTGTTCTCTAGCGCC ATTGAAAGAAGAGTTGAGAATACAGGGGGTGCCAAAGGTAGCCCACACCGAATTTTACCAAGGCCGTACTATGCGTT GGGCGCTGGCTTGGAGTTTCTATGATGACGTAACGATCCCTAACCCTCCGTCTAAAAAGCGCAAACTAGAGAAACCA AGGAAGCCGATGATGTTCTCTGTTTTAGAAACTACCGTGAAAATGTTGATGGACAAGTTCGATTGTAGCGTAGACAG TGAGCACGTCTCCGTCGTAACGGATTGTTTGAAGAAGATCCTTACCGACTTAAAAGTCCAACATAAACCGGTTCCAT GCGGTAATGGGGAGGAGTCTCTATTTCTAACTGCGATCGAGAATAGTTGGGTTCATATAAGACGTAAAAAGCGAGAT TGAGGACGAGGAAACGACTGAAAAGACAGTGTCAAGCAGTGAGAAATCCGTCAGTACATCAGGCATTGATGAAGCTG CCGCCCTACCCCAAATCCGGAGGATTCCATCTCCGAAAGTATGGGGGAAGACAGTCGTCAGCTGCCCGAGGAAGTT AAAGATACATCCGCACTAGGGCAGATAACCGACGTCGATGAGCACCAAAATACAATGGAGGCGTCTCAACCTTGTTC CTCAAATAGTGCCTTCCTGTTTAAGTGCCTAGTCAATGTTAAAAAGGAAGCTACCAATGTTTTAGTTGAAATGCACT GGGTGGAAGGTCATAATCGTGATCTGATGAACCAACTGTGCACTTACCTAAGGAATCAGATTTGTAAAATTGCAACG TCA

Seq. ID No: 162
>PsiHchimera 1

ATGTTCTGCCGTGGCCTGTTGAGTTTAATGGCAATCATCGTGTATTTTATAGCCCAAAAGAGGAGAAGAGCCAG ATTACCACCGGTCCTCGTGGCCTGCCACTGATCGGAAATTTGCACCAGGCACCGAAAGAGGCGGTGTGGCTAACCT TCCATAAATGGGTGAAGGAATATGGCAACCTTGTTTCTGTAAATTTTGGGGGCACGGAGATGGTGATACTTAATACG TTAGAGACGATTACAGATTTGCTAGAGAAGAGGGGATCAATTTACTCTGGCAGGCTGGAATCAACTATGGTCAACGA ACTGATGGGCTGGGAGTTTGATCTTGGCTTTATTACATATGGAGATAGGTGGCGTGAGGAAAGACGTATGTTTGCAA AGGAGTTCAGTGAAAAGGGAATTAAACAGTTTCGTCATGCCCAAGTTAAGGCCGCTCACCAATTAGTACAACAGTTA ACTAAGACACCAGATCGTTGGGCACAGCACATAAGACATCAAATCGCTGCTATGAGCCTTGACATTGGCTATGGCAT TGACTTAGCTGAGGATGATCCGTGGCTGGAGGCGACGCACTTGGCCAACGAGGGCCTAGCAATTGCCAGCGTTCCAG GGAAATTCTGGGTTGATTCTTTTCCAAGCCTGAAATATTTACCTGCTTGGTTCCCTGGAGCTGTTTTCAAAAGAAAA GCGAAGGTTTGGAGGGAAGCGGCCGATCACATGGTCGATATGCCCTACGAGACTATGAGAAAGTTGGCTCCTCAGGG GCTTACGCGTCCGAGTTACGCTAGTGCAAGATTACAAGCGATGGATCTTAATGGCGATTTAGAGCACCAGGAGCACG TAATCAAGAACACGGCGGCAGGTAAACGTTGGCGGAGGTGATACTACTGTGTCCGCCAATGTCCGCCTTCATCTTG GGATTATGATGAAGAAGACGACAGTTTACCCTATCTAACGGCGTGTATTAAAGAACTGTTTAGGTGGAATCAAATAG CCCCGCTGGCAATTCCACATAAACTTATGAAAGACGACGTGTATAGAGGCTACCTTATCCCCAAAAATACGCTAGTC TTCGCAAACACTGGGCTGTTCTAAACGATCCCGAAGTCTATCCAGATCCTAGTGTTTTTTAGACCAGAACGTTACTT AGGACCAGACGGAAAACCAGACAACACTGGTGATCCTCGTAAGGCAGCATTTGGCTATGGCAGACGTAATTGCC CGGGCATACATCTTGCGCAGAGTACCGTGTGGATAGCTGGGGCCACCCTTTTGTCAGCCTTTAATATTGAAAGGCCC GTCGATCAGAACGGTAAACCCATAGACATACCTGCTGACTTCACGACCGGGTTTTTCCGTCATCCAGTTCCCTTCCA ATGCCGTTTCGTACCTAGAACGGAACAGGTATCTCAAAGCGTAAGCGGACCT

Seq. ID No: 163
>PsiKchimera_1

Seq. ID No: 164
>PsiKchimera 2

ATGGCGTTCGACCTAAAGACCGAAGATGGTCTAATCACATATCTGACAAAGCACCTGTCTTTAGATGTAGATACCAG
CGGAGTTAAACGTCTATCCGGAGGGTTTGTTAACGTCACCTGGAGAATAAAACTTAATGCACCGTACCAAGGACACA
CGAGTATCATCCTAAAACACGCACAACCCCATATGTCAACGGATGAAGACTTTAAGATCGGAGTTGAGCGTAGCGTC
TACGAATATCAAGCGATTAAGTTGATGATGGCAAACCAGGAGGTGTTGGGTGGAGGCGACAGCCGTGTTAGCGTCC
CGAAGGCTTTCACTACGACGTTGAAAATAACGCATTAATCATGCAGGATGTTGGAACTATGAAAACTCTGTTAGACT
ATGCAACTGCAAAACCGCCACTTTCAACGGAAATCGCGGAGTCTAGTGGGGACCGAAATCGGGGCCTTTATCGCGCGT
CTTCACAACCTAGGTCGTAAACGTCGTGACCAACCGGCTTTCAAATTCTTCTCCCGGAAATATTGTAGGCCGTACAAC
AGCCGATCAGCTTTATCAAACCATTATTCCAAATGCGGCCAAGTACGGTATTAACGACCCACTACTACCCACTGTTG
TAAAAGATCTTGTCGAAGAGGTTATGAACAGTGAGGAAACCCTGATTATGGCAGATTTATGGAGCGGGAACATTCTA
CTGCAATTAGAGGAAGGGAACCCTTCAGAGTTGAAAAAGATCTTGGCTTGTTGACTGGGAATTTGTGAAGTACGGACC
AGCCAGCCTAGACATGGGGTACTTCCTAGGAGACACTGCTACCTTATTGCCAGATTTCAGGACGAGTTAGGTACGA
CTATGAGAAAAGCCTATCTAAAATCTTATGCGAGAAACCGCTTCAGACACTATAAATTACTCAAAGGTCACGGCAAGC
ATCGGGGCGCATCTAGTTATGTGGACCGATTTTATGAAGTGGGGAAATGACGAAGAAAGGGAAGA

Seq. ID No: 165
>PsiMchimera_1

Seq. ID No: 166
>PsiMchimera 2

Seq. ID No: 167
>PsiMchimera_3

Seq. ID No: 168

>SAM2

ATGTCTAAATCCAAGACTTTCTTATTTACTAGCGAGAGCGTAGGAGAAGGGCACCCAGATAAAATCTGTGACCAGGT
ATCTGATGCAATTCTGGATGCCTGCCTAGAACAAGACCCCTTCTCTAAGGTAGCCTGCGAAACCGCCGCAAAGACTG
GAATGATTATGGTCTTCGGCGAAATTACTACAAAGGCAAGACTAGATTATCAACAAATCGTTAGAGATACTATCAAA
AAGATCGGGTATGATGACTCCGCGAAAGGATTTGATTATAAGACGTGTAACGTACTTGTAGCAATTGAGCAGCAAAG
TCCAGACATTGCTCAGGGGCTGCATTACGAGAAGTCTCTTGAGGATTTAGGCGCAGGCGATCAGGGCATTATGTTCG
GGTATGCTACCGACGAGACGCCGGAGGGCCTTCCGTTAACGATATTGCTGGCGCATAAGCTAAACATGGCTATGGCC
GACGCACGTCGTGATGGGTCACTACCGTGGCTGAGGCCAGACACCAAAACTCAGGTGACCGTCGAATATGAAGATGA
CAACGGTAGATGGGTTCCGAAGCGTATTGACACGGTGGTTATCTCCGCCCAACACGCAGATGAGATCTCTACTGCGG
ATCTAAGGACTCAATTGCAGAAGGACATTGTCGAAAAGGTAATTCCGGAAAGATATGCTAGATGAGAACACTAAGTAT
TTTATCCAGCCAAGCGGGAGACTTTGTAATAGGTGGGCCGCAGGGTGATGCCGGCTTAACAGGTAGGAAAATAATAGT
CGATGCCTACGGCGGAGCCTCAAGCGTGGTGGTGGAGCATTTTCTGGGAAAGGACACTCAAAAGTTGATAGATCTG
CAGCGTATGCAGCGAGGTGGGTAGCCAAGTCCCTAGTGGCGGCCCGGATTGTGCAAGAGATTCAAGTGCAAATTTTCC
TACGCCATTGGTATTGCAGAACCCTTGAGCTTGCATGTGGATACCTACGGCACCGCGACAAAGAGTGATGACGAAAT
AATAGAAATTATTAAGAAGAAATTTTGATCTGAGACCTGGCGTTCTGGTCAAGGAGTTAAGACCTGGCCAAGACACTTGATTC
ATCTACCGACCGCGTCATATGGGCACCTTCACAAACCAGGAGTTATCATGGGCAAAACTTGAGTTC

Seq. ID No: 169

>SAM3

TAATAGCGAAGACGTCTCCGCCTCTCCTTTCGTCATAGCTCTGTCTAACACAGGCTCAATGGGAGCCAAGGTCAGTA
ATTTTATGAATGTCGTGATTTTAGTAGCAGTGGTGTCAGTATGCAATTCATGCGTCTATGCGAGCAGTAGGTTAATT
CAAGCCCTGGGCGCCAGCGGGCAATTGCCTTCTGTGTGTTCTTATATGGATAGGAAAGGGAGACCGCTTGTTGGTAT
CGGCATAAGTGGAGCCTTTGGTTTACTTGGATTTTTGGTGGCGAGCAAAAAGGAAGATGAGGTGTTTACGTGGCTAT
TTGCCTTATGCTCTATCAGCTCCTTCTTTACCTGGTTCTGCATCTGCATGTCCCAGATCAGGTTCAGAATGGCGTTA
AAAGCTCAAGGGAGGAGTAACGATGAAATAGCCTATAAAAGTATACTAGGTGTATATGGGGGTATCTTGGGGTGCGT
ATTGCACTCTTCTAATTGCGGGGGGAAATCTATGTGTCTGCGGCACCCGTCGGATCTCCCTCTTCTGCTGAGGCAT
TTTTCGAATATTGCCTGAGTATTCCCCATAATGATCGTAGTTTATTTTTGCCCATCGTTTTTTATAGGAGGGATTTCAAAAGCCCA
GAAAGAAGCTGAGGAACAGCTAATTGCATCTAAGCCGTTCTACTACAAAATTTACAGGTTCTGGTGT

Seq. ID No: 170

>SS02

Seq. ID No: 171
>T4H-CPR 1

TCTAGCTCTAGTGACGTGTTCGTACTGGGGTTAGGAGTCGTACTAGCAGCTCTTTACATATTTCGTGATCAGCTTTT CGCTGCCTCCAAGCCAAAGGTGGCACCGGTGAGCACAACGAAACCGGCTAATGGGAGCGCAAATCCTAGAGATTTTA TCGCCAAGATGAAACAGGGAAAGAAACGTATTGTTATTTTCTACGGCTCTCAGACAGGCACCGCGGAAGAATATGCA ATACGTTTAGCAAAGGAGGCAAAACAAAATTTGGACTAGCATCCCTAGTATGTGACCCAGAAGAATATGACTTCGA GAAGCTAGATCAGTTGCCTGAGGACTCTATAGCATTCTTCGTAGTAGCCACATATGGAGAGGGTGAACCGACAGATA ATGCGGTTCAACTATTACAAAACTTACAGGACGAATCATTCGAGTTCTCCTCAGGGGGAGCGTAAGTTGTCAGGACTT AAATATGTTGTCTTCGGCTTGGGCAATAAGACCTACGAGCATTATAATCTAATAGGGCGTACTGTAGACGCGCAGCT TGCTAAAATGGGAGCGATCAGAATCGGAGAAAGGGGTGAAGGAGGACGACGACAAATCTATGGAGGAGGACTACTTGG AATGGAAGGATGGAATGTGGGAGGCGTTCGCGACAGCGATGGGTGTCGAGGAGGGGCAGGGAGGTGATAGCGCCGAC GACTAAAGGCATTCATGACGCGAAGAACCCTTTCGCGGCTCCCATCGCAGTAGCGCGTGAACTGTTCCAGAGCGTAG TAGACAGGAACTGCGTGCATGTGGAATTTAACATAGAAGGGAGTGGAATAACCTACCAGCACGGCGATCATGTCGGC TTGTGGCCGTTGAATCCTGACGTAGAGGTGGAGCGTTTATTATGCGTTCTGGGTTTAGCGGAGAAAAGAGACGCAGT GATCTCCATTGAGTCCCTGGACCCAGCCCTTGCGAAAGTGCCATTCCCTGTTCCAACGACCTATGGAGCGGTCCTTA GACATTACATTGACATATCTGCCGTCGCCGGAAGGCAGATTCTTGGAACTCTATCAAAATTCGCACCAACTCCAGAG GCTGAGGCGTTTTTAAGGAACTTAAATACGAACAAGGAGGAATACCACAATGTCGTCGCGAACGGGTGTTTAAAAACT GGGCGAAATCCTGCAGATAGCGACTGGTAATGACATCACAGTACCGCCTACGACCGCCAATACCACTAAGTGGCCGA TACCCTTTGATATAATCGTATCCGCTATTCCCAGACTACAGCCTCGTTACTACAGTATCAGTTCTAGTCCAAAAATC CATCCGAACACAATACATGCGACGGTCGTGGTACTGAAGTATGAAAATGTTCCCACTGAACCTATCCCAAGAAAGTG AAAACGGGGAACAGAGGTCGGAGTTCCCGAGTACCTGATCGCAGGCCCTAGAGGCTCCTATAAGACTGAGAGCTTT TACAAAGCTCCAATCCACGTGCGTAGGTCAACATTTAGGTTGCCAACAAACCCCAAGAGTCCCGTAATCATGATCGG GCCAGGGACCGGAGTAGCACCCTTTCGTGGATTTGTGCAGGAGCGTGTTGCATTGGCAAGAAGGTCCATAGAGAAAA

ACGGCCCAGACTCTTTGGCGGATTGGGGCAGAATTTCACTTTTCTATGGATGTCGTCGTAGTGACGAGGACTTCTTA TACAAGGACGAATGGCCTCAGTATGAAGCCGAACTAAAGGGAAAGTTTAAATTACACTGTGCTTTTTCCCGTCAAAA TTACAAGCCTGACGGGTCAAAAATCTATGTGCAGGATCTGATATGGGAAGACACACATTGCAGATGCAATAC TAAATGGCAAAGGATATGTGTATATTTGCGGGGAGGCAAAGTCAATGTCTAAGCAGGTCGAGGAAGTCCTTGCGAAG ATTCTTGGAGAAGCTAAGGGTGGTTCAGGTCCCGTAGAAGGCGTTGCTGAGGTAAAGCTATTGAAGGAGAGGTCTAG GCTTATGCTGGATGTATGTCA

Seq. ID No: 172 >T4H-CPR 2

CGCTGCTTCTAAGCCAAAGGCTATACCGCTTACGAACAAACTGGCCGGTCTTGACAACGAAGGGAACCCGCGTGATT TCATAGCAAAGATGAAGGCAGGAAAGAAGCGTTTGGTCATATTTTACGGCTCTCAAACAGGAACCGCTGAAGAGTAC GCGATCAGGCTGGCCAAAGAAGCCAAATCTAAGTTCGGTTTGACCTCCCTTGTGTGCGATCCTGAAGAGTACGATTT ATAATGCGGTTCAGCTTATGCAGAATCTAGCCGACGAATCCTTCGAGTTCTCAGGCGGAGAAAGGAAATTGGAGGGT TTGAAATATGTAATATTCGCTTTAGGAAACAAACTTATGAGCACTACAATTTGATTGGTCGTAAAGTTGACACTCT TCTGACTGACATGGGTGGGGTCCGTTGCGGGGAACTAGGGGAAGGCGACGATGACAAGAGTATGGAAGAGGATTATT TGGAGTGGAAAGACGCGATGTGGGAGGACTTCGCGAGGAAGATGGGCGTCGAAGAGGGCCAGGGTGGTGATTCTGCT GATTTTGCAGTCAGCGAATTAGACACTCACGTGCCCGAGAAGGTGTATTTAGGAGAGTTGAGTGCTAGGGCATTGAC GAAGACGAAAGGGATACATGATGCCAAGAATCCGTATCCGGCGCCCATCGTAGCAAGTCGTGAATTGTTCCAGCAAG GTGGCGACAGGAATTGTGTTCATGTTGAACTATCCATTGAAGGCTCAGGAATTACCTATCAGCACGGCGATCACGTC GGAGTATGGCCCACGAATCCTGAGGTGGAAGTCAATAGGCTGCTTTGCGCCCTGGGTTTATGGGAGAAGAAGAAGAACCA TGAGGAATTACATTGACATCAGCGCAGTTACGGGGCGTCAAATCCTAGGCCACTTGAGTAAATACGCGCCAGCTCCC GACGTCGAGGAATTTCTGAAGGGTTTGTCTACAAACAAGGAACAATACGGTGCTACAGTAGCCAATGGTTGCTTGAA GTTAGGCGAGGTCCTACAACTTGCCGCGGGCAATGATCTGAAGGCTATACCAACGACTGAGAATACTACAGCGTGGA GTATCCCCTTCGACGTTATCGTGTCCGCCATTCCCCGTCTTCAACCACGTTATTACTCAATTTCATCATCCCCAAAG GTGGGTCTACGGCGTAGGTAGCAACTTCTTACTAAATTTAAAATACGCTGCTAATGGTGAACCAGCGCCATTCGTTA CTACCAATGGCTCAGCCGATCCTGCATCAGTTTATTATCCCACTTACGCAATCGAGGGCCCACGTGGCGCGTATAAA CAGGAAACTATATACAAATCCCCTATACACGTGAGAAGAAGTACATTCCGTCTGCCCACGAACCCTAAATCACCGGT CGATTGAGAAAAATGGAGCCGACGCGTTGGCTGACTGGGGCCGTATATCTCTTTTCTATGGGTGTCGTAAATCAACA GAGGATTTCTTATATAAAGAAGAGTGGCCGCAGTATACAGAGGAGTTAAAAGGGAAATTTAACATGCATAGTGCCTT TAGTAGAGAAGCACCTTACAAGGCTGACGGAAGCAAGATTTATGTCCAGGACCTGATCTGGGAAGATCGTGCCAATG TGAGCGATGCGATACTGAATGGCAAGGGATATATCTACATATGCGGTGATGCGAAATCAATGGCGAAACAGGTGGAA GACACGCTTGCTAAGATACTAGGAGAAGCGAAGGGTGGTACCGCGGAAGTCGAGGGAGCGGCGGAAATGAAGCTGTT AAAAGAAAGGTCTAGGCTAATGTTAGATGTTTGGTCA

Seq. ID No: 173
>T4H-CPR 3

TCTAGTTCTTCCTCAGGCGCCCGGGGCAGATAGCGACGAAAACCCTCGTGATTTCATTGCCAAAATGAAAGCAGGAAA GAAGAGGTTGGTCATCTTCTACGGCAGCCAAACAGGCACTGCCGAAGAGTTTGCGATCCGTTTGGCGAAAGAGGCAA AATCCAAGTTTGGACTAACGTCTCTAGTGTGCGACCCAGAAGAATATGATTTTGAAAACCTTGACCAGTTGCCTGAG GATTGTGCCGTGTTCTTTGTAATGGCCACTTATGGAGAAGCCGAGCCTACCGACAATGCGGTGCAGCTTATGCAGAA CTTGCAAGACGAGAGCTTTGAGTTCTCTAATGGCGAGAAAAGTTGGAAAGGGTTGAAATACGTAGTATTCGCATTGG GTAACAAAACCTACGAGCATTATAACTTAATAGGAAGAAAAAGTGGACAAATATTGGGGGAAAATGGGGGGCGGTGAGG TGCGGAGAGAGAGAGAGAGAGAGAAAATCAATGGAGGAAAAATCAATGGAGAAGAAAATTTTTAGAGTGGAAAGGACGCTATGTGGGA AGACTTTGCTCGTAAGATGGGGGTTGAAGAAGGACAATTGTTCTGCGCGTGCCTTGACCAAGACTAAAGGCATTCACGACGCT AAAAATCCATACCCCGCCCCTATCGTCGAGAGAAACTATTCCAAGTTGGTGGGACAGGAATTGTTGTACATGT

AGAGCTAGGCATTGAGGGATCAGGGATTACCTACCAGCACGGAGACCATGTCGGTGTGTGGCCTACAAATCCTGAAG TTGAGGTGACACGTCTATTATGCGCGCTGGGGTTGTGGGAGAAAAAGGATCAAGTTATTGGAATAGAGAGCTTAGAC GGTCACTGGGCGTCAAATCTTAGGGCATCTAAGTAAGTTTGCGCCGAGTCCAGATGCAGAGGCGTTTCTGAAATCCT TATCTACTAACAAGGAACAGTATGGCGCCATTGTAGCGAACGGATGTCTAAAACTTGGAGAAGTTCTGCAACTAGCC GCTGGGAATGATTTGAAAGCCGTTCCGAACGCTGAAAACACAACGAAATGGACAATCCCGTTTGACGTTATAGTAAG TGCTATTCCAAGATTACAGCCTAGATACTATAGTATAAGTTCTTCTCCGAAACTTAATCCTACGACAATACACGTCA CCGCCGTAGTCCTAAAGTACGAATCAGTGGCCTCTGAGAAAGTTCCGGCAAAGTGGGTATATGGCGTAGGGTCAAAC TTTCTATTGAACCTGAAGTATGCCGCGAATGGCGACGCAGCACCATTTGTCACAGCCAACGGTTCAGCCGATCCGGC CTCCGTTTATGCGCCGACCTATGCCATAGAAGGACCCAGAGGGGCTTATAAGCAGGAAACCATTTACAAGTCTCCTA TTCATGTAAGGAGAAGTACCTTTAGATTGCCGACAAACCCTAAGTCCCCGGTGATCATGATAGGTCCCGGCACTGGC GTGGCACCATTCCGTGGCTTTGTACAGGAAAGGGTTGCACTAGCCAGGCGTACGATTGAGAAGAATGGTCCAGATGC GCTTGCAGACTGGGGCAGAATAACATTATTTTACGGCTGTAGAAAGTCTACCGAAGATTTCCTATATAAAGATGAAT GGCCTCAATACACCGAAGAATTGAAAGGGAAATTTACCATGCATAGTGCGTTCTCTAGGGAACCCCCGTACAAGGCG GACGGGAGTAAAATTTATGTACAGGACCTTATCTGGGAAGATCGTGAGAAAGTCGCGGATGCTATACTTAATGGCAA GGGGTATGTTTATATATGCGGAGACGCAAAATCAATGGCAAAGCAGGTGGAAGACACCCTAGCCAAGATACTTGGAG AGAGTAAGGGCGGTTCAGCAGAGGTAGAAGGTGCAGCAGAAATGAAACTACTGAAGGAGAGGAGTAGACTAATGTTA GACGTCTGGTCT

Seq. ID No: 174
>T4H-CPR 4

TCATCAAGTAGCAGCTCCAAGTTGAGCGATGGCGACGAGAATCCTAGAGAACTTCATCGCAAAAATGAAGAATGGGAA GAAACGTCTTGTCATATTCTACGGGTCCCAGACGGGGACTGCAGAAGAATATGCTATAAGACTAGCCAAAGAAGCCA AAAGCAAATTTGGTCTTACCTCCTTAGTATGTGATCCCGAGGAGTATGACTTCGAGAATCTGGACCAGTTACCGGAC GACTGCGCAGCGTTTTTCGTCGTAGCAACGTATGGGGAAGGTGAACCTACCGACAATGCTGTACAACTAATGCAGAA GCAATAAGACTTATGAACACTATAATGTTATTGGGCGTATAGTAGACACGGAGCTTGCAAAAATGGGCGCTATACGT TGTGGGGAGAGGGGTGAGGGTGATGACGACAAGTCTATGGAAGAGGATTACTTAGAGTGGAAAGATGGAATGTGGGA GGAATTTGCCCGTATCATGGGAGTTGAAGAGGGTCAGGGAGGTGACACCCCAGACTTCAAAGTGACAGAGCTGCAAT CACATCCTAGTGAGAAGGTATATTTGGGCGAGCTTTCCGCGAGAGCACTGACAAAGACTAAGGGGATACACGACGCA AAGAATCCATACCCGGCCCCCATCCTAAAATCTAGGGAATTGTTCCAGAAACAGGGGGAGAGGAACTGCGTCCACTT GGAGCTGGGTATTGACGGGAGTGGAATCACATATCAACACGGAGATCACGTCGGCGTGTGGCCAAGCAATCCAGAGG TTGAGGTTAACCGTCTACTATGCGCGCTGGGCCTTTGGGACAAACGTGACCATGTCATCGGTATCGAAAGTCTTGAT CCAGCCCTTGCTAAGGTACCATTCCCCGTTCCCACAACTTACTCCACTGTTTTAAGAAACTATATCGACATATCAGC CGTTGCAGGAAGACAAATTTTGGGAAATCTGGCTCGTTTTTCACCCTCCCAGATGCTGAAGGGTTTATGAGAAGTT TGAATACGGATAAAGAGCAATACGGTAGGATCATAGCAAACGGATGTCTGAAACTAGGGGAAGTTTTGCAACTTGCG GCGGGAAACGACATAAAAGCAGTACCAACGTTAGAAAATACTACTGCGTGGCCGATCCCATTCGATGTAATCGTTAG CGCCATTCCTCGTTTACAACCTAGATATTTCAGCATAAGTAGTTCTCCCAAGCTACATCCTACAGCAATCCATGTTA CTGCCGTAGTGCTAAAGTATCAGAGTGTCGCTTCAGATAAGGTGCCACCGAAATGGGTGTACGGTGTTGGTTCAAAC TTTATCCTTAACCTAAAATACGCCGCTTGCGGCGAAACAGCTCCGCTTATTGCACAGAATGGAAGCGCCGATCCTGC TCACACACCCTTTCCCCTATACGCTATAGAAGGTCCACGTGGGGCATACAAGCAGGAAATGATCTATAAAAGCCCAA TCCATGTGAGAAGGAGTACATTTAGACTACCTACTAACCCTAAATCCCCTGTAATCATGGTTGGACCAGGTACCGGA GTCGCGCCGTTTCGTGGATTCGTTCAGGAACGTATCGCTCTAGCCCGTCGTACAATCGAGAAGAATGGTCCGGATGC ACTAGCTGATTGGGGTAGGATATCTTTATTTTATGGGTGCAGAAAAAGCAACGAGGACTTCCTATATAATGAAGAGT GGCCACAATACATCGACGAATTAAAAGGGAAGTTTACATTGCATACAGCTTTTTCAAGGGAGCCCCCGTATAAGCCG GATGGAAGTAAGATTTATGTGCAGGATCTATTATGGGATGACAGATCCAAGGTCGCAGACGCTATCATTAATGGAAA GGGCTACATCTATATATGCGGTGATGCAAAGTCGATGGCAAAGTCAGTGGAGGACGTGCTGGCGAAGATATTAGGGG GATGTTTGGTCT

Seq. ID No: 175

>T4H 1

ATGAAGACTAGGACTTCCAAACATCCTCCAGGCCCACGTGGGCTGCCCCTGATTGGTAATCTACTAGACATGCCCGC ATCATACGAGTGGTTACAATATAGGAAGTGGTCTGAGGAATTTAAGTCCGACATCATTTACCTGAATATCTTAGGCA CATTCCTTTCAACTGCCGAATAACTGCGCTATGGGGTGGGCGTGGAATCTGGCTCTAATGTCTTATGGGGACGAGTG GAGGGCCCACCGTAGGCTTGCCGCTAGAGGTTTCGATGCACAGGCGATGCCGAAATTTAACCACGCATTTACGCGTA ATACTCGTGGCCTGCTTAGGCGTCTTTTAGAGTCACCAGAGGCCTGGAATGAGCATGTAAGGCACGAGGTCGGGTCA ATGATAATTGAAATTACCTACGGGTTGGACGTGCTTTCTAAGAATGATCCCTTTATTGAGTCCGCCGACAAAGGACT AGCGACATTGGCCTTAGCAGTAGCACGTGCCTTTCTGGTTGACACTCTACCAATTCTTAAACACATACCTTCAT GGTTTCCAGGGGCTGGCTTCAAACGTAAGGCTAAGGAGTGGAAAAGATACGCCGATGAGGTTTTAGAAGCTCCTTAT AAGGCTCTAAAGGAAGAGAGCCAAGTGGAGCCGCGAAGCCTTCTTTTGTTCAAAGGTGTCTGCAGGACATGGACCC CTGCCAGCTTTATTGCAACGTTCGTGCTTGCTATGATACAGTACCCTCAGGTACAGCGTAGAGCACAAGCAGAGTTG GACTCTGTCTTAGGCCCAGATAGACTGCCAACCTTCGGCGATATGCCTAGCCTTCCGTATTTGTCCGCGATAACTAA AGAGTGTTTCCGTTGGGAAGTAATCACCCCCATAAGTATTCCACACATGCTTACAGAGGACGACGAGTATCGTGGTT TCCGTGTTCAATCCTGAAGATTCCTGAAGGATGGTAAAATAGACCTTGAAGTGCAGGACCCGCAGTTAGCGGCTTT TGGTTATGGGCGTAGAATTTGTCCCGGCATGAGGGTCGCCAATGCTTTTACGTGGTTAAGTGCTGGATCAATCTTGG CCTCATTCAACATTTCAAAACCGGCAGCGAAAGACGGGACCCCCATCGAGCTTGATGTTAAGTATCGTAGCTCCAGT ATTCGTCATCCAGAGGCCTTTGACTGTCTGTTTAAGCCCCGTTCAGAGAATACTAGAGACATGATCGTAAGCGCAGC CGCG

Seq. ID No: 176
>T4H 2

ATGAGTAAGAGGTCAAAACACCCACCTGGCCCCAGAGGCTTGCCGTTGATAGGGAACTTACTGGATATGCCTACGAA TGATGAGTGGTTACAATATCGTAAATGGAGTCAAGAGTTCAAGTCCGACATAATATACCTTAATGTTTGCGGTACTC GGTCTTGAATGGGCTTTCATCTTGATGCCTTATGGAGATGAGTGGAGAGCGCACAGGAGACTAGCAGCTAAAGGTTT CGACGCAAAGGCTATCCCAAAGTTTAATCCGACCTTCACGAGAAACGCGCAGGATCTACTGAGAAGGCTTTTAGAAT CTCCAGAGGCTTGGCATGAGCACGTTCGTCATCAAGTCGGAGCGATGATAATAGAAGTATCTTACGGATTAGATGTA TTGCACAAAAACGATCCCTTTATAGAGAGCGCGGATAAAGCAGCCGTGACGTTCGCAATGGCCATCAAACCCGGAGC TTTCCTTGTCAATACCGTGCCCATTTTAAAATACGTTCCTAGTTGGTTCCCCGGTGCAGGATTTCAGAGAAAAGCTA AGGAGTGGAAAAGGTATAACGACGCAGTGCTAGAAGCACCATTTAAGGCTTTGAAAGAAGAAGATTACCAATGGGGCG GCAAGACCATCTTTTGCCCAACAATGCCTGCAGAATATGGACCCGAACATTGACACGGCATATCAGGAACGTGTGAT AAAGGACACAAGTGCTGCGATGTATGGGGGAGGATCAGACACGTCAGTTTCATTTTTGGCTACATTCGTCCTGGCTA TGTTACAGTACCCCTCTGTCCAACGTCGGGCTCAGGTTGAGCTTGACTCCGTGCTAGGACGTGATCGTTTGCCAACA TTCGACGACATGCCGGACCTTCCCTATCTAGCAGCCGTTATGAAAGAGTGCCACAGATGGGAAATAGTTTTGCCGCT ATAGCTGGGCAATACTAAACGATCCTACGGTTTATCCCGATCCGTCTACTTTCAATCCTGAACGTTTCTTAAAAGAC GGGAAGATTGACCCCAATGTACAAGATCCCGAGCTTGCGGCTTTTGGATACGGCAGAAGGACTTGTCCCGGCCGTAG GATAACCAACGCTTTTACCTGGCTTTCCGCGGGATATATACTAGCCAGCTTCAATATAGAAAATGCAGTTGGTAATG ATGGTATGCCCATCGAGCCCAAAGTTAAGTACCGTTCTGAAACAATCAGACACCCAGATACTTTTGAGTGCGTCTTC ACCCCAAGGTCAGATGATACCAGAGATATGATCGGTAGCGCGTACACA

Seq. ID No: 177

>T4H 3

Seq. ID No: 178

>T4H_4

ATGTATCTATTTAAGGCATACCTACGTCCTTCTCGTAGGTTACCCCCAGGGCCAAGGGGGTGGCCCCTAATAGGAAA CTTGCTAGACATGCCGACCTCCGACGAATGGGTAAGATACGCCCAATGGGTCCGTGAGTTTAAGTCTGACGTTATCC ACTTAGAAGTGTGTGGGACGCACATCGTTATTCTTAATAGTGTAGAAAGCGCAGTTGATCTTTTAGAGAAGCGTTCA TCCCTGTACTCATCTCGTCCGCCAACGCCTATGATGAGTGACCTGATGGGGTGGTCTTGGAATACAGCTATGCTTCC GTACAACGACGAGTGGAGAGCGCAAAGGCGTCATTTCCACGGTGAGTTCGACGGTAGAGCAATAGGAAAGCATTATC CTCCGATCATTAGAAGCACGCACGATTTGTTGCAAAGATTGTTGGACACCCCAGAGCAATGGCAGAGTCATATAAGG AGCCGAAGCTGCCTTTGCCTCCGTATCTGAGGCTATGGTGCCAGGCGCTTTCCTTGTCGATGTACTGCCAATTTTGA TTTGATGCACCCTTCGCGGCGATGAAACAAGCAATGGCAGCGGGTACTGCGAAGTCTTCATTTGGCAGTAGAAGTCT GAGGGATATAGACATTAAGGGAAACGTACAGAGCCAAGAGTTCTCTATCCAGGCCGCGGCTGGCACCATGTATAATG GCGCAAGCCGAAATGGACTTAGTCCTAGGGAGAAGCAACTTGCCCACATTCGCTGACCAGGAGAGTTTGAGCTACTT AGCAGCTGTAATGCAAGAAGTTTTTAGGTGGCAAGTCGTCGCGCCCTTCGGCGTGCCGCACATGTCAACCGCAGACG ATGAATACCGTGGTTATTTCATACCGGAAGGTACCATTGTAATTCCGAACGCCCATCAGATGCTGAACGATGAAGAT GTTTATCCAGAGCCGTCCAAATTCAAACCCGAAAGATTTTTAAAGGATGGCAAGCTAGACTTATCAGTGCGTAGCCC CCTAATTGCAGCATTCGGCTTCGGTAGAAGGATTTGTCCTGGCAGAGCCTTAGGAGAGAACTCCGCCTGGTTGGCAG CTGGGTCCATCCTGACTATGTTCAATTTGTCTAAAGCGACGGACCACAATGGTGTCACGATAGAACCCTCCGGCAGA TATACATCAGGTCTGGTTAGACACCCCGAGACGTTTAAATGTCAAATTACTCCCAGATCCAATGAGCCGAGAAGAGA ACTGGCAGGGGAGATTGAATTGATCACGGGCAGGATTCAAGAGTCTGAAGAAGCG

Seq. ID No: 179
>T4H CPR chimera 1

GTAGAAAGATTATTATGCGTCCTAGGTCTAGCCGAAAAGAGAGACGCAGTTATAAGCATTGAGAGCCTAGACCCAGC TTTAGCTAAGGTCCCCTTTCCAGTACCTACCACCTACGGTGCAGTTCTACGTCACTACATCGACATATCCGCCGTTG CTGGCCGTCAGATCCTTGGCACTTTATCAAAATTCGCGCCGACTCCGGAAGCCGAAGCCTTTCTAAGGAATCTAAAT ACCAACAAGAAGAGTACCATAATGTCGTAGCCAACGGCTGCTTGAAGTTGGGTGAGATCCTGCAGATCGCGACTGG CAATGACATAACCGTTCCCCCGACCACGGCCAACACGACAAGTGGCCCATACCTTTTGACATTATAGTAAGCGCGA TACCAAGGTTGCAGCCAAGATATTATTCCATTAGTAGTTCCCCGAAAATCCACCCTAACACGATACATGCAACTGTC GTCGTATTAAAGTACGAAAACGTGCCGACAGAGCCCATTCCCAGGAAGTGGGTTTATGGGGTGGGGTCCAACTTTCT ATTAAACCTGAAGTATGCTGTGAACAAGGAGCCAGTACCCTACATCACGCAGAATGGTGAACAGCGTGTCGGAGTCC CAGAATATCTAATAGCGGGCCCTAGGGGGAGTTACAAAACAGAGTCCTTCTACAAGGCCCCCATACATGTGAGAAGA TCTACCTTCAGGCTACCCACCAATCCGAAAAGTCCAGTTATCATGATTGGACCGGGTACGGGCGTTGCACCGTTTCG TGGCTTCGTACAGGAGAGGGTCGCACTGGCTCGTTCCATTGAAAAGAATGGGCCGGACAGCCTGGCTGACTGGG GACGTATTTCCTTGTTTTACGGTTGCAGACGTAGCGATGAAGATTTCCTTTACAAAGATGAGTGGCCACAGTATGAG GCCGAGCTTAAAGGCAAGTTCAAGCTACACTGTGCTTTCAGCCGTCAGAACTATAAACCCGATGGCAGTAAAATTTA TGTGCAAGACCTGATATGGGAAGATCGTGAGCATATCGCAGATGCGATACTTAACGGTAAGGGTTATGTATACATCT GTGGAGAAGCAAAGTCAATGAGCAAACAGGTAGAAGAGGTTCTGGCCAAAATTCTGGGTGAAGCCAAAGGGGGCTCT GGTCCGGTAGAAGGAGTGGCCGAAGTCAAACTGTTGAAGGAGCGTAGCAGACTAATGCTAGACGTCTGGAGC

Seq. ID No: 180 >T4H CPR chimera 2

TCTTCATCATCCAGTTCAGGGACGATAGCTTATTTTACCAAAGGAACCTACTGGGGTATTGTCAAAGATCCATATGC TCCTAACTATCCTCCTGCAAATGGGAATAAGCCCGCCAAAACAAGAAATATTGTTGAGAAAAATGGACGAAAGCAACA TCACGTTTCGGGCTGGAAACGATGGTAGCTGATCTTGAGGACTATGACTTCGATAACTTGGACACACTAGGAGATGA CAAAGTTGCAATTTTTGTGTTGGCAACCTATGGTGAGGGGGGGCCCACAGATAACGCGGTTCAATTGCTACAGAATT TACAAGACGAGAGCTTTGAGTTTTCATCTGGCGAGAGGAAGCTAAGTGGATTGAAATATGTGGTCTTTGGACTAGGA AACAAGACATATGAACACTACAATTTGATAGGAAGAACCGTTGATGCTCAGCTTGCTAAGATGGGTGCTATACGTAT CGGAGAAAGAGGGGAAGGACGACGACAAATCTATGGAGGAGGACTATCTTGAATGGAAAGATGGGATGTGGGAGG CATTTGCCACGGCAATGGGGGTGGAAGAAGGCCAGGGTGGTGATTCCGCTGACTTTGTTGTGAGCGAATTGGAAAGT CATCCTCCTGAGAAAGTTTATCAAGGGGAATTTAGCGCGCGTGCTCTGACAAAGACTAAAGGAATACATGACGCAAA GAACCCCTTCGCCGCTCCCATAGCGGTCGCCAGGGAGCTGTTCCAGTCTGTCGTTGACAGAAATTGCGTGCACGTAG AGTTCAACATTGAAGGTAGTGGTATTACATACCAACATGGTGATCATGTCGGACTTTGGCCTCTTAACCCGGATGTA GAAGTTGAACGTCTGCTTTGTGTGTTAGGCCTGGCCGAAAAACGTGACGCCGTTATAAGCATTGAGTCTCTGGACCC TGCATTAGCAAAGGTCCCGTTCCCTGTTCCTACGACATACGGTGCTGTCCTTCGTCATTACATTGATATCAGTGCTG TAGCAGGAAGGCAAATTCTAGGGACCCTAAGTAAGTTTGCACCAACCCCGGAAGCAGAGCATTTTTACGTAACTTA AATACCAATAAAGAAGAATACCACAACGTAGTAGCGAACGGATGTCTAAAACTTGGAGAGATTTTACAAATTGCTAC CGGCAACGACATTACGGTACCGCCGACCACGGCCAATACAACTAAGTGGCCGATACCATTTGACATCATAGTGTCAG CCATACCGCGTTTGCAACCACGTTATTACTCTATCTCAAGTAGCCCAAAGATCCACCCCAACACAATTCATGCAACC GTGGTGGTTTTGAAGTATGAGAACGTCCCAACGGAGCCTATCCCCAGGAAGTGGGTATACGGAGTGGGTTCTAACTT TTTGTTAAACTTAAAATACGCAGTAAATAAAGAGCCTGTCCCGTACATAACACAGAATGGGGAACAGCGTGTTGGCG TGCCTGAGTATTTGATCGCTGGACCCAGAGGCTCTTATAAAACTGAAAGTTTTTTACAAGGCCCCGATCCACGTGAGG AGGAGCACCTTCAGATTACCCACCAATCCTAAGTCCCCAGTCATAATGATCGGGCCTGGAACAGGCGTGGCCCCCTT TAGGGGCTTTGTTCAAGAGAGAGTAGCATTGGCGCGTCGTTCCATAGAAAAGAACGGCCCAGATTCACTGGCCGACT GGGGCAGGATTAGTTTGTTTTACGGGTGCCGTCGTTCTGATGAAGATTTCTTGTACAAAGATGAGTGGCCGCAGTAC GAAGCGGAATTGAAAGGCAAATTTAAATTACACTGCGCCTTTAGTCGTCAGAACTACAAGCCGGACGGCAGCAAGAT TTATGTCCAGGATCTTATATGGGAGGACAGAGAACACATCGCAGATGCGATACTGAATGGTAAGGGCTACGTTTACA TATGTGGAGAAGCCAAATCCATGTCTAAACAGGTTGAAGAGGTCCTAGCCAAAATACTAGGGGAGGCAAAAGGGGGT AGTGGCCCCGTAGAGGGGGTGGCTGAAGTTAAGCTGTTAAAGGAGAGGAGTAGACTAATGTTAGATGTGTGGAGC

Seq. ID No: 181
>T5H-CPR 1

AGCAGTAGCTCCTCCTCAGGCGGCTTACTTGCCTTTTTATACTTATTTAGGGGTACGTTATTTGCATCAGGAAAAGC GAGCGATGCCGGGTCAAAATTAGCAGGAGGGTCTGATCTGGACAGCAGTGCTGACGCCGCTGCCAACGACTTTGTTA CTAAACTGACGTCCCAAAATAAACGTATAGCTATTTTCTACGGAAGCCAGACGGGAACAGCAGAAGAGTATGCGACA CAGTGGGTCTTATGGAGTTCTTAGATGGAGAAGATGTGCAGTTCAGCAATGGGTCTAGCCTGGATAATCTTAACTAC GTTATCTTTGGCCTAGGAAATAGAACTTACGAGCACTATAACGCAATCGCACGTAAACTAGACGCCCGTCTTGAATC TCTAGGGGCGAAGAGGATAGGCGAGAGGGGGGGGGAGATGACGATAAGAGTATGGAGGAGGATTATTTAGCTTGGA GTACGTGAGGTAGCAGATCACCCGGAAGATAAAGTGTATAGGGGTGAACTTTCTGCGAGAGCCTTGCTAGGCACGAA GGGCATTCATGATGCCAAGAACCCCTACAACGCAGTAGTAAAGGAGGCTAGGGAACTATTCGTCGAAGGGACAGCTG ACAGGACGTGTCCATGTTGAGTTCGACATCGAGGGTTCCGGAATCTCCTACCAACACGGTGATCATATAGCCGTA TGGGCTCATAATCCTGAACAGGAAGTTGAAAGAGCATTAGCCGTCCTTGGTTTGCTGGGCAAACGTGATACGGTGAT ATTACCTGGATATTTGTGCACACGCGAGCAGACAACTCTGAACAACTTCGCAAAGTATGCGCCCACCCCGAAGCC CGTGCTAAGCTGGAGAAAGCCTGCGGAGACAAGGCAGCGTTCCAAGAGGCCATAGGCCATAGATGTCTGAAAACTTT TGAGGCATTACAATTGATTGTCGGCGATGATCTAGGTGGTGACTCCGTTGCAAAAGCTACTGCCTGGGAGATACCAT TTGATAGAGTAATCTCTGACCTTCCCAGAGTCGGACCAAGGTTTTATTCAATATCATCTTCACCTAAGATGCACCCC AAGACGGTGCACATCACGGCTGTCGTGTTGAGATATAGGCCAGAGGCAGCAGGGCAAGACTCCCCGTACGTTCATGG CTTAGCAACGAACTTTATATCCGCTATAAAGATGGCTAAAAATAATGAGCAGCCTAGTGGACCGGATGATCCGAGAT TCGGAACTCCTGGGTATGACCTAGCAGGCCCCAGGGGTGCCTACACAAAAGAGAGTCTATTTAGGGCCCCTATCCAT ATAAGACGTAGTAATTTCCGTCTACCCACGTCACCCAAAATCCCAGTAATCATGGTAGGTCCTGGCACGGGGGTCGC AGGCCCTTCAGGACTGGGGTAATATCTGGCTATTCTATGGTTGTAGAAGGAGCAACGAAGACTTCCTGTATAAGGAT GAGTGGCCCGAGTACGCGAGCAAGCTGGGAGGGAAATTCCAAATGGAGACAGCCGTCAGTAGAGAAGATTCAAGCC AGACGGCAGTAAACTTTATGTGCAGGACTTAATATGGGAGAGGCGTAAAGAACTGGCACAAGATATACTAGATAAGA AAGCGTATATTTACATCTGTGGTGAGGCGAAAGGGATGGCCCACGATGTCGAAGAAATGTTTGGTAGGGTGCTTGAG GAGGCTAAAGGTTCCGCTGAAGCTGGCAGACGTGAACTTAAATTACTGAAGGAGAGGTCCCGTTTACTTTTAGACGT TTGGTCT

Seq. ID No: 182
>T5H-CPR 2

TCCTCCAGCTCTTCATCACTGTTCTCAACTACTGACGTGATTCTATTCAGCCTTATTGTGGGTGTCATGACATATTG GTTTCTGTTTCGTAAGAAGAAGAAGTGCCAGAATTTACAAAAATACAGACAACAACGAGTTCAGTGAAAGATC GTTCTTTCGTCGAAAAGATGAAGAAGACAGGTCGTAATATCATTGTGTTTTTATGGAAGTCAGACCGGGACCGCAGAG GAGTTTGCCAACCGTCTGTCCAAGGACGCGCACAGATATGGAATGCGTGGTATGGCTGCCGATCCTGAAGAGTACGA TCTAGCGGACCTGTCATCACTGCCTGAGATAGAAAAAGCCTTGGCAATCTTTTGTATGGCGACTTATGGTGAGGGCG GTCTTCGCCTTGGGAAACAAGACATACGAGCATTTCAACGCGATGGGAAAATACGTAGACAAAAGGCTAGAGCAACT TGGGGCACAGAGAATATTTGATCTTGGATTGGGAGATGATGACGGAAATTTGGAGGAAGACTTCATTACATGGAGGA AGCAGTTTTGGCCGGCTGTGTGCGAGCACTTTGGGGTCGAAGCCACCGGTGAGGAAAGCAGTATAAGGCAGTATGAA CTTATGGTGCATACCGATATGGACATGGCCAAAGTATATACGGGAGAGATGGGTCGTCTAAAGAGTTATGAAAATCA GAAGCCGCCCTTTGATGCCAAGAACCCTTTCCTGGCCGTTGTCACGACCAATAGAAAGCTAAATCAAGGCACGGAGA GGCACCTTATGCACCTGGAGCTTGATATTTCAGATAGCAAGATACGTTACGAAAGCGGGGACCATGTCGCCGTCTAT CCTGCAAACGACTCCGCACTGGTTAACCAGTTAGGAGAGATATTGGGCGCTGATCTTGATATAATAATGTCCCTAAA CAACCTGGACGAAGAAGCAACAAAAAGCATCCGTTTCCTTGCCCAACCAGCTACAGGACTGCGTTAACGTATTATT TATCTTAGCCATTCTACAGGATTATCCGTCCCTTAGGCCTCCCATAGACCATTTATGTGAGTTATTGCCCAGATTGC AAGCGAGATATTACTCCATCGCAAGTTCATCAAAAGTTCATCCTAATTCTGTGCACATCTGTGCGGTAGCGGTGGAA TATGAAACTAAAACGGGGAGGATTAATAAGGGTGTCGCTACGAGCTGGCTAAGGGGCTAAAGAGCCGGCTGGCGAAAA

Seq. ID No: **183** >T5H-CPR 3

AGTAGCTCCTCATCATCCGAGGCAGTAGCCGAGGAGGTTTCCCTGTTTTCTATGACTGATATGATCCTATTCTCCTT GATTGTTGGTTTGTTGACGTACTGGTTTCTTTTTCGTAAGAAGAAGAAGAGGTTCCGGAATTTACTAAGATTCAAA CTTTGACCAGTAGCGTCCGTGAGTCATCTTTCGTCGAAAAGATGAAAAAGACAGGTAGAAATATCATAGTATTCTAC GGCAGTCAAACCGGTACAGCGGAGGAGTTCGCTAACAGATTATCTAAGGATGCCCACCGTTATGGCATGAGAGGAAT GTCCGCTGATCCTGAGGAGTACGATCTGGCTGACCTAAGCTCCCTACCCGAAATTGATAATGCACTGGTGGTTTTTCT GTATGGCTACATACGGGGAGGGAGACCCGACGGACAACGCTCAAGACTTCTACGACTGGCTGCAGGAAACAGACGTT GACCTGTCTGGTGTAAAATTCGCGGTGTTTTGGCCTGGGGAATAAGACTTATGAGCACTTCAACGCGATGGGAAAATA TGTTGATAAAAGACTTGAGCAACTTGGAGCACAGAGGATTTTCGAACTTGGATTGGGAGATGACGACGGTAACTTAG AGGAGGATTTTATCACCTGGCGTGAACAATTCTGGCCCGCAGTGTGTGAACATTTCGGGGTGGAGGCGACCGGTGAG GAAAGCTCAATCAGGCAATACGAGTTGGTGGTTCATACCGATATAGACGCCGCCAAAGTTTACATGGGAGAGATGGG CAGACTGAAGTCTTACGAGAATCAAAAGCCCCCTTTCGACGCCAAGAACCCATTTTTAGCGGCAGTCACTAATA GGAAACTGAACCAAGGCACCGAACGTCACCTTATGCATCTGGAACTGGATATCAGCGATAGCAAGATCAGGTATGAA TCAGGAGATCATGTGGCGGTCTATCCTGCCAACGATTCAGCTCTTGTCAACCAGTTGGGAAAAATTTTGGGTGCTGA CTTAGACGTTGTAATGTCACTTAACAATTTAGATGAGGAGGAGCAACAAAAAGCACCCTTTCCCCTGCCCCACAAGCT ACAGGACCGCATTAACTTATTACCTAGACATAACGAACCCTCCACGTACTAACGTCTTATATGAATTGGCACAATAC GCCTCCGAACCGTCCGAACAGGAGTTACTGCGTAAGATGGCTAGTAGTTCAGGAGAAGGTAAGGAATTATACCTAAG TTGGGTTGTAGAGGCAAGGAGACACCTTGCCATATTGCAAGATTGTCCATCTCTGAGGCCACCAATCGACCACC TTTGCGAGTTGCTACCTAGACTTCAGGCGAGGTACTATAGTATAGCATCTTCCAGCAAAGTGCATCCCAATTCAGTG CTTTTAAAGCTACCACCCCGTAATAATGGTAGGTCCAGGAACCGGTGTAGCACCATTTATTGGTTTCATACAAGAA AGAGCTTGGCTAAGGCAGCAAGGAAAGGAAGTAGGCGAGACCTTGTTATATTATGGTTGTCGTCGTTCAGATGAGGA TTACCTGTACAGAGAGGAGCTGGCTCAATTCCATCGTGATGGGGCTCTGACCCAATTAAATGTGGCATTCAGCCGTG AACAATCTCACAAAGTGTATGTTCAACATTTGCTAAAACAGGATAGAGAACATCTATGGAAATTAATAGAAGGGGGT GCTCACATATATGTCTGCGGGGATGCCAGAAATATGGCGCGTGACGTGCAGAACACGTTTTATGACATTGTGGCCGA GCTAGGCGCGATGGAGCACGCCCAAGCCGTCGATTACATCAAAAAGTTGATGACGAAGGGCAGGTACTCATTAGATG **TGTGGAGT**

Seq. ID No: 184 >T5H-CPR 4

AACACCCGTGCAGGGCCAACGTGGCGGTAAGACGTGAGTTACACACGCCGGCAAGTGACAGGAGCTGCATTCATCTT GAGTTCGACATCGCCGGGACCTCACTTACGTACGAGACGGGAGATCACGTTGGAGTATATGCCGAGAACAGTACTGA GACGGTGGAGGAGGCGGAAAAACTACTTGATTACAGCCCAGATACTTATTTCAGCATTTATGCAGATCAAGAGGACG GTACCCCATTGTTTGGTGGTAGTCTGCCACCCCGTTTCCGCCATGTACAGTAAGGGTGGCTTTAGCAAGATATGCT GACCTATTAAATTCCCCCAAGAAGAGTGTATTATTAGCCCTGGCCGCTCATGCATCCGACCCCAAGGAAGCTGAGAG GCTGCGTCACCTGGCATCTCCGGCTGGAAAGAAGGAGTATTCTCAGTGGATTATAGCGTCTCAAAGGTCTCTGTTAG AGGTAATATCAGAGTTTCCCTCCGCTAAGCCACCACTGGGAGTTTTCTTCGCAGCGATTGCCCCGAGGTTACAACCG CGTTATTACTCCATTAGCAGCAGTCCCAGGATGGCGCCCACAAGAATACATGTCACCTGTTCATTGGTGCACGGCCA ATCTCCCACCGGTAGAATCCACAAAGGCGTATGCAGTACATGGATGAAAAACAGTACGCCCAGCGAGGAAGAGTCCG AGGAGTGTTCCTGGGCACCAATCTTTGTGAGACAATCCAATTTCAAGCTACCCGCCGATCCCACTGTCCCGATCATT ATGGTGGGGCCTGGAACAGGTCTAGCTCCATTCAGGGGTTTTCTACAGGAAAGACTGGCTTTAAAAGAAACGGGAGT ATTTTACGGAAAGTGGCGCGCTTTCCGAGCTGGTAGTTGCCTTTTCTCGTGAAGGTCCCACCAAGGAATATGTTCAA CACAAGATGGCAGAAAAAGCGGCAGATTTATGGTCAATAGTATCTCAAGGGGGTTATGTCTATGTGTGCGGGGACGC TAAGGGAATGGCACGTGACGTGCACAGAGCATTGCACACCATAGTACAGGAACAAGTCACACAAAGGACCTCCAACT TTGGGCTTTGGAAGTTCCGTCTTGTTTCACTAAAT

Seq. ID No: **18**5 > T5H-CPR 5

GTCCACCTCCGGTTAAGATTGAAGCCGACGCAGATGCTGATGATGGCAGGAAGAGGGTGACCGTGTTCTTTGGCACT CAGACCGGGACCGCAGAAGGCTTTGCCAAAGCGATGGCCGAAGAAGCTAGGGCCCGTTACGAAAAGGCTGTGTTCAA AGTCGTTGACCTGGATGACTATGCGGCAGAGGATGAGGAATATGAGGAAAAACTTCGTAAAGAAACCATCGTCTTAC TGTTCCTGGCGACGTATGGGGACGGTGAGCCTACCGACAATGCGGCGCGTTTCTATAAGTGGTTTACAGAAGGTAAA GAAAAAGAGGTTTGGCTAAAAGACCTAAAATATGCGGTATTTGGATTGGGTAACAGACAATACGAGCACTTTAATAA GGTCGCCAAGGTAGTCGATGAGCTATTGGAGGAACAAGGAGGGAAAAGACTTGTTCCCGTGGGTTTAGGAGATGATG ACCAGTGCATAGAGGATGATTTCACGGCTTGGAAGGAGCAGGTCTGGCCAGAACTTGATCAGCTTTTAAGAGACGAA GACGACACACGGGTGCATCTACACCTTACACTGCGGCCATACCCGAATATCGTATCGTTTTCATTGATAAGAGCGA TGTATCATTCAAGACAAGAGCTGGTCCCTTGCAAACGGTTCAGGGGTCATAGATATTCATCATCCTGTAAGGAGTA ACGTCGCAGTCCGTAAAGAGTTGCACAAGCCGGCTTCTGATAGGTCTTGTATCCACTTGGAGTTCGACATTTCAGGC ACCGGCCTTGTGTATGAGACCGGCGATCATGTCGGGGTGTATAGCGAGAATGCCATCGAAACAGTTGAGCAAGCGGA AAAGCTACTAGACCTTTCTCCAGATACGTTCTTTAGCGTCCATGCAGATGCAGAGGACGGATCTCCCAGAAAAGGAG GGGGATCTTTAGCCCCACCCTTCCCGTCTCCATGTACTCTTAGAACCGCCCTATTGAGGTATGCTGACCTGCTGAAC AGTCCTAAGAAAGCTGCATTAGTAGCTCTGGCAGCGCATGCGTCCGATCTAGCTGAAGCAGAAAGGCTACGTTTCTT GGCTTCCCCAGCCGGAAAAGATGAGTATTCACAATGGGTGGTAGCGTCCCAGAGGTCCCTGTTGGAAGTTATGGCCG CGTTTCCCAGTGCAAAGCCGCCGCTGGGAGTGTTCTTTGCAGCTGTCGCCCCCAGACTTCAACCACGTTACTACTCC ATTTCATCCTCTCCGAAAATGGCTCCCTCCCGTATCCACGTCACCTGCGCGCTAGTGTACGGCCCGACTCCTACAGG CCGTATACACCAGGGCGTTTGTAGCACGTGGATGAAGAATGCAATACCAAGCGAGTACAGTGAGGAGTGTTCCTGGG CACCCATATACGTTAGACAAAGTAATTTTAAACTACCCGCGGACCCGACGACCCCAATTATTATGATAGGACCCGGT ACAGGGCTTGCTCCATTTCGTGGCTTTCTACAAGAACGTTTGGCTTTAAAACAGTCTGGAGTTGAGCTGGGGAACTC TGTGTTATTTTCGGGTGTAGAAACCGTAATATGGATTATATTTACGAAGATGAACTACAGAACTTTATTCAGGAGG GCGCTTTGAGCGAGTTGATCGTCGCTTTTAGTAGGGAAGGCCCAGCGAAGGAATATGTCCAACACAAAATGACTGAA AAGGCAACGGAAATCTGGAATATAGTCTCTCAAGGTGGTTATATTTACGTTTGCGGGGATGCAAAGGGCATGGCTAG GGACGTCCACCGTGCTTTGCACACTATAGTACAAGAACAAGGCTCTCTTGATAGCAGTAAGACAGAGTCATATGTAA AATCTCTTCAAATGGACGGCCGTTATTTACGTGACGTCTGG

Seq. ID No: 186
>T5H-CPR 6

GGATTGTAATCTTTTATGGGAGCCAGACTGGTACCGCGGAGGAGTATGCGATTAGGATCGCTAAAGAAGCTAAAACG AAGTTCGGTCTTACCTCACTGGTTTGCGACCCTGAGGAATACGATTTCGAGAACCTGGACCAAGTACCAGAAGACTG CTGCGTATTCTTTGTGATGGCCACATACGGAGAGGGGGAACCGACGGACAATGCTGTTCAACTGATGCAAAACTTAG AGGATGAGTCCTTCGAGTTTAGTAATGGATCACACAGGTTGGACGGTTTGAAATATGTGGTGTTTTGCGCTGGGCAAC AAAACGTACGAGCACTATAACGCTATTGGACGTAAGGTAGACACATTGTTAACAGACATGGGGGCGACAAAAATCGG GGAACGTGGAGAGGAGACGACGATAAGTCAATGGAAGAGGATTATTTAGAGTGGAAAGATGGAATGTGGAAGGCGT TTTCTGAAGCGATGGGTGTAGAGGAAGGGCAGGGCGGGGATACTCCAGATTTTGCTGTTACTGAGCTTGATAGTCAC CCGCCAGAGAAAGTATATCTAGGCGAGCTTAGTGCCAGGGCCTTAACTAGGACTAAAGGCATTTATGACGGTAAAAA TCCATACCCCTCCGCCGTAAAACATAGTAGGGAACTTTTTCAGGCTGGTGCAGAGAGGAACTGCGTACACGCGGAAC TAGATATTGAGGGCTCTGGCATTACATATCAGCACGGTGATCATGTAGGAGTGTGGCCGAGCAACCCCGATGTTGAG GTCGATCGTATGCTATACGTGTTAGGTCTATATGGCAAGAAGACGCCGTGATAAATATAGATTCCCTAGACCCTGC GCTGGCGAAAGTACCCTTCCCCGTACCGACTACATATGCCACGGTTCTGAGACACTACATCGACATATGTGCTGTGG CTGGGCGTCAGATGTTGGGGGTCCTTAGCAAGTTCGCACCGCATCCGAAAGCCGAGGCTTTCCTGAAATCATTGAAT AGCGATAAGGAAGAGTACTCAAACATAGTAACGAACGGGTGTTTTTAAACTGGGTGAAGTTCTGCAGTTAGCGGCAGG CGACGATATTAAACTATGTCCCACCCCAGACAACACCACAGCTTGGGCAATACCCTTCGATATCATAGTATCCTCTA TACCGAGACTACAACCGCGTTTCTACAGTATTAGTTCCTCTCCCAAATTATACCCCAATGCAATCCATCTAACAGCT GTAGTGCTGAAGTACGATAGTATCCCAAATAGGCTGGTGGAGTCTCGTTTTGTATATGGCGTGGCCACAAATTTTCT ATTGAATGTGAAGTACGCAGCTAATGGTGAGACGGCTCCATTCATCGCCGAACCAGTAATATCTGAGCCGGCACATG TCTCACTTCCAAAATACGCCATAGAAGGACCTAGAGGAGCCCATATCGAGGACAATATTTATAAGATACCGATACAT GTCCGTAGATCCACTTTTAGGCTACCTGCTAATCCGAAGATTCCAGTAATCATGGTCGGACCGGGAACAGGCGTCGC GCCCTTTAGAGGGTTCGTGCAGGAGAGTTGCACTTGCTAAACGTAGCATTGAGAAAAATGGGCCAGACGCCCTTG CCGATTGGGGCAGCATTACACTGTTTTACGGTTGTAGGAAATCCAATGAAGACTTTTTATATAAGGAAGAGTGGCCT CAATATGCGGAAGAGTTAAAAGGTAAATTTAAGATGCATTGCGCTTTCAGTAGAGAGCCTCCTTACAAGCCTGACGG ATGTTTATATCTGCGGTGATGCAAAAGCCATGAGTCGTGCAGTCGAAGACACCCTGGCCAGGATTCTGGGAGAAGCA AAAGGTGGCAATGCAGAAGTGGAAGGTGCAGCAGAGATGAAGATCTTGAAGGAACGTAGTAGACTACTGCTTGACGT **ATGGTCT**

Seq. ID No: 187
>T5H-CPR 7

TCAAGCTCTTCCAGCAGCTCACTGTTTTCTACTACTGACATGGTACTGTTCTCTTTAATTGTCGGAGTCCTGACCTA TTGGTTCATTTTCAGAAAGAAGAAGAAGGAGATTCCCGAGTTCAGTAAAATACAGACTACCGCCCCACCTGTCAAGG AGAGCAGCTTTGTGGAGAAAATGAAGAAAACCGGCAGGAACATTATAGTCTTTTACGGCTCTCAGACCGGCACGGCG GAGGAGTTCGCAAACAGACTGTCCAAAGACGCCCATCGTTATGGTATGCGTGGCATGAGTGCGGACCCAGAAGAATA CGACCTTGCGGATTTATCATCCTTGCCGGAAATTGATAAGTCACTTGTGGTCTTTTGCATGGCAACATACGGAGAGG GTGACCCAACGGACAACGCGCAAGACTTTTATGACTGGCTTCAAGAGACGGATGTAGACTTAACTGGCGTTAAATTT GCCGTTTTTGGACTAGGTAATAAGACTTACGAACATTTCAACGCAATGGGCAAGTATGTTGATCAGCGTCTTGAGCA GCTGGGGGCCCAACGTATTTTCGAATTGGGCTTGGGAGACGATGATGGCAACTTAGAAGAGGACTTTATTACTTGGC GTGAGCAGTTTTGGCCTGCAGTGTGCGAGTTCTTCGGGGTGGAAGCTACCGGCGAGGAATCATCTATCCGTCAGTAT GAATTAGTGGTCCACGAGGACATGGATGTTGCTAAAGTGTATACCGGCGAAATGGGCAGGCTAAAATCTTACGAAAA TCAGAAGCCACCCTTCGACGCCAAGAATCCATTTCTAGCAGCGGTCACTGCCAATAGAAAACTTAATCAGGGGACTG AGAGACATCTAATGCATTTAGAACTAGACATCAGTGACTCAAAAATAAGATATGAATCCGGCGACCACGTTGCAGTG TACCCTGCCAACGATTCCGCGCTAGTAAACCAGATAGGTGAGATCTTAGGTGCGGACCTAGACGTAATCATGAGTTT GAATAACCTAGATGAAGAGTCTAATAAAAAGCACCCCTTCCCTTGTCCTACAACGTATAGGACGGCCCTTACATACT ACCTAGACATCACAAACCCGCCAAGAACTAACGTGCTTTATGAGTTAGCTCAATACGCCTCAGAACCTTCTGAGCAA ACACATATTAGCCATTCTGCAAGACTACCCATCTTTGCGTCCTCCCATCGACCATTTGTGCGAACTTTTGCCCCGTC GAATATGAGGCGAAATCCGGGCGTGTTAATAAGGGTGTCGCGACAAGTTGGCTACGTGCCAAGGAGCCCGCGGGTGA AAATGGGGGCAGGGCCCTAGTTCCTATGTTTGTAAGGAAGTCACAGTTTAGATTACCATTTAAAAGTACTACCCCAG

GGAAAGGAGGTTGGCGAGACGTTATTGTACTATGGATGTAGGAGGAGTGACGAAGACTACCTATACCGTGAAGAGCT
GGCGAGGTTTCACAAAGATGGTGCATTGACTCAGCTTAATGTGGCATTTTCCCGTGAGCAGGCCCCACAAGGTCTACG
TCCAACATCTGCTTAAACGTGATCGTGAGCATTTATGGAAACTGATTCACGAAGGCGGTGCTCATATCTATGTTTGT
GGTGATGCTAGGAATATGGCCAAAGATGTTCAAAATACATTTTATGATATAGTGGCTGAATTTGGGCCGATGGAGCA
TACTCAAGCCGTTGATTACGTGAAAAAGGTTGATGACAAAGGGCAGGTACAGCCTGGATGTATGGTCA

Seq. ID No: 188
>T5H-CPR 8

TCATCTAGCTCATCTGGGGGCTCTCCCATGTCCGATTCCGTTGTCGTAATCATCACGACGAGCTTCGCAGTCAT AATCGGCTTACTGGTGTTTCTTTGGAAACGTTCTTCAGACAGGAGTAAGGAGGTTACTCCGCTTGTTGTACCAAAAA GTCTTTCCGTGAAAGACGAAGAGGACGAAGCTGAAACACTTGCGGGCAAAACAAAGTCACAATTTTCTATGGTACT CAGACAGGCACGGCCGAAGGTTTTGCTAAGGCATTGGCGGAAGAGATAAAGGCTAGGTATGAGAAAGCAGCAGTCAA GGTTGTGGACTTAGATGATTACGCTATGGATGACCAGTACGAAGAAGAAATTAAAGAAGGAGACTCTAACGTTTT TCATGGTAGCAACTTATGGAGACGGTGAGCCAACAGACAATGCTGCAAGGTTTTACAAATGGTTCACAGAAGAGCAC GAGCGTGGGGTGTGGCTACAGCAGTTGACTTATGGGATCTTCGGGTTAGGAAATAGACAATACGAACATTTTAATAA GATAGCCAAAGTACTAGACGAGCAATTGAATGAGCAAGGCGCCAAGCGTTTAATTCCAGTAGGACTGGGAGACGATG ATCAGTGTATTGAGGACGACTTCACAGCGTGGAGGGAACTTCTATGGCCCGAGCTAGACAATTTACTACGTGACGAG GATGACGTCAACGGGGCAAGCACCCCGTACACAGCGGCAATACCGGAATATCGTGTCGTAATCCATGACGCCAGTGC TACGAGCTGCGAAGATAAAAGTGTGCTAGAGAATGGGAACACGTCCATCGACATCCACCACCCTTGCCGTGTAAACG TAGCCGTTCAAAAGGAACTGCACAAGCCTGAAAGCGACAGGAGCTGTATACATTTGGAATTTGACATTAGCGGTACA GGTATAATTTACGAGACTGGTGATCACGTGGGCGTGTACGCGGAGAATTTTGAGGAGAACGTTGAAGAAGCAGGGAA ACTTCTTGGCCAGCCTTTGGACCTATTGTTTAGTATTCACGCGGACAACGAGGATGGCGCCCCTTTAGGATCAAGTC AAGGCGGCACTAATAGCTTTAGCGGCCCACGCCTCAGAACCCTCTGAGGCAGAGAGACTTAAATACCTGAGTTCACC CGAAGGGAAGGACGAGTATAGTCAATGGATCGTTGGCAGCCAAAGGTCACTGCTGGAAGTGATGGCCGAATTTCCCT CTGCGCGTCCTCCTCTGGGCGTTTTCTTTGCTGCTATCGCGCCCAGGTTACAACCTAGGTACTACTCTATTTCTAGT TCTCCTAGGTTTGCACTGTCCAGAGTACATGTGACCTGTGCGCTAGTCTACGGTCCAACTCCAACGGGCAGAATCCA CAAGGGGGTATGTAGCACATGGATGAAGAATGCGGTGCCGCTAGAGAAGTCACACGACAGTAGTTGGGCGCCCGTGT TTATTCGTACCTCTAACTTTAAACTTCCAACAGACCCTTCAATACCTATCATTATGGTAGGTCCTGGGACCGGACTT GCGCCCTTTAGAGGTTTCCTGCAGGAGAGGATGGCGCTTAAAGAGGACGGTGCACAATTGGGGCCAGCTTTGCTGTT CTTCGGTTGCCGTAATAGGAGAATGGACTTTATCTACGAGGACGAGCTTAACTATTTTGTGGAACAGGGGGTAATTT CCGAATTAATCGTAGCCTTTTCTAGGGAAGGGCCGCAAAAAGAGTACGTCCAGCATAAGATGATGGACAAAGCAGCC TAGGACCCTACATACGATCGTCCAAGAACAAGGTAATTTGGACAGTTCCAAAACGGAGAGTATGGTCAAGAAATTGC AAATGGACGGTAGATACCTTAGAGACGTATGG

Seq. ID No: 189
>T5H-CPR 9

TCTTCCTCAAGTAGCTCCACTTCTTTCCACAAGTTAAAAAGAATTTTACACAAACACTTGCAGCGTAGTCATTCCAT
CGGAGCAGAATGTAAACCCCAAAGGTCCAATCACGAGGATCTATTAGCGGTGATGAACAGGAGTTCAATTAAGGTTT
CTATATTTTATGGTAGCCAGACAGGTACGGCGAAGAAGTTTGCAATCAACCTTGGGCATCACCTGCATAACTGTGGT
GTACGTAACTTGGTTATGGACCTGAGACAGACGAATATGGAAATCTTAGTGAACCTTATCTATGCTTGATAATTGCGT
AGCATTATTTGTTGTAGCCACTTACGGAGAAGGAGAACCGACGGATAGTGCTAGGCAATTTATGGACAACTTAAAGA
ACTCCTATCAAAAGTTGGATAATCTTCGTTTTGCAGTGTTTTGGATTGGAAATAGTATGTACACGTATTTCAATGCA
GTGGGAAAGTCTATCGACCGTTTGTTGATTCAACACGGAGGAAAGCGTTTGCAAACGTTAACACTGGGCGATGAAGT
AAACGAGTTGGAGTCTACATTCCTAAACTGGCGTTCCCACCTTACCAGTTTATTAATCGATTTCTTTGACTTGAACG
ATCACGATAGAAACTACTTAAATAAACAGTATAAAAGGATGTACTCACTGAAGAGATTTAACTGGAATTTACTT
CTACGCTTCTGTCGCAGTTAATCAAGAAGCTTTATCACAAATCCTCGCGATCATGTCGTCATATCGAGCTAGATGTCT
CCGCCTCTCAGCTTAGGTATAAGACTGGGGGACCATATTGCTATTTTTTGCGTCAAACCCATTTGGACCTTGTAGAGAAA
ATAGGAGATCTGCTGAACATCGACCTTAACGAAATGATCTCTTTTGGACCTGTCAAACCACAACCCATTAGAACAA

Seq. ID No: 190
>T5H-CPR 10

TCAAGCTCCTCTCCCGGGGGCAAAATATTTGATAAATTGAACTCTTCTCTCGATTCTGGGGACAGCACTAGCCC TGCATCACTGACGGCTTTATTAATGGAAAATAAGGATCTTATGATGATTCTGACAACTAGCGTTGCCGTCCTAATAG GGTGCGCGGTTGTCCTGATGTGGAGAAGATCCAGCACATCCGCGCGTAAGGTGGTAGAACTTCCCAAACTTGTAGTT CCCAAGTCTGTTGTAGAGCCTGAAGAAATCGACGATGGCAAGAAAAAGATAGCGATCTTTTTCGGGACTCAGACCGG CACGGCTGAGGGTTTTGCTAAGGCATTAGCAGAGGAAGCCAAGGCAAGATATGAAAAAGCAATATTTAAAGTCATTG AGACTGCTTCAAAAACCTACAATACGGTGTCTTTGGCCTAGGCAACCGTCAATATGAGCATTTTAATAAGATCGCGA AGGTGGTCGATGAACTGCTTGCTGAACAAGGCGGGCAGCGTCTAGTCCCAGTAGGATTAGGGGATGATGATCAGTGT ATAGAGGACGATTTTGCTGCTTGGCGTGAGTTGGTCTGGCCCGAGCTAGATAAGTTGCTGCTAGACGGTGATGATGC CACAGCAACGACCCCCTATACTGCTGCAGTGCTAGAGTACAGGGTGGTCACGTACGATAAGAGCAACTTCGATAACG ACTTGACTAACACGAACGGCCATGCGAACGGCCACGTCATTGTTGATGCCCAACACCCAGTTCGTGCCAATGTTGCG GTTCGTAAGGAGCTACACACCCCCGCGTCTGATAGGTCCTGCACCCACTTGGAGTTTGACATAAGTTGTACAGGACT TACTTATGAGACTGGAGATCATGTTGGCGTGTACTGCGAAAATTTTGTGGAAACGGTTGAAGAGGCGGAAAGACTTC CCTTCTCCATTTCCACCCTGTACACTAAGAACGGCGTTGACTAGATATGCAGACGTCTTGAGTTCACCAAAGAAGTC CTCCCTGCTTGCCCTGGCGGCCTGTTCATCAGATCCCAATGAGGCAGATAGACTGAGATACTTGGCCTCTCCCGCGG GAAAAGAGGAGTATGCGCAATGGATAGTTGCCAGTCAGAGAAGTTTGTTGGAGGTTATGGCGGAATTTCCGTCAGCT AAACCGTCCATAGGGGTGTTTTTCGCAAGCGTTGCACCTAGATTACAGCCGCGTTTCTACTCAATCTCTAGTTCTCC GAGAATGGCTGCATCCCGTATACACGTAACTTGCGCTTTAGTATACGATAAGATGCCGACGGGACGTATCCATAAAG GGGTTTGCAGCACCTGGATGAAAAACGCCATACCGTTGGAAGAAGTCTAAGTTGTAGCACCGCCCCGATCTTTGTT AGACAGTCAAATTTTAAACTTCCAGCCGACAACAAGGTTCCTATCATTATGATTGGTCCTGGCACGGGATTGGCGCC GGTGCCGTAACAGACAAATGGATTACATATATCAGGATGAATTAGATAACTTCCTTGAAGCCGGGGCGTTAAGTAAT CTAGTCGTCGCTTTTTCAAGAGAAGGACCCAACAAGGAATACGTCCAACACAAGATGACACAAAAGGCAGATGATAT TTGGAATATGATTTCTCAAGGGGGTTACGTTTATGTCTGCGGTGACGCAAAAGGCATGGCCAGAGACGTACACAGAA CACTTCATACTATCGCGCAGGATCAGGGGAGCCTAGACTCCTCTAAGGCAGAATCATTCGTCAAGAATCTGCAGACA ACCGGTAGGTACCTAAGGGACGTGTGG

Seq. ID No: 191 >T5H-CPR 11

TTACGACAAGGCAATATTTAAGGTTGTAGACTTAGATGATTACGCTGCCGAAGATGAGGAATACGAAGAGAAATTGA AGAAGGAAAAGCTGGCTCTGTTCTTTGTCGCTACGTACGGGGATGGGGAACCTACTGACAATGCCGCAAGATTTTAT AAATGGTTCACGGAAGGTAATGAAAGGGGTGTCTGGCTGAACGATTTTGAGTATGCGGTGTTCGGTCTAGGCAACCG TCAATACGAGCATTTCAACAAAGTAGCGAAAGTTGTTGATGAAATTCTTACAGAACAAGGGGGCAAGAGACTGGTAC CTGTCGGACTTGGTGACGATGATCAATGCATCGAGGATGATTTTAATGCATGGAAAGAGGCGCTGTGGCCCGAGCTG GATAGACTTTTGCGTGATGAGAACGATGCCAGCACGGGGACAACTTACACGGCAGCAATCCCGGAGTACCGTGTCGA GTTTATAAAGCCTGAAGAGGCGGCTCACCTGGAGAGAAACTTCAGCCTTGCTAACGGTCATGCCGTGCATGATGCTC AGCATCCGTGCCAGGCTAACGTGGCGGTTAGACGTGAGTTACATACGCCGGCGTCTGACAGGTCATGCACTCATTTG GAGTTCGACATTGCAGGCACCGGACTTACCTACGAAACGGGGGACCACGTTGGAGTGTACACAGAGAATTGCCCGGA GGTGGTTGAGGAAGCCGAGAGGTTGTTGGGTTACTCCCCGGACACTTTCTTCACAATTCACGCGGATAAAGAGGATG GTACTCCCTTGTCCGGCTCATCCCTAGCGCCACCATTTCCGTCTCCCATCACGGTAAGGAACGCCTTAGCCAGATAT GCCGATTTACTGAACTCTCCCAAAAAGACCAGCCTGGTAGCCCTAGCGACATACGCCAGTGATCCCGCTGAGGCGGA CAGGTTAAGGTTCCTGGCTTCTGCAGCGGGGAAAGATGAATATGCTCAATGGGTCGTGGCGTCACAAAGAAGTTTAC TAGAGGTCATGGCGAATTTCCATCTGCCAAACCGCCACTTGGCGTGTTTTTTCGCCGCCGCGTGGCGCCAAGGTTACAA CCCAGATATTATTCAATTTCCTCATCCCCATCGATGGCTGCCACGAGGATTCACGTAACTTGTGCCTTGGTTCATGA AACCACTCCAGCCGGGCGTGTACACAAGGGAGTTTGCTCAACATGGATCAAAAATGCAGTCCCCTCTGAGGAGAGCA AAGATTGTAGCTGGGCGCCGATTTTCGTAAGGCAAAGCAATTTCAAATTACCGGCCGATCCTTCAGTTCCCATAATA ATGATCGGGCCGGGAACAGGCCTTGCACCGTTTCGTGGCTTTTTGCAGGAACGTCTGGCCCAAAAGGAGTCTGGAGC AGAATTGGGCCCAAGCGTCTTTTTCTTTGGTTGTAGAAATTCAAAAATGGATTTCATCTATGAAGATGAACTTAACA ATTTCTTGGAACAGGGTGCCCTATCTGAACTTGTTTTAGCGTTCTCCCGTCAAGGGCCAACTAAGGAGTATGTTCAG CACAAAATGGCTCAGAAGGCGTCTGAAATATGGGACATGATTAGTCAGGGGGGCGTACATTTACGTTTGCGGGGATGC GAAGGCATGGCCAGAGACGTGCACAGAGTCCTACATACAATCGTCCAAGAACAAGGATCACTGGACAGTTCCAAGG CCGAGAGCTTCGTGAAGAACCTGCAGATGGAAGGACGTTATCTACGTGACGTGTGG

Seq. ID No: 192 >T5H-CPR 12

TCCTCATCTTCTTCCTCAGTAAGAGAATCTAGTTTCATAGAGAAAATGAAAAAGACCGGTAAGAATATCGTAGTGTT CTACGGATCACAAACTGGTACCGGTGAAGAGTTTGCGAATAGACTTGCAAAAGACGCTCACCGTTATGGAATGAGAG GGATGGCTGCTGATCCCGAAGAGTTCGAAATGACGGACTTGTCCAGATTAACAGAGATCGAAAATGCACTAGCAGTT TTCTGCATGGCTACCTACGGTGAAGGTGACCCCACTGATAATGCGCAAGACTTCTATGATTGGCTGCAGGAGACAGA TATCGATCTGGCCGGGCTAAAGTATGCCGTGTTTGGCCTGGGAAACAAAACGTACGAACATTTTAACGCTATGGGCA TTGGAAGAAGACTTTATCACGTGGAGAACAGTTCTGGCCGGCGGTTTGTGAACACTTTGGCGTCGAAGCGACAGG AGAAGACAGTAGCATTAGACAATACGAATTGGTCGTACATACGGATGAAAATATGAACAAGGTATATACAGGCGAAA AACAGAAAGCTGAATGAAGGGGGAGATAGACATTTTATGCATCTTGAACTAGATATTACGGGCTCAAAGATTCGTTA TGAGAGTGGCGATCACGTCGCAGTCTATCCTGCTAACGACGCGCGCACTGGTTAATAAATTAGGAGAAATTCTTGGAG CCGACTTAGAGACAGTTATTTCTCTGAACAATCTTGATGAAGAGTCTAATAAGAAACATCCCTTCCCTTGTCCGACT ACCTACAGGACGGCACTAACGTACTATCTGGATATCACGAATCCCCCGCGTACAAATGTTTTATACGAGTTGGCACA ATACGCCACCGATTCAAAGGAGCAAGAGAACCTACGTAAAATGGCGTCATCTGCGCAAGATGGTAAAGCACTGTACC TGTCTTGGGTGGTAGAATCCAGGCGTAACATATTAGCTATATTAGAAGACATACCATCACTGAGACCGCCTCTGGAC CACTTGTGTGAACTTTTACCCAGGTTACAGGCGAGATATTACTCTATAGCAAGCTCCAGCAAAGTCCACCCTAATAG TATTCACGTTTGCGCAGTCCTGGTGGAATATGAAACCAAAACTGGCCGTGAAAACAAAGGCGTCGCCACAAATTGGC CCATTTAAGCCATCCACACCCGTTATAATGATCGGTCCGGGTACCGGCATTGCGCCCTTTATGGGATTTATACAAGA ACGTGAATGGTTAAAGCAGCAAGGTAAAGACGTCGGCGAGACGGTACTATACTATGGTTGCAGGCATGAACATGAGG ATTTCTTGTACATAAACGAACTGAAAAGGTATCACAAAGAGGGAGTTCTAACGCAGTTGAACGTCGCGTTCTCTAGG GATCAAGCACACAAAGTGTACGTACAACACTTGCTAAAGAACAATAAGGAAATGGTTTGGAAGTTAATCCACGAGGA TAACGCTCATATTTATGTCTGCGGTGACGCCAGGAACATGGCCAGAGACGTACAAAATATCTTTTATGACATCGTTG AGGAATACGGCAAGCTAGATCACGCCCAAGCCGTAGACTACATAAAGAAATTAATGACTAAGGGGAGGTATTCACAG GATGTGTGGTCT

Seq. ID No: 193

>T5H_1

ATGCTACCGATCGTGGATCACCTACTTGACGTTTTAAACTTGGAACGTACACCCTTTCGTACATATGCTGTGACGGC ATTCAAAGCGTTTGAGGTGTTTCCCCGAGCCCCCGAATAGGTCCTGGATCTTGGGGCACCTGGGTCTTTTTGCCCCG AATACCGCTGATTAGTCTAATACATCCCGATACTATTAAACCAGTAGTTGCGGCACCAGCTTCTATCGCGCCTAAAG ACGCACTTTTCTACGGATTTTTAGAACCGTGGCTGGCCGACGGTCTACTTCTAAGCAGGGGCGAGAAGTGGGTTCGT CATAGACGTCTACTGACGCCCGCTTTCCATTTCGACATCCTGAAGCATTATGTCAAAATATTTAACCAGTCCACAGA TATTATGCATGCAAAGTGGAGACGTTTGTGTACAAAGGGGCCTGTCTTCCTTGATATGTTCGAGCACATAAGTCTAA TGACCCTGGACTCCTTATTAAAATGCACGTTCTCCTATGATTCTGACTGTCAGGAAAAGCCTTCAGATTATATCGCG GCGATATACGACTTGTCAGAGCTTATAGTGGAAAGAGAGCAATGCCCGCCTCATCACTTCGATTTCATCTATAGATT TTCTTCTAATGGGAGGAAGTTCCAGAGGGCCTGTCGTATCGTCCACGAGTTCACTGCAAATGTCGTCCAGCAGAGAA AGAAAGCGTTGCAAGAGAAAGGAGCGGAAAACTGGATAAGATCCAAAAAGGGCAAAACTCAAGACTTTATTGACATC CGAAGGGCACGATACTACCGCTTCCGGTCTGTCATGGATACTTTATAACTTGGCATCACATCCCGAATATCAGGAGA AATGTAGGGAAGAGGTGACACAACTGCTGAAAGGTGAGTCTACACACCTTGAGTGGGATGACTTATCCCTTCTTCCG TTCACCACTATGTGCATAAAGGAAAGTCTAAGGCTGCACCCGCCGGTAACGGCAGTGAGTAGAAGATGCACTGAGGA CATCGCAATGCCAGACGGGAAGGTAATTCCGAAAGGCAATATCTCTTTATATCTATTTACGGTACTCACCACAATC CAGCGGTTTGGCCTAACCCGGAAGTCTACGATCCTTACCGTTTCGATCCGAGTAGCACAGATGAAAGATCCTCCCAC GCCTTCGTTCCTTTCAGCGCGGGCCCTAGAAACTGTATCGGGCAAAATTTCGCTATGGCAGAGATGAAAGTCGTCCT GAGCGGAAGGTGGACTATGGTTGCAAGTCGAAGCCCTTAAAAGCAAGTCA

Seq. ID No: 194

>T5H 2

ATGGAGCTGTTGGGCTTGGTCTCTTGCTTCTTCTACTGACTTTGGTGGTTATCTGCTTTCTACTGTACTG TGGCTACATCCATTACCAGCACATGAAATATGACCACATACCCGGACCGCCCAGAGAGTCATTCTTGTTTGGACACG CCTGTTATACGTATAAATGCACTGCATAAAGTAACCATCGTTAGCGTCTCACCAGAGAGTGTCAAGGAAGTCTTAAT GTCTCCAAAATACCGTAAGGACTGGTTCTACGACCATTTGCACAGTCTATTCGGAGTCCGTCTAATGGGAAATGGTT TAGTGACAGATAGGGACAATGATCACTGGTATAAGCAGAGAAGAATCATGGACCCAGCATTCAGCAGAACGTACTTG ATTGGGCTACTAGGGCCGTTTAACGAGAAGGCTGAAGAACTGATGGAGCGTTTAGCAGAGGAAGCTGATGGGAGGAG TCATGTAGTTATGCACGCCATGATGAGTAGAGTGACTTTGGACGTAATTAGTAAAGTGGCCTTTGGAATGGAGATGA ACTCCTTGAAGGATGATGGGACGCCACTTCCCAGGGCGATCAGTCTTGTAATGAGGGCTCTTGTGGAGATGAGAAAT CCATTCATCAGGTACAGCAGAGAAAAACAAGCATTCATACGTGATGTTCAAGAGTCTGCCCGTTTATTGCGTAAAAC TGGTCGTGAATGCATAGAGCGTCGTCAAAAGGCGATACAGGACGGTGAGGAGATACCTGTTGACATATTGACCCAAA TCTTGAAAGGCGCCGCGTTGGAAGGGGACTGTGACATGGAAGATCTGCTGGATAATTTTGTGACGTTCTTTATTGCC GGCCAGGAACCACCGCGAACCAACTTGCGTTTACTATAATGGAGTTAGCGCGTAACCCCGAGATTCTGGAAAAGGC TCAGGCAGAAGTAGACGAAGTCATTGGAGTCAAGAGGGATATAGAATACGACGACCTAGGCAAGTTGCAATACTTAT CCCAGGTCCTGAAAGAGTCTCTTAGGCTGTATCCGACTGCTCCTGGGACAAGTAGGGCAATAGAGGAAGAGACGATA ATAGAGGGTTTTCGTATTCCCCCTAAAGTCCCGTTAATGTTCAACAGTTACATCATGGGGAGGATGCAACAGTTTTA CCTTGGGTCCGAGAAGTTGTATCGGACAGGTCTTCGCACAAATGGAAGCTAAAGTCATCATGGCCAAACTATTGCAA AGATTTCAATTCGAGCTAGTAGAGGGGCAGAGCTTCGGTATCATGGATACCGCCAGCCTTCGTCCGGAGGGCGGGGT

Seq. ID No: **1**95

>T5H_3

ATGAGCAGGCCTCAAGTCCCAAAGGGGCTAAAGAACCCTCCAGGCCCGTGGGGCTGGCCCTTGATCGGCCATATGCT AACCTTAGGGAAAAATCCACACTTAGCTCTTAGTAGAATGTCACAACAATATGGCGACGTTTTACAGATCCGTATTG ATGGGCCGCCAGGAGACGTCTTGCTCAAAATGGACTAAAGTCTTTTTCAATTGCTAGTGATCCCGCCTCTTCTACGT CTTGTTATCTGGAGGAGCATGTTTCAAAAGAAGCCGAGGTTTTGATCTCAACTCTTCAAGAATTGATGGCCGGACCA CGATCATAACCACCAAGAACTACTATCTTTAGTTAATTTGAACAATAATTTTGGAGAAGTTGTCGGGTCTGGGAACC CGGCGGACTTTATACCTATTCTAAGATATCTACCGAATCCCTCTCTTAATGCCTTCAAAGACTTGAACGAGAAATTC TATTCATTTATGCAGAAGATGGTGAAAGAGCACTATAAGACGTTCGAGAAGGGGCACATTAGAGACATTACAGATTC TCTAATAGAGCACTGCCAAGAGAAGCAGCTGGATGAGAATGCAAACGTTCAACTATCTGACGAGAAGATTATTAATA TCGTGTTAGACCTATTTGGCGCTGGCTTTGATACGGTCACCACAGCTATTTCTTGGTCCCTGATGTATTTAGTGATG AACCCTAGAGTTCAGAGGAAGATACAAGAAGAGCTGGATACCGTAATCGGGAGATCCAGACGTCCGCGTCTGAGTGA CAGAAGTCATTTACCCTACATGGAGGCCTTTATCTTAGAGACTTTTCGTCACAGCTCCTTAGTGCCTTTCACTATCC CACACAGTACGACGAGGGATACATCTTTGAAAGGTTTCTACATCCCAAAAGGGAGATGCGTATTTGTCAATCAGTGG CAAATAAACCACGACCAGAAACTATGGGTTAATCCAAGCGAATTTCTGCCTGAGCGTTTCCTTACTCCCGATGGCGC GGTGGGAAGTATTCCTTTTTCTGGCCATTTTATTACAGCGTGTAGAATTTAGTGTACCACTGGGGGTTAAGGTAGAT ATGACTCCCATATATGGGCTTACGATGAAACACGCGTGCTGTGAACACTTCCAAATGCAGTTGCGTTCC

Seq. ID No: 196

>T5H 4

ATGCCGACTCCTGGAGGCAGATTGGTTGCCTTCCTGCAGAGGAGGGGCAAGCTGGCAGGTAGTCTTGCTGTGATACT ACTGTTAATACTGAAGAGATTGAGGGACGCTCCAAGAAAGGTGAGGTGGTTGAGAGGACCGCCACTACTTGGGGTCG ACTTTTGCATATTGTGCCCCCGGAAAAATGGTTGTAGCAACAATCGATCCCAAAAACATAGAGCACGTTTTGAAGAC GAAATTTGATAATTACGTCAAGGGGCACGTGTTTGCCGAACCGTTTACGGATCTACTGGGCGATGGTATATTTAACG TGGAAAGCAATAGAAGCGAACACGGCCAAAGTAGGTAGGATATTGGAACGTTCCGAGGGAACCCTTGATATGTTCAA TCTTATGAACAGGTTTACCCTAGATACGATCGGGCGTATTGGATTTAGCAAAGATATTGGTTCTTTAGAGGACCCGT CATCACCCTTCCTGAGATCCTTCGACAGAGCACAACAAATTCTGATCTTACGCTTTTGGACTAATCCCGCTTGGAAA GTTCTAAGGTGGTTAGGGGTGGGCTGGGAACGTGAATTGAAGGAACACCTAGGTAGACTAGATGGGTATGCACGTGG AAGCGGCTCCTGCAGCTAGATCCCCCGAGCTACAAGAGAAGTTTATGAGGGACTTAGTACTGAATTTCTTGATAGCA GGCAGGGACACTACTGCACAATGTATTAGTTGGACTCTTTTCGAACTGACTCAGCACCCTGCCGTTGCGGCGAAAGC AAGGCAGGAGGTTTTAGATGTATGCGGCGAGGGCCCCGTCACTTTCGAGCATCTAAAATCCTTACAATACGTGAGAG CCATTTTAGACGAAGGCCTGAGACTTCACCCGTCTGTTCCTTACGACGGCAAACTATGTCTAGGCAAGGACACGTTG CCTGACGGCACTGTCGTGCCGGCCGGCTGCATAATTCAATACATCCCTTACGCTCAGGGCCGTTGTAAAGACATATG GGGTGAGGACGCTTGTTCCTTCAGACCTGAAAGGTGGCTAGAGATGCCCCGTAGACCATCCTCTTTCGCCTTTGCGG CCTTCAATGCTGGTCCCAGGGAGTGTCTTGGACGTAGGCTTGCGGAAGCGGAGATGGCGGCTCTTGTTTCCACAGTC GTTCGTGATTTCGACATGCGTTTAGAGGTAGAGCCATCTAGTGTGCGTTATGATGCGCAGTTAACATTAGGGATGTG TGGGTTGCCCGTTAGCGTGAGGCGTTGTCGTAGGGCCTATGGTGTTGCTGAACCACTTGCCGGAGCG

Seq. ID No: 197

>T5H 5

TACAAGCAAGTTAGGGATATTGTTCTTAACCCCGCGCGTAAAAGAACAAGGGCGCTGGACGGCTGGATATCAGGGTT CGCGAGGCACTACCCCAATCTGCCCGTGTTTTTCAACACTGGCTCAAACATGCATACTACGTTCAGGCAGATCTTTT TCGCCAACTTCACCAAAACGGATTTCGTACTTAGGGCGTTGGAAGACGAAGGCGGGCTTGGCGAAAATGGCGGCG CCTATTTTGCAAAGGTGGCTTGCAGGGAGCTTTCGTGAAAGCAAGTCAGGTGAGGGGAATTTATATATGGTGGAACC AGTGGCACCTCTGATTTTGTTTCTGCTGTTCGAAGTAGAAGTGGAGTCCATTCCGCCCGAATTGTTGACCGCCTTCT CAGACGTAGTAACTGTCGGTGCGTCATACTTTTTGCTGCCCCCACACTCACCGTATTGGCTACTGAGTGGAAAGGTG AAAGCTATTGCTCTGCTTAAAGATTTCCTACTAGAACACTGTAACGCGGCGAGACCCGAGTCACTGAAGGGCCGTGC TGTCGATTGGAGGAGCTTGGCGGCACAAATGCCCGCTTTTCTTCCTAAGGACGAGTGTCGTTGTCCATGTAGTGGGA CCCCGGCTGTAGATCCCGTCGATGCGTATTTGGAAGTCATATCAGTAATGGTTTGCGTTGCGGGTGTGACTGGCACT ACTAATGGGTTCACATCAGTCATAAGAAAATTCGCCGACGTACCTGTAGGACCTACAAAGTCCCGTTGGCCTAGTGC GCCTGTACAATGGCGTCCAGACGCTGATGATATGGTGAGACTTTACCGTAGGGACCCACTGGGTTTTATCTTGGAGG CCCTTCGTCTTGGTACACCTGTTGCAGGGACCCACCAGGTCTTAGAGGAGGAATTAACTTGTCCTTTCCTGCACAAG AGATGCTCTGGAATTTAGACCAGGAAGGGCTGCAAGGAACCGTTACCTGATGTGGAACGGACCCTTCGGTGAGGCCG CGCCGAGGCAGTGTCCCGGCGAACAGGTCGCGGCACATTGCATCAAAGTTTCTATCGATGCGTTCTTAGACATGCAC **AAGCCTCAA**

Seq. ID No: 198

>T5H 6

ATGGCTACGTCTATCCTATCCCTGAGCCTTATGGACTTGTTATATTGGGGTGCGTGTTTGTGCGTACTAAGTGTTTT GTACAAGATCTCAGCCCTATACCTTAGACAAAAGAATTTTGAAAAGGGTTTTCTCAGCATTTCCCGGACCGAAGAGGC ACTGGTTGTATGGCAACGCTCACGAGTTCAAGCAAGACGGAACAGACTTAGATATCCTGAACGGGTACGCAAAGCAG TTTGATTGCGCCTTTCCATTGTGGCTTGGAAACTTTTTCGCCTCCCTAGCTATATACCACCCAGACTATATAAAAGC TATCCTTAGTCGTCAAGACCCCAAGGATAACTTCGTTTATCACTTCATCACCCCGTGGATCGGCAAAGGACTACTTG TCCTAAGTGGCCAAAAATGGTATCAACATAGGAAACTTTTAACTCCCGGGTTTCACTATGACGTCTTAAAACCTTAT GTTGGCGTTATGAGTGATTGTTAACGTTATGTTGGATAAGTGGGAGCGTCTAGTCCCCGACAAGAAGCCAGTGGA ACTGTTTCACTATATTTCCCTAATGACGCTAGATACTATAATGAAATGCGCCTTCAGTTACCAAAGCAACTGTCAAA ACGACTCCGAAAATGAGTACATTAAGGCAGTTTATGAGTTGTCCTACTTGGTGGATCACCGTACTAGATGCCCTCCA TACCACAATGACTTTATTTTCTACTGGAGCCCGCACGGATTCAGACTGCGTCGTGCTTTGAAGACGGCTCATCAACA CACGGAGAAGGTAATAAAGTTGAGAAAAGAATCTCTTAAACAGGAGACGGAGCTTGAGAAGATAAAACAAAAGAGGA GAGGTCGATACCTTTATGTTCGAAGGGCATGACACTACTGCTTCTGGGGTCTCCTGGACGTTTTATTGCTTGGCAAA GAACCCAGAACATCAGGAAAAATGTCGTGAGGAAATACGTCAGGTCCTAGGCGACCGTAGAACCGTAGAGTGGGAGG ACTTGTCTAAGTTACCCTACACAACCATGTGCATCAAGGAGTCCATGCGTTTATATCCTCCGGTACCTGAGGTGGCA AGAGAATTAAAAGAGCCCATTACTTTCTGTGATGGCAGGAGCGTGCCAAAAGGTAGTATCGTTTTCTTATGTATCTA TGCTATCAATAGATGCCCTGGCATCTGGGAAGATCCTGAGGTTTTCGATCCGTTACGTTTTAGCCCCGAGAACTCTT CAACGAGACATTCCCATGCTTTTCTACCTTTTTCTGCGGGAGGCCGTAACTGCATAGGTCAGAATTTCGCGATGAAC GAGATGAAGATAGCCACTGCACTGACCCTACAGAGGTTCGAATTGCAATTGGAGACCAAAAGAGAGCCAGTCAAACG TGCTCAGTTAGTGTTAAGAAGCATGAATGGAATCTATATCAACCTTAAAAAAGATTCATAGCGACAAGACTAAGATTA TC

Seq. ID No: 199

>15H_/

ATGGTTTATGACCTTTATGACAGGTGCCTTAATATTATTACTAATTCTAGTGGTACTATGTTTTCTGCTGTACTG CGGTTACATATGACATATGACAGGTGCCTTAATATTACTAATTCTAGTGGTACTACGGTTACATATTACATGCATATGACATATGACATATGACCATATCCCCGGTCCTCCGAGAGATTCCTTCTTTTTTGTCACAGGTTAATGACATTAATGAGACATACGGA CCGGTCGTTCGTGTAAATCTATCATGTAGTACCATTGTTTTTTGTCATCAGGTCAAGAAGCCGTGAAAGAGTTTCTGAT GTCTCCCAAATACACGAAAGATAACTTTTACGAATGTGTAAGAACACTTTTCGGTGTCAGGTATATGGGTAAGTGCC TTTTGACTGACAGGGACTACGAGCACTGGCACAAGCAGCGTAGGATCATGGACCCTGCATTTAGTCGTAATTATCTG ATAGGTCTAATGGGGACATTCAACGAAATTGCAGAAGACCTGGTGGACATCTTGGGCCGACAAGGCAGACGGCAAGTG TCAGGTTGGTATGCATATGATGGGAAGACCTTA

Seq. ID No: 200

>T5H_8

ATGTGGACAATCCTTCTTTCTACCATCAACATAACGCTGGCAACAGCTCTAATGTTATCCTTCATAATAATCTACCT TCTATATATCCAAAATTCAACAAAACTGCCCCCTGGCCCCACCTCTTGGCCTTTAATTGGCTATACTAGCTGCCTTG GCACTGATGCGTTCAGGAAGATTCAAGATCTTAACAAGATATATGGCGACATAGTCAGCTTCCAAGTATTAGGGAAG ACTATAATTATATACAATTATGATTTAATCCATGAAGCTGCCAATGGCAATAGGTCTAAGGTGGGGGCGTTACAC CATGACCGTGAATGATTTGCTGGCGGAAAATAGCGGCATCTCTAATTATGACACGCAGAAGGCACTTGAAATGCGTA AAGCGTTCGTTAGGCTTGTCCACAACAATATCAAGACTACGGAGGAACATGAGGGCAACAAGCTACAACCGTTTATT AGCAAATCTCAGACACACTGGACGATATTTCCAGCAATAACCTGCAGAACCAGCTATTTCAAATCAGGCAGTTGCTG CCAAGGTTTTGTGTTAACATATTCAAGCACAGCCAGTTCGCCCGTAAGCTATTCGAGATCGAGGAAATAATCTACAA GTATAAAACTGTGAGACAATTAATTGATAATAATGTTGGAGAGATGCATAACTCCGATAGCTTGCTGGGTCAATTAA TAAACGATTTGAAACTGAATCTAACAAGAATGACATCTCCCGTCTAAGTTTTTGAATTTATGGCAGCTGGAACCGAT ACTACCTCTCAACCTTGACGTGGGCATGTGACTATTTAGCAAGAGCCCCGCCAAAGGAGTCACTGAAATTATCCTC AAGCTAATCAATACGGAGCAAAATTCTGATGAGATTCAGGAATCCGATAAGCCAATCCCCTTCTCTTGGTAGTAG ATCATGTCCGGGGGCTCGTATAGCAAATTTATTGATCGAACAAATTCTGACAGCCATTAACCAGGAGTTCCTTATTC AAAATATAACGCAGAGCCCGTTTGAGACCATTTCCCCAGGAAACCAGGAAAGTTTAACGCCTTTCGGGATTACTAGG ACTCCACATAAAAGTATGTATATTTCGTAACGAAACTAAATGGAAATCGTAGGACTTCAATT

Seq. ID No: 201

>T5H_9

ATGTCCCAGTTGCTATCGAGCTTGATAGAGCTACCTACTCAGACGCTGGTGCTTGCAACAGCAGTGGCTGTAGGGGC
AGCCGCCTTATTAGTCCACGCGTATCTTTTCGACGCCGTTGGGAAGCATGGAAACCTACCGCCGGGCCCACCAGTTG
ATTCACTATTTTCTGGACATAGAATACCGTCAACGCATCCTTGGAGGTACCTGGAGAAGCTAACAGAAGAATATGGC
GATATTTTTACCCTGAGGATTGGTAGATCACCTTTATTTGTCCTTGGAAGAGCTAGTTCAGCTCATCGTATTCTGGA
GAAACAAAGTGCGCTGAGCAGCTCCAGACCTCGTCTAGTTCTTGCCGGTGAACTATTGAGTAATAATAAAAGAATAT
TACTTATGCCTTATGGAGACCAGTGGAGGCTGTATAGAAAAAGCCATGCACGAAACATTGAACCACCGGTGGCGAAA
CAATATGAACCTATCCAAGAGAGGGAGGCTAGAATTGCGACGTTACACCCTAGGAAGGCTGGGTCAGGCCGATGGCGG
TGGAGGTGACTTCCAGCGTGTCTTGCACAGGTACGCGGCCAGCGTAATAATGCAAGTTACGTATGATTACCAGGTTC
AGACTCTGGACGATCCCCTGGTGAGGTCAGTGGCCCAGAGGGGTCACGCGTTGGCGATGTGCATCCGTCCTGGCGCT
TCTGTTCTTGACAGGTATCCACTTTTAGAGCACGTTCCCACGTGGTTGAATCCCTGGAAACAGGAAGGTTTGAGGCT
AAGAAAACTAGAGCAAGAGCTATATCTAGGCCAAGTGATCAAGGTCAGAGAAAAAAGAATGGAGAGAGGGGAGTGTGCCC
CGTGCTTTGTTTCTAAAAATGACTGAGCGTCAGCAAGAACTAGGGCTTACCGATCTGGATGTTGCCGGGGATGAGTGGG
AGTCTGTTCGGTGCTGGGTCAGATACAACGGCGAGCGCACTTTCCATCTTCGTGATGGCTTGCAGATATCCCGC
AGTGTTAGCCAGACTTCACGAGGAATTAGACAGGCGAGCGCACTTTCCATCTTCCGTGATGGCTGTTGCAGATATCCCGC
AGTGTTAGCCAGACTTCACGAGGAATTAGACAGGGTGGTAAGCCGTGATCGTATGCCCACCTTTTGATGACATTCCGC

AAATGCCCTATGTGCGTGCCACAGTGCAAGAAGTACTAAGATGGAGGCCAGTCTCTGCCGGTGGTTTCCAACACAGC CTGACAGCGGATGTAGAGTACAAGAGGAGCTACGTTTTGCCTAAGGGGTCCACGGTGGTGGGCCCCCATTGGTCAATCAG CAGGGACGAGCACGAATATCCTGAACACGATGTCTTTAAACCTGAAAGGTTTTTACAAAGCGGGGGAGCGAGGCTA ACGGCACTTCAGCCCAGGACGAAGTAAAAGGGACTTGGTTCGCGCCCGCACGTGGCTCTGTCGCATTTGGATTTGGG AGAAGAGTTTGTCCAGGGTTAAACGTTGCCATGCGTTCTTTACACATTAACATTGCTTGTATGGCATGGGCTTTTGA CATTGCCCAGCCCGATGGCAGACCCGGAGAGGGTCGATACGTTTGCGTTCAACTCTGCAGCGAACTCACATCCTCTAC CATTTGACGCTACCTTCACGTACAGGGACCCCGCGAGGAACGCGAACTCACAGGGGAGGTCGATACGTTGACGGGAAGAGAAAAGGCGTAGCTGCATCAAGAGGGGACTCACAGGGGAACTCACAGGGGAACTCACAGAGGGACCCCGCGAGGAAAAGGCGTAGTCGAGGAAAGAGAATATTGCTACAGGGGAACTCAAGAGGGACCCCGCAACCT

Seq. ID No: 202

>T5H_10

ATGTTAGAAGCATTGTCCAGTCTAGCTACAGCACTGTGGGCTGCTTTGAGACCTGATACCGTGCTTCTAGGGACACT GGCTTTTCTGCTATTTGTTGACTTCTTAAAAAGAAGGCATCCTAAAAACTATCCACCAGGGCCCCCTGGTCTACCGT TCGTGGGAAACCTGTTCCAACTAGATCCCGAAAAGGTGCCATTAGTCCTACACCAGTTTGTGAAAAAGTATGGGAAT GTCTTCTCCTTAGACTTTGGAACCGTCCCATCTGTGCTAATAACCGGCTTGCCGTTGATAAAAGAAGTGCTAGTTCA TCAAGGACAAATCTTCTCTAACAGGCCTATAGTCCCGCTACAAGAACATATCATTAATAACAAAGGCTTAATTATGT CATCAGGCCAATTATGGAAAGAACAACGTCGTTTTGCATTAACGACACTGAGAAATTTTGGTTTAGGGAAAAAGTCA CTTGAAGAGAGACCCAAGAAGAGGCCAGCTATTTAATCCAGACAATCAGAGAAAAACCGGACAGCCTTTTGATCC TCATCTGACGATTAATAATGCGGTTTCAAACATTATTTGTAGTATTACCTTCGGGGAAAGGTTTGACTACCAAGATG ACCAATTTCAGGAGCTGCTAAGGATGTTGGATGAGATACTAAACCTTCAGACATCCATGTGCTGTCAACTTTACAAT GTCTTTCCGAGAATAATGAACTTCCTGCCAGGACCACATCAGGCGCTTTTCAGTAACATGGAGAAAATGAAGATGTT TGTCGCAAGAATGATCGAGAATCACAAGAGAGACTGGAATCCTGCTGAGGCCCGTGATTTCATTGACGCCTATCTAC AGGAGATTGAAAAGCACAAGGGCGACGCCACATCCAGTTTTCAAGAAGAGAATCTAATTTATAATACACTTGATCTG TTTCTTGCGGGGACCGAGACTACGTCAACTAGCCTACGTTGGGGGCTACTGTTCATGGCTTTGAACCCGGAAATACA AGAAAAAGTTCAAGCAGAAATCGATCGTGTCCTGGGCCAGTCCCAACAGCCGTCAATGGCTGCCAGAGAAAGCATGC CCTATACTAACGCCGTAATACACGAAGTATTGAGGATGGGCAACATAATCCCCCTAAACGTCCCCAGAGAGGTTGCC GTAGATACTACCCTGGCGGGATACCACTTACCCAAAGGTACGATGGTTATGACTAATTTAACTGCGCTTCACCGTGA CCCCACAGAATGGGCTACACCCGATACTTTTAATCCCGAGCATTTTCTTGAGAATGGGCAGTTCAAGAAGAGAGAAT CTTTCCTGCCCTTCTCCATAGGGAAAAGAATGTGCCTTGGAGAACAACTGGCAAGGACCGAACTATTCATCTTTTTC ACAAGTTTACTGCAGAAATTCACTTTTCGTCCGCCTGAAAACGAGCAGTTGAGCTTAAAATTTAGAGTATCTCTTAC CCTAGCCCGGTAAGCCACAGGCTGTGTGCGGTCCCTCGTGGG

Seq. ID No: 203

>T5H 11

ATGAAGACCCCGCCCCAGTCCTCATGCCCTTTTCATGCGGTTGGACGTCCTCCCACACCCCCTAGATCATCTGCGGG CAGATGGCCCCCAGGACCAGAGTCAGGTCTGACGGGTTGGGGGGTTATTAAAGCTGATGAGCAGAGATTTAATGGGAA CGCTTGCAGGGTGGCAAAGGGAGTTTGGCGATCTTGTGCATGTCAGGACCTGGCCTGAGCATCAAGTCATAGTGTCC GATCCACAACTAGCGAGAGAACTTCTAGTCAATCAAGCCGACGCATTACAAAGGTGGGAGCGTGCGCTTACAGTATA TCGTAGGGTTCACGGACACAGCGTCCTGATAGCCGAGGGCCAGGCCTGGAGGAGAAGAAGACAAGCCCTTCAGCCCG ACTTTACAAGGAAATCAGTACAGGCCTTTAGTCCCAGTATCGTAGAAGCAGCGCGTAGGGCGTTCGAACAGTGGCCT GCGAGGCATGCTGCTTGGCCAATTGAATCCGAGCTTACCTCAGTTACGATGGAGGTGATACTTCGTATGATGTTTAG CAGTGGAGTGGGTTCTGAAGCCCAGCAAGCTGAGGAAGCTGTACATACCCTAATGGTGGCATCAACCGAAGAGCTTT GGAGACCCGCCAGCTTGCCTGATTGGGTTCCCTGGCAAAGGAAAGAAGGCGTGCGAGACTACTAATGAACGGTCTA ATTGAAAGGCACTTGCAGGCGCGACTAGCAATGCCTCAGGATGCTTGGCCCGAGGACTTGTTGAGTCGTTTACTTCG TCTTCACTTGCAACAGCCCCAATCCTGGCCACTACAGGCTGTGAGGGATGAGTGCAAAACAGCATTCTTGGCTGGGC ACGAAACTGTCGCAACATCACTTACATGGTGGGCTTGGTGCATGGCGTCTCATCCGGAAATCCAGGAGAGGGCTCGT AGAAACTATGCGTCTATACCCTGCCGTCCCCTTACTTATGAGTAGAAGGAGCACTGAAACCAGTGACTCTGGGCGACT GGACTTTTCCTGCGAAGACTGTCTTCATGGTTCCAATGCAGCTTATGCAGCATGACGAGCGTTGGTTCCCGGAACCG AGATCTTATCGTCCAGAAAGATTTGGGCCTGATGCTGCCCGTCCACAACAGGGAGCGTATTTGCCATTCGGAGGGGG CCCTCGTGTGTGTTTAGGACACATCTAGCTATGGCGGAAATGGCGTTGGTGGCAGCACAGCTGCTTCTTAGGTATA

Seq. ID No: 204

>T5H 12

ATGAAACTTGCAGGTAAAAGGTTCAGGCTACCCCCTGGGCCATCAGGAGCGCCTATTGTCGGCAACTGGCTTCAAGT GGGGGATGATCTAAATCACAGAAATCTAATGGGTCTAGCTAAGAGATTTGGAGAAGTGTTCCTTTTGAGGATGGGTG TGAGGAATCTAGTTGTCGTGTCTTCACCAGAACTTGCTAAAGAGGTTCTGCACACCCAAGGAGTTGAGTTTGGTTCA AGGACGAGGAATGTAGTGTTTGATATTTTTACGGGCAAAGGACAAGATATGGTCTTCACCGTTTACGGGGACCACTG GCGTAAGATGCGTCGTATAATGACGGTGCCGTTCTTTACCAATAAGGTAGTTGCGCAAAATAGAGTCGGTTGGGAAG AGGAAGCCAGACTTGTGGTGGAAGATTTGAGGGCGGACCCTGCAGCAGCAACCAAAGGGGTAGTAGTCAGAAGGCGT TTGCAACTTATGATGTACAACGATATGTTTAGGATCATGTTCGACAGAAGGTTTGAAACCGTGGCAGACCCCCTGTT CAACCAACTTAAAGCACTCAATGCGGAGAGGTCCATCCTTAGTCAGAGCTTCGATTACAACTATGGAGATTTTATTC CGGTGCTGCGTCCCTTTCTGAGACGTTACTTAAACAGGTGTACTAATTTAAAAACGAAGAGGATGAAGGTCTTCGAA GATCACTTTGTCCAACAGAGAAAAGAAGCCCTAGAGAAAACTGGCGAGATCAAGTGTGCAATGGATCACATATTGGA AGCAGAGCGTAAAGGTGAAATTAATCATGATAATGTCCTTTATATTGTGGAAAACATCAATGTTGCGGCGATCGAGA CGACACTATGGTCTATTGAGTGGGGTCTAGCAGAGCTGGTCAATCACCCCGAAATACAGCAGAAACTTAGAGAGGAA ATTGTAGCGGTGCTAGGTCCAGGTACACCAGTAACGGAGCCCGATTTGGAACGTCTGCCTTATTTGCAGTCCGTAGT AAAAGAAACACTGAGGTTACGTATGGCTATTCCTTTACTGGTCCCTCACATGAACTTGAGCGATGCGAAATTAGCCG GGTATGATATTCCGGCGGAATCAAAGATCCTGGTGAATGCCTGGTTCTTGGCAAACGACCCAAAGAGGTGGGTCAGA GCGGATGAGTTTAGACCCGAAAGATTCTTGGAGGAGGAAAAGAGCGTGGAAGCACATGGGAACGATTTCCGTTTTGT CCCCTTCGGCGTTGGCAGAAGGAGCTGTCCAGGCATAATATTAGCCTTGCCGATTATTGGTATTACCCTGGGTAGGT TGGTACAGAATTTTGAGCTGTTACCGCCACCTGGCCAGGACAAATTGATACTACGGAAAAGCCGGGTCAATTCTCC AACCAGATCTTAAAACACGCAACAATAGTATGCAAGCCGCTAGAGGCT

Seq. ID No: 205

>T5H 13

ATGCACACGGATACCCCTGACACGACCGCCGATCAACCGCTTAGGCGTATAAAAGATTTGCCAGGACCTAGACCTTT GCCCCTTATAGGCAACGGTCATCAGATAAAACCCCAGAGGATTCACCAGCATGTAGAGAGATGGAGTCTTCAGTACG GGCCCCTAATGAGGATGTACTTCGGAGCGACTCCCATTTTGGTCGTCGCAGATCACGAAATGGTAGGTGCTGTCTTA CGTGATAGACCTGACGGGTTTCGTCGTCCCAGTATAAGTGCTACGATTTCAAATGAGATGGGAGGCATACCGGGCTT ATTCCTGGCAGAAGGAGCAGACTGGCGTAATCAGAGACGTATGGTTATGGCAGGCTTCGCGCCCACGGCAATAAAAG CGTATTTTCCTGCACTGGTCGCGGTAGCTCTAAGGCTAAGAAGACGTTGGCAAGCAGCAGCATCCGCAAGAAAGGCT ATCGATCTTGAGAGCGACCTGAAGAGGTACACAGTTGATATAATAGCTGGATTGGCCTTCGGGTCAGATGTTAATAC CCTGGAGTCTGGAGAAGATGTCAAAGACATCTTGATGACATCCTTCCGGCAGTCGCACGTCGTTCTTTGGCAT TAGTACCCTATTGGCGTTACGTGAAACTTCCGGCCGATCGTAGATTAGATAGGTCAGTGGCCGTGCTAAGAACTGCC GTTCAGGACCTTATTGGGCAGGCTCGTCAGAGAATGCTTGATAACCCGGCCAGACGTGAGAGGCCCCCGAATCTTTT GGAGGCTATGATAGCTGCCGCGGACCAGAGCGGTAGTGGAGTTACCGATTTGAACGTTGCTGGGAACGTCACCAATA TGTTATTAGCTGGAGAGGACACTACTGCGAACACAATATCCTGGATGATCTACCTTCTGCAGCGTCACCCTCATACC TTGCAAAAAGCTAGAGACGAAGTTAGGAGAAACGCCCCTGACGCAGCCAGATTTACGATCGAGCAACTAGATTCTTT GGACTACTTAGGCGCCTGTGCGAACGAGGCCATGAGACTTAAACCTGTTGCGCCTTATTTGCCTCTGGAGGCTCTAA GAAAAGCACTTCCCCGATCCACTGTTGTTCGACCCACAGAGATGGCTGCAGGCTGATGGAAAGCCGAACTCCGATAA GCGTGTTACAATGCCCTTCGGTGCCGGACTAAGAACTTGTCCAGGCAGATATCTGGCTTTACTAGAGATCAAAATCG CAATGGCTATGTTGCTGGGAAGTTTTGATATTGCCGGGGTGGACACGCCGGACGCAAGGAGGCTCAGGAGCTTATG GGGTTTGTGATGTCTCCAGTTGGATTATCTTTGAGATTAGAG

Seq. ID No: 206

>T5H_14

CAAAGTTACCGATTATTGGGAACTTGCATCAGCTTGGCAACATGCCTCACCTTTCCCTGCATAACTTGGCAAAGAAA TATGGGTCAATTATCTTTCTTCAACTGGGGGAAATTCCCACCGTGGTAGTCAGCTAGGCTTGCGAAAGAGGT AATGAAAACTCATGACCTTGCTCTGAGTTCTAGGCCGCAAATTTTCTCAGCGAAGCATCTTTTCTACAACTGCACAG ATGTTGTATTCAGTCCGTACGGCGCTTACTGGCGTCACATTAGGAAGATCTGTATCCTGGAGTTACTGTCAGTTAAG AGGGTCCAGAGTTACTCTTTTGTGAGGGAGGAAGAAGTGGCTCGTTTAGTCAGGAGAGTCGCAGAGTTTTACCCAGG CACTACGGACTTGACTAAGATACTGGGATTATACGCAAATGACGTCCTTTGCCGTGTAGCCTTTGGCAGAGATTTCA GTGGGGGCGGAGAGTATGATCAGCACGGGTTCCAGAAAATGCTGGAGGAGTACCAGGAATTGTTGGGCGGTTTCTCT CTAGGTGACTTTTTCCCCAGTATGGAGTTCGTGCACAGTTTAACCGGGATGAAGAGTCGTTTGCAAGACACGTTTCG TGGTGGACGTGTTATTAGACTTACAAAAGAATGCCTACGATGAAATGCCGCTGACAACGGACAATATCAAAGCTATA ATATTGGACATGTTTGCGGCAGGGACCGATACTACGTTTATCACTTTAGATTGGGGGGATGACTGAACTAATCATGAA TGCCTCAGCTACATTACATTAAGGCCGTCATCAAAGAGATCTTTAGACTACATCCCCCGGCACCCGTTTTGGTGCCC AGGGAATCTATGGAAGACGTTAGTATAGATGGTTATAATATCCCTAGCAAAACCAGGTTCTTCGTTAATGCGTGGGC TATTGGGCGGGACCCAGAGTCCTGGGAAAACCCCAACGCTTTCGAACCAGAAAGATTTATGGACAGTACAATAGATT TCAAAGGTCAGCACTTTGAACTTATTCCCTTTGGTGCAGGTAGGCGTAGTTGCCCCGCAATCGCCTTCGGCGAAGCG ACTATCGAATTAGCCCTAGCGCAACTTTTGCATAGCTTTGACTGGGAGCTGCCTCCAGGTACGACGCCCAAAGATCT TGACATGTCAGAAGTGTTTGGAATCACTATGCACCGTATTGCCCATTTAATAGTCATCGCGAAACCGAGATTTCCCG **TCGGCCAAAACAAA**

Seq. ID No: 207

>T5H 15

ATGCCCAAACAGAAGAAACGTTTGCCGCCAGGGCCTCCAACACTACCAATCATTGGGAACATGCACCAGCTGGGAGA ACTTGCGCACAAATCTCTGTCCGAGCTGTCAAAGAAGTATGGCCCTATTATGCTTTTAAAAAATTGGTAGTAAAACAA TAATCAACATAAGTAGCGCAGAAGCGGCGAGACAGGTATTGAAAGTGCATGATTTGGATTGTTGCTCAAGACCGGTA GAGGAAAATCTGCGCACTAGAGCTGTTGAGCGTGGCGAGAGTGCAAAGCTATCGTTTCATTAGAGAGGAAGAAGTCG ACAGTGAACATACTTTGCAGGACTGCGTTCGGTAAAAGTTTCAGAGGACTGGACAATGGTAAATTAAGAGA GGTCGTCCACGAGGCTGAAGTCATGTTCGCGAGCTTTTCTGCGACCGAATTTTTCCCCTACGTAGGTTGGATTATTG ATCGTCTAAGCGGACGTATAAGAAGATTAGAGAAAATTTTTAGAGGGCTAGACGATTTCCTGCAACAGGCTATTGAT TTGCACTTAAAACCTAAAAAGACCGAACAAGACCATGAAGATCTAATTGACGTACTATTGAAGATAGAGCGTGACCA ACAAACCAATACGGGGGCACCCCGTTCAACAAGGACACATCAAGGCCATACTTTTTGATATGTTCTTGGGTGGAT CAAATACAGCCGCAGTGACCATGTTGTGGGCTATGGCTGAACTAGCAAGGAACCCCAGAGCTATGAAGAAAGCTCAA GATGAGGTACGTAATGTCGTAGGCAATCGTGGAAAAGTCACTGAAAGTGACATCACACATTTGCATTACCTGAAGAT GACCATCAAAGAGACGTTTAGGTTACACCCGCCCGCAGCGATACTTCTTCCAAGGCAAACTATGGCCGAGGTCAAGA ATGAACCCCGAAGAGTTCTACCCAGAGAGATTCGTTGACTCTAGCATAGATTACAAGGGACAACATTTCGAATTATT ACCTTTTGGTTCAGGTCGTAGGGGCTGCCCGGGTATGCACATGGGAACAACAACGGTCGAGTTAGCATTGGCTAACT TGCTGTATTGCTTCGACTGGAAGTTGCCCAGTGGTCTTAAAGAGGAGGATATTAATATGGATGAGTCTACGGGTCCG GGGCTGACCCAAAAGAGAACGACACTGAAGTTAGTGCCGGTGAAGTTGTTT

Seq. ID No: 208

>T5H 16

ATGAAGCTACTGCTAGATAGGACCAGAACTAATGGGTACCTTCCCCCTAGCCCTCCAAAGCTACCCATCATTGGTAA
TTTACATCAATTAGGCAAAATGCCGCACATCAGCCTGTGTGAGCGTGCTCAGAAGTTGGGACCGATTATGTTCTTGC
AACTTGGAGAGGTACCGACTGTAGTCATCTCCTCAGCGGCTATGGCAAAGGAGGTGATGAAAACGCATGATTTAGCT
TTCTCAAGTAGACCGCAGTTATATTCCGCCAAGTGGTTGTTCTACAATTGCACTAATATCGTATTTTCACCTTATGG
AGCGTATTGGAGACACGTTAGAAAGATTTGCATTTTAGAGCTGCTGTCCACTAAAAGGGTCCAGTCTTATGGGTTTA
TTCGTCAAGAAGAGGGTTTCAAGACTACTTCATAGAATAGCTGATTCTTGCAGCAAGCCAATAAATCTAAGCAAATTG
TTGGGCCTTTACGCGAATGATGTGCTATGCCGTGCTGTCCTGGGCAGAAATTTTAGTGAAGGCGGGGATTATGATAT

Seq. ID No: 209

>T5H 17

ATGAGAATGGACGGAAATTCAACTACGATGTTCCCTCTTCTGATAACGGTCATAATGCTTTTGGCCTCTGTGTTATT TTATATATTCAACAGGTGGACTCATAGGTATAGTAAGTCAGGAATACTGCCTCCTAGTCCGCCTAAGTTACCCCTGT TAGGTCACCTGCACTTGCTTTCAGATCAACCGCACGTTGCCCTGTCAAGGTTAGCTCAAAAGTATGGCCCAATTATG TACTTAGAGCTGGGACAAGTGCCGACTGTGGTTGTTAGCTCAGCGTCCTTGGCACGTGAAGTCCTTAAAACCCACGA CCATGTATTTTGTAATCGTCCGCAAACTATAGCCGCACAGTACATATCATTCGGGTGTTCAGACGTGACTTTTTCTC CTTATGGGCCGTATTGGAGACAGGTGAGAAAAATATGCGTCACAGAATTATTGACCCTGAGGAGGGTTAACTCTTTT CAGTTAATACGTGAAGAGGAAACTAATAGGTTGCTTACGGCCGTCGGAGCGCACTCAGGGAGTGAACTTAAC GAAATTATTTTCAATTTGGCCAATGATACGCTATGCAGAGCCGCATTCGGAACGAGATTCATGAGCGAGTCTACCC AGTTAGAAAGGCAAAGGGCAAAAGACTTGAGGATATTCTGATTGAGACCGTAAAACTGTTAAGTGGATTCTAT GTGGGCGAGTTCTTTCCCAGGTGGGGTGGATTAACAGCGTCAGCGGTTTCAAACGTAGACTTGAGAGAAACTTAGC AGATTTGCGTTCAGTAGGTGATGAGATAATCCAAGAACACATTAAGAAGAGGACGTGGTAACGAAGAAGAGGATT TTGTAGACGTATTGTTACGTGTCCAACGTCAACAAGACTTGCAAGTCCCAATCACTGATGACAACGTAACGGCACTT GTTATGGATCTTTTCGTGGCGGGGACAGATACCACATCCTCCACTTTGGAGTGGACGATGACCGAAATGGCCAGGCA CCCGGAGGTGATGAAAAAGGCTCAAGCAGAAGTGAGATCTATGTCACCCGAAGGGGGCACGTTGGACGAGTCCCATT TAAGACATTTGCACTATCTTAAAGCTGTTATTAAAGAGGCACTTAGATTACATCCACCAATACCTCTACTTCTGCCC ACTTGGAAGGGACCCCGATTCTTGGGACGACCCTCTTCGTTATAACCCTGCCCGTTTTATGGGTGGCGATGAACATA AAATCGATTTCAAAGGGGAAGATTTCAGATTTGTTCCGTTTGGCGGTGGTAGACGTGGGTGTCCCGGCTACTCCCTG GGACTTGCTACCGTTGAATTGACCCTAGCCCGTTTACTATACCATTTTGACTGGAAGTTGCCGCCTGGAGTAGAGGC AGAGAAAATTGATTTGACAGAAATTTTCGGCCTAGCTACTAGGAAGAAAACCCCATTACTGCTTATTCCGACTGCCA **GGAAAGCTCCACCGCATGAA**

Seq. ID No: 210

>T5H_18

Seq. ID No: 211

>T5H 19

ATGCCCCTAAGCGACAGCACTATCTCCCTTCTACTGGCCGTGTTGCCGATTAGCGGGATCATTTTCGCCCTATATAA CCAGTACCAGATTTGGCTTAAATCTCCGATAAGAGGGCTGCCCTATCCCCCTGGACCACCCTTGTTGTTGGGGAACG CGAACAGGGCTGTACAGTCTAGGCCCTGGTTAACGTATACAGAGTGGGCCAAGCAGTACGGAGACATAATATGTC AATATATACGGAGAACACACGGTCATTTTGAATAACTTAGAGGATGTTATGGAACTGTTCGAACAGAGATCAAGGGT TTATTCTTCCAGACAAACCACCCATACATCGAGCTGATGGGATGGCAGTTTAACGCTGGGCTTCTGCCCTATGGTG ATAGCTAAGACCCACAACCTACTGAATGATTTACTGCAAACACCTAGCGACTTCATAGAGCATATCAAACGTAACAG TTCTGCCATGATAATGAGTATCCTATACGGTCAAGACATCTCTGACGAAATGTCTGCCCAATTCGTTTCTGTGGCTG CTGCCAGCCTGGTTTCCCGGAGCAGATTTCAACGTCAAGCTGCTGAGGTGAAAAAGCTAACTACCAAAATGAAAGA TGAGCCAATTGATTTCGTAGGGAAGGGTCTGTTACACGGCACAGCATCAGCATCTCTTGTGGCAGACCTATTGGAAA ACTGCTATGTGCAAAGAGAATACGACGTAATTAAAGACGTAGCCGCGACCGTTTTTGCAGCGGGGGCAGATACCTCT GTGGCAGCATTGGAGTCCTTTTTCCTAGCTATGAGTCTTTTCCCGGAAGCTCAGAAAAAGGCCCAGGCTGAGATGGA CAGAGTAATTGGTAATAAAAGATTACCAACGACCGATGACAGGCCACTGCTACCTTATCTGGAAGCCGTATACCGTG AGCTGATGAGGTGGGCTCCTGTAGTGCCTCTAAACGCGGCGCACACCACAATCGCGGACGACATCTACAAAGGCTAT TACATACCGAAGGGCACTGCAGTCTACGCTAACACGTGGGCCTTGACGCGTAATGAGGAAAAGTACCCCAATCCAGA CATATTTAATCCCGATAGGTTCTTTACCGAGACCGGAGAGCTAAATGACGATGATACGGTATTGACTTTCGGGTTTG GAAGGCGTATATGTCCGGGCAGGCACATGGCATCTACGACGGTTTGGTTAACTATTGCTTCAGTTTTAAGTAATTTT GATATAAAGGGGAAAGGCACAAATACGAAAGATCAGAAATTTACTAGCATCGGGGAAATGTTTACCGACAACTTCAT

Seq. ID No: 212 >T5H 20

ATGGCGTTCGAAACGACGAACGGTATCCTATTAGCTGCCAGTCTATTCGCGGGGGGTGGTTCTATATCTGCAAAAGAG AAAGAGATACACCCTACCGTATCCTCCGGGGCCAAAGAAGCACTTCCTTTTGGGCAACTTACTAGATGTTCCAACCA CGTTTGCATGGAAGAGATACGCAGAGTGGGGGAAGACTTTTGATTCTGATGTGCTACACTTGAGCGTTGCAGGGAGC ACAGATGATAATGTTTAGCGAACTGATCGGTTGGGATTGGCTGATGAGCGGCATGGTCTATGGGGAGCCTTGGCGTG AAAGGAGGAAGGCGTTCCAACAATATTTTCACGTAGGCAATGCCCACTTATATGAACCCGTTCAGATGCAAGCAGTG AGAAAGATGCTACCACGTCTGTTAAAAGAACCTGAAGACTTTTTAAGCATCACGAGGCATGCGCTTGGCAGTATGGC CTATAGGTGAAGTCGCAATTCCAGGCGCTTTTCTTGTGGACATGATCCCGGCGCTGAAATATGTACCTGAATTTTTC CCTGGAGCAGGTTTTAAGAAAAAGGCACGTATTTGGAGAAAAGTCCAGGAAAACATGCGTGAGATACCTTTCGCTGC TACACTGAAGAATATAGCGAGTGGTAGCGCCAAGGTCAGTTTTACAAGTACATGCCTAGAAAACCTTGATGAATCAA GGGACGTAGACCACCAACGTACTATTATTAAAGATACGGCCGGAAATATGTTTGCCGCTGCGACTGATACAACTATT AGTGCTATCCATACCTTCTTTGTTGCGATGTTGTGCTTTCCCGAGGTCCAGAAAAAGGCTCAACAAGAAATTGACAG GGTATTACAAGGTAGGTTACCTGAGTTTAGTGATGAGGCCGACTTACCGTACTTATCTGCATTGGTTAAAGAAACGC TGAGGTGGGAGCCTAGCACCCCTATCGGTGTGCCGCACTACAGTTCTGAAGATGATGTCTATAACGGATATCACATA CCGAAAGGAAGTCTAGTTATCGGAAATGCGTGGGCAATGCTTCACAATGAGGAGGATTACCCGGAGCCTTCACTTTT

Seq. ID No: 213

>T5H 21

ATGATTATCGATTCTAGTAACTCCGAAGGCAATAGTGAAGGCCAGTACACCATCGATGGACCTAAGGCCAAAGGACT GAGAAGGATGTTTAGAATCTTCCACTTAATCTTACAGCCGACTAAGTATATGGAGTCTTCCGTACAGAGGTACGGTA GTATGTTTCAGATAGGAAGCGAAGGAGCATCACCATTAGTATACGTAGGAGAACCAGAAGTTGTGAAAGAGATTTTC GCTTTGGACGGAGATCAAGTCGTGACAGGGCAGGGTAACGGAGTGCTAGAGACTATGGTTGGCAAGCACAGTATTCT TTTACTTGATGGCGACCCTCACCGTCAACAAAGAAAGTTGTTAATGCCTCCATTCCACGGTGAGCAGCTAAGGGCAT ACGCACATTTGATTTGCGATATTACCAGGCAGATCAGTGCACAGTGGCAGCCGGGACAAACCATCGTGGCTAGACCG CCCATTCAGAATCTTACTCTAGGAGTGATCCTACAGGCAGTGTTTGGGGTCCCCTCTGGCGAAAGGTTGTCCCGTCT TCAACAACTTATGTCCACGCTGTTAGACTCTTTTGCCTACCCCATATCAGCATCATTTTTATTCTTCCCGGCGTTAC GAAATTAGGGATAGAAGGCAGCTTAGAGAGAGCCCAATTGAGCAAGACGAAAAACTTGGAGAGAAGTTAGGCGA GAAGACAGATATATTAACCTTGCTACTACAAGCGCGTGACGAGGACGGAGGGGCGATGTCTGATGCTGAGCTTCACG TACCTTCCTGAAGTGCAGCAGAAGTTGCGTGCCGAGCTGGATGCGTTGGGACCCGGACCCTGATCCTATGGCTATAGC ACAGCTTCCCTACCTGACCGCCGTGTGCCAAGAAGCACTGAGGATATATCCTATCACTCCAACCACATTTATTAGAC GTTTAAGGGAGCCTATGACTCTTGCAGGTTACAGATTTAAAGCGGGTACGGCACTTATGCCGGCGACGTACATCATC CATCAAAGACCCGATCTATACCCCGAGCCTAAACAATTTAGGCCAGAGAGGTTCCTAGAAAGACAGTTTGCTCCGCA TGAGTTTTTACCATTCGGCGGGGGCCATAGATATTGCATCGGAAGTGCCTTGGCCATGATGGAGTTGAAGTTATCAA TTGCAACGCTGCTTGCGGATTTCGAACTGGCATTACTGCACTCCAGGCCGTTGCTGCCAGCTAGGAGAGGACTAACA ATGGCTCCACCAGCAGCAATGAAGTTAAGGATCAAGGCGAGAAAAACCAACAAAGCT

Seq. ID No: 214

>T5H 22

ATGCCCGCGCCTAAAACTGCACCGAGCACACTGCCATTACCACCAGGAAGGTTAGGATTGCCGTGGATTGGTGAAAC ACTGTCATTTTTGAGGGACCCAAACTTTGCGACAAAAAGACAGGCACAGTATGGTAGTTTGTTCAAATCTAGGATCA TTGGCCAGCCGACCGTATTCTTTTGCGGACCAGAGGCGAATGCTTTCCTTCTGTCCAGCCACGCGGACTGCTTCTCC TGGAGAGATGGCTGGCCAGGCACATTTCAAGAACTTCTTGGTGAGTCCTTATTTTTACAAGAGGGTGAGACTCATTT ACGTAACCGTAGACTGCTGATGCCAGCCTTTCACGGAAAAGCGTTGGCAAGTTATTTCAGCACTATGGTTGCCCTTT CCGATAGCTATCTGGCCCGTTGGGAGAAGAAACAGCAATTGACATGGTTCCTAGAGTTCAAAAAGTTTACGTTTGAA GTAGCCTCTGTTCTATTGGTCGGCTCAGCCCCAGGTCACGACGACGACAACACTATCGGCACGGCTGAAAGTGC GTTGGGGTCCCACGACCTATAGGAAGGCCCTAAGAGGCAGGGATAGATTGCTGAGTTATATAGAACAGGAGATTACT AAAAGGAGACAATTATTGGCACGTTTACAAACCGATCCAACCGCAGCTCTACCGACGGATGTTTTAACCTTACTTCT TCAAACGGAAGATGATGAGGGAAACAGACTTTCTGAGGCAGAAATCAAGGTTCAGACATTGCTAATGCTGTTTGCGG GGCACGAGACGACGACCTCTATGCTAACTTCATTAGTTATGTCTCTTGCCCAAAACCCGGACGTCCTAGCCAAAGCA CGTGCGGAGCAACAAGCGTTCCCTGCAGAGTCAGCCCTAACGTTTGAACAGATACAACAAATGCCATATTTAGATCA ATGGATACCATGTCCCTGCAGGTTGGCTGGCATTATACAGGATTGATGCGGCGCACAAGGACGAAAGATGTTATACG AACCCGTCAGACTTTGACCCTGATAGATTCAGCCCTGAGCGTGCTGAACAAAAACGTTATGACTACTCACTTGTTGG GTTCGGTGGGGGCCCACGTGTGTCCCAAGCATGGCGTTTGCCAAGCTCGAAATGAAAATAATGGCTGCACAATTGC TTAGACGTTATCACTGGCAACTAGACGCTGATCAAGATCTGACTATGAACCCTGTACCTAGTTTGAGGCCTGCGGAC GGTTTGAAGGTCCGTTTCAGTAAGCTAAGTTTCACAGCC

Seq. ID No: 215

>T5H 23

ATGTTGGATATGCCCTCCGTGAAACCTTGGCTAACCTTCTCAGACTGGGCCTCCAAGTTCGGTGATATAAGTCATTT TCTACTCCGATCGTCCGGTATTACCAATGGGTGGGGAATTAGTAGGCTGGAGAAATACCCTGGTCCTATTACCGTAT GGAGATAACTTCAGGGAATATAGAAGGAATTTTCACAGAGTGATTGGAAGCCGTGCGGCTATGAGCGTTTACCACGC GATTGAAGAGGAGGAAACTCATAAGTTTCTACAAAGAGTGCTGACGAAACCGGCTGATTTGAGTGCTCATGTAAGGA CAACAGCCGGTGCAATTATTCTAAGGATTAGTCATGGGTATCATATTCAAGAAGACGGGGACCCATTTGTCAGTTTG GCGGATACAGCTGTGGATCAATTCTCCCGTAGTACGGCTACAGGAGCGTTCATGGTTGACCTGATCCCGGCCCTAGC TTACGTACCAGAATGGTTTCCTGGAGCTAGTTTCCAAAGAAAAGCGCGTGAGTGGAGGGCCACATTACACGAGATGG TCAATCAGCCATATAAGTTCGTGCAAGACCAGATGGCTGCCGGCATAGCCCCTAAGAGCTTTACCAGTAACCTGCTG GAGGGACGTACATTAACGGAAGAGGAGGAGCATATTATCAAATGGTCAGGTGCGTCTCTGTACAGCGGGGGTGCCGA CACTACGGTTAGTGCCATTTATGGATTTTTCCTGGCCATGACGCTTTATCCCGAGGCGCAGAAGAAGCCCAGGCCG AGATCGACGCAGTAGTCGGGAGTGATCGTCTACCCACATTTGCAGACAGGGAATCTCTACCTTACGCTGAAGCATTG GTCAAAGAAGTTCTTAGATGGTGTCCCGTCGTCCCGATTGTAGTTCCGCACCGTGTTACCGCAGATGATATACATAA TGGATATTATATTCCCAAGGGTACCTTAGTACTAGCTAATGCTTGGTATATGTTGAGGGACCCGTCAATATATCCCG ATCCAATGAACTTTAACCCCGATAGGTTCCTTCCGTCAGGCGGGAAGGAGCCCCCAACAGACCCGCGTGATATTTGT TTTGGTTTTGGACGTAGAATCTGCCCTGGAATGCACTTGGCGGACGCTAGTGTTTGGTTATCCGCCGTAATGTCTCT GGCGGTGTTTAATGTCTCAAAGGTGGTCGAAAACGGTGTGGAGATCACCCCTGAAGTCGATCCTAGTTCCGGAACTA TCAGTCACCCGAAGCCCTTCAAATGTTCTATTAAGCCAAGATCTGCTAAAGCACTAGAGCTAATTCAGCAAACGCCA CATTAC

Seq. ID No: 216

>T5H_24

ATGCACTTACCTCCAGGTCCAAGGCCGCTTCCATTCCTTGGGAATTTGCTTCAGATGAACAGACGTGGATTGTTGAG GAGCTTTATGCAGTTGCAAGAGAAGTACGGCGATGTATTTACAGTGCACCTTGGTCCTAGGCCAGTCGTAATTCTAT GCGGGACCGATACAATTAGAGAAGCCTTGGTGGATCAGGCCGAAGCGTTCTCCGGAAGAGGTACCGTTGCTGTTCTG CATCCCGTCGTCCAAGGCTACGGAGTCATTTTTGCAAATGGCGAGAGATGGAAAATCCTACGTTCTTTAGTCTAGT TACTATGAGAAATTTCGGAATGGGAAAGAGGAGCGTCGAGGAAAGGATAAAAGAGGAGGACAATGCTTGGTTGAAG AGCTAAAGAAATACAAAGGCGCGCTACTAAACCCAACTTCCATCTTTCAGAGTATTGCTGCAAACATAATCTGTTCC ATAGTTTTTGGGGAAAGATTTGATTACAAAGACCATCAATTTTTAAGGTTACTGGACTTGATTTATCAGACATTTTC TCTTATGGGCTCATTGAGTAGTCAAGTATTCGAGCTATTTTCCGGTTTTCTGAAGTATTTCCCTGGGGTGCACAAAC AGATTAGTAAAAACTTGCAGGAGATTTTAAATTATAGATCATTCCGTTGAGAAGCACCGTGCCACATTGGACCCA AATACTCCCAGGGACTTCATCGACACATACCTACTTCACATGGAAAAGGAAAAATCTAACCATCACACTGAATTTCA CCATCAAAACTTGGTAATTTCCGTCCTGTCCTGTTCTTTGCAGGCACCGAGACCACTTCCACGACTTTACGTTACT CATTTTTAATCATGCTGAAATATCCACACGTCGCAGAAAAGGTTCAAAAGGAGATCGACCAAGTGATATCTAGTCAT AGGTTGCCGACGTTGGATGACAGGATTAAGATGCCCTATACCGACGCAGTCATCCATGAAATTCAGCGTTTTGCAGA CCTAGCGCCAATAGGGTTACCGCACAGGGTTACAAAAGATACAATGTTCCGTGGATATCTGCTACCTAAAAATACCG AGGTATATCCGATTTTATCCTCCGCACTTCATGATCCGAGATACTTCGACCATCCTGACACTTTTAACCCGGAACAC TTCTTAGACGCTAATGGAACGTTGAAAAAGTCCGAGGCATTCCTGCCGTTCAGTACAGGAAAGAGAACTTGTCTGGG TGAGGGAATAGCACGTAACGAGTTGTTCATTTTCTTTACAGCCCTACTTCAGAATTTTAGCCTTGCCAGCCCTGTCG CACCCGAGGACATTGATCTTACTCCAATAAACTCCGGGGCGGGTAAAATTCCAAGTCCATACCAAATCAATTTTCTA AGTCGTTGTGTCGGA

Seq. ID No: 217

>T5H 25

Seq. ID No: 218 >T5H 26

ATGTATGATACGTTCCTTGAATGGATCGAAAAGTATGGACCTGTAGTACGTCAACTCATCTCACCTCAACCTTCGT CATTGTGATTTCCCCCGAGGGAGTTAAGGAATTTCTTATGTCACCCAAGTATACCAAGGATAATTTCTATGAACGTA CGTAGGATGATGGACCCCGCGTTCAGCAGGACGTATTTAATAGGTTTAATGGGGACCTTTAATGAGACTGCCGAGGA CCTTATGGACGTGCTAGGTGACAAAGCGGACGGTAAGTGCCAGGTGGGGATGCATGACATGTTATCTCGTGTGACTC TTGATGTTATTGCGAAGGCCGCTTTCGGGATGGAGCTGAACAGTTTACATGACGATCAAACACCTTTCACAAGAGCG ATAAGTACCGTAATGAAAGGGATGGTAGAGACCAGAAACCCTCTAGCACGTTACATACCGGGGAAACAAGCGTTTAT AAGATGGAGAGGATATACCGATGGATATATTAACGCAAATCTTGAAAGGGGCCGAGATCGAGGACGGATGCAGTTTA GAAGATTTGATCGATAACTTCGTTACGTTCTTTGTCGCGGGACAGGAAACGACAGCGAATCAATTGAGTTTCGCGGT TATGGAATTAGCCAGGAACCCAGAGATTCTTACCAGAGTACAAACGGAAGTGGATGAGGTACTTGGATCTAAGCGTG GCTCCAGGAACATCCAGAGCCCTGGAGAAGGAGACCGTTATTGAAGGTGTAAGGGTTCCACCCGGCACTACACTTAT GTTCAACAGCTATATAATGGGACGTATGGAGAAGTATTACCACGATCCTTTTATCTTCAATCCAGACAGGTTCCATC CGGATGCGCCCAAGCCAAGCTGCGCTTATTTCCCATTTTCCCTTGGACCACGTTCCTGTATTGGGCAAGTTTTTGCT AGGATGGAAGCAAAGGTCGTCATGGCCAAGCTATTACAGCGTTTCGAGTTTGAGTTGGATGAAGGACAGTCTTTTAG AATCATGGATACGGGTACCCTCAGGCCGATGGATGGGGTTATATGCAGACTTAGACCGCGTGCAGAGAAAATCCA **GGAAG**

Seq. ID No: 219

ACAGCATCTTCACTACATGAAGGCGGTAATAAAGGAGACGATGAGGCTACACCCGCCAGTGCCCCTTTTAGTCCCAA GGGAGTCAATGAAAAATGCGCCCTAGACGGGTATGAAATCCCTGCCAAGACACGTGTCCTGATTAACACTTACGCT ATCGGTCGTGACCCGAAATCATGGGAAAATCCCCTAGACTATGACCCAGAAAGGTTCATGGAGGACGACATTGACTT TAAGGATCAAGATTTCAGATTCCTTTCGGTTTTTGGCGGAGGGCGTAGAGGCTGCCCTGGTTATTCCTTCGGACTTGCGA CAATTGAGATAACACTAGCCCGTCTTCTATATCACTTCGATTGGGCTTTACCGCATGGAGTAGAGGCGGACGATGTG GACTTGAGCGAGGTGTTCGGACTAGCAACTCGTAAAAAAGACTGCTCTGGTTTTAGTGCCGACGGCAAACAAGGATTT CCAGTTTAGAGGGCATGACTTC

Seq. ID No: 220

>T5H_28

ATGGGGAAAAACAAAGTGCCGCCAGGACCGATCGGACTGCCGTTCATCGGTAACCTGCATCAGTTCGATACTCTAGC ACCACATATCTACTTTTGGGAGCTATCCAAAAAGTACGGAAAAATCTTCTCATTTAAGTTGACGAGTAACGTGCCTA TAATAGTGGTTAGCAGTGCAAAATTGGCGAAAGAAGTGCTGAAGACACAGGATCTAGTGTTTTTGCAGCAGACCATCA CTGGTCGGACAGCAAAAGCTGTCATACAATGGGCATGACATAGGCTTCGCACCATATAACGATTATTGGAGGGAAAT GAGGAAAATTTGCGTACTTCACCTATTCTCTGAAGAAGGTGCAGCTATTTTCCCCCATTCGTGAGGATGAGGTTA GCCGTATGATCAAGAAAATCTATCAACAAGCAGTGAACAGTCAAGTCACCTAACCTATCCAACCTAATGATCAGCTTA AATTCTACTATAATATGTCGTGTAGCGTTCGGAGTAAGATTCGATGAAGAAGCCCATGAGAGAAAGAGATTCAACTA AGTTGACAGGGATGATCGATAGGCTAGAAAAGAATTTTAAAGACCTTGACGAATTTTATGAGGAACTTATAGAACAG CACTACAATCCTAACAGGCCGAAAAGTATGGAGGGAGACTTTATTGATATTCTGCTACAGCTCAAAAAGGACCAGCT AACTCCTATAGACTTGAGCCTGGAGGATATTAAAGGAATCTTGATGAATGTACTATTGGCAGGCTCTGACACCTCTA GTAGTGTCATAATTTGGGCGATGACTATATTAATCAAGAACCCCAAGGCAATGAAGAAGGTGCAAGAGGAAATTCGT AACCTAATCGGGAATAAAGGGATAGTCAATGAGGATGACATCCAAAACATGCACTATCTAAAGGCCGTCATCAAAGA AACTCTTAGACTATTTCCGCCAGCACCTCTACTTATTCCTCGTGAGTCAATGAAGATCTCTACTCTGGAGGGGTACG AGTTTCAGCCAAGAACTATCGTATACGTCAATGCATGGGCGATCGCTAGGGACCCGGAAATATGGGAAAACCCAGAA GAGTTCATGCCAGAACGTTTTCTGAATAGTAACATTGATTTTAAGGGACAAGACTACGAACTAATACCATTTGGCGC TCGACTGGGAGTTACCCTATGGCTTGAAGAAGGAGGACATAGACATTAATGGTAAACCGGGGGATCACAGTTAACAAG AAGAACGATCTGTGTCTTATCCCCAAGAAGTACTTT

Seq. ID No: 221

>T5H 29

ATGAAGTTAACGGGGAAGCGTTATAGATTACCACCAGGACCTGCCGGCGCTCCCGTGGTTGGGAATTGGCTTCAAGT GGGTGACGACCTGAATCACAGAAACTTAATGTCTTTGGCGAAGCGTTTCGGTGATATTTTCCTGCTGCGTATGGGAG TTAGGAACTTAGTGGTGGTGTCAACGCCCGAACTTGCAAAGGAGGTTCTACATACCCAAGGGGTAGAATTTGGGTCT CGAACACGTAATGTTGTGTTTGACATTTTTACAGGCAAAGGACAAGACATGGTTTTCACTGTATATGGCGACCATTG AAGAAGCGAGGCTTGTAGTGGAGGATGTAAGAAAAGACCCCCGTGCAGCCGCCGAGGGAGTTGTAATCCGTAGACGT TTACAATTAATGATGTACAATGACATGTTTAGGATAATGTTCGACACTAGATTTGAATCAGAGCAGGACCCCTTGTT TAATAAGTTAAAAGCATTGAATGCGGAGCGTTCACGTCTTTCCCAATCTTTTGAATACAATTACGGAGACTTCATAC CTGTCCTGAGACCTTTTCTGAGAGGGTACCTAAATCGTTGTCATGATTTGAAAACCCGTAGAATGAAGGTTTTCGAG GATAACTTCGTACAGGAACGTAAGAAAGTAATGGCGCAAACCGGAGAGATCCGTTGCGCTATGGATCACATTCTTGA AGCGGAGAGAAAGGCGAGATAAACCACGATAATGTTCTTTATATTGTTGAGAACATCAATGTGGCTGCAATAGAAA CGACACTATGGTCTATCGAGTGGGGCATTGCGGAGCTAGTTAACCATCCCGCGATTCAAAGTAAACTACGTGAAGAA ATGGATAGTGTACTGGGCGCCGGAGTACCCGTGACCGAGCCTGACTTAGAAAGACTACCCTATCTACAAGCCATTGT TAAAGAAACACTTCGTCTTCGTATGGCGATACCTCTGTTAGTCCCCCATATGAACCTAAATGATGGGAAACTAGCTG GATATGACATCCCCGCGGAATCAAAGATATTAGTTAACGCCTGGTTCCTTGCAAATGACCCAAAGAGATGGGTCAGA CCTGACGAGTTCAGACCAGAGCGATTTTTAGAGGAGGAAAAGACAGTAGAGGCGCATGGGAATGATTTTAGATTCGT ACCATTCGGGGTAGGAAGAAGGTCATGCCCAGGTATCATTTTAGCTTTACCAATCATCGGCATCACGCTAGGCAGAT AACCAAATCGCCAAACATGCTACAATTGTGTGTAAGCCCCTAGAAGCG

Seq. ID No: 222

>T5H_30

ATGAAACCGCGTGGCGCTAAATATCCTAATAGTCTTCCATGTTTGCCCTTCATCGGCTCACTGTTGCACCTTGCATC ACTACATCGTAATAGTAAATCATCATGAACATGCTAAGGAGGTATTACTGAAGAAGGGTAAAACATTTGGTGGTCGT CCTAGAGCTGTGACCACAGACTTGCTAACTAGGAATGCTAAGGATATTGCTTTTGCGGACTATAGCCCCACGTGGAA GTTCCATCGTAAACTTGTACACGCAGCACTGTCTATGTTTGGTGAGGGGACTGTAGCGATAGAGAAAATCATTTCAC GTGAAGCCGCCTCCCTTTGTCAAACTCTTATTACATTTCAAGGGAGCCCCTTAGATATGGCCCCGGAGCTGACCCGT GCGGTGACGAACGTAGTATGCGCACTTTGTTTCAACGCGAGATACAAAAGATGTGATCCTGAATTTGAAGAGATGCT TGCATATTCCAAAGGAATCGTTGACACGGTCGCTAAAGATAGTCTGGTAGACATTTTTCCCTGGTTGCAAATATTTC CCAATAAAGACCTGGAGATTCTGAAGAGATCAGTGGCCATTAGAGACAAACTATTACAGAAAAAGCTGAAGGAACAT AAGGAGGCATTTTGTGGGGAAGAGGTGAATGACCTGCTGGACGCGTTATTAAAAGCAAAGCTGTCAATGGAAAACAA CAACTCAAATATATCCCAGGAAGTCGGGCTTACAGACGACCATCTTTTGATGACCGTGGGTGACATATTTGGCGCGG GAGTTGAGACAACCACCACAGTACTAAAGTGGGCTGTAGCGTATCTACTACCACTATCCGAAGGTCCAAGCTAAGATT CAAGAAGAATTAGATGTCAAGGTAGGTTTCGGGAGACATCCGGTTTTGTCCGATCGTCGTATCCTGCCCTACTTGGA CGCGACGATTAGCGAAGTCCTAAGGATAAGACCAGTTGCCCCTCTACTGATCCCCCACGTCGCATTACACGAAAGCA GTATAGGGGAATATACCATCCCACAGGATGCGAGAGTTGTAATAAATCTGTGGAGCCTGCATCACGATCCTAACGAA TGGGAGAACCCCGAGGAGTTCATTCCTGACCGTTTTCTTGACGAAAATGGGAACCATCTTTACACTCCTAGCCAAAG CTACCTACCCTTCGGTGCAGGCATTCGTGTTTGTTTGGGGGAGGCATTGGCTAAGATGGAGATTTTTCTATTTCTGT CATGGATCTTACAGAGGTTCACGCTAGAAGTCCCTGCCGGGGATTCCCTGCCGGATCTTGACGGGAAGTTTGGCGTG GTGTTGCAAGTGAAGAAATTTCGTGTAACAGCGAAGCTGCGTGAAGTGTGGAAGAACATCGACCTTACAACA

Seq. ID No: 223

>TAT2

ATGACGGAGGATTTCATTTCTTCTGTTAAAAGATCCAACGAAGAATTAAAAGAGAGAAAATCCAATTTTGGATTTGT ACGGGAAAAGGAATATTTCAAAGGTGTGTTGACAGTTTCAAAAGTCCCTTAGACGGATCTTTTGACACATCAAAT CTAAAACGTACGCTAAAGCCCAGACATCTTATCATGATCGCTATAGGTGGGAGTATAGGAACTGGTCTGTTCGTCGG GTACCATCCACGGACTAGGCGAAATAACCGTCAGATTCCCCGTGGTCGGCGCGTTCGCGAATTACGGAACTAGGTTC TTAGATCCATCAATATCATTTGTCGTGTCTACTATCTACGTACTTCAATGGTTCTTCGTACTACCGCTGGAGATCAT CGCAGCGGCTATGACAGTGCAGTACTGGAACTCATCAATTGATCCGGTCATCTGGGTTGCGATCTTCTATGCCGTCA TAGTCAGCATAAATTTGTTTGGTGTACGTGGATTTGGAGAGGCAGAATTTGCATTCTCTACGATAAAGGCCATCACG GTGTGCGGTTTCATAATACTATGCGTGGTACTTATTTGCGGCGGGGGTCCTGATCACGAATTTATAGGGGCCAAGTA CTGGCACGATCCAGGCTGTCTAGCAAATGGGTTTCCGGGCGTACTTTCCGTACTGGTCGTTGCCTCATATAGCTTGG GCGGTATAGAGATGACCTGCTTAGCGTCAGGGGAGACGGACCCCAAGGGATTACCGTCTGCCATAAAGCAGGTGTTC TGGAGAATACTGTTCTTTCTGATTTCTCTTACGCTTGTTGGATTTCTTGTCCCGTACACGAATCAGAATTTACT GGGAGGGTCCAGCGTCGATAACAGCCCCTTCGTGATCGCAATAAAGCTGCACCACATCAAAGCCCTTCCCTCAATCG TCAACGCGGTAATCTTGATCAGTGTTCTGAGTGTAGGTAACAGTTGTATCTTTGCGTCCAGTAGAACATTGTGTTCA AAACAGTTTGTTTGGACTTCTAGCTTTCTTAGTGAAGTCAGGCTCAATGAGCGAAGTATTCAACTGGTTAATGGCGA TAGCGGGGCTGGCCACTTGCATAGTCTGGTTATCTATAAATCTTTCCCATATACGTTTTAGGTTGGCAATGAAAGCG CAAGGCAAATCCCTAGATGAGCTAGAGTTTGTAAGTGCAGTTGGTATATGGGGTTCCGCTTATTCTGCGTTGATAAA AAATCTTTTTCCAAAACTATCTGTGCGCCCTAATTATGCTGTTCATTTTCATTGTTCATAAAATCTATTACAAATGC AATTGTGAAGCAAGAGATCGCCGAAAAGAAATGTACCTAGATAGCAGACCCTGGTATGTAAGACAGTTTCATTTCT GGTGC

Seq. ID No: 224

>TMO 1

ATGAGCACGTTAGCAGATCAGGCATTGCATAACAACAATGTCGGCCCGATTATTCGTGCAGGGGACCTAGTCGAACC CGGCAGAAGGGGAGCTAATATTGACTCGTAAGACTCTTGAGGAACAGCTAGGTAGACCGTTTAATATGCAGGAACTA GAGATAAATCTAGCCTCATTCGCTGGGCAAATACAGGCAGATGAAGACCAAATCAGATTTTATTTCGATAAGACAAT GGGCGGAGGGAGTGGTGAGGGAAGAGGCAGCCTTCTTACTTGTGGAGACGTGGAAGAAAACCCCGGGCCCATGTTTA ACATACAATCTGACGATCTATTACATCACTTTGAAGCTGATAGTAATGATACACTATTGTCCGCCGCGCTTCGTGCT GAACTTGTATTCCCCTACGAATGCAACTCAGGTGGTTGCGGCGCTTGTAAAATCGAACTACTTGAAGGAGAAGTATC CAATTTATGGCCGGACGCACCTGGGTTAGCCGCCAGAGAGCTACGTAAGAATAGGTTTCTGGCCTGCCAGTGTAAGC CGCTTTCTGATCTTAAAATTAAAGTTATCAATAGAGCCGAGGGCCGTGCTTCACATCCCCCGAAGAGGTTCTCTACG AGAGTTGTAAGCAAAAGGTTTTTAAGTGACGAAATGTTTGAACTACGTCTGGAGGCCGAACAGAAGGTCGTTTTCTC CCCCGGACAGTATTTTATGGTGGACGTTCCAGAGTTAGGCACCAGGGCATATAGCGCCGCGAACCCAGTTGATGGTA ATACACTAACGCTAATCGTAAAAGCCGTGCCGAACGGAAAGGTGAGCTGCGCTCTAGCTAATGAGACGATCGAGACA CTACAACTTGACGGACCTTATGGTTTGAGCGTGCTGAAGACTGCTGATGAAACGCAGTCCGTATTTATCGCGGGAGG GAGTGGTATAGCTCCTATGGTCTATGGTCAATACTTTAATAGCACAAGGCTACGAGAAGCCTATTACGGTCTTCT ACGGTTCTCGTTTGGAGGCGGAACTAGAGGCAGCCGAGACATTGTTCGGCTGGAAGGAGCACCTAAAATTGATTAAC GTGAGCAGTTCCGTCGTTGGTAATTCCGAGAAAAAGTATCCCACCGGGTACGTGCATGAGATCATACCGGAATACAT GGAAGGCCTGTTAGGTGCGGAGTTCTACCTGTGTGGTCCACCACAAATGATCAACTCTGTCCAGAAACTGTTGATGA TTGAAAATAAGGTCCCATTCGAGGCGATTCATTTTGATAGGTTCTTC

Seq. ID No: 225

>TMO_2

ATGGCCATGCATCCGCGTAAAGATTGGTATGAGCTGACGCGTGCGACCAATTGGACACCTTCATACGTGACGGAAGA ACAACTGTTTCCAGAACGTATGAGCGGTCACATGGGTATTCCACTTGAGAAATGGGAGTCCTATGACGAGCCGTACA AGACTTCGTACCCGGAGTATGTTTCCATACAAAGAGAAGGACGCGGGTGCCTATTCTGTTAAAGCTGCCCTGGAA CGTGCGAAGATTTATGAAAATAGTGATCCCGGTTGGATTAGTACATTGAAGTCCCACTATGGCGCTATTGCCGTGGG TGAATACGCAGCGGTTACTGGTGAGGGTAGAATGGCTAGATTCAGTAAAGCCCCTGGCAATAGGAACATGGCTACTT TCGGTATGATGGACGAGCTGAGGCATGGTCAATTACAACTATTTTTCCCCCACGAATACTGCAAAAAGGACAGGCAA TTCGACTGGGCCTGGAGAGCTTACCATTCTAACGAATGGGCCGCCATCGCGGCCAAACACTTTTTCGACGATATCAT CACAGGCAGGGACGCTATATCTGTCGCGATCATGCTGACATTTTCATTCGAAACGGGTTTCACAAACATGCAGTTTC TAGGACTTGCTGCTGATGCAGCCGAGGCGGGAGACTACACGTTTGCGAACCTTATATCAAGCATTCAAACCGATGAA TCCAGACATGCACAGCAGGGTGGTCCCGCATTACAACTGCTAATTGAAAACGGTAAGCGTGAGGAAGCGCAGAAGAA AGTCGATATGGCAATTTGGAGGGCCTGGAGATTATTCGCAGTGCTGACCGGTCCGGTAATGGACTATTATACGCCCT TGGAGGATCGTTCCCAAAGTTTCAAGGAGTTCATGTATGAATGGATCATTGGCCAGTTCGAACGTAGCCTGATTGAC TTGGGTTTGGATAAACCCTGGTACTGGGATTTGTTCTTAAAGGACATCGACGAGCTACACCACAGTTATCACATGGG AAAAATATCCGGGATGGAATAAGCGTTGGGGCAGGTGCTGGGACGTGATAACCGAGAATGTCCTAAATGACAGAATG GATTTAGTGTCTCCAGAGACATTACCCTCTGTCTGCAACATGTCTCAGATTCCATTAGTTGGAGTACCGGGCGACGA CTGGAACATAGAGGTCTTTAGTCTGGAACATAACGGCAGATTGTATCACTTCGGAAGTGAGGTAGACAGATGGGTTT TCCAGCAAGATCCGGTCCAATATCAAAATCATATGAACATCGTTGATAGATTCCTGGCGGGCCAAATTCAACCCATG ACATTAGAAGGTGCGCTTAAATACATGGGGTTCCAGTCCATCGAGGAAATGGGGAAGGACGCTCACGATTTCGCATG GGCAGATAAGTGCAAACCGGCAATGAAGAAGTCAGCAGGTGGGGGCAGCGGAGAAGGCAGGGGAAGCCTGTTAACCT GTGGCGACGTAGAGGAGAATCCCGGTCCTATGTCATTCGAAAAGATTTGCTCTCTGGATGATATCTGGGTTGGTGAA ATGGAGACGTTCGAAACTTCAGATGGAACAGAGGTTTTGATCGTGAACTCTGAGGAACACGGCGTTAAAGCATACCA TATGGACATTCAATGACGGCACGGGCCACGGCATTAACCCCGATGACTGCTGTTTAGCGGAGTACCCTGTGGAGGTT AAGGGTGATGACATTTATGTCAGTACCAAAGGTATACTTCCCAATAAGGCACACAGC

Seq. ID No: 226

>TMO_3

ATGTCTTTTACCAAGGTTTGTTCTGTCGGAGGATATCTGGGAGGGGGAAATGGAGCCATTTACTGTTGATGGTCACGA GATATTACTTGTAGGTGTGGAAGGGGAGGGATCAAAGCCTTCCAGGGTATCTGTCCTCACCAAGATATAGCGTTGT CAGAGGGGAAATTTGATGGGAAGAAACTTATCTGCCGTGCACACCTATGGCAATTCGATGCCAGCAACGGAAAAGGT ATCAACCCAGACGATTGCGCCCTAGCCGAATACCCTGTCAAGGTTGACGGCGACGACGTCTACGTACAGACTGCTGG AAATATGTAACGGAGTCTGAATTGTTTCCGCCCGAGCTGTCAGGAGACCACGGAATACCTATGGAGAAGTGGGAAAC TTATGATGAACCCTACAAGCAGACTTATCCAGAGTATGTTAAAGTACAAAGGGAAAAGGATGCGGGCGCCTATAGTG TTAAGGCAGCCCTGGAAAGATCCCAGATCTATGAGCGTTCTGACCCGGGGTGGCTAACGGTTATGAAGCAGCACTAT GGCGCGATTGCACTTGGAGAGTACGCCGCTTCATCAGCAGAGGCCAGGATGATGAGATTTAGTAAAGCTCCAGGTAT GAGAAACATGGCCACACTAGGGAGCATGGATGAAATACGTCACGGACAGATACAGCTATATTTTCCCCATGAGCATG TTTCCAAGGATCGTCAGTTTGATTGGGCAGCTAAGGCTTTCCACACCAACGAATGGGCAGCGATAGCTGCGCGTCAC TTTTTCGACGATATAATGATGACCAGAGATGCTATAAGCGTAGCAATTATGCTTACATTCTCATTCGAGACGGGGTT TACGAATATGCAGTTTCTTGGCTTGGCAGCAGACGCGGCGGAGGCTGGAGATCACACATTTGCAAGTTTGATATCCT CCGTACAAACAGATGAGAGCAGGCATGCCCAGATTGGAGGCCCTACGCTGCAAATCCTTATTGAGAACGGCAAGAAG GCTGAAGCCCAAAAGAAGGTGGATATCGCTTTCTGGCGTGCCTGGAGACTGTTTTCCGTCCTGACTGGTCCAGTCAT GGATTACTATACGCCGCTAGAACACCGTAAACAGAGCTTTAAGGAATTTATGCAAGAATGGATAGTCGCGCAGTTCG AGAGAGCACTTAGCGATCTAGGGCTGGATAAACCCTGGTATTGGGATACGTTCTTACAGCAGCTTGACCAACAGCAT CACGGGATGCACCTGGGGGTCTGGTATTGGAGACCAACGGTTTGGTGGAACCCTGCTGCTGCGGTTACACCAGCAGA AAGGGATTGGCTGGAAGAAAAATACCCCGGCTGGAACGATACTTGGGGACAATGCTGGGACGTGATTATTGACAATT TAGTTGACGGCAACATAGCTCAAACATATCCGGAGACATTGCCGATTGTCTGCAACATGTGCAATCTGCCTATAAAC TGCACGCCCGGCAATGGTTGGGCCGTGCAAGATTACCCGCTGGAATACAACGGGCGTCTATACCACTTTGGGAGTGA GCCTGATCGTTGGTGTTTTGAACAGGAACCTGAGCGTTATGCGGGCCACATGACCCTTGTCGATCGTTTTCTGGCTG GTCTAGTGCAACCAATGGACCTGGGCGGGGCCCTGGCCTATATGGGGCTGGCGCCAGGGGAAATAGGGGACGATGCA CACGGGTATAGCTGGGTCGATATTTATAAGAAAATGCGTATGAAGAAGGCAAGC

Seq. ID No: 227
>TMO 4

ATGTCAGTTGCATCAAGCGCGCAAGCGTATCATAACAACATGGTCGGACCCGTTATGAGAGCAGGCGACTTAGCGTT AGCAGTAATTGAAGCGGCCAGGGTAGACAATCCAGGCAAGGAGGTTTTTGTTGATGATAAACGTGCTTATGTACGTA CTTGAGGTAGATTTAAGTAGTTTTTGCGGGGCAAATCGAATCTTTGGATGACGCCGTTAGATTTTACTTCACAAAGAA GTTGGGTGGGGATCTGGCGAAGGGAGGGTAGCCTATTGACATGTGGGGACGTGGAGGAAAATCCGGGACCATCAT CTGAGGGCTGGTGTTGGGCTGTCCTACGAGTGTAACTCCGGTGGCTGTGGAGGGTGCAAGTTCGAACTACTGGAGGG AGAAGTGGACACGTTGTGGCCGGATGCTCCCGGGCTATCCGACAAAGACAGAAGGAGAGGGCGTCACCTAGCTTGCC AGTGTCGTGCTAGGGGGCCTGTCAGTATAAAAGCCGCGACGGGAGCCGAGTACGTGCCTAAGGTCGTTCCACAAAGA CAAACGGCTAGACTGGTTGGGAGCACTGATATTACGCACGACCTTAGAGAGTTTAGGTTCAGATCCGCGGCAGGAGC CAGTTTCTTGCCCGGGCAGTTCGCCATGCTAGATCTACCCGGGCTTGCGAGTGCTAGGGCCTATTCTATGAGTAACA CTGCCAATGATGATGGGGAGTGGCATTTCCAAGTGAGGAGAGTCCCGCATGGGCAAGGGACTCATGTATTGTTTGAC AGGCTGGGGGTCGGAGACCGAAATCGGGTTGGACGGACCTTACGGAGTAGCCTGGCTAAGAACTGGTGCTCCCAGAGA TATAGTATGCGTAGCGGGTGGGAGTGGACTGGCTCCTATGGTCTCCATCGCAAGAGGAGCCGCCGCCGCCGCCATGC TAAAGGATAGGAAACTGTATTTCTTTTATGGCGCAAGAACTCCTAGGGACGTTTGTGGAGCGGAGATGCTTGCACAG CTGGATGGCTTCGGGGAACGTATCATATCTTCCGGTGGTTTCTCTCCGGGTGGCGAGGGTGAATGGCAGGGGGA GACTGGTTACGTACACGATGCAGTAGCTAGGACACTACCCGGCTCATTGGCGGGTTTTCGAGTTTTATTTTGCTGGGC CGCCGCCGATGACGCAAGCCCTGCAAGAGATGCTGATGGTAGGACACAGGGTTCCTTTTGAGCAAATTCATTTTGAT CGGTTTTTC

Seq. ID No: 228
>TPH_1

ATGCCGTCCAGACTGAATAAGGATGAATATCAGTTTTACATCGATCTTGATAATAAGTCCACACCAGCCTTGAATGA
AATTGTTAAATGTTTACGTCTTGACATTGGCGCGACAGTGCATGAGTTGAGCAGAGATAAGAAGAAGAAGATGCGGTGC
CGTGGTTTCCGAAAACAATACAAGACTTGGACAAATTCGCGAACCAGATCCTTTCCTACGGCGCTGAACTTGATTCT
GATCACCCTGGCTTCACTGATCCCGTCTATAGAGCTAGAAGGAAAGAATTTGCTGACATTGCTTTTCATTATAAGCA
CGGCCAGCCAATCCCTTGCGTAACGTACACAGAGGAAGAAGAAGAAGAATTTGCTGACATTCCAAAGAGTTAAAGT
TGCTTTATCCGACTCACGCATGCTACGAACATAATCACGTTTTTCCTTTACTAGAGAAATATTGCGGTTATAACGAG
AACAACATTCCTCAATTAGAGGACGTCTCTAAATTTCTTCAGACCTGTACGGGATTTCGTCTGAGGCCGGTTGCAGG
CCTTCTGAGTTCCAGGGACTTCTTAGCTGGCCTAGCTTTCCGTGTATTCCACTCAACTCAATACATTCGTCACTGGA
GTAAGCCAATGTATACGCCTGAACCGGACATCTGTCACGAGCTATTGGGCCACGCTCCGCTTTTTGCAGATCCAAGT
TTCGCTCAATTCTCACAAGAAATCGGCCTGGCGTCACTGGGCGCTCCAGATGAATACATAGAGCGTCTAGCGACTCT
TTACTGGTTCACAGTAGAGTTCGGATTATGTAAGCCAGGATGACAAAATTAAGGCCTATGGAGCCGGACTTCTTTCAT
CTTTCGGCGAGCTTCAGTATTGCCTTACAGATAAGCCTGAATTGAAGCCCTTTTGAGCCAGAAAAGACGTCCCTTCAG
AAGTACCCGATTACAGAATTTCAACCTGTGTACTTCATAGCCGAGTCATTCGAAGAGACGCTAAAGAGAAAATTCGCCACTATACAAGAAAATTCAACCTGTTCATAGACCATTCATAGCCGATTTAGACCAATG

Seq. ID No: 229
>TPH 2

ATGATCGAGGATAATAAAGAAAATAAAGATCACAGTCTGGAACGTGGCAGGGCTTCATTGATATTCTCTTTAAAGAA TGAGGTAGGCGGCTTGATAAAGGCGCTTAAAATATTCCAAGAGAAACATGTTAACCTATTGCATATCGAGAGTAGAA AAAGTAAAAGGCGTAACTCCGAGTTCGAGATATTCGTAGATTGTGATATTAACAGGGAACAGCTGAATGACATTTTC CATCTTCTAAAGAGCCACACTAACGTACTGTCTGTAAACCTACCGGACAATTTTACCCTAAAGGAAGATGGTATGGA AACAGTCCCTTGGTTTCCCAAAAAGATAAGTGATTTGGACCACTGCGCTAACAGAGTGCTAATGTATGGAAGCGAGT TAGATGCCGACCATCCTGGATTTAAGGACAACGTTTATAGGAAGAGGAGGAAGTATTTCGCTGATTTGGCGATGAAT TATAAACATGGCGATCCAATTCCCAAGGTTGAGTTCACTGAAGAGGAGATTAAAACTTGGGGAACCGTTTTTCAAGA GTGGCAGGCTATCTATCACCTAGAGATTTTCTAAGTGGGTTAGCATTCAGGGTATTCCATTGCACACAATACGTCCG TCACAGTAGTGATCCGTTCTATACACCAGAGCCCGATACATGCCACGAGCTTTTAGGCCACGTTCCTTTACTTGCGG AGCCGTCCTTTGCACAATTCTCTCAGGAGATCGGACTTGCATCCCTTGGCGCTTCCGAAGAAGCAGTTCAGAAACTT GCCACTTGCTACTTCTTTACTGTAGAGTTTGGCTTGTGCAAGCAGGATGGGCAACTGAGAGTGTTTGGGGCGGGATT GCTTTCCAGCATCAGCGAGTTGAAGCATGCGTTAAGCGGACATGCAAAAGTCAAGCCATTCGATCCAAAAATCACAT GCAAGCAGGAGTGCTTGATCACAACTTTCCAGGACGTTTATTTCGTGTCTGAATCTTTTGAAGACGCCAAGGAGAAG ATGAGGGAGTTCACGAAAACTATTAAGCGTCCTTTCGGGGTAAAATATAATCCGTACACAAGATCCATTCAGATTCT GAAAGACACAAAATCAATCACGTCTGCGATGAACGAACTTCAACACGACTTGGATGTAGTTTCAGATGCCCTAGCTA AGGTTTCCAGGAAGCCTTCTATA

Seq. ID No: 230 >TPH 3

Seq. ID No: 231

>TPH 4

Seq. ID No: 232

>TPH_5

ATGTTGATTTCCTTTACGCTTAACCTGGTCCACCAAAAGAAGAACAGCGAGTTTGAGATTTTCCTAGACTGCGACAG TAACAGGGAACAACTAAACGAGATATTCCAGCTGCTAAGACCCCACGTCAATCTGATAACCATGAATCCGCAAGAGG ACTTTAGCGTGGAAGAAGATGACATGGAGTCAGTACCCTGGTTTCCCATCAAAATTAGCGATTTAGATAAAAGCGCA AACAGGGTGCTTATGTACGGCAGTGACTTAGACGCGGACCATCCTGGCTTCAAGGATAACGTATATAGAAGAAGACG TAAATATTTTGCCGACGTCGCGATGAATTATAAATACGGTGACCCAATCCCACACATCGAGTTCACTGAAGAGAGG TGAAAACATGGGGGACTGTGTTCCGTGAATTAAATAAGCTACACCAAACCCACGCATGCCGTGAATACCTAAAGAAT TTACCTTTGTTAGTCAAGCACTGTGGGTATAGGGAAGACAACATTCCACAACTAGAGGACGTTTCCAGATTTTTGAA AGAACGTAGTGGCTTTACCATCCGTCCGGTCGCCGGCTACTTATCCCCGAGGGATTTCTTAGCTGGCCTAGCCTTTA GAGTATTTCACTGCACTCAATATGTTCGTCACTCATCAGATCCGTTATACACGCCGGAGCCCGACACCTGCCATGAG TTGCTAGGCCATGTACCTTTGTTAGCTGAGCCCAGTTTTGCACAGTTTAGTCAGGAGATAGGTTTGGCCAGCTTGGG CGCCTCTGATGAAGCTGTCCAGAAGTTGGCCACCTGCTATTTCTTTACGGTGGAGTTCGGTCTGTGTAAACAAGAAG GGAAACTAAAGGTGTACGGCGCTGGGCTTCTGTCTAGTATCTCAGAGTTGAAACACAGCCTGTCAGGTAATGCAAAT GTGAAACCGTTCGATCCAATGGTCACTTGCTCACAAGAATGCATCACAAGTTTTCAGGAAGTTTATTTTACTC TGAATCATTTGAGGAAGCTAAAGAGAAGATGAGAGAATTTGCCAAGACAATAAAACGTCCGTTTGGTCTGAAATACA ATCCGTACACGCAGAGCGTACAAATGTTGAAGGATACCCAGTCTATCACTACGCTAGTATCTGAACTTCGTCACGAG

Seq. ID No: 233

>TPH 6

GCAGGATTAAGCGTCCCTTCGCGGCGAGGTATGACCCATATACAGTCTCCATCGAGGTGTTGGACTCCCCTGGTCAA
ATTCAAAGTTCTTTGGAGGAACTTAAAGACGAGTTGCAGACACTGACTACAGCGTTAAATATACTATCT

Seq. ID No: 234

>TPH 7

GGAGGAATGTCCATATATTAACGCAGTACAATCCCATCACCAGAATGTCCAGGAAATGTCCATAATCATATCGTTAG TTAAGAATATGAATGACATGAAGTCTATCATCTCCATTTTCACAGATCGTAATATCAATATCATATTGAAAGT AGGCTGGGCAGGCTGAACATGAAGAAACATACTGAGAAGTCCGAATTTGAGCCCCTAGAGTTATTAGTTCACGTAGA GGTACCCTGCATAGAAGTCGAAAGGTTGTTGGAAGAACTTAAATCATTTAGTTCTTACCGTATCGTCCAGAACCCGT TGATGAATTTACCTGAGGCGAAGAATCCAACCTTGGACGACAAGGTGCCGTGGTTTCCCAGGCACATAAGTGACCTT GATAAGGTGAGCAATAGTGTTCTTATGTACGGGAAAGAGTTAGATGCCGATCATCCCGGATTCAAAGATAAGGAGTA CAGGAAAAGGAGGATGATGTTTGCCGACATAGCTCTAAACTATAAGTGGGGCCAACAGATTCCCATTGTTGAGTATA CTGAAATAGAGAAGACAACTTGGGGAAGAATTTATAGGGAATTAACCAGACTATATAAGACGTCCGCATGTCACGAG TTTCAGAAGAATCTAGGGTTACTACAAGATAAGGCGGGGTACAACGAATTTGACCTGCCGCAACTACAGGTAGTCTC CGACTTTTTGAAGGCCAGGACTGGATTTTGTCTTCGTCCCGTTGCGGGGTATCTTAGTGCAAGGGATTTCCTTAGCG GACTAGCCTTTAGGGTCTTTTACTGTACTCAGTATATTCGTCACCAGGCCGATCCGTTCTACACACCCGAACCAGAT TGCTGCCATGAGCTTCTTGGACACGTTCCGATGCTGGCGGACCCCAAGTTTGCTCGTTTCTCACAAGAAATAGGGCT TGCGTCACTAGGTACCAGTGATGAAGAAATTAAGAAATTAGCAACTTGTTATTTCTTTACGATAGAGTTCGGCTTGT GACAAAGCGGTTATCAAACCGTTTATTCCTATGAAGGTAATAAATGAGGAATGTTTGGTTACAACATTCCAAAATGG CTATTTCGAGACCAGTTCATTTGAAGATGCTACTCGTCAAATGAGGGAATTTGTCAGAACGATCAAGCGTCCTTTCG ATGTCCACTATAATCCGTACACTCAATCTATTGAAATAATCAAAACCCCAAAATCTGTAGCAAAATTAGTACAAGAT TTACAATTTGAGCTAACCGCAATTAATGAGTCCTTGCTGAAAATGAACAAGGAGATTCGTAGTCAACAGTTTACCAC AAACAAGATTGTGACTGAAAATCGTAGTTCC

Seq. ID No: 235 >TrpHalo 1

ATGTCTACAGCTTCAAAGAACATAGATATTACAAGATTCCCCAAGAAATACGATGCGGCCACGAAAGACTCTGATTT TTATGATGTTGTAATCGTAGGTGCTGGCCCAGGTGGCAGTACAACTGCTTACTACTTGGCAAAAGAAGGAAAAAGG TTTTATTGCTTGAGAAGAAAAGTTCCCCAGAGATAAGATATGCGGTGACGCTATATGCAAACTAGCCATAGAGATG CTTATGGATATGGGTGTCTACGAGGGATTAGTTAGGGAGAAGAAGCTCGTGTAGCTCACAACGGAGGATTAGTTTC TCCCTCCGGCCTTAGTTTCATCGGGAATACGTACCTAAAGCCGGGGGAGATCCCTGCTGCAGCTGCAAACGTA TGGTCCTGGACGAAGCCATCGCTAAGGCCGCTATTGGGGCCGGAGCCGAACTAAAAGAAAATTCCCCAGTGACAGAC GCTGTCTTCGATAGTACCGGGCTGTGGACGATTAGCATTGAGGGCAGTGATGTGAAACATATGGGCCGTGTGTT AGTATGTGCAGACGGTGCTCCTAGTAAACTAGCTACGCAATTAGGCATCGTAAAACAGGCGCCCCAGGGGGTGTGTA GCAGAGCGTATATTAAGGAAGGTACACATAGATTCAGAGCGGACGGCGTCGTATTTTATCCGAGAAATATCTTACCA GCATATGCTGCCCTTTTCAGGCACATAGACGACACTGTCGCGTACTGCACCTATATATTACCCTTTAACCCAAAAGT TACGACAGACGACCTGTCATATTGGCATCATCGTCTATTAGAGGAGGACCCTTCTATTTCTCAAGCAGTCGGTAAAA ATGCTGATATGGAGAGAATGAAAGCCTGGGGTCTGCGTATGGGAGGTGAACCCGTGACGTATGGTAACCATGTTTTG CGCCGCACATTTCCTATGCGAAGCCATAGCGGTTGGGAATTTTGACAAGGAAGTCATGAAGGAATACCAGAACAGGT GGCTTTACACGTTCGGAAATGACTACAAATGGAGCCAGGCCATATGCCACTTTTTATATCGTTTCCCTATCTTCATC GATGCTACTGCCGCCGCCGCACAAAGGCGTGGGAACAACTTTCTTGCTCTTTACGCAGACATTATGACCGGGAGGAT ACCTAAGGCCAATATTTTCCGTCCCGATATTAGTTTGCCCATAGCATTTGAAGTCTTGGTACTATTGTGGAAGATGA TGTTCACTGGGGGGGGGGGTAATAATAAAATGAAGTCACAG

Seq. ID No: 236 >TrpHalo 2

TACTACTTTTGGAAAAGAAAAGTTTCCGAGGGACAAAATTTGTGGAGATGCTATATGCAAGTTAGCGATCGAGATG CTTATGGATATGGGCGTCTACGAGGGTCTGGTAAGGGAGAAAAAGGCAAGAGTTGCACATAACGGGGGTCTAGTTAG TCCAAGTGGTTTAAGTTTCATAGGCAACACGTACCTTAAACCAGGCGAGATTCCTGCCGCCGCAGCGTGCAAAAGAA GCCGTGTTCGATTCTAGTACCGGTCTGTGGACAATCTCTATCGAAGGTTCAGACGTAAAACATATGGGCAGGGTCCT AGTTTGTGCGGACGGAGCACCCAGCAGACTTGCGATGCAATTAGGCATCGTCAAGGGGACACCTAAATGCGTTTGCT CCAGAGCGTACATAAAAGGCGGGACCCACCGTTTTAAAGAGGACGGAATGGTATTCTATGTACCTTCTATCCTACCG GGGTACGTGGCTTTGTTGCGTCATATCGACGACCAACTTACATACTGCACCTACATTCTACCAGGGAACCCAAGAGC AACTACGAAGGATTTGTCTTATTGGCATCATAGACTTCTTGAGGAAGACCCAAACATAAGCCAGGCAGTCGGGAAGA ACGCCGAACTTGAGAAGATGAAAGCCTGGGACTTACGTGTGGGCGGTGAACCAGTAACGTACGGTAATCATGTCCTT TGCCGCTCACTTTTTGTGTGAAGCTATTGCAGTGGGTAATTTCGATAAGGAAGTTATGAAAGAGTACCAGAATAGAT GGTTGAAGGCATTCGGAAATGACTTCAGATGGTCTCAAGCTATCGGCAATTTTCTTTACCGTTATCCGATTTTCATC GACGCAACCGCCGCTGTCGCCGAGAAGAAAGGAGACAGGTTCTTAGCAAGGTGGGCAGATATTATGGCAGGAAGAAT TTTTCAAAGGGGGTTATGGAAAGAAGACAAAGATTCTA

Seq. ID No: 237 >TrpHalo 3

ATGAGTAGCTTAATCGCGCCAAAAGTAGATACCATAGATATTACAAGGTTCCCCAAAAAGTACGACCCTGCAGCGGA GGACTCCGATTTCTACGACGTAGTAATAGTCGGAGCGGGTCCCGGTGGCAGCACGACTGCGTATTACCTAGCGAAGA AGGGTAAGAAAGTGTTACTACTAGAAAAGAAGAAATTTCCTAGAGACAAGATCTGTGGTGACGCAATCTGTAAAACG GCAATTGAAATTTTAATGGATATGGGGGTCTACGGCGGACTGATCAGGGAACAGAAGGCTTACATGATTGACTACGG GGGACTTGTGTCCCCTTCCGGTTTGAGCTTTGTCGGCCACACCCATGAGCTTTTCGGTGAAATACCAGGAGCTGTTG TGTGCAAGAGAGTTGTGTGGACAAGGTAATATCAAGAACGGCACAATCAGCTGGAGCTGAATTGTTGGAGAACTCC CCTGTAACAGATGCAGTTTTCGATTCCAGCACTGGTCTTTGGACTATTTCTATTGAGGGCTCAGACGTGAAGCATAT GGGTAGAGTACTGGTATGCGCTGACGGAGCACCTTCCAGATTGGCCATGCAACTAGGAATTGTCAAGGGGACACCAA AGTGTGTTTGTAGTCGTGCCTATATTAAAGGCGGCACCCATAGGTTCAAAGAAGACGGCATGGTGTTCTATGTCCCT TCAATACTTCCCGGATATGTCGCCCTTCTTCGTCATATAGATGACCAGCTGACTTACTGTACGTATATCTTACCTGG AAATCCCAGAGCTACCACTAAGGACCTTTCTTACTGGCACCATAGGCTGCTAGAGGAGGACCCCAATATTAGCCAAG CAGTTGGTAAAAATGCCGAATTAGAGAAAATGAAGGCCTGGGACCTAAGAGTGGGCGGAGAACCCGTCACGTACGGC CGGAGGCCGTATCGCGGCTCACTTTCTTTGCGAGGCTATAGCTGTCGGCAACTTTGACAAAGAAGTCATGAAGGAGT ATCAAAATCGTTGGTTAAAGGCATTTGGTAATGATTTTAGATGGTCCCAAGCGATTGGGAACTTCCTATATAGATAC CCGATATTTATAGATGCCACTGCGGCCGTGGCTGAGAAGAAGGGTGACAGATTCCTGGCCCGTTGGGCTGACATCAT GGCGGGTAGGATTCCCAAAATATCCGTCTTGAGACCGCAATTCCTGTTGGCAGTAGGATTCCAAGCCCTTCTGCTTT TCTATAAGAAGATTTTTAAAGGGGGCTACGGTAAGAAACTAAGATCCTT

Seq. ID No: 238 >TrpHalo 4

Seq. ID No: 239 >TrpHalo 5

ATGGACGAAATAGACGACCCCCGTATAAGGAGTGTAGTGATAGTGGGAGGCGGTACCGCGGGGTGGATGACCGCCGC CGCTTTAGTTCAGCACTTTAGAACCGCGCCTCTAAAAATAACGGTGGTGGAGAGTTCCGATATTGGGACTATTGGTG TAGGTGAAGCTACGATTCCGACCATTCGTAGATTCTATGGCCAACTAGGACTTAGGGACGACGATGTGATGAGAGCT ACGCAAGCGACATGTAAATTGGGCATCAGGTTCTTAGATTGGAGTGGACCTGGGTCCGACTTTATTCATCCCTTTGG TCTTTATGGCCAAGATGTTAAGGGCATTGGCTTCCACCACTATTGGCTTAAACAAAGGCGTGCCGGAGATGCAGCGC CGTTGGCTGCGTACAGCTTAGGAGCGGCACTGGCTGCCGGTGGCAAATTTACGTTGCCCAGTCCTCATCCACCCTCT CAACTGTCTGTATTTGATTGGGCATTGCACCTTGACGCAGGCCTATTCGCCCAGCACCTAAGAGCGTACGCAGAAGC CGGTGGCTGTGCCAGAATTGATGCCCGTATAAGATCAGTTGAGCTTAGACCAGAAGACGGCTTTGTCAGAGCCCTTA CATTGGACGACGGAAGAGAGGTAGAGGGGGACTTGTTCGTGGACTGTAGCGGGTTCAAAGGACTTGTTATCGGTGAG GCGCTGGGAGTTGGGTTCGAAGACTGGGGGAGGTGGTTACCTTGCGACGCAGCGTATGCTGTACAGTCTGAAAACAG GCCAGGCGATGCGCCAGCTCCGTTCACACGTGTTACAGCTAGAAGCGCCGGATGGCAGTGGGGCATACCGCTTAGAC ATAGGGCGGGTAACGGGTTAGTATTTTCAAGTGCCCATCTGTCAGACGACCAAGCCCTTGCTGAGTTGATGCCGCAT TTATTAGGAGACCCCCTTACCGAGCCGAGGCGTATACCTTTCCGTCCCGGCCGTAGATCTCAAGCGTGGGCAAAGAA TTGTGTGGCTATTGGCCTTTCATCCGGCTTCTTAGAGCCCCTGGAGTCCACTAGCATCGCTCTGATCGAGACAGGAA TTGAACGTTTGAAAGCCCTGTTCCCTGACCGTAGGTTCGCGCAACCTATCCTAGACGAATTTAATGATCAAACGGCG AGAGAGATGGAGAGGGTTCGTGACTTTATCATACTACATTATAAACTTAATAGGAGAACTGACACCGACTTCTGGAG AGACTGCAGGGAAATGCCCGTTCCCGAAACATTGGAGAGAAAGATAGCCCTATGGACGGCAAGAGGACAGTTTGTAC GTTATCGTTGGGAAATGTTCCATCCAGCAAGCTGGTTAGCGATCTATGATGGTTTCGGCCTTTATCCCGATCACCAT GATCCAGCGGTGGATGCTATGGACCCCGCCTATTTAGCTAGGTCATTAGCGGAAATGAGAGCTAACATTGCGGACTT AGTTGCGCGTACCCCGAACATGCTCAGTTCCTTGCTGGGTTGGACCCGGCGGCTTCGGCCGCT

Seq. ID No: 240 >TrpHalo 6

Seq. ID No: 241 >TrpHalo 7

TGAGCGTATTTCTGTAACAGTTGTAGAATCAGCGAGGGTCGGGACGATAGGGGTTGGCGAAGCTACCTTCAGCACAG TAAGACACTTTTTCGAATACCTGGGGTTAAGTGAGGAAACATGGATGCCAGCTTGCAATGCTACGTATAAACTAGGG ATCAGATTTGAAAACTGGAGAGCGCCAGGGCACCATTTTTATCATCCTTTTGAAAGACAGAGGGTAGTGGACGGGTT CACCCTGCCAGACTGGTGGCTGGCCGATGGCGGGGCCACCGAGAGATTCGATAAGGAATGCTTCCTGGTTGGCACAC TGTGTGACACTATGAGATCCCCTAGACACATGGACGGTGCTTTATTTGAGGGCCGATCTAACGGACAGGCCCGCTGGA ACGTGATTACGCTGTGGCGAGAGGGGTCTTGCATGTTGTGGACGATGTGGTTCACGTGGCTAGGGACGAAAGGGGAT TTACTTATTAACGACGCTTTGGACGAGCCGTTTGAGTCTTATCAAGACACCCTACCGAATGATTCCGCAGTGGCTCT GCGTGTACCAGTTGACATGGAGCGTGAAGGCTTGAGGCCATGTACCACATCAACCGCTCAAGCGGCGGGGTGGATAT GGACTATTCCACTTTTTGGACGTGTTGGAACCGGCTATGTCTACGCGAGGGATTACTGCACACCTGAGGAAGCTGAA CGTACGCTGCGTCGTTTCGTAGGCCCGGCTGCCGACGACTTAGAGGCCAATCACATTCGTATGAGAATTGGAAGGAG TAGACGTTCATGGGTCAACAATTGCGTCGCAGTGGGTTTAAGCAGCGGGTTCGTAGAACCGTTAGAAAGTACCGGTA TCTTCTTTATTCAGCACGCAATAGAACAACTTGTTAAACACTTCCCCGATGCGGACTGGGACCCCGCTCTGCGTTCC GCCTACAACACCTTGGTTAACAGGTGCATGGACGGAGTAAGGGAGTTCTTGGTCTTGCACTATTACGGGGCAGCGAG AGCTGACAATGAATATTGGAGAGATACAAAGACGAGGAAAATCCCCGACTCTTTGGCGGAGAGGGTGGAGCAGTGGC GTACCAAATTGCCCCATCCAGAGAGTGTGTACCCTCACTATCATGGTTTTGAAGCGTACTCCTACGTCTGTATGGTG CTTGGACTGGTGGTATTCCTCTAAAACCGAGCCCTGCCCTACGTATGCTTGACCCCTCCGCAGCCCAGCGTGAGTT CCGTCTGTTGGCGACTCAAGCAGAGGATCTTAGGCGTACCCTACCGTCTCAATATGCTTACTTCGCACAGTTTAGA

Seq. ID No: 242 >TrpHalo 8

ATGAATAAACCTATAAAGAATATAGTGATCGTCGGAGGCGGAACCGCAGGCTGGATGGCAGCGTCATATTTAGTAAG GGCCCTTCAGCAGCAGGCCAATATAACCTTAATTGAATCCGCTGCTATACCTCGTATCGGTGTCGGGGAGGCCACCA TTCAAGGCAGCTATCAAGTTTGTTAATTGGAGGAAAAGCCCGGACCCTTCCAGGGATGACCATTTCTACCATCTATT CGGCAATGTTCCGAATTGCGATGGCGTGCCCCTAACGCACTACTGGTTGCGTAAGAGGGAGCAGGGATTTCAGCAAC CGATGGAGTACGCTTGCTATCCCCAGCCTGGGGCGTTAGACGGCAAATTAGCGCCATGCCTTTCCGATGGCACACGT CAAATGAGTCACGCTTGGCATTTCGACGCTCACTTGGTAGCTGATTTTCTGAAGAGGTGGGCCGTTGAGAGGGGCGT CAATAGAGTAGTTGATGAGGTCGTCGATGTCAGATTGAATAACCGTGGCTACATAAGTAATTTACTGACCAAAGAGG GGAGAACTTTGGAAGCGGACTTATTCATTGATTGCTCCGGGATGCGTGGACTGCTGATTAACCAAGCGTTAAAAGAA CCATTTATAGATATGTCCGATTACTTACTGTGTGATTCTGCCGTTGCGAGTGCCGTACCCAATGACGACGCCCGTGA CGGGGTTGAGCCCTATACGTCTAGTATCGCGATGAATAGCGGCTGGACGTGGAAGATACCAATGTTAGGTCGTTTCG GTAGTGGATACGTCTTTAGCTCACATTTCACGAGTCGTGACCAAGCAACAGCGGATTTCTTAAAGCTGTGGGGACTA TCTGACAACCAACCCTTGAACCAGATTAAATTCCGTGTCGGGCGTAATAAGAGAGCCTGGGTAAATAATTGCGTCTC AATCGGGCTATCAAGTTGTTTCCTGGAACCGCTAGAATCTACTGGGATTTACTTTATATACGCAGCATTATATCAAC TGGTCAAACACTTCCCGGATACGTCTTTTGATCCACGTTTATCAGATGCCTTCAACGCCGAGATCGTACATATGTTC GACGATTGCCGTGACTTTGTCCAAGCGCATTATTTCACAACTTCGAGAGACGACACCCCGTTCTGGTTAGCAAACAG GCATGATCTAAGACTTAGCGATGCGATCAAAGAAAAAGTCCAGCGTTACAAAGCTGGGCTTCCTCTTACCACAACGA GTTTCGACGACTCTACCTATTATGAAACGTTTGACTACGAATTTAAAAAATTTTTGGTTAAACGGCAACTATTATTGT ATTTTTGCGGGTCTTGGGATGTTGCCGGATCGTAGCCTTCCCCTTCTGCAACACCGTCCCGAGAGTATAGAAAAAGC

AGAGGCTATGTTTGCGTCCATCCGTAGGGAGGCAGAAGATTGAGGACCAGTCTACCAAACTATGACTACTTGAGATCCCTACGTGATGGTGACGCGGGATTAAGCAGAGGCCAAAGGGGACCGAAACTTGCCGCACAAGAGTCTTTG

Seq. ID No: 243

>TrpM 1

ATGAGTCCCGTCGCACTTTCTCCTAAAAGGGTTGACATAGTAGATATTAGAGGGAACGACATGCAGTATAGTTTAGT
CAACGAAATTCATAAAGGTCTAAATCCTCCTAACGGTACCAGGAGAAGCCTTCCCACAATGCTATTATACGATAGTG
AAGGGCTTAAACTATTTGAGAAAATTACTTACGTCGATGAGTACTATCTGACTAACGCAGAGATTGAGGTCTTGGAA
AAGCATTCCCGTAGGTTAGTGGAGAAAATTCCGAGTAACGCGCAACTGCTAGAGTTGGGCTCCGGTAATCTTAGGAA
AATTGAGATCCTTCTGAGAGAGATTTGAGCGTGTAGGTAAGCCCGTCGATTACTACGCATTGGATCTGTCACTGAGTG
AATTAGAGCGTACCTTCAGCAATGTCTCATTAGAAGAATATAAGTCTGTAGGATTTCATGGCTTTGCACCGGTACATAT
GACGATGCACACACTTGGCTTTCTGACCCGAAAAATCGTGAGAGGCCCACTGTCGTTTTTGTCAATGGGGTCTAGTCT
AGGGAACTTTTCTCCCCCTGATGCAGCTGCCTTCCTTGCTGGGTTTGCAACCCTTTTGAAACCCTCCGACTTCATGG
TCATTGGTTTAGATGCCTTGCAAATGCAGATCGTGTATATAAAGGCTTACAACGACAGTGCCGGTATAACGAGAAAG
TTTTATGAGAACGGCCTTGCAAATGCAAATAAAACTCTGGGTCACGAGGTATTTAGACCTGACGAGTGGGAAGGTGAAAGTTTTATGAGACGTGGGGAAAAGTTATCTTCGCTGAGGCATTTAAGTACCAAAGGACGTAAGCGTGAAAAGTTGTGGCAC
GACGCTGGACTGATTGAAGCAGCCGAGTTCGCTCCGGGAGTGAGAGACTTATATAAA

Seq. ID No: 244

>TrpM_10

Seq. ID No: 245

>TrpM_11

TACATGGAGTCTTGGACCGACTCACAGAGCCTATATGACCTGCATTTGGTTTATAAGAGTCCCTTCCACTTCACACG
TAAGTTTGATAGCCACAAATAA

Seq. ID No: 246

>TrpM 12

Seq. ID No: 247

>TrpM_13

Seq. ID No: 248

>TrpM_14

ATGAGCCAGATAGAAGTTCTGGACATTCGTGGAAGCAAGGAAGCTACAGGTTCTACACCACACTTGAGGGCGGAAAT
TTTGCAAGGTCTTTCAAAGTCACCTGGGCATCGTACCATTCCCGGTGAGACCTTATTTGATGAGACCGGGTTGAAGA
TGTATGACGAGGGGATGAAGACTTGGAGAAAGTGGTATTACCCGTTCGAGGCTGAGAAGGAAATCCTTGAAGTTAGG
GGTCTGGAGATAGCCAAATTGTTGAAAACCAGTTCCAAAGGGGAAGCCGTACTAATTGAATTAGGCGCTGGGTCTTT
AGAGAAAACTTCACAAATACTTTTATCTGCCGCTCAGATAGCCGAAACAGCCGATAACAGCACTACTAACCCCCATTA
CATACTACGCACTAGACCTGGAACATAGAGAGCTGGAGAGAACACTGGCGGCCTTACAAGACGCTATCGGTCCGAGA
ATCGCTGGTAAAATCACAACCAAAGGGATGTGGGGGGACCTACGAAGACGGAATTAGAGTCGTGGAAAAGGAATGATCT
AAAATTTCCTTCAGATGTACCTTTACACATCCTATTTCTAGGAGGAACCATTGGCAACTTTTCTAAAGCTGATGGCG
ATATTGCATTTTTGAAGAGCCTGCCTTTGAATCGTAAGAGGGAGATACATTGCTATTGGGAGTGGACAGAGCTAAG
GCGGTTGAACTAATTGAAAGAGCCTACGGCTTCGCGGCTGCTACAGGTTGGAAAGGTACACCGAGTACAACGAGCAACTAG
GAAGATATGAAGCAGGATGAAGAGCCGGAAGGATCAAACAATAAAGGTTGCTAAGGGTACAACGAGCATCTTTTTAGT

AAGGATGAAGTCATTCTAGTTACTTACTCAAATAAGTATACTGATGCTGAAATAAAGACGGTCTTTGACGGTGCCGG ACTGGAAATTGTGGAATCTTGGATGGACAAAAAGGCACAGTATTGCTTGTTTTTACTAAAAGCCTGA

Seq. ID No: 249

>TrpM 2

Seq. ID No: 250

>TrpM_3

Seq. ID No: 251

>TrpM_4

Seq. ID No: 252

>TrpM_5

Seq. ID No: 253

>TrpM_6

Seq. ID No: 254

>TrpM_7

Seq. ID No: 255

>TrpM 8

Seq. ID No: 256 >TrpM 9

Seq. ID No: 257 >TrpS 1

TCAACTTGAGGAGGCATTTGTGTCCGCACAAAAAGATCCGGAGTTCCAGGCTCAATTTGCCGATCTGCTAAAGAATT ATGCAGGGAGACCGACGCGCTTACTAAGTGCCAGAACATCACAGCCGGGACCAGGACCACACTATACCTTAAAAGA GAAGACCTGCTGCATGGTGCCCATAAAACGAACCAGGTTTTAGGCCAGGCTCTTTTAGCCAAACGTATGGGAAA AAGCGAAATCATAGCAGAAACGGGAGCTGGGCAGCATGGTGTAGCCTCTGCCTTAGCCTCCGCTCTATTAGGCCTGA AGTGCCGTATCTACATGGGGGCAAAAGATGTGGAGAGGCAGAGTCCCAATGTTTTTCGTATGCGTCTGATGGGAGCG GAAGTCATCCCAGTACACTCTGGGTCAGCTACGGTAAAAGACGCGTGCAACGAGGCGTTGCGTGACTGGAGTGGGTC ATACGAGACAGCCCATTATATGCTTGGGACAGCAGCTGGCCCGCACCCGTACCCTACGATAGTAAGGGAATTTCAAA GGATGATTGGTGAAGAGACAAAAGCTCAGATATTAGATAAAGAGGGAAGGCTGCCTGATGCGGTGATCGCATGCGTT GGAGGGGGTAGTAATGCCATTGGCATGTTTGCTGACTTTATCAATGACACAAGCGTTGGCCTAATTGGTGTCGAACC GGGCGGCATGGCATCGAGACTGGAGAACATGGTGCCCCACTGAAACACGGCAGAGTTGGGATATACTTTGGGATGA AGGCACCTATGATGCAGACGGCCGACGGTCAAATAGAAGAGTCATACAGCATAAGTGCGGGGCTAGATTTTCCAAGT GTTGGTCCACAACATGCCTATCTGAACTCCATCGGGAGAGCGGATTATGTTAGCATTACTGACGACGAAGCACTAGA GGCCTTTAAGACCCTGTGCAGGCATGAGGGCATAATTCCGGCATTGGAAAGTAGTCACGCTCTAGCGCACGCGTTAA ACAGTACATGACATCTTGAAGGCTAGAGGGGAAATA

Seq. ID No: 258

>TrpS 2

ATGTGGTTTGGAGAATTTGGAGGCCAATATGTCCTAGAAACACTAATAGGACCACTAAAGGAGTTAGAGAAAGCATA TAAGCGTTTTAAAGACGACGAGGAGTTCAATCGTCAGCTTAACTATTACCTGAAGACCTGGGCAGGAAGGCCAACGC GGGGGCGCACACAAAACAAATAACGCCATAGGTCAGGCCCTACTAGCTAAGTTTATGGGAAAAACTAGGTTAATTGC CGAAACAGGAGCAGGACAGCACGGCGTTGCCACAGCGATGGCTGGGGCTTTGCTTGGAATGAAAGTAGATATATACA TGGGAGCGGAAGACGTTGAACGTCAGAAAATGAATGTTTTTTAGGATGAAGCTATTGGGCGCTAATGTCATACCAGTT AACAGCGGTTCCAGGACACTGAAGGACGCAATCAATGAAGCATTACGTGATTGGGTGGCGACGTTTGAGTACACACA AGGCCAAAGCTCAAATACTAGAAGCTGAAGGGCAATTGCCTGATGTCATCGTTGCTTGTGTCGGGGGAGGCAGTAAC GCTATGGGGATATTTTATCCATTTGTTAACGACAAAAAGGTTAAATTGGTAGGTGTCGAGGCAGGGGGAAAAGGTCT GCGTATCTAAAGAAATCCAGAGGGCGGAGTACGTTGCGGTAACAGACGAAGAAGCGTTAAAGGCCTTTCACGAGCT ATCTAGGACAGAAGGTATTATTCCAGCCCTAGAATCCGCGCACGCGGTGGCATACGCTATGAAGTTAGCCAAGGAAA TGAGTCGTGACGAAATTATTATAGTGAACCTATCTGGGAGGGGCGACAAGGATCTGGACATAGTATTAAAAGTGTCA **GGGAACGTA**

Seq. ID No: 259
>affibody_tag_1

Seq. ID No: 260
>affibody_tag_2

AACGCAGCAATTAGAAGCAGTAGTGCTAGTAGTGGTGGATCAGGAGGTTCCTCATCCTCCGTGGATAATAAGTTTAA CAAAGAAACAATACAAGCATCACAGGAGATTAGACTATTGCCAAACCTTAATGGGAGACAGAAACTGGCGTTCATTC ACAGTCTATTAGACGATCCCAGCCAATCCGCCAATCTACTTGCAGAGGCCAAGAAACTGAACGATGCACAGGCACCG AAA

Seq. ID No: 261
>affibody tag 3

Seq. ID No: 262
>affibody_tag_4

ATGGTGGACAACAAATTCAACAAGGAGCTGGGTTGGGCCACCTGGGAAATCTTCAATCTTCCAAACCTTAACGGCGT ACAAGTAAAGGCTTTCATCGACTCTCAAGAGACGATCCGTCACAGAGTGCTAATCTGTTGGCCGAAGCGAAGAAGC TGAATGACGCTCAGGCTCCCAAAGGCAACGCGGCCATAAGATCAAGCTCAGCTTCCTCTGGAGGTAGCGGCGGTTCC AGTTCTTCA

Seq. ID No: 263
>affibody_tag_5

ATGGTAGACAACAAGTTCAATAAAGAGATGAGAAATGCTTACTGGGAGATCGCTCTGCTACCAAACTTAAATAATCA ACAAAAGAGAGCATTTATTAGAAGTTTATATGACGACCCATCCCAGTCCGCGAACCTTCTTGCGGAGGCAAAGAAAT

TGAACGATGCTCAGGCTCCGAAGTCAAGTAACGCAGCAATACGTTCTTCCAGTGCAAGCTCTGGGGGAAGTGGGGGAAGTTCATCCTCC

Seq. ID No: 264
>affibody_tag_6

AATGCCGCCATCAGGTCTTCATCAGCCTCAAGTGGCGGCTCTGGAGGGTCCAGCTCCTCTGGGGTCGATAATAAGTT TAATAAAGAGATGAGGAACGCATATTGGGAAATTGCCTTACTGCCGAATCTGAATAATCAGCAGAAAAGGGCTTTCA TCAGATCCCTGTACGATGACCCGTCCCAGAGCGCGAATCTTTTGGCAGAAGCGAAAAAGCTGAACGACGCACAGGCA CCAAAG

Seq. ID No: 265 >cofold 1

ATGAAAATCGAGGAGGGAAGCTAGTTATCTGGATCAACGGGGATAAGGGCTATAATGGCCTAGCCGAAGTAGGAAA GAAGTTTGAGAAAGACACCGGTATAAAAGTGACAGTGGAGCACCCTGATAAGTTGGAGGAGAAGTTCCCTCAGGTGG CTGCTACTGGGGATGGTCCAGATATTATCTTCTGGGCTCATGACCGTTTCGGCGGATACGCCCAAAGTGGATTGCTT GCTGAAATAACGCCAGATAAAGCATTCCAGGACAAATTGTACCCATTCACCTGGGACGCGGTGCGTTACAATGGAAA CCTGGGAAGAGTTCCAGCATTAGACAAAGAATTGAAAGCAAAAGGCAAGAGTGCTCTGATGTTTAATTTACAAGAG CCGTATTTTACCTGGCCCTTGATCGCCGCGGACGGGGGTTACGCTTTTAAGTATGAAAACGGTAAGTACGACATCAA GGATGTTGGAGTAGATAACGCCGGAGCAAAAGCGGGTCTTACCTTTTTAGTAGATCTGATCAAGAATAAGCATATGA ACGCTGATACGGATTATAGCATCGCAGAAGCGGCATTTAATAAGGGTGAGACAGCGATGACAATAAACGGCCCCTGG GCATGGTCTAATATCGATACTTCTAAGGTGAATTACGGAGTGACTGTCTTACCTACTTTCAAAGGGCAACCTAGCAA GCCGTTTGTTGGAGTCCTGTCTGCGGGGATTAACGCAGCATCCCCTAATAAGGAGTTGGCTAAAGAATTTTTGGAAA ATTATCTGCTTACCGATGAGGGTTTGGAGGCGGTTAATAAAGATAAACCCCTGGGGGCGGTGGCTCTTAAATCATAC GAAGAAGAGCTGGCGAAAGATCCAAGAATAGCTGCTACAATGGAGAATGCACAGAAGGGTGAGATAATGCCGAATAT TCCACAAATGTCTGCCTTTTGGTACGCTGTCAGGACTGCGGTCATTAATGCTGCCTCAGGAAGGCAAACGGTGGACG AGGCGTTAAAAGACGCCCAGACAAACTCAAGTAGTAATAATAACAACAATAACAACAACAATAATTTAGGTATTGAA GGTAGG

Seq. ID No: 266 >cofold 2

ATGGTGTCTAAGGGTGAGGAGTTGTTCACCGGAGTTGTCCCAATTTTAGTGGAATTAGACGGAGACGTCAACGGACA CAAATTCAGCGTCAAGGGAGAGGGGGAGAGCGCGACTTACCGGAAAACTTACCCTAAAACTGATATGTACGACGG GAAAACTTCCAGTACCCTGGCCTACTCTAGTTACAACTTTAGGGTATGGCCTACAGTGTTTCGCGCGTTATCCAGAC CACATGAAACAACACACGACTTTTTCAAGTCAGCTATGCCGGAGGGCTACGTTCAAGAACGTACCATTTTCTTCAAAGA TGATGGAAATTACAAAACAAGAGGGGAGGTCAAATTTGAGGGAGATACCCTAGTAAATCGTATAGAACTGAAAGGGA TAGACTTTAAAGAAGATGGAAACATCCTAGGCCATAAACTTGAGTATAATTACAATTCCCACAATGTGTACATTACG GCTGATAAACAGAAAAAACGGGATCAAGGCCAATTTCAAGATTCGTCATAACATCGAGGATGGAGGGGTGCAATTAGC AGACCACTACCAACAGAATACTCCTATTGGTGACGGACCTGTCCTTTTACCGGACAATCACTATTTGAGTTACCAGT CTGCTCTGTCCAAAGACCCGAATGAGAAACACGTGACCACACTGGTGTTATTGGAGTTCGTGACAGCAGCTGGAATCACG CTTGGTATGAGTTGTATAAA

Seq. ID No: 267 >cofold 3

ATCCGTTTCAGAAGAAGGAGGAAGGAAGGTTCAGGCTCTGGA

Seq. ID No: 268

>cofold 4

Seq. ID No: 269 >cofold 5

ATGGCAGACAGGATAGGTCTGGGATATACGGAGGGGCTCACGCAACCTATGGCCAGCAGCAGCAGCAAGGTGGAGG
TGGTAGGCCGATGGGGGAACAAGTCAAAGGAATGCTTCACGACAAAGGGCCGACGCTAGTCAGGCTCTGACGGTCG
CGACACTTTTTCCCCTGGGCGGTTTATTGCTAGTGCTTAGTGGACTGGCCCTAACGGCGTCAGTGGTGGGATTGGCT
GTAGCTACCCCAGTTTTCTTGATATTTAGTCCTGTTCTAGTACCAGCCGCCCTTTTGATTGGAACAGCGGTGATGGG
CTTCCTGACGAGCGGCGCTTTAGGCTTAGGAGGGCTTATCTAGTCTTACTTGTCTTGCAAACACGGCACGTCAGGCTT
TTCAAAGAACGCCTGATTACGTAGAGGAGGCTCATAGAAGAATGGCGGAGGCTGCCGCGCATGCCGGACATAAAACG
GCTCAAGCGGGCCAGGCTATTCAGGGCCGTGCTCAGGAAGCTGGGGCCGGAGGTGGAGCGGA

Seq. ID No: 270
>oxidase 1

ATGAAGATCTTAATCTTGGGCATCTTTCTGTTTCTATGTAGCACTCCAGCTTGGGCCAAGGAGAAGCACTATTACAT CGGGATTATAGAGACGACGTGGGATTATGCCAGCGACCACGGCGAGAAGAACTTATTAGCGTGGACACTGAGCACT CTAACATCTATCTTCAGAATGGCCCAGATAGGATAGGACGTTTATATAAAAAGGCATTATACCTTCAATATACTGAC GAAACTTTCAGAACGACGATTGAAAAGCCTGTGTGGCTAGGGTTCCTGGGGCCTATCATTAAGGCGGAGACGGGAGA TAAGGTCTACGTACACCTAAAGAACCTTGCTAGTCGTCCTTACACATTTCACTCCATGGTATTACATACTACAAGG AGCATGAGGGTGCTATTTATCCAGACAACACCACAGATTTCCAAAGAGCCGATGACAAAGTTTACCCAGGGGAACAG TACACCTATATGCTACTGGCAACGGAGGAACAAAGTCCCGGGGAGGGCGACGGGAACTGCGTAACAAGAATCTACCA TAGCCATATCGACGCACCAAAGGATATAGCAAGCGGCCTAATCGGGCCTCTGATTATTTGCAAGAAGGACTCCCTGG ATAAAGAGAAAGAGAAGCATATTGATCGTGAGTTTGTGGTGATGTTCTCAGTAGTTGACGAAAATTTCAGCTGGTAT CTGGAGGACAACATTAAGACATATTGTAGCGAACCGGAGAAGGTAGATAAAGATAATGAAGATTTTCAAGAGTCTAA TAGGATGTATAGTGTAAACGGTTATACCTTTGGCTCACTTCCAGGGCTGAGTATGTGCGCAGAGGATAGAGTTAAAT TATAGAATCGATACAATAAATCTATTCCCAGCTACGCTGTTTGACGCCTACATGGTTGCTCAAAACCCCGGAGAATG GATGCTATCTTGTCAGAATTTGAATCACCTTAAAGCCGGTTTGCAAGCATTCTTTCAGGTACAAGAGTGTAATAAGT CCTCATCTAAAGATAACATTAGAGGAAAGCACGTCCGTCATTACTACATCGCGGCGGAGGAAATAATTTGGAATTAT GCACCCAGCGGCATAGACATCTTTACTAAAGAGAACTTGACTGCCCCTGGGTCTGACAGTGCCGTGTTCTTCGAGCA AGGTACCACCCGTATTGGTGGATCTTATAAGAAACTTGTCTATAGGGAATATACCGACGCTAGTTTCACTAACCGTA AAGAAAGAGCCCTGAGGAAGACACCTAGGAATCTTAGGGCCGGTCATTTGGGCGGAAGTGGGGGACACAATACGT GTTACCTTCCATAATAAAGGTGCTTATCCATTGTCCATCGAGCCAATCGGCGTAAGATTTAACAAGAATAACGAGGG GACTTATTACTCTCCTAACTATAACCCTCAGTCAAGATCTGTGCCCCCAAGCGCCTCACACGTTGCTCCAACTGAAA CTTTTACTTACGAATGGACGGTACCCAAAGAGGTCGGGCCCACTAATGCTGACCCTGTATGCCTAGCTAAGATGTAC TATTCCGCTGTAGATCCTACCAAAGATATCTTTACGGGGTTAATAGGACCCATGAAAATCTGTAAGAAAGGTAGCCT ACACGCCAATGGCAGACAAAAGGACGTGGATAAGGAGTTTTATCTTTTCCCTACAGTTTTTGACGAAAATGAAAGCC TTCTATTGGAGGATAATATCCGTATGTTCACTACCGCGCCCGACCAAGTTGATAAAGAGGACGAAGACTTTCAAGAG AGTAATAAGATGCACAGTATGAACGGATTCATGTACGGCAATCAGCCGGGCCTTACCATGTGCAAGGGTGATTCAGT GAGGCGAAAGACGTGACACAGCAAATCTTTTCCCACAGACGAGTCTAACGCTACACATGTGGCCAGATACGGAAGGA ACTTTCAATGTGGAGTGTCTTACGACCGATCATTACACCGGGGGAATGAAGCAGAAGTACACCGTCAACCAGTGCAG GAGACAAAGCGAGGATTCAACCTTCTACCTTGGAGAACGTACATACTACATTGCAGCTGTCGAGGTGGAGTGGGATT ATTCTCCTCAGCGTGAATGGGAAAAAGAACTTCATCACCTGCAAGAGCAAAATGTCTCTAACGCGTTTCTCGACAAA GGAAAGAAAGGCAGAGGAAGAGCACCTGGGCATACTAGGCCCTCAGTTGCACGCGGACGTCGGGGACAAAGTAAAGA TCATATTTAAGAACATGGCTACTAGGCCGTATAGCATACATGCACACGGAGTACAAACCGAGAGTTCCACAGTCACA

Seq. ID No: 271
>oxidase 2

ATGGGACTGAACTCCGCGATACCGTCTTTAGCGATTTTGGCACTGTCCGTAGGATCTTATGCCGCAATCGGGCCAGT ATCTGACCTACACATTGTAAACAAAGATTTGGCACCCGACGGCGTGCAGAGGCCCACAGTATTAGCTGGCGGCACGT TCCCCGGAACGTTAATAACTGGACAGAAGGGTGATAATTTTCAACTTAACGTTATCGATGACCTTACCGATGACCGT ATGCTAACCCCTACGAGCATCCATTGGCATGGCTTTTTCCAGAAAGGTACTGCCTGGGCAGACGGTCCAGCTTTTGT TACGCAATGCCCGATTATTGCGGACAATAGTTTCTTATACGATTTTGATGTGCCAGACCAGGCGGGAACTTTCTGGT ACCACTCCCATTTATCAACACACTGCGACGGTCTACGTGGGGCATTTGTCGTATATGACCCGAACGATCCCCAT AAAGATCTTTATGATGTCGATGATGAAAGTACAGTCATCACACTAGCAGATTGGTACCACGTCTTAGCGCAAACAGT TAGCCGTAATCAGCGTAGAGCACAATAAGAGGTATAGATTCAGACTTGTGTCTATATCTTGCGACCCAAACTTCACC TTCTCTATAGATGGTCACAACATGACCGTAATCGAGGTCGATGGGGTAAATACCCGTCCTTTAACCGTGGATTCCAT TCAAATTTTCGCCGGCCAAAGATATTCTTTTGTCTTGAATGCAAATCAGCCGGACGACAACTACTGGATTAGAGCCA TGCCGAATATAGGTAGGAATACGACGACCCTAGACGGTAAGAACGCGGCTATACTAAGATATAAAAATGCTTCCGTA CGTGCCGGGAAATGCGGTCCCGGGAGGTGCAGATATTAATCACAGATTGAACCTGACATTTTCCAATGGGCTGTTCT CCATAAATAACGCAAGTTTCACAAACCCATCCGTACCGGCATTACTGCAGATCCTGAGCGGTGCACAAAACGCGCAG GACCTTCTGCCAACAGGTTCCTACATTGGGTTAGAGCTGGGGAAGGTGGTAGAACTTGTCATCCCGCCACTAGCGGT AGGGGGTCCTCATCCACTTCCACTTACACGGGCATAACTTCTGGGTTGTCAGATCAGCCGGGAGCGATGAATATAACT TCGACGATGCTATACTTAGGGATGTGGTTTCCATTGGTGCGGGCACGGACGAGGTGACCATTAGGTTTGTCACCGAC AACCCGGGGCCCTGGTTCTTACACTGTCACATAGATTGGCATCTGGAAGCGGGACTAGCTATCGTATTCGCTGAAGG TATAAACCAGACTGCCGCTGCAAACCCGACCCCTCAAGCATGGGACGAACTATGCCCTAAATACAACGGGCTTAGCG CGAGCCAAAAGGTTAAACCGAAAAAGGGTACCGCTATT

Seq. ID No: 272 >oxidase 3

CTTGTCCCAGACGGAGCGTGTACGTCTTACCGTCAAATTCAAGCATAGAAATATCTTTTCCAGCCACCGCCAATGC CCCGGGCACGCCCACCGCCAATGC CCCGGGCACGCCCATCCGTTTCACCTGCATGGCCACACTTTCGCCGTCGTCAGGTCTGCCGGATCTAGTGAATATA ACTATGACAACCCAATCTTCAGGGATGTTGTCAGCACGGGTCAGCCAGGCGATAACGTGACTATAAGGTTCCAGACT AATAATCCCGGTCCCTGGTTTTTGCATTGCCATATAGACTTTCACCTAGAGGCCGGATTTGCAGTTGTTCTTGCGGA GGATACCCCTGATACGGCAGCAGTGAATCCAGTGCCACAGTCCTGGAGCGACTTATGCCCAATCTATGACGCGCTAG ACCCTTCTGACTTG

Seq. ID No: 273
>oxidase 4

ATGAAATTCTTGTTACTATCCGCACTGCTTTTCCTGCATTCTTCATTGGCTTGGACTAGGGAGAAGCACTACTACAT CGGGATTACCGAGGCGGTATGGGATTACGCGAGCGGAAGCGAAGAAAAAGAGTTAATTTCCGTAGACACAGAACAAT CCAATTTCTACCTTAGGAATGGCCCTGACAGGATCGGTCGTAAATACAAGAAAGCCTTGTACAGCGAGTACACAGAC GGCACATTTACAAAAACCATAGACAAACCAGCCTGGTTGGGATTCCTGGGCCCCGTAATAAAGGCCGAAGTAGGGGA TAAGGTTTCCGTACACGTGAAGAACTTCGCCTCACGTCCTTACACATTTCATGCTCATGGTGTTACTTATACCAAAG CAAACGAGGGTGCTATTTACCCTGACAACACAACAGACTTCCAGAGAGCAGACGATAAGTTATTTCCGGGTCAGCAA TATCTATACGTTCTTCGTGCGAATGAACCAAGTCCTGGCGAAGGGGATTCCAATTGCGTGACGAGGATATACCACAG TCATGTTGACGCTCCAAAGGACATCGCTTCTGGACTGATCGGCCCCTTGATTCTATGTAAGAAGGGCAGTTTGCACA AGGAAAAGGAAGAACATTGATCAAGAGTTCGTGTTGATGTTTAGCGTGGTCGATGAGAACTTGTCATGGTACTTG GAAGACAACATCAAAACATTTTGTTCCGAACCAGAAAAGGTTGATAAAGACAACGAGGATTTTCAGGAATCTAACAG GATGTATTCTATAAACGGTTACACATTCGGAAGTTTACCTGGACTAAGCATGTGCGCCGAAGACCGTGTAAAATGGT ATCTTTTTGGTATGGGAAACGAGGTGGATGTTCATAGCGAACTGTTCCACGGACAAGCCCTTACCTCCAAGAATTAC CATACAGACATAATTAACCTGTTTCCCGCCACATTAATTGACGTGTCAATGGTGGCACAGAACCCCGGCGTATGGAT GCTATCCTGCCAGAATCTTAACCACTTAAAAGCTGGATTGCAGGCATTCTTCCAAGTCCGTGATTGTAACAAACCAT CCCCTGACGATGACATCCAAGACCGTCATGTCAGGCACTATTACATAGCCGCGGAGGAAACGATCTGGGATTACGCG CCATCAGGGACAGATACGTTTACAGGCGAAAATTTTACCTCCTTAGGATCAGATTCGAGAGTGTTTTTCGAACAAGG AGCTACTAGAATCGGCGGATCGTACAAGAAGTTGGTCTACAGGGAGTATACGGATGATTCCTTTACTAACAGGAAGG AGCGTGGCCCAGATGAGGAACATTTGGGGATATTAGGGCCGGTGATCTGGGCGGAAGTCGGCGATATCATTAGGGTT ACCTTTCACAATAAGGGTCAGTTTCCGCTAAGTATACAACCTATGGGAGTGCGTTTCACTAAAGAAAATGAGGGAAC TTATTATGGGCCAGATGGAAGGAGCAGCAAACAAGCGAGCCATGTCGCCCCGAAAGAACTTTCACTTACGAATGGA ACTAAAGATATATTTACAGGCCTTATTGGCCCTATGAAGATATGCAAGAAAGGAAGTTTATTGGCTGACGGTAGACA GAAAGACGTAGATAAAGAGTTCTACCTTTTCGCGACGGTCTTTGACGAAAATGAGAGTCTTCTACTGGACGACAATA ATGAATGGCTTTATGTATGGCAACTTGCCCGGGCTAAACATGTGCCTTGGTGAATCTATCGTTTGGTATCTTTTCTC CGGCCAATCTGTTCCCTCACAAGTCCTTAACGCTTCTGATGACACCTGACACAGAGGGGAGCTTTGATGTCGAATGC CTGACAACTGACCATTATACAGGAGGCATGAAGCAAAAGTACACGGTCAACCAATGCAAAGGACAATTCGAAGACGT CACCCTGTACCAGGGTGAACGTACGTACTACATAGCGGCTGTAGAAGTAGAATGGGACTATAGTCCCAGCAGGGATT GGGAGATGGAGCTTCACCATCTGCAGGAGCAAAACGTGAGTAACGCATTCTTAGATAAGGAAGAATTTTTCATCGGT AGAGCACTTGGGTATGTTGGGGCCCTTAATCCACGCAGACGTAGGTGCTAAGGTCAAGGTCGTCTTTAAGAATATGG CTACGAGGCCGTATTCAATACACGCGCATGGGGTCAAAACCAAGAGTTCCACCGTAGCACCAACACTACCGGGTGAA GTAAGAACCTACATATGGCAAATTCCCGAAAGAAGTGGTGCAGGTACCGAGGATTCACCCTGCATCCCGTGGGCTTA CTATAGCACGGTAGATCGTGTAAAAGACTTATATAGCGGCCTGATAGGGCCGTTAATAGTATGCAGAAAATCATACG TTAAAGTCTTCAATCCTAAGAAGAAGATGGAATTTTCTCTGTTATTTCTGGTGTTCGATGAGAACGAGTCATGGTAC CTTGATGATAATATTAATACATATCCAGATCATCCTGAGAAGGATAATAAGGATAATGAAGAGTTTATTGAGAGTAA TAAGATGCACGCAATCAATGGGAAAATGTTCGGAAACCTTCAGGGGCTGACCATGCACGTAGGTGACGAAGTAAACT GGTACGTCATGGCTATGGGCAATGAGATCGATTTACACACAGTTCACTTTCATGGCCACTCTTTTCAGTATAAGCAC AGAGGGATTCATAGTAGTGATGTATTCGACTTCTTTCCTGGAACGTATCAAACCCTAGAGATGTTCCCTCAAACGCC CGGAACGTGGTTGCTACATTGCCACGTTACCGATCACATACACGCTGGTATGGTTACTACGTACACTGTGCTTCCAA ACCAGGAAACCAAATCCGGG

Seq. ID No: 274 >oxidase 5

ATGAACTTCGTCACGGCGCTGCCTCTGATTGCGCAGTTGATAGGAACAGCAAGGGCGGCTATAGGCCCGGTCACAAA CCTTTTGGTGAAAAACGCGGACATACCCCCGGACGGATTCACTAGGGCTGCGGTTGTCGCTAATAATCAGTTTCCTG GTCCTGTTATCAGGGCCACTAAAGGAGATACGCTTTCCCTAAACGTGGTAAATCAGCTAACTGATGCCACCATGCTT ATGGGGACTTCAATACATTGGCACGGATTCCACCAGAAGGGTACCTCTTGGGCCGACGGAGTTGTAGGCGTTACCCA ATGTCCGATAGCTCCCGGACATAGCTTCTTGTATCAATTCCCTACAGCCAATCAAGCTGGGACTTTCTGGTACCACT CTCATTATTCCACACAATACTGCGATGGTCTAAGGGGAGCGTTAATAGTTTATGACCCAACTGACCCATACAGGACC TGGTATGACATTGACGACGAGTCTACCATAATTACACTAGCGGATTGGTACCATAAGGCTGCCCCTCTGCAAACGTT AAGAACCGCGAAAGAGGATAGCGTACTGATCAACGGACAAGGCAGAGTCCCAGGGGATAAGACCACCGACAGTACAC CGTTGTCCGTGATTAATATACTCCTCAGAAGAGATATAGGTTTAGGCTGATTTCAATATCATGCGATCCAGCATTT TCTTTTCAATAGACGGGCATAGCATGACTGTCATCGAGGCCGATTCACAAAGCGTCCAACCGTTGACGGTCAACGA GATAACTATTTTCGCGGGACAGCGTTATTCTTTCATCCTGTACGCGAACACCCGGTTGGTAATTACTGGATTCGTT CACAGCCTACATACCCTGACGACGGTATTCAAGGGTATGCAGGGGGTATCAACTCCGCAATTTTGAGGTATTCAGGC GCTCCTGCCGTCAACCCAACTACGAAGAAGGCATCCATTACCATCCCGCTGGTAGAGGCCGATCTAAGACCATTATA TAGTCCCGCCGCTCCTGGATTGCCTTCACCCGGTGCGGCAGATGTGAATATCAAACTGGATATAAGTTATAATTCTC CGTCTGAGACATTTTTCGTAAACAACTCCACATTTCCTGAAGTTCCTGTGCCTGTCCTTTTGCAAATCCTGAGTGGC GCGCAAAGCGCCAACGATTTGTTGCCCGCTGGCAGCGTGTATACCCTTCCGCCCAATAAAGTAATCGAGATTAGTAT GCCAGGGGCCGTCCTGGGAGTCCGCATCCTATGCATCTACATGGTCATGACTTCAGTGTGGTAAGATCTGCAGGAT CAAATAGGTATAATTATGCCAACCCCGTTAGGAGAGACGTAGTGAATATTGGGATGGAGGACACTGATAATGTCACG ATCAGGTTCCGTGTTTGCAGTCATACTTATTTGAGTTTACATTGTCATATCGATTTCCATTTGGAAGACGGACAGTC TGGGACCCTAGTTCCACCTCTTCCACACAGATTGCCGCCACGTGGAAGGATCAGGTGTAGACTACATAGAGGCATTT TAGTAAGAGGCAGGCTTGGACCTGACCTTCAG

Seq. ID No: 275
>phosphatase 1

ATGCAGGGCCGTGGGTTCTTTTACTGTTGGGCCTGAGACTACAACTATCTCTGGGCATTATCCCTGTAGAAGAGGA GAATCCAGATTTCTGGAACCGTCAGGCTGCCGAGGCCCTGGGTGCAGCTAAAAAGCTGCAACCCGCCCAGACGGCAG CTAAGAATTTGATCATTTTCTTGGGAGACGGCATGGGTGTTTCTACTGTAACAGCGGCTAGGATTCTAAAGGGGCAA AAGAAAGACAAACTTGGACCAGAAACGTTCCTTGCAATGGATCGTTTTCCTTATGTGGCGCTGAGCAAGACTTACTC AGTGGACAAGCATGTCCCTGATTCCGGAGCAACCGCAACAGCTTATCTTTGTGGAGTCAAAGGTAATTTTCAAACCA TAGGGTTGAGTGCGGCAGCAAGATTTAATCAATGCAACACAACAAGGGGGAACGAAGTGATTAGTGTAATGAATAGG GCCAAGAAGGCTGGCAAGTCCGTAGGGGTCGTTACGACCACTAGAGTTCAACACGCGAGCCCCGCTGGGGCGTATGC ACACACTGTAAACAGAAATTGGTATAGCGACGCCGATGTGCCTGCTTCTGCAAGACAAGAGGGATGTCAGGACATCG CTACGCAATTGATAAGTAACATGGATATTGATGTTATTTTGGGCGGAGGCAGAAAATACATGTTCCCTATGGGAACG CCGGACCCTGAATATCCTGACGACTATTCACAAGGGGGAACTAGGTTAGACGGAAAGAATTTGGTTCAGGAGTGGTT GGCCAAACACCAAGGCGCACGTTACGTGTGGAATCGTACGGAGTTATTACAGGCATCTCTTGACCCATCTGTAACGC ATCTGATGGGCCTTTTCGAGCCCGGTGACATGAAATACGAGATCCATCGTGATTCTACTTTGGACCCAAGTCTTATG CGACCACGGGCACCATGAGTCTCGTGCCTATAGGGCGTTAACCGAGACCATTATGTTCGACGATGCAATCGAGCGTG CCGGGCAACTGACCTCTGAGGAAGATACTCTGTCCCTTGTAACCGCGGATCATTCTCACGTATTCTCATTTGGCGGA TATCCTTTACGTGGCAGTTCTATCTTTGGGTTAGCTCCAGGTAAGGCGCGTGATAGAAAAGCCTACACAGTGCTTTT GTACGGGAATGGCCCCGGTTATGTTTTGAAAGACGGCGCAAGACCAGACGTTACCGAATCCGAAAGCGGTAGTCCAG AGTATAGGCAGCAAAGCGCAGTTCCTTTGGATGGGGAGACTCACGCAGGGGAAGATGTTGCTGTGTTCGCGCGTGGA CCGCAGGCTCACCTTGTGCATGGCGTGCAGGAGCAAACCTTTATTGCCCATGTGATGGCTTTTGCAGCGTGTTTAGA GCCCTATACTGCCTGTGACTTGGCTCCACGTGCGGGCACAACAGATGCTGCACACCCCGGCCCCTCTGTTGTACCGG CTCTGCTTCCGCTACTTGCTGGCACGTTACTGCTATTGGGAACAGCTACCGCACCT

Seq. ID No: 276
>phosphatase_2

ATGCAAGGCGCTTGTGTGCTGTTGCTTCTTGGCTTGCACTTGCAACTATCACTTGGTCTAGTTCCTGTCGAAGAAGA AGACCCAGCGTTCTGGAATAGGCAGGCCGCGAAGCATTAGACGTCGCCAAGAAGCTGCAACCTATCCAAACGGCCG CTAAAAACGTCATCCTGTTCCTTGGCGACGGGATGGGGGTCCCTACAGTCACAGCCACACGTATACTTAAAGGCCAA ATGAATGGTAAATTGGGGCCGGAAACTCCACTGGCTATGGACCAGTTCCCCTACGTCGCATTATCCAAGACGTACAA TGTAGACCGTCAGGTACCCGACTCCGCAGGAACCGCCACGGCTTATCTATGTGGTGTAAAAGGCAACTACAGAACGA TTGGGGTCTCTGCCGCAAGATACAATCAATGTAAAACAACTAGGGGTAATGAAGTCACGAGTGTCATGAACAGA GCTAAAAAGGCGGGGAAGAGCGTAGGCGTGGTCACAACAACGAGAGTACAACATGCTTCTCCCGCGGGAGCCTACGC CAGCGCAGCTAGTAAACAATATGGACATCGATGTAATATTAGGGGGTGGCAGGAAATATATGTTCCCAGTCGGGACG CCAGATCCGGAATATCCCGACGACGCTAGTGTAAATGGCGTCAGAAAGAGGAAGCAGAATTTAGTTCAAGCCTGGCA GGCTAAACATCAAGGCGCTCAGTACGTATGGAATAGGACCGCACTGCTTCAAGCTGCAGATGATTCCAGCGTGACAC ATCTGATGGGCCTGTTTGAACCCGCAGACATGAAGTACAATGTACAGCAGGACCATACTAAAGATCCAACTCTACAG GAAATGACTGAGGTCGCATTGAGAGTCGTTAGTAGAAACCCCAGGGGCTTTTACCTATTTGTCGAAGGCGGGAGAAT CGATCACGGTCACCACGACGATAAAGCGTACATGGCCTTAACTGAAGCCGGCATGTTCGACAATGCGATAGCCAAAG CCAACGAACTTACGAGTGAACTAGACACGTTAATTCTAGTAACTGCGGACCACAGTCACGTCTTTTCATTCGGCGGC TATACTCTAAGGGGCACATCCATATTTGGGCTTGCACCGTCTAAGGCTCTCGATTCTAAGTCATACACCAGCATATT GTACGGCAACGGACCTGGCTATGCATTAGGGGGTGGATCACGTCCCGACGTCAATGATTCAACCAGTGAAGATCCGT CTTACCAGCAACAGGCCGCCGTGCCTCAAGCCAGCGAGACACACGGTGGCGAGGACGTTGCTGTGTTTGCTAGGGGA CCTCAGGCACATTTGGTACACGGCGTCGAAGAAGAAACCTTTGTAGCCCACATAATGGCGTTCGCCGGATGTGTTGA GCCTTATACCGATTGTAACCTGCCAGCTCCGACAACGGCAACTTCTATTCCAGACGCGGCACATCTTGCAGCCTCTC

Seq. ID No: 277
>phosphatase_3

ATGCAGGGTCCTTGGGTATTATTGTTGCTTGGATTGCGTCTGCAGCTATCCCTTGGTGTAATCCCAGCCGAAGAAGA AAACCCAGCTTTCTGGAATAGGCAAGCAGCGGAGGCCCTGGACGCCGCCAAAAAGCTGCAGCCTATTCAGAAGGTAG CCAAAAATTTGATATTGTTCTTGGGAGACGGTCTGGGTGTACCAACCGTAACAGCTACCCGTATCCTAAAGGGTCAG AAGAATGGCAAGTTAGGACCTGAAACACCGTTAGCTATGGACAGATTCCCCTACCTTGCCCTGAGCAAGACTTACAA CGTGGATCGTCAGGTACCTGATTCCGCTGCAACAGCAACCGCGTATCTTTGTGGAGTCAAGGCCAATTTTCAAACAA TCGGACTATCTGCAGCCGCCAGATTTAACCAATGCAACACAACTAGAGGAAACGAGGTTATTTCTGTGATGAATCGT GCAAAGCAAGCTGGAAAGAGTGTCGGGGTGGTAACAACGACGCGTGTTCAACATGCTTCTCCTGCGGGAACATATGC GCACACTGTTAACAGGAATTGGTACTCAGACGCGGATATGCCCGCGTCAGCCAGACAGGAGGGCTGCCAAGACATCG CCACTCAATTAATATCCAACATGGATATCGACGTCATTCTAGGAGGCGGTAGGAAGTATATGTTCCCTATGGGGACA CCAGACCCTGAATACCCCGCTGACGCCTCTCAGAATGGCATAAGACTTGACGGGAAAAATCTAGTACAAGAATGGTT ACCTGATGGGGCTTTTTGAACCCGGCGATACAAAGTACGAGATCCACCGCGATCCCACACTTGACCCTTCTTTAATG GAAATGACCGAAGCGGCACTGCGTTTGCTGTCCAGAAACCCCAGAGGCTTTTACCTTTTTGTGGAGGGTGGTAGAAT AGATCACGGACACCACGAGGGCGTGGCATACCAAGCTCTAACTGAGGCGGTAATGTTTGATGACGCAATTGAAAGGG CCGGACAACTGACCTCCGAAGAAGATACTTTGACCTTAGTCACCGCCGACCATTCCCATGTCTTTTCCTTTGGTGGT TATACCCTGAGAGGTTCCTCTATATTCGGACTAGCTCCCTCTAAGGCGCAAGACAGCAAAGCATATACGAGTATCCT GTACGGGAATGGACCGGGCTACGTATTTAACTCAGGTGTTAGGCCCGACGTAAATGAAAGTGAGTCCGGCTCCCCAG ACTATCAGCAGCAGGCGGCTGTTCCACTTTCATCAGAAACCCACGGAGGTGAGGACGTAGCGGTGTTTGCCAGGGGC CCCCAGGCTCATTTAGTTCACGGAGTTCAAGAGCAGTCATTCGTTGCTCACGTGATGGCATTTGCCGCATGTTTGGA GCCCTACACTGCCTGTGATTTAGCTCCTCCCGCTTGCACAACAGACGCGGCACATCCTGTCGCAGCTTCCCTGCCAT TATTAGCTGGAACTTTACTTCTTCTAGGAGCGTCAGCCGCTCCT

Seq. ID No: 278
>phosphatase_4

ATGCAAGGCGCCTGGGTATTACTTTTATTGGGTTTCCGTTTGCAGCTGTCTCTGAGCGTAATCCCTGTAGAAGAAGAAATCCGGCGTTTTGGACGCAAAAAGCTGCTGACGCGTTGAACGTGGCGAAGAAGTTACAGCCAATTCAGACAAGTGCCAAGAATCTAATATTTTTTAGGAGATGGTATGGGTGTTGCAACAGTAACGGCCACGAGGATCTTAAAGGGTCAG

CTGGAAGGGAATTTGGGTCCCGAAACACCGCTGGCGATGGACCACTTCCCGTATATGGCTCTTTCCAAGACTTACTC AGTTGATAGACAGGTACCGGATAGCGCATCTACAGCTACTGCTTATCTGTGCGGCGTAAAGACAAACTATAAGACGA GCAAAGAAGCCGGGTAAATCCGTGGGCGTGGTGATCATACGAGGGTGCAGCACGCGAGTCCGGCTGGCACATACGT GCACACCGTTACGTCTAATTGGTATGGGGATGCAGACATGCCAGCCCTGCCGTTGCAAGAGGGTTGCAAGGACATAG CGACGCAGTTGATTAGTAACATGGATATAAACGTAATACTTGGTGGGGGCAGAAAATATATGTTTCCGGCTGGTACA CCCGATCCTGAGTATCCAAATGATGTCAATGAAACAGGCACGCGTCTTGATGGCAAGAATTTAGTTCAAGAGTGGCT ATCCAAACACCAGGGTAGCCAGTACGTTTGGAACAGGCAAGAGTTAATTCAAAAGTCCTTGGACCCTAGTGTTACCT ATTTGATGGGTCTATTTGAGCCAGTAGACACGAAGTTCGAAATACAACGTGACCCTCTGATGGACCCCAGTTTGAAG GATATGACAGAGGCTGCGCTTCACGTGCTTTCTAGGAACCCTAAAGGATTCTACCTATTCGTAGAGGGTGGCCGTAT AGATAGAGGGCACCACTTGGGTACCGCCTATCTGGCACTAACTGAGGCCGTCATGTTTGATTCTGCGATAGAAAGAG CATCACTACAAGCGTCTGAGCAAGACACCCTAACTATCGTGACGGCAGACCACAGCCACGTCTTTTCCTTCGGGGGGT ACCAACAACAAGCAGCGGTCCCTGTTAAAAGTGAGACAACTGTGGGAAAGGATGTGGCAATCTTTGCGCGTGGACCT CAGGCACACTTACTGCATGGCGTACAGGAGCAGAATTATATAGCACACGTTATGGCTTTTGCTGGGTGCTTGGAACC CTACACGGATTGCGGCCTAGCTCCACCTGCTGACGAGAATAGACCTACGACACCTGTACAGAACTCCACGACAACGA CTACGACTACTACCACACCACTACAACCACTACTACTAGAGTCCAAAACTCAGCTTCCTCACTTGGGCCAGCA ACCGCCCCTCTTGCTTGGCATTACTGGCCGCGTCGT

Seq. ID No: 279
>phosphatase 5

ATGTCAGGATCTAGCGTTACAGGCGGGGGTGCAAGCCTACCTGCGGAATTGTACAAGGGGTCCGCTGACTCAATCTT
GCCAGCCAATTTCTCTTATGCTGTTACGGGTAGCGGTACGGGTAAAAATGCGTTCCTGACGAACAACTCTAGCTTGT
TCGGTACAACCGGCACAGTTCATTACGCGGGGTCCGATTCTGTTCTGTCCGGCAGCGAATTGACCACCTACAATTCA
AACTACAATGGCACCTATGGTCCCTTAATCCAGATACCTAGTGTGGCGACTTCTGTTACCGTGCCGTACCGTAAAGA
TGGTAACACTACGCTTAATTTGACATCAGCACAATTGTGTGACGCATTTAGTGGAGCTAAGACAACTTGGGGTCAAC
TACTTGGCACAACTGACTCTACACCCCATTAGGATAGTCTATAGGACAGGGTCATCAGGGACTACCGAATTGTTTACT
AGACACTTAAACTCTATTTGCCCCACAAGGTTTGCGACAAACAGCACCTTCACCAATGCGAGATTACCCGCCGGAGG
GACTCTACCTAGTAATTGGGTTGGTGTAGCAGCTACGTCTACAGTAGTGAGCACGGTGAAAGCTACGAACGGCAGTC
TGGGTTATGTATCTCCTGACGCAGTTAACATAAATTCCAATGCGGAGGTTAGTAGGGTCAATGGAAACTTACCTACA
CAGGCCAATGTGTCAACCGCGTTGGGGTCCGTGGCACCCCCGGGCCAATGCGGCAGATCGTGCAGATCCATCAAAGTG
GGTCCCAGTATTCACAAATCCTAGTGCCGGTTATTCAATCGTGGGATATACTAATTTCGTGTTTTGGCCAGTGCTATA
AAGACGCCTCTGTCTCCACGGACGTTAGAGCCTTTATCAATAAGCACTATGGAGGCACAACCACCAATGCAGCGGTC
GCGGCGCATGGCTTCATTCCGTTGACACCAGCCTGGAAATCCGCTATAGTATCCGCCTTTTATACTGGTACGTCTGA
AAATTTAGCGATAGGCAATACAAACGTATGTAACACTAAGGGAAGGCCC

Seq. ID No: 280
>phosphatase 6

Seq. ID No: 281
>scaffold

ACCGAATTTGAATAGCTTGCAAGTAGTCGCCTTCATCAATTCCCTTCGTGACGATCCTTCTCAAAGTGCCAACCTTC GTAGATAATAAGTTTAACAAGGAGGCGCAAACCGCCGGGGTTGAAATAATGGAGTTGCCAAACTTGAATACACGTCA GCTATTGGCTTTCATTCAAAGTTTACGTGATGATCCCTCTCAGAGCGCGAATTTATTAGCGGAAGCTAAGAAATTAA ACGATGCTCAGGCCCCAAAGACAAGTGGAGGCTCCAGCGCGTCATCTGCAGGTGGATCAAGCGTGGATAATAAGTTC AACAAAGAGAGGAGGATGGCGGCCTACGAGATAATCGATCTGCCTAATCTAAATTGGTTTCAATTAGAGGCGTTCAT CCAAGGGATCAGGCTCTAACGCCGCAATTCGTTCTAGCGGGAGTGGGTCCGTAGATAACAAATTTAACAAGGAAAGA GTAATTGCTATTGGAGAAATCATGAGGTTGCCTAACCTTAACTCCCTTCAGGTAGTGGCATTTATAAACAGTTTACG TGATGACCCTTCACAGAGCGCAAACCTACTTGCAGAAGCCAAGAAATTAAATGATGCACAGGCGCCCAAAGGAGGGT CAAGTGCGTCCTCTGCAGGAGGGAGTAGTGTTGATAATAAATTTAATAAAGAAGCCCAAACAGCGGGTGTTGAAATT ATGGAACTACCGAACTTAAACACCCGTCAATTACTGGCATTTATTCAGAGCCTGAGAGATGATCCATCTCAATCCGC TAACCTCCTAGCTGAGGCGAAGAAACTTAATGATGCCCAGGCGCCAAAAACCTCAGGTTCAGGTTCAGCAAACGCTG CTATTCGTAGTGCAGGATCTGGAAGCGTAGATAAAATTCAACAAAGAACGTCGTATGGCTGCTTATGAGATCATC CCTACTAGCGGAAGCGAAGAAGCTAAACGACGCTCAAGCTCCTAAAGGTTCAGGGGCGTCTGGTTCTGGTGCGGGCG GCAGTTCCGTAGATAACAAATTTAACAAAGAAGAGTTATCGCCATAGGGGAAATTATGCGTCTGCCGAATCTGAAT AGTCTGCAAGTCGTCGCATTTATAAACTCTTTACGTGATGATCCCAGCCAATCTGCGAATTTACTGGCAGAGGCTAA GAAGCTAAACGATGCGCAAGCCCCGAAGGGCTCTGGCGCGTCTGGTAGTGGGGCAGGTGGGAGCAGCGTAGACAACA AGTTTAACAAGGAGGCCCAGACTGCAGGAGTCGAAATCATGGAATTACCTAATTTGAACACCAGACAGCTGCTGGCG TTTATACAATCTCTTAGAGATGATCCTAGCCAGTCCGCTAATTTACTAGCCGAGGCCAAAAAGTTGAATGACGCACA GGCACCGAAGACAAGTGGTTCCGGGTCCGCTAACGCAGCGATAAGGTCCGCGGGTTCCGGATCTGTGGACAATAAGT TTAATAAAGAGCGTAGGATGGCCGCGTACGAAATAATCGATCTTCCTAATCTAAATTGGTTTCAGTTAGAGGCCTTT ATTACTAGCCTTTCCGATGACCCCAGTCAGTCAGCGAACCTATTAGCGGAGGCCAAAAAGCTGAACGACGCGCAGGC ACCTAAG

Seq. ID No: 282

>sec 1

ATGCAGCTATTAAGGTGTTTTTCTATTTTCTCAGTTATAGCCTCCGTGTTGGCCCAAGAGCTAACTACCATCTGCGAGCAGATCCCATCTCCTACGCTAGAATCAACCCCATATAGTTTATCAACGACCACAATCTTGGCTAATGGCAAA

Seq. ID No: 283

>sec 2

ATGCTATCTTTGAAAACGCTGCTGTTACGCTGTTAACGGTTTCATCAGTTCTAGCCACACCCGTACCCGCTCGTGA
TCCATCCTCTATTCAATTTGTCCATGAAGAAAATAAGAAGCGTTATTATGATTACGATCATGGAAGCCTTGGTGAA

Seq. ID No: 284

>sec_3

Seq. ID No: 285

>sec 4

ATGGAGGGCGTGTCACTAGAAAAACGAGAGGCTGAGGCA

Seq. ID No: 286

>sec_5

ATGAAAAAGACAGCGATTGCTATAGCGGTAGCCTTGGCGGGCTTTGCCACAGTCGCTCAGGCC

Seq. ID No: 287

>vac_1

ATGTTCTCTTTGAAAGCTCTACCACTTGGCTTTGTTGTTGGTAAGCGCAAATCAAGTTGCAGCGAAGGTTCATAA GGCTAAAATATATAAACACGAACTGTCA

Seq. ID No: 288

>vac 2

ATGACGAAGAACTTTATTGTTACACTGAAAAAGAACACTCCAGATGTCGAGGCGAAAAAGTTCCTGGATAGTGTACA TCACGCAGGGGGTTCCATAGTACATAAATTTGACATAATTAAGGGCTATACAATAAAAGTTCCAGATGTGTTGCACC TAAACAAACTAAAAGAGAAACATAATGACGTGATAGAGAACGTGGAAGAGGACAAGGAGGTCCACACCAAT

Seq. ID No: 289

>vac_3

ATGGAAGAGCAGAGGGAAATCCTTGAGCAATTAAAGAAGACATTACAAATGCTAACTGTGGAGCCTAGCAAGAACAA CCAAATCGCAAATGAGGAGAAAAAGGAAAAAGGAAAACGAGAACTCCTGGTGCATTCTTGAACACAATTATGAAGACA TCGCGCAGGAGTTTATTGATTTTATCTATAAGAATCCCACCACCACCACCATGTCGTTTCATTCTTCGCAGAATTACTT GACAAGCATAATTTCAAGTACCTATCTGAGAAGAGCAACTGGCAGGACAGTATCGGCGAAGATGGCGGT

Seq. ID No: 290

>6xHIS

Seq. ID No: 291

>AADC_1

METVNKSCCSLATPHLPLMSPHLLHSHRDSPVLKIIHSIVLTVQNNHSCLQAFLGIGTDNVILVKTNDRGKMIPEDL DHKIQKVKSEGSVPFLVSTTCGTTVFGAFDPLEGIADVCERHSLWLHVDAAWGGSALLSSRHRHLLKGIERADSVTW NPHKLLGVGLQCSAFLLRDTTQLLERCHAANATYLFQTDKFYNLQYDTGDKSIQCGRRVDCLKLWLMWKALGSKGLE TRVDRVLDHTRYLVEEMKRREGFRLIMEPEFVNLCFWYVPPSLRNKENSPDFWTRLGKVAPVIKERMMKKGSMMVGY QPHGNMVNFFRQIVVNPEVTKEDLDFFLDEIERLAEDL

Seq. ID No: 292

>AADC 2

MWGCGNGDCIHVLLLISHTSPPPLSPHLLHSHRDSPVLKIIHSIVLTVQNNHSCLQGHVPFYVSATAGTTVYGAFDP FVKIADICQKHGLWMLHVDAAWGGGLLMSRKHRHKMNGIERADSVTWNPHKMMGVLLQCSAILLKEKGILQGCNQMC AGYLFQQDKQYDISYDTGDKAIQCGRHVDIFKFWLMWKAKGTVGFEQQINKCLELSEYLYSKICNREDFEMVFKGEV SLHRLEEGIK

Seq. ID No: 293

>AADC_3

METVNKSCCSLATPHLPLMSPHLLHSHRDSPVLKIIHSIVLTVQNNHSCLQGHVPFYVSATAGTTVYGAFDPFVKIA DICQKHGLWMHVDAAWGGGLLLSKKHRTKLSGIERANSVTWNPHKMMGVPLVKDNMDLLKRCHSAEASYLFQQDKFY DVRYDTGDKSIQCSRRADAFKFWMMWKALGTLGLEERVNRALALSKYLAKEIKKRDGFELIWEPEYANICFWYIPPS LRKMENKGPEYWQRLNQVAPTIKERMMKKGSMMIGYQPHRDKVNFFRHIIISPQVSREDMDFVLDEIDLLGRDL

Seq. ID No: 294

>AADC 4

MNASEFRRRGKEMVDYVANYMEGIEGRQVYPDVEPGYLRPLIPAAAPQEPDTFEDIINDVEKIIMPGVTHWHSPYFF AYFPTASSYPAMLADMLCGAIGCIGFSWAASPACTELETVMMDWLGKMLELPKAFLNEKAGEGGGVIQGSASEATLV ALLAARTKVIHRLQAASPELTQAAIMEKLVAYSSDQAHSSVERAGLIGGVKLKAIPSDGNFAMRASALQEALERDKA AGLIPFFMVATLGTTTCCSFDNLLEVGPICNKEDIWLHVDAAYAGSAFICPEFRHLLNGVEFADSFNFNPHKWLLVN FDCSAMWVKKRTDLTGAFRLDPTYLKHSHQDSGLITDYRHWQIPLGRRFRSLKMWFVFRMYGVKGLQAYIRKHVQLS HEFESLVRQDPRFEICVEVILGLVCFRLKGSNKVNEALLQRINSAKKIHLVPCHLRDKFVLRFAICSRTVESAHVQR AWEHIKELAADVLRAERE

Seq. ID No: 295

>AADC 5

MASGYPGAGAQQPPAAPASGSGSPVSMPYYASELARAKHEDDMKMPEHGIEPRHCLRRIEDYHLLDFSERLNTSSYV NVVFEPEEETVANMGLKVNLADQTVYPESFRMHNDTVNMIAKLWNCPKPADFDEYGCYAGAGTVGSTEACLLGGLAL KFRWRKWYAAKHGMDQNKVRGVYPNLVITTMFQAAWEKLFKYMDIEPRFVTPSWKTFTMDPSGLEKVVDDKTIGVVC IMGNHYGGQYDPVWEVNDVLEKINKEKGLQVGIHVDGASGGFIAPFQEGLPAWDFRLKNVLSISASGHKFGNSCCGT GWIIWRERKGLSDTVAINVSYLGGSADSYTLNFSRPAQGVYVQ

Seq. ID No: 296

>AADC_6

MAGSIDVMLRDLNLDTVESLPADFDPTTVINDILPPVVNDAKLVNGIEKPREIVLGRNVHTSSLEVTEPDADDEVTG EREAYMASVLARYRKSLLERTKHHLGYPYNLDFDYGALSQLQHFSINNLGDPFIESNYGVHSRQFEVGVLDWFARLW ELERNEYWGYITNCGTEGNLHGILVGREVFPDGILYASSESHYSIFKAARMYRMDCEKVNTLISGEIDCEDFKAKLS LHKDKPAIINVNIGTTVKGAVDDLDLVIKTLEESGFSHDRFYIHCDGALFGLMMPFVKLAPKVSFKKPIGSVSVSGH KFVGCPMPCGVQITRLEHINALSRNVEYLASRDATIMGSRNGHAPLFLWYTLNRKGYRGFQKEVQKCLRNAHYLKGR LTEAGIGAMLNELSSTVVFERPQDEEFTRKWQLACQGNIAHVVVMPNINIDKLDHFVNELVERRAVWYENGKLKSPC VASEIGNSNCLCALHK

Seq. ID No: 297

>AADC 7

MVRAVEKPVQAIVNAAFRGKDAYHVFRTTVLAAVLLRLWRHLRRVMAHEGLKAYFMSLVAPHLKKLPYVQNKLKKEM DKTMTKMRNTFRKEVTDPRTSLPVDGIPEKQILELIQHRKELDTKEWTKGMTTGCVYHGGQDHYDFVGQIFASWGFA NPLHPTTFPSLRQMDSEVVQMVINMYHGDSECCGAFTTGGTESILMAMKAYRDWGKAEKGITDPNIVICNTAHAAFD KAGKYFNIFVKHARTNSEMEIDLGHLRSLIDSNTVAIVGSACQFSHGTVDPIQEMAKIAMKRRVGLHVDCCLGGFLV PFMEKAGFQLPPFDFRVKGVTSISCDPHKYGFAPKGSSVVMFSNRHLRHYMYCFLTEWSGGIYATATMTGSRAGGPV AATWASMCKFGEKGYIETTKQIVGATKKIAAGIAEIEGLRVVGRPDVCVVAFTCTEGSGMNCYAVGDCMHQDFHWEL QSCQNPACVHLALTLPTSRNADKFVADLRQAVEAVRSDKDGKFASTAGMYGTAASLPAAFFEDGAAAYLDAMCEAIP AGDALLPEEPATKESPAAAGAPAQATGGA

Seq. ID No: 298

>AADC 8

MNASEFRRRGKEMVDYVITNYLEQIELRQVYPSVEPGYLRPMIPDSAPEEGETYEDIMKDIERVIMPGVTHWNSPYF FAYFPAATSYPAMLADMLCGSLGCIGFSWAASPACTELETVMLDWLGKTIGLPEQFLAGTNGEGGGVIQGTASEATL MALLAARTKVTRRLQAENPDLSEAEIISRMVAYSSDQAHSSVERAGLISGVRMKKIPSDENFTARGEALKKALEEDK AEGFIPVFLCATLGTTTSCAFDNLMELGPICNAENMWLHIDAAYAGSAFICPENRYLMKGVEFADSFNFNPHKWLLV NFDCSAFWVKKRSDLICAFKIDPVYLQHDQQESGLVTDYRHWQIPLGRRFRSLKLWFVLRMYGVKGLQAHIRKHIRL

AQEFHEFVKNDDRFEICAPVILGLVCFCLKGSNTLNKSLLQKINTLKKIHLVPSCLGDKFILRFAVCARTLESNHIV FAWKHIEELATEVLKEGEKO

Seq. ID No: 299

>AADC 9

MQNCNQMHASYLFQQDKHYDLSYDTGDKALQCGRHVDIFKLWLMWRAKGTTGFEVQIDKCLELAEYLYDKIKNREGY ELVIEGKPQHTNVCFWYIPPSLRHMEDNEERMARLVKVAPVIKARMMEYGTTMVSYQPLGDKVNFFRMVISNPAATH QDIDFLIDEIERLGQDL

Seq. ID No: 300

>AADC_10

MWGCGNGDCIHVLLLISHTSPPPLSPHLLHSHRDSPVLKIIHSIVLTVQNNHSCLQGHVPFYVSATAGTTVYGAFDP FVKIADICQKHGLWMHVDAAWGGGLLLSKKHRTKLSGIERANSVTWNPHKMMGVPLFQCSAFLLRDTTQLLERCHAA NATYLFQTDKFYNLQYDTGDKSIQCGRRVDCLKLWLMWKALGSKGLERRVDRVLDHTRYLVEEMKNREGFRLIMEPE FVNLCFWYVPPSLRNKENSPDFWTRLG

Seq. ID No: 301

>AADC 11

MGSLGTNPTSFSAFPDDKAAFEPLNPEDVRAYLHKAVDFISDYYTNVESMPVLPNVKPGYLQDELTASPPTHSAPFD VTMKELRTSVVPGMTHWASPNFFAFFPSTNSAAAIAGDLIASAMNTVGFTWQASPAATEMEVLALDWLAQLLHLPTT FMNRTSTGRGTGGGVILGTTSEAMLVTLVAARDAALRRSGSVGVSDIPRLAVYAADQTHSTFFKACRLAGFDPANIR SIPTGPETNYGLDPAKLLEVMQADADAGLVPTYVCATVGTTSSNAVDPVGAVADVAAMFNAWVHVDAAYAGSACICP EFRHHLDGVERVDSISMSPHKWLLTCLDCTCLYVRDAHRLSDSLETNPEYLKNDVTDSGEVTDLKDMQVGVGRRFRG LKLWMVMRTYGTAKLQEHIRSDVAMAKMFEDSVRADNRFEVVVPRNFALVCFRIKARGDMTEEDADEVNRLLMENLN KTGKAYLAHTVVGDRFVLRFAVGSSLOEERHVRSAWDLIKKTTSSIMD

Seq. ID No: 302

>AADC 12

MDPLKAVEMVDENTICVAAILGSTLTGEFENVKLLNELLTKKNKDTGWDTPIHVDAASGGFIAPFLYPDLEWDFRLP LVKSINVSGHKYGLVYPGVGWVVWRSKGDLPDELIFHINYLGSDQPTFTLNFSKGNNISTHAYKKPKCRFYFLTNQI LSRRYLLHRLKSGTSLNSLL

Seq. ID No: 303

>AADC 13

 ${\tt MQPGYLSRMLPDSAPNHPESLEDIFNDISAKILPGVTHWQSPNYFAYFPSNSSIAGFLGEMLSAGLNIVGFSWITSPAATELEMIVLDWLAKLLKLPDDFLSGGTS}$

Seq. ID No: 304

>AADC 14

MVVDYKDWQIPLGRRFRSLKLWMVLRLYGIENLQCYIRNHIKLAQQFEVLVAQDLRFEIVSPRIFSLVCFRLLPSQN CKDHGNELNHHLLDTVNSTGKVFLSHTVLSGKYILRFAVGAPLTEERHVTAAWKVLQDEASALLQSL

Seq. ID No: 305

>AADC 15

MGSLDIKQESSPLMTNPLDSEEFRRQGYMVIDFLAEYYKNIQKFPVRSQVEPGYLRKRLPESAPYEPESIERILKDV HDDIVPGLTHWQSPNYYAYFPSSGSTAGLLGETLAAGFNVVGFNWISSPASTELESIVMDWLAEMLNLPKSFTFSGD GGGVMMGTTCEAILTTITAARDRILDRIGREHINKLVVYGSDQTHCSFFKSAKIAGILPNNFRQVKTSRVNAFSMRP DALRAAIQADADAGLVPFFLCTTVGTTSTAAVDPVALLCEVTKDYGMWVHIDAAYAGNACICPEFRHMINGVENADS FSFNAHKWFLTTLDCCCLWVKDPSSLVRCLSTNPEYLKNKATDTQQVVDYKDWQITLSRRFRSL

Seq. ID No: 306

>AADC 16

MDGQMLKPMDAEQLREYGHQMVDFVADYYKTIESFPVLSQVQPGYLRELVPTNPPTHPESLQDVLDDVKAKILQGVT HWQSPGYFAYFPCNSSTAGFLGEMLSAGINIVGFSWMSCPAATELEVIVLDWLSKL

Seq. ID No: 307

>AADC 17

MVLRLYGQEGLQSYIRNHIALAKQFEELVIQDSRFEMVTPRRFSLVCFRLLPRSTDENQADKLNRALLDAVNLTGAI FISHTVLSGMYVLRLAVGAPLTEERHVIAAWKVLQEKATALLEGNVAQEPNGHAQLSNGVVELDGALDNGVTTEQHG HVDDLPIKSK

Seq. ID No: 308

>AADC 18

MSLSRHIDAERLIEQIKEHPHKKHSSAESRRGLHRSWRRDEDAADLPKYTLPKHGINSKAAYQLLHDETALDGNPLL NLASFVHTWMPEDADKLIMENINKNIVDMDEYPAASLIHNRCISMLADLWKAPKEGKVIGTATAGSSEAIMLGGLAL KKRWQEARKAAGKDYFHPNIVFGSNAQVALEKFARYFDVETRLVPVKEENGFVMNPHDAIPYIDENTIGVIVILGST YTGHFEDVKLMSDLLDDLEKRTGLDVKIHVDGASGAFIAPFAYPHLKWSFDVPRVVSINTSGHKFGLVYAGLGWVLW RDESFLHRDLVFELHYLGSTEYSFTLNFSKPAAPVIAQMFNFLNLGFEGYKKIAYKDMRNARMLSRALESTTYFKVF SNIHVPRNSDSAHVSSNNKDDPETYHAGLPVVAFRLSDEFNQNYPNVRQVWIQTLLRTKGWIVPNYNAPLGAENIEI LRIVVRETLSEDLIERLIVDIVAVTESLTTEEGNVFAGITASGAVVKPDLDEARPDSSNFNDSGDGEAQGQTGYSRQ C

Seq. ID No: 309

>AADC 19

MALSKHVNTDKLIRDSRDKKSPKEKAHHTATAHQEATYSYGDRYVTNPVPKYNIASKGISADAAYRLIHDELALDGS TVLNLASFVHTWMPPQGEQLVHENIAKNLIDSDEYPATQIIHTRCVSILADLWHAPSAKQAVGTATTGSSEAIQLGG LAMKKMWQARMKAAGKNIHEPGPNIVMGANAQVALEKFARYFDVECRLVPVSVESKYRLDPKKAMDFVDENTIGIFI ILGSTYTGHYEPVKEMSDLLDEYEKRTGIYVPIHVDGASGGFVAPFVHPKMVWDFKLPRVVSINTSGHKFGLSYVGV GWVVWRDKAHLPKDLIFELHYLGSVEYSFSLNFSRPAAPILAQYFNLVHLGFEGYRSVGLADMKNARELSRALEKTG YYTVLSDIHRAVGAKDPHGIDDADIEAYEPGLPVVAFRFSDNFKEKHPEIQQKWIQTLLRAKGWIVPNYELPPSLEQ IEILRVVVRENVTEVLIDKLIDDIVEITEQLADSSSSMHSLNNLGHIQRPKKHEHPESNLKEGEGSDYSGTYARPC

Seq. ID No: 310

>AADC 20

MALNAVSAARGSARQYISTFLTLDNAKSGLFYYVLLVQAIKVKRHLRARGISASLKELYTWISQQIIRLLLRLPATR KKVASQMDQAKLDIENRLVPKGANVTRHLSLPSEGKSLEWITQEMDKMDTELGGTSDAWRQGKLSGAVYHGGDELAK IIVAAYSRYCVSNPLHPDVFPAVRKMEAEIVAMCLKMYRGPEGAAGAMTSGGTESIVMSVKTHRDWARSVKGIKEPE MVVPVSAHAAFDKAAAYLGIKLHSIPVDSYTRQVNIKHVKRAINSNTIMIVGSCIGFPDGNQDDIEALGALAKKYNI GLHVDCCLGSFIVPFLEPAGLAKGDNKGRYKLTPFDFTVDGVTAISCDTHKYGFAPKGTSVIMYRSAELRRFQYYVN PIWPGGVYASPSLSGSRPGALIAGCWAVMQYMGTEGYLSSCRDIVIATRKIADAITDDIPELYVLGNPPASVVAFGS RNPTVDPLEVGDGMRKRGWHLNGLSSPKSVHIACTRLTLPVVDQFIADLKDCVREAKVAPSGKGTMVSVYGLGNSSA VGPDMVSQLASAFLDALYKA

Seq. ID No: 311

>AADC 21

MELKTAANEICNSNQMCQGENYSQNMLLRDGLIDLKNQIKEGDEGLGHGFSDFSNVFASDLLPARNGEKYTEGFLLE VFNILFSYIRKTFDRKSKVLDFHHPHQLLEGLEGFNLELSDQPEPLEQILGDCRDTLKYGVKTAHPRYFNQLSSGLD MVGLAGEWLTGAANTNMFTYEIAPVFIIMEGLLIKKMHELVGWGELEADGIFSPGGTISNLYSVLVARYKFFPIVKL KGMAALPRIVLFTSEHSHYSFQKASATLGIGIENVIAVKCDERGKMIPSDLDEKIMAQKEK

Seq. ID No: 312

>AADC_22

MWKAKGTRGFELQIDSCLENAEYLYKKLKSRNGFELVFPDEPEHTNVCFWYIPPSLKGMPRDKEWNTKLHKVAAKIK AOMMEEGTVMVSYOPLKNKPNFFRMVFSNPASKKSDIDFLLDEIERLGSDLEF

Seq. ID No: 313

>AADC 23

MFGSQHQMDVAALDRQLKEDKESGKLPLLLVANAGTPGAGHTDKLARLKELCHQYNIWLHVEGVNLATLALGYVSAS VLAATKCDSMTLTLGPWLGLPAVPAVTLYRHEDPSLSLAAGLTTSQPVEKLRALPLWLSLQYLGHNGIVERIKHASQ LSQRLLENLKDVTSIKTSVEPDGNSPVVVFKFFYDGPGSGSTINLNTIERESDAMNQWLGEQLAALIPSCAVDTVEL EDEGVCVRFNPMMTSAVLGTTIEDVDQLVECVKVKIPIIHNTLQLKEEFRLEVERIAGLTYVVDYSWAGLGVLRYDH VSEELDGSRREAELEKINASLLKKLNELESDLSFSSGPEFGAEKNCVYIGMATEDVDVSELVETIAVMGREIEENSK LLENMTEVVRKGILEAEVQLQKANEERLLEEGVLRQIPLVGSVLNWLSPVQATPKGRTFNLTAGSLESTEITYASKA QANGTSPPPTPSLGHAKRHPGQKLFKRLSRNSDAMSETSSVSHLEEVENLEASPTPEPQPGHPTEPPVPSVESNSEE PHEAEALDTKTVESESLR

Seq. ID No: 314

>ADK1

MSSSESIRMVLIGPPGAGKGTQAPNLQERFHAAHLATGDMLRSQIAKGTQLGLEAKKIMDQGGLVSDDIMVNMIKDE LTNNPACKNGFILDGFPRTIPQAEKLDQMLKEQGTPLEKAIELKVDDELLVARITGRLIHPASGRSYHKIFNPPKED MKDDVTGEALVQRSDDNADALKKRLAAYHAQTEPIVDFYKKTGIWAGVDASQPPATVWADILNKLGKD

Seq. ID No: 315

>A00S 1

MSNAAIRSSRAVSVSSSTKYYDFTVIGSGVAGLRYALEVAKQGTVAVITKDEPHESNTNYAQGGVSAVLCPLDSVES HMRDTMVAGAHLCDEETVRVVCTEGPERIRELIAMGASFDHGEDGNLHLAREGGHSHCRIVHAADMTGREIERALLE AVLNDPNISVFKHHFAIDLLTSODGLNTVCHGVDTLNIKTNEVVRFISKVTLLASGGAGHIYPSTTNPLVATGDGMA MAHRAQAVISNMEFVQFHPTALADEGLPIKLQTARENAFLITEAVRGDGGILYNLGMERFMPVYDERAELAPRDVVA RSIDDQLKKRNEKYVLLDISHKPREKILAHFPNIASECLKHGLDITRQPIPVVPAAHYMCGGVRAGLQGETNVLGLF VAGEVACTGLHGANRLASNSLLEALVFARRAVOPSTELMKRTRLDVCASEKWTRPVVATARLLGDEVIAKIIALTKE VRRELQEVMWKYVGIVRSTIRLTTAERKIAELEAKWETFLFEHGWEQTVVALEACEMRNLFCCAKLVVSSALARHES RGLHYMTDFPFVEESKRIPTIILPSSPTTASWSSRRLQNISSSSLIDCGSGEGRGSLLTCGDVEENPGPSSSSSSOT TELVPYKLQRLVKEFKSLTEPIDRLKWVLHYASLLPQMPESSKTESNRVMGCTARVWLDAELGQDGKMRFCADSDSD VSKGMCSCLIQVLDEASPVEVMELKTEDLAELNVGLLGGERSRVNTWYNVLVSMQKKTRRLVAEREGKVPSFEPFPS LVLTAHGIEAKGSFAQAQAKYLFPEESRVEELVNVLKEKKIGVVAHFYMDPEVQGVLTAAQKHWPHISISDSLVMAD SAVTMAKAGCQFITVLGVDFMSENVRAILDQAGFEKVGVYRMSDETIGCSLADAASAPAYLNYLEAASRSPPSLHVV YINTSLETKAFAHELVPTITCTSSNVVQTILQAFAQMPELTVWYGPDSYMGANIVKLFQQMTLMTNEEIANIHPKHS LDSIKSLLPRLHYFQEGTCIVHHLFGHEVVERIKYMYCDAFLTAHLEVPGEMFSLAMEAKKREMGVVGSTQNILDFI KOKVOEAVDRNVDDHLOFVLGTESGMVTSIVAVIRSLLGSSANSKLKVEVVFPVSSDSMTKTSSDSSNSIKVGDVAL PVVPGVAGGEGCSIHGGCASCPYMKMNSLSSLLKVCHKLPDLENVYGGFIAERFKRQTPQGKLIADVGCEPILHMRH **FQANKELPDKLVHQVLSCESKR**

Seq. ID No: 316

>A00S 2

MNTLPEHSCDVLIIGSGAAGLSLALRLADQHQVIVLSKGPVTEGSTFYAQGGIAAVFDETDSIDSHVEDTLIAGAGI CDRHAVEFVASNARSCVQWLIDQGVLFDTHIQPNGEESYHLTREGGHSHRRILHAADATGREVETTLVSKALNHPNI RVLERSNAVDLIVSDKIGLPGTRRVVGAWVWNRNKETVETCHAKAVVLATGGASKVYQYTTNPDISSGDGIAMAWRA GCRVANLEFNQFHPTALYHPQARNFLLTEALRGEGAYLKRPDGTRFMPDFDERGELAPRDIVARAIDHEMKRLGADC MFLDISHKPADFIRQHFPMIYEKLLGLGIDLTQEPVPIVPAAHYTCGGVMVDDHGRTDVEGLYAIGEVSYTGLHGAN RMASNSLLECLVYGWSAAEDITRRMPYAHDISTLPPWDESRVENPDERVVIQHNWHELRLFMWDYVGIVRTTKRLER ALRRITMLQQEIDEYYAHFRVSNNLLELRNLVQVAELIVRCAMMRKESRGLHFTLDYPELLTHSGPSILSPGNHYIN RGSGEGRGSLLTCGDVEENPGPGSVMFDPDTAIYPFPPKPTPLSIDEKAYYREKIKRLLKERNAVMVAHYYTDPEIQ QLAEETGGCISDSLEMARFGAKHPASTLLVAGVRFMGETAKILSPEKTILMPTLQAECSLDLGCPVEEFNAFCDAHP

DRTVVVYANTSAAVKARADWVVTSSIAVELIDHLDSLGEKIIWAPDKHLGRYVQKQTGGDILCWQGACIVHDEFKTQ ALTRLQEEYPDAAILVHPESPQAIVDMADAVGSTSQLIAAAKTLPHQRLIVATDRGIFYKMQQAVPDKELLEAPTAG EGATCRSCAHCPWMAMNGLQAIAEALEQEGSNHEVHVDERLRERALVPLNRMLDFAATLRG

Seq. ID No: 317

>ATMT 1

MTPAAGKTFNTSIAGADDLIRLHLSESPHGASKAALQAAERELARVNVYPDPERQELVRALAAHWGVGPEHIAVANG SDELVLATALTLGDRNLPGLVTDGTFPGYRACLELLGRGCTAVPPDGTAVDVAGFAARLPGHGIGYLCNPHNPSGAA LTRQELAALVEVSGRSGVPLVFDEAYMEFAGPDVPQTRDLTAAGDAPVVALRTFSKAYGLAALRVGYAVGRPDLIAG LRGTLRALPFSVNRLAQAAAIAALGDPDFVDGVRRSTAERRRWFVGELDRRGRAHLPSVTNFVAVAARDCARAQDRL AADFGILVRNAGLFGFPGYLRTSLGEKKDLERFLDALDEIEQNPGGGSGEGRGSLLTCGDVEENPGPMTAPLSRDGL RAMGESVFRPAEWQGAAHTPLDADTAFNGFISTHVVFALEQLGLFAWFDESDRLDVPQYCWRRKLDERVFRQLVSAA EAFGYLDVHDDLVTPTPAWSELRRKIGFFTWGVGGYHDVFANAASIARGERAFGKDVLRDEAMVALGSAQADMALMR DLLDEQIAALDFSVIADLGSGISERVCRLVKSRPGARGLGVDISASATALAAGTVERHELADRVQPICADVLDVLFH GRRIEGADQVDVAMSFMFLHDLLVDPTTRTDVIPALRKAFPRAHTFLLADTTVRPRDEKDTLPVFSSGFELAHALMG VPIYTREEYENLFHEGGLHLRRTVPFGAPHTYLFVLEAO

Seq. ID No: 318

>ATMT 2

MQALPVKGDTVSRPPTVHSLHHEHERADGMLRLHCNENPYGPPSGVIASVTKELEGRCSTYPDSEVTALREALAGQV GVGTDMVAVGNGADELVLLITLASAGPGDTVVVTESTFPGYAASAAVAGATVRGVPLHRDRVSATALVEAVDDGARL VFVCNPHNPTGTVLSPAAVEEILRACERTGAVPVFDEAYIEFAGPGFDHALDAVRAGRRLLVLRTFSKAWGLAALRA GYAVGPADLVAGIMEARRPLPFSVNRLAQQAALAALGSPDHIAEVYERTTRERERLCRALTGLGVAYVPSVTNFVMV KTPGNSTRFASRLADEHGILVRDLAPFGYPGHVRVSVGTAEDTDQFCAALGSLLASPRSHAATGHGLGASSGAGGAG NAAIRSARDVLPVPTLDPVAPQDLFNGYVGAHAVFALTRLGVWDRLAEGSEPTVDALAVQAGTDATGLMPLLRVAAL LGYVSLTDGSAPAVRLTESGRELVRMRGFFTWGVGGYHEVLRSLPALARGTSVFEQDVDRDGGMVAVGSGEVGREMM LPLEQEVLATVDFRTVADLGCGDATRLLRLCDGHPHRRGTGIEINQGACVQANKRVADAGLADRVDIVHGDALDLSG RTFPEVDLVTSFLMMHDLFDATGDPVGVMRTLREVFPRARHFLIGDTVAQDWEERREGLPMFSVGFELVHAFMDTPI MNRGTYEDAFAGAGLRVARREPLGAPSTWLWLLSTE

Seq. ID No: 319

>ATMT 3

MRRRWAVTASASWWGTACELHASASAAYTPPCHSPGTGGRGTESGPMTAPVRQETRNYNASVPSADDLVRLHLSESP YGASPAAVAAVTGELERINRYPAPGREGLVQALARHWELPEEHIAVANGSDELVLATALTLGDPGSPGLVTAGTFPG YLAALERIGRGAVQVPLAGSGTDTAAFADRLPGCGIGYVCNPHNPCGSALTHDELHRLVAAARDSGTPLVFDEAYHE FGPPAQPQARTHLREDTPVLALRTFSKAYGLAALRIGYALGPADLIAEVRRTLTVLPFSVNRAAQAAALAALDDQEF LGSVRRDSAARRQWFCAELERRGYRYLPSVTNFVAVEVAASAEAQDVLARDHGILVRDTGMFGFPGHLRVSLGSVEE LRGFLDALDRVTAGSRGGGSGEGRGSLLTCGDVEENPGPMTGPVSTSAPSRWPRTWRPNRLEPTSRGGQPGHAARRS PAAGRRRRASEARPPPSGRQPAVRTERCERVSPLNTLPSEWQGQAPTPLNPDTAFNGYICANVLHGLERLGVFELL RDEKSLDMDRFCETNGLDSAVFRALVGAAESFGYLDVRGAQVRATSVGEDVARYLGFFTWGVGGYHDIFASAAPVAR GERRFGVDLHRDEGMVALGSAQADTALMRHILDEEIAGIDFRTLVDLGAGVSERVSRLVKARPGTRGIGIDISRPAT ELARDTVAGYGLAGTVEPVCADVLDILFNGQEIDGGDAADVVMSFMFLHDLLAAPERREEVVPRLRKAFPRAHTFLL ADTTIRPRNEEGDGRLPVFSSGFELAHALMGVPLHTREEYEELFERGGMKLRRSVPFGAPHTYLFVLEAS

Seq. ID No: 320

>ATMT 4

MTNDPSPRDARDELPVRDELRGQSPYGAPQLDVPVRLNTNENPYPLPEALVERIAERVREAARSLNRYPDRDAVELR TELARYLTRTAGHEVTAAHVWAANGSNEVLQQLLQTFGGPGRTAIGFEPSYSMHALISRSTGTGWISGPRNDDFTID VDAARAAIAEHRPEVVFITSPNNPTGTAVRAETVLALYEAAQAARPSIVVVDEAYGEFSHHPSLLPLIEGRRHLVLS RTMSKAFGAAGLRLGYLAADPAVVDAVQLVRLPYHLSSVTQATALAALEHTDTLLGYVAQLKGERDRLVAELRAIGY EVTESDANFVQFGRFDDSHAVWRQILDRGVLVRDNGVPGWLRVTAGTPEENDAFLDAVRELKKEHDAGGGSGEGRGS

LLTCGDVEENPGPSSSSSTRTDFAQSAVASIFTGAIASHAAVLADDLGLFDALAKGKLRNRDLDRSPWLRNRIRISG ALEALCRVGAVQRCTDGYELTDVGTELAGQVPVFRLWLGGYASVLAGQISIGADPATGVHGGIVAESSGAIGARYLD ETIVNLLESLRPEGRICDIGCGTGARLLRVCRRVNQPGIGYDLSAKAVEAARETVDEARRIGVDIDVRQGDATALTQ DHPDVDIVTQAFMTHHIAPDEYCAAVLRSYRSRFPRARYLVIFDTVPSQDSEEPEIFAPGFDYIHALQNMEPRSRGA ARRMFTEAGYICREEVELAVPNSYAWVLEMRDREGPAS

Seq. ID No: 321

>ATMT 5

MTNDPSPRDARDELPVRDELRGQSPYGAPQLDVPVRLNTNENPYPLPEALVERIAERVREAARSLNRYPDRDAVELR TELARYLTRTAGHEVTAAHVWAANGSNEVLQQLLQTFGGPGRTAIGFEPSYSMHALISRSTGTGWISGPRNDDFTID VDAARAAIAEHRPEVVFITSPNNPTGTAVRAETVLALYEAAQAARPSIVVVDEAYGEFSHHPSLLPLIEGRRHLVLS RTMSKAFGAAGLRLGYLAADPAVVDAVQLVRLPYHLSSVTQATALAALEHTDTLLGYVAQLKGERDRLVAELRAIGY EVTESDANFVQFGRFDDSHAVWRQILDRGVLVRDNGVPGWLRVTAGTPEENDAFLDAVRELKKEHDAGGGSGEGRGS LLTCGDVEENPGPAQAAPTTVTEVFNHAITASAISAAWEMGAFDALRVSERLDADEFAAREGLDTRSTHELFRALAA ADIVSRDGAQIRRGPNFAEADRCKSLFHWMTRGCGELFSTLPALVREKNRVGSFYRRDAAAISVACREINAEWWDPV FWPVVSGLDFTSVADLGCGSGERLIRLARTGPEVMALGIDFAAGAIEVATAAVAEAGLSDRISLVQGDATALEPRPE FAGVDLLTCFMMGHDFWPRAEAVASLRRIREVFPDLKHFLLADATRTTSYPDTDMPVFSMAFELAHAVMGDYLPTLE EWRPVFEEAGWRCEGEHPISVPADSVMFHLVPN

Seq. ID No: 322

>ATMT 6

MTNDPSPRDARDELPVRDELRGQSPYGAPQLDVPVRLNTNENPYPLPEALVERIAERVREAARSLNRYPDRDAVELR TELARYLTRTAGHEVTAAHVWAANGSNEVLQQLLQTFGGPGRTAIGFEPSYSMHALISRSTGTGWISGPRNDDFTID VDAARAAIAEHRPEVVFITSPNNPTGTAVRAETVLALYEAAQAARPSIVVVDEAYGEFSHHPSLLPLIEGRRHLVLS RTMSKAFGAAGLRLGYLAADPAVVDAVQLVRLPYHLSSVTQATALAALEHTDTLLGYVAQLKGERDRLVAELRAIGY EVTESDANFVQFGRFDDSHAVWRQILDRGVLVRDNGVPGWLRVTAGTPEENDAFLDAVRELKKEHDAGGGSGEGRGS LLTCGDVEENPGPSTEVSEAQARRAVADIFNSTLASSAIGAAWELGALDELRENGKLDVSDFAVRHDLHEPAVVGMF TALASVGIVRREGATVVVGPYFDEANHHRSLFHWLNQGSGELFRRMPQVLPNENRTGKFYQRDAGAISYACREISER YFDPAFWAAVDGLGYTPTTVADLGSGSGERLIQIARRFPGVRGLGVDIADGAIAMAEKEVAAKGFGDQISFVRGDAR TIDQVSARGEFAEVDLLTCFMMGHDFWPRENCVQTLRKLRAAFPNVRRFLLGDATRTVGIPDRELPVFTLGFEFGHD MMGVYLPTLDEWDGVFEEGGWRCVKKHAIDSLSVSVVFELE

Seq. ID No: 323

>BH4reg 1

MAASGEARRVLVYGGRGALGSRCVQAFRARNWWVASIDVVENEEASASVIVKMTDSFTEQADQVTAEVGKLLGDQKV DAILCVAGGWAGGNAKSKSLFKNCDLMWKQSIWTSTISSHLATKHLKEGGLLTLAGAKAALDGTPGMIGYGMAKGAV HQLCQSLAGKNSGMPSGAAAIAVLPVTLDTPMNRKSMPEADFSSWTPLEFLVETFHDWITGNKRPNSGSLIQVVTTD GKTELTPAYF

Seq. ID No: 324

>BH4reg 2

MTALTQAHCEACRADAPHVSDEELPVLLRQIPDWNIEVRDGIMQLEKVYLFKNFKHALAFTNAVGEISEAEGHHPGL LTEWGKVTVTWWSHSIKGLHRNDFIMAARTDEVAKTAEGRK

Seq. ID No: 325

>BH4syn 1

MEGGRLGCAVCVLTGASRGFGRALAPQLAGLLSPGSVLLLSARSDSMLRQLKEELCTQQPGLQVVLAAADLGTESGV QQLLSAVRELPRPERLQRLLLINNAGTLGDVSKGFLNINDLAEVNNYWALNLTSMLCLTTGTLNAFSNSPGLSKTVV NISSLCALQPFKGWGLYCAGKAARDMLYQVLAVEEPSVRVLSYAPGPLDTNMQQLARETSMDPELRSRLQKLNSEGE LVDCGTSAQKLLSLLQRDTFQSGAHVDFYDI

Seq. ID No: 326

>BH4syn 2

MHSPSLSAEENLKVFGKCNNPNGHGHNYKVVVTIHGEEAIMKPLDHKNLDLDVPYFADVVSTTENVAVYIWENLQRL LPVGALYKVKVYETDNNIVVYKGE

Seq. ID No: 327

>BH4syn 3

MPSLSKEAALVHEALVARGLETPLRPPVHEMDNETRKSLIAGHMTEIMQLLNLDLADDSLMETPHRIAKMYVDEIFS GLDYANFPKITLIENKMKVDEMVTVRDITLTSTCEHHFVTIDGKATVAYIPKDSVIGLSKINRIVQFFAQRPQVQER LTQQILIALQTLLGTNNVAVSIDAVHYCVKARGIRDATSATTTTSLGGLFKSSQNTRHEFLRAVRHHN

Seq. ID No: 328

>BH4syn 4

MHHHHHHTSSTPVRTAYVTRIEHFSAAHRLNSVHLSPAENVKLFGKCNHTSGHGHNYKVEVTIKGQINPQSGMVINI TDLKKTLQVAVMDPCDHRNLDIDVPYFESRPSTTENLAVFLWENIKSHLPPSDAYDLYEIKLHETDKNVVVYRGE

Seq. ID No: 329

>BH4svn 5

MHHHHHHSSKEHHLVIINGVNRGFGHSVALDYIRHSGAHAVSFVLVGRTQHSLEQVLTELHEAASHAGVVFKGVVVS EVDLAHLNSLDSNLARIQSAAADLRDEAAQSTRTITKSVLFNNAGSLGDLSKTVKEFTWQEARSYLDFNVVSLVGLC SMFLKDTLEAFPKEQYPDHRTVVVSISSLLAVQAFPNWGLYAAGKAARDRLLGVIALEEAANNVKTLNYAPGPLDNE MQADVRRTLGDKEQLKIYDDMHKSGSLVKMEDSSRKLIHLLKADTFTSGGHIDFYDE

Seq. ID No: 330

>DAC 1

MVDADIALNWAGGLHVCIVRPPGHHAEPGAACGFCFFNNVALAARYAQSLQSPSDPPLRVMILDWDIHHGNGTQHIF QDDASVLYVSLHRYDDGTFFPSSEDAAHDKVGSGPGEGFNVNIPWNGGKMGDVEYLLAFHRIVMPIAYEFNPQLVLV SAGFDAARGDPLGGCRVSPEGYAHMTHLLMGLAGGKVVVVLEGGYNLTSISESMSMCTRTLLGDPLPFISDLHAPRP AALRAISSVLGVHOKYWRSLCINVGPP

Seq. ID No: 331

>DAC 2

MKTHPHPERPDRLQAIAASLATAGIFPGRCYPIPAREITKEELQMVHSLEHIETVELTGQILYSYFTPDGTNPHNRL KLDNRKLAGILSQRMFVILPCGGLGVDSDTIWNDLHSSNAARWAAGSVIDLAFKVVTRELKNGFALVRPPGHHADPS TAMGFCFFNSVAIAAKQLQQKLNVRKILIVDWDVHHGNGTQRVFYRDPNVLYISLHRHDDGNFFPGSGAADEVGANS GEGFNVNVAWAGGLDPPMGDAEYLAAFRTVVMPIAHEFAPDVVLVSAGFDAAEG

Seq. ID No: 332

>DAC 3

MMATEPIASGSGTMDIDSEKTPSTSQANPMADTFQTREAVLGLGEVVEHVGGRWVAEQEWIRSPERKMAYTQGTKKK VCYYYDGDVGNYYYGQGHPMKPHRIRMTHNLLLNYGLYRKMEIYRPHKANAEEMTKYHSDDYIKFLRSIRPDNMSEY SKQMQRFNVGEDCPVFDGLFEFCQLSTGGSVASSVKLNKQQTDIAVNWAGGLHHAKKSEASGFCYVNDIVLAILELL KYHORVLYIDIDIHHGDGVEEAFYTTDRVMTVSFHKYGEYFPGTGDLRDIGAGKGKYYAVNYPLRDGIDDES

Seq. ID No: 333

>DAC_4

MDAGTRRVDDAAVPSTGPSASLLRSANMLSAAFGLTASLYSRLRGVCSSRRALSTSARTSEAAGVGAKPGVAAALTV PSTGPSASEASPAALLRIQVAEEWARASGLLDREDCQVGLAFDEAMHLHSGPAGHPERPARTKEILAQLHASGLVRA CAQVPSREATEEELLLVHDARHVERVLRHEAAGHKKAKAFSFPFGPDTYVCEHTARCARLAVGCLLSLVDASLDPAS PVRTGMAVVRPPGHHATSDRASGFCLFNNVAVAARHLQRRHGLKRVAIVDWDVHHGNGTNDLFTEDPNILFFSVHRF DNHGFFPGSGFLEDVGHAQARGYTVNVPLEKGYGDLDIVHVVKYVLCPVLERFKPDAILVSAGFDAVKGDPLGECRV

SPEAFGWMTRCLHRLAQRYCDGRLFLVLEGGYNPDMIAQCCIECVQSLVAEAAGLRGPWPEFPAVGVPLAEGAQLSA PSSAPTSAPGTPTSTSPASSPALSAAAPPLASPGSTPTSSPCLRPSGGEAPPRSPPSASASAGGGARQRARAPSSKT VRAVRQLTEIHHLLPLELPVAPRPGDGPGAANKSARKNERRRLGRGRRGPEEEGASSDSSGWAIACGLSDAEPWPSP QASPVASLSQGASSLPTLELPPAFPSLDGVGSTAGNSYLGTSGNVGIDAAGHSASSWLGSPTTAATAVAPPARGDRK VKRR

Seq. ID No: 334

>DAC 5

MVDADIALNWAGGLHGHHAGRGCSEGFCLLNNVAVAAAYARSAHPEQVRRVLVLDWDVHHGQGTQEIFWRDPGVLYA SVHRDGGEGFYPGTGAAEQVGDGAGRGFTVNVPLPTGYGDGCLWAACAEVLLPAARRFRPDLILVSAGFDAVAGDPL GGCRCTARGFGALTGELRKLAGELCSGRLLLALEGGYDLRTLRACVGEVCOALAAPEPAEGGA

Seq. ID No: 335

>DAC 6

MRNRSSGFCLVNNVAVAAEYARDRYPEVERVLIFDWDVHHGQGTQQIFEQSPDVLVISVHRHDGHSFYPATGSAGEV GSGPGRGYSVNVALPAGYGGAALWTACAHVLLPAARNFQPQLILVSAGFDAAASDPLGGCFVEPRVFGALTAELRRL AAEVAEGRLILALEGGYNPEVLADCVDEVAAALVADASSSGVEAFAEAPSWLAGSACFGAIRRTCEAHRMAPLRLPL PSSRIDRRRAAARQAEALSSPSSRDAGDTGGGEVSAHGATTTVTTSANLGAGTLAARPSSMVTGEGRRANGQLVDVL GIALAGKPSASPWPEAQRTQGSAPGTPAPATGGALPPAETAESPGSVASGAAVAQGPVECQAAARQAGECPGQAPAP AGAGAAPGGRGVEAAAAQHGQDLAPAAGPGAAALVELQTGELVVRIAPLPRPKDVVVSAEELWVWHDQGGPLGVQRW RFEGVRAENSGALRCAEFRSKRHELTVRLRLG

Seq. ID No: 336

>DAC 7

MVRSSQATTFSSSPYFADRGIHGTAQPITERINPRKCTFHILPPGLGGWLYLFPKMSKTVAYFYDPDVGNFHYGTGH PMKPHRLALTHSLVLHYGLYKKMIVFKPYQASQHDMCRFHSEDYIDFLQRVSPNNMQGFTKSLNAFNVGDDCPVFPG LFEFCSRYTGASLQGATQLNNKICDIAINWAGGLHHAKKFEASGFCYVNDIVIGILELLKYHPRVLYIDIDIHHGDG VQEAFYLTDRVMTVSFHKYGNYFFPGTGDMYEVGAESGRYYCLNVPLRDGIDDQSYRHLFQPVIKQVVDFYQPTCIV LQCGADSLGCDRLGCFNLSIRGHGDCVQYVKSFNIPLLVLGGGGYTVRNVARCWTYETSLLVDETISEELPYSEYFE YFAPDFTLHPDVSTRIENQNTRQYLDQIRQTIFENLKMLNHAPSVQIHDVPSDLLSYDRTDEPDPEERGAEDNYTRP EASNEFYDGDHDNDKESDVEI

Seq. ID No: 337

>DAC 8

MWDVHHGQGIQYIFEDDPSVLYFSWHRYEHGSFWPNLSESDYDSIGKGRGTGFNINLPWNQTGMGNADYVAAFFHVL LPLAFEFNPELVLVSAGYDSGIGDPEGHMRATPECFSHLTHMLMHLAGGKLCMILEGGYHLRSLSESVSMTVRTLLR DPVPRLSGEMTPCYSALESIQNTRHAHSPYWKCLLHDETRLVEEISTKGLKAPGPLHVDASVVDEFLENHMKKILHP TPPITTMVVASVENTLNLPAGVQLEESTVTPEQARHAISVFNPDELNENVLNSVSKMLPALEKLVN

Seq. ID No: 338

>DAC 9

MKTHPHPERPDRLQAIAASLATAGIFPGRCYPIPAREITKEELQMVHSLEHIETVELTGQILYSYFTPDTYANQHSA HAARLAAGLCADLAKEVFSGRAKNGFALVRPPGHHAGVRQAMGFCLHNNAAVAALAAQVAGAKKILIVDWDVHHGNG TQEIFEQNKSVLYISLHRHEGGKFYPGTGAAHEFGTMGAEGYCVNIPWSRGGVGDNDYIFAFQHVVLPIASDFAPDF TIISAGFDAARGDPLGCCDVTPAGYAQMTHMLNILSGGKLLVILEGGYNLRSISSSATAVIKVLLGESPGCNPKNFL PSKAGVQTVLEVLKIQMNFWPALGSIYSDLQTQWGMYCMKTKKKQIKKRQRAAAPLWWKWGQKSFLYHLLNGHLHVK SKGC

Seq. ID No: 339

>DAC_10

MFLVRHHLYKWKSHFRIDADGKFVEDQFFPKNLKSGRRFLRSIGASITCSNGIGKDPYILSNEKISDARLIYAVAPA MGHNQESHPESHFRVPAIVNALEKMEMTPKFRGSEIIELQSFKPALVDDIASVHARAYVSGLEKAMDQASQQGIIFI DGSGPTYATATTFHESLVAAGAGIALVDSVVAASKNHLDPPVGFALIRPPGHHAIPLGPMGFCVFGNVAIAARYAQR AHGLKRVFIIDFDVHHGNGTNDAFYDDPDIFFLSTHQDGSYPGTGKVDEVGRGDGEGTTLNLPLPGGSGDIAMTTVF DEVIAPCAQRFKPDIILVSAGYDGHVLDPLASLQFTTGTYYMLASKIKLLAKDLCGGRCVFFLEGGYNLESLSYSVA DSFRAFLGEQSLASEFDNPAILYEEPSTKVKQAIQRVKHIHSL

Seq. ID No: 340

>DAC 11

MVDADIALNWAGGLHHAKKSEASGFCYVNDIVLGILELLKVHRRVLYVDIDVHHGDGVEEAFYATDRVMTVSFHKFG DFFPGTGHIKDTGWGPGKNYALNVPLNDGMDDESFRGLFRPIIQGVMEVYQPDAVVLQCGADSLSGDRLGCFNLSVK GHADCLRFLRSFNVPLMVLGGGGYTIRNVARCWCYETAVAVGVEPDNKLPYNEYYEYFGPDYTLHIEPCNMENLNTP KDMEKIRNMLLEQLSRIPHVPSVPFQTTPPTTQVPEEAEEDMDRRPKCRIWNGEDYDSDPDEDEKPRHTEPNSELRD VVDEMDEDKREEHPPS

Seq. ID No: 341

>DAC 12

MCSDANGKVGNISVMSTEGISQVESKKARLNGLLTLEDIYNLPDELDDDEDDSDWEPLLEPLAVRKWFCTNCTMVNF DGFDFCETCEEHKESGILKQGFFASPALQGTRSTQIESEVIERYTESICDISASALSTVVGFDERMLLHSEVVLKPH PHPHPERPDRLRAIAASLSTAGIFPGKCHPIAAREITQEELLKVHSLEHVEAVEVTRQMLSSYFTPDTYANEHSAQA ARLAAGLCADLASEIYSGRAKNGFALIRPPGHHAGVHQSMGFCLHNNAAVAALAAQVAGAKKVLIVDWDVHHGNGTQ EIFERNKSVLYVSLHRHEAGKFYPGTGAAHEVGTMGAEGYCVNVPWSRGRVGDNDYIFAFQNVVIPIAHEFSPDFII ISAGFDAARGDPLGGCDVTPAGYACMTHMLSALAGGKMLVILEGGYNLRSISSSATAVIKVLLGEKPKCQFENIEPS ASGLQALLEVLKVQTNFWPCLSSKLTQLQSCWEAYLSGRKKQKKRRFRTVAPPPIWWAWGRKRFLYFLRCQRFRMKP

Seq. ID No: 342

>DAC 13

MAGAEELHVFWEEGMLKHETGRGVFDTGSDPGFLDVLEKHPENADRVRNMVSILKRGPIAPFVSWHQGRPASLPELL SFHSSEYIEELEEADRAGGKMMCCGTFLNPGSWNAALLAAGTTLSAVKYILDGHGKIAYALVRPPGHHAQPTQADGY CFLNNAGLAVQLALDEGCRKVAVIDIDVHYGNGTAEGFYCSNKVLTISLHMNHGSWGPSHRQSGTHDELGDGDGFGY NMNIPLPNGSGDRAYEYAMQELVVPAVQKFGPDMIVLVVGQDSSAFDPNGRQCLTMDGYRQVARIVRGLADMHCKGK LLVVQEGGYHITYAAYCLHATLEGALNLPSPLLSDPIAYYPEDEGFAVKVIDAMKEHYKSNVPFLKEIN

Seq. ID No: 343

>DAC_14

MGFCIFGNIAIAARYAQRVHGLKRVFIIDFDVHHGNGTQDVFYEDPDIFFLSTHKEGSYPGTGKIHEVGCGPGEGTT LNLPLPGGTGDVAMRTVFDEVIVPCAQRFKPDIILVSAGYDAHFLDPLANFQFKTATYYTLAANIKQLAKELCGGRC VFFLEGGYNLKSLSYSVADSFRAFLGEPSCASDVDPTFLYDEPSTKIEQAIDKVKAIHSL

Seq. ID No: 344

>DAC 15

MEQLWVPSLPILGGRILPMLRHYCGFGSHHPLTWRSLQITGRKQKHNGCWIAYCLPSHNGTSISDTNGVRKDLALPD NLLRDAHILYCTSPAMGHNKEAHPETNKRVPAIVDALEKLELTSKHRGSQVLEIQDFQPASLDDIALVHSRSYITGL EKAMSRASDEGLIFIEGTGPTYATQTTFQECLLSAGAGITLVDSVVAASKLGPKPPLGFALVRPPGHHAVPEGPMGF CVFGNIAVAARYAQNQHGLKRVMIIDFDVHHGNGTCDAFYEDPDIFFLSTHQLGSYPGTGKIHQVGQGNGEGTTLNL PLPGGSGDYAMRCAFDEVIAPAAQRFKPDIILVSAGYDAHALDPLAGLQFTTGTFYMLAARIREVAAELCGGRCVFF LEGGYNLESLSSSVADTFRAFLGEPSLAARFDDPAMLYEEPTRKIREAIDKAKHLHSL

Seq. ID No: 345

>DAC_16

MMATEPIASGSGTMDIDSEKTPSTSQANPMADTFQTRRPRASSLPLQPSNLKVGYIYSSEMMNHFCPGGHPEQPLRI QQIWATIVNEQLHKRMKWMPIREVKKGEALLVHSEDHWNKVIAIQYLTDQQRADSVDYYEQMSLYVMSGTTRSALLS CGGVVEACLAVARNELKKTFAIVRPPGHHAEPDEHMGFCFFNNVAVAARVVQQRTKLKKILILDWDVHHGNGTQRAF NDDPSVLYISLHRYEQGTFYPCGPFGSLTSCGEGPGTGFSVNVPWPCAGMGDAEYIYAFQKVILPIATEFAPELVII SAGFDAAAGDELGECLVSPAGYAHMTHMLAGLAGGRMVVALEGGYNLDSISQSALAVTKVLLGEPPDELPPLKANEE GTETVWLVAREQSKYWKSVDPKACEPQADVEPISFSVPEILKAHRQHYLYTKHDMMQVPMMTPELEEKFSSQIMCTS DIFESKTLVIFVHEFGNLRLELESSTTCDVHLERSYLIDFSKELVGWVKSEGYSLLDANLYPKPSTTPTPNLRHKTM EEVGRDVLVYLWDNYVQLSGAERVILIGHGPGCKPLVDLLNRRTTSVTKSAKAIIQVVGSQRMPSYPSDVDDARPWY QKSSLVIVPQSHPVMGPHIKPKDIRRHGVMVPIDETRQIKLITRALPAIKQFVQETLSSFPLANRTNRP

Seq. ID No: 346

>DAC 17

MSKRKVAYFYDPDVGAYTYGWSHLMKPHRMRITHELATAYGMLDKMHVLRPKRATPEAMTAFHTDEYVQFLHSVTPE TADKLTGQKTRFLVGDDNPAFEGVFEFCSISAGGSIGAAERIASGAADIAINWAGGLHHAKKREAAGFCYINDIVLG ILELLRTYPRVLYIDIDCHHGDGVEEAFYTTDRVMTCSFHKFGEFFPGTGTQEDTGTGKGKGYSVNVPLKDGIQDES FKSVFDPVISKILEVFQPSAVVLQCGADSLAGDKLGCLNLTMQGHAHCVQFLRKSNIPLILLGGGGYTVKNVARAWT YETACAIGIENEIDLNMPWSQYFEWFGPTYRLEVPENNMEDMNVKEGTLDHVRTTALAQLQQLASRCAPSVQMQDVP RTSLGGHLGFKRDKREHRDELDERLAQHTRYLYDLQESESESEDTESSDSDASSVSFVNNWRRAPHRANSLPRILSG RHSSNPPGHISASERRRMSIVTGKYFDIPIHESGYNHYEYGAAPTKSSKRIFFQSGLDIYNDDNDFEGIINARTSVS NGFGNGIHDLHGLMERGGRSLNENLEDGDDEVEGEEYEDDAAMSDS

Seq. ID No: 347

>DAC 18

MEEHFWDVLYKDKYSKLLSKARDFLDDTGGPGDDVLVFISCGMDACEHEYESMSRHNRKVPASFYHRFARDACAFSD RYAGGRLISVLEGGYSDRALISGAMAHLSGLVDTPDGIQVDEQWWNIPNLVKLEAATKKRRGGRPSLPAKGSVEPWI ERTLSIFSSIDGSASTTSSRSTFIPPSSRTLRDRTKGREAMPKSPPASSASTKPVSRSKVKPGANIKSGDESFASTG SSPLTSPSPSSSEDEAPPIKRL

Seq. ID No: 348

>DMAT 1

MTIINSRIIDIRQSTFEESIPDQVTAGLSTTPKTLPALLFYSGEGIRHWIEHSTAADFYPRHEELRILRARAAEMVD SIANNSVVVDLGSASLDKVLPLLEALEASKKNITFYALDLSFSELQSTLQSLPYEQFKFVKIGALHGTFEDGVQWLK DTPGVQDRPHCLLLFGLTVGNYSRPNAAKFLQNIASNALAASPVQSSILLSLDSCKMPTKVLRAYTAEGVVPFALAS LDYGNTLFAPNKMGEKVFQPSDWYFLSEWNYMLGRHEASLITKGKEVRLGGPLNDIVIEKHEKIRFGCSYKYDTDER QVLFGSAGLTDVKEWSVEGCDVSFYQLQMCPN

Seq. ID No: 349

>DMAT 2

MTISAPPIIDIRQAGLESSIPDQVVEGLTKEVKTLPALLFYSTKGIQHWNRHSHAADFYPRHEELCILKAEASKMAA SIAQDSLVIDMGSASMDKVILLLEALEEQKKSITYCALDLSYSELASNFQAIPVDRFHYVRFAALHGTFDDGLHWLQ NAPDIRNRPRCILLFGLTIGNFSRDNAASFLRNIAQSALSTSPTQSSIIVSLDSCKLPTKILRAYTADGVVPFALAS LSYANSLFHPKGDRKIFNEEDWYFHSEWNHALGRHEASLITQSKDIQLGAPLETVIVRRDEKIRFGCSYKYDKAERD OLFHSAGLEDAAVWTAPDCDVAFYOLRLN

Seq. ID No: 350

>DMAT 3

MSKPNVLDIRLATFEDSIVDLVINGLRKQPKTLPALLFYANEGLKHWNHHSHQPEFYPRHQEVQILKKKAQEMAASI PMNSVVVDLGSASLDKVIHLLEALEVQKKNISYYALDVSASQLESTLAAIPTQNFRHVRFAGLHGTFDDGLHWLKEA PEARDVPHTVLLFGLTIGNFSRPNAAAFLSNIGQHAFQGKSGDQCSILMSLDSCKVPTQVLRAYTCEGVVPFALQSL TYANGLFSEKNKTQASGDVQHKVFNLDEWYYLSEWNFVLGRHEASLIPRSKDIKLLPPLDGILVSKDEKVRFGCSYK YDQEERMELFAAAGVKNEVTWSDEGCDVAFYQLKLS

Seq. ID No: 351

>DMAT 4

MGSINPPQILDIRRSKFEESIPKQVEAGLLSSPKTLPALLFYSTEGIQHWNRYSHASDFYPRHEEIQILKDKATDMA ASIADGSVVVDLGSASLDKVIHLLEALEAAQKKVTYYALDLSFSELTSTLQAIPTDQFVHVQFSALHGTFDDGLQWL KETLVIRDQPHCLLLFGLTIGNFSRPNAAKFLHNIASHALVESPSQSSILLTLDSCKVPTKVIRAYTAEGVVPFALE SLKYGNTLFQQDAGENVFDPEDWYFLSEWNYVLGRHEASLVPRSKDIKLGRPLDKIVVGKHEKVRFGCSYKYDSEER KELFGTAGLRDVKSWSKEGCDVAFYOLKCCPN

Seq. ID No: 352

>DMAT_5

MPALPVIDIRSNHVEDSLPEQIIKGLTSQPKTLPPLLFYSNEGLEHWNHHSRQPDFYPRRQEIEILKQGGNDIARSI APSSVILDLGSANLEKVGYLLEALEAQEKDVLYFALDISAPQLATTLKEIPSSNFRHVRFAGLHGTFEDGLRWINET PEIRDLPHCVLLLGLTIGNFSRQNAAAFLQNIANHALTGASKNKSSILLSLDSCKVPTKVTRAYTSDGVVPFALQAL TYAKALLCDRIDNGIDEKVLSCNLRPEHWHYLSEWNFALGRHEASLIPRFGDVCLGSMLQDIIVKKEEKVRFACSYK YDAKEROKLFLDSGVDOGMVWTNEGCDVAIYELKLA

Seq. ID No: 353

>DMAT 6

MLYKPKVLDIRSGSVEDSLRHSVMDGIREDPRTLPTLILYGPEGLQHWDDHSHAPDYYLRHEELHILRSRAYEMAET IADNTAMVDLGSAQVSRFHESPCLLAPTLSLDKAALLLDALEVQAKNVTYYALDLDHAELQKTLCRLPLGKYKHVQC VGLQGTFEDGLEWIKNDPEQSRRPHCLLFLGSTIGNFSRENAARFIRSMASSAFLSESAKSSIILSIDSCKLPTKVL RAYNSEGVVPFAMAGLKHASAILCEAACRQEDAVTETFLPDDWYYLSHYNHVLGRHEASFTPRNRDIQLGSPLEDVV IRLGETIRFGYSHKYDFAEIEQLFREAGVAAVNSWGAVGCDLSFYQLGTA

Seq. ID No: 354

>DMAT 7

MAAPSVIDIRSHLVEDSLPDQVVKGLGSDPKTLPALLFYSNEGLEYWNHHARQPDFYPRHQEIEILKRKGDEIARSV APNSVILDLGSANLEKVTYLLEALEAQAKNVTYFALDLSAPQLMSTLKAIPTTKFRHVRFAGLHGTFVDGLRWISET PDIRDLPHCVLLFGLTIGNFSRPNAATFLRNIASQALRGASEDKSSIFLSLDSCKVPTQILRAYTSDGVVPFALQSL AYAKTLFCEQTQNDFNEKPSSCHLNPDDWHYHSEWNFVLGRHEASLIPRLNDIHLGPLLHDIVVKKDEKVRFGCSYK YDDLERDKLFVDAGVKDEMAWTNEGCDIAIYELKSM

Seq. ID No: 355

>FEX1

MIFNPVISNHKLSHYIHVFCTFTTFCILGTETRQAITALSTYTPAFVTAPTVLWSNCSSCMLMGIMQSLNAYTWMKD HQVLFLGVTTGYCGALSSFSSMLLEMFEHSTNLTNGNIANHTKLPNRAYGIMEFLSVLLVHLMVSMGSLIFGRQLGK EVIVAYGSSSFSKPYTPPSDTVKENAGDVDTQEMEKNILEFKFKTPAPFFKKFFDIVDKLAYALAFPLIILFVVLCA YYENYSRGKWTLPCLFGIFAGFLRYWLAEMFNKTNKKFPLGTFLANVFATLLIGIFTMVQRGKKHFSTDVPIVNSLN SCHIVSALISGFCGTLSTISTFINEGYKLSFINMLIYYTVSIAISYCLLVITLGSYAWTRGLTNPIC

Seq. ID No: 356
>IDI1 for fusion

GGSGGSSGSGGSSSTADNNSMPHGAVSSYAKLVQNQTPEDILEEFPEIIPLQQRPNTRSSETSNDESGETCFSGHDE EQIKLMNENCIVLDWDDNAIGAGTKKVCHLMENIEKGLLHRAFSVFIFNEQGELLLQQRATEKITFPDLWTNTCCSH PLCIDDELGLKGKLDDKIKGAITAAVRKLDHELGIPEDETKTRGKFHFLNRIHFMAPSNEPWGEHEIDYILFYKINA KENLTVNPNVNEVRDFKWVSPNDLKTMFADPSYKFTPCFKIICENYLFNWWEQLDDLSEVENDRQIHRML

Seq. ID No: 357

>INMT_1

MAAPHTSQQDYIDNFNARDYLQTSYTPGKGILFGEWIEFATQNLHETFTTGGVRGDTLLDFGTGPTIYQLISACEVF DKIIVSDFLEQNRAEFRKWLNKDPDAFDWTPIIKGVCELEGNREDWEKKATKLRSKVKEVLKCDALKRNPYDPIVVP PVDCLLSCLCLEAPCKDIKSYCEVLKNFQSLIKPGGHLLILSGLNATFYYVGKTYFSSMTTKKEELEMAFKEAGYII KKAVYTPRADKSKIDVADYEGHYFIHAHKPK

Seq. ID No: 358

>INMT 2

MAAPHTSQQDYIDNFNARDYLQTSYTPGKGILFGEWIEFATQNLHETFTTGGVRGDTLLDFGTGPTIYQLISACEVF DKIIVSDLLEQNRTEFQKWLNKDPDAFDWTPIIKGVCELEGNRENSEKKAEKLRSKVKQVLKCDALKRNPYDPVIVP PADCLLVCLCLEIPCKDMKSYCNVLKNFKDLLKPEGQILILGTLNGTYYHAGKKRFSLLSSKKEDLEMAFKEAGYII EKAVYTLRADKSNIDVADYEGHYFIHAHKPK

Seq. ID No: 359

>INMT 3

MSDFTNTREYEEQFDPRLYLETYFHLGSGSLADDFLRFVLDNFNKTFKSGAVKGSTLIDIGTAPSIYQLLSACESFD DIIVTWHTNRELKELQKWLNSEADAFDWSSIVKHVCEIEGNRMAQKEKEEKLKGKIKQVLMCDVSKSNPLSPHEVPK ADCLLTTVCLEAACKNYESYGTALKNLSNLLKPKGHLLMAGDLGANYYEVGSNKVFSLPVNEKFLKKVISESGYEII QLVSFGKPENADFETSDYEGFYFVHAQKV

Seq. ID No: 360

>INMT 4

MDCLISCLCLEAPCKDLEDFTNTLKKFKELLKPGGHIIIQSVLNCSLYFVGNKSFSCLSITKDELEQAFKEAGYEIV KLKVVPRSEKIWANVSDHSEYYYIHARKPQ

Seq. ID No: 361

>INMT 5

MSDFTGKNEYQTFFNPKAYLESYYQLGSGSMGDEYLQFVLKELAETFNPGKVKGDTLIDIGTGPTIYQLLSACEAFK NIIVSDFTDKNREEFNVWLKNQPGAFDWSPVVKHVCRLEGDRIPWEQKEERLRKTIKQVLKCDVFNINPIDPVTIPQ VDCLLSCLCLEGACKDFESYITALKNMTTLLKIGGYLVMTGDLGNTYYMVGDVKFSGLNLNENFLREAITGAGYVIE SFQQSKKTEDSVEDKADFTAYYVIVARKERNV

Seq. ID No: 362

>INMT_6

MESGFTSKDTYLSHFNPRDYLEKYYKFGSRHSAESQILKHLLKNLFKIFCLDGVKGDLLIDIGSGPTIYQLLSACES FKEIVVTDYSDQNLQELEKWLKKEPEAFDWSPVVTYVCDLEGNRVKGPEKEEKLRQAVKQVLKCDVTQSQPLGAVPL PPADCVLSTLCLDAACPDLPTYCRALRNLGSLLKPGGFLVIMDALKSSYYMIGEQKFSSLPLGREAVEAAVKEAGYT IEWFEVISQSYSSTMANNEGLFSLVARKLSRPL

Seq. ID No: 363

>INMT 7

MKGGFTGGDEYQKHFLPRDYLATYYSFDGSPSPEAEMLKFNLECLHKTFGPGGLQGDTLIDIGSGPTIYQVLAACDS FQDITLSDFTDRNREELEKWLKKEPGAYDWTPAVKFACELEGNSGRWEEKEEKLRAAVKRVLKCDVHLGNPLAPAVL PLADCVLTLLAMECACCSLDAYRAALCNLASLLKPGGHLVTTVTLRLPSYMVGKREFSCVALEKGEVEQAVLDAGFD IEQLLHSPQSYSVTNAANNGVCCIVARKKPGP

Seq. ID No: 364

>INMT_8

MSDIDDGALASAQAIVDGNRLAGQIELRQQPDPDRVFAGVLRQGEAVAFCVCNPPFHESLEHARRAAGAKWQRLGRA VQGKEMNYQGSPAELCCNGGEVGFVTRMAEESAQPRRQRACVWFSAMLSRESSIAPVRERLGELGARRRAWELRQGR TTKWVVAWTFYPRGERDQRLREMAQRRADPEARAEAGAEAATARDVGAGGDGADGVGGSLVRRSAGAGGSAA

Seq. ID No: 365

>INMT 9

MDFTGGEIYQSSFDPKAYLASFCSLGSGRDDILMFRLKKCFETFGPGGLRGDVLVDIGTGPAIYHLLSACESFPYII ATDFTDNNRQELEKWLRREPGTFDWLETVKIVCDLEGDSRDDWVEKEDKLRSRIQKVLKCDVTKTNPLDPTVIPPAD CLITALCLETACTDIDTYFCSLRNITTLLKPGGHLVLIGVLGNSFYKVGEKKFYCLSLDEQTVRNAVIDAGYSIKDL ELYYLPNPASCAHITDTYANIFLVAQKNET

Seq. ID No: 366

>INMT 10

MEIVSTSYNHIYDNFDARKYLDRYYGLASETQEIEEESVFLLTFLSNVFSSGRVKGHSFIEIGVGPSIHSILSACEV FEKIYLTDYSQGNLNEIEKWLNSENDAFDWTPYIRFVCDLENNGSTPKGKKEKLRRAVSLMKCDVNLSNPLHPHSLP LTDCLLTASCLSATCKTFTDFKMSLKIIVSLIKPGGHLILIDYLRASYYWVGEVKLPILSLDEHVVREAVVESGCKI EEFKWFKEFHMPDELSDCKTVFSLLAQKL

Seq. ID No: 367

>INMT 11

MDSSNYKLYHVHEFNSRSFLDNYFSDGPQMTFVDDTLVFPIENLKKTFAEGHIKGDVMIDLSIGAMVHHLYAACEFF KDIIVLKASDRCIMELKRWVGTRTGAFYWGHATKLHADTEGNSELLQDKEEKVRSAIQHVVKCDVTKELMTDPIVLP PADCIISAWLLDAISSNQDDFITYLRRFIKLLKPGGHLILIGALEQTSYSVGNEKYQFLTYNEDFARKALIAEGLVI DDCKIKKRTAKSDLADYKSILYLVSHKK

Seq. ID No: 368

>INMT 12

MDPCLNLYYPSHEVNAKRLLHEYFSQNVPYSIFKESTINIMKCCYKAFSSGLLSGTTLIDISVGPSIVHLLSVCEFV EEISILKVNDASIRELELWKNKDPETFDWTHTLKLFMELKGTSRDGWKDAQEMLRRKVKHIVKCDFSKSNLTKPFAL PRADCVTCIWGLETISRDHDEWKTTLRKISDLVKLGGHVLIHADINASYFKIGEDKYHLFNFDDAFLRKTLTDGGFA IVHYENLEREACTDCLDHSHK

Seq. ID No: 369

>INMT 13

MELKRWVDTRTGAFDWSHAAKLHVDTEGNSDELQEKNEKVKSAIQHVVKCDLEKENMTHPIVLPPADCIISFALLDV ISKDKDDYIKYLRKFSKLLKPGGHLILIGDLDTTYITVGKHKVHYLTYDEEFVRNALAGEGFVIDCCKVKERTVESD LCDYKGMIFIVAHKEK

Seq. ID No: 370

>INMT_14

MELKRWVDTRTGAFDWSHAAKLHVDTEGNSDELQEKNEKVKSAIQHVVKCDLEKENMTHPIVLPPADCIISFGFLDV VCKDQEDYIRYLRKFSRLLKPGGHLILIGGVDATYFTVGKEKHHFFTYDEAFVRKALEGEGFVIDDCKVKKRTAVSD FTDYKGSIFIAAHKEH

Seq. ID No: 371

>INMT 15

MSDFTNTSEYEEQFDPRLYLETYFHLGSGSLADDFLRFVLDNFNKTFKSGAVKGSTLIDIGTAPSIYQLLSACESFD DITVTWHTNRELKELQKWLNNEADAFDWSSIVKHVCEIEGNRMGQKEKEEKLKGKIKQVLMCDVSKSNPLSPHEVPK ADCLLTTVCLEAACKNYESYGTALKNLSNLLKPKGHLLMAGDLGANYYEVGSNKVFSLPVNEKFLKKVISESGYEII QLVSFGKPENADFDTSDYEGFYFVHAQKV

Seq. ID No: 372

>INMT_16

MALQERQEPDVYQENFEPTSYLEYYRMNQDPVGDEVLHFLLKHYNATFKPGGLEGKLLIDIGSGPTIYQFLSACESFQEIIATDYTDKNLQELEKWLKKMPGAFDWSPVVKYVCELEGNRDKWAEKEERVRRAVTQVLKCDVLKERPLEPAVLP

PADGLISSLCLEAACPTPQACRDALRHLRTLLRPGGHLVLSGGFETTFFMVGDKRFSTLPLNEKFLREALQEAGFII EKLEKVTRAAETHLDNRSDYTGLFFLVARRGD

Seq. ID No: 373

>INMT 17

MDKISAPFFSGTSPAAASVAGVDEDDRLCFQAQELMFAYNISMVLRAAIQLGLLDALSAAGGKALTPNELVENVETS SNKAEAAAAVDRILRYLSCFNVVTCSSEAAGPDGTLVRRYTTGPLCRWLTKDRGDGTLSPFAVFVVDPDHLFPWHHI AEAVTAGGPSAFERTQKWPYYEYMGKNQRLGTLFDNAMAQHSVILVTKMLERFKGFDGVQRLVDVGGGTGSTLGMIT SKYKHMTGINYDLPHVIAQGLPLPGVEHVAGDMYESIPTGDAVLLQWITLMLNDDEFVKILSNCHNALPKDGKVIVV DGILPENPDSSLTARDAFTLDIIMFVLFKGAKORTEKEFARLAKOAGFTGGIKKTYIFFNFYALEFTK

Seq. ID No: 374

>INMT 18

MDANKRYHGPPVLLGVVRDSEKFDFCMCNPPFFETMEEAGLNPKTSCGGTPEEMICPGGEKAFITRIIEDSAVLNQS FRWYTSMVGRKSNLKSLISKLREVGVTIVKTTEFVQGQTCRWGLAWSFVPPVRKIVSPHVAEKNIISFMLEVWVPGF SICRVGDDLVPKSKSPHLSPILGTKN

Seq. ID No: 375

>INMT 19

MEEAGLNPKTSCGGTPEEMICPGGEKAFITRIIEDSAVLNQSFRWYTSMVGRKSNLKSLISKLREVGVTIVKTTEFV QGQTCRWGLAWSFVPPVRKIVSPHVAEKNIISFMLEGLQRQFSAIHVLQSIESFFRTCGASSELNASSFTVDITATN DHCKAILNNELQSIDEATSCEHVPETSNSSSSLHPHSNGLGFRISVYQQIPGTLLVKGSLQHKNNPVSGAFSLIIQR LEEDLKYKFCR

Seq. ID No: 376

>INMT_20

MNRSNYIHWIEDLLASDITEKNEANGGKVRGFDIGTGANCIYPLLGASLLGWSFVGSDVTEVALDWAEQNVRSNPHI SELIEIRRVDVDDPASSSGTVESSGGSRMEDSSQGQCDVVELASLEMKEFCDVGVTCKGGTDKNQRRYDEAKHSNVA KGYQGPPILLGVVKEGEKFDFCMC

Seq. ID No: 377

>INMT 21

MEEAGLNPKTCCGGTPEEMVCQGGERAFISRIIEDSATLKQSFRWYTSMVGRKSNLKFLMSKLREVGVTIVKTTEFV QGQTCRWGLAWSFMPTAKRSVPSHVAEKRNLSFMLEGLHRQTSAFNVLQSMESFFSHFGALCKSNPSSFTVDVSVSS DHCDAILKSDVEKLDEASSHSCVAESPGSASSYDPMVVSFRLSVFQQIPGTLLVRGSLQQRDSPLSGAFLSVFQQLE KFLKHKFCRERGLQFNQR

Seq. ID No: 378

>INMT 22

MATEIDDESYESARRNISNNNMQSRIHVEKASPDQSILFPLEDDRTFEFTMCNPPFYGSAAEVVQSAEAKEFPPNAV CTGADIEMIYPHGGEEGFVMKILDESERFMTRCKWYTSMLGKMSSVATIVEVLRQRSITNYAVTEFVQGQTRRWAIA WSFADTRLPDTMARIQSISPKHALYPCMPPKNTLVQAFPGPATHLVSTKLIETLHGIEGVSYTTTSLNSFFVEARQN TWSRSARRSRANKNSSKKPDPSSLDADDILSGSQPALTCSCRVLADTAHADPVNVVENQWIFGNDRALFESFVGHVS RKVGMGLRDVK

Seq. ID No: 379

>INMT_23

MLLESYKTFEPANYLQEYYSTVDLENRSLLAFFAEAYKGIDPNSVMLEFSGGPSLYSLITAAAHVKEIHFSDFLERN VEEIKLWKRFRHRSYIWINFFKEALMAEGLSEVSTDDILEREELLSKKLSDFLLCDAFNRHPLGQRCYQRYDVVAAN FVAESITPSLKTWEEVVNNICSTLKPSGTLIMTAIQGASFYCVENHRYPAIAVTPEDVIRVLSYQGFDVDNLLMRHI PAEITDISAKDYKGYQGMLFVKATR

Seq. ID No: 380

>INMT 24

MESGFTSKDTYLSHFNPRDYLEKYYSFGSRHCAENEILRHLLKNLFKIFCLDGVKGELLIDIGSGPTIYQLLSACES FTEIIVTDYTDQNLWELQKWLKKEPGAFDWSPVVTYVCDLEGNRTKGPEKEEKLRRAIKQVLKCDVSQSQPLGGVSL PPADCLLSTLCLDAACPDLPAYRTALRNLGSLLKPGGFLVMVDALKSSYYMIGEQKFSSLSLDREAVRDAVEEAGYT IEQFEVISQSYSSTTSNNEGLFSLVGRKPVGSE

Seq. ID No: 381

>INMT 25

MEIVSTSYNHVYENFDARKYLDRYYGIAPEAEKIDEESVFLLTFLSNVFSSGRVKGHSFIEIGVGPSIHSILSACEA FEKLYLTDYFQGNLDEIKKWLNSENDAFDWTPYIRFVCDLENNGSTPREKKEKIRRCVSLMKCDVNLSNPLHPHSLP LTDCLLTACCLTSTCKTFTDFKMSLKTIVSLIKPGGHLILIDYLRASYYWVGEAKLPLLSLDEHGVREAVEESGCKI EEFQWFKEFHMPDEVSDCKTVFILLAQKL

Seq. ID No: 382

>INMT 26

MRNLHETFGPGGVKGDILIDFGAGPTIYQLLSACEVFNTIITSDFLEQNREQLKKWLRKDPDALDWSNFAKYVCELE GKSDNWEKKEETLRRKVTKVLKCDALAEKPYDPVPMPEADCLISCLCLEVACKDLEDF

Seq. ID No: 383

>INMT 27

METPFTSQQTYVDEFKASDYFKTYYVAEGGIANEEWTDFALRTLHETFTKGGVKGETLIDFGAGPTIYHLLSACEVF DKIITSDYLEQNRAELEKWLKKDPSAFDWTPIIKFVCELEGNRNYEKKAEKLRNKVKEVLKCDALKRNPFDPIVLQP ADCLLTCLCLEAPCEDMKSYFNVLKNFKDLIKPGGHLVILSVLDATFYYVGDKYFSSMTTRKEELEQALKEAGFEIE KAVYTTRKDRSQMDIADYQGFYYIHARNPK

Seq. ID No: 384

>INMT 28

MEGSFTGGEEYQKYFQPRDYLTTYYNFDGSPTPEAEMLKFNLECLHKTFGPGGLRGDTLIDIGSGPTIYQVLAACES FRDITLSDFTDRNREELEKWLKKEPEAYDWSSVVKFACELEGDSGRWQEKEKKLRSVVKRVLKCDANLASPLAPAAL PPADCVLTLLAMECACCSLDAYRAALCNLASLLKPGGHLVTTVTLGISSYMVGKREFSCVVLEKEGVEQAVLDAGFD IQQFLHIPKCYSATIAANNGVCFIVARKKPAP

Seq. ID No: 385

>INMT_29

MEGSFTGPDEYQKYFSPKDYLDTYYSFEHGPSPETEMIKFSLQFLHKVFGPGGIRGETLIDVGSGPTIYQVLAACEA FSDITLSDFTDRNREELQKWLRKDAGAFDWTPVLKFACELEGNSSHWQEKAEKLRATVKRVLKCDVNLGKPLAPVEL PAADCVLTLLAMECACCSLAAYRAALCNLGSLLKPGGHLVTSITLQISSYMVGKHQFSCLYITKEEVERAILDAGFD IEQLLHSEQSYSATIAPNKGICFIVARKRSGP

Seq. ID No: 386

>INMT 30

MDAQLTQLRNADVSWAAFDPIAYVDHNYRDLQAEDAEILHLVRDHFGDHFRKQGGGPVSGIDVGAGANLYPALAMMP WCEEITLFERSPANVRYLKSQVDSYDANWDQFWDALCAHEAYNSLGTDPRERFGKVVWVEQGDLFDLARYERRWSMG TMFFVAESMTTSYQEFMLGVERFMRALSPGAPFAAAFMEHSKGYHAGEHFFPACDVGESEVRASLEGFAGDFKVQRL ESAAQLRDGYSGMIVAY

Seq. ID No: 387

>INMT_31

MSDFTNASEYEKQFDPRLYLETYFHLGSGSLADDFLRFTLGNFHKTFTEGEVKGTTLIDIGTAPSIYQLLSACEYFQ DITVTWYTNRELQELQKWLNKDPGAFDWSSTVKHVWELEGKRGMLEEKEEKLRGMIRQVLLCDVSKKNPLEPVTLPK ADCLISTVCLEAACRNYDSYRTALKNLSTLLKPGGHLLLAGDLGANYYEVGSNKVFSLPVNETFLRKAVNESGYVIN KLVSFGKPEDAGYDTSDYEGFYFIHAQKC

Seq. ID No: 388

>IOMT 1

MSSKLDNQNITANEEEEAFHQAMQLAMSTILPMVLKAAIDLDLLEIIAKAGPAGCKLSPIEIASHLPTKNPDASSII DRILRVLASHSILTCDLATNEDGHVQRLYGLAPIAKYFLHNDDGISLIPTLTISTDKYLLGAWYHLREATLEGGAIP LVKAYGMDLFELAAKNDEISGKFNNTMGNQTAIIMKKVLEIYKGFEGINQLVDVGGGLGINLKLIVSKYPQIKGINF DLPHVVKDAPHFLGVDHVGGDMFIEVPQGEVIFMKWILHDWGDDRCLKLLKNCYNALPKFGKVVVVELVVPESPMTD IVTKNTLTLDAGLFIVVPGAKERTKEEYEALAKKAGFSTFRLVCRAYSYWVMEFHKNVIV

Seq. ID No: 389

>IOMT 2

MGSQAEVGKAMTEEEACEFAMQLVSSSILPMTLKAALELELLEIMATAGEGAQLTPAEIAAQLPTSNPDAPIMLDRM LRLLACHSVLTASTYTDDDGKVRRRYGLAPVCKFLVRNQDGVSTAALSLVNQDKVTMESWYYLKDAVLEGGIPFNRA HGMTAFDYPGTDPRFNRVFNQGMSNHSTLTMKKILETYTGFRGLHSLVDVGGGIGAILSLIVAKFPHIKGINFDLPH VIDDAPQFPGVEHVGGDMFASVPTAEAILLKLILHDWGDEHCVKLLKNCCKALPEDGKVVVVEAILPEGIDHSYASA CVYQVDMIMLVTNPGGKERTLKEFEELAKAGGFAGIRPICCVYGSWVMEFYKKM

Seq. ID No: 390

>IOMT 3

MGSTAETQLTPVQVTDDEAALFAMQLASASVLPMALKSALELDLLEIMAKNGSPMSPTEIASKLPTKNPEAPVMLDR ILRLLTSYSVLTCSNRKLSGDGVERIYGLGPVCKYLTKNEDGVSIAALCLMNQDKVLMESWYHLKDAILDGGIPFNK AYGMSAFEYHGTDPRFNKVFNNGMSNHSTITMKKILETYKGFEGLTSLVDVGGGIGATLKMIVSKYPNLKGINFDLP HVIEDAPSHPGIEHVGGDMFVSVPKGDAIFMKWICHDWSDEHCVKFLKNCYESLPEDGKVILAECILPETPDSSLST KOVVHVDCIMLAHNPGGKERTEKEFEALAKASGFKGIKVVCDAFGVNLIELLKKL

Seq. ID No: 391

>IOMT 4

MGSTAADMAASADEEACMYALQLVSSSILPMTLKNAIELGLLETLVAAGGKLLTPAEVAAKLPSTANPAAADMVDRM LRLLASYNVVSCTMEEGKDGRLSRRYRAAPVCKFLTPNEDGVSMAALALMNQDKVLMESWYYLKDAVLDGGIPFNKA YGMSAFEYHGTDPRFNRVFNEGMKNHSIIITKKLLEVYKGFEGLGTIVDVGGGVGATVGAITAAYPAIKGINFDLPH VISEAQPFPGVTHVGGDMFQKVPSGDAILMKWILHDWSDEHCATLLKNCYDALPAHGKVVLVECILPVNPEATPKAQ GVFHVDMIMLAHNPGGRERYEREFEALAKGAGFKAIKTTYIYANAFAIEFTK

Seq. ID No: 392

>IOMT 5

MGSAGETQITPTHVNDEEANLFAMQLASASVLPMILKSALELDLLEIIAKAGPNAQLSSSDIASQLPTKNPDAAVML DRMMRLLACYNVLSSSLRTLPDGKIERLYGLAPVAKYLVKTEDGVSIAPLSLMNQDKVLMESWYYLTEAVLEGGIPF NKAHGMTSFEYHGKDARFNKVFNKGMADHSTITMKKILETYTGFEGLKSLVDVGGGTGAVISMIVSKYPSIKGFNFD LPHVIEEAPSYPGVEHVGGDMFVSVPKADAVFMKWICHDWSDEHCVKFLKNCYDALPENGKVIVAECILPVAPDSSL ATKGVVHIDVIMLAHNPGGKERTEKEFEALAKGAGFQGFRVCCSAFNSYIIEFLKKP

Seq. ID No: 393

>IOMT_6

MGSTAETQITPVQVTDDEAALFAMQLASASVLPMVLKSALDLDLLEIMAKNSSPMSPSEIASKLQTKNPEAPVMLDR ILRLLTSYSILTCSNRTILGGDSVERIYGLGPVCKYLTKNEDGVSIAALCLMNQDKVLMESWYHLKDAVLDGGIPFN KAYGMSAFEYHGKDLRFNTVFNNGMSNHSTITMKKILETYKGFEGLTSLVDVGGGIGATLKMIVSKYPDLKGINFDL

PHVIEEATSHPGIDHVGGDMFVSVPKGDAIFMKWICHDWSDEHCVKFLKNCYEALPEDGKVILAECILPETPDSSLS TKOVVHVDCIMLAHNPGGKERTEKEFEALAKGSGFKGINVACNAFGVYVIELLKKM

Seq. ID No: 394

>IOMT 7

MEMINFMHHMDSTWNLCGKDVVQAFDFSEFHTVYDLGGCSGGLAKQFVSTYNDSTVTIMDLPKVVQTAKKYFVTDQE QQIHFIEGDLFNDPIPEADLFIMARIIHDWTEEKCLELLRKIYQSCRPGGGVLLVEVLLNEDKSGPLMSQLFSLNML VQTEGRERTPSEYTKLLTDSGFRDIQVKITGKIYDA

Seq. ID No: 395

>IOMT 8

MERLLDACVGLKLLKVELKSNKGYYSNTDVSTMYLVKSSPRTLYYMIMFYSKTTYMCYNFLPQAVREGQCQYERAFG ISSKDLFEALYRSEEDTLAFMYFMNSTWSICGKYVVQAFDLSEFHTIYDLGGCTGALAKQLVSTYKESTVTIMDMPN IVQAAKKHFVTDKEQQIHFLEGDFFNDPIPEA

Seq. ID No: 396

>IOMT 9

MIPFNKAYGMTAFEYHGKDDRFNKVFNAGMFNHSTMTMKKILDIYDGFNNLTTLVDVGGGTGASLNMIVSKHPSVKG INFDLPHVIQDATTYPGIEHVGGDMFESVPKGDAIFMKWICHDWSDAHCLKFLKNCYKALPDNGKVIVA

Seq. ID No: 397

>IOMT 10

MAQAAAEAEGITPVMDLLFAAQGSSALLVCARLGLFDYISSQGEEGVSCKQLASRAQWSTRAASAVMVSLAASGILA VKPSSAGAQHCFEHSYTLTPRAQRFLVTEKPGSMSAYTEIHWEASPELLLKKAAETEDEKRNFMLETGGGAPSEVFL AAMQGQSSYAAMVLTRLVDLSDTRTFVDVGGGSGTFAIEACKATPNLQGVVYDLAGACPTTDGFIARAGMAERVKTH AGNMFEDERFPAADCYAFGNVLHDWSDQDNSKLLRKAFESLPAQGKVLLLEMLVEEDVVSTSPSAAGLNLCMVTNEL GRQFKASELRAMLLEAGFAGAEVVSSPLTPYSLVVGTKGEANPVASKPEAAAAAESESITPLMDVLFSAQHSAVLIV CSRLGVFDFVGAQGESGASCAQVAAHAKWTTRAASAMLVSLACSGLLEPTPGSAAAQHCFEHSYRLTPLARRFLVAG QPGQLSAYTEIFWGASPKQLLEKASASLGEWGEGNFMLDAEGGAPSEVFLAAMQAQSTYAAMVLTRLVDLSDVRTFV DVGGGSGTLAIEACRAAPGLQGVVYDLAGACPVTDGFIARAGMAERVKTHAGNMFADERFPAADCYAFGNVLHDWSD QDDGKLLRKAFESLPANGKVLLLEMLLAEDVESSTRSATGLNIVMVTNEQGRQFKGSELEAMLRAAGFAATEVVRSP LTPYALVVGTKG

Seq. ID No: 398

>IOMT_11

MSRTSWDEGEDVDLDSVAYGFMASQALFTGLELGIFDHIAAAGAGGLSAAGIGKACGIEAPRVQTLLTSLVAVKCLK RDASAMYTLSPNTAQYMVTSSRHFYGDYLRYQIGRQFYHRMGALPEVMTSGKAPSYASWFSDPEVARTYTQAQHNGS VATAKYLIKKKLQLGGISAMLDVGGGSGAFSYVFTQATPGLHSKVLELPEVCRTGEGIREKQPEDVRSRVSFVELDA SSPTWPVDDSAFDVVLMSYISGSVPEPIIGSLYANAMKALRPGGRLLVHDFMVNDSLDGPALGALWGLQHVTVNADG LGLCPKEVIARMGAAGFDTSKCEAMEMIHGMTKLIVGHKG

Seq. ID No: 399

>IOMT 12

MCSSKELDFPHILIDYQHGFLVSKTIFTACELGVFDLLHEVQEPVPAATIASRLSTSEDGMERLLDACVGLKLLKVY LKNNKGYYSNTDVSTIYLVKSSPKTLHYMMIYYSKITYMCWHFLPQAVREGKRQYERALGTTSNDLFEIVYRSEEEM TTFMHFMDSTWNLCGKDIVQAFDLSEFHTVYDLGGCSGSLAKQLVSTYKESTVTIMDLPKVVQAAKKHFVTDKEQQI HFLEGDFFNDPLPEADLFIVARIIHDWTEETCIKLLKKMYHSCRPGGGVVIVELLLNEDKSGPVISQVYSLYMLVQA EGKERTPSEYTKLLTDSGFKDIKVKATEKLFGAILGRK

Seq. ID No: 400

>IOMT 13

MCSQEGEGYSLLKEYANGFMVSQVLFAACELGVFELLAEALEPLDSAAVSSHLGSSPQGTELLLNTCVSLKLLQADV RGGKAVYANTELASTYLVRGSPRSQRDMLLYAGRTAYVCWRHLAEAVREGRNQYLKAFGIPSEELFSAIYRSEDERL QFMQGLQDVWRLEGATVLAAFDLSPFPLICDLGGGSGALAKACVSLYPGCRAIVFDIPGVVQIAKRHFSASEDERIS FHEGDFFKDALPEADLYILARVLHDWTDAKCSHLLQRVYRACRTGGGILVIESLLDTDGRGPLTTLLYSLNMLVQTE GRERTPAEYRALLGPAGFRDVRCRRTGGTYDAVLARK

Seq. ID No: 401

>IOMT 14

MGYAAPQARQSDKQIFDIYFGFLHSYALLFADEVGLFDLLRCEALTLDQVSMATSLPSRSSQALLSLCASLGLLEKR GERFALSALTEGFLVREAETSFCGVLASARGQAAAFSYDFFKASLLKGESQLFGGRDLFDNNAQDPEHCEIFTRAMH SKSKGPAQAWVEKIDLSAHACLLDVGGGSGVHAISALARWPNLNAVVFDLPPVCAIADTFIERYQMTARAQTHGGDI WYTDYPFADAHFYSDIFHDWPLERCRFLARKSFDALPSGGRIILHEMLFNAQKTGPRNVAAYNANMLLWTQGQQLSE PEAADLLQAAGFVEILAFPTGYGDWSLVTGVKP

Seq. ID No: 402

>IOMT 15

MGSIDAQMAAVEEESCIYAMQLAYTVVLPMTLKNAIELGMLEILMGAGGKMLSASEVAAQLPSTTTNPDAPAMVDRM LHLLASYKVVSCEVEEGTHSRRYGPAPVCKWFTSNKDGDGASLAAMLLLTNEKVLLESLNHLKDAVLDGGHPFLKAH GMTVYEYNKTDARMKRVFSQAMNNYSTIINRKLVEMYMGFHDIAFLVDVGGGVGTTIRAITSKYPHIKGINFDLPHV IADAPQCPGVQHVAGDMFRNVPSGDAIILKWMLHNWTDEHCTTLLRNCYDALPPHGKVFIVENILPLKPDATSRGQQ TSLSDMIMLMHTPAGRERSQREFQELGKAAGFTGFKTTYIYGNSWVIELTT

Seq. ID No: 403

>IOMT 16

MSFDTQHALQPYWDLAVAPVQADGLAAALELGIFEVLATPHTPAQLADVLSLHGPHTALLLELLWSMQVLERDGADA DTDANALRYRCTATTLQYFCRDAVAFCGDAWLYRLHALRHFATQLNTLVRDGGKVTPYSTASGVNWAAAAQQQIGQE QRAVTMRAALCVMQRVAPFADGNTPLRLLDAGGGPGWVAIALAQAHAGVHGCVFDWPETVAVAAANIAHAQLSDRLE TLGGDLDSDDIGGGYDLIWCSSVLHFVPDMAAALRKMQAALKPGGVLVCIQAEIAAAPGDAARVLPYYLPMRMLGRT VTRHGELAQLLRDTGWRQVEQYGASDFPMAPVOVLIARA

Seq. ID No: 404

>IOMT 17

MQLASASVLPMVLKSAIELDLLDIIAKAGPGAYLSPSEVASQLPTSNPDAPVMLDRILRLLASYSVLTYSLRTLPDG RVERLYGVGPVCKFLTKNEDGVSIAALCLMNQDKVLMESWYYLKDAVLEGGIPFNKAHGMTSFEYHGKDLRFNKVFN KGMSDHSTITMKKILETYKGFEDLTSLVDVGGGTGAVLSTIVSKYPSIRGINFDLPHVIEDAPSYPGVDHVGGDMFV SVPKGDAIFMKWICHDWSDEHCLKFLKNCYEALPDNGKVIVAECILPVAPDTSLAAKGVIHIDVIMLAHNPGGKERT EKEFEALAKGAGFQGFRVMCCAFNTYIMEFIKKL

Seq. ID No: 405

>IOMT 18

 $\label{thm:liskyphikginfdlphvvqhapsypgvehvggdmfksv} MLNHTTMVIKKILECYKGFETLKQLVDVGGGLGVALNLITSKYPHIKGINFDLPHVVQHAPSYPGVEHVGGDMFKSV\\ PKADAIFMKWILHDWSDEHCVKLLKNCYAAIPNDGNVIVVDAVLPKMPEVSTSMRCTSQLDVLMLTQNPGGKERTEE\\ EFMALATKAGFKGIRYQECFVNTFWLMEFFK$

Seq. ID No: 406

>IOMT 19

MERKEEVALLKGQAEIWQHLFAFADSMALKCAVELRLADIIHSHGVPITLSQIASAIDSPSPDIAYLSRIMRSLVYK KIFTEHHPSDGGETVLYGPTHTSRWLLHDAELTLAPFVLMENNQWQLAPWHFLSQCVKEGGIAFKKAHGFEMWDFAA RNPEFNKIFNDAMACTTKILMGVLLAEYKDGFGSIGSLVDVGGGTGEMIAEIIKQHPHIKGMN

Seq. ID No: 407

>IOMT 20

MGSASGSAERTQMGEDEACSFAMTITSGSVPPMVLKAVIELDVLEIIKRAGPGAHLSPAEIAAQLPTTNPGAAAMLD RMLRLLASYDVLSYSLHTLPDGRVERLYGLAPVCQFLTNNEDGVTLSALSLMNQDKVLMESWYHLKDAVLDGGIPFN KAYGMTAFEYHGTDPRFNKVFNNGMSNHSTITMKKLLENYKGFEGVSTLVDVGGGTGATLNMIISKHPTIKGINFDL PHVIEDAPTYPGVEHIGGDMFVSVPKGDAIFMKWICHDWSDEHCLRFLKNCYAALADHGKVIVCEYILPVAPETNHA ARTVFHVDAIMLAHNPGGKERTEQEFESLAKGAGFEGFRVAFFF

Seq. ID No: 408

>IOMT 21

MALNPPHQNNVMEKEDLCSFALSIATSSSLSMVLKAIIELDIIGIINRAGPGAHLSPAQIAAQLPTKDPGATASMLD RMLRVLANNSILSCSLRALPNDGPIERLYGLAPVCQFFTKPEDFGPMVLFSQDKVYTDTWHHLKDAVLDGGSAFKKA HGTTLFEYLGTDMRFSKVFNDAMSSSSTITMKKMLENYNGFDGLSTLVDVGGGTGETLNMIIAKYPTIRGINFDLPH VINDAPNYDGVEHVVGDMFVSVPKGDAIFMKWICHDWSDKLCLKLLKNCYTALPNHGKVIVCECILPVAPETSHSAR VASNLDMHMLAYCRGGKERTEQEFEALAKGAGFESFRVVCSAYDLKLYMC

Seq. ID No: 409

>IOMT 22

MAEIPTSSNPSDDPETQKLNGNEEDYDHHHDEDPESDDENYEYALQIAEMLPFPMVMHTAIELDLLGIIATAGPDRQ LSAAEIAAALPAAGNPDAPAMLDRMLYLLATYSVVTCTAVDGGASGGVVRKYGLAPVAKYFVSNKDGVSLGAVISLN QDQAVLASWSKLKEAVLEGGIPFNKVHGMDAFEYQGTNPRFNEIFNKAMYDQSTYIIKKIVRRYKGFENIQRLVDVG GGLGHTLRVITSNYPSIKGINFDLPHVIQHAPTIPGVEHVGGDMFESIPHGDAIFMKCILHDWSDEHCLKTLKNCYK ALPRKGKVIVVQMNMIEEPQTTPLAKAISQMDLWMMTQNPGGKERTRREFQALAEAAGFAEFNPVCHVAGFWVMEFL K

Seq. ID No: 410

>IOMT 23

MSPIDLANELQTLVTSTYSGDVTDPFKLYKAKHSISDLCLSLLRAVQGPEEYTAILAESCQESSALNVVASLGVADH IAESPNGELTLQELSEKVKADEKYLSVVLSSLVYHGYFKEVGGFGSQVYANNDFSSLLLSEETNAKGGKSMKDAIGL SADDGAKATTRLLDAATGKAKGEAKTAANIAFDFSESLFQWMASPGNEWRGKRTAKAMVQLHGMANGGIGEDYPWEK LATPIIDIGGGIGSFQGMLLALPKNKELTFTIFDIEKTVEHAKKVWAGKPQWMQDKVSFIAGDFMKSSPNDSKIPTP AQGAGTYVIRHVLHDWDDAQVVTILKHVRNAMLGSPASTPPKLLLVEMMLNETSSRFTRTTSLQLLSLNGGITRTEV QFRRLIKEAGFTVDSVTEVRGVDLVVELSPASL

Seq. ID No: 411

>IOMT_24

MPSTTISQLVGLIQQSVMALEKLCLENRTSLPDLDAFHFDQSSETFRSLPGAAQDAKIAVAACMQLIAILSPPTDTV YRAALGGHLSFATRTCLEANITEILREAGPEGLHINDIASKCGLDPSKLGRVIRYLVIHHIYREVKPDVFTNNRTSS TMDTGKPLDKLISEPDRKYDDTGFPALISHFMDVDQKCGAVGWDVLKDPVLGHSCDLTETIFSRAFNTKSKYWDFFD HPENHYMRRRFDYAMKGLGAIEDHDMVLHAFSWEDLDKGSVIVDVGGGIGTAMLPLARKYPNFDIVIQDLPIVIEEG TKFWSQNLPDAVANGNIKLHAHNFFDEQPIKNASVFYLRHVLHDWPMPDMVKILRRLRDVAAANTTLIILDYILPYS CKMFADKDAVSIASARYYSEAPEPLLPNYTHKNVISDSDMYVFQMMFHYNSQEHTYLSLKSLLDASGWRLVRLRAID PRNDYFQSIECKILA

Seq. ID No: 412

>IOMT 25

MAQPMMLALAKLISDSVAKVDQLCIEQGVIFPSLDDPFTTESESIKLHPDVAEASNYIISAAAQLIAILRPVPVTLS TSAIHVHVSSALRVVVDSNVVEILREAGPQGLHVKKISEKNGVEAGKLGRLLRLLASGHMFKEITPDVFATNRISSA LDTGKPYEELVKNPGEKLIGTNGIAAYISRSTDESVKSSGFLYEALTYSSSEKVPLPPSPFNLAFNTELHIFSWLAQ KGNEHRLQRFGIAFDGFDKMLPVNGVTKGYRWGSLPKGSIVVDVGGGVGSESMKIAKTFPDLKVIIQDAEGVVANGV KFYETRFPEGLSSGQVTFQAHDFFTPNPVTNARVFFMRFVLHDWPDATCVKILKNLRAAAAPDTELIINECLIQYAC

STESEISKSIPGGRFKPPPSPLLPNLGYARIFHYLIDLQMAIVAHGVERTVEQYASILQKSGWKLKEVLRMPESAYS LHKLVAVPOPE

Seq. ID No: 413

>IOMT 26

MTRLTDSLGMLRSKLVPPQATMLQLLTGYRVSQGIYVVAKLGIADLLATGSKTSQDLAAITNVHAPSLYRLMRSLAS LGIFTETENGRFELTPLAATLRSDHPNSVHDAAIMFLEDWHWQAWGNFFDCVKTGETALEKTFGTSNVFDYFETQNP EAGQHFDNAMTNTSVMTNQALPTAYNFGAFKTLVDVGGGQGSFLSALFHQWDHLHGILFDLPPVIESAEQQNLLSGF EKRTTLAAGDFFKAVPDGADAYLLKTIIHDWDDASAIAILKTCRRAMNHDSKLLLVELIVPSGNAPSLSKILDLEML AVFGGVERTEAEYRSLLLSAGLKLTRIYDSPCPWSVIEAIPV

Seq. ID No: 414

>IOMT 27

MSMPPAHSRLYSRSFLSMLPDAITPFPYLPPDATDTRPLLAELEALLEIINSSARLAITEYKKHGNNVPTIYSTEFH PLDFATDTVALKKAIRLLEDACQQLCASLAPPQHTLANVSRVHHRQYVTQLTTHDILEKYPSGSHIRELSQTVGLEK GKLARILRVFAFKGCFIEVDTDVFASNRLSLIMKSSNDCGCLTCIHAQDVSQGAGVLYETLTEPEYAMSYEPDKAPM IYVLKRKGLKGSFFDWMKADAKRRENYHYAMIALGPVMGSLSILHHYPWNDVATVCDVGASVGSVSIPLSKAHPHLK ITDQDLPEVLEAARSVWEKEAFEALREKRVEFLTLDFFKEAPVPGKDVYYLRHIIHDWPDAEAAVILRNISKAMEPH SRLLIHNYVIAGANRRPDEEQRAPEPMLPNFGAGDSRKYRQDLNMWILHNAKERTVDDQITLA

Seq. ID No: 415

>IOMT 28

MAPGREGELDRDFRVLMSLAHGFMVSQVLFAALDLGIFDLAAQGPVAAEAVAQTGGWSPRGTQLLMDACTRLGLLRG AGDGSYTNSALSSTFLVSGSPQSQRCMLLYLAGTTYGCWAHLAAGVREGRNQYSRAVGISAEDPFSAIYRSEPERLL FMRGLQETWSLCGGRVLTAFDLSRFRVICDLGGGSGALAQEAARLYPGSSVCVFDLPDVIAAARTHFLSPGARPSVR FVAGDFFRSRLPRADLFILARVLHDWADGACVELLGRLHRACRPGGALLLVEAVLAKGGAGPLRSLLLSLNMMLQAE GWERQASDYRNLATRAGFPRLQLRRPGGPYHAMLARRGPRPGIITGVGSNTTGTGSFVTGIRRDVPGARSDAAGTGS GTGNTGSGIMLQGETLESEVSAPQAGSDVGGAGNEPRSGTLKQGDWK

Seq. ID No: 416

>IOMT 29

MEVVPSWFKETLDKSQFSAPYEYAVETAKQKALEVARRMHVKHLKTPDIVIGADTIVTLEGAILEKPFDKQDAYNML SRLSGKEHSVFTGVVIVHCRSKEENHLETDIIDFYEETKVKFADLSEDLLWEYIDSGEPMDKAGGYGIQSLGGMLVE SVHGDFLNVVGFPLNHFCRKLTEIYYPPPKQAICRVKHDSIPYVESFENLSDVETDCTSTSKACEAKKAVQDGVCKA DGSGSAVLQNGIEERPVHCAQQLSKITQLLDGFKASQTLFAASKLKVFDKLKDKGALKAMEIAEKINASVHGTERLL DACVALGLLEKTHQVYSNTELANTYLVSDGAFSIHEYITYSSDHLWSHFTHLDSAVVEGGGQHQTAVKKACDNRNGS EVKERFMRAMHCMLKITARDLVTAFDLSKYSSACDLGGCTGALAHELVWTYPEMKVNVFDLPEVIKHTSQFQPESFD SSRVTFSSGNFMEDTLPEADLYILSRVLHDLPEGKLNHLLKKVSEACCPGRSALLVAEIVLDEDKKESRGLLQSLSM GEGKQRSGTEYKKLLENHGFNSVQIKSTGNLLDAILAIKTS

Seq. ID No: 417

>IOMT 30

MDTVKNLQASNVPSSLSQEDEEVFTSGLHVCSSEVFSHALSNCIQLGLFDIIAEAGPSAYLTATEITAQLPTKNPDA VSMIDRMLRLFSCHSLLNSSLKTVADDVVETRYGLSPIGHLFVRKKDGVTMAACFTDYKAWTEAWLHLKDAILEGGN PYEKAHGVPIYEHISSDTESVKGFSQAMDSISSFIMKKVLENYSGFKGLGSLVDVGGGSGFALNMITSEYPSISCIN FDLPHVVQEAPYHPGVKHVGGDMFLDIPSADAIMIKEVLHNWGNEDCVKVLKNCYEALPKGGKVIVVSHVMPEVVGS SNAAAKYVCQLDVMMLLFGGGKERTEKEFKALGKAAGFSGFQLICFAAYNAVAVMEFYK

Seq. ID No: 418

>IOMT_31

MAEDVAAVADEEACMYAMQLASSSILPMTLKNALELGLLEVLQKDAGKALAAEEVVARLPVAPTNPAAADMVDRMLR LLASYDVVKCQMEDKDGKYERRYSAAPVGKWLTPNEDGVSMAALALMNQDKVLMESWYYLKDAVLDGGIPFNKAYGM TAFEYHGTDPRFNRVFNEGMKNHSVIITKKLLEFYTGFDESVSTLVDVGGGIGATLHAITSHHSHIRGVNFDLPHVI SEAPPFPGVQHVGGDMFKSVPAGDAILMKWILHDWSDAHCATLLKNCYDALPEKGGKVIVVECVLPVTTDAVPKAQG VFHVDMIMLAHNPGGRERYEREFRDLAKAAGFSGFKATYIYANAWAIEFIK

Seq. ID No: 419

>IOMT 32

MTSLQDLDYPQQLLEYKDGFLVSKTMFTACELGIFDLLHKSDEALSALTISSHLGTSADGTDRLLSACVGLKLLKVE MKNNEAFFSNTDVSDVYLVQLSPRSLYHMMMYYSQTLYKCWHFLPDAIREGKSQYERAFGVSSGDIFKALYRSEEEM VTFMHHMDSVWNICGKDIIAAFDLSSFNEVCDLGGCSGGLAKQLLSIYPSSSVTILDLPEVVQTAKKHFITDADCNI AFLQGNFFNDPIPEADLYIMARIIHDWTQEKCLQLLNKIYKSCRPGGGVLLVEVLLNEDRSGPLTSQLYSLNMLVQT EGRERSPCEYTKLLAHSGFRDIQVKATGKIYDAILGRK

Seq. ID No: 420

>MUP1

MSEGRTFLSQLNVFNKENYQFSSSTTKKEVSNSTVDADNGASDFEAGQQFATELDQGEKQLGILSCIGLICNRMLGT GVFAVSSTIYTLCGSVGLALIMWAVGAIIAISGLYVYMEFGTAIPKNGGEKNYLEAIFRKPKFFITCMYAAYIFFLG WAAGNSINTAIMFLTAADTEVTKWNQRGIGVAVVFFAFLINSLNVKIGLYLQNILGIFKIGIVLFISITGWVALGGG LKDGYQSHNFRNAFEGTETATAYGIVNALYSVIWSFVGYSNVNYALGEVKNPVRTLKIAGPTSMVFLAIIYIFVNIA YFAVVPKDKLISSKLILAADFFDIVFGGQAKRAAAALVGLSALGNVLSVIFSQGRIIQQLGREGVLPFSNFFASSKP FNSPMVGLFQHFIVCTVTILAPPPGDAYLLVQNLISYPMNIINFAISAGLLWIYWQRRQGKIEWNPPIKAGVFVTGF FTLSNLYLIIAPYVPPSNGESVYSSMPYWIHCVIAWGIFFFGGVYYVVWAQLLPRWGHYKLVSKDVLGEDGFWRVKI AKVYDDTIGDVDTQEDGVIETNIIEHYKSEQEKSL

Seq. ID No: 421

>NAT_1

MAPIEEEEPLPEELVLLERTLADGSTEQIIFSSAGDVNVYDLQALCDKVGWPRRPLTKIAASLRNSYLVATLHSVTM PSKAEGEERKQLIGMARATSDHAFNATIWDVLVDPSYQGQGLGKALMEKVIRTLLQRDISNITLFADNKVVDFYKNL GFEADPOGIKGMFWYPRF

Seq. ID No: 422

>NAT_2

MSTPSVHCLKPSPLHLPSGIPGSPGRQRRHTLPANEFRCLTPEDAAGVFEIEREAFISVSGNCPLNLDEVQHFLTLC PELSLGWFVEGRLVAFIIGSLWDEERLTQESLALHRPRGHSAHLHALAVHRSFRQQGKGSVLLWRYLHHVGAQPAVR RAVLMCEDALVPFYQRFGFHPAGPCAIVVGSLTFTEMHCSLRGHAALRRNSDR

Seq. ID No: 423

>NAT 3

MTSDVGADEHATTEAGGGRLQAGGHSSAEEASERCPPAAAPPSGMKGAADCGPQDSSARDDVSFIPYKDETDMPGIV ELIEKDLSEPYSIFTYRYFINNWPELCFLTMRGDSCVGAIVCKLDVHRCRNTNRGYIAMLAVEKGLRGKGIGSTLVR LCLDKMREMGADECVLETEVTNKGALGLYRNMGFVKEKRLHKYYLNGNDAFRLKFLFKLPEGFDRGEGCLGPLCEVP PVTT

Seq. ID No: 424

>NAT 4

MVSIRPATVDDLLAMQACNLCCLPENYQMKYYFYHMLSWPQLLYVAEDYGKKIVGYVLAKMEEDSSEVHGHITSLAV LRSHRKLGLASKLMRAAMAAMEETFGAEHVSLHVRVTNRAAFTLYSETLGFEINDVEHKYYADKEDAYDMRKMFETG LKKQEAGKQKKKEKEKEKEKEKEKEKEKEKEKEKGKDSQPVEQQGGAAGADKEAQRSKRARSGDRKRNGRPRRRSGS G

Seq. ID No: 425

>NAT 5

MLPRPPVGAAKEGHLTLFYRELRWLCPGTRFYFVVRDPAENVRSIADRLALGPEGLRRPPRIVARADLGWREVLNMS YAGVREESALGTLVGRWNLMARLYLDAPKGAMALVRYEDLVAEATWEAEVRRVAAAETLDLRERVLWPGRPDLCTLP GDESALHFGAVAAGKVLGVISVFLSPEPGGRAQFRKFAVDPEVQGRGLGRRLLEQAVAAAREAGAGSLFCHARADQQ GFYERRGLHVVGEPFEKYGGKPYVEMEVPFQ

Seq. ID No: 426

>NAT 6

MKGSRIELGDVTPHNIKQLKRLNQVIFPVSYNDKFYKDVLEVGELAKLAYFNDIAVGAVCCRVDHSQNQKRLYIMTL GCLAPYRRLGIGTKMLNHVLNICEKDGTFDNIYLHVQISNESAIDFYRKFGFEIIETKKNYYKRIEPADAHVLQKNL KVSSPAPNADVQKSEN

Seq. ID No: 427

>NAT 7

MSTPSIHCLKPSPLHLPSGIPGSPGRQRRHTLPANEFRCLTPEDAAGVFEIEREAFISVSGNCPLNLDEVRHFLTLC PELSLGWFVEGRLVAFIIGSLWDEERLTQESLTLHRPGGRTAHLHALAVHHSFRQQGKGSVLLWRYLQHAGGQPAVR RAVLMCEDALVPFYQRFGFHPAGPCAVVVGSLTFTEMHCSLRGHAALRRNSDR

Seq. ID No: 428

>NAT 8

MSSGGVIVDLHRNSTNWAKVVDDIVKLERKIFPKHESLARSFDEELGKKNTGLIYMEVDGEVVGYAMYSWPSSMYAC VTKLAVKENCRRQGHGEALLKAAIKKCRTRNVHRISLHVDPLRNPAISLYKKFGFQVDNLIDGYYSSDRNAYRMYLD FDAD

Seq. ID No: 429

>NAT 9

MDERVVVELKKSLADYPKVLEELVRIEKKVFPKHESLSRSFDEELGKKNSGLLYICSNGEVAGYVMYSWPSALLAVI TKLAVKEKYRRQGYGEALLRAAIQKCKTRNIQRISLHVDPSRTPAANLYKKLGFRIDSLVEKYYAADRDAYRMYLDF DADV

Seq. ID No: 430

>NAT 10

MMEGAQEDEETEEKAEFDASEIEYVSYGGEHHLPLIMCLVDHELSEPYSIFTYRYFVYLWPQLCFLAFHKGRCVGTV VCKMGDHRHTFRGYIAMLVVIKPYRGRGIATELVTRAIKVMMESGCDEVTLEAEVTNNGALALYGRLGFIRAKRLFR YYLNGVDAFRLKLLFPRSEMHPSLHLLADQDGHDDQIAMEGEA

Seq. ID No: 431

>NAT 11

MKQVGISLDAVREKNLMQLKKLNVVLFPVRYNDKYYADALASGEFTKLAYYSDICVGAIACRLEKKDPGAVRVYIMT LGVLAPYRGLGIGTELLNHVLEQCSKQNISEIYLHVQTNNDDAINFYKKFGFEVTETIQNYYTNITPPDCYVVSKRL EAQPKK

Seq. ID No: 432

>NAT 12

MNIRVAKVEDLMGMQACNLQNLPENYMMKFWMYHSMTWPQISFVAEDHKGRIVGYVLAKIEDPSEEGTTEEIHGHVN SISVLRSYRRLGLAKKLMLLSQEAMSSIYKASYVSLHVRKSNKAAIALYKDTLGFEVAKVEKKYYGDGEDALSMRLS LKNP

Seq. ID No: 433

>NAT_13

MSDFQVAPLTARELARVRDLHAKLLPVQYPVSFFIHLLVIPSRACYVAYSHGSPVGFISAALHNPTRCFISGDSEVS PRLEILTLGVLPAFQHRGLARRLIMSLVNAFKQDPATPILIYANVSTTNTRALQFYERMGILVSSDIITNLYRTLSY GSRDAYLVVGAL

Seq. ID No: 434

>NAT 14

MLSIHPLKPEALHLPLGTSEFLGCQRRHTLPASEFRCLTPEDATSAFEIEREAFISVSGTCPLHLDEIRHFLTLCPE LSLGWFEEGCLVAFIIGSLWDKERLTQESLTLHRPGGRTAHLHVLAVHRTFRQQGKGSVLLWRYLHHLGSQPAVRRA VLMCENALVPFYEKFGFQAMGPCAITMGSLTFTELQCSLRCHTFLRRNSGC

Seq. ID No: 435

>NAT 15

MADAPSGPSVLSHYPGAGLALPPGDEQEDGEEEEEGRYEPRRGHHHHRRHHQQQQLNGLISPDLRHIKALKSKLPPP PHDERTGAPNGLERLQDLEEEEAVLASRMGACSLHPGDGSIRYVRYESELQMPDIMRLITKDLSEPYSIYTYRYFIH NWPQLCFLAMVEEECVGAIVCKLDMHKKMFRRGYIAMLAVDSKYRRKGIGTNLVKKAIYAMVEGDCDEVVLETEITN KSALKLYENLGFVRDKRLFRYYLNGVDALRLKLWLR

Seq. ID No: 436

>NAT 16

MDAAMPTEISFRQPTPDDAARCFEIETSAYEGDEAATLEKIATRIALYPEGFVILEADGKIAGFINSGCAFEVVMSD EEFKELVGHDPAAPNAVIMSVVVDPAEQGKGYSKLLMQHFIARMKAMDKKTIHLMCKEAHVPLYARMGYRYTRPSAS DHGGMAWHEMVMEL

Seq. ID No: 437

>NAT 17

MEGLHSEWEVGAELKALGAVPKPFIGSHVSGKLIQRLKQDLRQSWDRGQSQARPTCTLPQPLPAPLGSSVPSASAQT QVSRLVPVAPPQPDPAMSVLNAVPFMRPIHLRSPRQQRRHTLPASEFRCLSPEDAVSVFEIEREAFISVSGDCPLHL NEVRHFLTLCPELSLGWFEEGRLVAFIIGSLWNQDRLSQDALTLHKAEGSSVHIHVLAVHRTFRQQGKGSILLWRYL QYLRCLPFARRAVLMCEDFLVPFYSKCGFKAVGPCDITVGPLTFIEMQCPVQGHAFMRRNSGC

Seq. ID No: 438

>PSIK 1

MQANRPISDQDQDQFKLNLTTADGTRSYLEKHLSLNVEAVERLSGGFINFVWRAKLGTPYEGQNSIVVKHAPPFTAM DSSLNVAVERLKFEYDSLKMIGSEPSIAGEDALISVPSVYHHDNIKHVLIMQDVGTMSTLRDFMGASPPPPTDMAAL IGCQLATFIAGLHNWGRNNESARAGLSANAYGRTVMDLCGYQTVVPNATASGILDPLLSTAMAALAERDKTSEETAI MGDFWALNVLVDIDMSASGEKALKNIWIVDWEACRYGSPAVDVATFAGDCYLISRIHNETATDAMRRNFLGTYVALA KVDPMEVVIGMGTMWIMWTKYQEDIGEAEKRERVAKGVEYIHKGWERSREWLPVSLAQELIA

Seq. ID No: 439

>PSIK 2

MDLTTGDGVRVYLTAHMTLKVESTERLSGGYCNFVWRAKLKTPYEGQNSVIVKYAAPFTSWDQTIELGVERLAFECM SLKMITSETPLLEENGLVAVPTVYHYDSTANVLVMQDIGSIATLHGFLRSNTPPTVPMAALIGAKLAAFIAGVHNWG RNNLPAHTRLSANTVGRTAMKKLCYETIVPKAAKSGVVDPLLPMVVAALSEEAMTNDETLVMGDFWTANVLIDVQES HTGEQVLKKLWVIDWESCRYGNPATDIASFAGDSYLVSRFQDHGLGEALRHSFLETYAALAKVDPLRVALGLGAHWI MWTDDLGQGGEAETRECVDKGLEYIQRAWDQSAEWVSLSLAKELVVL

Seq. ID No: 440

>PSIK_3

MANENPOLLTVAGVLRFLAPTPFASDEVHPLSGGNCNFVYRIHLRTPYNNISTLVLKHAEPYVAASAHRMPLAVERQ NTEVTAMNAVKAILSSDAVVIVPTIHHFDDVAHVVIMDDCGVGAVTLKQLMLKNPPPVSVAKALGAGLGEFLSRLHV WGRDPQTSNHVSFDQNQQGRTISGYVTYGRLVSTLTGKDNIPALSDPPLDIAQSKLDTISALSSEKIHAINTSHQTL

TMGDFWPGNIMVRLNPAGDSLERAYVLDWEVAKPGVAGLDIGQFCAEMHSLRRFSPACDASATTVLDAFLKTYRDAA GVDVGVAKDAMVHVGAHLVAWTPRVPWGSKERTREVVEEGVGYLVEGYAATOEWLRGSLVGRLV

Seq. ID No: 441

>PSIK 4

MEIEWCDLDLTSESRPPTHKYTYFATALMPFDLTTRDGVRMYLTAYLALDVMSVERLSGGYCNFSWRAKLESPYEGQ ISIVVKHAAPFTSWDRNTELGVERLAFEYKALKILNSEPSVIAKNSLVAVPAVYHYDPTANALIMQDVGSIPTLHAL LRNNALPPVPMAEKISNELAAFIAGIHNWGRNNQEARANLSQNLVGRTAIRKLCYETLVPKAEKSGVDDPLLQQVAA ALSEEVMNSEETLVMGDFWTANVMVDIQETGAGVRSLRKIWVIDWEGCRYGSPAADIASFAGDSYLVARFHHHDLGE TLRHSFLETYAGLAKVDPFRVALGSGAHWIMWTDDLSEQEEGEIRECVDKGVEYIHRAWEQSTKWISLSLAKELVT

Seq. ID No: 442

>PSIM 1

MHFSYDFTMCNPPFYGDYAELTRLRESKLKGPFGGAHEGVSTELFTAGGEIHEFIASELNQGKTLRWVVGWTFHKDL FDKKVIEPLHILIKLKPLSCNTLELLDSDHELATPYSKKRCLRRISFTPKGRPPTKQTISVMHPNEASWASLLNHLQ ALDISVTVGNHFLTAEVKDPTWTRAWRRSSKVTSKITPFSFSGQFSDPPERLLVLQLLVDESQTSEDILLSFQSL

Seq. ID No: 443

>PSIM 2

MHPRNPYRTPPDYAALARSFPELKPYVSRNANGTVSVDYQDEAALRCLTRALLYRDFGLSVDLPKDRLCPTVPNRLN YILWIEDILNVSSLSRLQSNSEATVRGLDIGTGASAIYPLLGCRVSPRWDFYATDIDAQSLAHARANITRNGLQGRI NLVAADPKGSIFGPLESKHDTTFEFTMCNPPFYSSEEDIAQSAAVKKLASNAVCTGAAVEMITPGGEAAFVVRMVRE SLALKMRCQWYTSMLGKMSSLTEIVGLLRENSIDNYAITEFVQGKTRRWAIAWSFGHVRLLDSLARLSGGPLQSLMP TRNTCRRSFAVPRMVLHKHLILVLDGIEGTSQTPMSIPVGAGDADGLYGLQISASRDTWSRAARRKRQHGAMDISLD NDEVGMKCLIKVLSVEEAREGAEAVVLECTWVYGHERALFESFWGHVCRKIGEANG

Seq. ID No: 444

>PSIM 3

MHARSIFNPNSAQFQARLTFSELSNEFPKLKPFLKYKRSRKQNEADPLSSQCTFIDFKDPVATRAYNEVLLKKYFDL SLEFLPGSLCPAVPNRLNYTLWLEDVLNVFPGSMGANNQRDELRGLDIGTGSSCIYPLLICRTHPNWRMAGSDINPS SIEIAKKNVQENRLLDRIQLFLTTDKRDSVLEGQIFQTHLFFNSKKCLQDEKPARFCYDFTMCNPPFYSDVEDLNNS RQAKTTTILGGGHEGVSSELFTTGGELLFLSQMVEESFLYKDKVGLVSSYFFVLKCIVEILRLLGQHKIQETIASKL IQGKTIRWVIGWTFHKDLFDLKHPSCNTLKVQDIHCTNEEAPASKKICLGKIPLNSKEHIPSKQLISSSQSSDIGWT RLKSRLGDLRIEFSLEKLSLIGKVVYPTWTRAWRRNGKAKSKPTPFSFSAQQSDASETTIQLELLASEIEEPDENTL VSFQSLCNHLRSYLKD

Seq. ID No: 445

>PSIM 4

MSDIDAQSLVYARANVARNALEGRIAVVTAEPEGSIFGPIEAEKEIQFDFTMCNPPFYASAEDIAQSAATKELGPNA VCTGAAVEMITSGGEGAFVARMIDNYAITEFVQGQTRRWAIAWSFGHDRLPDSLARLSSGPLQSLMPTRNTCRRSFT FARMNLLSRLEQVLNNIEGLSHSNMSPSEDRGSGGRPSSLLVSVARDTWSRAARRKKQRGSMDTSLDNDTSGLICSV KVLFDEEGREGSEIASLECTWIHGRERALFESFWGHICRKVGEVSG

Seq. ID No: 446

>PSIM 5

EGLSPFLLMHPRNQYCKKKPDFADLAKSHPPLREHLKWKTEDYATIDFKSPSAQKELTRALLKQDFHLDVDMPVDKL VPTVPQKLNYIHWIEDLLSGGRSDSIPRGEGIRGIDIGTGPACIYPLLATSLNKWTFVATDIDAVSLEYAVKNVSRN DMEGRIRVKGVDPDTLLVGVVRDEQFDFCMCNPPFYGIDEDHHDNQRPPPPYSSCSAQAHEVRVQGGEVGFVSRMVE ESLLLPSRVRWFTSMVGKKGSLKSLRALLRKREVPTVTTTEFVQGVTKRWAVAWSFTEQVPCIPSHSLPCTVPLLGS TSSAEGRAYAEQWLERVLNHMEVTFTKKDQDGYTCTAERATWANQRRKRRLMQRPMMSPEAAAKRSCGGSDNTSEGV

PRNDSDTLVSAGHLSPKADSLERNASSDLAAQLSALTPPYHVTFWCGVQPSVPPSTNKAELELKMVLIDGGSGTQPL OPIAOYMKNNWSATDSRPTSDRSSO

Seq. ID No: 447

>PSIM 6

CIYPLLGATMNGWYFLATEVDDICFDYATKNVEQNNLSDLIKVVKVPQKTLLMDALKEETEIVYDFCMCNPPFFANQ LEAKGVNSRNSRRPPPSSVNTGGVTEIMAEGGELEFVKRIIHDSLQLKKRLRWYSCMLGKKCSLAPLKEELRKQGVP KVTHTEFCQGRTMRWALAWSFYDDVIVPSPPNKKRKLERARKPLSFTLPEAGLKELQSKALALGGTACSPVDRVAAL LEKTLTDLRVLHKRVPCRKQEQSLFLTAVENTWIHGRQKRREQSRQLRELPRAPPCAGTSSQTTVATADSVKTPASQ TQSASTQNSNSQDDSSQNKRASAQELAGQQPTDKAGSSASSDEISIKVLHNSTGEQKEVTENLSSEAVDMEFSTSTE AVQETGSKEAPSAESEPPSKRPLSPGTVEQFLFKCLLNVMLEESDVMIEMHWVEGQNKDLMNQLCTYLKNTLLKSVA KS

Seq. ID No: 448

>PSIM 7

MGSKKRRRREERPTIHPKNKYSENPPDFALLASLYPSFEPFVFYSRDGRPRIDWTDFNATRELTRVLLLHDHGLNW WIPDGQLCPTVPNRSNYIHWIEDLLSSNIIPTTSRNGDKVKGFDIGTGANCIYPLLGASLLGWSFVGSDMTDVALEW AEKNVKSNPHISELIEIRKVDNSESTPSIQESLTGKSVQDESNMDMSGHMDEEAEPSSSSSFNLPAGAQSSYHGPPV LVGVVRDGEQFDFCICNPPFFESMEEAGLNPKTSCGGTPEEMVCSGGERAFITRIIEDSVALKQTFRWYTSMVGRKS NLKFLISKLRKVGVTIVKTTEFVQGQTCRWGLAWSFVPPARKIISPHVAEKKNLSFMLECTLINRSLYQMINVTQS

Seq. ID No: 449

>PSIM 8

MHPRNPYRQLLDFASLAEAYEPLKPHLKPTRSPTAGGLSYTIDFKNSESQRQLTKAILYRDFGLRIALPDHRLCPPV PNSRLNYILWLQDIIKAHDEYMDRPASCICGLDIGTGASAIYLLLGCRVEPSFRFIGTELDDISFSYATQNVESNGL SDRIHLIKTTSNDPILLPFDLNPAWSCDFTMCNPPFYESEEEMARSAQAKELAPNAVCTGAQVEMVTPGGELAFVSQ IVKESLKYTTRCRWYTSMLGKLSSLTKLVGLLREYAISNYAITEFVQGQTRRWAVAWSFGETHLPDSVARISNPTLQ PLLPERNTSRHVINISLPPFSTRTVKSKQSIKALSEVLSQIKDVTVQRLYQVEHLEPTEEEEEDKSLYRLLVYAKQN MWSRSARRQRGRETGHKANDKGCAVGGPLTSIPATLDGLLCGIEIKAPLIKQEQQDVEMEFVFQWVHGQDRSMFESF VNHVTRKMKCNIVLD

Seq. ID No: 450

>PSIM 9

MALNKSMHPRNRYKDKPPDFAFLASKYPEFKQHVDVGLSGKVGLNFKDPGAVRALTCTLLKEDFGLTIDIPLERLIP TVPLRLNYIHWVEDLINFHDSDKTTVRRGIDIGTGASCIYPLLGATLNGWYFLATEVDDICYNYAKKNVEQNHLADL IKVVKVPQKTLLMDALKEESGIIYDFCMCNPPFFANQMEAQGVNSRNPRRPPPSSVNTGGITEIMAEGGELEFVKRI IHDSLQLKKRLRWYSCMLGKKCSLAPLKEELRIQGVPKVAHTEFYQGRTMRWALAWSFYDDVTIPNPPSKKRKLEKP RKPMMFSVLETTVKMLMDKFDCSVDSEHVSVVTDCLKKILTDLKVQHKPVPCGNGEESLFLTAIENSWVHIRRKKRD RMRQLRELPRAPDENFLLVQKDERQAEDEETTEKTVSSSEKSVSTSGIDEAAALPPNPEDSISESMGEDSRQLPEEV KDTSALGQITDVDEHQNTMEASQPCSSNSAFLFKCLVNVKKEATNVLVEMHWVEGHNRDLMNQLCTYLRNQICKIAT S

Seq. ID No: 451
>PsiHchimera 1

MFCRGLLSLMAIIIVYFIAQKRRRARLPPGPRGLPLIGNLHQAPKEAVWLTFHKWVKEYGNLVSVNFGGTEMVILNT LETITDLLEKRGSIYSGRLESTMVNELMGWEFDLGFITYGDRWREERRMFAKEFSEKGIKQFRHAQVKAAHQLVQQL TKTPDRWAQHIRHQIAAMSLDIGYGIDLAEDDPWLEATHLANEGLAIASVPGKFWVDSFPSLKYLPAWFPGAVFKRK AKVWREAADHMVDMPYETMRKLAPQGLTRPSYASARLQAMDLNGDLEHQEHVIKNTAAEVNVGGGDTTVSAMSAFIL AMVKYPEVQRKVQAELDALTNNGQIPDYDEEDDSLPYLTACIKELFRWNQIAPLAIPHKLMKDDVYRGYLIPKNTLV FANTWAVLNDPEVYPDPSVFRPERYLGPDGKPDNTVRDPRKAAFGYGRRNCPGIHLAQSTVWIAGATLLSAFNIERP VDQNGKPIDIPADFTTGFFRHPVPFQCRFVPRTEQVSQSVSGP

Seq. ID No: 452
>PsiKchimera 1

MKTKFCTGGEAEPSPLGLLLSCGSGLVPRGSPQPPADEQPEPRTRRRAYLWCKEFLPGAWRGLREDEFHISVIRGGL SNMLFQCSLPDTTATLGDEPRKVLLRLYGAILQMRSCNKEGSEQAQKENEFQGAEAMVLESVMFAILAERSLGPKLY GIFPQGRLEQFIKMKTLLDYVTAKPPLATDIARLVGTEIGGFVARLHNIGRERRDDPEFKFFSGNIVGRTTSDQLYQ TIIPNAAKYGVDDPLLPTVVKDLVDDVMHSEETLVMADLWSGNILLQLEEGNPSKLQKIYILDWELCKYGPASLDLG YFLGDCYLISRFQDEQVGTTMRQAYLQSYARTSKHSINYAKVTAGIAAHIVMWTDFMQWGSEEERINFVKKGVAAFH DARGNNDNGEITSTLLKESSTA

Seq. ID No: 453
>PsiKchimera 2

MAFDLKTEDGLITYLTKHLSLDVDTSGVKRLSGGFVNVTWRIKLNAPYQGHTSIILKHAQPHMSTDEDFKIGVERSV YEYQAIKLMMANQEVLGGGDSRVSVPEGFHYDVENNALIMQDVGTMKTLLDYATAKPPLSTEIASLVGTEIGAFIAR LHNLGRKRRDQPAFKFFSGNIVGRTTADQLYQTIIPNAAKYGINDPLLPTVVKDLVEEVMNSEETLIMADLWSGNIL LQLEEGNPSELKKIWLVDWELCKYGPASLDMGYFLGDCYLIARFQDELVGTTMRKAYLKSYARTASDTINYSKVTAS IGAHLVMWTDFMKWGNDEEREE

Seq. ID No: 454
>PsiMchimera 1

MDSAGNIYRHKVDFTALALQDPAFKETLSAKGRLDFSNPDAVRQLTVSLLRRDFGLEVELPDDRLCPPVPNRLNYIL WLQDLIDCTGDDYHEGFNADRDVVGLDIGTGSSAIYPMLACARFKAWSMVGTEVERKCIDTARLNVVANNLQDRLSI LETSIDGPILVPIFEATEEYEYEFTMCNPPFYDGAADMQTSDAAKGFGFGVGAPHSGTVIEMSTEGGESAFVAQMVR ESLKLRTRCRWYTSNLGKLKSLKEIVGLLKELEISNYAINEYVQGSTRRYAVAWSFTDIQLPEELSRPSNPELSSLF

Seq. ID No: 455
>PsiMchimera 2

MSATTNIYKEDIDFITLGREDSDFGKLLNSNGQLDFSDPKSVQQLTKSLLKRDFGLKLILPDDRLCPPVPNRLNYVL WIEDIFNYTNKTLGLSDDRPIKGVDIGTGASAIYPMLACARFKAWSMVGTEVERKCIDTARLNVVANNLQDRLSILE TSIDGPILVPIFEATEEYEYEFTMCNPPFYDGAADMQTSDAAKGFGFGVGAPHSGTVIEMSTEGGESAFVAQMVRES LKLRTRCRWYTSNLGKLKSLKEIVGLLKELEISNYAINEYVQGSTRRYAVAWSFTDIQLPEELSRPSNPELSSLF

Seq. ID No: 456
>PsiMchimera_3

MAQNSTIYEDEVDFATLALQDSEFAKILKSNGQLDFSNPESVQQLTKSLLKRDFKLKLSLPPDRLCPPVPNRLNYII WIQNLLDTTSDSYNDKYDPEREVLGLDIGTGASAIYPMLACARFKAWSMVGTEVERKCIDTARLNVVANNLQDRLSI LETSIDGPILVPIFEATEEYEYEFTMCNPPFYDGAADMQTSDAAKGFGFGVGAPHSGTVIEMSTEGGESAFVAQMVR ESLKLRTRCRWYTSNLGKLKSLKEIVGLLKELEISNYAINEYVQGSTRRYAVAWSFTDIQLPEELSRPSNPELSSLF

Seq. ID No: 457

>SAM2

MSKSKTFLFTSESVGEGHPDKICDQVSDAILDACLEQDPFSKVACETAAKTGMIMVFGEITTKARLDYQQIVRDTIK KIGYDDSAKGFDYKTCNVLVAIEQQSPDIAQGLHYEKSLEDLGAGDQGIMFGYATDETPEGLPLTILLAHKLNMAMA DARRDGSLPWLRPDTKTQVTVEYEDDNGRWVPKRIDTVVISAQHADEISTADLRTQLQKDIVEKVIPKDMLDENTKY FIQPSGRFVIGGPQGDAGLTGRKIIVDAYGGASSVGGGAFSGKDYSKVDRSAAYAARWVAKSLVAAGLCKRVQVQFS YAIGIAEPLSLHVDTYGTATKSDDEIIEIIKKNFDLRPGVLVKELDLARPIYLPTASYGHFTNQEYSWEKPKKLEF

Seq. ID No: 458

>SAM3

MDILKRGNESDKFTKIETESTTIPNDSDRSGSLIRRMKDSFKQSNLHVIPEDLENSEQTEQEKIQWKLASQPYQKVL SQRHLTMIAIGGTLGTGLFIGLGYSLASGPAALLIGFLLVGTSMFCVVQSAAELSCQFPVSGSYATHVSRFIDESVG

FTVATNYALAWLISFPSELIGCALTISYWNQTVNPAVWVAIFYVFIMVLNLFGVRGFAETEFALSIIKVIAIFIFII IGIVLIAGGGPNSTGYIGAKYWHDPGAFAKPVFKNLCNTFVSAAFSFGGSELVLLTSTESKNISAISRAAKGTFWRI AIFYITTVVIIGCLVPYNDPRLLSGSNSEDVSASPFVIALSNTGSMGAKVSNFMNVVILVAVVSVCNSCVYASSRLI QALGASGQLPSVCSYMDRKGRPLVGIGISGAFGLLGFLVASKKEDEVFTWLFALCSISSFFTWFCICMSQIRFRMAL KAQGRSNDEIAYKSILGVYGGILGCVLNALLIAGEIYVSAAPVGSPSSAEAFFEYCLSIPIMIVVYFAHRFYRRDWK HFYIKRSEIDLDTGCSVENLELFKAQKEAEEQLIASKPFYYKIYRFWC

Seq. ID No: 459

>SS02

MSNANPYENNNPYAENYEMQEDLNNAPTGHSDGSDDFVAFMNKINSINANLSRYENIINQIDAQHKDLLTQVSEEQE MELRRSLDDYISQATDLQYQLKADIKDAQRDGLHDSNKQAQAENCRQKFLKLIQDYRIIDSNYKEESKEQAKRQYTI IQPEATDEEVEAAINDVNGQQIFSQALLNANRRGEAKTALAEVQARHQELLKLEKTMAELTQLFNDMEELVIEQQEN VDVIDKNVEDAQQDVEQGVGHTNKAVKSARKARKNKIRCLIICFIIFAIVVVVVVVPSVVETRK

Seq. ID No: 460

>T4H-CPR 1

SSSSDVFVLGLGVVLAALYIFRDQLFAASKPKVAPVSTTKPANGSANPRDFIAKMKQGKKRIVIFYGSQTGTAEEYA IRLAKEAKQKFGLASLVCDPEEYDFEKLDQLPEDSIAFFVVATYGEGEPTDNAVQLLQNLQDESFEFSSGERKLSGL KYVVFGLGNKTYEHYNLIGRTVDAQLAKMGAIRIGERGEGDDDKSMEEDYLEWKDGMWEAFATAMGVEEGQGGDSAD FVVSELESHPPEKVYQGEFSARALTKTKGIHDAKNPFAAPIAVARELFQSVVDRNCVHVEFNIEGSGITYQHGDHVG LWPLNPDVEVERLLCVLGLAEKRDAVISIESLDPALAKVPFPVPTTYGAVLRHYIDISAVAGRQILGTLSKFAPTPE AEAFLRNLNTNKEEYHNVVANGCLKLGEILQIATGNDITVPPTTANTTKWPIPFDIIVSAIPRLQPRYYSISSSPKI HPNTIHATVVVLKYENVPTEPIPRKWVYGVGSNFLLNLKYAVNKEPVPYITQNGEQRVGVPEYLIAGPRGSYKTESF YKAPIHVRRSTFRLPTNPKSPVIMIGPGTGVAPFRGFVQERVALARRSIEKNGPDSLADWGRISLFYGCRRSDEDFL YKDEWPQYEAELKGKFKLHCAFSRQNYKPDGSKIYVQDLIWEDREHIADAILNGKGYVYICGEAKSMSKQVEEVLAK ILGEAKGGSGPVEGVAEVKLLKERSRLMLDVWS

Seq. ID No: 461
>T4H-CPR 2

SSSSDVLILGLGVALAALYLFRDQLFAASKPKAIPLTNKLAGLDNEGNPRDFIAKMKAGKKRLVIFYGSQTGTAEEY AIRLAKEAKSKFGLTSLVCDPEEYDFENLDQLPEECAVFFVMATYGEGEPTDNAVQLMQNLADESFEFSGGERKLEG LKYVIFALGNKTYEHYNLIGRKVDTLLTDMGGVRCGELGEGDDDKSMEEDYLEWKDAMWEDFARKMGVEEGQGGDSA DFAVSELDTHVPEKVYLGELSARALTKTKGIHDAKNPYPAPIVASRELFQQGGDRNCVHVELSIEGSGITYQHGDHV GVWPTNPEVEVNRLLCALGLWEKKDQVIGIESLDPALAKVPFPVPTTYATVLRNYIDISAVTGRQILGHLSKYAPAP DVEEFLKGLSTNKEQYGATVANGCLKLGEVLQLAAGNDLKAIPTTENTTAWSIPFDVIVSAIPRLQPRYYSISSSPK LNPTSIHVTAVVLKYQSVASEKLPAKWVYGVGSNFLLNLKYAANGEPAPFVTTNGSADPASVYYPTYAIEGPRGAYK QETIYKSPIHVRRSTFRLPTNPKSPVIMIGPGTGVAPFRGFVQERVALARRTIEKNGADALADWGRISLFYGCRKST EDFLYKEEWPQYTEELKGKFNMHSAFSREAPYKADGSKIYVQDLIWEDRANVSDAILNGKGYIYICGDAKSMAKQVE DTLAKILGEAKGGTAEVEGAAEMKLLKERSRLMLDVWS

Seq. ID No: 462
>T4H-CPR 3

SSSSSGAGADSDENPRDFIAKMKAGKKRLVIFYGSQTGTAEEYAIRLAKEAKSKFGLTSLVCDPEEYDFENLDQLPE DCAVFFVMATYGEGEPTDNAVQLMQNLQDESFEFSNGERKLEGLKYVVFALGNKTYEHYNLIGRKVDTILGEMGAVR CGERGEGDDDKSMEEDYLEWKDAMWEDFARKMGVEEGQGGDSADFAVSELESHAPEKVYLGELSARALTKTKGIHDA KNPYPAPIVESRELFQVGGDRNCVHVELGIEGSGITYQHGDHVGVWPTNPEVEVTRLLCALGLWEKKDQVIGIESLD PALAKVPFPVPTTYITVLRNYIDISAVTGRQILGHLSKFAPSPDAEAFLKSLSTNKEQYGAIVANGCLKLGEVLQLA AGNDLKAVPNAENTTKWTIPFDVIVSAIPRLQPRYYSISSSPKLNPTTIHVTAVVLKYESVASEKVPAKWVYGVGSN FLLNLKYAANGDAAPFVTANGSADPASVYAPTYAIEGPRGAYKQETIYKSPIHVRRSTFRLPTNPKSPVIMIGPGTG VAPFRGFVQERVALARRTIEKNGPDALADWGRITLFYGCRKSTEDFLYKDEWPQYTEELKGKFTMHSAFSREPPYKA

DGSKIYVQDLIWEDREKVADAILNGKGYVYICGDAKSMAKQVEDTLAKILGESKGGSAEVEGAAEMKLLKERSRLML DVWS

Seq. ID No: 463
>T4H-CPR 4

SSSSSSKLSDGDENPRDFIAKMKNGKKRLVIFYGSQTGTAEEYAIRLAKEAKSKFGLTSLVCDPEEYDFENLDQLPD DCAAFFVVATYGEGEPTDNAVQLMQNLQDESFEFSGGERKLEGLKYVVFALGNKTYEHYNVIGRIVDTELAKMGAIR CGERGEGDDDKSMEEDYLEWKDGMWEEFARIMGVEEGQGGDTPDFKVTELQSHPSEKVYLGELSARALTKTKGIHDA KNPYPAPILKSRELFQKQGERNCVHLELGIDGSGITYQHGDHVGVWPSNPEVEVNRLLCALGLWDKRDHVIGIESLD PALAKVPFPVPTTYSTVLRNYIDISAVAGRQILGNLARFSPSPDAEGFMRSLNTDKEQYGRIIANGCLKLGEVLQLA AGNDIKAVPTLENTTAWPIPFDVIVSAIPRLQPRYFSISSSPKLHPTAIHVTAVVLKYQSVASDKVPPKWVYGVGSN FILNLKYAACGETAPLIAQNGSADPAHTPFPLYAIEGPRGAYKQEMIYKSPIHVRRSTFRLPTNPKSPVIMVGPGTG VAPFRGFVQERIALARRTIEKNGPDALADWGRISLFYGCRKSNEDFLYNEEWPQYIDELKGKFTLHTAFSREPPYKP DGSKIYVQDLLWDDRSKVADAIINGKGYIYICGDAKSMAKSVEDVLAKILGEAKGGTMEVEGAAELKLLKERSRLML DVWS

Seq. ID No: 464

>T4H 1

MKTRTSKHPPGPRGLPLIGNLLDMPASYEWLQYRKWSEEFKSDIIYLNILGTQIVVTNTLESTLDLLEKRSSKYSGR HSFQLPNNCAMGWAWNLALMSYGDEWRAHRRLAARGFDAQAMPKFNHAFTRNTRGLLRRLLESPEAWNEHVRHEVGS MIIEITYGLDVLSKNDPFIESADKGLATLALAVVPGAFLVDTLPILKHIPSWFPGAGFKRKAKEWKRYADEVLEAPY KALKEEMASGAAKPSFVQRCLQDMDPNIDTTNQERVIKNTAAEMYVAGADTSASFIATFVLAMIQYPQVQRRAQAEL DSVLGPDRLPTFGDMPSLPYLSAITKECFRWEVITPISIPHMLTEDDEYRGWFLPSGTVVIPNSWAIMNDPTVYPDP SVFNPERFLKDGKIDLEVQDPQLAAFGYGRRICPGMRVANAFTWLSAGSILASFNISKPAAKDGTPIELDVKYRSSS IRHPEAFDCLFKPRSENTRDMIVSAAA

Seq. ID No: 465

>T4H 2

MSKRSKHPPGPRGLPLIGNLLDMPTNDEWLQYRKWSQEFKSDIIYLNVCGTQIVVTNTLESTLDLLERRSSKYSGRM GLEWAFILMPYGDEWRAHRRLAAKGFDAKAIPKFNPTFTRNAQDLLRRLLESPEAWHEHVRHQVGAMIIEVSYGLDV LHKNDPFIESADKAAVTFAMAIKPGAFLVNTVPILKYVPSWFPGAGFQRKAKEWKRYNDAVLEAPFKALKEEITNGA ARPSFAQQCLQNMDPNIDTAYQERVIKDTSAAMYGGGSDTSVSFLATFVLAMLQYPSVQRRAQVELDSVLGRDRLPT FDDMPDLPYLAAVMKECHRWEIVLPLAIPHMLTADDEYRGWFLLSGTLVIPNSWAILNDPTVYPDPSTFNPERFLKD GKIDPNVQDPELAAFGYGRRTCPGRRITNAFTWLSAGYILASFNIENAVGNDGMPIEPKVKYRSETIRHPDTFECVF TPRSDDTRDMIGSAYT

Seq. ID No: 466

>T4H 3

MGRWPIIGNLLDMPQKSPWLTYAKWSEDCDSDIIHLNVLGTSIVVLSSLEAISTLLEGKAVDFSDRPKSTMMSELMG WERGFAFMPYGQLWRSHRKAFHQEFSPQVAHRNHPKLIKATHNLLRLLLNTPQHWHGHIRRQAGASIMDIAYGIEVL PENDPYLDIAEAAVKAFNDASVPGAFLVDSIPLLKHVPAWVPGAGFQLKAKEGRQALENLIDSPYNAMKKDLAGGKA KSSYTSRSLAAMDATGVIEENETIIRETAAMVYLGGSDSTPSTTSVFILAMLAHPEVQRKAHAELDSVIGKAQLPTF KDRGSLPYVTAVAKEVLRWEPVAPLAVPRKVRVDSEYKGYRIPKGSIVFQNSWALLHDEKTYPNPLAFNPERFLKDG QLDPNVQDPDVVAFGYGRRSCPGKTMGYDSVWLNVASILAAFDIKKVANPDSTNVEPKFEPFGITV

Seq. ID No: 467

>T4H_4

MYLFKAYLRPSRRLPPGPRGWPLIGNLLDMPTSDEWVRYAQWVREFKSDVIHLEVCGTHIVILNSVESAVDLLEKRS SLYSSRPPTPMMSDLMGWSWNTAMLPYNDEWRAQRRHFHGEFDGRAIGKHYPPIIRSTHDLLQRLLDTPEQWQSHIR HLVGATILDVAYGIEVLPADDPYVRTAEAAFASVSEAMVPGAFLVDVLPILKHMPSWMPGAGFKRKAVAWKKLADAV FDAPFAAMKQAMAAGTAKSSFGSRSLRDIDIKGNVQSQEFSIQAAAGTMYNAGSDTTVALLETFMLAMVLHPEVQTK

AQAEMDLVLGRSNLPTFADQESLSYLAAVMQEVFRWQVVAPFGVPHMSTADDEYRGYFIPEGTIVIPNAHQMLNDED VYPEPSKFKPERFLKDGKLDLSVRSPLIAAFGFGRRICPGRALGENSAWLAAGSILTMFNLSKATDHNGVTIEPSGR YTSGLVRHPETFKCQITPRSNEPRRELAGEIELITGRIQESEEA

Seq. ID No: 468 >T4H CPR chimera 1

SSSSSGSVAYFTKGTYWAVPKDPYASSYGAANGAKAGKTRDIIEKMEETGKNCVIFYGSQTGTAEDYASRLAKEGSQ RFGLKTMVADLEEYDYENLDKWPEDKVAFFVLATYGEGEPTDNAVQLLQNLQDESFEFSSGERKLSGLKYVVFGLGN KTYEHYNLIGRTVDAQLAKMGAIRIGERGEGDDDKSMEEDYLEWKDGMWEAFATAMGVEEGQGGDSADFVVSELESH PPEKVYQGEFSARALTKTKGIHDAKNPFAAPIAVARELFQSVVDRNCVHVEFNIEGSGITYQHGDHVGLWPLNPDVE VERLLCVLGLAEKRDAVISIESLDPALAKVPFPVPTTYGAVLRHYIDISAVAGRQILGTLSKFAPTPEAEAFLRNLN TNKEEYHNVVANGCLKLGEILQIATGNDITVPPTTANTTKWPIPFDIIVSAIPRLQPRYYSISSSPKIHPNTIHATV VVLKYENVPTEPIPRKWVYGVGSNFLLNLKYAVNKEPVPYITQNGEQRVGVPEYLIAGPRGSYKTESFYKAPIHVRR STFRLPTNPKSPVIMIGPGTGVAPFRGFVQERVALARRSIEKNGPDSLADWGRISLFYGCRRSDEDFLYKDEWPQYE AELKGKFKLHCAFSRQNYKPDGSKIYVQDLIWEDREHIADAILNGKGYVYICGEAKSMSKQVEEVLAKILGEAKGGS GPVEGVAEVKLLKERSRLMLDVWS

Seq. ID No: 469 >T4H CPR chimera 2

SSSSSGTIAYFTKGTYWGIVKDPYAPNYPPANGNKPAKTRNIVEKMDESNKNCVVFYGSQTGTAEDYASRLAKEGK SRFGLETMVADLEDYDFDNLDTLGDDKVAIFVLATYGEGEPTDNAVQLLQNLQDESFEFSSGERKLSGLKYVVFGLG NKTYEHYNLIGRTVDAQLAKMGAIRIGERGEGDDDKSMEEDYLEWKDGMWEAFATAMGVEEGQGGDSADFVVSELES HPPEKVYQGEFSARALTKTKGIHDAKNPFAAPIAVARELFQSVVDRNCVHVEFNIEGSGITYQHGDHVGLWPLNPDV EVERLLCVLGLAEKRDAVISIESLDPALAKVPFPVPTTYGAVLRHYIDISAVAGRQILGTLSKFAPTPEAEAFLRNL NTNKEEYHNVVANGCLKLGEILQIATGNDITVPPTTANTTKWPIPFDIIVSAIPRLQPRYYSISSSPKIHPNTIHAT VVVLKYENVPTEPIPRKWVYGVGSNFLLNLKYAVNKEPVPYITQNGEQRVGVPEYLIAGPRGSYKTESFYKAPIHVR RSTFRLPTNPKSPVIMIGPGTGVAPFRGFVQERVALARRSIEKNGPDSLADWGRISLFYGCRRSDEDFLYKDEWPQY EAELKGKFKLHCAFSRQNYKPDGSKIYVQDLIWEDREHIADAILNGKGYVYICGEAKSMSKQVEEVLAKILGEAKGG SGPVEGVAEVKLLKERSRLMLDVWS

Seq. ID No: 470
>T5H-CPR 1

SSSSSSGGLLAFLYLFRGTLFASGKASDAGSKLAGGSDLDSSADAAANDFVTKLTSQNKRIAIFYGSQTGTAEEYAT KIAKEAKARFGTSSLVCDPEEYEFEKLDQLPSDCVACFVMATYGEGEPTDNAVGLMEFLDGEDVQFSNGSSLDNLNY VIFGLGNRTYEHYNAIARKLDARLESLGAKRIGERGEGDDDKSMEEDYLAWKDGMFEALASSLGFEEGGGGDVADFK VREVADHPEDKVYRGELSARALLGTKGIHDAKNPYNAVVKEARELFVEGTADRTCVHVEFDIEGSGISYQHGDHIAV WAHNPEQEVERALAVLGLLGKRDTVIDVESLDPTLAKVPFPVPTTYEAVFRHYLDICAHASRQTLNNFAKYAPTPEA RAKLEKACGDKAAFQEAIGHRCLKTFEALQLIVGDDLGGDSVAKATAWEIPFDRVISDLPRVGPRFYSISSSPKMHP KTVHITAVVLRYRPEAAGQDSPYVHGLATNFISAIKMAKNNEQPSGPDDPRFGTPGYDLAGPRGAYTKESLFRAPIH IRRSNFRLPTSPKIPVIMVGPGTGVAPFRSFVQERVCSAQKTCDKVNQSPAEALQDWGNIWLFYGCRRSNEDFLYKD EWPEYASKLGGKFQMETAVSREKFKPDGSKLYVQDLIWERRKELAQDILDKKAYIYICGEAKGMAHDVEEMFGRVLE EAKGSAEAGRRELKLLKERSRLLLDVWS

Seq. ID No: 471
>T5H-CPR 2

SSSSSLFSTTDVILFSLIVGVMTYWFLFRKKKEEVPEFTKIQTTTSSVKDRSFVEKMKKTGRNIIVFYGSQTGTAE EFANRLSKDAHRYGMRGMAADPEEYDLADLSSLPEIEKALAIFCMATYGEGDPTDNAQDFYDWLQETDVDLSGVKYA VFALGNKTYEHFNAMGKYVDKRLEQLGAQRIFDLGLGDDDGNLEEDFITWREQFWPAVCEHFGVEATGEESSIRQYE LMVHTDMDMAKVYTGEMGRLKSYENQKPPFDAKNPFLAVVTTNRKLNQGTERHLMHLELDISDSKIRYESGDHVAVY PANDSALVNQLGEILGADLDIIMSLNNLDEESNKKHPFPCPTSYRTALTYYLDITNPPRTNVLYELAQYASEPTEHE QLRKMASSSGEGKELYLRWVLEARRHILAILQDYPSLRPPIDHLCELLPRLQARYYSIASSSKVHPNSVHICAVAVE

YETKTGRINKGVATSWLRAKEPAGENGGRALVPMYVRKSQFRLPFKATTPVIMVGPGTGVAPFIGFIQERAWLRQQG KEVGETLLYYGCRRSDEDYLYREELAGFHKDGALTQLNVAFSREQPQKVYVQHLLKKDKEHLWKLIHEGGAHIYVCG DARNMARDVQNTFYDIVAEQGAMEHAQAVDYVKKLMTKGRYSLDVWS

Seq. ID No: 472
>T5H-CPR 3

SSSSSSEAVAEEVSLFSMTDMILFSLIVGLLTYWFLFRKKKEEVPEFTKIQTLTSSVRESSFVEKMKKTGRNIIVFY GSQTGTAEEFANRLSKDAHRYGMRGMSADPEEYDLADLSSLPEIDNALVVFCMATYGEGDPTDNAQDFYDWLQETDV DLSGVKFAVFGLGNKTYEHFNAMGKYVDKRLEQLGAQRIFELGLGDDDGNLEEDFITWREQFWPAVCEHFGVEATGE ESSIRQYELVVHTDIDAAKVYMGEMGRLKSYENQKPPFDAKNPFLAAVTTNRKLNQGTERHLMHLELDISDSKIRYE SGDHVAVYPANDSALVNQLGKILGADLDVVMSLNNLDEESNKKHPFPCPTSYRTALTYYLDITNPPRTNVLYELAQY ASEPSEQELLRKMASSSGEGKELYLSWVVEARRHILAILQDCPSLRPPIDHLCELLPRLQARYYSIASSSKVHPNSV HICAVVVEYETKAGRINKGVATNWLRAKEPAGENGGRALVPMFVRKSQFRLPFKATTPVIMVGPGTGVAPFIGFIQE RAWLRQQGKEVGETLLYYGCRRSDEDYLYREELAQFHRDGALTQLNVAFSREQSHKVYVQHLLKQDREHLWKLIEGG AHIYVCGDARNMARDVQNTFYDIVAELGAMEHAQAVDYIKKLMTKGRYSLDVWS

Seq. ID No: 473
>T5H-CPR 4

SSSSSAAAADGDGGQSRRLLALLATSLAVLVGCGVALLFRRSSSGAAPLARQAAAAKPLAAKKDQEPDPDDGRQRV ALFFGTQTGTAEGFAKALAEEAKARYDKAVFKVLDLDDYAAEDEEYEEKLKKENIAFFFLATYGDGEPTDNAARFYK WFSEGNERGEWLSNLQYGVFALGNRQYEHFNKVGKEVDQLLAEQGGKRIVPVGLGDDDQCIEDDFNAWKELLWPELD KLLRVEDNSSAAQSPYTAAIPQYRIVLTKPEDATHINKSFSLSNGHVVYDSQHPCRANVAVRRELHTPASDRSCIHL EFDIAGTSLTYETGDHVGVYAENSTETVEEAEKLLDYSPDTYFSIYADQEDGTPLFGGSLPPPFPPCTVRVALARYA DLLNSPKKSVLLALAAHASDPKEAERLRHLASPAGKKEYSQWIIASQRSLLEVISEFPSAKPPLGVFFAAIAPRLQP RYYSISSSPRMAPTRIHVTCSLVHGQSPTGRIHKGVCSTWMKNSTPSEEESEECSWAPIFVRQSNFKLPADPTVPII MVGPGTGLAPFRGFLQERLALKETGVELGRAILFFGCRNRQMDFIYEDELNNFTESGALSELVVAFSREGPTKEYVQ HKMAEKAADLWSIVSQGGYVYVCGDAKGMARDVHRALHTIVQEQVTQRTSNFGLWKFRLVSLN

Seq. ID No: 474 >T5H-CPR 5

SSSSSSAAAAGGDPLAALAATAAALVAGVVILAVWFRSGGGAPPKAAAPPPRPPPVKIEADADADDGRKRVTVFFGT QTGTAEGFAKAMAEEARARYEKAVFKVVDLDDYAAEDEEYEEKLRKETIVLLFLATYGDGEPTDNAARFYKWFTEGK EKEVWLKDLKYAVFGLGNRQYEHFNKVAKVVDELLEEQGGKRLVPVGLGDDDQCIEDDFTAWKEQVWPELDQLLRDE DDTTGASTPYTAAIPEYRIVFIDKSDVSFQDKSWSLANGSGVIDIHHPVRSNVAVRKELHKPASDRSCIHLEFDISG TGLVYETGDHVGVYSENAIETVEQAEKLLDLSPDTFFSVHADAEDGSPRKGGGSLAPPFPSPCTLRTALLRYADLLN SPKKAALVALAAHASDLAEAERLRFLASPAGKDEYSQWVVASQRSLLEVMAAFPSAKPPLGVFFAAVAPRLQPRYYS ISSSPKMAPSRIHVTCALVYGPTPTGRIHQGVCSTWMKNAIPSEYSEECSWAPIYVRQSNFKLPADPTTPIIMIGPG TGLAPFRGFLQERLALKQSGVELGNSVLFFGCRNRNMDYIYEDELQNFIQEGALSELIVAFSREGPAKEYVQHKMTE KATEIWNIVSQGGYIYVCGDAKGMARDVHRALHTIVQEQGSLDSSKTESYVKSLQMDGRYLRDVW

Seq. ID No: 475
>T5H-CPR 6

SSSSSSAAAYLFRDQIFRSSSPKVVVPAPSKLANGHGNPRNFVSKMKEGKKRIVIFYGSQTGTAEEYAIRIAKEAKT KFGLTSLVCDPEEYDFENLDQVPEDCCVFFVMATYGEGEPTDNAVQLMQNLEDESFEFSNGSHRLDGLKYVVFALGN KTYEHYNAIGRKVDTLLTDMGATKIGERGEGDDDKSMEEDYLEWKDGMWKAFSEAMGVEEGQGGDTPDFAVTELDSH PPEKVYLGELSARALTRTKGIYDGKNPYPSAVKHSRELFQAGAERNCVHAELDIEGSGITYQHGDHVGVWPSNPDVE VDRMLYVLGLYGKKDAVINIDSLDPALAKVPFPVPTTYATVLRHYIDICAVAGRQMLGVLSKFAPHPKAEAFLKSLN SDKEEYSNIVTNGCFKLGEVLQLAAGDDIKLCPTPDNTTAWAIPFDIIVSSIPRLQPRFYSISSSPKLYPNAIHLTA VVLKYDSIPNRLVESRFVYGVATNFLLNVKYAANGETAPFIAEPVISEPAHVSLPKYAIEGPRGAHIEDNIYKIPIH VRRSTFRLPANPKIPVIMVGPGTGVAPFRGFVQERVALAKRSIEKNGPDALADWGSITLFYGCRKSNEDFLYKEEWP

QYAEELKGKFKMHCAFSREPPYKPDGSKIYVQDLIWEERETIAKAILEGKAYVYICGDAKAMSRAVEDTLARILGEA KGGNAEVEGAAEMKILKERSRLLLDVWS

Seq. ID No: 476
>T5H-CPR 7

SSSSSSLFSTTDMVLFSLIVGVLTYWFIFRKKKEEIPEFSKIQTTAPPVKESSFVEKMKKTGRNIIVFYGSQTGTA EEFANRLSKDAHRYGMRGMSADPEEYDLADLSSLPEIDKSLVVFCMATYGEGDPTDNAQDFYDWLQETDVDLTGVKF AVFGLGNKTYEHFNAMGKYVDQRLEQLGAQRIFELGLGDDDGNLEEDFITWREQFWPAVCEFFGVEATGEESSIRQY ELVVHEDMDVAKVYTGEMGRLKSYENQKPPFDAKNPFLAAVTANRKLNQGTERHLMHLELDISDSKIRYESGDHVAV YPANDSALVNQIGEILGADLDVIMSLNNLDEESNKKHPFPCPTTYRTALTYYLDITNPPRTNVLYELAQYASEPSEQ EHLHKMASSSGEGKELYLSWVVEARRHILAILQDYPSLRPPIDHLCELLPRLQARYYSIASSSKVHPNSVHICAVAV EYEAKSGRVNKGVATSWLRAKEPAGENGGRALVPMFVRKSQFRLPFKSTTPVIMVGPGTGIAPFMGFIQERAWLREQ GKEVGETLLYYGCRRSDEDYLYREELARFHKDGALTQLNVAFSREQAHKVYVQHLLKRDREHLWKLIHEGGAHIYVC GDARNMAKDVQNTFYDIVAEFGPMEHTQAVDYVKKLMTKGRYSLDVWS

Seq. ID No: 477
>T5H-CPR 8

SSSSSGGSPMSDSVVVIITTSFAVIIGLLVFLWKRSSDRSKEVTPLVVPKSLSVKDEEDEAETLAGKTKVTIFYGT QTGTAEGFAKALAEEIKARYEKAAVKVVDLDDYAMDDDQYEEKLKKETLTFFMVATYGDGEPTDNAARFYKWFTEEH ERGVWLQQLTYGIFGLGNRQYEHFNKIAKVLDEQLNEQGAKRLIPVGLGDDDQCIEDDFTAWRELLWPELDNLLRDE DDVNGASTPYTAAIPEYRVVIHDASATSCEDKSVLENGNTSIDIHHPCRVNVAVQKELHKPESDRSCIHLEFDISGT GIIYETGDHVGVYAENFEENVEEAGKLLGQPLDLLFSIHADNEDGAPLGSSLAPPFPGPCTLRTALSHYADLLNPPR KAALIALAAHASEPSEAERLKYLSSPEGKDEYSQWIVGSQRSLLEVMAEFPSARPPLGVFFAAIAPRLQPRYYSISS SPRFALSRVHVTCALVYGPTPTGRIHKGVCSTWMKNAVPLEKSHDSSWAPVFIRTSNFKLPTDPSIPIIMVGPGTGL APFRGFLQERMALKEDGAQLGPALLFFGCRNRRMDFIYEDELNYFVEQGVISELIVAFSREGPQKEYVQHKMMDKAA QIWSLISERGYIYVCGDAKGMARDVHRTLHTIVQEQGNLDSSKTESMVKKLQMDGRYLRDVW

Seq. ID No: 478 >T5H-CPR 9

SSSSSTSFHKLKRILHKHLQRSHSIGAECKPQRSNHEDLLAVMNRSSIKVSIFYGSQTGTAKKFAINLGHHLHNCG VRNLVMDLRQTNMEILVNLSMLDNCVALFVVATYGEGEPTDSARQFMDNLKNSYQKLDNLRFAVFGLGNSMYTYFNA VGKSIDRLLIQHGGKRLQTLTLGDEVNELESTFLNWRSHLTSLLIDFFDLNDHDRNYLNKQYKRMYSLKRFNWNVPL VSHFVNMFINKAHVKETLPYENDNYFYASVAVNQELYHKSSRSCRHIELDVSASQLRYKTGDHIAIFASNPLDLVEK IGDLLNIDLNEMISLDAVDPDSLTKHPFPCPCTYRHAFMHFVDITGPPGKSLLSACLDSVTNPEESQFVQLLISDSE DGKKLYSKWILEDHRGLVDVLQDLKSFRPPADLLLELLNPLKPRLYSISSSSLVHTNRIHITASIVKYKTNSGRIFK GLATNWLKSLQSTNTERHLKIPVAIHTSNFNLPRSRTIPVIMIASGTGLAPFRAFIQERLKVAHDKVGKTGQMVLFF GCRHENKDFIYSDELKQACSTGLLEMFTAFSRDCLDGNKVYVQHKVLEMGNMVWKLLDECYAYIYVCGDAAGMVRDV HLCLIELVVQRSNLTREAATSYVLNLRKQGRYRTDVWK

Seq. ID No: 479 >T5H-CPR 10

SSSSSGGKIFDKLNSSLDSGDSTSPASLTALLMENKDLMMILTTSVAVLIGCAVVLMWRRSSTSARKVVELPKLVV PKSVVEPEEIDDGKKKIAIFFGTQTGTAEGFAKALAEEAKARYEKAIFKVIDMDDYAADDEEYEEKLKKEKLAFFFL ATYGDGEPTDNAARFYKWFEEGKERGDCFKNLQYGVFGLGNRQYEHFNKIAKVVDELLAEQGGQRLVPVGLGDDDQC IEDDFAAWRELVWPELDKLLLDGDDATATTPYTAAVLEYRVVTYDKSNFDNDLTNTNGHANGHVIVDAQHPVRANVA VRKELHTPASDRSCTHLEFDISCTGLTYETGDHVGVYCENFVETVEEAERLLNISPDTFFSIHTDKEDGTPLGGSSL PSPFPPCTLRTALTRYADVLSSPKKSSLLALAACSSDPNEADRLRYLASPAGKEEYAQWIVASQRSLLEVMAEFPSA KPSIGVFFASVAPRLQPRFYSISSSPRMAASRIHVTCALVYDKMPTGRIHKGVCSTWMKNAIPLEESLSCSTAPIFV RQSNFKLPADNKVPIIMIGPGTGLAPFRGFLQERMALKEEGADLGPAVLFFGCRNRQMDYIYQDELDNFLEAGALSN LVVAFSREGPNKEYVQHKMTQKADDIWNMISQGGYVYVCGDAKGMARDVHRTLHTIAQDQGSLDSSKAESFVKNLQT TGRYLRDVW

Seq. ID No: 480 >T5H-CPR 11

SSSSSSGDGAEGRALVATLAAAVLGAALFVLWRRAAAGKKRKREAAAAAVAEATEVKARAAKGGEDEKAADDGRKK VTVFFGTQTGTAEGFAKALAEEAKARYDKAIFKVVDLDDYAAEDEEYEEKLKKEKLALFFVATYGDGEPTDNAARFY KWFTEGNERGVWLNDFEYAVFGLGNRQYEHFNKVAKVVDEILTEQGGKRLVPVGLGDDDQCIEDDFNAWKEALWPEL DRLLRDENDASTGTTYTAAIPEYRVEFIKPEEAAHLERNFSLANGHAVHDAQHPCQANVAVRRELHTPASDRSCTHL EFDIAGTGLTYETGDHVGVYTENCPEVVEEAERLLGYSPDTFFTIHADKEDGTPLSGSSLAPPFPSPITVRNALARY ADLLNSPKKTSLVALATYASDPAEADRLRFLASAAGKDEYAQWVVASQRSLLEVMAEFPSAKPPLGVFFAAVAPRLQ PRYYSISSSPSMAATRIHVTCALVHETTPAGRVHKGVCSTWIKNAVPSEESKDCSWAPIFVRQSNFKLPADPSVPII MIGPGTGLAPFRGFLQERLAQKESGAELGPSVFFFGCRNSKMDFIYEDELNNFLEQGALSELVLAFSRQGPTKEYVQ HKMAQKASEIWDMISQGAYIYVCGDAKGMARDVHRVLHTIVQEQGSLDSSKAESFVKNLQMEGRYLRDVW

Seq. ID No: 481
>T5H-CPR 12

SSSSSVRESSFIEKMKKTGKNIVVFYGSQTGTGEEFANRLAKDAHRYGMRGMAADPEEFEMTDLSRLTEIENALAV FCMATYGEGDPTDNAQDFYDWLQETDIDLAGLKYAVFGLGNKTYEHFNAMGKYVDKRLEELGAERIFELGMGDDDGN LEEDFITWREQFWPAVCEHFGVEATGEDSSIRQYELVVHTDENMNKVYTGEMGRLKSYETQKPPFDAKNPFLANATV NRKLNEGGDRHFMHLELDITGSKIRYESGDHVAVYPANDAALVNKLGEILGADLETVISLNNLDEESNKKHPFPCPT TYRTALTYYLDITNPPRTNVLYELAQYATDSKEQENLRKMASSAQDGKALYLSWVVESRRNILAILEDIPSLRPPLD HLCELLPRLQARYYSIASSSKVHPNSIHVCAVLVEYETKTGRENKGVATNWLKNKQPSDNGHKSSVPMFVRKSQFRL PFKPSTPVIMIGPGTGIAPFMGFIQEREWLKQQGKDVGETVLYYGCRHEHEDFLYINELKRYHKEGVLTQLNVAFSR DQAHKVYVQHLLKNNKEMVWKLIHEDNAHIYVCGDARNMARDVQNIFYDIVEEYGKLDHAQAVDYIKKLMTKGRYSQ DVWS

Seq. ID No: 482

>T5H 1

MLPIVDHLLDVLNLERTPFRTYAVTALLLLFVGIIARALLKMMLFIQEYSANSKRLRCFPEPPNRSWILGHLGLFAP NEEGMTEFSKQVSKFTYYMKTWMGPVIPLISLIHPDTIKPVVAAPASIAPKDALFYGFLEPWLGDGLLLSRGEKWVR HRRLLTPAFHFDILKHYVKIFNQSTDIMHAKWRRLCTKGPVFLDMFEHISLMTLDSLLKCTFSYDSDCQEKPSDYIA AIYDLSELIVEREQCPPHHFDFIYRFSSNGRKFQRACRIVHEFTANVVQQRKKALQEKGAENWIRSKKGKTQDFIDI LLLSKDEDGNTLSDQEMRDEVDTFMFEGHDTTASGLSWILYNLASHPEYQEKCREEVTQLLKGESTHLEWDDLSLLP FTTMCIKESLRLHPPVTAVSRRCTEDIAMPDGKVIPKGNISLISIYGTHHNPAVWPNPEVYDPYRFDPSSTDERSSH AFVPFSAGPRNCIGQNFAMAEMKVVLALTLLNFKVALDPNRVVRRKPELVLRAEGGLWLQVEALKSKS

Seq. ID No: 483

>T5H_2

MELLGLVSWLLLLLTLVVICFLLYCGYIHYQHMKYDHIPGPPRESFLFGHGSAIWKVMRKNQLVYDLFLNWVETYG PVIRINALHKVTIVSVSPESVKEVLMSPKYRKDWFYDHLHSLFGVRLMGNGLVTDRDNDHWYKQRRIMDPAFSRTYL IGLLGPFNEKAEELMERLAEEADGRSHVVMHAMMSRVTLDVISKVAFGMEMNSLKDDGTPLPRAISLVMRALVEMRN PFIRYSREKQAFIRDVQESARLLRKTGRECIERRQKAIQDGEEIPVDILTQILKGAALEGDCDMEDLLDNFVTFFIA GQETTANQLAFTIMELARNPEILEKAQAEVDEVIGVKRDIEYDDLGKLQYLSQVLKESLRLYPTAPGTSRAIEEETI IEGFRIPPKVPLMFNSYIMGRMQQFYPDPLTFNPDRFHPDAPKPYYSYFPFSLGPRSCIGQVFAQMEAKVIMAKLLQ RFQFELVEGQSFGIMDTASLRPEGGVICRLTIRTNPGKAKKDD

Seq. ID No: 484

>T5H_3

MSRPQVPKGLKNPPGPWGWPLIGHMLTLGKNPHLALSRMSQQYGDVLQIRIGSTPVVVLSGLDTIRQALVRQGDDFK GRPDLYTFTLISNGQSMSFSPDSGPVWAARRRLAQNGLKSFSIASDPASSTSCYLEEHVSKEAEVLISTLQELMAGP GHFNPYRYVVVSVTNVICAICFGRRYDHNHQELLSLVNLNNNFGEVVGSGNPADFIPILRYLPNPSLNAFKDLNEKF YSFMQKMVKEHYKTFEKGHIRDITDSLIEHCQEKQLDENANVQLSDEKIINIVLDLFGAGFDTVTTAISWSLMYLVM

NPRVQRKIQEELDTVIGRSRRPRLSDRSHLPYMEAFILETFRHSSLVPFTIPHSTTRDTSLKGFYIPKGRCVFVNQW QINHDQKLWVNPSEFLPERFLTPDGAIDKVLSEKVIIFGMGKRKCIGETVARWEVFLFLAILLQRVEFSVPLGVKVD MTPIYGLTMKHACCEHFQMOLRS

Seq. ID No: 485

>T5H 4

MPTPGGRLVAFLQRRGKLAGSLAVILLIIKRLRDAPRKVRWLRGPPLLGVVLKVFQGLREHALLDMYDRWHQRLGP TFAYCAPGKMVVATIDPKNIEHVLKTKFDNYVKGHVFAEPFTDLLGDGIFNADGEMWHRQRKTASRMFTKRQFETHI WKAIEANTAKVGRILERSEGTLDMFNLMNRFTLDTIGRIGFSKDIGSLEDPSSPFLRSFDRAQQILILRFWTNPAWK VLRWLGVGWERELKEHLGRLDGYARGIVRELRQKAEAGQDDSFVGLFMKEEQAAPAARSPELQEKFMRDLVLNFLIA GRDTTAQCISWTLFELTQHPAVAAKARQEVLDVCGEGPVTFEHLKSLQYVRAILDEGLRLHPSVPYDGKLCLGKDTL PDGTVVPAGCIIQYIPYAQGRCKDIWGEDACSFRPERWLEMPRRPSSFAFAAFNAGPRECLGRRLAEAEMAALVSTV VRDFDMRLEVEPSSVRYDAQLTLGMCGLPVSVRRCRRAYGVAEPLAGA

Seq. ID No: 486

>T5H 5

MLPLRHKMLTGEAEPCLVSKTAETDAEWTRDAFGMGQYTAGRCDHLLSWVVFLLLAPVLLIVWLPLSCICCASPVLL VQRFAGWVLSGCLARTYLGVLLIRLCGKCDLILTGMHFIRTGSQRFWMDTLDPQDWAYHNETYGRNIILWANLRVGS YKQVRDIVLNPARKRTRALDGWISGFARHYPNLPVFFNTGSNMHTTFRQIFFANFTKTDFVLRALEDEGAGLAKMAA PILQRWLAGSFRESKSGEGNLYMVEPVAPLILFLLFEVEVESIPPELLTAFSDVVTVGASYFLLPPHSPYWLLSGKV KAIALLKDFLLEHCNAARPESLKGRAVDWRSLAAQMPAFLPKDECRCPCSGTPAVDPVDAYLEVISVMVCVAGVTGT TNGFTSVIRKFADVPVGPTKSRWPSAPVQWRPDADDMVRLYRRDPLGFILEALRLGTPVAGTHQVLEEELTCPFLHK ETTFPKGTVVCANLNACHTDPEEWGSDALEFRPGRAARNRYLMWNGPFGEAAPRQCPGEQVAAHCIKVSIDAFLDMH KPQ

Seq. ID No: 487

>T5H 6

MATSILSLSLMDLLYWGACLCVLSVLYKISALYLRQKNFERVFSAFPGPKRHWLYGNAHEFKQDGTDLDILNGYAKQ FDCAFPLWLGNFFASLAIYHPDYIKAILSRQDPKDNFVYHFITPWIGKGLLVLSGQKWYQHRKLLTPGFHYDVLKPY VGVMSDCVNVMLDKWERLVPDKKPVELFHYISLMTLDTIMKCAFSYQSNCQNDSENEYIKAVYELSYLVDHRTRCPP YHNDFIFYWSPHGFRLRRALKTAHQHTEKVIKLRKESLKQETELEKIKQKRRLDFLDILLCARDENGQGLSDEDLRA EVDTFMFEGHDTTASGVSWTFYCLAKNPEHQEKCREEIRQVLGDRRTVEWEDLSKLPYTTMCIKESMRLYPPVPEVA RELKEPITFCDGRSVPKGSIVFLCIYAINRCPGIWEDPEVFDPLRFSPENSSTRHSHAFLPFSAGGRNCIGQNFAMN EMKIATALTLQRFELQLETKREPVKRAQLVLRSMNGIYINLKKIHSDKTKII

Seq. ID No: 488

>T5H_7

MGLWTFMTGALILLILVVLCFLLYCGYIYYMHMKYDHIPGPPRDSFFFGHSPTIMKLMRNNVIMYDTFLEWVKTYG PVVRVNLSCSTIVFVISQEAVKEFLMSPKYTKDNFYECVETLFGVRYMGKGLLTDRDYEHWHKQRRIMDPAFSRNYL IGLMGTFNEIAEDLVDILGDKADGKCQVGMHDMMGRVTLDIIAKVAFGMELNSLHDDQTPFTRAITTVMRGMVETRN PLARYIPGKQALIRDIKESLKFLRKTGRECILQRRKAIQDGEDIPRDILTQILKGAETEGDCSLENLIDNFVTFFIA GQETTANQLSFAVMELGRHPEILTRVQAEVDEVLGSKRDIEYEDLGKLQYLSQVLKETLRLYPIAPGTSRALEKEMV IEGVRVPPGTTLMFNAYIMGRMEKYYHDPLVFNPDRFHPDAPKISYAYLPFSLGPRSCIGQVFAQMEAKVVMAKLLQ RFEFELVEGQSFRILDTGTLRPLDGVICRLRPRAEHKSRK

Seq. ID No: 489

>T5H_8

MWTILLSTINITLATALMLSFIIIYLLYIQNSTKLPPGPTSWPLIGYTSCLGTDAFRKIQDLNKIYGDIVSFQVLGK TIIILYNYDLIHEAANGNRSKVGRYTMTVNDLLAENSGISNYDTQKALEMRKAFVRLVHNNIKTTEEHEGNKLQPFI SQNIINAQINKLIRQLRIRQGKPVNVLQLMRCTVWRIIWNLIFGKECQLTDKQISDTLDDISSNNLQNQLFQIRQLL PRFCVNIFKHSQFARKLFEIEEIIYKYKTVRQLIDNNVGEMHNSDSLLGQLINDLKLNLTKNDISRLSFEFMAAGTD

TTSLTLTWACDYLARAPPKESLKLSSDLIDMIHRWASVVPLSLPHIVRESFKLKNYYIPKSSILIYNLYAVHNSQIK KLINTEQNSDEIQESDKPIPFSLGSRSCPGARIANLLIEQILTAINQEFLIQNITQSPFETISPGNQESLTPFGITR TPHKSMYIFVTKLNGNRRTSI

Seq. ID No: 490

>T5H 9

MSQLLSSLIELPTQTLVLATAVAVGAAALLVHAYLFDAVGKHGNLPPGPPVDSLFSGHRIPSTHPWRYLEKLTEEYG DIFTLRIGRSPLFVLGRASSAHRILEKQSALSSSRPRLVLAGELLSNNKRILLMPYGDQWRLYRKAMHETLNDTVAK QYEPIQEREARIATLHLGRLGQADGGGGDFQRVLHRYAASVIMQVTYDYQVQTLDDPLVRSVAQRGHALAMCIRPGA SVLDRYPLLEHVPTWLNPWKQEGLRLRKLEQELYLGQVIKVRERMERGECAPCFVSKMTERQQELGLTDLDVAGMSG SLFGAGSDTTASALSIFVMAVCRYPAVLARLHEELDRVVSRDRMPTFDDIPQMPYVRATVQEVLRWRPVSAGGFQHS LTADVEYKGYVLPKGSTVVGPHWSISRDEHEYPEHDVFKPERFLQSGGAEANGTSAQDEVKGTWFAPARGSVAFGFG RRVCPGLNVAMRSLHINIACMAWAFDIAQPDGRPERVDTFAFNSAANSHPLPFDATFTYRDPARKGVVEEENIATGE LDRIAASRGAT

Seq. ID No: 491

>T5H 10

MLEALSSLATALWAALRPDTVLLGTLAFLLFVDFLKRRHPKNYPPGPPGLPFVGNLFQLDPEKVPLVLHQFVKKYGN VFSLDFGTVPSVLITGLPLIKEVLVHQGQIFSNRPIVPLQEHIINNKGLIMSSGQLWKEQRRFALTTLRNFGLGKKS LEERIQEEASYLIQTIREENGQPFDPHLTINNAVSNIICSITFGERFDYQDDQFQELLRMLDEILNLQTSMCCQLYN VFPRIMNFLPGPHQALFSNMEKMKMFVARMIENHKRDWNPAEARDFIDAYLQEIEKHKGDATSSFQEENLIYNTLDL FLAGTETTSTSLRWGLLFMALNPEIQEKVQAEIDRVLGQSQQPSMAARESMPYTNAVIHEVLRMGNIIPLNVPREVA VDTTLAGYHLPKGTMVMTNLTALHRDPTEWATPDTFNPEHFLENGQFKKRESFLPFSIGKRMCLGEQLARTELFIFF TSLLQKFTFRPPENEQLSLKFRVSLTLAPVSHRLCAVPRG

Seq. ID No: 492

>T5H 11

MKTPPQSSCPFHAVGRPPTPPRSSAGRWPPGPESGLTGWGLLKLMSRDLMGTLAGWQREFGDLVHVRTWPEHQVIVS DPQLARELLVNQADALQRWERALTVYRRVHGHSVLIAEGQAWREKRQALQPDFTRKSVQAFSPSIVEAARRAFEQWP ARHAAWPIESELTSVTMEVILRMMFSSGVGSEAQQAEEAVHTLMVASTEELWRPASLPDWVPWQRKRRRARLLMNGL IERHLQARLAMPQDAWPEDLLSRLLRLHLQQPQSWPLQAVRDECKTAFLAGHETVATSLTWWAWCMASHPEIQERAR EEALAALSGGGQADPAALQYVNQTLLETMRLYPAVPLLMSRRALKPVTLGDWTFPAKTVFMVPMQLMQHDERWFPEP RSYRPERFGPDAARPQQGAYLPFGGGPRVCLGQHLAMAEMALVAAQLLLRYRLSAPEGAEPPRPVFHVSQRPSQPLT LGIARI

Seq. ID No: 493

>T5H_12

MKLAGKRFRLPPGPSGAPIVGNWLQVGDDLNHRNLMGLAKRFGEVFLLRMGVRNLVVVSSPELAKEVLHTQGVEFGS RTRNVVFDIFTGKGQDMVFTVYGDHWRKMRRIMTVPFFTNKVVAQNRVGWEEEARLVVEDLRADPAAATKGVVVRR LQLMMYNDMFRIMFDRRFETVADPLFNQLKALNAERSILSQSFDYNYGDFIPVLRPFLRRYLNRCTNLKTKRMKVFE DHFVQQRKEALEKTGEIKCAMDHILEAERKGEINHDNVLYIVENINVAAIETTLWSIEWGLAELVNHPEIQQKLREE IVAVLGPGTPVTEPDLERLPYLQSVVKETLRLRMAIPLLVPHMNLSDAKLAGYDIPAESKILVNAWFLANDPKRWVR ADEFRPERFLEEEKSVEAHGNDFRFVPFGVGRRSCPGIILALPIIGITLGRLVQNFELLPPPGQDKIDTTEKPGQFS NQILKHATIVCKPLEA

Seq. ID No: 494

>T5H_13

MHTDTPDTTADQPLRRIKDLPGPRPLPLIGNGHQIKPQRIHQHVERWSLQYGPLMRMYFGATPILVVADHEMVGAVL RDRPDGFRRPSISATISNEMGGIPGLFLAEGADWRNQRRMVMAGFAPTAIKAYFPALVAVALRLRRRWQAAASARKA IDLESDLKRYTVDIIAGLAFGSDVNTLESGEDVIQRHLDDILPAVARRSLALVPYWRYVKLPADRRLDRSVAVLRTA VQDLIGQARQRMLDNPARRERPPNLLEAMIAAADQSGSGVTDLNVAGNVTNMLLAGEDTTANTISWMIYLLQRHPHT

LQKARDEVRRNAPDAARFTIEQLDSLDYLGACANEAMRLKPVAPYLPLEALRDTVIGDVAVPAGTMIWCVLRHDSVA EKHFPDPLLFDPQRWLQADGKPNSDKRVTMPFGAGLRTCPGRYLALLEIKIAMAMLLGSFDIAGVDTPDGKEAQELM GFVMSPVGLSLRLE

Seq. ID No: 495

>T5H 14

MLMKTLMASLQWLKESFQPFMLLFASIFLAVLLKFFFKEKSRKRSNLPPSPPKLPIIGNLHQLGNMPHLSLHNLAKK YGSIIFLQLGEIPTVVVSSARLAKEVMKTHDLALSSRPQIFSAKHLFYNCTDVVFSPYGAYWRHIRKICILELLSVK RVQSYSFVREEEVARLVRRVAEFYPGTTDLTKILGLYANDVLCRVAFGRDFSGGGEYDQHGFQKMLEEYQELLGGFS LGDFFPSMEFVHSLTGMKSRLQDTFRRFDQLFDLFLTEHRDPKRETEEHKDLVDVLLDLQKNAYDEMPLTTDNIKAI ILDMFAAGTDTTFITLDWGMTELIMNPEVMERAQAEVRSVVGDREVVLQSDLPQLHYIKAVIKEIFRLHPPAPVLVP RESMEDVSIDGYNIPSKTRFFVNAWAIGRDPESWENPNAFEPERFMDSTIDFKGQHFELIPFGAGRRSCPAIAFGEA TIELALAQLLHSFDWELPPGTTPKDLDMSEVFGITMHRIAHLIVIAKPRFPVGQNK

Seq. ID No: 496

>T5H 15

MPKQKKRLPPGPPTLPIIGNMHQLGELAHKSLSELSKKYGPIMLLKIGSKTIINISSAEAARQVLKVHDLDCCSRPV SSTAGRLTYNFKDIVFAPYGDYWREMRKICALELLSVARVQSYRFIREEEVASLVNSISQSASSATPVDLSEKMLAL TVNILCRTAFGKSFRGSGLDNGKLREVVHEAEVMFASFSATEFFPYVGWIIDRLSGRIRRLEKIFRGLDDFLQQAID LHLKPKKTEQDHEDLIDVLLKIERDQQTNTGAPPFNKDNIKAILFDMFLGGSNTAAVTMLWAMAELARNPRAMKKAQ DEVRNVVGNRGKVTESDITHLHYLKMTIKETFRLHPPAAILLPRQTMAEVKIGGYDIGPNSLLQVNAWALGRDPEYW MNPEEFYPERFVDSSIDYKGQHFELLPFGSGRRGCPGMHMGTTTVELALANLLYCFDWKLPSGLKEEDINMDESTGP GLTQKRTTLKLVPVKLF

Seq. ID No: 497

>T5H 16

MKLLLDRTRTNGYLPPSPPKLPIIGNLHQLGKMPHISLCERAQKLGPIMFLQLGEVPTVVISSAAMAKEVMKTHDLA FSSRPQLYSAKWLFYNCTNIVFSPYGAYWRHVRKICILELLSTKRVQSYGFIRQEEVSRLLHRIADSCSKPINLSKL LGLYANDVLCRAVLGRNFSEGGDYDMHGFQSMLKEYQELLGGFSIGDFFPSKEFVHLLTGHKRRLQNTFKRFDNFFQ QVVREHLDPERNYEGEKDILDVLLDIQKNGSSEMPLTLDNVKAILLDMFAAGTDTSFIVLDWGMTELIMNPKVMKKA QAEIRRVVGERQVVLENDLPQLHYLKAVIKEIFRLHPPVPVLVPRESIQDVTIEGYNIPAKTRVFINVWAIGRDPES WKNPETFDPERFVGSTIDFKGQDFELLPFGAGRRGCPGITFGAVTVELALAQLLHSFDWKLPLGVEAKDLDLTEAFG ISMPKTSDLIVVAKPCFA

Seq. ID No: 498

>T5H_17

MRMDGNSTTMFPLLITVIMLLASVLFYIFNRWTHRYSKSGILPPSPPKLPLLGHLHLLSDQPHVALSRLAQKYGPIM YLELGQVPTVVVSSASLAREVLKTHDHVFCNRPQTIAAQYISFGCSDVTFSPYGPYWRQVRKICVTELLTLRRVNSF QLIREEETNRLLTAVGAHSGSEVNLTKLFFNLANDTLCRAAFGTRFMSESTQLERQREGKRLEDILIETVKLLSGFY VGEFFPRWGWINSVSGFKRRLERNLADLRSVGDEIIQEHIKKRGRGNEEEDFVDVLLRVQRQQDLQVPITDDNVTAL VMDLFVAGTDTTSSTLEWTMTEMARHPEVMKKAQAEVRSMSPEGGTLDESHLRHLHYLKAVIKEALRLHPPIPLLLP RESMDKCAIDGYEIPAKTRVLINNFALGRDPDSWDDPLRYNPARFMGGDEHKIDFKGEDFRFVPFGGGRRGCPGYSL GLATVELTLARLLYHFDWKLPPGVEAEKIDLTEIFGLATRKKTPLLLIPTARKAPPHE

Seq. ID No: 499

>T5H 18

MELTMASTMSLALLVLSAAYVLVALRRSRSSSSKPRRLPPSPPGWPVIGHLHLMSGMPHHALAELARTMRAPLFRMR LGSVPAVVISKPDLARAALTTNDAALASRPHLLSGQFLSFGCSDVTFAPAGPYHRMARRVVVSELLSARRVATYGAV RVKELRRLLAHLTKNTSPAKPVDLSECFLNLANDVLCRVAFGRRFPHGEGDKLGAVLAEAQDLFAGFTIGDFFPELE PVASTVTGLRRRLKKCLADLREACDVIVDEHISGNRQRIPGDRDEDFVDVLLRVQKSPDLEVPLTDDNLKALVLDMF VAGTDTTFATLEWVMTELVRHPRILKKAQEEVRRVVGDSGRVEESHLGELHYMRAIIKETFRLHPAVPLLVPRESVA

PCTLGGYDIPARTRVFINTFAMGRDPEIWDNPLEYSPERFESAGGGGEIDLKDPDYKLLPFGGGRRGCPGYTFALAT VOVSLASLLYHFEWALPAGVRAEDVNLDETFGLATRKKEPLFVAVRKSDAYEFKGEELSEV

Seq. ID No: 500

>T5H 19

MPLSDSTISLLLAVLPISGIIFALYNQYQIWLKSPIRGLPYPPGPPLLLGNANRAVQSRPWLTYTEWAKQYGDIIYV NIYGEHTVILNNLEDVMELFEQRSRVYSSRQNNPYIELMGWQFNAGLLPYGDLWRRHRKLLQQCFRRKISTQYEPIQ IAKTHNLLNDLLQTPSDFIEHIKRNSSAMIMSILYGQDISDEMSAQFVSVAEESVKALGKCLRPGTYLVSYIPMLRY LPAWFPGAEFQRQAAEVKKLTTKMKDEPIDFVGKGLLHGTASASLVADLLENCYVQREYDVIKDVAATVFAAGADTS VAALESFFLAMSLFPEAQKKAQAEMDRVIGNKRLPTTDDRPLLPYLEAVYRELMRWAPVVPLNAAHTTIADDIYKGY YIPKGTAVYANTWALTRNEEKYPNPDIFNPDRFFTETGELNDDDTVLTFGFGRRICPGRHMASTTVWLTIASVLSNF DIKGKGTNTKDQKFTSIGEMFTDNFISRPVPFECDIVPRKNAALLASK

Seq. ID No: 501

>T5H_20

MAFETTNGILLAASLFAGVVLYLQKRKRYTLPYPPGPKKHFLLGNLLDVPTTFAWKRYAEWGKTFDSDVLHLSVAGS HFIILNSFKAANDLFEKRSSIYSSRAQMIMFSELIGWDWLMSGMVYGEPWRERRKAFQQYFHVGNAHLYEPVQMQAV RKMLPRLLKEPEDFLSITRHALGSMALTLAYGLDIQEKNDPYLRVSEAAVKSIGEVAIPGAFLVDMIPALKYVPEFF PGAGFKKKARIWRKVQENMREIPFAATLKNIASGSAKVSFTSTCLENLDESRDVDHQRTIIKDTAGNMFAAATDTTI SAIHTFFVAMLCFPEVQKKAQQEIDRVLQGRLPEFSDEADLPYLSALVKETLRWEPSTPIGVPHYSSEDDVYNGYHI PKGSLVIGNAWAMLHNEEDYPEPSLFKPERFIKDGKLNPNVRDPAEMAFGFGRRLCPGNHIAISALWLTAATVLATF NITEAIDDDGRPIKPCVEYESALICHPLPFKCTIKPRSKECTMLIQAAADSY

Seq. ID No: 502

>T5H 21

MIIDSSNSEGNSEGQYTIDGPKAKGLRRMFRIFHLILQPTKYMESSVQRYGSMFQIGSEGASPLVYVGEPEVVKEIF ALDGDQVVTGQGNGVLETMVGKHSILLLDGDPHRQQRKLLMPPFHGEQLRAYAHLICDITRQISAQWQPGQTIVARP PIQNLTLGVILQAVFGVPSGERLSRLQQLMSTLLDSFAYPISASFLFFPALQKDLGEWSPWGKFIRLREEVRSLIYA EIRDRRQQLERSAIEQDEKLGEKLGEKTDILTLLLQARDEDGGAMSDAELHDEIVTLLLAGHETTASAIVWMLYWIH YLPEVQQKLRAELDALGPDPDPMAIAQLPYLTAVCQEALRIYPITPTTFIRRLREPMTLAGYRFKAGTALMPATYII HQRPDLYPEPKQFRPERFLERQFAPHEFLPFGGGHRYCIGSALAMMELKLSIATLLADFELALLHSRPLLPARRGLT MAPPAAMKLRIKARKTNKA

Seq. ID No: 503

>T5H_22

MPAPKTAPSTLPLPPGRLGLPWIGETLSFLRDPNFATKRQAQYGSLFKSRIIGQPTVFFCGPEANAFLLSSHADCFS WRDGWPGTFQELLGESLFLQEGETHLRNRRLLMPAFHGKALASYFSTMVALSDSYLARWEKKQQLTWFLEFKKFTFE VASVLLVGSAPGHDETDNTIGTAESAETEAQIAQLASWFADLTNGLFTLPIRWGPTTYRKALRGRDRLLSYIEQEIT KRRQLLARLQTDPTAALPTDVLTLLLQTEDDEGNRLSEAEIKVQTLLMLFAGHETTTSMLTSLVMSLAQNPDVLAKA RAEQQAFPAESALTFEQIQQMPYLDQILKEVERQYPPVGGGFRRVIKPFNFNGYHVPAGWLALYRIDAAHKDERCYT NPSDFDPDRFSPERAEQKRYDYSLVGFGGGPRVCLGMAFAKLEMKIMAAQLLRRYHWQLDADQDLTMNPVPSLRPAD GLKVRFSKLSFTA

Seq. ID No: 504

>T5H 23

MLDMPSVKPWLTFSDWASKFGDISHLEIFGQHIVVLNSAKTAVEMLDRKSSIYSDRPVLPMGGELVGWRNTLVLLPY GDNFREYRRNFHRVIGSRAAMSVYHAIEEEETHKFLQRVLTKPADLSAHVRTTAGAIILRISHGYHIQEDGDPFVSL ADTAVDQFSRSTATGAFMVDLIPALAYVPEWFPGASFQRKAREWRATLHEMVNQPYKFVQDQMAAGIAPKSFTSNLL EGRTLTEEEEHIIKWSGASLYSGGADTTVSAIYGFFLAMTLYPEAQKKAQAEIDAVVGSDRLPTFADRESLPYAEAL VKEVLRWCPVVPIVVPHRVTADDIHNGYYIPKGTLVLANAWYMLRDPSIYPDPMNFNPDRFLPSGGKEPPTDPRDIC

FGFGRRICPGMHLADASVWLSAVMSLAVFNVSKVVENGVEITPEVDPSSGTISHPKPFKCSIKPRSAKALELIQQTPHY

Seq. ID No: 505

>T5H 24

MHLPPGPRPLPFLGNLLQMNRRGLLRSFMQLQEKYGDVFTVHLGPRPVVILCGTDTIREALVDQAEAFSGRGTVAVL HPVVQGYGVIFANGERWKILRRFSLVTMRNFGMGKRSVEERIKEEAQCLVEELKKYKGALLNPTSIFQSIAANIICS IVFGERFDYKDHQFLRLLDLIYQTFSLMGSLSSQVFELFSGFLKYFPGVHKQISKNLQEILNYIDHSVEKHRATLDP NTPRDFIDTYLLHMEKEKSNHHTEFHHQNLVISVLSLFFAGTETTSTTLRYSFLIMLKYPHVAEKVQKEIDQVISSH RLPTLDDRIKMPYTDAVIHEIQRFADLAPIGLPHRVTKDTMFRGYLLPKNTEVYPILSSALHDPRYFDHPDTFNPEH FLDANGTLKKSEAFLPFSTGKRTCLGEGIARNELFIFFTALLQNFSLASPVAPEDIDLTPINSGAGKIPSPYQINFL SRCVG

Seq. ID No: 506

>T5H 25

MYLIPDFSKETWILLIILLALLAYYGIWPYRLFKKYGIPGPKPLPFFGTFLENRNGVFEFDMECFKKFGKVWGFYDG RQPVLAIMDPVIIKAILVKECYTVFTNRRNFGLNGPLNSAVSIAADDQWKRIRTVLSPTFTSGKLKQMFPIIKQYGD LLVKNIQKKVDNKEFIDMKNIFGSYSMDIVLSTSFSVNVDSLNNPNDPFVTNGRNLFTFSFLNPLFLTTLLCPFLIP ILDKLNFCFLPISVLNFFQDAITSIKKNRQKGIHKDRVDFLQLMVDAQANDSKGGADHGYKELTDTEIMAQGLIFII AGYETTSTTLMFLAYHLATHPDVQTKLQEEIDIILPNKAPPTYEALMQMEYLDMVLYENLRLYPAAGRIERVCKATT EINGVTIPKGVVTVIPAFVLHRDPELWPEPDEFRPERFSKENRETQDPYTFLPFGAGPRNCIGMRFALINMKSVITL LLQNFSFRTCKDTPIPLQIDTRGFLKTTKPVILNLVPREAQKTEK

Seq. ID No: 507

>T5H 26

MYDTFLEWIEKYGPVVRVNSSHSTFVIVISPEGVKEFLMSPKYTKDNFYERIETLFGARFLGKGLVTDRDYDHWHKQ RRMMDPAFSRTYLIGLMGTFNETAEDLMDVLGDKADGKCQVGMHDMLSRVTLDVIAKAAFGMELNSLHDDQTPFTRA ISTVMKGMVETRNPLARYIPGKQAFIREVKESIKLLRETGRECILQRRKEIQDGEDIPMDILTQILKGAEIEDGCSL EDLIDNFVTFFVAGQETTANQLSFAVMELARNPEILTRVQTEVDEVLGSKRDIEYEDLGKLQYLSQVLKETLRLYPI APGTSRALEKETVIEGVRVPPGTTLMFNSYIMGRMEKYYHDPFIFNPDRFHPDAPKPSCAYFPFSLGPRSCIGQVFA RMEAKVVMAKLLQRFEFELVEGQSFRIMDTGTLRPMDGVICRLRPRAERKSRK

Seq. ID No: 508

>T5H 27

MAARPKPATPPSPPALPVIGHLHLLTDMPHHTFADLSNSLGPLIYLRLGQVPTIVIHSAHLAKLVLRTHDHAFANRP QLISAQYLSFGCSDVTFSSYGAYWRQARKICVTELLSAKRVHSFRLVRKEEVDRLLDAVLTSSGKEVDMSQMLFCLA NDVLCKVAFGRRFMAEKDGKGKNLGSVLMETQALFAGFCLGDFFPKWEWVNSMSGYRKRLLKNLKDLKEVCDEIIEE HLKKKKKKKNGTENADDDDDYNEKEDFVDVLLRVQKREDLEVPITDDNLKALVLDMFVAGTDTSSATLEWVFTELARH PRVMKKAQEEVRMIASGNGKVDESDLQHLHYMKAVIKETMRLHPPVPLLVPRESMEKCALDGYEIPAKTRVLINTYA IGRDPKSWENPLDYDPERFMEDDIDFKDQDFRFLPFGGGRRGCPGYSFGLATIEITLARLLYHFDWALPHGVEADDV DLSEVFGLATRKKTALVLVPTANKDFQFRGHDF

Seq. ID No: 509

>T5H 28

MGKNKVPPGPIGLPFIGNLHQFDTLAPHIYFWELSKKYGKIFSFKLTSNVPIIVVSSAKLAKEVLKTQDLVFCSRPS LVGQQKLSYNGHDIGFAPYNDYWREMRKICVLHLFSLKKVQLFSPIREDEVSRMIKKIYQQAVNSQVTNLSNLMISL NSTIICRVAFGVRFDEEAHERKRFNYILAEAQAMFAGFFMSDFFPSLSWIDKLTGMIDRLEKNFKDLDEFYEELIEQ HYNPNRPKSMEGDFIDILLQLKKDQLTPIDLSLEDIKGILMNVLLAGSDTSSSVIIWAMTILIKNPKAMKKVQEEIR NLIGNKGIVNEDDIQNMHYLKAVIKETLRLFPPAPLLIPRESMKISTLEGYEFQPRTIVYVNAWAIARDPEIWENPE EFMPERFLNSNIDFKGQDYELIPFGAGRRGCPGLALGVASVELALSNLLYAFDWELPYGLKKEDIDINGKPGITVNK KNDLCLIPKKYF

Seq. ID No: 510

>T5H 29

MKLTGKRYRLPPGPAGAPVVGNWLQVGDDLNHRNLMSLAKRFGDIFLLRMGVRNLVVVSTPELAKEVLHTQGVEFGS RTRNVVFDIFTGKGQDMVFTVYGDHWRKMRRIMTVPFFTNKVVAQNRVGWEEEARLVVEDVRKDPRAAAEGVVIRRR LQLMMYNDMFRIMFDTRFESEQDPLFNKLKALNAERSRLSQSFEYNYGDFIPVLRPFLRGYLNRCHDLKTRRMKVFE DNFVQERKKVMAQTGEIRCAMDHILEAERKGEINHDNVLYIVENINVAAIETTLWSIEWGIAELVNHPAIQSKLREE MDSVLGAGVPVTEPDLERLPYLQAIVKETLRLRMAIPLLVPHMNLNDGKLAGYDIPAESKILVNAWFLANDPKRWVR PDEFRPERFLEEEKTVEAHGNDFRFVPFGVGRRSCPGIILALPIIGITLGRLVQNFQLLPPPGQDKIDTTEKPGQFS NOIAKHATIVCKPLEA

Seq. ID No: 511

>T5H 30

MKPRGAKYPNSLPCLPFIGSLLHLASHLAPHILFNKLQEKYGSLYSFKMGSHYIVIVNHHEHAKEVLLKKGKTFGGR PRAVTTDLLTRNAKDIAFADYSPTWKFHRKLVHAALSMFGEGTVAIEKIISREAASLCQTLITFQGSPLDMAPELTR AVTNVVCALCFNARYKRCDPEFEEMLAYSKGIVDTVAKDSLVDIFPWLQIFPNKDLEILKRSVAIRDKLLQKKLKEH KEAFCGEEVNDLLDALLKAKLSMENNNSNISQEVGLTDDHLLMTVGDIFGAGVETTTTVLKWAVAYLLHYPKVQAKI QEELDVKVGFGRHPVLSDRRILPYLDATISEVLRIRPVAPLLIPHVALHESSIGEYTIPQDARVVINLWSLHHDPNE WENPEEFIPDRFLDENGNHLYTPSQSYLPFGAGIRVCLGEALAKMEIFLFLSWILQRFTLEVPAGDSLPDLDGKFGV VLQVKKFRVTAKLREVWKNIDLTT

Seq. ID No: 512

>TAT2

MTEDFISSVKRSNEELKERKSNFGFVEYKSKQLTSSSSHNSNSSHHDDDNQHGKRNIFQRCVDSFKSPLDGSFDTSN LKRTLKPRHLIMIAIGGSIGTGLFVGSGKAIAEGGPLGVVIGWAIAGSQIIGTIHGLGEITVRFPVVGAFANYGTRF LDPSISFVVSTIYVLQWFFVLPLEIIAAAMTVQYWNSSIDPVIWVAIFYAVIVSINLFGVRGFGEAEFAFSTIKAIT VCGFIILCVVLICGGGPDHEFIGAKYWHDPGCLANGFPGVLSVLVVASYSLGGIEMTCLASGETDPKGLPSAIKQVF WRILFFFLISLTLVGFLVPYTNQNLLGGSSVDNSPFVIAIKLHHIKALPSIVNAVILISVLSVGNSCIFASSRTLCS MAHQGLIPWWFGYIDRAGRPLVGIMANSLFGLLAFLVKSGSMSEVFNWLMAIAGLATCIVWLSINLSHIRFRLAMKA QGKSLDELEFVSAVGIWGSAYSALINCLILIAQFYCSLWPIGGWTSGKERAKIFFQNYLCALIMLFIFIVHKIYYKC QTGKWWGVKALKDIDLETDRKDIDIEIVKQEIAEKKMYLDSRPWYVRQFHFWC

Seq. ID No: 513

>TMO 1

MSTLADQALHNNNVGPIIRAGDLVEPVIETAEIDNPGKEITVEDRRAYVRIAAEGELILTRKTLEEQLGRPFNMQEL EINLASFAGQIQADEDQIRFYFDKTMGGGSGEGRGSLLTCGDVEENPGPMFNIQSDDLLHHFEADSNDTLLSAALRA ELVFPYECNSGGCGACKIELLEGEVSNLWPDAPGLAARELRKNRFLACQCKPLSDLKIKVINRAEGRASHPPKRFST RVVSKRFLSDEMFELRLEAEQKVVFSPGQYFMVDVPELGTRAYSAANPVDGNTLTLIVKAVPNGKVSCALANETIET LQLDGPYGLSVLKTADETQSVFIAGGSGIAPMVSMVNTLIAQGYEKPITVFYGSRLEAELEAAETLFGWKENLKLIN VSSSVVGNSEKKYPTGYVHEIIPEYMEGLLGAEFYLCGPPQMINSVQKLLMIENKVPFEAIHFDRFF

Seq. ID No: 514

>TMO 2

MAMHPRKDWYELTRATNWTPSYVTEEQLFPERMSGHMGIPLEKWESYDEPYKTSYPEYVSIQREKDAGAYSVKAALE RAKIYENSDPGWISTLKSHYGAIAVGEYAAVTGEGRMARFSKAPGNRNMATFGMMDELRHGQLQLFFPHEYCKKDRQ FDWAWRAYHSNEWAAIAAKHFFDDIITGRDAISVAIMLTFSFETGFTNMQFLGLAADAAEAGDYTFANLISSIQTDE SRHAQQGGPALQLLIENGKREEAQKKVDMAIWRAWRLFAVLTGPVMDYYTPLEDRSQSFKEFMYEWIIGQFERSLID LGLDKPWYWDLFLKDIDELHHSYHMGVWYWRTTAWWNPAAGVTPEERDWLEEKYPGWNKRWGRCWDVITENVLNDRM DLVSPETLPSVCNMSQIPLVGVPGDDWNIEVFSLEHNGRLYHFGSEVDRWVFQQDPVQYQNHMNIVDRFLAGQIQPM TLEGALKYMGFQSIEEMGKDAHDFAWADKCKPAMKKSAGGGSGEGRGSLLTCGDVEENPGPMSFEKICSLDDIWVGE

METFETSDGTEVLIVNSEEHGVKAYQAMCPHQEILLSEGSYEGGVITCRAHLWTFNDGTGHGINPDDCCLAEYPVEV KGDDIYVSTKGILPNKAHS

Seq. ID No: 515

>TMO 3

MSFTKVCSVGDIWEGEMEPFTVDGHEILLVGVEGGGIKAFQGICPHQDIALSEGKFDGKKLICRAHLWQFDASNGKG INPDDCALAEYPVKVDGDDVYVQTAGVEALFAHSGGGSGEGRGSLLTCGDVEENPGPMALLNRMDWYDLARTTNWSP KYVTESELFPPELSGDHGIPMEKWETYDEPYKQTYPEYVKVQREKDAGAYSVKAALERSQIYERSDPGWLTVMKQHY GAIALGEYAASSAEARMMRFSKAPGMRNMATLGSMDEIRHGQIQLYFPHEHVSKDRQFDWAAKAFHTNEWAAIAARH FFDDIMMTRDAISVAIMLTFSFETGFTNMQFLGLAADAAEAGDHTFASLISSVQTDESRHAQIGGPTLQILIENGKK AEAQKKVDIAFWRAWRLFSVLTGPVMDYYTPLEHRKQSFKEFMQEWIVAQFERALSDLGLDKPWYWDTFLQQLDQQH HGMHLGVWYWRPTVWWNPAAGVTPAERDWLEEKYPGWNDTWGQCWDVIIDNLVDGNIAQTYPETLPIVCNMCNLPIN CTPGNGWAVQDYPLEYNGRLYHFGSEPDRWCFEQEPERYAGHMTLVDRFLAGLVQPMDLGGALAYMGLAPGEIGDDA HGYSWVDIYKKMRMKKAS

Seq. ID No: 516

>TMO 4

MSVASSAQAYHNNMVGPVMRAGDLALAVIEAARVDNPGKEVFVDDKRAYVRIHTEQEMILRRETIEEELGRPFKMND LEVDLSSFAGQIESLDDAVRFYFTKKLGGGSGEGRGSLLTCGDVEENPGPSSNPIIHNQKDGSRFAQREGDTILRAA LRAGVGLSYECNSGGCGGCKFELLEGEVDTLWPDAPGLSDKDRRRGRHLACQCRARGPVSIKAATGAEYVPKVVPQR QTARLVGSTDITHDLREFRFRSAAGASFLPGQFAMLDLPGLASARAYSMSNTANDDGEWHFQVRRVPHGQGTHVLFD RLGVGDEIGLDGPYGVAWLRTGAPRDIVCVAGGSGLAPMVSIARGAAAAGMLKDRKLYFFYGARTPRDVCGAEMLAQ LDGFGERIIYLPVVSLPGGEGEWQGETGYVHDAVARTLPGSLAGFEFYFAGPPPMTQALQEMLMVGHRVPFEQIHFD RFF

Seq. ID No: 517

>TPH **1**

MPSRLNKDEYQFYIDLDNKSTPALNEIVKCLRLDIGATVHELSRDKKKDAVPWFPKTIQDLDKFANQILSYGAELDS DHPGFTDPVYRARRKEFADIAFHYKHGQPIPCVTYTEEEKKTWGTVFKELKLLYPTHACYEHNHVFPLLEKYCGYNE NNIPQLEDVSKFLQTCTGFRLRPVAGLLSSRDFLAGLAFRVFHSTQYIRHWSKPMYTPEPDICHELLGHAPLFADPS FAQFSQEIGLASLGAPDEYIERLATLYWFTVEFGLCKQDDKIKAYGAGLLSSFGELQYCLTDKPELKPFEPEKTSLQ KYPITEFQPVYFIAESFEDAKEKMRKFATTIPRPFSVRYNPYTQSIEVLDNVQQLKNLADCINSEIGTLCCA

Seq. ID No: 518

>TPH 2

MIEDNKENKDHSLERGRASLIFSLKNEVGGLIKALKIFQEKHVNLLHIESRKSKRRNSEFEIFVDCDINREQLNDIF HLLKSHTNVLSVNLPDNFTLKEDGMETVPWFPKKISDLDHCANRVLMYGSELDADHPGFKDNVYRKRRKYFADLAMN YKHGDPIPKVEFTEEEIKTWGTVFQELNKLYPTHACREYLKNLPLLSKYCGYREDNIPQLEDVSNFLKERTGFSIRP VAGYLSPRDFLSGLAFRVFHCTQYVRHSSDPFYTPEPDTCHELLGHVPLLAEPSFAQFSQEIGLASLGASEEAVQKL ATCYFFTVEFGLCKQDGQLRVFGAGLLSSISELKHALSGHAKVKPFDPKITCKQECLITTFQDVYFVSESFEDAKEK MREFTKTIKRPFGVKYNPYTRSIQILKDTKSITSAMNELQHDLDVVSDALAKVSRKPSI

Seq. ID No: 519

>TPH 3

MSGLALDRSSQPHEVRTLEVNELDPKVFAVVEVRKDEPGVLGDVLKVFTESSINITNIESRFKSFARDGPAFHIDFE GEAREHRVQRVLRDVKSVPGVSQVTVMEEREVPWFPINIRDLDLTTDTLDGGTALINEDHPGFNDLAYRQRREEIVT AAKEHRHGDRIARVQYLEHEVETWRAVYEQLRECHSRWACTEYLEMLPQMERFCGYAPGNIPQLADISDFLQQRTGF TLRPITGLLSARDFLNALAFRVFYSTQYIRHHGNPFYTPEPDICHELMGHVPLFANAAFADFSQEIGLASLAASDDD IARLAAVYWFTVEFGLVRQGGEVKAYGAGLLSSFGEMEWSCSREPSTTCREMGSVAELQAPSIVPLDPTQAGKQAYP ITTYQPLYFCAESMQDAKAKISQFCDTLTRPFFPQYDPLTQNIRVTKAVRRARRISTVEMQMAKQLDYFEKQ

Seq. ID No: 520

>TPH_4

MAVPWFPKTIQDLDKFANQILSYGAELDSDHPGFTDPVYRTRRKEFADIAFHYKHGQPIPRVTYTEEEKKTWGTVFK ELKLLYPTHACYEHNHVFPLLEKYCGYNENNIPQLEDVSNFLQTCTGFRLRPVAGLLSSRDFLAGLAFRVFHSTQYI RHWSKPMYTPEPDICHELLGHAPLFADPSFAQFSQEIGLASLGAPDEYIERLATLYWFTIEFGLCKQDDKIKAYGAG LLSSFGELQYCLTDKPDLKPFEPEKTSLQKYPITEFQPVYFIAESFEDAKEKVRKFATTIPRPFSVRYNPYTQSIEV LDNVQQLKNLADCINSEIGILCCALRKLE

Seq. ID No: 521

>TPH 5

MLISFTLNLVHQKKNSEFEIFLDCDSNREQLNEIFQLLRPHVNLITMNPQEDFSVEEDDMESVPWFPIKISDLDKSA NRVLMYGSDLDADHPGFKDNVYRRRKYFADVAMNYKYGDPIPHIEFTEEEVKTWGTVFRELNKLHQTHACREYLKN LPLLVKHCGYREDNIPQLEDVSRFLKERSGFTIRPVAGYLSPRDFLAGLAFRVFHCTQYVRHSSDPLYTPEPDTCHE LLGHVPLLAEPSFAQFSQEIGLASLGASDEAVQKLATCYFFTVEFGLCKQEGKLKVYGAGLLSSISELKHSLSGNAN VKPFDPMVTCSQECIITSFQEVYFYSESFEEAKEKMREFAKTIKRPFGLKYNPYTQSVQMLKDTQSITTLVSELRHE LDIISDALNKMNKOLGV

Seq. ID No: 522

>TPH 6

MHSPEPDCCHELLGHVPMLADKTFAQFSQDIGLASLGVTDEEIEKLSTLYWFTVEFGLCKQDGEVKAYGAGLLSSYG ELLHALSDKPEVRPFDPDEAAIQPYQDQNYQPVYFVSESFTDAKEKLRNYASRIKRPFAARYDPYTVSIEVLDSPGQ IQSSLEELKDELQTLTTALNILS

Seq. ID No: 523

>TPH 7

MMISTESDLRRQLDENVRSEADESTKEECPYINAVQSHHQNVQEMSIIISLVKNMNDMKSIISIFTDRNINILHIES RLGRLNMKKHTEKSEFEPLELLVHVEVPCIEVERLLEELKSFSSYRIVQNPLMNLPEAKNPTLDDKVPWFPRHISDL DKVSNSVLMYGKELDADHPGFKDKEYRKRRMMFADIALNYKWGQQIPIVEYTEIEKTTWGRIYRELTRLYKTSACHE FQKNLGLLQDKAGYNEFDLPQLQVVSDFLKARTGFCLRPVAGYLSARDFLSGLAFRVFYCTQYIRHQADPFYTPEPD CCHELLGHVPMLADPKFARFSQEIGLASLGTSDEEIKKLATCYFFTIEFGLCRQDNQLKAYGAGLLSSVAELQHALS DKAVIKPFIPMKVINEECLVTTFQNGYFETSSFEDATRQMREFVRTIKRPFDVHYNPYTQSIEIIKTPKSVAKLVQD LQFELTAINESLLKMNKEIRSQQFTTNKIVTENRSS

Seq. ID No: 524

>TrpHalo_1

MSTASKNIDITRFPKKYDAATKDSDFYDVVIVGAGPGGSTTAYYLAKEGKKVLLLEKKKFPRDKICGDAICKLAIEM LMDMGVYEGLVREKKARVAHNGGLVSPSGLSFIGNTYLKPGEIPAAAACKRMVLDEAIAKAAIGAGAELKENSPVTD AVFDSSTGLWTISIEGSDVKHMGRVLVCADGAPSKLATQLGIVKQAPQGVCSRAYIKEGTHRFRADGVVFYPRNILP AYAALFRHIDDTVAYCTYILPFNPKVTTDDLSYWHHRLLEEDPSISQAVGKNADMERMKAWGLRMGGEPVTYGNHVL VVGDAAGMIDPLTGEGIHHAMDGGRIAAHFLCEAIAVGNFDKEVMKEYQNRWLYTFGNDYKWSQAICHFLYRFPIFI DATAAAAQRRGNNFLALYADIMTGRIPKANIFRPDISLPIAFEVLVLLWKMMFTGGGGNNKMKSQ

Seq. ID No: 525

>TrpHalo 2

MSTASKNIDITRFPKKYDAATKDSDFYDVVIVGAGPGGSTTAYYLAKEGKKVLLLEKKKFPRDKICGDAICKLAIEM LMDMGVYEGLVREKKARVAHNGGLVSPSGLSFIGNTYLKPGEIPAAAACKRMVLDEAIAKAAIGAGAELKENSPVTD AVFDSSTGLWTISIEGSDVKHMGRVLVCADGAPSRLAMQLGIVKGTPKCVCSRAYIKGGTHRFKEDGMVFYVPSILP GYVALLRHIDDQLTYCTYILPGNPRATTKDLSYWHHRLLEEDPNISQAVGKNAELEKMKAWDLRVGGEPVTYGNHVL VVGDAAGMIDPLTGEGIHHAMDGGRIAAHFLCEAIAVGNFDKEVMKEYQNRWLKAFGNDFRWSQAIGNFLYRYPIFI DATAAVAEKKGDRFLARWADIMAGRIPKISVLRPQFLLAVGFQALLLFYKKIFKGGYGKKTKIL

Seq. ID No: 526

>TrpHalo_3

MSSLIAPKVDTIDITRFPKKYDPAAEDSDFYDVVIVGAGPGGSTTAYYLAKKGKKVLLLEKKKFPRDKICGDAICKT AIEILMDMGVYGGLIREQKAYMIDYGGLVSPSGLSFVGHTHELFGEIPGAVVCKRVVLDKVISRTAQSAGAELLENS PVTDAVFDSSTGLWTISIEGSDVKHMGRVLVCADGAPSRLAMQLGIVKGTPKCVCSRAYIKGGTHRFKEDGMVFYVP SILPGYVALLRHIDDQLTYCTYILPGNPRATTKDLSYWHHRLLEEDPNISQAVGKNAELEKMKAWDLRVGGEPVTYG NHVLVVGDAAGMIDPLTGEGIHHAMDGGRIAAHFLCEAIAVGNFDKEVMKEYQNRWLKAFGNDFRWSQAIGNFLYRY PIFIDATAAVAEKKGDRFLARWADIMAGRIPKISVLRPQFLLAVGFQALLLFYKKIFKGGYGKKTKIL

Seq. ID No: 527 >TrpHalo 4

MSGKIDKILIVGGGTAGWMAASYLGKALQGTADITLLQAPDIPTLGVGEATIPNLQTAFFDFLGIPEDEWMRECNAS YKVAIKFINWRTAGEGTSEARELDGGPDHFYHSFGLLKYHEQIPLSHYWFDRSYRGKTVEPFDYACYKEPVILDANR SPRRLDGSKVTNYAWHFDAHLVADFLRRFATEKLGVRHVEDRVEHVQRDANGNIESVRTATGRVFDADLFVDCSGFR GLLINKAMEEPFLDMSDHLLNDSAVATQVPHDDDANGVEPFTSAIAMKSGWTWKIPMLGRFGTGYVYSSRFATEDEA VREFCEMWHLDPETQPLNRIRFRVGRNRRAWVGNCVSIGTSSCFVEPLESTGIYFVYAALYQLVKHFPDKSLNPVLT ARFNREIETMFDDTRDFIQAHFYFSPRTDTPFWRANKELRLADGMQEKIDMYRAGMAINAPASDDAQLYYGNFEEEF RNFWNNSNYYCVLAGLGLVPDAPSPRLAHMPQATESVDEVFGAVKDRQRNLLETLPSLHEFLRQQHGR

Seq. ID No: 528 >TrpHalo 5

MDEIDDPRIRSVVIVGGGTAGWMTAAALVQHFRTAPLKITVVESSDIGTIGVGEATIPTIRRFYGQLGLRDDDVMRA TQATCKLGIRFLDWSGPGSDFIHPFGLYGQDVKGIGFHHYWLKQRRAGDAAPLAAYSLGAALAAGGKFTLPSPHPPS QLSVFDWALHLDAGLFAQHLRAYAEAGGCARIDARIRSVELRPEDGFVRALTLDDGREVEGDLFVDCSGFKGLVIGE ALGVGFEDWGRWLPCDAAYAVQSENRPGDAPAPFTRVTARSAGWQWGIPLRHRAGNGLVFSSAHLSDDQALAELMPH LLGDPLTEPRRIPFRPGRRSQAWAKNCVAIGLSSGFLEPLESTSIALIETGIERLKALFPDRRFAQPILDEFNDQTA REMERVRDFIILHYKLNRRTDTDFWRDCREMPVPETLERKIALWTARGQFVRYRWEMFHPASWLAIYDGFGLYPDHH DPAVDAMDPAYLARSLAEMRANIADLVARTPEHAQFLAGLDPAASAA

Seq. ID No: 529 >TrpHalo 6

MIRSVVIVGGGTAGWMTASYLKAAFDDRIDVTLVESGNVRRIGVGEATFSTVRHFFDYLGLDEREWLPRCAGGYKLG IRFENWSEPGEYFYHPFERLRVVDGFNMAEWWLAVGDRRTSFSEACYLTHRLCEAKRAPRMLDGSLFASQVDESLGR STLAEQRAQFPYAYHFDADEVARYLSEYAIARGVRHVVDDVQHVGQDERGWISGVHTKQHGEISGDLFVDCTGFRGL LINQTLGGRFQSFSDVLPNNRAVALRVPRENDEDMRPYTTATAMSAGWMWTIPLFKRDGNGYVYSDEFISPEEAERE LRSTVAPGRDDLEANHIQMRIGRNERTWINNCVAVGLSAAFVEPLESTGIFFIQHAIEQLVKHFPGERWDPVLISAY NERMAHMVDGVKEFLVLHYKGAQREDTPYWKAAKTRAMPDGLARKLELSASHLLDEQTIYPYYHGFETYSWITMNLG LGIVPERPRPALLHMDPAPALAEFERLRREGDELIAALPSCYEYLASIQ

Seq. ID No: 530

>TrpHalo 7

MLESIVVVGGGTSGWMTASYLSAAFGERISVTVVESARVGTIGVGEATFSTVRHFFEYLGLSEETWMPACNATYKLG IRFENWRAPGHHFYHPFERQRVVDGFTLPDWWLADGGATERFDKECFLVGTLCDTMRSPRHMDGALFEGDLTDRPAG RSTLAEQGTQFPYAYHFDAALLADFLRDYAVARGVLHVVDDVVHVARDERGWISHVATRGSGDLAGDLFVDCTGFRG LLINDALDEPFESYQDTLPNDSAVALRVPVDMEREGLRPCTTSTAQAAGWIWTIPLFGRVGTGYVYARDYCTPEEAE RTLRRFVGPAADDLEANHIRMRIGRSRRSWVNNCVAVGLSSGFVEPLESTGIFFIQHAIEQLVKHFPDADWDPALRS AYNTLVNRCMDGVREFLVLHYYGAARADNEYWRDTKTRKIPDSLAERVEQWRTKLPHPESVYPHYHGFEAYSYVCMV LGLGGIPLKPSPALRMLDPSAAQREFRLLATQAEDLRRTLPSQYAYFAQFR

Seq. ID No: 531
>TrpHalo_8

MNKPIKNIVIVGGGTAGWMAASYLVRALQQQANITLIESAAIPRIGVGEATIPSLQKVFFDFLGIPEREWMPQVNGA FKAAIKFVNWRKSPDPSRDDHFYHLFGNVPNCDGVPLTHYWLRKREQGFQQPMEYACYPQPGALDGKLAPCLSDGTR QMSHAWHFDAHLVADFLKRWAVERGVNRVVDEVVDVRLNNRGYISNLLTKEGRTLEADLFIDCSGMRGLLINQALKE PFIDMSDYLLCDSAVASAVPNDDARDGVEPYTSSIAMNSGWTWKIPMLGRFGSGYVFSSHFTSRDQATADFLKLWGL SDNQPLNQIKFRVGRNKRAWVNNCVSIGLSSCFLEPLESTGIYFIYAALYQLVKHFPDTSFDPRLSDAFNAEIVHMF DDCRDFVQAHYFTTSRDDTPFWLANRHDLRLSDAIKEKVQRYKAGLPLTTTSFDDSTYYETFDYEFKNFWLNGNYYC IFAGLGMLPDRSLPLLQHRPESIEKAEAMFASIRREAERLRTSLPTNYDYLRSLRDGDAGLSRGQRGPKLAAQESL

Seq. ID No: 532

>TrpM_1

MSPVALSPKRVDIVDIRGNDMQYSLVNEIHKGLNPPNGTRRSLPTMLLYDSEGLKLFEKITYVDEYYLTNAEIEVLE KHSRRLVEKIPSNAQLLELGSGNLRKIEILLREFERVGKPVDYYALDLSLSELERTFSNVSLEEYKSVGFHGLHGTY DDAHTWLSDPKNRERPTVVLSMGSSLGNFSPPDAAAFLAGFATLLKPSDFMVIGLDACEDPDRVYKAYNDSAGITRK FYENGLANANKTLGHEVFRPDEWEVVTEYDAVNGRHQVFYVPTKDVSVGDVLLRRGEKIIFAEAFKYGCQAREKLWH DAGLIEAAEFGSGSEDYRTYI*

Seq. ID No: 533

>TrpM 10

MLGPVPSPSPVPIPPGSRPGASPGLEATIPIIDIRSTAHSVTVAALEDGIRANVLSGFTKPYNEKELPNLLLYNEEG LRLFEQITYQPDYYLTRLEIDILSRHAHQIANSVPDGAILLELGAGALRKTALILDALEAQGKDVTYFALDLDKPEL LRTLAEVKGRYTHVSLAGLWGTYDDGCTWLKQVKDRPRIILWLGSSVGNMSRKEAGQFIRTFGDILAPRDRFIVAID SKNHKLNDIRAAYDDRAGVTRRFALNALGNINDLFNADVVDVSSFDYNPYYNEVQGRNEAYFRCLKDTQVRIPSETP ILVHEGEYIRFAFSHKYDRVERQVLWTAAGAYPVQEWMSQDGDYALTMLSWSS*

Seq. ID No: 534

>TrpM_**11**

MTYSIVDIRKTDTCLKNSIINGINQSTKSIPAIVLYDELGLQYYEKVTYLKEYYLTEAEIDILKNKADQISDYIPEG SSLIELGSGALRKTRLLLDSIEKQKKKVIYYALDLMEGELKRTLSSLGKFQYVKLVGLWGVYEDGIDYASNLPGDSH KTILWMGSSIGNFNRDEAANFVKTIQDKAMNPGDLFLIGIDRRKNPDKITAAYNDPKGINAKFIMNGLNHVNAIFDQ PIFDSNNFEHVTMYNDDVGRHEAYCKVKNDTTLEFKESKDNPKTIIKLNKNELINIGYSHKYNKAETDALFDFSLLS YMESWTDSQSLYDLHLVYKSPFHFTRKFDSHK*

Seq. ID No: 535

>TrpM 12

MSKDVQVLDIRASPQSKGSIPNLRTAILDGLQKAPGMRTLPSEILYDDRGLKIYNDCIRSWSEWYYPISAETEILEI NGKDIARVFSTSDRGEAVLIELGAGSLDKTSKILVSLSETVQNVSDSQPPITYYALDLERSELQRTLSELQKNIGEK IAGKIATKGMWGTYDDGIRSVENNELHLDAAVPVHFLFLGGTIGNFSKGEGDVTFLRNLPLNAQRGDTILLGIDREK SKEIIERAYNFPAAREWIMNGLNVSGHLLSGDKDLFQLDNWDRYAMYDEKLGRLEAGYRSKIDQIIEVTANYSIPFK KDESVMAIFSNKYTDDELNFLISKANLKTINSWVDHKALYYIFSLRKV*

Seq. ID No: 536

>TrpM 13

MPRIQVLDIRGSKESVGSTPHLRAAILEGLLKPPGSRTLPSETLYDEVGLKMYNDGMKAWAEWYYPVEAERQILERY GRDIAKLFTTSAKGKAVLIELGAGSLDKTSQVLLSAAEITRTTGPMNNIAYYALDLERGELERTIGRLQEVIGDQIA GKISTAGMWGTYDDGIRVIEKNELELEPDIPVHILFLGGTIGNFSKQDGDVAFLKSLPLDHKRGDTLLVGMDRHKSA DAIERSYGFAAAKDWIMNGLKVSGRVLTGDEGLFEIGNWERYAKYNEELGRYEAGYKSQKEHALKISEGVDITFLKD EVVLVMFSNKYTDAEMDSVVDSAGLVKNGSWMDEKAQYCLLSLRANNGPV*

Seq. ID No: 537

>TrpM_14

MSQIEVLDIRGSKEATGSTPHLRAEILQGLSKSPGHRTIPGETLFDETGLKMYDEGMKTWRKWYYPFEAEKEILEVR GLEIAKLLKTSSKGEAVLIELGAGSLEKTSQILLSAAQIAETADNSTTNPITYYALDLEHRELERTLAALQDAIGPR IAGKITTKGMWGTYEDGIRVVERNDLKFPSDVPLHILFLGGTIGNFSKADGDIAFLKSLPLNRKRGDTLLLGVDRAK AVELIERAYGFAAATGWIMNGLKVSGRVLTGDEELFESGNWERYSKYNEELGRYEAGYKSRKDQTIKVAKDVDIVFS KDEVILVTYSNKYTDAEIKTVFDGAGLEIVESWMDKKAQYCLFLLKA*

Seq. ID No: 538

>TrpM 2

MTLSLANYLAADSAAEALRRDVRTGLTATPKSLPPKWFYDAVGSDLFDQITRLPEYYPTRTEAQILRTRSAEIIAAA GADTLVELGSGTSEKTRMLLDAMRDADLLRRFIPFDVDAGVLRSAGAAIGAEYPGIEIDAVCGDFEEHLGKIPRVGR RLVVFLGSTIGNLTPQPRAEFLATLADTLQPGDSLLLGTDLVKDTGRLVRAYDDAAGVTAAFNRNVLAVVNRELSAD FDLDAFEHIAKWNDDEERIEVWLRARTAQHVRIPALDLEIDFAAGEQMLTAVSCKFRPDSVAAELAEAGLRQTHWWT DPAGDFGLSLAVR*

Seq. ID No: 539

>TrpM 3

MTLSLANYLAADSAAEALRRDVRAGLTAAPKSLPPKWFYDAVGSDLFDQITRLPEYYPTRTEAQILRTRSAEIIAAA GADTLVELGSGTSEKTRMLLDAMRDAELLRRFIPFDVDAGVLRSAGAAIGAEYPGIEIDAVCGDFEEHLGKIPHVGR RLVVFLGSTIGNLTPAPRAEFLSTLADTLQPGDSLLLGTDLVKDTGRLVRAYDDAAGVTAAFNRNVLAVVNRELSAD FDLDAFEHVAKWNSDEERIEVWLRARTAQHVRVAALDLEVDFAAGEEMLTAVSCKFRPENVVAELAEAGLRQTHWWT DPAGDFGLSLAVR*

Seq. ID No: 540

>TrpM 4

MRVSGANHLGEDAGHLALRRDVYSGLQKTPKSLPPKWFYDTVGSELFDQITRLPEYYPTRAEAEILRARSAEVASAC RADTLVELGSGTSEKTRMLLDALRHRGSLRRFVPFDVDASVLSATATAIQREYSGVEINAVCGDFEEHLTEIPRGGR RLFVFLGSTIGNLTPGPRAQFLTALAGVMRPGDSLLLGTDLVKDAARLVRAYDDPGGVTAQFNRNVLAVINRELEAD FDVDAFQHVARWNSAEERIEVWLRADGRQRVRVGALDLTVDFDAGEEMLTAVSCKFRPQAVGAELAAAGLHRIRWWT DEAGDFGLSLAAK*

Seq. ID No: 541

>TrpM 5

MTLTLSNYLAADSAATALRRDVHEGLTQSPKMLPPKWFYDSVGSDLFDQITRLPEYYPTRTEAQILTHRSPEIVAAA GADTLVELGSGTSEKTRMLLDAMRDGGQLRRFIPFDVDAGVLRAAGAAIGQEYPGIEIDAVCGDFEEHLGKIPAVGR RLVAFLGSTIGNLTPGPRADFLASLAETLQPGDSVLLGTDLVKDTGRLVSAYDDSAGVTAAFNRNVLSVVNRELDAD FDLDAFAHVAKWNAEEERIEVWLRADAPQQVRIAGLDLDVAFGAGEEMLTAVSCKFRADGVADELAKAGLRQTHWWT DEAGDFGLSLAVK*

Seq. ID No: 542

>TrpM 6

MLEATSTQNLVSFQIPIVDIRTPSCLEETIRKKVVSGLARPYNKKSIPDLLLYNETGLRLFEDLTYQPDYYLTGLEI EILSKHSLQIADSIPVGSLIMELGAGALRKTALILDALEAQKKEVAYLALDLDRPELVRTLGQLNGKYTHVKLGGLW GTYDDGRRWLSENTSDSPRTILWLGSSIGNVKRDDAGDFIRSFGDVLSSKDRFVVAIDSRYHEVDTICRAYNDREGF AERFCLNGIDSFNQLFGRAIIDISCAKYRTVYNEVKGRHEVYYRCTHDFEIRLPGDYPPTFLYEGELILLAHSYKYA AVERETLWLRAGARPEKEWMTDGSYTVTMLSWP*

Seq. ID No: 543

>TrpM_7

MSPSTVNKIASSPVFDIRSDETKGFAKAPIEDELAGLQAVYNEKTLPNVLLYDAKGLQLFEKITYTNDYYLTGLEMD LLGEHADEMAEWIKDGAALVELGAGALRKTAILLDAIERQGKRITFYALDLDHSELTRTLAELEGRYRHITLCGLWG TYDDGRAWLASTNEEQRVLLWLGSSIGNLSRQEAKDFLHSFGRALRPGIDKFIVAMDSKYNAVSSMTRAYNDSEGVT

ASFALNLLDAFNAKVGFKALPPSSFCYSPFFNQAQGRNEAYLRARHGVRFEVNGIAVEVRDEELIRFAYSHKYDNAE RDLLWRAAEANVEOEWLHSPOSGRARYSISLLSFRD*

Seq. ID No: 544

>TrpM 8

MTLSLSNHLPANSAARVLRRDVLDGLTQTPKALPPKWFYDSVGSDLFDQITRLPEYYPTRTEAQILRTRSAEIAEAS GADTLVELGSGTSEKTRMLLDALRDNGTLRRFIPFDVDAGVLNAAGAAIQKEYPGVEVDAVCGDFEEHLGEIPRVGR RLIAFLGSTIGNLTPQPRARFLTALAQTMRPGDSLLLGTDLVKDTERLVRAYDDSAGVTARFNRNVLAVINRELDAD FDLAAFDHVARFNAAEERIEVWLRARGAQRVYVRELDLTVDFADGEEMLTAVSCKFRPDGVAAELAAAGLRRTHWWT DPAGDFGLSLSTK*

Seq. ID No: 545

>TrpM 9

MTISIANYLAADSAATALRRDVREGLAGTPKSLPPKWFYDSVGSDLFDQITRLPEYYPTRAEAQILRTHAVDVAAAS GADTLVELGSGTSEKTRLLLDALHRADSLRRFIPFDVDASILQSAGAAISQEYPDVEIEAVCGDFEEHLGKIPLQGR RLVVFLGSTIGNLTSGPRATFLSALADSLQPGDTLLLGTDLVKDVDRLKRAYDDAAGVTARFNKNVLTVVNRELGAD FDLDAFEHVCKWNADEERIEVWLRANTLQRVHISGLELDVEYAAGEEMLTAVSCKFRPEGIAAELAAVGLNRTHWWT DDAGDFGLSLAVK*

Seq. ID No: 546

>TrpS 1

MTTLLNPYFGEFGGMYVPQILMPALNQLEEAFVSAQKDPEFQAQFADLLKNYAGRPTALTKCQNITAGTRTTLYLKR EDLLHGGAHKTNQVLGQALLAKRMGKSEIIAETGAGQHGVASALASALLGLKCRIYMGAKDVERQSPNVFRMRLMGA EVIPVHSGSATVKDACNEALRDWSGSYETAHYMLGTAAGPHPYPTIVREFQRMIGEETKAQILDKEGRLPDAVIACV GGGSNAIGMFADFINDTSVGLIGVEPGGHGIETGEHGAPLKHGRVGIYFGMKAPMMQTADGQIEESYSISAGLDFPS VGPQHAYLNSIGRADYVSITDDEALEAFKTLCRHEGIIPALESSHALAHALKMMREQPEKEQLLVVNLSGRGDKDIF TVHDILKARGEI

Seq. ID No: 547

>TrpS 2

MWFGEFGGQYVLETLIGPLKELEKAYKRFKDDEEFNRQLNYYLKTWAGRPTPLYYAKRLTEKIGGAKVYLKREDLVH GGAHKTNNAIGQALLAKFMGKTRLIAETGAGQHGVATAMAGALLGMKVDIYMGAEDVERQKMNVFRMKLLGANVIPV NSGSRTLKDAINEALRDWVATFEYTHYLIGSVVGPHPYPTIVRDFQSVIGREAKAQILEAEGQLPDVIVACVGGGSN AMGIFYPFVNDKKVKLVGVEAGGKGLESGKHSASLNAGQVGVSHGMLSYFLQDEEGQIKPSHSIAPGLDYPGVGPEH AYLKKIQRAEYVAVTDEEALKAFHELSRTEGIIPALESAHAVAYAMKLAKEMSRDEIIIVNLSGRGDKDLDIVLKVS GNV

Seq. ID No: 548
>affibody tag 1

MVDNKFNKETIQASQEIRLLPNLNGRQKLAFIHSLLDDPSQSANLLAEAKKLNDAQAPKNAAIRSSSASSGGSGSS SS

Seq. ID No: 549
>affibody tag 2

NAAIRSSSASSGGSGGSSSSSVDNKFNKETIQASQEIRLLPNLNGRQKLAFIHSLLDDPSQSANLLAEAKKLNDAQAP K

Seq. ID No: 550
>affibody_tag_3

NAAIRSSSASSGGSGSSSSGVDNKFNKELGWATWEIFNLPNLNGVQVKAFIDSLRDDPSQSANLLAEAKKLNDAQA PK

Seq. ID No: 551
>affibody_tag_4

MVDNKFNKELGWATWEIFNLPNLNGVQVKAFIDSLRDDPSQSANLLAEAKKLNDAQAPKGNAAIRSSSASSGGSGGS SSS

Seq. ID No: 552
>affibody_tag_5

MVDNKFNKEMRNAYWEIALLPNLNNQQKRAFIRSLYDDPSQSANLLAEAKKLNDAQAPKSSNAAIRSSSASSGGSGG SSSS

Seq. ID No: 553
>affibody_tag_6

 ${\tt NAAIRSSSASSGGSGSSSSSGVDNKFNKEMRNAYWEIALLPNLNNQQKRAFIRSLYDDPSQSANLLAEAKKLNDAQAPK}$

Seq. ID No: 554

>cofold 1

MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLL AEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQE PYFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPW AWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSY EEELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNNLGIE GR

Seq. ID No: 555

>cofold 2

MVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKLICTTGKLPVPWPTLVTTLGYGLQCFARYPD HMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIT ADKQKNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSYQSALSKDPNEKRDHMVLLEFVTAAGIT LGMDELYK

Seq. ID No: 556

>cofold 3

MAMFCTFFEKHHRKWDILLEKSTGVMEAMKVTSEEKEQLSTAIDRMNEGLDAFIQLYNESEIDEPLIQLDDDTAELM KQARDMYGQEKLNEKLNTIIKQILSISVSEEGEKEGSGSG

Seq. ID No: 557

>cofold 4

MYLLGIGLILALIACKQNVSSLDEKNSVSVDLPGEMKVLVSKEKNKDGKYDLIATVDKLELKGTSDKNNGSGVLEGV KADKSKVKLTISDDGSG

Seq. ID No: 558

>cofold 5

MADRDRSGIYGGAHATYGQQQQQGGGGRPMGEQVKGMLHDKGPTASQALTVATLFPLGGLLLVLSGLALTASVVGLA VATPVFLIFSPVLVPAALLIGTAVMGFLTSGALGLGGLSSLTCLANTARQAFQRTPDYVEEAHRRMAEAAAHAGHKT AQAGQAIQGRAQEAGAGGGAG

Seq. ID No: 559
>oxidase_1

MKILILGIFLFLCSTPAWAKEKHYYIGIIETTWDYASDHGEKKLISVDTEHSNIYLQNGPDRIGRLYKKALYLQYTD ETFRTTIEKPVWLGFLGPIIKAETGDKVYVHLKNLASRPYTFHSHGITYYKEHEGAIYPDNTTDFQRADDKVYPGEQ YTYMLLATEEQSPGEGDGNCVTRIYHSHIDAPKDIASGLIGPLIICKKDSLDKEKEKHIDREFVVMFSVVDENFSWY LEDNIKTYCSEPEKVDKDNEDFQESNRMYSVNGYTFGSLPGLSMCAEDRVKWYLFGMGNEVDVHAAFFHGQALTNKN YRIDTINLFPATLFDAYMVAQNPGEWMLSCQNLNHLKAGLQAFFQVQECNKSSSKDNIRGKHVRHYYIAAEEIIWNY APSGIDIFTKENLTAPGSDSAVFFEQGTTRIGGSYKKLVYREYTDASFTNRKERGPEEEHLGILGPVIWAEVGDTIR VTFHNKGAYPLSIEPIGVRFNKNNEGTYYSPNYNPQSRSVPPSASHVAPTETFTYEWTVPKEVGPTNADPVCLAKMY YSAVDPTKDIFTGLIGPMKICKKGSLHANGRQKDVDKEFYLFPTVFDENESLLLEDNIRMFTTAPDQVDKEDEDFQE SNKMHSMNGFMYGNQPGLTMCKGDSVVWYLFSAGNEADVHGIYFSGNTYLWRGERRDTANLFPQTSLTLHMWPDTEG TFNVECLTTDHYTGGMKQKYTVNQCRRQSEDSTFYLGERTYYIAAVEVEWDYSPQREWEKELHHLQEQNVSNAFLDK GEFYIGSKYKKVVYRQYTDSTFRVPVERKAEEEHLGILGPQLHADVGDKVKIIFKNMATRPYSIHAHGVQTESSTVT PTLPGETLTYVWKIPERSGAGTEDSACIPWAYYSTVDQVKDLYSGLIGPLIVCRRPYLKVFNPRRKLEFALLFLVFD ENESWYLDDNIKTYSDHPEKVNKDDEEFIESNKMHAINGRMFGNLQGLTMHVGDEVNWYLMGMGNEIDLHTVHFHGH SFQYKHRGVYSSDVFDIFPGTYQTLEMFPRTPGIWLLHCHVTDHIHAGMETTYTVLQNEDTKSG

Seq. ID No: 560 >oxidase 2

MGLNSAIPSLAILALSVGSYAAIGPVSDLHIVNKDLAPDGVQRPTVLAGGTFPGTLITGQKGDNFQLNVIDDLTDDR MLTPTSIHWHGFFQKGTAWADGPAFVTQCPIIADNSFLYDFDVPDQAGTFWYHSHLSTQYCDGLRGAFVVYDPNDPH KDLYDVDDESTVITLADWYHVLAQTVVGAATPDSTLINGLGRSQTGPADAELAVISVEHNKRYRFRLVSISCDPNFT FSIDGHNMTVIEVDGVNTRPLTVDSIQIFAGQRYSFVLNANQPDDNYWIRAMPNIGRNTTTLDGKNAAILRYKNASV EEPKTVGGPAQSPLNEADLRPLVPAPVPGNAVPGGADINHRLNLTFSNGLFSINNASFTNPSVPALLQILSGAQNAQ DLLPTGSYIGLELGKVVELVIPPLAVGGPHPFHLHGHNFWVVRSAGSDEYNFDDAILRDVVSIGAGTDEVTIRFVTD NPGPWFLHCHIDWHLEAGLAIVFAEGINQTAAANPTPQAWDELCPKYNGLSASQKVKPKKGTAI

Seq. ID No: 561
>oxidase 3

MSRFQSLLSFVLVSLAAVANAAIGPVADLTLTNAAVSPDGFSREAVVVNGITPAPLIAGQKGDRFQLNVIDNLTNHT MLKTTSIHWHGFFQHGTNWADGVSFVNQCPIASGHSFLYDFQVPDQAGTFWYHSHLSTQYCDGLRGPFVVYDPNDPQ ASLYDIDNDDTVITLADWYHVAAKLGPRFPLGADATLINGLGRSPGTTTADLAVIKVTQGKRYRFRLVSLSCDPNHT FSIDGHTMTVIEADSVNTQPLEVDSIQIFAAQRYSFVLDASQPVDNYWIRANPAFGNVGFAGGINSAILRYDGAPEV EPTTTQTTSTKPLNEADLHPLTPMPVPGRPEAGGVDKPLNMVFNFNGTNFFINNHSFVPPSVPVLLQILSGAQAAQD LVPDGSVYVLPSNSSIEISFPATANAPGTPHPFHLHGHTFAVVRSAGSSEYNYDNPIFRDVVSTGQPGDNVTIRFQT NNPGPWFLHCHIDFHLEAGFAVVLAEDTPDTAAVNPVPQSWSDLCPIYDALDPSDL

Seq. ID No: 562 >oxidase 4

MKFLLLSALLFLHSSLAWTREKHYYIGITEAVWDYASGSEEKELISVDTEQSNFYLRNGPDRIGRKYKKALYSEYTD GTFTKTIDKPAWLGFLGPVIKAEVGDKVSVHVKNFASRPYTFHAHGVTYTKANEGAIYPDNTTDFQRADDKLFPGQQ YLYVLRANEPSPGEGDSNCVTRIYHSHVDAPKDIASGLIGPLILCKKGSLHKEKEENIDQEFVLMFSVVDENLSWYL EDNIKTFCSEPEKVDKDNEDFQESNRMYSINGYTFGSLPGLSMCAEDRVKWYLFGMGNEVDVHSELFHGQALTSKNY HTDIINLFPATLIDVSMVAQNPGVWMLSCQNLNHLKAGLQAFFQVRDCNKPSPDDDIQDRHVRHYYIAAEETIWDYA PSGTDTFTGENFTSLGSDSRVFFEQGATRIGGSYKKLVYREYTDDSFTNRKERGPDEEHLGILGPVIWAEVGDIIRV TFHNKGQFPLSIQPMGVRFTKENEGTYYGPDGRSSKQASHVAPKETFTYEWTVPKEMGPTYADPVCLSKMYYSGVDL TKDIFTGLIGPMKICKKGSLLADGRQKDVDKEFYLFATVFDENESLLLDDNIRMFTTAPENVDKEDEDFQESNKMHS MNGFMYGNLPGLNMCLGESIVWYLFSAGNEADVHGIYFSGNTYLSKGERRDTANLFPHKSLTLLMTPDTEGSFDVEC LTTDHYTGGMKQKYTVNQCKGQFEDVTLYQGERTYYIAAVEVEWDYSPSRDWEMELHHLQEQNVSNAFLDKEEFFIG SKYKKVVYREFTDSTFREQVKRRAEEEHLGMLGPLIHADVGAKVKVVFKNMATRPYSIHAHGVKTKSSTVAPTLPGE VRTYIWQIPERSGAGTEDSPCIPWAYYSTVDRVKDLYSGLIGPLIVCRKSYVKVFNPKKKMEFSLLFLVFDENESWY LDDNINTYPDHPEKDNKDNEEFIESNKMHAINGKMFGNLQGLTMHVGDEVNWYVMAMGNEIDLHTVHFHGHSFQYKH RGIHSSDVFDFFPGTYQTLEMFPQTPGTWLLHCHVTDHIHAGMVTTYTVLPNQETKSG

Seq. ID No: 563

>oxidase_5

MNFVTALPLIAQLIGTARAAIGPVTNLLVKNADIPPDGFTRAAVVANNQFPGPVIRATKGDTLSLNVVNQLTDATML MGTSIHWHGFHQKGTSWADGVVGVTQCPIAPGHSFLYQFPTANQAGTFWYHSHYSTQYCDGLRGALIVYDPTDPYRT WYDIDDESTIITLADWYHKAAPLQTLRTAKEDSVLINGQGRVPGDKTTDSTPLSVINIIPQKRYRFRLISISCDPAF SFSIDGHSMTVIEADSQSVQPLTVNEITIFAGQRYSFILYANNPVGNYWIRSQPTYPDDGIQGYAGGINSAILRYSG APAVNPTTKKASITIPLVEADLRPLYSPAAPGLPSPGAADVNIKLDISYNSPSETFFVNNSTFPEVPVPVLLQILSG AQSANDLLPAGSVYTLPPNKVIEISMPGGRPGSPHPMHLHGHDFSVVRSAGSNRYNYANPVRRDVVNIGMEDTDNVT IRFRVCSHTYLSLHCHIDFHLEDGQSGTLVPPLPHRLPPRGRIRCRLHRGILVRGRLGPDLQ

Seq. ID No: 564
>phosphatase 1

MQGPWVLLLLGLRLQLSLGIIPVEEENPDFWNRQAAEALGAAKKLQPAQTAAKNLIIFLGDGMGVSTVTAARILKGQ KKDKLGPETFLAMDRFPYVALSKTYSVDKHVPDSGATATAYLCGVKGNFQTIGLSAAARFNQCNTTRGNEVISVMNR AKKAGKSVGVVTTTRVQHASPAGAYAHTVNRNWYSDADVPASARQEGCQDIATQLISNMDIDVILGGGRKYMFPMGT PDPEYPDDYSQGGTRLDGKNLVQEWLAKHQGARYVWNRTELLQASLDPSVTHLMGLFEPGDMKYEIHRDSTLDPSLM EMTEAALLLLSRNPRGFFLFVEGGRIDHGHHESRAYRALTETIMFDDAIERAGQLTSEEDTLSLVTADHSHVFSFGG YPLRGSSIFGLAPGKARDRKAYTVLLYGNGPGYVLKDGARPDVTESESGSPEYRQQSAVPLDGETHAGEDVAVFARG PQAHLVHGVQEQTFIAHVMAFAACLEPYTACDLAPRAGTTDAAHPGPSVVPALLPLLAGTLLLLGTATAP

Seq. ID No: 565
>phosphatase 2

MQGACVLLLLGLHLQLSLGLVPVEEEDPAFWNRQAAQALDVAKKLQPIQTAAKNVILFLGDGMGVPTVTATRILKGQ MNGKLGPETPLAMDQFPYVALSKTYNVDRQVPDSAGTATAYLCGVKGNYRTIGVSAAARYNQCKTTRGNEVTSVMNR AKKAGKSVGVVTTTRVQHASPAGAYAHTVNRNWYSDADLPADAQMNGCQDIAAQLVNNMDIDVILGGGRKYMFPVGT PDPEYPDDASVNGVRKRKQNLVQAWQAKHQGAQYVWNRTALLQAADDSSVTHLMGLFEPADMKYNVQQDHTKDPTLQ EMTEVALRVVSRNPRGFYLFVEGGRIDHGHHDDKAYMALTEAGMFDNAIAKANELTSELDTLILVTADHSHVFSFGG YTLRGTSIFGLAPSKALDSKSYTSILYGNGPGYALGGGSRPDVNDSTSEDPSYQQQAAVPQASETHGGEDVAVFARG POAHLVHGVEEETFVAHIMAFAGCVEPYTDCNLPAPTTATSIPDAAHLAASPPPLALLAGAMLLLLAPTLY

Seq. ID No: 566
>phosphatase 3

MQGPWVLLLLGLRLQLSLGVIPAEEENPAFWNRQAAEALDAAKKLQPIQKVAKNLILFLGDGLGVPTVTATRILKGQ KNGKLGPETPLAMDRFPYLALSKTYNVDRQVPDSAATATAYLCGVKANFQTIGLSAAARFNQCNTTRGNEVISVMNR AKQAGKSVGVVTTTRVQHASPAGTYAHTVNRNWYSDADMPASARQEGCQDIATQLISNMDIDVILGGGRKYMFPMGT PDPEYPADASQNGIRLDGKNLVQEWLAKHQGAWYVWNRTELMQASLDQSVTHLMGLFEPGDTKYEIHRDPTLDPSLM EMTEAALRLLSRNPRGFYLFVEGGRIDHGHHEGVAYQALTEAVMFDDAIERAGQLTSEEDTLTLVTADHSHVFSFGG YTLRGSSIFGLAPSKAQDSKAYTSILYGNGPGYVFNSGVRPDVNESESGSPDYQQQAAVPLSSETHGGEDVAVFARG PQAHLVHGVQEQSFVAHVMAFAACLEPYTACDLAPPACTTDAAHPVAASLPLLAGTLLLLGASAAP

Seq. ID No: 567
>phosphatase 4

Seq. ID No: 568 >phosphatase 5

MSGSSVTGGGASLPAELYKGSADSILPANFSYAVTGSGTGKNAFLTNNSSLFGTTGTVHYAGSDSVLSGSELTTYNS NYNGTYGPLIQIPSVATSVTVPYRKDGNTTLNLTSAQLCDAFSGAKTTWGQLLGTTDSTPIRIVYRTGSSGTTELFT RHLNSICPTRFATNSTFTNARLPAGGTLPSNWVGVAATSTVVSTVKATNGSLGYVSPDAVNINSNAEVSRVNGNLPT QANVSTALGSVAPPANAADRADPSKWVPVFTNPSAGYSIVGYTNFVFGQCYKDASVSTDVRAFINKHYGGTTTNAAV AAHGFIPLTPAWKSAIVSAFYTGTSENLAIGNTNVCNTKGRP

Seq. ID No: 569 >phosphatase 6

MNFVTALPLIAQLIGTARAAIGPVTNLLVKNADIPPDGFTRAAVVANNQFPGPLITGNQGINFQINVVARLNNECSS RPLWYHWHGFFQKGTNWADGPAFVNQCPISTGNSFLYDFTAADQAGTFWYHSHLSTQYCDGLRGPMVVYDPNDPHAS LYDVDDESTVITLSDWYHTAARLGSAFPLGPDSVLINGLGRFAGGDGNAELAVIPVTQGKRYRFRLISLSCDPNFVF SIDKHNMTVIEADAVSHEPVTVDSIHIYAGQRYSFVLSAHRDIDNYWIRALPSGGTVNFVGGVNSALIRYDGAAEVE PVTNTTMSIAPLVETDLVPLDSPAAPGEASIGGVDYALSLVPSFVSRTLFCVRSIADDLRLRTGRTILSGSTELPSS HPPCRVYTLPSNATIELSFPITATNAPGAPHPFHLHGHVFSVVRSAGSSEYNYANPPRRDVVNTGTAGDNVTIRFRV CSHTYLSLHCHIDFHLEDGQSGTLVPPLPHRLPPRGRIRCRLHRGILVRGRLGPDLQ

Seq. ID No: 570
>scaffold

GGASASGVDNKFNKERVIAIGEIMRLPNLNSLQVVAFINSLRDDPSQSANLLAEAKKLNDAQAPKGGSSASSAGGSS VDNKFNKEAQTAGVEIMELPNLNTRQLLAFIQSLRDDPSQSANLLAEAKKLNDAQAPKTSGGSSASSAGGSSVDNKF NKERRMAAYEIIDLPNLNWFQLEAFITSLSDDPSQSANLLAEAKKLNDAQAPKGSGSNAAIRSSGSGSVDNKFNKER VIAIGEIMRLPNLNSLQVVAFINSLRDDPSQSANLLAEAKKLNDAQAPKGGSSASSAGGSSVDNKFNKEAQTAGVEI MELPNLNTRQLLAFIQSLRDDPSQSANLLAEAKKLNDAQAPKTSGSGSANAAIRSAGSGSVDNKFNKERRMAAYEII DLPNLNWFQLEAFITSLSDDPSQSANLLAEAKKLNDAQAPKGSGASGSGAGGSSVDNKFNKERVIAIGEIMRLPNLN SLQVVAFINSLRDDPSQSANLLAEAKKLNDAQAPKGSGASGSGAGGSSVDNKFNKEAQTAGVEIMELPNLNTRQLLA FIQSLRDDPSQSANLLAEAKKLNDAQAPKTSGSGSANAAIRSAGSGSVDNKFNKERRMAAYEIIDLPNLNWFQLEAFITSLSDDPSQSANLLAEAKKLNDAQAPKTSGSGSANAAIRSAGSGSVDNKFNKERRMAAYEIIDLPNLNWFQLEAFITSLSDDPSQSANLLAEAKKLNDAQAPK

Seq. ID No: 571

>sec 1

MQLLRCFSIFSVIASVLAQELTTICEQIPSPTLESTPYSLSTTTILANGK

Seq. ID No: 572

>sec_2

MLSLKTLLCTLLTVSSVLATPVPARDPSSIQFVHEENKKRYYDYDHGSLGE

Seq. ID No: 573

>sec 3

MKLQSLLVSAAVLTSLTENVNAWSPNNSYVPANVTCDDDINLVREASGLSDNETEWLKKRDAYTKE

Seq. ID No: 574

>sec 4

MEGVSLEKREAEA

Seq. ID No: 575

>sec_5

MKKTAIAIAVALAGFATVAQA

Seq. ID No: 576

>vac 1

MFSLKALLPLALLLVSANQVAAKVHKAKIYKHELS

Seq. ID No: 577

>vac_2

MTKNFIVTLKKNTPDVEAKKFLDSVHHAGGSIVHKFDIIKGYTIKVPDVLHLNKLKEKHNDVIENVEEDKEVHTN

Seq. ID No: 578

>vac_3

MEEQREILEQLKKTLQMLTVEPSKNNQIANEEKEKKENENSWCILEHNYEDIAQEFIDFIYKNPTTYHVVSFFAELL DKHNFKYLSEKSNWQDSIGEDGG

What is claimed is:

1. A non-naturally occurring nucleic acid comprising a sequence encoding an enzyme or regulatory protein in tryptamine metabolism,

wherein the enzyme or regulatory protein is an N-methyltransferase (INMT, PsiM, TrpM), a tryptophan decarboxylase (AADC), a tryptophan hydroxylase (TPH), a tryptamine 4' hydroxylase (T4H), a tryptamine 5' hydroxylase (T5H), a truncated cytochrome p450 reductase (T4H-CPR, T5H-CPR), an hydroxytryptamine O-methyltransferase (IOMT or CaffOMT), an N-acetyltransferase (NAT), a deacetylase (DAC), a hydroxyl tryptamine kinase (PsiK), a tryptophan synthase (TrpS), a toluene monooxygenase (TMO), an aminotransferase/methyltransferase fusion (ATMT), a phosphatase, an oxidase, a dimethylallyltryptophan synthase (DMATS), an isopentenyl-diphosphate isomerase (IDI1), a tryptophan halogenase (TrpHalo), an aspartate oxidase/quinolinic acid synthase fusion (AOQS), a tryptophan importer (TAT2), a methionine importer (MUP1), or a SAMe importer (SAM3).

- 2. The nucleic acid of claim 1, encoding a methyltransferase or hydroxylase.
- 3. The nucleic acid of claim 2, wherein the methyltransferase or hydroxylase is a tryptamine N-methyltransferase (INMT), a hydroxytryptamine O-methyltransferase (IOMT), a tryptamine 5' hydroxylase (T5H) or a tryptophan N-methyltransferase (TrpM).
 - 4. The nucleic acid of claim 1, encoding an amino acid sequence that is naturally occurring.
- 5. The nucleic acid of claim 1, encoding an amino acid sequence that is not naturally occurring.
- 6. The nucleic acid of claim 1, wherein the sequence is codon-optimized for yeast expression.
- 7. The nucleic acid of claim 1, further comprising nucleotides encoding amino acids that are not part of the enzyme or regulatory protein.

8. The nucleic acid of claim 7, having a 5' end, wherein the additional nucleotides are at the 5' end of the nucleic acid and encode a codon optimized cofolding peptide.

- 9. The nucleic acid of claim 8, wherein the codon optimized cofolding peptide comprises an amino acid sequence of any one of SEQ ID NO:554-558.
- 10. The nucleic acid of claim 9, wherein the codon optimized cofolding peptide is encoded by any one of SEQ ID NOs:265-269.
- 11. The nucleic acid of claim 7, wherein the amino acids that are not part of the enzyme or regulatory protein are an affibody tag, a localization scaffold, a vacuolar localization tag, a secretion signal, a 6xhis tag, or any combination thereof.
 - 12. The nucleic acid of claim 1, comprising the sequence of SEQ ID NOs:1-289
- 13. The nucleic acid of claim 1, further comprising a promoter functional in a recombinant microorganism.
 - 14. The nucleic acid of claim 13, wherein the recombinant microorganism is a yeast.
 - 15. An expression cassette comprising the nucleic acid of claim 13.
 - 16. The expression cassette of claim 15, which is a yeast expression cassette.
- 17. A recombinant microorganism comprising the expression cassette of claim 15, that expresses the enzyme or regulatory protein encoded therein.
 - 18. The recombinant microorganism of claim 17, which is an E. coli.
 - 19. The recombinant microorganism of claim 17, which is a yeast cell.

20. The yeast cell of claim 19, which is a species of Saccharomyces, Candida, Pichia, Schizosaccharomyces, Scheffersomyces, Blakeslea, Rhodotorula, Aspergillus or Yarrowia.

- 21. The yeast cell of claim 19, which is a Saccharomyces cerevisiae.
- 22. A non-naturally occurring enzyme or regulatory protein comprising an amino acid sequence encoded by the nucleic acid of any one of claims 1-12.
- 23. A recombinant microorganism expressing at least one enzyme or regulatory protein of claim 22.
 - 24. The recombinant microorganism of claim 23, which is an E. coli.
 - 25. The recombinant microorganism of claim 23, which is a yeast cell.
- 26. The yeast cell of claim 25, which is a species of Saccharomyces, Candida, Pichia, Schizosaccharomyces, Scheffersomyces, Blakeslea, Rhodotorula, Aspergillus or Yarrowia.
 - 27. The yeast cell of claim 25, which is a Saccharomyces cerevisiae.
- 28. The recombinant microorganism of claim 23, expressing INMT, wherein the recombinant microorganism produces at least one hydroxy substituted tryptophan compound.
- 29. The recombinant microorganism of claim 28, wherein the at least one hydroxy substituted tryptophan compound is 5-OH-NMTP, 5-OH-DMTP or 5-OH-TMTP.
- 30. The recombinant microorganism of claim 23, expressing INMT, wherein the recombinant microorganism produces at least one hydroxy substituted tryptamine compound.
- 31. The recombinant microorganism of claim 30, wherein the at least one hydroxy substituted tryptamine compound is bufotenine, 5-OH-NMT, or 5-OH-TMT.

32. The recombinant microorganism of claim 23, expressing INMT, wherein the recombinant microorganism produces at least one methoxy substituted tryptamine compound.

- 33. The recombinant microorganism of claim 32, wherein the at least one methoxy substituted tryptamine compound is 5-MeO-NMT, 5-MeO-DMT, or 5-MeO-TMT.
- 34. The recombinant microorganism of claim 23, expressing IOMT, wherein the recombinant microorganism methylates the primary amine on the 5-hydroxy moiety on an indole ring.
- 35. The recombinant microorganism of claim 34, wherein the microorganism acts on (a) bufotenine to create 5-MeO-DMT, or (b) N-acetylserotonin to create melatonin.
- 36. The recombinant microorganism of claim 23, expressing T5H, wherein the recombinant microorganism hydroxylates at the 5' position of an indole ring.
- 37. The recombinant microorganism of claim 36, wherein the microorganism generates serotonin from tryptamine.
- 38. The recombinant microorganism of claim 36, wherein the T5H is a fusion polypeptide with a cytochrome P450 reductase (CPR).
- 39. The recombinant microorganism of claim 36, wherein the T5H is a fusion polypeptide with an IOMT.
- 40. The recombinant microorganism of claim 23, expressing TrpM, wherein the recombinant microorganism catalyzes the alkylation of the primary amine of L-tryptophan to produce NMTP, DMTP, TMTP, or any combination thereof.
- 41. The recombinant microorganism of claim 23, expressing PsiM, wherein the recombinant microorganism methylates norbaeocystin.

42. The recombinant microorganism of claim 41, wherein the PsiM comprises a domain from an rRNA methyltransferase from Ascomycota.

- 43. The recombinant microorganism of claim 23, expressing AADC, wherein the recombinant microorganism decarboxylates an aliphatic carboxylic acid.
- 44. The recombinant microorganism of claim 43, wherein the recombinant microorganism creates tryptamine from L-tryptophan, creates serotonin from 5-HTP, creates bufotenine from 5-OH-DMTP, creates 5-MeO-DMT from 5-MeO-DMTP, or any combination thereof.
- 45. The recombinant microorganism of claim 23, expressing TPH, wherein the recombinant microorganism adds a hydroxy group to the 5-carbon of L-tryptophan.
- 46. The recombinant microorganism of claim 23, expressing T4H, wherein the recombinant microorganism hydroxylates the 4' position of an indole ring.
- 47. The recombinant microorganism of claim 46, wherein the recombinant microorganism converts tryptamine to 4-OH-tryptamine.
- 48. The recombinant microorganism of claim 46, wherein the T4H is a chimera of sequences from T4H from different species, wherein the T4H comprises a yeast p450 N terminus.
- 49. The recombinant microorganism of claim 46, wherein the T4H is a chimera of a mushroom PsiH and a yeast p450 N terminus.
- 50. The recombinant microorganism of claim 23, expressing NAT, wherein the recombinant microorganism adds an acetyl group from acetyl-CoA to the terminal amino group of a tryptamine.
- 51. The recombinant microorganism of claim 50, wherein the recombinant microorganism acts on serotonin to generate N-acetylserotonin.

52. The recombinant microorganism of claim 23, expressing DAC, wherein the recombinant microorganism removes an acetyl group from the terminal amino group of a tryptamine.

- 53. The recombinant microorganism of claim 52, wherein the recombinant microorganism acts on melatonin to create 5-MeO-tryptamine.
- 54. The recombinant microorganism of claim 23, expressing PsiK, wherein the recombinant microorganism phosphorylates a hydroxy-indole.
- 55. The recombinant microorganism of claim 54, wherein the PsiK is a chimera of a PsiK and a yeast kinase.
- 56. The recombinant microorganism of claim 23, expressing TrpS, wherein the recombinant microorganism combines an indole with L-serine or L-threonine to create variants of tryptophan or beta-methyl tryptophan, respectively.
- 57. The recombinant microorganism of claim 56, wherein the TrpS is coexpressed with a multidrug exporter, wherein the recombinant microorganism exports indole while continuing bioproduction of tryptophan and/or tryptamine analogs.
- 58. The recombinant microorganism of claim 23, expressing TMO, wherein the recombinant microorganism hydroxylates the indole ring of tryptamines.
- 59. The recombinant microorganism of claim 58, wherein the TMO comprises four subunits that are fused into a fusion polypeptide.
- 60. The recombinant microorganism of claim 23, expressing a phosphatase, wherein the recombinant microorganism dephosphorylates a phosphorylated tryptamine.
- 61. The recombinant microorganism of claim 60, wherein the recombinant microorganism dephosphorylates psilocybin into psilosin.

62. The recombinant microorganism of claim 23, expressing an oxidate, wherein the recombinant microorganism creates a tryptamine radical which reacts with another tryptamine to form a dimer or oligomer.

- 63. The recombinant microorganism of claim 62, wherein the oxidase is a chimera with a yeast laccase.
- 64. The recombinant microorganism of claim 63, wherein the oxidase is coexpressed with a yeast t-SNARE.
- 65. The recombinant microorganism of claim 23, expressing a DMATS, wherein the recombinant microorganism prenylates a tryptophan and/or a tryptamine.
- 66. The recombinant microorganism of claim 65, wherein the DMATS is a fusion polypeptide with IDI1.
- 67. The recombinant microorganism of claim 23, expressing a TrpHalo, wherein the recombinant microorganism adds fluorine (F), chlorine (Cl), bromine (Br), and/or iodine (I) to an indole or biogenic amine.
- 68. The recombinant microorganism of claim 67, wherein the TrpHalo further comprises a secretion tag.
- 69. The recombinant microorganism of claim 68, wherein the TrpHalo further comprises a 6xhis tag.
- 70. The recombinant microorganism of claim 67, wherein the TrpHalo is coexpressed with a fluoride exporter.
- 71. The recombinant microorganism of claim 23, expressing more than one of the enzyme and/or regulatory protein.

72. The recombinant microorganism of claim 71, expressing TPH, TrpM, and AADC, wherein the recombinant microorganism produces at least one hydroxy substituted tryptamine compound.

- 73. The recombinant microorganism of claim 72, wherein the at least one hydroxy substituted tryptamine compound is bufotenine, 5-OH-NMT, or 5-OH-TMT.
- 74. The recombinant microorganism of claim 71, expressing TPH, TrpM, AADC, and IOMT, wherein the recombinant microorganism produces at least one methoxy substituted tryptamine compound.
- 75. The recombinant microorganism of claim 74, wherein the at least one methoxy substituted tryptamine compound is 5-MeO-NMT, 5-MeO-DMT, or 5-MeO-TMT.
- 76. The recombinant microorganism of claim 71, expressing AADC, T5H and INMT, wherein the recombinant microorganism produces at least one hydroxy substituted tryptamine compound.
- 77. The recombinant microorganism of claim 76, wherein the at least one hydroxy substituted tryptamine compound is bufotenine, 5-OH-NMT, or 5-OH-TMT.
- 78. The recombinant microorganism of claim 71, expressing AADC, T5H, INMT, and IOMT, wherein the recombinant microorganism produces at least one methoxy substituted tryptamine compound.
- 79. The recombinant microorganism of claim 78, wherein the at least one methoxy substituted tryptamine compound is 5-MeO-NMT, 5-MeO-DMT, or 5-MeO-TMT.
- 80. The recombinant microorganism of claim 71, expressing TrpM and TPH, wherein the recombinant microorganism produces at least one hydroxy substituted tryptophan compound.

81. The recombinant microorganism of claim 80, wherein the at least one hydroxy substituted tryptophan compound is 5-HTP, 5-OH-NMTP, 5-OH-DMTP or 5-OH-TMTP.

- 82. The recombinant microorganism of claim 71, expressing TrpM, TPH and IOMT, wherein the recombinant microorganism produces at least one methoxy substituted tryptophan compound.
- 83. The recombinant microorganism of claim 82, wherein the at least one methoxy substituted tryptophan compound is 5-MeO-NMTP, 5-MeO-DMTP or 5-MeO-TMTP.
- 84. The recombinant microorganism of claim 71, expressing INMT and T5H, wherein the recombinant microorganism produces at least one hydroxy substituted tryptamine compound.
- 85. The recombinant microorganism of claim 84, wherein the at least one hydroxy substituted tryptamine compound is bufotenine, 5-OH-NMT, or 5-OH-TMT.
- 86. The recombinant microorganism of claim 71, expressing INMT, T5H and IOMT, wherein the recombinant microorganism produces at least one methoxy substituted tryptamine compound.
- 87. The recombinant microorganism of claim 86, wherein the at least one methoxy substituted tryptamine compound is 5-MeO-NMT, 5-MeO-DMT, or 5-MeO-TMT.
- 88. The recombinant microorganism of claim 71, expressing INMT and IOMT, wherein the recombinant microorganism produces at least one methoxy substituted tryptophan compound.
- 89. The recombinant microorganism of claim 88, wherein the at least one methoxy substituted tryptophan compound is 5-MeO-NMTP, 5-MeO-DMTP or 5-MeO-TMTP.
- 90. The recombinant microorganism of claim 71, expressing INMT and AADC, wherein the recombinant microorganism produces at least one hydroxy substituted tryptamine compound.

91. The recombinant microorganism of claim 90, wherein the at least one hydroxy substituted tryptamine compound is bufotenine, 5-OH-NMT, or 5-OH-TMT.

- 92. The recombinant microorganism of claim 71, expressing INMT, AADC and IOMT, wherein the recombinant microorganism produces at least one methoxy substituted tryptamine compound.
- 93. The recombinant microorganism of claim 92, wherein the at least one methoxy substituted tryptamine compound is 5-MeO-NMT, 5-MeO-DMT, or 5-MeO-TMT.
- 94. The recombinant microorganism of claim 71, expressing INMT and IOMT, wherein the recombinant microorganism produces at least one methoxy substituted tryptamine compound.
- 95. The recombinant microorganism of claim 94, wherein the at least one methoxy substituted tryptamine compound is 5-MeO-NMT, 5-MeO-DMT, or 5-MeO-TMT.
- 96. The recombinant microorganism of claim 71, expressing TPH and AADC, wherein the recombinant microorganism generates serotonin from L-tryptophan through a 5-HTP intermediate.
- 97. The recombinant microorganism of claim 71, expressing NAT and IOMT, wherein the recombinant microorganism generates melatonin from serotonin through an N-acetylserotonin intermediate.
- 98. The recombinant microorganism of claim 71, expressing DAC and INMT, wherein the recombinant microorganism generates 5-MeO-DMT from melatonin through a 5-MeO-tryptamine intermediate.
- 99. The recombinant microorganism of claim 71, expressing ATMT and AADC, wherein ATMT is a fusion polypeptide of aminotransferase and methyltransferase, wherein the recombinant microorganism produces meta-methylated tryptamine analogs.


100. The recombinant microorganism of claim 71, wherein the recombinant microorganism does not express Pdc5, Aro10, Aro7, Pdz1, Pdz2, Bna2, SPE2, Glc3 or any combination thereof.

- 101. The recombinant microorganism of claim 71, wherein the recombinant microorganism overexpresses an enzyme that promotes conversion of L-methionine to SAMe, does not express an off-pathway gene that encodes for enzymes that deplete SAMe for unwanted side products, overexpresses a permease, or any combination thereof.
- 102. The recombinant microorganism of claim 71, wherein the recombinant microorganism overexpresses a Sam2, Adk1, Mup1, Sam3.
 - 103. The nucleic acid of claim 1, further comprising a promoter functional in a plant.
 - 104. A plant expression cassette comprising the nucleic acid of claim 103.
- 105. A recombinant plant comprising the plant expression cassette of claim 104, capable of expressing the enzyme or regulatory protein encoded therein.
- 106. The recombinant plant of claim 105, expressing TrpM and TPH, wherein the recombinant plant produces at least one hydroxy substituted tryptophan compound.
- 107. The recombinant plant of claim 106, wherein the at least one hydroxy substituted tryptophan compound is 5-HTP, 5-OH-NMTP, 5-OH-DMTP or 5-OH-TMTP.
- 108. The recombinant plant of claim 105, expressing TrpM, TPH and IOMT, wherein the recombinant plant produces at least one methoxy substituted tryptophan compound.
 - 109. The recombinant plant of claim 105, which is a tobacco or *Arabadopsis* plant.
 - 110. A method of producing a substituted indole, the method comprising
- (i) growing the recombinant microorganism of any one of claims 23-102 or the recombinant plant of any one of claims 105-109;

(ii) expressing the at least one enzyme or regulatory protein in the recombinant microorganism;

- (iii) producing or synthesizing substituted indoles and tryptamines in the recombinant microorganism; and
 - (iv) isolating the substituted indole from the recombinant microorganism.
- 111. The method of claim 110, wherein precursor chemicals are added to the growing recombinant microorganism or plant, wherein the precursor chemicals are utilized by the at least one enzyme or regulatory protein.

OHOHOMAN
$$\beta$$
 $\dot{\alpha}$
 $\dot{\alpha}$
 $\dot{\beta}$
 $\dot{\alpha}$
 $\dot{\alpha}$
 $\dot{\alpha}$
 $\dot{\beta}$
 $\dot{\alpha}$
 $\dot{\alpha}$
 $\dot{\alpha}$
 $\dot{\beta}$
 $\dot{\alpha}$
 $\dot{\alpha}$
 $\dot{\alpha}$
 $\dot{\beta}$
 $\dot{\alpha}$
 \dot




- methylation
- halogenation
- prenylation
- hydroxylation
- O-phosphorylation
- O-methylation
- N-Acetylation

- O cleavage
- O deamination
- decarboxylation
- + oligomerization

FIG. 1

FIG. 2






CA 03181733 2022-12-6


FIG. 4


N-ACETYLSEROTONIN


SEROTONIN



FIG











FIG. 11






FIG. 13

A) Conversion of alpha-methyl-tryptamine (AMT) examples




FIG. 14

15/26

A)

B)





FIG. 15

FIG. 16








FIG. 18




FIG. 19




FIG. 20




FIG. 21




FIG. 22




FIG. 23





FIG. 24

26/26

HPLC chromatogram- 270nm wavelength



UV-vis spectral library match of fermentation derived DMT with the DMT analitycal standard





FIG. 26



- methylation
- halogenation
- prenylation
- hydroxylation
- O-phosphorylation
- O-methylation
- N-Acetylation

- O cleavage
- O deamination
- O decarboxylation
- + oligomerization